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The Making of a Global Health Crisis: Extensively Drug-Resistant
Tuberculosis and Global Science in Rural South Africa
Abstract
This dissertation is a study of the social, scientific, political and rhetorical origins of extensively drug-resistant
tuberculosis (XDR-TB) and the ability of a technical medical term, in concert with local clinical and
government responses, to influence global biomedical action. XDR-TB, a form of tuberculosis that is resistant
to most anti-tuberculosis drugs, was first creatively named and defined in 2005 in the context of a global
laboratory survey documenting increasing tuberculosis drug resistance patterns around the world. In 2006,
XDR-TB attracted international attention after a deadly cluster of drug-resistant tuberculosis was discovered
in the rural South African town of Tugela Ferry, KwaZulu-Natal. International media and global health
workers, responding to this news, defined XDR-TB as a critical threat to global health emanating from
Southern Africa. As this dissertation shows, the association of XDR-TB with South Africa shaped the global
response to XDR-TB, tying it closely to HIV/AIDS and linking it to the well-known history of South African
AIDS denialism and public health inaction. The careful scrutiny given to South African XDR-TB by global
public health experts profoundly impacted South African government responses to XDR-TB at the national,
provincial, and regional levels.
This detailed, multifaceted case study of global health knowledge in-the-making is based on nearly two years
of fieldwork in South African clinical and community settings and interviews with international and South
African tuberculosis researchers, policy makers, clinicians, administrators and patients. Widely circulated
representations of XDR-TB are juxtaposed with the personal experience of South African nurses and local
government administrators to make the case that responsibility for and control of successful global health
interventions is more broadly distributed than common conceptions of global health research imply. In
addition, this research uses published documents, unpublished policy literature, and promotional materials to
trace how medical, public, and political understandings of XDR-TB in South Africa changed over time and
across geographical space. This research changes our understanding of the politics and practices of health
interventions in Africa by linking together activities ranging from the crafting of scientific publication, to
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  generosity	  of	  strangers,	  many	  of	  whom	  are	  now	  my	  friends	  and	  colleagues.	  In	  Durban	  I	  found	  an	  academic	  home	  at	  the	  University	  of	  KwaZulu-­‐Natal	  and	  was	  welcomed	  by	  Julie	  Parle,	  Catherine	  Burns,	  Keith	  Breckenridge,	  Jeff	  Guy,	  and	  several	  of	  their	  colleagues.	  Catherine	  Burns,	  especially,	  has	  been	  a	  node	  in	  South	  African	  –	  American	  transatlantic	  research,	  and	  I	  thank	  her	  for	  fascinating	  conversations	  and	  helpful	  pointers	  while	  sitting	  at	  her	  and	  Keith’s	  kitchen	  table.	  Gail	  Robbins	  shared	  her	  work	  with	  me	  over	  tea	  at	  the	  University	  and	  pointed	  me	  in	  several	  useful	  directions.	  At	  the	  Medical	  Research	  Council	  in	  Durban,	  I	  would	  like	  to	  thank	  Roxana	  Rustomjee	  and	  Paul	  Ngcobo	  for	  providing	  me	  with	  insights	  and	  resources	  (including	  transport	  to	  Tugela	  Ferry).	  	  At	  King	  George	  V	  Hospital	  Iqbal	  Master	  showed	  me	  around,	  welcomed	  me	  to	  meetings,	  and	  shared	  his	  perspective	  on	  research	  in	  South	  Africa.	  Janet	  Giddy	  has	  been	  a	  mentor	  and	  friend	  from	  the	  time	  we	  met	  at	  McCord	  Hospital	  in	  2003	  and	  I	  thank	  her	  for	  incorporating	  me	  into	  her	  household	  when	  I	  needed	  it.	  Thanks	  also	  to	  Marian	  Loveday	  for	  explaining	  local	  networks	  in	  TB	  research	  and	  for	  providing	  a	  bed	  to	  stay	  in	  Pietermaritzburg.	  Over	  the	  course	  of	  my	  training	  and	  research	  several	  families	  have	  let	  me	  into	  their	  homes	  to	  teach	  me	  Zulu	  language	  and	  culture,	  and	  to	  provide	  a	  base	  within	  the	  communities	  I	  was	  working	  in.	  From	  deep	  in	  my	  heart	  I	  would	  like	  to	  thank	  Lunga	  Mkhize	  and	  her	  family	  in	  Maqongqo,	  who	  made	  it	  their	  mission	  to	  teach	  me	  Zulu	  even	  as	  they	  were	  suffering	  death	  and	  loss.	  Near	  Durban,	  I	  thank	  Tilly	  Mazibuko,	  Nozipho	  Mazibuko,	  Granny	  and	  Abulele	  in	  Molweni	  for	  welcoming	  me	  into	  their	  family	  and	  sharing	  the	  daily	  commute	  from	  the	  almost	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rural	  homestead	  to	  the	  hospital	  in	  the	  city.	  I	  thank	  Nozipho	  for	  letting	  me	  in	  to	  her	  social	  life	  as	  a	  young	  adult,	  and	  Abulele	  for	  bringing	  light	  into	  my	  day	  whenever	  I	  was	  home.	  I	  also	  thank	  Michelle	  and	  Kevin	  Gordon	  with	  their	  children	  Alex	  and	  Gigi	  in	  Austerville	  for	  being	  wonderful,	  steadfast	  friends	  and	  for	  taking	  me	  in	  when	  I	  needed	  to	  be	  closer	  to	  town	  or	  wanted	  to	  hear	  about	  life	  in	  the	  medical	  school.	  Thank	  you	  Siva	  Danaviah	  for	  restorative	  meals	  and	  conversations.	  In	  Tugela	  Ferry	  Isah	  and	  Thobani	  T.	  Buthelezi	  graciously	  welcomed	  me	  into	  their	  home,	  where	  I	  also	  got	  to	  know	  their	  beautiful	  daughters,	  Zipporah,	  S’thokozile	  and	  Ruth.	  Thobani’s	  brother	  Mdumiseni	  (Bafana)	  also	  helped	  me	  navigate	  life	  in	  Tugela	  Ferry.	  Thank	  you	  for	  letting	  me	  in	  with	  open	  arms	  and	  for	  incorporating	  me	  into	  your	  family.	  At	  the	  Church	  of	  Scotland	  Hospital	  and	  at	  the	  Philanjalo	  Care	  organisation	  in	  Tugela	  Ferry	  my	  research	  was	  made	  possible	  with	  help	  and	  guidance	  from	  numerous	  people,	  especially	  Dr.	  Tony	  Moll	  and	  Dr.	  Gerald	  Friedland,	  who	  agreed	  to	  take	  on	  the	  risk	  of	  having	  an	  outsider	  study	  their	  activities	  and	  ask	  questions	  about	  it.	  CEO	  Hans	  Human	  and	  Matron	  Dube	  also	  facilitated	  my	  presence.	  Others	  who	  welcomed	  and	  assisted	  me	  as	  colleagues	  and	  at	  times	  as	  friends	  included	  Dr.	  Sheela	  Shenoi,	  Dr.	  Sheila	  Bamber,	  Dr.	  Theo	  van	  der	  Merwe,	  Dr.	  Francois	  Eksteen,	  Dr.	  Claudio	  Marra,	  Dr.	  Nuala	  Hale,	  Dr.	  Jim	  Periselneris,	  Sister	  Msomi,	  Sister	  Madi,	  and	  the	  entire	  staff	  of	  the	  TB	  DOTS	  office,	  Mdu	  Mntambo,	  Nelisiwe	  Nhlangothi,	  Mxolisi	  Myeza,	  Hlengiwe	  Myende,	  Cebile	  Fuse,	  Njabulo	  Malembe,	  Thobeka	  Majola,	  and	  all	  the	  other	  research	  staff	  at	  Philanjalo,	  Eugene	  Meyers,	  Ralph	  Brooks,	  Nqobizwe	  Ngubane,	  Lungi	  Zondi,	  Vi	  Buthelezi,	  Goodness	  Zuma,	  Michelle	  and	  Chuck	  Possin,	  and	  many,	  many	  others.	  I	  thank	  you	  all	  and	  apologize	  to	  those	  who	  have	  not	  been	  mentioned	  –	  may	  the	  list	  be	  more	  complete	  when	  I	  publish	  the	  edited	  version	  of	  the	  book.	  Nomnikelo	  Mvelase	  deserves	  a	  special	  mention	  as	  a	  research	  assistant,	  translator,	  and	  transcriber	  who,	  mostly	  with	  good	  humor	  and	  spirit,	  took	  on	  the	  job	  of	  being	  my	  companion	  and	  cultural	  mediator	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and	  helped	  me	  navigate	  some	  of	  the	  difficult	  cultural	  and	  political	  terrain	  of	  TB	  in	  Tugela	  Ferry.	  I	  appreciated	  her	  efforts	  greatly,	  and	  without	  her	  I	  would	  not	  have	  been	  able	  to	  complete	  this	  dissertation.	  I	  would	  like	  to	  thank	  all	  the	  many	  people	  who	  shared	  their	  stories	  with	  me,	  patiently	  answered	  my	  questions,	  and	  whose	  willingness	  to	  engage	  with	  me	  was	  the	  foundation	  for	  this	  dissertation.	  I	  shared	  my	  time	  in	  Tugela	  Ferry	  and	  Durban	  with	  many	  other	  itinerant	  and	  visiting	  researchers	  and	  medical	  workers,	  and	  shared	  housing	  with	  several	  of	  them,	  as	  well.	  I	  will	  not	  mention	  all	  of	  them	  here,	  but	  would	  like	  to	  highlight	  a	  few:	  Sara	  Sani,	  Zahir	  Kanjee,	  Krisda	  Chayachati,	  Elizabeth	  Wahl,	  David	  Carel,	  Lindsay	  Ryan.	  Many	  others	  were	  also	  a	  pleasure	  to	  spend	  time	  with.	  Thank	  you	  for	  sharing	  Tugela	  Ferry	  with	  me,	  for	  sharing	  good	  meals	  and	  touristy	  weekend	  trips,	  for	  engaging	  in	  deep	  conversations	  about	  the	  meaning	  of	  XDR-­‐TB	  research	  in	  Tugela	  Ferry,	  for	  sharing	  your	  own	  experiences	  and	  research,	  and	  for	  your	  friendship.	  This	  project	  would	  not	  have	  been	  possible	  without	  generous	  support	  from	  the	  University	  of	  Pennsylvania	  School	  of	  Medicine	  Combined	  Degree	  Program	  and	  the	  University	  of	  Pennsylvania’s	  School	  of	  Arts	  and	  Sciences	  (SAS).	  SAS	  funding	  included	  a	  Benjamin	  Franklin	  Fellowship,	  a	  Penfield	  Dissertation	  Research	  Fellowship,	  the	  Samuel	  H.	  Preston	  Presidential	  Prize	  Summer	  Research	  Fellowship	  and	  the	  Helfand	  Fund	  for	  History	  and	  Sociology	  of	  Science.	  In	  addition,	  fieldwork	  in	  South	  Africa	  was	  supported	  by	  the	  Social	  Science	  Research	  (SSRC)	  Council	  International	  Dissertation	  Research	  Fellowship,	  the	  Fulbright-­‐Hays	  Doctoral	  Dissertation	  Research	  Abroad	  Fellowship	  and	  the	  Social	  Science	  Research	  Council	  Dissertation	  Proposal	  Development	  Fellowship.	  Both	  SSRC	  grants	  also	  gave	  me	  wonderful	  opportunities	  to	  connect	  with	  colleagues	  in	  my	  field	  and	  to	  engage	  in	  intellectual	  conversation	  with	  an	  amazing	  group	  of	  smart	  people	  immersed	  in	  their	  research.	  It	  was	  a	  privilege	  to	  share	  this	  stage	  of	  research	  development.	  Zulu	  language	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training	  in	  South	  Africa	  was	  supported	  by	  the	  Fulbright-­‐Hays	  Intensive	  Intermediate-­‐Advanced	  Zulu	  Group	  Project	  Abroad	  program	  directed	  by	  Audrey	  Nonhlanhla	  Mbeje.	  This	  program	  not	  only	  improved	  my	  isiZulu	  skills	  but	  also	  put	  me	  in	  touch	  with	  a	  sassy	  group	  of	  people	  with	  an	  interest	  in	  South	  Africa,	  many	  of	  them	  talented	  scholars.	  Early	  experiences	  with	  South	  African	  AIDS	  science	  and	  research	  were	  supported	  by	  Williams	  College	  and	  the	  Robert	  G.	  Wilmers,	  1990,	  Memorial	  Fellowship	  in	  2002,	  and	  a	  2003	  Fulbright	  Fellowship	  to	  South	  Africa.	  Thank	  you	  to	  my	  fellow	  travelers	  in	  the	  Penn	  MD/PhD	  program	  for	  being	  friends	  and	  colleagues	  on	  a	  long	  journey.	  Soon	  our	  class	  will	  be	  complete.	  Maggie	  Krall,	  Skip	  Brass,	  Maureen	  Kirsch	  and	  Mary	  Tiedeman	  have	  all	  worked	  hard	  to	  ensure	  our	  successful	  training	  and	  graduation.	  I	  thank	  Maggie	  for	  her	  regular	  “check-­‐ins,”	  efficient	  problem-­‐solving,	  and	  friendship.	  She	  was	  in	  fact	  the	  first	  person	  to	  read	  the	  entire	  dissertation	  from	  start	  to	  finish,	  and	  I	  am	  honored	  by	  that.	  I	  thank	  Skip	  for	  continuing	  to	  believe	  in	  the	  mission	  of	  training	  MD/PhDs	  in	  the	  social	  sciences	  and	  for	  remaining	  flexible,	  welcoming,	  and	  supportive	  as	  I	  carved	  my	  own	  path.	  At	  the	  medical	  school	  I	  would	  also	  like	  to	  thank	  “Suite	  100,”	  specifically	  Helene	  Weinberg	  and	  Barbara	  Wagner	  for	  working	  with	  me	  as	  my	  combined	  schedule	  became	  increasingly	  complex	  and	  was	  made	  more	  so	  by	  my	  moving	  to	  Boston	  and	  my	  increasing	  loss	  of	  hearing.	  Thank	  you	  for	  never	  doubting	  that	  things	  can	  be	  worked	  out.	  Last,	  but	  not	  least,	  I	  would	  like	  to	  thank	  my	  family.	  My	  parents,	  Helen	  Dwyer	  and	  James	  Dwyer	  have	  supported	  me	  emotionally	  and	  intellectually	  throughout	  my	  studies,	  and	  both	  have	  read	  and	  commented	  on	  significant	  portions	  of	  my	  work.	  My	  sister,	  Anne	  Dwyer,	  has	  been	  an	  inspiration	  for	  many	  years.	  Whenever	  I	  have	  difficulty	  writing	  or	  working	  out	  a	  problem,	  she	  is	  the	  person	  I	  go	  to	  first	  for	  conceptual	  and	  organizational	  help.	  My	  brother,	  Paul	  Dwyer,	  brings	  music	  into	  our	  lives,	  and	  his	  energy,	  incentive,	  and	  perseverance	  are	  a	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 This	  dissertation	  is	  a	  study	  of	  the	  social,	  scientific,	  political	  and	  rhetorical	  origins	  of	  extensively	  drug-­‐resistant	  tuberculosis	  (XDR-­‐TB)	  and	  the	  ability	  of	  a	  technical	  medical	  term,	  in	  concert	  with	  local	  clinical	  and	  government	  responses,	  to	  influence	  global	  biomedical	  action.	  XDR-­‐TB,	  a	  form	  of	  tuberculosis	  that	  is	  resistant	  to	  most	  anti-­‐tuberculosis	  drugs,	  was	  first	  creatively	  named	  and	  defined	  in	  2005	  in	  the	  context	  of	  a	  global	  laboratory	  survey	  documenting	  increasing	  tuberculosis	  drug	  resistance	  patterns	  around	  the	  world.	  In	  2006,	  XDR-­‐TB	  attracted	  international	  attention	  after	  a	  deadly	  cluster	  of	  drug-­‐resistant	  tuberculosis	  was	  discovered	  in	  the	  rural	  South	  African	  town	  of	  Tugela	  Ferry,	  KwaZulu-­‐Natal.	  International	  media	  and	  global	  health	  workers,	  responding	  to	  this	  news,	  defined	  XDR-­‐TB	  as	  a	  critical	  threat	  to	  global	  health	  emanating	  from	  Southern	  Africa.	  As	  this	  dissertation	  shows,	  the	  association	  of	  XDR-­‐TB	  with	  South	  Africa	  shaped	  the	  global	  response	  to	  XDR-­‐TB,	  tying	  it	  closely	  to	  HIV/AIDS	  and	  linking	  it	  to	  the	  well-­‐known	  history	  of	  South	  African	  AIDS	  denialism	  and	  public	  health	  inaction.	  The	  careful	  scrutiny	  given	  to	  South	  African	  XDR-­‐TB	  by	  global	  public	  health	  experts	  profoundly	  impacted	  South	  African	  government	  responses	  to	  XDR-­‐TB	  at	  the	  national,	  provincial,	  and	  regional	  levels.	  This	  detailed,	  multifaceted	  case	  study	  of	  global	  health	  knowledge	  in-­‐the-­‐making	  is	  based	  on	  nearly	  two	  years	  of	  fieldwork	  in	  South	  African	  clinical	  and	  community	  settings	  and	  interviews	  with	  international	  and	  South	  African	  tuberculosis	  researchers,	  policy	  makers,	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clinicians,	  administrators	  and	  patients.	  Widely	  circulated	  representations	  of	  XDR-­‐TB	  are	  juxtaposed	  with	  the	  personal	  experience	  of	  South	  African	  nurses	  and	  local	  government	  administrators	  to	  make	  the	  case	  that	  responsibility	  for	  and	  control	  of	  successful	  global	  health	  interventions	  is	  more	  broadly	  distributed	  than	  common	  conceptions	  of	  global	  health	  research	  imply.	  In	  addition,	  this	  research	  uses	  published	  documents,	  unpublished	  policy	  literature,	  and	  promotional	  materials	  to	  trace	  how	  medical,	  public,	  and	  political	  understandings	  of	  XDR-­‐TB	  in	  South	  Africa	  changed	  over	  time	  and	  across	  geographical	  space.	  This	  research	  changes	  our	  understanding	  of	  the	  politics	  and	  practices	  of	  health	  interventions	  in	  Africa	  by	  linking	  together	  activities	  ranging	  from	  the	  crafting	  of	  scientific	  publication,	  to	  global	  policy	  decision	  making,	  local	  public	  resource	  allocation	  and	  in-­‐home	  nursing	  care.	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 1 
INTRODUCTION:	  Engaging	  Global	  Health	  	  “I	  have	  been	  a	  witness,	  and	  these	  pictures	  are	  my	  testimony.”-­‐James	  Nachtwey,	  photographer.	  	  On	  October	  3rd	  2008	  well-­‐renowned	  war	  photographer	  James	  Nachtwey,	  with	  help	  of	  the	  TED	  Prize	  and	  corporate	  sponsors,	  launched	  the	  website	  www.xdrtb.org.1	  The	  link	  directed	  viewers	  to	  a	  video	  slide	  show	  of	  black	  and	  white	  photographs	  Nachtwey	  had	  taken	  in	  South	  Africa,	  Cambodia,	  Swaziland,	  Thailand,	  Siberia,	  Lesotho	  and	  India.	  The	  images	  depicted	  gaunt,	  ill-­‐appearing,	  grimacing	  patients	  being	  handled	  by	  doctors	  and	  nurses	  with	  gloved	  hands,	  looked	  upon	  by	  masked	  faces,	  and	  being	  injected	  with	  long	  needles.	  Between	  images	  terse,	  all-­‐caps	  declarations	  in	  yellow	  and	  white	  lettering	  on	  a	  black	  background	  asked:	  “Tuberculosis:	  the	  next	  pandemic?”	  The	  text	  called	  attention	  to	  “XDR-­‐TB”	  or	  “extreme	  drug	  resistant	  tuberculosis,”	  for	  which	  “there	  is	  no	  reliable	  cure,”	  and	  from	  which	  “patients	  often	  die	  within	  weeks	  of	  diagnosis.”	  The	  slides	  declared	  that	  “XDR-­‐TB	  is	  a	  critical	  threat	  to	  global	  health”	  and	  called	  for	  action	  against	  the	  “extremely	  preventable”	  disease.	  The	  viewer	  needed	  to	  “Spread	  the	  story.	  Stop	  the	  disease,”	  and	  “Go	  to	  xdrtb.org	  now”	  since	  “We	  are	  the	  treatment.”	  The	  website	  provided	  links	  to	  sign	  a	  petition	  and	  to	  donate	  funds	  towards	  the	  fight	  against	  XDR-­‐TB.	  
                                                1	  XDRTB.org,	  accessed	  October	  3,	  2008,	  http://www.xdrtb.org	  .This	  domain	  has	  since	  been	  sold.	  You	  can	  still	  see	  the	  presentation	  elsewhere,	  including	  at	  Time.com.	  “Images	  of	  a	  Forgotten	  Plague,”	  Time,	  accessed	  January	  17,	  2013,	  http://content.time.com/time/video/player/0,32068,1832238880_1847043,00.html.	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Nachtwey’s	  campaign	  was	  not	  limited	  to	  the	  website	  –	  he	  contributed	  photos	  and	  essays	  to	  magazines	  and	  blogs,2	  and	  his	  photographs	  of	  tuberculosis-­‐related	  suffering	  were	  displayed	  in	  small-­‐scale	  and	  larger	  than	  life	  formats	  in	  fifty	  cities	  worldwide,	  including	  a	  projection	  on	  PR	  Newswire’s	  Reuters	  sign	  in	  New	  York’s	  Times	  Square.3	  His	  stated	  goal	  was	  to	  “create	  a	  critical	  mass	  of	  awareness	  that	  stimulates	  action.”4	  XDR-­‐TB	  –	  which	  officially	  stands	  for	  extensively	  (not	  extreme)	  drug-­‐resistant	  tuberculosis	  –	  was	  a	  new	  name	  coined	  in	  2006	  to	  describe	  a	  form	  of	  tuberculosis	  that	  was	  resistant	  to	  most	  tuberculosis	  drugs.	  The	  absence	  of	  potent	  drugs	  to	  treat	  it	  made	  it	  more	  life-­‐threatening	  than	  “regular”	  tuberculosis.	  While	  the	  name	  and	  definition	  were	  new,	  such	  cases	  of	  highly	  drug-­‐resistant	  tuberculosis	  had	  been	  documented	  at	  least	  as	  early	  as	  1997	  and	  had	  previously	  been	  included	  under	  the	  name	  multi-­‐drug	  resistant	  tuberculosis	  (or	  MDR-­‐TB),	  a	  form	  of	  tuberculosis	  resistant	  to	  at	  least	  the	  two	  most	  powerful	  anti-­‐TB	  drugs	  (isoniazid	  and	  rifampin).5	  Work	  around	  MDR-­‐TB	  had	  gained	  significant	  attention	  and	  funding	  from	  public	  and	  private	  sources	  in	  the	  late	  1990s	  and	  early	  2000s,	  but	  compared	  to	  some	  infectious	  diseases	  funding	  remained	  limited,	  and	  attention	  in	  the	  media	  and	  in	  professional	  circles	  waxed	  and	  waned.	  Research	  funding	  for	  TB-­‐specific	  programs	  increased	  from	  a	  few	  million	  dollars	  a	  year	  in	  the	  1980s	  to	  $400	  million	  in	  2005,	  of	  which	  $158	  million	  
                                                2	  James	  Nachtwey,	  “Raising	  awareness	  about	  TB,”	  The	  Blog	  (blog),	  HuffingtonPost.com,	  October	  10,	  2008,	  http://www.huffingtonpost.com/james-­‐nachtwey/raising-­‐awareness-­‐about-­‐t_b_133060.html;	  Alice	  Park,	  “The	  Forgotten	  Plague,”	  Time	  October	  2,	  2008,	  http://content.time.com/time/magazine/article/0,9171,1846717,00.html	  3	  “James	  Nachtwey	  and	  TED’s	  creative	  campaign	  to	  fight	  the	  XDR-­‐TB	  pandemic,”	  accessed	  January	  2,	  2014,	  Photowings.org,	  http://www.photowings.org/pages/index.php?pgA214.	  4	  Nachtwey,	  “Raising	  awareness	  about	  TB.”	  5	  Antonio	  Guerrero	  et	  al.,	  "Nosocomial	  Transmission	  of	  Mycobacterium	  bovis	  Resistant	  to	  11	  Drugs	  in	  People	  with	  Advanced	  HIV-­‐1	  Infection,"	  Lancet	  350	  (1997):	  1738-­‐1742;	  Paul	  A.	  Willcox,	  "Drug-­‐resistant	  Tuberculosis:	  Worldwide	  Trends,	  Problems	  Specific	  to	  Eastern	  Europe	  and	  other	  Hotspots,	  and	  the	  Threat	  to	  Developing	  Countries,"	  Current	  Opinion	  in	  Pulmonary	  Medicine	  7,	  no.	  3	  (2001):	  148-­‐153.	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came	  from	  the	  American	  National	  Institutes	  of	  Health	  (NIH).6	  By	  comparison,	  in	  2005	  the	  NIH	  alone	  spent	  $2,921	  million	  on	  HIV/AIDS	  research	  and	  allocated	  $187	  and	  $183	  million,	  respectively,	  to	  smallpox	  and	  anthrax.7	  This	  dissertation	  is	  about	  the	  discovery	  and	  naming	  of	  XDR-­‐TB,	  how	  it	  came	  to	  be	  understood	  as	  a	  “critical	  threat	  to	  global	  health,”	  and	  how	  medical,	  public	  and	  political	  concepts	  of	  XDR-­‐TB	  changed	  over	  time	  and	  across	  geographical	  space.	  It	  is	  also	  about	  the	  ways	  nurses,	  regional	  government	  agencies	  and	  global	  health	  researchers	  experienced	  first-­‐hand	  a	  disease	  that	  was	  widely	  represented	  as	  a	  global	  phenomenon.	  I	  specifically	  look	  at	  the	  ways	  XDR-­‐TB	  came	  to	  be	  associated	  with	  one	  particular	  town	  in	  South	  Africa	  and	  how	  the	  response	  to	  XDR-­‐TB	  played	  out	  there.	  This	  response	  in	  turn	  shaped	  global	  understandings	  of	  XDR-­‐TB	  as	  a	  deadly	  disease.	  When	  Nachtwey’s	  xdrtb.org	  website	  was	  launched	  in	  2008	  I	  was	  already	  documenting	  the	  efforts	  of	  researchers	  and	  public	  health	  experts	  in	  the	  US	  and	  South	  Africa	  to	  create	  and	  promote	  this	  new	  category	  of	  extensively	  drug-­‐resistant	  tuberculosis.	  XDR-­‐TB	  had	  received	  substantial	  media	  coverage	  as	  a	  deadly	  scourge	  in	  the	  years	  leading	  up	  to	  Nachtwey’s	  efforts	  to	  place	  it	  “on	  the	  radar	  screen	  in	  terms	  of	  public	  awareness.”8	  A	  global	  survey	  that	  identified	  374	  XDR-­‐TB	  isolates	  from	  reference	  laboratories	  on	  six	  continents	  was	  first	  published	  by	  the	  American	  Centers	  for	  Disease	  Control	  and	  Prevention	  (CDC)	  in	  March	  2006.	  Later	  that	  same	  year,	  international	  science	  and	  lay	  media	  coverage	  focused	  on	  one	  outbreak	  of	  XDR-­‐TB	  in	  Tugela	  Ferry,	  a	  small	  town	  in	  rural	  South	  Africa,	  where	  a	  group	  of	  researchers	  had	  uncovered	  a	  cluster	  of	  52	  deaths	  from	  XDR-­‐TB.	  One	  notable	  New	  York	  
                                                6	  Stefan	  H.	  E.	  Kaufmann	  and	  Shreemanta	  K.	  Parida,	  "Changing	  Funding	  Patterns	  in	  Tuberculosis,"	  
Nature	  Medicine	  13	  (2007):	  299-­‐303	  .	  7	  Cindra	  Feuer,	  "Tuberculosis	  Research	  and	  Development:	  A	  Critical	  Analysis,"	  	  (New	  York:	  Treatment	  Action	  Group,	  2006).	  8	  Nachtwey,	  “Raising	  Awareness	  About	  TB.”	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Times	  article	  stated	  that	  “Virulent	  TB	  in	  South	  Africa	  May	  Imperil	  Millions.”9	  In	  2007,	  the	  case	  of	  an	  American	  lawyer	  who	  traveled	  to	  Europe	  for	  his	  wedding	  despite	  warnings	  from	  the	  CDC	  that	  he	  had	  XDR-­‐TB,	  thus	  possibly	  putting	  air	  travelers	  at	  risk,	  made	  US	  headlines.10	  What	  were	  the	  particular	  circumstances	  that	  allowed	  XDR-­‐TB	  to	  become	  the	  important	  and	  compelling	  threat	  of	  those	  particular	  moments?	  Some	  diseases	  attract	  ample	  attention	  and	  funds,	  while	  other	  apparently	  worthy	  diseases	  are	  neglected,	  and	  the	  causes	  are	  not	  obvious.11	  Suffering	  and	  death	  due	  to	  hunger,	  war,	  AIDS,	  cholera	  or	  national	  disasters	  often	  make	  their	  way	  to	  our	  inboxes,	  browsers	  and	  television	  screens	  –	  yet	  they	  are	  not	  always	  (or	  even	  usually)	  coded	  in	  terms	  of	  “XDR-­‐TB.”	  Nachtwey’s	  photographs	  do	  not	  tell	  us	  who	  gave	  XDR-­‐TB	  its	  name	  or	  who	  allowed	  it	  to	  be	  understood	  as	  a	  new	  and	  dangerous	  manifestation	  of	  an	  already	  well-­‐known	  disease.	  As	  this	  dissertation	  will	  show,	  public	  health	  researchers,	  physicians,	  policy	  makers,	  journal	  editors,	  PR	  specialists,	  journalists	  and	  photographers,	  among	  others,	  employed	  exciting	  language,	  flexible	  scientific	  categories,	  and	  powerful	  emotional	  associations	  to	  create	  a	  sense	  of	  urgency	  and	  importance	  around	  XDR-­‐TB.	  This	  allowed	  them	  to	  argue	  for	  attention	  and	  funds	  both	  in	  front	  of	  experts	  and	  the	  lay	  public.	  This	  process	  was	  not	  straightforward	  or	  part	  of	  a	  well-­‐executed	  master	  plan.	  Nor	  was	  the	  process	  dishonest	  or	  devious	  –	  thousands	  of	  people	  were,	  in	  fact,	  dying	  of	  potentially	  preventable	  and	  curable	  illness.	  As	  we	  will	  see,	  the	  current	  understanding	  of	  XDR-­‐TB	  came	  together	  and	  solidified	  over	  a	  period	  of	  several	  years.	  Between	  2005	  and	  2007	  the	  name,	  abbreviation,	  definition	  and	  primary	  location	  associated	  with	  XDR-­‐TB	  all	  changed.	  The	  instability	  of	  the	  XDR-­‐TB	  
                                                9	  Michael	  Wines,	  “Virulent	  TB	  in	  South	  Africa	  May	  Imperil	  Millions,”	  The	  New	  York	  Times,	  January	  28,	  2007.	  10	  Vikki	  Valentine,	  “A	  Timeline	  of	  Andrew	  Speaker’s	  Infection,”	  NPR.org,	  http://www.npr.org/news/specials/tb/.	  11	  Jeremy	  Shiffman,	  “A	  Social	  Explanation	  for	  the	  Rise	  and	  Fall	  of	  Global	  Health	  Issues,”	  Bulletin	  of	  the	  
World	  Health	  Organization	  87	  (2009):	  608-­‐613.	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concept	  was	  part	  of	  what	  gave	  it	  power,	  however,	  as	  different	  groups	  of	  tuberculosis	  researchers,	  clinicians,	  funders	  and	  activists	  reshaped	  XDR-­‐TB	  into	  an	  entity	  which	  could	  draw	  attention	  to	  the	  particular	  challenges	  around	  tuberculosis	  that	  they	  wanted	  to	  highlight.	  Nachtwey’s	  xdrtb.org	  website	  was	  a	  rather	  explicit	  attempt	  to	  harness	  the	  power	  of	  the	  internet	  and	  its	  capacity	  to	  broadly	  distribute	  images	  to	  promote	  awareness	  of	  XDR-­‐TB.	  With	  his	  gut-­‐wrenching	  images	  of	  suffering	  in	  poor	  places,	  Nachtwey	  sought	  to	  provide	  the	  local	  “human	  face”	  to	  a	  global,	  devastating	  disease	  that	  had	  mostly	  been	  described	  in	  terms	  of	  numbers.12	  For	  Nachtwey,	  tuberculosis	  was	  a	  “merciless,	  man-­‐eating	  predator	  lurking	  in	  the	  shadows”13	  needing	  to	  be	  exposed,	  and	  he	  argued	  for	  the	  importance	  of	  the	  public’s	  attention	  to	  XDR-­‐TB:	  “Maybe	  because	  TB	  is	  a	  disease	  of	  the	  poor	  -­‐	  located	  for	  the	  most	  part	  in	  the	  developing	  world	  -­‐	  it	  gets	  overlooked.	  When	  any	  critical	  issue	  becomes	  part	  of	  our	  mass	  consciousness,	  solutions	  become	  facilitated.	  Funding,	  research,	  new	  initiatives	  -­‐	  are	  all	  necessary	  and	  happen	  much	  more	  quickly	  once	  a	  problem	  emerges	  from	  the	  shadows.”14	  Intriguingly,	  the	  language	  used	  by	  the	  photographer	  was	  not	  so	  different	  from	  that	  of	  the	  public	  health	  specialists	  who	  published	  the	  first	  studies	  on	  XDR-­‐TB.	  As	  Dr.	  Sarita	  Shah,	  the	  CDC	  officer	  who	  compiled	  the	  first	  study	  on	  XDR-­‐TB,	  explained	  to	  me,	  the	  CDC	  and	  the	  World	  Health	  Organization	  (WHO)	  first	  started	  documenting	  extensively	  drug-­‐resistant	  tuberculosis	  in	  2005	  in	  order	  to	  “bring	  attention	  and	  funds”	  to	  the	  escalating	  potential	  of	  drug	  resistance	  to	  tuberculosis.15	  She	  and	  her	  colleagues	  often	  discussed	  the	  strategies	  they	  might	  use	  to	  do	  so	  more	  effectively.	  Experts	  and	  scientists	  at	  the	  CDC	  and	  the	  WHO	  put	  their	  heads	  together	  to	  determine	  the	  most	  effective	  ways	  to	  study,	  frame,	  and	  propagate	  
                                                12	  James	  Nachtwey,	  “Take	  a	  Look	  at	  Extreme	  Drug-­‐resistant	  TB,”	  video,	  TED.com,	  accessed	  January	  15,	  2014,	  http://www.ted.com/talks/james_nachtwey_fights_xdrtb.html.	  13	  Nachtwey,	  “Raising	  Awareness	  About	  TB.”	  14	  Nachtwey,	  “Raising	  Awareness	  About	  TB.”	  15Sarita	  Shah,	  interview	  by	  author,	  phone	  interview,	  30	  March	  2007.	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information	  about	  drug-­‐resistant	  tuberculosis.	  Faced	  with	  the	  very	  real	  deaths	  from	  difficult-­‐to-­‐treat	  tuberculosis	  they	  self-­‐consciously	  used	  the	  tools	  at	  their	  disposal	  to	  seek	  resources	  to	  improve	  the	  response	  to	  the	  deadly	  disease.	  
Engaging	  global	  health	  The	  public	  health	  experts	  collecting	  health	  statistics	  on	  drug-­‐resistant	  tuberculosis	  and	  the	  documentary	  photographer	  presenting	  the	  plight	  of	  the	  sick	  in	  dispersed	  locations	  were	  both	  engaged	  in	  what	  has	  come	  to	  be	  called	  “global	  health,”	  a	  field	  that	  has	  grown	  dramatically	  over	  the	  past	  15	  years.16	  Global	  health	  can	  be	  seen	  as	  a	  field	  of	  academic	  research,	  a	  branch	  of	  philanthropy,	  a	  market	  for	  private	  enterprise,	  a	  domain	  of	  policy	  engagement,	  and	  a	  frame	  through	  which	  to	  consider	  national	  security	  threats.	  In	  an	  attempt	  to	  define	  the	  unwieldy	  thing	  that	  is	  “global	  health”	  Koplan	  et	  al.	  have	  suggested	  that	  “global	  health	  is	  an	  area	  for	  study,	  research,	  and	  practice	  that	  places	  a	  priority	  on	  improving	  health	  and	  achieving	  equity	  in	  health	  for	  all	  people	  worldwide.	  Global	  health	  emphasizes	  transnational	  health	  issues,	  determinants,	  and	  solutions;	  involves	  many	  disciplines	  within	  and	  beyond	  the	  health	  sciences	  and	  promotes	  interdisciplinary	  collaboration;	  and	  is	  a	  synthesis	  of	  population-­‐based	  prevention	  with	  individual-­‐level	  clinical	  care.”17	  Others	  have	  invoked	  a	  simpler	  definition	  of	  global	  health	  that	  primarily	  emphasizes	  a	  desire	  to	  travel	  in	  order	  to	  help	  poor	  people.	  For	  Dr.	  Patrick	  Lee,	  founding	  director	  of	  the	  Global	  Primary	  Care	  Program	  at	  Massachusetts	  General	  Hospital,	  global	  health	  is	  about	  a	  cohort	  of	  optimistic	  young	  professionals	  who	  are	  enthusiastic	  about	  “making	  a	  difference”	  in	  the	  lives	  of	  people	  less	  fortunate	  than	  themselves,	  no	  matter	  where	  they	  are	  located.18	  Anthropologist	  Betsey	  
                                                16	  Johanna	  T.	  Crane,	  “Unequal	  ‘Partners.’	  AIDS,	  Academia,	  and	  the	  Rise	  of	  Global	  Health,”	  Behemoth	  3,	  no.	  3	  (2010):	  78-­‐97.	  17	  Jeffrey	  P.	  Koplan	  et	  al.,	  “Towards	  a	  Common	  Definition	  of	  Global	  Health,”	  The	  Lancet	  373,	  no.	  9679	  (2009):	  1993–1995.	  18	  Patrick	  Lee,	  “7	  Billion	  Well,”	  video	  for	  TEDxSF,	  2012,	  accessed	  December	  15	  2012,	  http://www.youtube.com/watch?v=h-­‐piyAt_ldA&feature=youtube_gdata_player.	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Brada,	  in	  contrast,	  has	  articulately	  warned	  that	  “global	  health”	  is	  less	  a	  “thing-­‐in-­‐the-­‐world”	  than	  a	  set	  of	  arguments	  about	  the	  spatial	  and	  temporal	  configurations	  of	  power	  and	  the	  claims	  to	  expertise	  and	  moral	  action	  that	  these	  enable.19	  These	  moral	  arguments	  then	  are	  broadly	  put	  into	  practice,	  as	  many	  academic	  institutions	  across	  North	  America	  have	  recently	  made	  it	  their	  mission	  to	  attract	  and	  train	  enthusiastic	  individuals	  and	  facilitate	  global	  health	  experiences	  for	  them.20	  At	  Harvard	  University	  a	  group	  of	  global	  health	  practitioners	  has	  engaged	  in	  self-­‐conscious	  discipline	  building,	  providing	  trainees	  with	  case	  studies	  and	  a	  foundation	  in	  social	  theory	  applied	  to	  the	  new	  global	  health	  presented	  in	  the	  form	  of	  a	  textbook.21	  Successful	  global	  health	  promoters	  present	  a	  world	  that	  is	  both	  divided	  and	  interconnected.	  Abandoned,	  poor,	  sick	  people	  in	  peripheries	  require	  medical	  humanitarian	  assistance,	  and	  healthy	  people	  in	  the	  metropolis	  are	  drafted	  to	  the	  task	  of	  providing	  it	  through	  money,	  political	  pressure,	  and	  individual	  action.	  While	  Nachtwey	  relies	  on	  the	  emotional	  power	  of	  photography	  and	  the	  pulling	  of	  heartstrings	  to	  get	  this	  message	  across,	  others,	  such	  as	  Columbia	  economist	  Jeffrey	  Sachs,	  have	  made	  quantitative	  arguments	  that	  a	  financial	  investment	  in	  health	  will	  not	  only	  save	  lives	  but	  enable	  economic	  gains	  world-­‐wide.22	  Medical	  journalist	  Laurie	  Garrett	  scares	  her	  readers	  into	  action	  by	  warning	  of	  the	  security	  risks	  potentially	  caused	  by	  crumbling	  public	  health	  systems.23	  New	  York	  Times	  Columnist	  Nicholas	  Kristof	  tells	  compelling	  human	  interest	  stories	  of	  destitute	  people	  in	  far-­‐
                                                19	  Betsey	  Brada,	  “‘Not	  Here’:	  Making	  the	  Spaces	  and	  Subjects	  of	  ‘Global	  Health’	  in	  Botswana,”	  Culture,	  
Medicine,	  and	  Psychiatry	  35	  (2011):285–312.	  20	  Johanna	  T.	  Crane,	  Scrambling	  for	  Africa:	  AIDS,	  Expertise,	  and	  the	  Rise	  of	  American	  Global	  Health	  
Science	  (Ithaca:	  Cornell	  University	  Press,	  2013),	  chapter	  5.	  	  21	  Paul	  Farmer	  et	  al.	  “A	  Biosocial	  Approach	  to	  Global	  Health,”	  in	  Reimagining	  Global	  Health,	  ed.	  Paul	  Farmer,	  Jim	  Yong	  Kim,	  Arthur	  Kleinman	  and	  Matthew	  Basilico	  (Berkeley:	  University	  of	  California	  Press,	  2013).	  22	  Amir	  Attaran	  and	  Jeffrey	  Sachs,	  "Defining	  and	  Refining	  International	  Donor	  Support	  for	  Combating	  the	  AIDS	  Pandemic,"	  Lancet	  357	  no.	  9249	  (2001):	  57–61.	  "Commission	  on	  Macroeconomics	  and	  Health	  report."	  (http://www.who.int/macrohealth/background/who_hq_20Dec2001.pdf	  23	  Laurie	  Garrett,	  Betrayal	  of	  Trust:	  The	  Collapse	  of	  Global	  Public	  Health	  (Hyperion,	  2001).	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away	  places	  who	  are	  empowered	  and	  healed	  through	  “the	  right”	  humanitarian	  assistance	  (and	  provides	  links	  to	  places	  his	  readers	  can	  donate).24	  Global	  health	  advocate,	  physician	  and	  anthropologist	  Paul	  Farmer	  makes	  his	  argument	  based	  on	  political	  economy	  and	  social	  theory,	  as	  well	  as	  compelling	  personal	  vignettes.	  He	  argues	  that	  the	  structural	  violence	  expressed	  in	  the	  economic	  power	  structures	  on	  which	  the	  world	  is	  based	  makes	  his	  wealthy,	  educated	  readers	  in	  America	  and	  Europe	  directly	  liable	  and	  morally	  responsible	  for	  alleviating	  the	  suffering	  of	  the	  global	  poor	  and	  sick.25	  Global	  health	  is	  no	  straightforward	  humanitarian	  endeavor,	  but	  denotes	  a	  wide	  range	  of	  activities	  at	  the	  intersection	  between	  research,	  humanitarianism	  and	  economic	  development.	  The	  necessary	  flow	  of	  action	  and	  resources	  is	  not	  as	  unidirectional	  as	  these	  types	  of	  representations	  of	  global	  health	  might	  make	  it	  seem.	  When	  global	  health	  activities	  take	  the	  form	  of	  research	  and	  training,	  trainees	  from	  developed	  countries	  (especially	  the	  US)	  cut	  their	  teeth	  in	  under-­‐developed	  settings	  and	  benefit	  from	  the	  wealth	  of	  clinical	  material	  available	  for	  study	  and	  practice.	  Science	  studies	  scholar	  Johanna	  Crane	  argues	  that,	  in	  fact,	  the	  “awkward	  relationship	  between	  science,	  aid,	  and	  development	  is	  […]	  a	  defining	  characteristic	  of	  global	  health	  research.”26	  Nachtwey’s	  photographs	  on	  xdrtb.org	  provide	  important	  insight	  into	  the	  power	  dynamics	  that	  are	  at	  play	  when	  talking	  about	  XDR-­‐TB	  as	  a	  global	  health	  issue.	  “Global	  health”	  –	  or	  rather,	  global	  disease	  –	  is	  experienced	  primarily	  by	  the	  poor	  in	  developing	  countries,	  and	  witnessed	  by	  donors-­‐to-­‐be	  and	  powerful	  policy	  makers	  who	  are	  located	  in	  developed	  countries.	  The	  exploitative	  gaze	  mediated	  by	  the	  photographer	  is	  evident	  in	  images	  that	  expose	  the	  skin	  and	  bones	  of	  people	  who	  are	  clearly	  
                                                24	  See,	  for	  example,	  Nicholas	  Kristof,	  “Helping	  Kids	  in	  Haiti,”	  On	  The	  Ground	  (blog),	  December	  7,	  2013,	  http://kristof.blogs.nytimes.com/.	  25	  Paul	  Farmer,	  Pathologiess	  of	  Power:	  Health,	  Human	  Rights,	  and	  the	  New	  War	  on	  the	  Poor	  (Berkeley:	  University	  of	  California	  Press,	  2005).	  26	  Johanna	  T.	  Crane,	  Scrambling	  for	  Africa:	  AIDS,	  Expertise,	  and	  the	  Rise	  of	  American	  Global	  Health	  
Science	  (Ithaca:	  Cornell	  University	  Press,	  2013):	  111.	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ill.	  Many	  of	  his	  photographic	  subjects	  are	  shown	  experiencing	  the	  agony	  of	  medical	  procedures	  at	  the	  very	  moment	  the	  picture	  is	  taken.	  For	  some	  of	  them	  the	  act	  of	  breathing	  itself	  has	  become	  agonizing	  due	  to	  disease.	  Though	  the	  photographer	  employs	  this	  material	  to	  advocate	  for	  medical	  help,	  I	  wonder	  what	  choice	  patients	  had	  to	  remove	  their	  bodies	  from	  this	  particular	  exposé	  of	  global	  suffering	  and	  plea	  for	  medical	  intervention.	  Similarly,	  researchers	  and	  medical	  professionals	  engaged	  in	  global	  health	  activities	  often	  find	  themselves	  in	  a	  morally	  ambiguous	  zone,	  somewhere	  between	  extractors	  (of	  clinical	  material)	  and	  ambivalent	  saviors	  (of	  desperate	  lives).	  	  Nachtwey’s	  photographs	  depicting	  tuberculosis	  do	  not	  only	  highlight	  the	  vulnerable	  position	  of	  dying	  patients,	  but	  also	  raise	  questions	  about	  the	  health	  workers	  (including	  home	  carers,	  nurses,	  doctors,	  and	  priests)	  he	  shows	  treating	  and	  caring	  for	  people	  with	  tuberculosis.	  They	  are	  present	  in	  almost	  every	  image,	  often	  represented	  by	  gloved	  hands,	  their	  faces	  out	  of	  frame,	  covered	  by	  a	  mask,	  or	  otherwise	  obscured.	  Who	  are	  these	  sometimes	  faceless	  global	  health	  workers?	  It	  is	  not	  clear	  if	  they	  are	  courageous	  fighters	  against	  a	  global	  scourge	  or	  merely	  curators	  of	  suffering;	  props	  for	  the	  photographer,	  demarking	  the	  absence	  of	  medical	  resources	  by	  their	  presence.	  Global	  health	  workers	  at	  all	  levels	  (from	  lay	  community	  health	  workers,	  to	  fully	  trained	  nurses,	  to	  internationally	  renowned	  academic	  physicians,	  to	  world	  policy	  makers,	  with	  many	  steps	  in	  between)	  are	  crucial	  to	  allowing	  any	  kind	  of	  global	  health	  intervention	  to	  occur.	  Throughout	  this	  dissertation	  we	  encounter	  many	  of	  the	  different	  day-­‐to-­‐day	  practices	  that	  contribute	  to	  global	  health	  work.	  In	  the	  case	  of	  XDR-­‐TB	  in	  South	  Africa,	  for	  example,	  nurses	  who	  make	  home	  visits	  to	  their	  patients	  in	  order	  to	  give	  them	  regular	  injections	  of	  medication	  don’t	  only	  serve	  a	  crucial	  clinical	  function,	  but	  form	  the	  front	  line	  of	  American	  research	  on	  the	  success	  of	  community-­‐based	  tuberculosis	  treatment	  strategies.	  These	  nurses	  report	  their	  activities	  in	  tuberculosis	  registers	  and	  adverse	  event	  report	  forms	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that	  make	  their	  way	  both	  to	  government	  public	  health	  agencies	  and	  academic	  research	  offices.	  These	  nurses	  also	  constitute	  an	  innovative	  stop-­‐gap	  measure	  for	  a	  provincial	  tuberculosis	  program	  whose	  central	  tuberculosis	  hospital	  was	  completely	  overwhelmed	  by	  the	  number	  of	  drug-­‐resistant	  tuberculosis	  cases	  in	  Tugela	  Ferry.	  By	  what	  process	  do	  these	  nurses’	  and	  others’	  clinical	  and	  administrative	  experiences	  shape	  global	  health	  decisions?	  In	  what	  form	  is	  the	  pain,	  suffering,	  and	  death	  of	  a	  patient	  mediated	  to	  decision	  makers	  in	  halls	  of	  power?	  Vice	  versa,	  how	  does	  the	  priority	  setting	  and	  hand	  wringing	  over	  global	  health	  emergencies	  in	  Atlanta,	  Geneva	  or	  Seattle	  manifest	  itself	  “on	  the	  ground,”	  in	  places	  like	  Tugela	  Ferry,	  South	  Africa,	  where	  patients	  seek	  and	  experience	  care	  and	  treatment?	  Critics	  of	  global	  health	  projects	  have	  correctly	  pointed	  out	  that	  an	  important	  weakness	  of	  many	  global	  health	  programs	  is	  a	  lack	  of	  feedback	  between	  on	  the	  ground	  providers	  and	  higher	  level	  administrators	  that	  can	  lead	  to	  the	  insistent	  implementation	  of	  ineffective	  or	  even	  damaging	  programs	  that	  defy	  local	  common	  sense.	  Existing	  grant-­‐funding	  structures	  can	  lead	  organizations	  to	  veer	  away	  from	  the	  needs	  they	  find	  most	  urgent	  in	  order	  to	  fulfill	  the	  needs	  that	  they	  can	  receive	  funding	  for.	  Similarly,	  a	  focus	  on	  global	  standards	  without	  taking	  into	  account	  locally	  relevant	  information	  about	  diseases	  and	  medical	  practices	  can	  dramatically	  hamper	  programs.27	  	  In	  addition,	  Laurie	  Garrett	  and	  others	  have	  convincingly	  warned	  of	  the	  perils	  of	  implementing	  top-­‐down,	  single-­‐disease,	  time-­‐limited	  global	  health	  projects	  that	  undercut	  local	  and	  national	  public	  health	  structures	  by	  syphoning	  off	  resources	  and	  personnel	  from	  other	  health	  programs	  –	  “stove	  piping,”	  as	  Garrett	  called	  it.28	  Thus	  a	  sudden,	  exclusive	  focus	  
                                                27	  Steven	  Feierman,	  “When	  Physicians	  Meet:	  Local	  Medical	  Knowledge	  and	  Global	  Public	  Goods,”	  in	  
Evidence,	  Ethos	  and	  Experiment:	  The	  Anthropology	  and	  History	  of	  Medical	  Research	  in	  Africa,	  ed.	  Wenzel	  Geissler	  and	  Catherine	  Molyneux	  (Berghahn	  Books	  2011).	  28	  Laurie	  Garrett,	  “The	  Challenge	  of	  Global	  Health,”	  Foreign	  Affairs,	  January/February	  2007,	  http://www.foreignaffairs.com/articles/62268/laurie-­‐garrett/the-­‐challenge-­‐of-­‐global-­‐health.	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on	  TB	  and	  HIV	  specific	  interventions	  could	  potentially	  have	  unintended	  negative	  consequences	  for	  a	  health	  system	  as	  a	  whole.	  Even	  global	  health	  programs	  that	  explicitly	  pride	  themselves	  in	  working	  together	  with	  their	  academic	  and	  government	  partners	  in	  recipient	  countries	  find	  themselves	  at	  risk	  of	  undermining	  them.	  Crane	  describes	  American	  institutions	  going	  to	  great	  lengths	  to	  circumvent	  local	  bureaucratic	  structures	  in	  order	  to	  efficiently	  handle	  transnational	  financial	  transfers,	  local	  hiring,	  and	  tax	  issues,	  and	  argues	  that	  the	  building	  of	  outside	  structures	  in	  global	  health	  is	  common	  practice,	  because	  local	  structures	  are	  seen	  as	  “too	  difficult”	  to	  deal	  with.29	  This	  avoidance	  of	  bureaucratic	  barriers	  is	  no	  neutral	  work-­‐around,	  however.	  To	  quote	  Elise	  Carpenter’s	  work	  on	  HIV	  treatment	  in	  Botswana:	  “Barriers	  are	  called	  bureaucracy,	  success	  is	  called	  partnership.	  This	  effectively	  negates	  the	  contributions	  of	  [Batswana]	  government	  bureaucrats.”30	  This	  also	  assumes	  that	  bureaucratic	  blockages	  have	  no	  possible	  merit,	  but	  are	  at	  best	  mechanical	  or	  technocratic,	  arising	  from	  disorganization	  or	  provincial	  outlook,	  rather	  than	  a	  legitimate	  attempt	  on	  the	  part	  of	  recipient	  countries	  to	  regulate	  global	  health	  activities.	  At	  worst,	  local	  governments	  are	  accused	  of	  blatant	  mismanagement,	  nepotism,	  obstructionism,	  ignorance,	  and	  unhelpful	  efforts	  to	  avoid	  embarrassment	  when	  they	  do	  not	  rapidly	  facilitate	  global	  health	  engagement.	  Again,	  Nachtwey’s	  xdrtb.org	  photo	  series	  is	  informative:	  Nachtwey	  apparently	  kept	  the	  true	  nature	  of	  his	  project	  secret	  from	  the	  governments	  whose	  citizens	  he	  photographed	  until	  the	  launch	  of	  xdrtb.org	  in	  order	  to	  side-­‐step	  potential	  government	  objections	  to	  bringing	  the	  images	  of	  tuberculosis	  patients	  directly	  to	  potential	  donors.31	  	  	  	  
                                                29	  Crane,	  Scrambling	  for	  Africa,	  164.	  30	  Elise	  Carpenter,	  quoted	  in	  Crane,	  Scrambling	  for	  Africa,	  164.	  31	  See	  Ethan	  Zuckerman,	  “Putting	  a	  Face	  on	  XDR-­‐TB,”	  My	  Heart’s	  in	  Accra	  (blog),	  October	  3,	  2008,	  http://www.ethanzuckerman.com/blog/2008/10/03/putting-­‐a-­‐face-­‐on-­‐xdr-­‐tb/.	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As	  we	  will	  see,	  the	  government	  of	  South	  Africa,	  in	  particular,	  has	  been	  heavily	  and	  appropriately	  criticized	  by	  international	  global	  health	  experts	  and	  South	  African	  civil	  society	  for	  its	  active	  opposition	  to	  attempts	  to	  bring	  treatment	  for	  HIV/AIDS	  to	  South	  Africa	  before	  2003.32	  Thus,	  when	  an	  outbreak	  of	  XDR-­‐TB	  among	  South	  African	  HIV/AIDS	  patients	  in	  rural	  Tugela	  Ferry	  was	  first	  reported	  in	  2006,	  a	  readily	  available	  narrative	  was	  that	  international	  researchers	  and	  policy	  makers,	  with	  the	  help	  of	  South	  African	  partners,	  were	  doing	  their	  best	  to	  contain	  this	  outbreak,	  despite	  the	  indifference	  or	  blockage	  of	  South	  African	  government	  health	  agencies.33	  This	  was	  not	  just	  the	  narrative	  constructed	  by	  outside	  journalists.	  When	  I	  first	  interviewed	  South	  African	  TB	  clinicians	  and	  researchers	  in	  2007,	  they	  expressed	  profound	  frustration	  about	  their	  government’s	  slow	  response	  to	  the	  XDR-­‐TB	  problem,	  and	  were	  concerned	  that	  the	  international	  contributions	  to	  XDR-­‐TB	  research	  and	  management	  would	  not	  be	  enough.	  As	  events	  unfolded,	  however,	  it	  became	  increasingly	  clear	  that	  South	  African	  authorities,	  especially	  regional	  and	  provincial	  health	  administrators,	  engaged	  extensively	  with	  the	  XDR-­‐TB	  problem	  and	  contributed	  in	  positive	  ways	  to	  the	  management	  of	  drug-­‐resistant	  tuberculosis	  by	  providing	  funds,	  material	  resources,	  human	  resources,	  and	  policy	  support,	  sometimes	  pre-­‐empting	  international	  recommendations	  or	  the	  needs	  of	  international	  researchers.	  This	  did	  not	  mean,	  however,	  that	  South	  African	  government	  bureaucrats	  always	  aligned	  themselves	  with	  international	  XDR-­‐TB	  researchers	  or	  outside	  health	  policy	  consultants.	  Just	  how	  to	  best	  respond	  to	  XDR-­‐TB	  in	  South	  Africa	  was	  an	  open	  question,	  and	  from	  the	  perspective	  of	  South	  African	  government	  employees	  it	  was	  not	  clear	  that	  the	  expertise	  in	  this	  regard	  lay	  entirely	  with	  the	  outside	  experts.	  As	  we	  will	  see	  in	  the	  second	  half	  of	  this	  dissertation,	  local	  public	  health	  
                                                32	  “The	  Durban	  Declaration,”	  Nature	  406,	  no.	  6791	  (2000):	  15-­‐16;	  Kerry	  Cullinan	  and	  Anso	  Thom,	  The	  
Virus,	  Vitamins	  &	  Vegetables:	  The	  South	  African	  HIV/AIDS	  Mystery	  (Jacana	  Media,	  2010);	  Nicoli	  Nattrass,	  Mortal	  Combat:	  AIDS	  Denialism	  and	  the	  Struggle	  for	  Antiretrovirals	  in	  South	  Africa	  (University	  of	  KwaZulu-­‐Natal	  Press,	  2007).	  33	  See	  for	  example	  Wines,	  “Virulent	  TB	  in	  South	  Africa	  May	  Imperil	  Millions.”	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authorities	  were	  not	  exclusively	  obstructionist,	  but	  often	  sought	  creative,	  though	  at	  times	  stubborn	  ways	  to	  interact	  with	  outside	  researchers	  and	  authorities	  that	  could	  simultaneously	  push	  forward	  efforts	  to	  fight	  XDR-­‐TB	  and	  help	  them	  assert	  their	  authority	  over	  and	  independence	  from	  the	  regime	  of	  global	  health	  experts.	  
Dealing	  with	  absences	  and	  presences	  –	  where	  is	  health	  global?	  Global	  health	  research	  is	  often	  described	  in	  terms	  of	  absences	  and	  limitations.	  A	  key	  “problem”	  of	  global	  health	  research	  is	  how	  to	  provide	  good	  medicine	  and	  how	  to	  conduct	  good	  research	  in	  “resource-­‐limited,”	  or	  “resource-­‐poor”	  settings.	  These	  and	  related	  terms	  are	  frequently	  used	  in	  scientific	  papers,	  policy	  reports,	  and	  promotional	  materials	  to	  denote	  the	  places	  of	  lack	  where	  “global	  health”	  is	  done.	  A	  place	  completely	  devoid	  of	  medical,	  intellectual,	  and	  infrastructural	  resources,	  however,	  is	  not	  a	  site	  where	  global	  health	  knowledge	  can	  be	  generated.	  Biomedical	  scientists	  need	  laboratory	  infrastructure;	  epidemiologists	  require	  trained	  technicians	  who	  can	  conduct	  surveys	  and	  compile	  data;	  doctors	  need	  nurses,	  pharmacists	  (with	  stocked	  pharmacies),	  laboratory	  specialists	  and	  clerical	  staff	  to	  function	  effectively.	  While	  some	  global	  health	  projects	  have	  attempted	  to	  build	  most	  of	  the	  infrastructure	  and	  logistics	  required	  for	  their	  research	  and	  activities	  from	  scratch,	  most	  have	  not,	  as	  this	  is	  an	  expensive,	  time-­‐consuming	  undertaking	  which	  requires	  expertise	  and	  influence.	  Instead,	  global	  health	  researchers	  tend	  to	  place	  their	  studies	  in	  areas	  where	  they	  already	  have	  personal	  and	  professional	  connections	  and	  that	  already	  have	  key	  resources	  in	  place,	  though	  these	  may	  need	  to	  be	  substantially	  expanded.	  Often,	  internationally	  funded	  research	  projects	  cluster	  around	  academic	  institutions	  in	  mostly	  urban	  locations	  that	  have	  invested	  in	  laboratory	  infrastructure.	  Over	  time,	  crowded	  researchers	  may	  start	  looking	  to	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more	  remote	  locations,	  but	  they	  often	  still	  rely	  on	  the	  connections	  and	  infrastructure	  of	  the	  city.34	   When	  international	  AIDS	  funding	  expanded	  towards	  the	  end	  of	  the	  20th	  century,	  American	  biomedical	  researchers	  built	  on	  past	  relationships	  with	  established	  institutions	  in	  countries	  across	  Africa	  to	  initiate	  new	  HIV/AIDS	  research.	  South	  Africa	  was	  a	  particularly	  convenient	  country	  for	  global	  health	  work	  by	  Americans	  and	  Europeans	  because	  it	  combines	  high	  rates	  of	  HIV/AIDS	  and	  poverty	  with	  well-­‐developed	  infrastructure	  for	  higher	  education	  and	  medical	  services,	  including	  modern	  laboratories,	  and	  a	  relatively	  large	  educated	  elite	  that	  can	  hold	  its	  own	  in	  international	  settings.	  Although	  South	  Africa	  has	  eleven	  official	  languages,	  English	  is	  the	  most	  commonly	  used	  language	  in	  the	  country,	  and	  local	  doctors,	  nurses	  and	  biomedical	  researchers	  are	  proficient	  in	  English,	  even	  if	  their	  patients	  are	  not.	  Visitors	  to	  South	  Africa	  do	  not	  need	  to	  suffer	  major	  deprivations,	  as	  basic	  infrastructure	  (such	  as	  clean	  water,	  electricity,	  rental	  cars,	  hotels,	  etc.)	  is	  available	  in	  the	  cities,	  and	  is	  usually	  within	  reach	  even	  in	  more	  remote	  areas.	  The	  locally	  specific	  process	  through	  which	  research	  sites	  have	  arisen	  means	  that	  certain	  types	  of	  global	  health	  knowledge	  have	  become	  associated	  with	  certain	  places	  and	  certain	  research	  networks	  and	  institutional	  sponsors.	  The	  location	  most	  closely	  associated	  with	  XDR-­‐TB	  on	  the	  global	  health	  map	  is	  the	  Church	  of	  Scotland	  Hospital	  (COSH)	  in	  the	  rural	  town	  of	  Tugela	  Ferry,	  South	  Africa,	  which	  made	  international	  headlines	  in	  2006	  as	  the	  center	  of	  a	  deadly	  outbreak	  of	  XDR-­‐TB.	  	  When	  researchers	  affiliated	  with	  Yale	  University	  presented	  news	  of	  Tugela	  Ferry’s	  XDR-­‐TB	  outbreak	  at	  the	  2006	  International	  AIDS	  
                                                34	  This	  claim	  is	  based	  primarily	  on	  the	  author’s	  long-­‐term	  experience	  conducting	  and	  studying	  HIV/AIDS	  research	  in	  South	  Africa.	  Similar	  examples	  in	  Ugandan	  HIV/AIDS	  research	  are	  described	  by	  Johanna	  Crane,	  whose	  subject	  (and	  employer)	  Jason	  Biehl	  moves	  from	  city	  to	  countryside	  to	  escape	  a	  crowded	  research	  landscape	  (Crane,	  Scrambling	  for	  Africa).	  In	  addition,	  Betsy	  Brada	  describes	  a	  type	  of	  global	  health	  one-­‐upmanship	  which	  leads	  global	  health	  trainees	  to	  push	  “out	  into	  smaller	  hospitals,	  clinics,	  villages,	  and	  homes	  [...]	  to	  make	  reality	  match	  fantasy”	  of	  remote,	  destitute,	  resource	  poor	  locations,	  no	  matter	  what	  the	  danger	  (Brada,	  “Not	  Here,”	  307).	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Conference,	  it	  created	  a	  minor	  media	  frenzy,	  with	  public	  health	  experts	  wondering	  out	  loud	  what	  this	  meant	  for	  the	  continental	  and	  global	  spread	  of	  an	  apparently	  aggressive	  and	  highly	  deadly	  strain	  of	  seemingly	  untreatable	  tuberculosis.	  In	  the	  aftermath,	  anti-­‐tuberculosis	  efforts	  in	  Tugela	  Ferry	  and	  the	  surrounding	  region	  were	  reassessed	  and	  revamped.	  Tuberculosis	  programs	  in	  other	  countries	  looked	  to	  South	  Africa,	  both	  as	  a	  warning	  for	  what	  could	  go	  wrong,	  and	  as	  a	  model	  for	  addressing	  XDR-­‐TB	  once	  it	  had	  made	  itself	  known.	  The	  first	  scientific	  reports	  of	  XDR-­‐TB	  had	  not	  mentioned	  South	  Africa	  at	  all.35	  Now,	  XDR-­‐TB	  came	  to	  be	  popularly	  (though	  incorrectly)	  understood	  as	  a	  deadly	  South	  African	  disease	  that	  had	  specifically	  emerged	  from	  the	  small	  town	  of	  Tugela	  Ferry.36	  	  For	  public	  health	  experts	  Tugela	  Ferry	  became	  synonymous	  with	  XDR-­‐TB,	  and	  some	  scientific	  and	  news	  articles	  incorrectly	  referred	  to	  Tugela	  Ferry	  as	  the	  original	  source	  of	  XDR-­‐TB.	  Not	  surprisingly,	  it	  is	  one	  of	  the	  places	  featured	  in	  Nachtwey’s	  2008	  photo-­‐series	  on	  XDR-­‐TB.	  It	  is	  also	  one	  of	  the	  main	  locations	  featured	  in	  this	  dissertation.	  The	  central	  importance	  of	  Tugela	  Ferry	  to	  the	  story	  of	  XDR-­‐TB	  cannot	  be	  taken	  for	  granted.	  Throughout	  this	  dissertation	  I	  consider	  the	  scientific,	  political	  and	  epidemiological	  processes	  that	  put	  Tugela	  Ferry	  in	  the	  frame	  as	  the	  epicenter	  for	  XDR-­‐TB.	  I	  also	  consider	  Tugela	  Ferry	  as	  an	  ideal	  global	  health	  location	  that	  is	  simultaneously	  poor	  and	  remote,	  as	  well	  as	  well-­‐resourced	  and	  well-­‐connected.	  Tugela	  Ferry	  is	  located	  in	  the	  administrative	  district	  of	  Msinga,	  one	  of	  the	  poorest	  districts	  in	  South	  Africa,	  and	  is	  notable	  for	  poor	  basic	  infrastructure,	  high	  illiteracy	  and	  unemployment	  rates,	  as	  well	  as	  a	  history	  of	  violence	  related	  to	  faction-­‐fighting	  and	  crime.	  According	  to	  the	  Statistics	  South	  Africa	  2007	  community	  survey,	  only	  an	  estimated	  2.2%	  of	  the	  population	  in	  the	  district	  in	  which	  Tugela	  
                                                35	  Abigail	  Wright	  et	  al.,	  “Emergence	  of	  Mycobacterium	  Tuberculosis	  with	  Extensive	  Resistance	  to	  Second-­‐Line	  Drugs	  -­‐	  Worldwide,	  2000-­‐2004,”	  Morbidity	  and	  Mortality	  Weekly	  Report	  55,	  no.	  11	  (2006):	  301–305.	  36	  See,	  for	  example,	  Evelyn	  Leopold,	  "Deadly	  TB	  Strain	  Seen	  in	  Africa	  Now	  in	  Rich	  Nations,"	  Reuters,	  http://www.reuters.com/article/healthNews/idUSN225535720070323.	  
 16 
Ferry	  is	  located	  has	  access	  to	  piped	  water	  in	  their	  dwellings	  or	  yards,	  and	  about	  50%	  get	  water	  from	  open	  rivers	  or	  streams.	  (It	  is	  estimated	  that	  less	  than	  10%	  of	  the	  population	  has	  access	  to	  consistently	  clean,	  potable	  water.)	  Similarly,	  48.9%	  of	  households	  have	  no	  provision	  for	  sanitation,	  while	  38.8%	  have	  either	  pit	  latrines	  or	  dry	  toilet	  facilities.	  Only	  12.8%	  of	  the	  population	  has	  access	  to	  electricity,	  and	  there	  is	  no	  formal	  system	  for	  refuse	  removal.	  In	  addition,	  adult	  illiteracy	  in	  the	  region	  is	  high	  at	  68%.	  The	  housing	  stock	  in	  the	  region	  is	  poor,	  leading	  to	  overcrowding	  in	  inadequate	  housing,	  and	  there	  is	  an	  acute	  shortage	  of	  rental	  housing	  in	  Tugela	  Ferry	  for	  people	  who	  come	  to	  the	  town	  from	  outlying	  areas	  for	  work.37	  At	  the	  same	  time,	  the	  Church	  of	  Scotland	  Hospital,	  which	  is	  the	  district	  hospital	  located	  in	  Tugela	  Ferry,	  provides	  basic	  medical	  services	  around	  the	  clock,	  in	  addition	  to	  referrals	  to	  a	  network	  of	  higher-­‐level	  hospitals	  that	  in	  some	  instances	  are	  able	  to	  provide	  high-­‐technology	  “first-­‐world”	  medicine.	  The	  area	  is	  less	  than	  two	  hours	  drive	  from	  the	  provincial	  capital	  of	  Pietermaritzburg,	  and	  less	  than	  3	  hours	  drive	  from	  Durban,	  which	  is	  arguably	  the	  third-­‐largest	  city	  of	  South	  Africa,	  and	  center	  to	  many	  laboratories	  and	  internationally	  renowned	  academic	  resources	  around	  HIV/AIDS	  and	  tuberculosis.	  Tugela	  Ferry	  is	  often	  neglected	  on	  South	  African	  maps,	  which	  have	  historically	  under-­‐charted	  the	  areas	  where	  black	  South	  Africans	  lived.	  A	  Zulu	  outreach	  worker	  at	  a	  Christian	  mission	  in	  Tugela	  Ferry	  once	  told	  me	  how	  proud	  she	  was	  to	  host	  numerous	  missionaries	  each	  year	  from	  other	  parts	  of	  South	  Africa	  as	  well	  as	  from	  overseas	  (including	  several	  from	  Germany,	  the	  Netherlands	  and	  the	  US).	  She	  was	  delighted	  because	  even	  though	  Tugela	  Ferry	  was	  so	  small	  that	  it	  wasn’t	  on	  her	  physical	  map,	  the	  visitors	  knew	  how	  to	  find	  her	  because	  Tugela	  Ferry	  was	  on	  God’s	  map.	  
                                                37	  Msinga	  Municipality	  Integrated	  Development	  Plan,	  2012	  (Msinga	  Municipality,	  2012),	  accessed	  at	  http://devplan.kzntl.gov.za/idp_reviewed_2012_13/IDPS/KZ244/Adopted/MSINGA%20MUNICIPALITY%20%20INTEGRATED%20DEVELOPMENT%20PLAN%202012.pdf	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Tugela	  Ferry	  has	  also	  been	  a	  location	  on	  the	  global	  health	  map	  for	  some	  time,	  even	  before	  the	  discovery	  of	  XDR-­‐TB.	  In	  fact,	  international	  (non-­‐South	  African)	  medical	  professionals	  (especially	  medical	  missionaries)	  have	  been	  instrumental	  in	  assessing	  and	  treating	  patients	  at	  the	  Church	  of	  Scotland	  Hospital	  since	  its	  founding	  as	  a	  mission	  hospital	  in	  the	  1920s.38	  Since	  the	  early	  2000s,	  however,	  the	  influx	  of	  a	  mostly	  secular	  international	  presence	  has	  accelerated,	  as	  dozens	  of	  Americans	  and	  other	  non-­‐South	  African	  citizens	  have	  come	  through	  Tugela	  Ferry	  for	  periods	  lasting	  from	  days	  to	  years	  in	  order	  to	  in	  some	  way	  be	  part	  of	  the	  research	  and	  care	  endeavor	  around	  HIV	  and	  TB	  which	  has	  developed	  in	  Tugela	  Ferry.	  
A	  global	  health	  site	  Photographer	  James	  Nachtwey	  first	  visited	  Tugela	  Ferry	  in	  2000	  (8	  years	  before	  returning	  to	  photograph	  XDR-­‐TB)	  to	  take	  photographs	  of	  AIDS	  in	  Africa	  for	  Time	  magazine.	  He	  delivered	  devastating	  images	  of	  people	  who	  were	  close	  to	  death.	  The	  accompanying	  article	  by	  Johanna	  Mcgeary,	  which	  was	  dramatically	  titled	  “Death	  stalks	  a	  Continent,”	  painted	  a	  depressing	  picture	  of	  deprivation,	  despair,	  disease	  and	  ignorance	  across	  the	  continent,	  including	  in	  Tugela	  Ferry.	  She	  also	  featured	  the	  hopeful	  work	  of	  Tugela	  Ferry	  based	  physician	  Dr.	  Anthony	  Moll,	  who	  had	  started	  a	  home	  based	  care	  program	  and	  hospice	  to	  help	  the	  many	  people	  in	  the	  region	  who	  were	  dying	  of	  AIDS.39	  The	  article	  had	  a	  broad	  audience,	  and	  Dr.	  Moll	  anonymously	  came	  to	  stand	  in	  for	  all	  frustrated	  health	  workers	  in	  Africa	  when	  the	  Time	  article	  was	  quoted	  by	  American	  President	  George	  Bush	  in	  his	  2003	  State	  of	  the	  Union	  address:	  “A	  doctor	  in	  rural	  South	  Africa	  describes	  his	  frustration.	  He	  says,	  “We	  have	  no	  medicines,	  many	  hospitals	  tell	  people,	  
                                                38	  It	  has	  been	  a	  government	  hospital,	  not	  affiliated	  with	  any	  church,	  since	  the	  1970s.	  39	  Johanna	  Mcgeary,	  “Death	  Stalks	  A	  Continent,”	  Time,	  February	  12,	  2001,	  http://www.time.com/time/magazine/article/0,9171,999190,00.html.	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‘You've	  got	  AIDS.	  We	  can't	  help	  you.	  Go	  home	  and	  die.’”40	  President	  Bush	  went	  on	  to	  state	  that	  “In	  an	  age	  of	  miraculous	  medicines,	  no	  person	  should	  have	  to	  hear	  those	  words,”41	  and	  announced	  his	  Presidential	  Emergency	  Plan	  for	  AIDS	  Relief	  (PEPFAR),	  which	  would	  provide	  billions	  of	  dollars	  for	  AIDS	  programs	  in	  fifteen	  countries,	  including	  South	  Africa.42	  Dr.	  Moll’s	  compassionate,	  clinical,	  and	  scientific	  work	  is	  heavily	  featured	  in	  this	  dissertation.	  A	  white	  Southern	  African	  who	  had	  studied	  medicine	  in	  Stellenbosch,	  he	  had	  moved	  to	  Tugela	  Ferry	  in	  the	  1980s	  in	  order	  to	  do	  God’s	  work	  with	  other	  Christian	  colleagues,	  serving	  the	  rural	  Zulu	  population	  of	  the	  KwaZulu	  homeland.	  When	  AIDS	  hit	  the	  region	  in	  the	  1990s	  he	  stepped	  up	  to	  the	  plate	  for	  his	  patients	  and	  sought	  help	  from	  programs	  in	  Durban	  and	  elsewhere.	  Through	  these	  efforts,	  Dr.	  Moll	  became	  connected	  to	  national	  and	  international	  biomedical	  research	  networks.	  By	  2003,	  he	  was	  collaborating	  with	  American	  physician	  and	  researcher	  Dr.	  Gerald	  Friedland	  from	  Yale	  University	  in	  order	  to	  provide	  life-­‐saving	  medication	  to	  a	  subset	  of	  his	  AIDS	  and	  tuberculosis	  patients	  in	  Tugela	  Ferry.	  Eventually,	  patients	  in	  Tugela	  Ferry	  and	  the	  region	  would	  in	  fact	  benefit	  from	  American	  PEPFAR	  funding,	  as	  well.	  Dr.	  Moll	  was	  one	  of	  the	  first	  physicians	  in	  the	  region	  to	  treat	  a	  cohort	  of	  patients	  from	  a	  public	  hospital	  with	  HIV	  medications,	  and	  people	  sometimes	  came	  from	  afar	  to	  see	  his	  ground-­‐breaking	  program	  in	  action.	  I	  myself	  first	  met	  Dr.	  Moll	  in	  2004	  when	  I	  was	  spending	  a	  year	  after	  my	  BA	  degree	  in	  Durban,	  South	  Africa	  as	  a	  Fulbright	  scholar	  working	  at	  another	  pioneering	  HIV	  treatment	  program	  in	  the	  city.	  I	  joined	  two	  English	  medical	  students	  to	  travel	  to	  Tugela	  Ferry	  for	  a	  day	  to	  see	  what	  a	  rural	  South	  African	  hospital	  looked	  like.	  Dr.	  Moll	  was	  generous	  with	  his	  time	  and	  allowed	  me	  to	  shadow	  him	  as	  he	  saw	  HIV	  patients,	  and	  he	  showed	  me	  the	  room	  where	  patients	  sat	  
                                                40	  George	  W.	  Bush,	  “Transcript	  of	  State	  of	  the	  Union,	  Part	  5:	  Compassion,”	  CNN.com,	  January	  29	  2003,	  http://www.cnn.com/2003/ALLPOLITICS/01/28/sotu.transcript.5/index.html.	  41	  George	  W.	  Bush,	  “Transcript	  of	  State	  of	  the	  Union,	  Part	  5:	  Compassion,”	  CNN.com,	  January	  29	  2003,	  http://www.cnn.com/2003/ALLPOLITICS/01/28/sotu.transcript.5/index.html.	  42	  Ibid.	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together	  making	  calendars	  for	  the	  coming	  month,	  stapling	  packets	  of	  daily	  pill	  doses	  to	  a	  paper	  calendar	  in	  order	  to	  help	  them	  remember	  when	  to	  take	  their	  medicines.	  The	  lively	  chatter	  and	  active	  participation	  of	  patients,	  nurses,	  and	  HIV	  counselors	  in	  this	  new	  and	  life-­‐saving	  program	  was	  inspiring	  to	  me.	  At	  that	  time,	  any	  effort	  to	  provide	  rural	  South	  Africans	  with	  HIV	  medications	  could	  be	  seen	  as	  revolutionary.	  Later,	  it	  was	  through	  this	  ongoing	  program	  and	  Dr.	  Moll’s	  collaboration	  with	  Dr.	  Friedland	  that	  high	  rates	  of	  tuberculosis	  drug	  resistance	  in	  Tugela	  Ferry	  eventually	  came	  to	  be	  discovered	  in	  2005	  and	  internationally	  known	  in	  2006,	  featured	  at	  conferences	  and	  publications	  as	  a	  deadly	  disease	  with	  global	  significance.	  
Local	  outbreak	  as	  global	  phenomenon	  	   In	  Tugela	  Ferry,	  XDR-­‐TB	  was	  simultaneously	  experienced	  as	  a	  local	  outbreak	  and	  personal	  tragedy	  as	  well	  as	  a	  global	  phenomenon	  whose	  significance	  went	  well	  beyond	  the	  lives	  of	  the	  people	  in	  the	  region	  immediately	  affected	  by	  the	  disease.	  This	  dissertation	  traces	  how	  a	  particular	  disease	  –	  extensively	  drug-­‐resistant	  tuberculosis	  	  –	  in	  a	  particular	  place	  –	  Tugela	  Ferry,	  South	  Africa	  –	  was	  converted	  from	  a	  non-­‐entity	  to	  a	  local	  health	  problem	  and	  then	  to	  an	  emergent	  global	  health	  problem.	  How	  should	  we	  understand	  the	  relationship	  between	  transnational	  global	  health	  expertise	  (CDC/WHO),	  American	  academia	  (Yale),	  provincial	  public	  health	  programs	  (South	  Africa)	  and	  the	  patients	  who	  came	  to	  the	  hospital	  in	  Tugela	  Ferry	  for	  care	  and	  ended	  up	  as	  a	  data	  point	  in	  globally	  distributed	  statistics?	  While	  the	  first	  half	  of	  this	  dissertation	  outlines	  the	  role	  of	  global	  experts	  in	  creating	  XDR-­‐TB	  as	  a	  new	  entity,	  the	  second	  half	  focuses	  on	  the	  role	  that	  the	  small	  town	  of	  Tugela	  Ferry	  played	  in	  bringing	  tuberculosis	  to	  global	  attention.	  I	  highlight	  the	  role	  of	  South	  African	  doctors,	  nurses,	  and	  government	  officials	  in	  generating	  and	  enabling	  responses,	  both	  locally	  and	  globally,	  to	  XDR-­‐TB,	  often	  in	  concert	  with	  an	  expansive	  group	  of	  “international”	  health	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workers	  (many	  of	  whom	  were	  American)	  who	  came	  to	  Tugela	  Ferry	  as	  researchers,	  clinicians,	  and	  trainees.	  	  XDR-­‐TB	  as	  global	  health	  phenomenon	  is	  a	  multi-­‐headed	  beast	  located	  everywhere	  and	  nowhere	  at	  once.	  The	  power	  to	  name,	  define	  and	  promote	  XDR-­‐TB	  as	  an	  important	  policy	  issue	  did	  not	  lie	  with	  any	  one	  person	  or	  agency,	  and	  tuberculosis	  experts	  were	  not	  unanimous	  about	  the	  new	  disease	  name’s	  significance	  or	  usefulness.	  Similarly,	  the	  power	  to	  act	  against	  XDR-­‐TB	  in	  Tugela	  Ferry	  was	  unevenly	  but	  broadly	  distributed.	  Many	  narratives	  about	  XDR-­‐TB	  in	  South	  Africa	  emphasize	  the	  role	  of	  American	  doctors	  and	  researchers	  fighting	  a	  deadly	  disease	  against	  the	  odds	  of	  poor	  health	  infrastructure	  and	  languishing	  bureaucracy,	  or	  highlight	  the	  role	  of	  heroic	  South	  African	  individuals	  such	  as	  Dr.	  Moll	  who	  continued	  to	  heal	  the	  sick	  despite	  poverty	  and	  a	  lack	  of	  resources.	  I	  partially	  echo	  such	  narratives	  as	  I	  tell	  the	  origin	  story	  of	  XDR-­‐TB	  research	  in	  Tugela	  Ferry	  based	  on	  accounts	  of	  American	  and	  South	  African	  researchers	  who	  were	  directly	  involved	  in	  it.	  At	  the	  same	  time,	  I	  try	  to	  tell	  a	  more	  nuanced	  story	  that	  acknowledges	  that	  the	  locus	  of	  control	  and	  action	  is	  not	  always	  where	  it	  seems.	  XDR-­‐TB	  came	  to	  light	  in	  the	  context	  of	  a	  AIDS	  research	  collaboration	  whose	  funds	  initially	  came	  from	  American	  charitable	  and	  research	  sources,	  as	  did	  the	  expertise	  required	  to	  administer	  and	  study	  life-­‐saving	  AIDS	  medications.	  Many	  of	  the	  resources	  used	  to	  discover	  and	  treat	  XDR-­‐TB	  in	  Tugela	  Ferry,	  however,	  were	  provided	  directly	  or	  indirectly	  from	  South	  African	  government	  sources.	  This	  included	  medications	  and	  laboratory	  tests	  for	  tuberculosis,	  physical	  government	  clinic	  and	  hospital	  facilities	  where	  patients	  were	  seen	  and	  recruited,	  as	  well	  as	  some	  of	  the	  nurses	  and	  vehicles	  used	  for	  visiting	  patients	  in	  their	  homes.	  Similarly,	  while	  international	  researchers	  provided	  much	  of	  the	  intellectual	  motivation	  for	  work	  on	  XDR-­‐TB	  they	  relied	  on	  the	  significant	  expertise,	  hands-­‐on	  work,	  and	  emotional	  investment	  of	  nurses,	  community	  health	  workers,	  public	  school	  teachers,	  and	  local	  authorities	  to	  help	  identify	  and	  treat	  XDR-­‐
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TB	  patients.	  By	  drawing	  on	  interviews	  with	  nurses,	  tuberculosis	  research	  assistants,	  local	  government	  administrators	  and	  bureaucrats,	  as	  well	  as	  my	  experiences	  living	  and	  researching	  in	  Tugela	  Ferry	  and	  Durban	  I	  expand	  that	  global	  health	  narrative	  to	  include	  people	  who	  are	  not	  as	  actively	  involved	  in	  publication	  and	  promotion.	  The	  relatively	  small	  group	  of	  academics	  conducting	  work	  from	  abroad	  was	  not	  in	  the	  position	  to	  put	  in	  place	  an	  entire	  health	  system	  for	  people	  in	  the	  Tugela	  Ferry	  region	  suffering	  from	  these	  infectious	  diseases,	  nor	  did	  they	  intend	  to.	  The	  region	  already	  had	  a	  (flawed)	  public	  tuberculosis	  diagnosis	  and	  treatment	  infrastructure	  in	  place,	  and	  it	  was	  this	  infrastructure	  which	  was	  built	  upon	  and	  expanded,	  under	  the	  authority	  of	  regional	  and	  provincial	  government,	  with	  expert	  input	  of	  visiting	  Americans,	  but	  also	  with	  considerable	  South	  African	  expert	  and	  administrative	  involvement.	  American	  researchers	  continued	  to	  study	  and	  support	  new	  strategies	  tuberculosis	  management	  in	  Tugela	  Ferry	  and	  the	  surrounding	  region,	  but	  new	  tuberculosis	  treatment	  programs	  had	  to	  be	  actively	  supported	  by	  government	  bureaucrats	  and	  coffers	  to	  be	  successful.	  Local	  government	  agencies	  rightly	  wondered	  how	  to	  reassert	  administrative	  and	  programmatic	  control	  over	  hospital	  clinicians	  who	  were	  using	  South	  African	  government	  resources	  not	  only	  for	  clinical	  care	  but	  also	  for	  American-­‐driven	  research.	  Tuberculosis	  researchers	  and	  practitioners	  found	  different	  ways	  to	  come	  to	  terms	  with	  these	  conflicting	  narratives	  as	  they	  sought	  to	  understand	  the	  origins	  and	  meaning	  of	  XDR-­‐TB	  in	  South	  Africa	  and	  globally.	  
How	  to	  study	  this	  multi-­‐headed	  beast	  In	  recent	  years	  anthropologists,	  historians,	  and	  science	  studies	  scholars	  have	  written	  nuanced	  accounts	  of	  global	  health	  in	  action	  from	  multiple	  perspectives,	  including	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those	  of	  patients,43	  doctors	  and	  nurses,44	  scientists,45	  research	  assistants,46	  program	  directors	  and	  policy	  makers,47	  clinical	  trial	  participants,48	  health	  activists,49	  and	  medical	  students50	  among	  others.	  Taken	  together,	  these	  accounts	  go	  well	  beyond	  simplistic	  donor	  –	  recipient	  narratives	  favored	  in	  some	  popular	  understandings	  of	  global	  health	  intervention.	  They	  reveal	  that	  diseases,	  treatments,	  and	  the	  populations	  to	  be	  intervened	  upon	  in	  global	  health	  cannot	  be	  taken	  as	  givens,	  and	  that	  relationships	  among	  the	  various	  actors	  in	  global	  health	  are	  extremely	  complex.	  Adriana	  Petryna,	  Vinh-­‐Kim	  Nguyen,	  Joao	  Biehl	  and	  others	  have	  argued	  that	  new	  types	  of	  citizenship	  and	  governance	  are	  constituted	  through	  the	  process	  of	  global	  health	  intervention,	  as	  the	  quest	  for	  health	  and	  the	  fight	  against	  death	  and	  disease	  (especially	  in	  the	  form	  of	  pharmaceutical	  intervention)	  becomes	  a	  legitimate	  way	  of	  staking	  claims	  on	  national	  and	  international	  assistance	  in	  settings	  where	  more	  “conventional”	  methods	  of	  claims-­‐making	  are	  ineffective.	  The	  process	  of	  framing	  social	  inequality	  in	  terms	  of	  health	  may	  provide	  politically	  active	  language	  with	  which	  to	  achieve	  political	  goals	  of	  state	  representation	  and	  care	  by	  claiming	  biological	  citizenship.51	  Yet	  biological	  citizenship	  does	  not	  offer	  the	  full	  complement	  of	  rights	  and	  responsibilities	  
                                                43	  Susan	  Reynolds	  Whyte	  et	  al.	  “Therapeutic	  Clientship:	  Belonging	  in	  Uganda’s	  Projectified	  Landscape	  of	  AIDS	  Care,”	  in	  When	  people	  come	  first,	  critical	  studies	  in	  global	  health,	  João	  Biehl	  and	  Adriana	  Petryna,	  eds.	  (Princeton:	  Princeton	  University	  Press,	  2013);	  Ippolytos	  Kalofonos,	  “’All	  I	  eat	  is	  ARVs’:	  the	  paradox	  of	  AIDS	  treatment	  interventions	  in	  central	  Mozambique,”	  Medical	  Anthropology	  
Quarterly	  24	  no.	  3,	  (2010):363-­‐80;	  Joao	  Biehl,	  Will	  to	  Live:	  AIDS	  Therapies	  and	  the	  Politics	  of	  Survival	  (Princeton	  University	  Press,	  2007).	  44	  Julie	  Livingston,	  Improvising	  Medicine:	  An	  African	  Oncology	  Ward	  in	  an	  Emerging	  Cancer	  Epidemic	  (Durham	  and	  London:	  Duke	  University	  Press,	  2012).	  	  45	  Crane,	  Scrambling	  for	  Africa.	  46	  Crystal	  Biruk,	  “Seeing	  Like	  a	  Research	  Project:	  Producing	  “High-­‐quality	  Data”	  in	  AIDS	  Research	  in	  Malawi”	  Medical	  Anthropology	  31,	  no.	  4	  (2012):	  347-­‐66.	  47	  M.	  Catherine	  Maternowska,	  Reproducing	  Inequities:	  Poverty	  and	  the	  Politics	  of	  Population	  in	  Haiti	  (Rutgers	  University	  Press,	  2006).	  48	  Adriana	  Petryna,	  When	  Experiments	  Travel:	  Clinical	  Trials	  and	  the	  Global	  Search	  for	  Human	  Subjects	  (Princeton:	  Princeton	  University	  Press,	  2009).	  49	  Vinh-­‐Kim	  Nguyen,	  The	  Republic	  of	  Therapy:	  Triage	  and	  Sovereignty	  in	  West	  Africa’s	  time	  of	  AIDS	  (Durham	  and	  London:	  Duke	  University	  Press,	  2010).	  50	  Claire	  L.	  Wendland,	  “Moral	  Maps	  and	  Medical	  Imaginaries:	  Clinical	  Tourism	  at	  Malawi’s	  College	  of	  Medicine,”	  American	  Anthropologist	  114,	  no.	  1	  (2012):	  108-­‐122;	  Brada,	  “Not	  Here.”	  51	  Adriana	  Petryna,	  Life	  Exposed:	  Biological	  Citizens	  After	  Chernobyl	  (Princeton	  University	  Press,	  2002).	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granted	  a	  modern	  citizen	  of	  a	  wealthy	  nation.	  In	  Giorgio	  Agamben's	  terms,	  biological	  citizens	  are	  granted	  "bare	  life"	  absent	  of	  intrinsic	  human	  rights.52	  Applying	  these	  concepts	  to	  AIDS	  in	  South	  Africa,	  Jean	  Comaroff	  has	  asked	  why	  "the	  biomedical	  definition	  of	  life	  [has]	  become	  so	  central	  a	  site	  of	  contestation	  where	  other	  kinds	  of	  populist	  politics	  –	  the	  politics	  of	  labor	  movements,	  for	  instance	  –	  seem	  to	  be	  eroding."	  She	  argues	  that	  we	  are	  at	  risk	  of	  reducing	  the	  analysis	  of	  political	  economic	  structures	  of	  inequality	  to	  access	  to	  medicines,	  “rather	  than,	  say,	  jobs,	  clean	  air,	  or	  freedom	  from	  war.”53	  	  Not	  only	  citizens	  but	  also	  diseases	  and	  epidemiologic	  and	  biological	  categories	  are	  newly	  constituted	  through	  the	  power	  dynamics	  of	  global	  health	  activities	  –	  concepts	  like	  “treatable”	  and	  “untreatable,”	  “adherent”	  and	  “non-­‐adherent,”	  even	  HIV	  and	  AIDS,	  and,	  as	  we	  shall	  see,	  MDR-­‐TB	  and	  XDR-­‐TB	  are	  contested	  on	  the	  international	  battle	  ground	  of	  global	  health	  policy	  and	  treatment.	  Arthur	  Kleinman,	  a	  Harvard-­‐based	  anthropologist	  who	  has	  been	  engaged	  in	  teaching	  global	  health	  courses	  together	  with	  leading	  global	  health	  hero	  Paul	  Farmer	  for	  many	  years,	  succinctly	  summarized	  the	  leading	  theoretical	  frameworks	  that	  underlie	  much	  of	  the	  current	  scholarship	  in	  global	  health	  in	  2010.54	  He	  selected	  four	  themes:	  Merton’s	  unintended	  consequences	  of	  social	  action;	  the	  social	  construction	  of	  reality	  (conceived	  originally	  by	  Berger	  and	  Luckman);	  the	  theory	  of	  social	  suffering	  (whereby	  suffering	  and	  ill-­‐health	  is	  not	  an	  individual	  experience	  with	  individual	  causes,	  but	  rather	  is	  a	  social	  experience	  caused	  by	  socioeconomic	  and	  sociopolitical	  forces	  and	  social	  institutions);	  and	  Foucault’s	  biopower	  and	  its	  more	  recent	  theoretical	  expression,	  biological	  citizenship.	  I	  build	  upon	  these	  well-­‐established	  fundamentals,	  taking	  as	  a	  starting	  condition	  the	  fact	  that	  even	  the	  most	  solid	  biomedical	  “facts”	  are	  socially	  constructed	  and	  contingent	  upon	  time	  and	  space.	  I	  reapply	  the	  fact	  that	  who	  is	  sick	  and	  who	  is	  healthy	  is	  a	  matter	  of	  
                                                52	  Giorgio	  Agamben.	  Homo	  Sacer:	  Sovereign	  Power	  and	  Bare	  Life	  (Stanford	  University	  Press,	  1998).	  53	  Jean	  Comaroff,	  “Beyond	  the	  Politics	  of	  Bare	  Life,”	  Public	  Culture	  1	  (2007):	  197-­‐219,	  206.	  54	  Arthur	  Kleinman,	  “Four	  Social	  Theories	  for	  Global	  Health,”	  The	  Lancet	  375	  (2010):	  1518-­‐1519.	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definition,	  and	  that	  scientific	  definitions	  are	  negotiated	  entities,	  as	  has	  been	  effectively	  argued	  by	  Ian	  Hacking	  and	  Robert	  Aronowitz,	  among	  others.	  55	  Global	  health	  operates	  at	  many	  spatial	  levels	  and	  different	  levels	  of	  authority,	  across	  continents,	  across	  hierarchies	  of	  governmental	  order,	  and	  across	  hierarchies	  of	  expert	  study	  and	  practice.	  As	  will	  emerge	  from	  the	  chapters	  of	  this	  dissertation,	  these	  many	  layers	  of	  global	  health	  action	  are	  interconnected,	  depend	  on	  each	  other	  and	  operate	  simultaneously.	  Yet	  their	  diverse	  locations	  and	  access	  points	  make	  them	  difficult,	  if	  not	  impossible,	  to	  capture	  in	  a	  single	  study.	  Accounts	  that	  eliminate	  local	  governments	  from	  the	  story,	  for	  example,	  miss	  the	  work	  done	  by	  bureaucratic	  absences	  and	  presences	  that	  provide	  the	  space	  for	  non-­‐governmental	  global	  health	  players	  to	  act.	  Insufficient	  attention	  to	  the	  science	  and	  policy	  workings	  of	  transnational	  and	  international	  players	  like	  the	  WHO	  and	  CDC,	  meanwhile,	  means	  missing	  important	  global	  cues	  for	  action.	  The	  scientists	  and	  epidemiologists	  who	  produce,	  compile,	  and	  package	  the	  data	  that	  justify	  policy	  action	  also	  hold	  power	  that	  is	  often	  overlooked.56	  In	  this	  dissertation	  I	  use	  XDR-­‐TB	  as	  a	  lens	  through	  which	  to	  consider	  these	  different	  levels	  of	  geography,	  expertise,	  and	  authority.	  I	  attempt	  to	  bridge	  localities,	  perspectives	  and	  disciplines	  in	  order	  to	  weave	  together	  a	  multi-­‐sited,	  multi-­‐level	  story	  from	  multiple	  points	  of	  view.	  I	  pay	  particular	  attention	  to	  the	  different	  ways	  knowledge	  around	  XDR-­‐TB	  is	  generated,	  as	  well	  as	  to	  the	  relationships	  between	  different	  types	  of	  experts	  and	  their	  professional	  networks.	  In	  order	  for	  a	  global	  health	  project	  to	  come	  together,	  information	  (mostly	  in	  the	  form	  of	  “data”)	  needs	  to	  flow	  between	  sites	  of	  clinical	  activity,	  like	  Tugela	  Ferry,	  and	  sites	  of	  academic	  production,	  like	  New	  Haven,	  with	  many	  steps	  in	  between.	  
                                                55	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  London	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  28	  no.	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  (2006):	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  and	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  (Cambridge	  University	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Global	  health	  actors	  at	  all	  levels	  contribute	  to	  the	  blockage	  and	  flow	  of	  information,	  and	  as	  such	  hold	  some	  component	  of	  the	  global	  health	  system	  in	  their	  hands.	  Thus,	  this	  is	  neither	  a	  story	  about	  the	  dangers	  of	  top-­‐down	  global	  health	  implementation,	  nor	  is	  it	  a	  grass-­‐roots	  story	  from	  below	  which	  focuses	  on	  the	  individual	  experience	  of	  patients	  and	  their	  families.	  Instead	  I	  focus	  on	  the	  flow	  of	  knowledge,	  information,	  and	  international	  expertise.	  This	  focus	  on	  international	  expertise	  and	  packaged	  knowledge	  runs	  a	  risk	  of	  being	  intrinsically	  depoliticizing,	  in	  as	  much	  as	  international	  experts	  often	  have	  little	  knowledge	  of	  local	  specifics,	  and	  instead	  apply	  universal	  templates	  to	  the	  world’s	  problems.57	  For	  this	  reason,	  my	  own	  analysis	  does	  not	  ignore	  the	  “local,”	  but	  instead	  engages	  earnestly	  with	  clinical	  and	  scientific	  experiences	  and	  perspectives	  based	  in	  Tugela	  Ferry	  and	  Durban,	  South	  Africa.	  At	  the	  same	  time,	  this	  work	  does	  prioritize	  processes	  of	  scientific	  knowledge	  production	  over	  a	  detailed	  understanding	  of	  the	  politics	  of	  race,	  poverty,	  and	  wealth	  distribution	  in	  Tugela	  Ferry	  and	  South	  Africa.	  This	  is	  also	  a	  problem	  for	  the	  global	  health	  endeavor	  itself,	  which,	  while	  inextricably	  entwined	  with	  global	  political	  processes,	  also	  serves	  a	  depoliticizing	  function.	  Under	  the	  rubric	  of	  research	  and	  care,	  international	  actors	  gain	  access	  to	  contested	  spaces	  and	  bodies,	  uncover	  secrets,	  and	  make	  public	  the	  real	  and	  perceived	  failings	  of	  a	  host	  country’s	  ability	  to	  take	  care	  of	  its	  citizens.	  Yet	  global	  health’s	  conscious	  de-­‐emphasis	  of	  the	  nation	  state58	  and	  focus	  on	  individual	  sufferers	  and	  the	  microbes	  that	  ail	  them,	  which	  is	  then	  mediated	  through	  non-­‐governmental	  organizations	  and	  institutions	  of	  learning,	  creates	  a	  type	  of	  anti-­‐politics	  of	  global	  health,	  not	  so	  different	  from	  the	  anti-­‐political	  rhetoric	  of	  the	  development	  projects	  of	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the	  1980s	  documented	  by	  James	  Ferguson	  in	  Lesotho.59	  	  I	  have	  stated	  that	  I	  will	  be	  using	  XDR-­‐TB	  in	  South	  Africa	  as	  a	  case	  that	  tells	  us	  something	  about	  how	  global	  health	  research	  works.	  As	  importantly,	  however,	  this	  dissertation	  contributes	  to	  our	  understanding	  of	  the	  role	  (drug-­‐resistant)	  tuberculosis	  has	  played	  as	  a	  key	  disease	  that	  has	  shaped	  the	  fields	  of	  clinical	  medicine,	  public	  health,	  and	  global	  health.	  Thus,	  before	  turning	  to	  a	  chapter	  overview	  and	  the	  rest	  of	  the	  dissertation,	  I	  will	  provide	  a	  brief	  overview	  of	  the	  history	  of	  drug-­‐resistant	  tuberculosis	  in	  international	  health.	  
	  
Historical	  overview	  of	  tuberculosis	  Tuberculosis	  is	  a	  particularly	  interesting	  disease	  entity	  with	  which	  to	  track	  the	  recent	  history	  of	  the	  workings	  of	  global	  health,	  as	  well	  as	  the	  much	  longer	  history	  of	  public	  health.	  Tuberculosis	  has	  been	  at	  the	  center	  of	  key	  debates	  about	  the	  causation	  and	  meaning	  of	  disease	  for	  several	  centuries.60	  As	  geographer	  Matthew	  Gandy	  has	  argued,	  “the	  history	  of	  TB	  was	  marked	  from	  the	  outset	  by	  rival	  bodies	  of	  medical	  thought	  rooted	  in	  alternative	  explanations	  for	  the	  transmission	  of	  disease.	  The	  gradual	  acceptance	  of	  various	  ‘germ	  theories’	  undermined	  the	  moralistic	  discourses	  of	  nineteenth-­‐century	  medicine	  and	  strengthened	  the	  political	  salience	  of	  the	  public	  health	  movement.	  Yet	  by	  the	  middle	  decades	  of	  the	  twentieth	  century	  the	  recognition	  that	  TB	  was	  a	  social	  disease	  rooted	  in	  poverty	  and	  poor	  housing	  became	  gradually	  obscured	  by	  an	  emphasis	  on	  the	  success	  of	  new	  forms	  of	  biomedical	  intervention.”61	  Before	  the	  medical	  discoveries	  and	  events	  that	  are	  now	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summarized	  as	  the	  bacteriologic	  revolution,	  medical	  professionals	  engaged	  in	  a	  vigorous	  debate	  around	  the	  question	  of	  TB’s	  origins:	  Was	  it	  contagious,	  transmitted	  from	  person	  to	  person?	  Was	  it	  passed	  down	  in	  families?	  Or	  did	  it	  arise	  from	  unhealthy	  urban	  environments,	  where	  dirt	  and	  decay	  was	  ubiquitous	  and	  overcrowding	  was	  rampant?62	  	  On	  March	  24,	  1882,	  Robert	  Koch	  convincingly	  demonstrated	  to	  the	  public	  that	  a	  microscopic	  germ	  could	  cause	  tuberculosis,	  apparently	  putting	  an	  end	  to	  this	  debate.	  He	  showed	  that	  the	  bug	  –	  Mycobacterium	  tuberculosis	  –	  could	  be	  transmitted	  from	  host	  to	  host,	  and	  that	  tuberculosis	  did	  not	  exist	  in	  the	  absence	  of	  the	  germ.	  In	  the	  same	  decade,	  a	  series	  of	  other	  disease-­‐causing	  bacteria,	  including	  cholera,	  diphtheria	  and	  tetanus	  were	  discovered.63	  For	  many	  medical	  professionals	  it	  became	  clear	  that	  the	  next	  step	  in	  the	  treatment	  of	  disease	  would	  be	  to	  identify	  specific	  agents	  that	  could	  kill	  these	  specific	  germs.	  For	  Koch,	  the	  discovery	  of	  the	  tuberculosis	  bacillus	  was	  merely	  the	  beginning	  of	  a	  long	  and	  intense	  preoccupation	  with	  developing	  a	  therapeutic	  agent	  effective	  against	  tuberculosis.64	  Historian	  Sheila	  Rothman	  argued	  that	  the	  “new	  understanding	  of	  tuberculosis	  in	  the	  bacteriological	  era	  bred	  not	  only	  a	  fear	  of	  contagion,	  but	  also	  a	  heady	  optimism	  about	  the	  prospects	  for	  cure.”65	  Not	  all	  leading	  physicians	  of	  the	  day	  were	  convinced	  that	  they	  should	  immediately	  discard	  the	  environment	  and	  living	  conditions	  as	  a	  cause	  of	  disease,	  however.	  Rudolf	  Virchow,	  a	  renowned	  physician	  and	  the	  founder	  of	  cellular	  pathology,	  actively	  resisted	  the	  new	  bacteriology.	  In	  1847,	  towards	  the	  beginning	  of	  his	  career,	  he	  had	  been	  appointed	  to	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investigate	  a	  deadly	  typhus	  outbreak	  in	  Upper	  Silesia	  and	  was	  convinced	  that	  it	  was	  deplorable	  living	  conditions,	  including	  bad	  housing	  and	  malnutrition,	  which	  had	  caused	  workers	  to	  succumb	  to	  disease.	  In	  his	  report	  he	  stated	  that	  social	  interventions	  were	  as	  important	  as	  medical	  ones.	  According	  to	  Leon	  Eisenberg,	  Virchow	  argued	  that	  “nothing	  but	  prosperity,	  culture,	  and	  freedom	  could	  bring	  about	  improvement	  and	  these	  could	  only	  be	  achieved	  on	  the	  basis	  of	  ‘complete	  and	  unrestricted	  democracy.’”66	  	  Virchow	  continued	  to	  doubt	  the	  importance	  of	  contagious	  germs	  until	  the	  end	  of	  his	  career.	  At	  the	  end	  of	  the	  nineteenth	  century,	  tuberculosis	  was	  one	  of	  the	  leading	  causes	  of	  death	  across	  the	  globe,	  including	  in	  the	  US	  and	  Europe,67	  and	  had	  killed	  more	  people	  than	  any	  other	  disease	  up	  until	  that	  point.68	  At	  the	  turn	  of	  that	  century,	  therapeutic	  efforts	  focused	  primarily	  on	  the	  institutional	  treatment	  of	  tuberculosis	  in	  sanatoria	  –	  institutions	  which	  focused	  on	  the	  salubrious	  characteristics	  of	  outdoor	  environmental	  conditions	  (such	  as	  cold	  mountain	  air),	  rich	  foods,	  and	  moderate	  exercise.	  Tuberculosis	  became	  the	  focus	  of	  early	  public	  health	  campaigns	  in	  the	  US,	  the	  UK	  and	  France,	  as	  well	  as	  other	  countries	  in	  Europe,	  whereby	  “the	  threat	  of	  contagion	  fostered	  a	  significant	  expansion	  of	  public	  health	  mandates.”69	  Authorities	  could	  demand	  diagnostic	  testing	  (such	  as	  X-­‐ray	  screens),	  ban	  spitting	  in	  public	  places	  (in	  order	  to	  contain	  germs),	  and	  order	  sick	  people	  to	  be	  treated	  in	  sanatoria.	  70	  The	  location	  of	  tuberculosis	  treatment	  in	  these	  closed	  institutions	  meant	  that	  public	  health	  authorities	  sometimes	  found	  it	  hard	  to	  
                                                66	  Leon	  Eisenberg,	  “Rudolf	  Ludwig	  Karl	  Virchow,	  Where	  Are	  You	  Now	  That	  We	  Need	  You?”	  The	  
American	  Journal	  of	  Medicine	  77,	  no.	  3	  (1984):	  524–532.	  67	  WHO,	  Global	  Tuberculosis	  Control	  2011	  WHO	  Report	  (Geneva:	  World	  Health	  Organization,	  2011).	  68	  Barnes,	  “Historical	  Perspectives	  on	  the	  Etiology	  of	  Tuberculosis.”	  69	  Rothman,	  Living	  in	  the	  Shadow	  of	  Death,	  6.	  70	  Ibid.	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distinguish	  between	  the	  goals	  of	  curing	  tuberculosis	  patients	  and	  confining	  dangerous	  sources	  of	  contagion.71	  With	  the	  advent	  of	  effective	  antibiotic	  therapy	  in	  the	  1940s	  and	  1950s,	  scientists	  and	  physicians	  were	  optimistic	  that	  the	  disease	  would	  be	  eliminated	  in	  the	  near	  future,	  and	  announced	  the	  end	  of	  tuberculosis.72	  In	  fact,	  as	  Thomas	  McKeown	  illustrated	  in	  the	  1960s,	  rates	  of	  tuberculosis	  infection	  had	  been	  dropping	  in	  industrialized	  countries	  for	  decades	  prior	  to	  the	  discovery	  of	  anti-­‐tuberculosis	  drugs,	  most	  likely	  due	  to	  improved	  living	  conditions	  in	  the	  cities.73	  Once	  the	  drugs	  were	  available	  and	  shown	  to	  be	  effective,	  tuberculosis	  saw	  an	  even	  more	  rapid	  decline	  and	  was	  less	  and	  less	  a	  problem	  which	  physicians	  and	  scientists	  found	  interesting.	  As	  Baron	  Lerner	  shows	  in	  his	  book	  Contagion	  
and	  Confinement,	  however,	  tuberculosis	  did	  not	  drop	  off	  the	  radar	  of	  American	  medical	  professionals	  and	  public	  health	  specialists	  immediately.	  Tuberculosis	  efforts	  in	  Seattle	  increasingly	  focused	  on	  poor,	  unemployed	  alcoholics	  with	  myriad	  social	  problems	  who	  were	  “recalcitrant”	  to	  long-­‐term	  antibiotic	  therapy.	  By	  the	  1970s,	  however,	  tuberculosis	  rates	  in	  the	  US	  had	  dramatically	  dropped,	  and	  tuberculosis	  programs	  across	  the	  country	  were	  reduced	  or	  shut	  down.74	  The	  study	  of	  tuberculosis,	  then,	  illustrates	  important	  themes	  in	  the	  history	  of	  medicine	  and	  society,	  including	  debates	  regarding	  the	  causation	  and	  transmission	  of	  disease,	  the	  importance	  of	  social	  conditions	  on	  the	  health	  of	  people,	  and	  the	  role	  of	  professionals	  and	  government	  in	  enforcing	  compliance	  with	  medical	  care	  and	  providing	  
                                                71	  Ibid,	  194.	  72	  For	  example,	  Selman	  Waksman,	  the	  discoverer	  of	  the	  first	  anti-­‐TB	  drug,	  streptomycin,	  announced	  the	  “Conquest	  of	  Tuberculosis”	  in	  the	  title	  of	  his	  book:	  Selman	  A.	  Waksman,	  The	  Conquest	  of	  
Tuberculosis	  (Berkeley:	  University	  of	  California	  Press,	  1964).	  73	  Thomas	  McKeown	  and	  R.	  G.	  Record,	  “Reasons	  for	  the	  Decline	  of	  Mortality	  in	  England	  and	  Wales	  During	  the	  Nineteenth	  Century,”	  Population	  Studies	  16	  (1962):	  94–122.	  74	  Barron	  H.	  Lerner,	  Contagion	  and	  Confinement:	  Controlling	  Tuberculosis	  Along	  the	  Skid	  Road	  (Baltimore:	  Johns	  Hopkins	  University	  Press,	  1998).	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resources	  for	  the	  care	  of	  the	  indigent.	  The	  story	  of	  tuberculosis	  also	  demonstrates	  how	  global	  priority	  setting	  around	  health	  follows	  the	  interests	  and	  fears	  of	  wealthy	  countries,	  rather	  than	  a	  rational	  understanding	  of	  global	  epidemiology.	  Tuberculosis	  was	  essentially	  considered	  “solved”	  by	  medical	  elites	  and	  public	  health	  specialists	  by	  the	  1970s	  (and	  for	  many	  people	  much	  earlier)	  in	  view	  of	  the	  fact	  that	  anti-­‐tuberculosis	  drugs	  were	  known	  and	  tuberculosis	  rates	  in	  the	  US	  and	  Western	  Europe	  had	  reached	  very	  low	  levels.	  Globally,	  however,	  tuberculosis	  had	  never	  disappeared,	  though	  interest	  in	  tuberculosis	  had	  clearly	  fallen.75	  In	  the	  1950s	  -­‐1970s,	  the	  World	  Health	  Organization	  (WHO)	  participated	  in	  a	  strong	  push	  to	  support	  anti-­‐tuberculosis	  campaigns	  focusing	  on	  prevention	  and	  treatment	  of	  tuberculosis	  around	  the	  world.	  Efforts	  included	  mass	  vaccination	  campaigns	  with	  BCG	  vaccine	  (thought	  to	  prevent	  tuberculosis	  infection),	  and	  programs	  to	  screen	  large	  parts	  of	  the	  population	  for	  tuberculosis	  by	  using	  mobile	  X-­‐ray	  units.	  Researchers	  in	  India	  and	  Africa	  sponsored	  by	  the	  UK	  Medical	  Research	  Council	  and	  the	  WHO	  continued	  to	  investigate	  the	  best	  strategies	  for	  treating	  tuberculosis,	  assessing	  the	  differences	  between	  inpatient	  and	  outpatient	  treatment,	  and	  adjusting	  the	  length	  of	  time	  that	  was	  required	  in	  order	  for	  patients	  to	  be	  treated	  successfully.76	  Yet	  the	  WHO’s	  involvement	  in	  tuberculosis-­‐related	  activities	  eventually	  followed	  the	  trends	  seen	  in	  industrialized	  countries,	  and	  WHO-­‐led	  anti-­‐tuberculosis	  campaigns	  were	  dismantled	  by	  the	  1970s.	  While	  tuberculosis	  was	  proclaimed	  vanquished	  (or	  at	  least	  irrelevant)	  by	  scientists	  in	  wealthier	  countries,	  most	  developing	  countries	  maintained	  moderate	  to	  high	  rates	  of	  
                                                75	  The	  WHO’s	  global	  TB	  program	  famously	  had	  a	  staff	  of	  only	  two	  people	  in	  the	  late	  1980s.	  J.	  Peter	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  Must	  Be	  Some	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  Way	  Out	  of	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  Diseases	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  no.	  S3	  (2010):	  S195–S200.	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  Gene	  Bukhman	  and	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  Kidder,	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  and	  Global	  Health	  Equity:	  Lessons	  From	  Tuberculosis	  Control	  Then	  and	  Now,”	  American	  Journal	  of	  Public	  Health	  98,	  no.	  1	  (2008):	  44–54;	  Sunil	  Amrith,	  “Plague	  of	  Poverty?	  The	  World	  Health	  Organization,	  Tuberculosis	  and	  International	  Development,	  C.	  1945–1980”	  (M	  Phil,	  Christ’s	  College,	  2002).	  76	  Helen	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  The	  WHO-­‐MRC	  Trials	  at	  the	  Madras	  Chemotherapy	  Centre	  in	  the	  1950s	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  in	  Tuberculosis	  Then	  and	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  ed.	  Flurin	  Condrau	  and	  Michael	  Worboys	  (Montreal	  &	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  University	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  213–234.	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tuberculosis	  throughout	  the	  twentieth	  century,	  with	  individual	  governments	  running	  their	  own	  tuberculosis	  programs	  with	  varying	  levels	  of	  success.77	  It	  was	  not	  until	  tuberculosis	  unexpectedly	  resurged	  as	  a	  problem	  in	  the	  US	  in	  the	  late	  1980s	  that	  the	  international	  public	  health	  community	  took	  up	  the	  cause	  of	  tuberculosis	  once	  again.	  To	  everyone’s	  great	  dismay,	  tuberculosis	  was	  on	  the	  rise	  again	  in	  developed	  countries.	  This	  was	  dramatically	  illustrated	  by	  a	  widely	  publicized	  tuberculosis	  outbreak	  that	  occurred	  in	  New	  York	  City	  in	  the	  late	  1980s	  and	  early	  1990s.	  The	  under-­‐funded	  New	  York	  public	  health	  infrastructure,	  combined	  with	  rising	  numbers	  of	  people	  with	  HIV/AIDS,	  had	  enabled	  tuberculosis	  to	  take	  a	  firm	  hold,	  eventually	  necessitating	  drastic	  and	  expensive	  measures	  to	  regain	  control	  over	  the	  city's	  tuberculosis	  statistics.78	  In	  fact,	  tuberculosis	  rates	  were	  increasing	  in	  cities	  and	  countries	  across	  the	  world,	  and	  very	  visibly	  –	  driven	  by	  the	  global	  HIV	  epidemic,	  failing	  public	  health	  systems,	  and	  harsh	  economic	  conditions	  which	  were	  undermining	  the	  capacity	  of	  states	  and	  their	  citizens	  to	  cope	  with	  ill	  health.	  In	  his	  book	  Infections	  and	  Inequalities	  Paul	  Farmer	  emphatically	  argues	  that	  tuberculosis	  never	  disappeared,	  even	  in	  wealthier	  nations,	  but	  that	  “the	  ‘forgotten	  plague’	  was	  forgotten	  in	  large	  part	  because	  it	  ceased	  to	  bother	  the	  wealthy,”	  while	  tuberculosis	  continued	  to	  “hide”	  among	  poor	  people,	  only	  to	  “reemerge”	  by	  becoming	  dangerous	  to	  the	  non-­‐poor.	  79	  In	  addition,	  the	  neoliberal	  economic	  reforms	  that	  occurred	  in	  the	  early	  1990s	  in	  the	  wake	  of	  the	  fall	  of	  the	  iron	  curtain	  and	  the	  Soviet	  Union	  left	  public	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  Tuberculosis	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  International	  Development,	  C.	  1945–1980.”	  78	  Gandy,	  “Life	  Without	  Germs:	  Contested	  Episodes	  in	  the	  History	  of	  Tuberculosis”;	  Thomas	  R.	  Frieden	  et	  al.,	  “Tuberculosis	  in	  New	  York	  City—turning	  the	  Tide,”	  New	  England	  Journal	  of	  Medicine	  333,	  no.	  4	  (1995):	  229–233.	  79	  Farmer,	  Paul.	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  The	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  Plagues,	  Updated	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  Press,	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health	  systems	  in	  Eastern	  Europe	  and	  Central	  Asia	  in	  disarray	  and	  populations	  vulnerable	  to	  diseases	  like	  tuberculosis.80	  According	  to	  WHO	  figures,	  approximately	  one	  third	  of	  the	  world’s	  population	  harbors	  the	  tuberculosis	  bacillus.	  Yet	  most	  of	  these	  people	  do	  not	  become	  ill	  with	  active	  tuberculosis.	  It	  is	  estimated	  that	  someone	  carrying	  the	  tuberculosis	  bacillus	  has	  about	  a	  10%	  chance	  over	  a	  lifetime	  of	  progressing	  to	  active	  disease.	  Usually	  active	  tuberculosis	  affects	  people	  who	  are	  particularly	  susceptible	  to	  it	  due	  to	  a	  weakened	  immune	  system,	  poor	  nutrition,	  high	  stress,	  old	  age	  and	  other	  only	  partially	  understood	  predisposing	  factors.	  In	  Eastern	  Europe,	  increasing	  rates	  of	  tuberculosis	  were	  exacerbated	  by	  prison	  conditions,	  a	  failing	  medical	  system,	  and	  high	  rates	  of	  alcohol	  abuse.	  In	  other	  parts	  of	  the	  world,	  the	  rise	  of	  tuberculosis	  was	  primarily	  due	  to	  its	  association	  with	  another	  “social	  disease”	  –	  HIV/AIDS.	  Infection	  with	  HIV	  raises	  a	  person’s	  risk	  of	  going	  from	  inactive	  to	  active	  tuberculosis	  disease	  from	  10%	  in	  a	  life	  time	  to	  about	  10%	  a	  year.	  In	  South	  Africa,	  which	  by	  any	  measure	  has	  a	  very	  high	  burden	  of	  HIV/AIDS,	  tuberculosis	  is	  the	  most	  common	  cause	  of	  death	  for	  people	  with	  HIV/AIDS,	  and	  70%	  of	  tuberculosis	  patients	  in	  the	  country	  are	  coinfected	  with	  HIV.81	  To	  quote	  one	  review	  article:	  “In	  2007,	  South	  Africa,	  with	  0·7%	  of	  the	  world’s	  population,	  had	  17%	  of	  the	  global	  burden	  of	  HIV	  infection,	  and	  one	  of	  the	  world’s	  worst	  tuberculosis	  epidemics.”82	  Tuberculosis’	  close	  but	  distinct	  relationship	  to	  HIV/AIDS	  is	  also	  helpful	  for	  interrogating	  the	  nature	  of	  global	  health.	  Much	  of	  today’s	  global	  health	  infrastructure	  (especially	  in	  Africa)	  is	  built	  around	  research	  and	  care	  dealing	  with	  the	  massive	  global	  AIDS	  
                                                80	  Farmer,	  Pathologies	  of	  Power.	  81	  Salim	  S.	  Abdool	  Karim	  et	  al.,	  “HIV	  Infection	  and	  Tuberculosis	  in	  South	  Africa:	  An	  Urgent	  Need	  to	  Escalate	  the	  Public	  Health	  Response,”	  The	  Lancet	  374,	  no.	  9693	  (2009):	  921–933.	  82	  Ibid.,	  921.	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pandemic.83	  Tuberculosis	  is	  much	  older	  than	  AIDS	  and	  the	  history	  of	  its	  scientific	  discovery	  and	  treatment	  is	  profoundly	  different	  from	  that	  of	  AIDS.84	  The	  philosophies	  and	  strategies	  of	  the	  scientific	  and	  policy	  communities	  dealing	  with	  tuberculosis	  and	  AIDS	  also	  developed	  in	  very	  different	  and	  conflicting	  ways,	  whereby	  the	  management	  of	  tuberculosis	  focused	  on	  surveillance	  and	  prioritized	  the	  protection	  of	  the	  public	  from	  infection	  over	  the	  dignity	  of	  the	  individual	  patient,	  while	  the	  acceptable	  management	  paradigm	  of	  AIDS	  developed	  around	  concepts	  of	  human	  rights,	  knowledge,	  empowerment	  and	  individual	  agency	  (despite	  the	  potential	  risk	  to	  the	  masses).	  In	  contemporary	  debates,	  these	  differing	  philosophies	  are	  often	  summarized	  as	  the	  “public	  health”	  approach	  versus	  the	  “human	  rights”	  approach.	  Yet,	  at	  the	  same	  time,	  as	  South	  African	  nurses	  have	  told	  me	  over	  and	  over,	  AIDS	  and	  tuberculosis	  are	  “twins”	  or	  “siblings.”	  In	  South	  Africa,	  more	  often	  than	  not,	  the	  two	  diseases	  occur	  in	  the	  same	  body.	  Tuberculosis	  is	  both	  a	  common	  early	  manifestation	  of	  AIDS	  (you	  are	  at	  increased	  risk	  for	  tuberculosis	  even	  before	  your	  immune	  system	  has	  completely	  collapsed),	  and	  a	  frequent	  final	  manifestation	  (tuberculosis	  is	  the	  most	  common	  immediate	  cause	  of	  death	  in	  people	  with	  HIV/AIDS).	  In	  the	  past,	  physicians	  who	  shied	  away	  from	  disclosing	  AIDS	  on	  a	  death	  certificate	  would	  write	  “tuberculosis”	  as	  a	  cause	  of	  death;	  and	  South	  Africans	  can	  list	  a	  litany	  of	  celebrities	  and	  politicians	  who	  unexpectedly	  died	  of	  TB…	  but	  not	  without	  a	  question	  mark.	  	  As	  poet	  Eddie	  Vulani	  Maluleke	  declared:	  “We	  died	  of	  TB	  /	  That	  was	  us	  /	  Whispering	  it	  at	  funerals	  /	  Because	  nobody	  ever	  said	  AIDS.”85	  At	  the	  same	  time,	  unexpected	  disease	  courses	  and	  poor	  outcomes	  in	  the	  tuberculosis	  ward	  were	  
                                                83	  Crane,	  “Unequal	  ‘Partners’.	  AIDS,	  Academia,	  and	  the	  Rise	  of	  Global	  Health.”	  84	  AIDS	  was	  only	  identified	  in	  the	  early	  1980s,	  though	  cases	  have	  been	  traced	  back	  to	  the	  middle	  of	  the	  20th	  century.	  85	  Eddie	  Vulani	  Maluleke,	  “Nobody	  Ever	  Said	  AIDS,”	  in	  Nobody	  Ever	  Said	  AIDS:	  Stories	  and	  Poems	  from	  
Southern	  Africa,	  ed.	  Nobantu	  Rasebotsa,	  Meg	  Samuelson,	  and	  Kylie	  Thomas	  (Cape	  Town:	  Kwela	  Books,	  2004),	  17–20.	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sometimes	  quickly	  attributed	  to	  overwhelming	  AIDS,	  even	  in	  the	  absence	  of	  a	  definitive	  HIV	  diagnosis,	  or	  the	  careful	  consideration	  of	  alternative	  explanations,	  such	  as	  drug	  resistance.	  Tuberculosis	  also	  is	  a	  suitable	  disease	  through	  which	  to	  consider	  the	  historical	  and	  present	  role	  of	  the	  South	  African	  government	  in	  ensuring	  the	  welfare	  of	  its	  country’s	  citizens.	  The	  historiography	  of	  disease	  in	  South	  Africa	  has	  emphasized	  the	  features	  of	  the	  national	  political	  economy	  that	  have	  made	  many	  South	  Africans	  extremely	  vulnerable	  to	  ill	  health	  due	  to	  apartheid	  and	  the	  legal	  exploitation	  of	  black	  labor.86	  Randall	  Packard’s	  study	  of	  tuberculosis	  in	  South	  Africa	  documents	  how	  segregationist	  policies	  and	  the	  interests	  of	  the	  mining	  industry	  not	  only	  jeopardized	  the	  health	  of	  black	  workers	  but	  also	  altered	  the	  scientific	  understanding	  of	  tuberculosis	  among	  South	  African	  medical	  professionals.87	  	  Marks	  and	  Andersson	  employ	  tuberculosis	  and	  other	  diseases	  of	  poverty	  and	  deprivation	  to	  illustrate	  the	  ways	  in	  which	  apartheid	  South	  Africa’s	  political	  economy	  was	  detrimental	  to	  the	  health	  of	  its	  majority	  black	  population,	  especially	  in	  the	  so-­‐called	  homelands	  or	  Bantustans.88	  These	  were	  the	  undesirable	  parts	  of	  South	  Africa	  that	  were	  reserved	  for	  blacks	  by	  the	  white	  minority	  government	  and	  were	  divided	  by	  dubious	  tribal	  affiliations.	  Blacks	  were	  not	  given	  permanent	  residence	  in	  white	  South	  Africa,	  and	  needed	  permits	  to	  work	  there	  as	  part	  of	  an	  exploitative	  system	  of	  migrant	  labor.	  In	  a	  very	  small	  way,	  this	  research	  can	  be	  seen	  as	  a	  study	  of	  health	  in	  the	  post-­‐apartheid	  homeland.	  Tugela	  Ferry,	  my	  primary	  research	  site	  and	  the	  town	  that	  became	  internationally	  famous	  for	  harboring	  an	  XDR-­‐TB	  ‘epidemic,’	  used	  to	  be	  in	  KwaZulu,	  the	  
                                                86	  World	  Health	  Organization	  and	  International	  Conference	  on	  Apartheid	  and	  Health,	  Apartheid	  and	  
Health	  (Geneva :	  Albany,	  N.Y:	  World	  Health	  Organization ;	  WHO	  Publications	  Centre	  USA	  [distributor],	  1983).	  Mark	  Hunter,	  Love	  in	  the	  Time	  of	  AIDS:	  Inequality,	  Gender,	  and	  Rights	  in	  South	  
Africa	  (Bloomington:	  Indiana	  University	  Press,	  2010).	  Shula	  Marks	  and	  Neil	  Andersson,	  “Issues	  in	  the	  Political	  Economy	  of	  Health	  in	  Southern	  Africa,”	  Journal	  of	  Southern	  African	  Studies	  13,	  no.	  2	  (1987):	  177–186.	  87	  Randall	  M.	  Packard,	  White	  Plague,	  Black	  Labor:	  Tuberculosis	  and	  the	  Political	  Economy	  of	  Health	  
and	  Disease	  in	  South	  Africa	  (University	  of	  California	  Press,	  1989).	  88	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  and	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homeland	  designated	  for	  Zulu	  people,	  and	  is	  now	  located	  in	  the	  hyphenated	  successor	  province	  of	  KwaZulu-­‐Natal.	  Packard’s	  historical	  analysis	  found	  tuberculosis	  devastating	  the	  homelands,	  even	  as	  South	  African	  tuberculosis	  statistics	  were	  improving,	  in	  part	  due	  to	  the	  progressive	  exclusion	  of	  the	  homelands	  not	  just	  from	  South	  African	  citizenship,	  but	  also	  from	  statistical	  capture.	  In	  contrast,	  I	  was	  drawn	  to	  this	  former	  homeland	  by	  the	  internationally	  available	  and	  devastating	  tuberculosis	  statistics.	  Tuberculosis	  was	  wreaking	  more	  havoc	  than	  ever,	  more	  than	  a	  decade	  after	  the	  first	  democratic	  elections	  and	  the	  end	  of	  legal	  apartheid.	  Packard	  and	  Marks’	  focus	  on	  national	  economy	  and	  polity	  is	  very	  compelling	  in	  explaining	  the	  social	  context	  of	  illness	  in	  apartheid	  South	  Africa.	  In	  my	  work,	  however,	  the	  crucial	  dynamic	  is	  one	  not	  between	  state	  and	  industry,	  but	  between	  the	  state	  and	  international	  expertise.	  The	  international	  community	  has	  focused	  on	  post-­‐apartheid	  South	  Africa’s	  biomedical	  ills,	  discussing	  problems	  of	  child	  welfare,	  gender	  inequality	  and	  poverty	  in	  the	  idioms	  of	  immunodeficiency	  and	  infectious	  disease.	  This	  is	  the	  angle	  from	  which	  I	  approach	  the	  history	  of	  tuberculosis	  in	  South	  Africa.	  
Outline	  of	  the	  dissertation	  In	  this	  dissertation	  I	  explore	  how	  a	  sad	  but	  commonplace	  occurrence	  –	  the	  death	  of	  rural	  South	  Africans	  from	  HIV	  and	  tuberculosis	  –	  was	  transformed	  into	  an	  extraordinary	  and	  dangerous	  event	  of	  global	  interest	  accompanied	  by	  language	  that	  was	  powerful	  enough	  to	  make	  claims	  on	  government	  agencies	  and	  to	  demand	  action	  from	  humanitarian	  organizations.	  This	  dissertation	  consists	  of	  two	  interconnecting	  parts.	  In	  Part	  I	  (Chapters	  1-­‐3),	  I	  tell	  the	  story	  of	  the	  rhetorical	  and	  scientific	  origins	  of	  extensively	  drug-­‐resistant	  tuberculosis	  (XDR-­‐TB).	  Setting	  it	  against	  the	  backdrop	  of	  public	  policy	  debates	  around	  multi-­‐drug	  resistant	  tuberculosis	  (MDR-­‐TB)	  that	  took	  place	  in	  the	  1990s,	  I	  show	  that	  XDR-­‐TB	  was	  deliberately	  named	  and	  defined	  to	  maximize	  both	  scientific	  and	  moral	  impact	  in	  the	  face	  of	  a	  truly	  devastating	  problem.	  Public	  policy	  experts	  consciously	  collected	  data	  on	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tuberculosis	  drug-­‐resistance	  that	  they	  hoped	  would	  have	  the	  power	  to	  call	  attention	  to	  the	  dangers	  of	  underfunded	  tuberculosis	  programs.	  Careful	  consideration	  was	  given	  to	  scientific	  parameters	  such	  as	  standardization	  and	  quality	  controls	  to	  maximize	  scientific	  credibility	  of	  the	  new	  XDR-­‐TB	  concept.	  This	  scientific	  legitimacy	  served	  to	  mobilize	  moral	  authority,	  enabling	  demands	  for	  intervention	  into	  the	  lives	  of	  the	  sick	  and	  dying	  based	  on	  scientific,	  public	  health,	  humanitarian,	  and	  ethical	  arguments.	  It	  is	  well	  established	  that	  diseases	  are	  socially	  constructed	  and	  are	  framed	  by	  the	  social	  realities	  in	  which	  they	  are	  embedded.89	  Indeed,	  science	  does	  not	  exist	  independent	  of	  society;	  "science	  and	  society	  [are]	  co-­‐produced,	  each	  underwriting	  the	  other's	  existence."90	  Part	  I	  provides	  insights	  into	  the	  social	  construction	  of	  XDR-­‐TB	  in	  a	  very	  literal	  sense,	  from	  the	  viewpoint	  of	  the	  experts	  who	  had	  the	  power	  to	  convene	  meetings,	  assemble	  numbers,	  and	  decide	  a	  new	  disease	  name	  was	  needed	  to	  describe	  an	  existing	  phenomenon;	  thus	  inventing	  XDR-­‐TB	  was	  part	  of	  their	  work.	  The	  case	  of	  XDR-­‐TB	  makes	  it	  very	  clear	  that	  the	  disease	  did	  not	  have	  to	  be	  defined	  just	  the	  way	  it	  was,	  and	  that	  it	  was	  not	  automatically	  endowed	  with	  the	  power	  to	  generate	  public	  health	  and	  media	  attention.	  Several	  sources	  argued,	  for	  example,	  that	  the	  use	  of	  the	  letter	  “X”	  to	  describe	  extensively	  drug-­‐resistant	  tuberculosis	  was	  one	  of	  the	  reasons	  that	  XDR-­‐TB	  captured	  the	  imagination	  of	  journalists	  and	  funders.	  To	  say	  that	  XDR-­‐TB	  is	  socially	  constructed,	  or	  even	  that	  policy	  makers	  and	  scientists	  “invented”	  XDR-­‐TB,	  however,	  does	  not	  mean	  that	  XDR-­‐TB	  is	  a	  made-­‐up	  disease.	  Even	  as	  I	  lay	  bare	  the	  processes	  and	  negotiations	  that	  underlie	  the	  coming-­‐to-­‐be	  of	  extensively	  drug-­‐
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  Studies	  in	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  Co-­‐production	  of	  Science	  and	  Social	  Order,	  International	  Library	  of	  Sociology	  (London ;	  New	  York:	  Routledge,	  2004),	  17.	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resistant	  tuberculosis,	  I	  am	  not	  arguing	  that	  the	  resources	  and	  attention	  given	  to	  XDR-­‐TB	  were	  inappropriate,	  exaggerated	  or	  somehow	  the	  result	  of	  deception	  or	  fraud.	  Though	  I	  do	  interrogate	  the	  notion	  that	  XDR-­‐TB	  is	  a	  distinct	  pathological	  disease	  entity	  independent	  from	  the	  experts	  who	  diagnose,	  study,	  and	  manage	  it,	  I	  also	  stress	  that	  extensively	  drug	  resistant	  tuberculosis	  is	  a	  contagious,	  fatal	  disease	  that	  affects	  thousands	  of	  people,	  causing	  significant	  illness	  and	  death,	  leading	  to	  stories	  of	  suffering	  in	  countless	  individuals	  around	  the	  globe.	  This	  dissertation	  does	  not	  deal	  directly	  with	  this	  suffering,	  however,	  but	  instead	  traces	  how	  biomedical	  experts	  convert	  suffering	  into	  data	  which	  can	  be	  manipulated,	  “cleaned,”	  graphed,	  charted,	  and	  acted	  upon	  with	  the	  tools	  of	  epidemiology	  and	  public	  health.	  The	  early	  international	  meetings	  around	  XDR-­‐TB	  used	  disease	  definitions,	  laboratory	  guidelines,	  statistical	  methods	  and	  bullet-­‐pointed	  action	  plans	  as	  their	  primary	  tools	  with	  which	  to	  understand	  and	  intervene	  against	  drug-­‐resistant	  tuberculosis.	  In	  Part	  II	  of	  the	  dissertation	  (Chapters	  4-­‐5)	  the	  focus	  shifts	  away	  from	  international	  meetings	  and	  conferences	  to	  Tugela	  Ferry,	  South	  Africa,	  which	  became	  the	  town	  best	  known	  for	  the	  discovery	  of	  the	  biggest	  cluster	  of	  deadly	  XDR-­‐TB	  cases.	  In	  chapter	  4	  I	  focus	  primarily	  on	  the	  role	  of	  the	  local	  department	  of	  health	  in	  making	  an	  expansion	  of	  MDR-­‐TB	  services	  in	  Tugela	  Ferry	  and	  the	  surrounding	  region	  possible.	  The	  publications,	  international	  presentations,	  and	  popular	  retellings	  of	  the	  story	  of	  MDR-­‐TB	  and	  XDR-­‐TB	  in	  Tugela	  Ferry	  could	  lead	  to	  the	  impression	  that	  American	  global	  health	  workers	  single-­‐handedly	  brought	  effective	  tuberculosis	  treatment	  to	  rural	  KwaZulu-­‐Natal.	  Here	  I	  show	  that	  to	  a	  large	  extent	  American	  researchers	  relied	  on	  South	  African	  resources	  in	  order	  to	  be	  able	  to	  conduct	  their	  work,	  and	  even	  as	  they	  provided	  knowledge,	  expertise,	  advice,	  and	  organizational	  leadership,	  South	  African	  government	  officials	  had	  good	  reasons	  to	  attempt	  to	  rein	  in	  outside	  influence.	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Chapter	  5	  considers	  the	  labor	  and	  documents	  that	  go	  into	  providing	  and	  representing	  Tugela	  Ferry’s	  answer	  to	  MDR-­‐TB	  and	  XDR-­‐TB:	  community-­‐based	  treatment.	  The	  initiation	  of	  the	  community-­‐based	  management	  of	  MDR-­‐TB	  that	  occurred	  in	  the	  aftermath	  of	  the	  discovery	  of	  XDR-­‐TGB	  was	  simultaneously	  a	  state-­‐driven	  public	  health	  program	  and	  an	  externally	  funded	  global	  health	  research	  program.	  While	  the	  needs	  of	  research,	  public	  health	  and	  clinical	  care	  often	  overlap,	  the	  key	  products	  that	  result	  from	  these	  efforts	  –	  peer-­‐reviewed	  journal	  articles,	  government	  reports,	  and	  cared-­‐for	  patients,	  respectively	  –	  are	  not	  the	  same.	  While	  state-­‐funded	  public	  health	  nurses	  spent	  a	  large	  part	  of	  their	  work-­‐day	  filling	  out	  forms	  in	  order	  to	  comply	  with	  bureaucratic	  guidelines	  enforced	  by	  the	  department	  of	  health	  hierarchy	  (which	  is	  itself	  subject	  to	  international	  reporting	  needs),	  research-­‐funded	  nurses	  intervened	  into	  the	  process	  of	  care-­‐provision	  in	  ways	  that	  ensured	  the	  completeness	  of	  the	  medical	  record	  according	  to	  the	  needs	  of	  their	  bosses	  who	  hoped	  to	  publish	  in	  high-­‐prestige	  biomedical	  journals.	  
Methods	  This	  dissertation	  was	  researched	  over	  the	  period	  from	  early	  2007	  to	  late	  2011.	  Much	  of	  the	  information	  about	  XDR-­‐TB	  and	  its	  origins	  was	  assembled	  from	  published	  sources,	  including	  peer-­‐reviewed	  journal	  articles,	  meeting	  abstracts,	  conference	  reports,	  press	  releases,	  web	  presentations,	  fundraising	  materials,	  etc.	  I	  also	  had	  access	  to	  some	  private	  correspondence	  around	  the	  early	  definition	  of	  XRD-­‐TB.	  I	  attended	  several	  conferences	  and	  meetings	  at	  which	  drug-­‐resistant	  tuberculosis	  was	  discussed,	  including	  the	  2010	  World	  Meeting	  of	  the	  International	  Union	  Against	  Tuberculosis	  and	  Lung	  Disease	  in	  Berlin,	  the	  2010	  South	  African	  TB	  Conference,	  and	  the	  2011	  South	  African	  AIDS	  Conference.	  I	  also	  attended	  a	  2010	  TB	  conference	  organized	  for	  staff	  at	  McCord	  Hospital	  in	  Durban,	  and	  a	  2010	  conference	  on	  TB	  diagnostics	  organized	  by	  the	  KwaZulu-­‐Natal	  Research	  Institute	  for	  TB	  and	  HIV	  (K-­‐RITH)	  in	  Durban.	  In	  addition,	  I	  conducted	  over	  80	  interviews	  with	  public	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health	  experts,	  scientists,	  WHO	  officials,	  South	  African	  government	  employees,	  physicians,	  nurses,	  research	  workers,	  patients,	  and	  others.	  Most	  of	  these	  interviews	  I	  conducted	  in	  English	  either	  by	  phone	  or	  in	  person,	  in	  some	  cases	  at	  the	  conferences	  listed	  above.	  In	  South	  Africa	  I	  conducted	  some	  interviews	  together	  with	  a	  research	  assistant,	  Nomnikelo	  Mvelase.	  Most	  of	  those	  were	  in	  Zulu	  and	  English,	  with	  Mvelase	  translating	  between	  the	  two	  languages	  when	  needed.	  Mvelase	  also	  conducted	  a	  handful	  of	  interviews	  with	  tuberculosis	  patients	  independently	  and	  transcribed	  and	  translated	  these	  interviews.	  I	  gave	  the	  people	  I	  interviewed	  the	  option	  to	  either	  be	  interviewed	  “on	  the	  record”	  or	  to	  remain	  anonymous.	  Most	  (though	  not	  all)	  international	  experts,	  academics,	  and	  physicians	  were	  willing	  to	  be	  on	  the	  record	  for	  most	  or	  all	  of	  their	  interview	  and	  allowed	  me	  to	  record	  the	  interview.	  Most	  (though	  not	  all)	  nurses,	  auxiliary	  hospital	  staff	  and	  patients	  chose	  to	  remain	  anonymous	  and	  preferred	  I	  only	  take	  notes,	  without	  an	  audio	  recording.	  As	  a	  result	  there	  is	  a	  clear	  imbalance	  in	  power,	  position,	  race,	  and	  language	  between	  those	  people	  who	  are	  directly	  quoted	  and	  those	  who	  are	  summarized	  and	  represented	  as	  a	  group	  (“some	  nurses	  say,”	  “a	  staff	  member	  argued”).	  Despite	  this,	  I	  use	  and	  attribute	  quotes	  from	  interviews	  when	  available.	  In	  some	  cases	  I	  do	  not	  disclose	  the	  source	  of	  a	  particular	  statement	  or	  claim.	  Quotes	  that	  are	  not	  attributed	  are	  anonymous.	  It	  would	  be	  impractical,	  however,	  to	  make	  this	  entire	  dissertation	  anonymous,	  in	  part	  because	  the	  location	  of	  the	  events	  I	  describe	  is	  well-­‐known	  (and	  easily	  googled),	  and	  the	  leading	  researchers	  and	  clinicians	  who	  work	  there	  are	  well-­‐known	  in	  the	  research	  community	  and	  have	  published	  extensively.	  In	  some	  cases	  they	  have	  been	  interviewed	  on	  the	  record	  on	  similar	  topics	  by	  other	  people.	  In	  2010,	  after	  piecing	  together	  much	  of	  the	  story	  of	  how	  XDR-­‐TB	  in	  South	  Africa	  came	  to	  be	  a	  matter	  of	  global	  concern	  from	  my	  home	  base	  in	  Philadelphia,	  with	  visits	  to	  New	  Haven	  and	  New	  York,	  as	  well	  as	  a	  two-­‐month	  stay	  in	  Durban	  in	  2007,	  I	  based	  the	  rest	  
 40 
of	  my	  research	  in	  South	  Africa.	  I	  first	  spent	  four	  months	  in	  Durban,	  where	  I	  attended	  TB-­‐related	  events,	  interviewed	  Durban-­‐based	  scientists,	  and	  observed	  some	  of	  the	  TB-­‐related	  activities	  at	  McCord	  Hospital.	  To	  help	  me	  gain	  some	  insights	  into	  local	  South	  African	  perspectives	  on	  the	  XDR-­‐TB	  outbreak	  in	  Tugela	  Ferry,	  South	  Africa	  I	  then	  moved	  to	  Tugela	  Ferry	  itself	  to	  live	  there	  for	  eleven	  months.	  There	  I	  engaged	  in	  participant-­‐observation	  in	  clinical,	  research	  and	  community	  settings.	  I	  was	  officially	  affiliated	  with	  Philanjalo,	  the	  non-­‐governmental	  organization	  and	  hospice	  founded	  by	  Dr.	  Moll	  that	  provided	  care	  to	  people	  with	  HIV/AIDS	  and	  tuberculosis.	  This	  was	  also	  the	  organization	  through	  which	  most	  XDR-­‐TB	  research	  activities	  were	  officially	  channeled.	  I	  spent	  much	  of	  my	  day	  observing	  the	  work	  of	  TB	  nurses,	  TB	  researchers,	  and	  clinicians.	  I	  spent	  work-­‐time	  and	  off-­‐time	  with	  nurses,	  doctors,	  research	  assistants	  and	  coordinators,	  administrators,	  peace	  corps	  workers,	  community	  health	  workers,	  and	  patients,	  and	  participated	  actively	  in	  hospital	  and	  community	  life.	  This	  was	  facilitated	  by	  my	  living	  situations	  –	  I	  first	  stayed	  with	  a	  local,	  middle-­‐class	  Zulu	  family	  who	  actively	  participated	  in	  church	  and	  community	  life,	  and	  later	  lived	  on	  the	  hospital	  compound	  in	  housing	  built	  for	  visiting	  researchers	  and	  clinicians,	  with	  a	  rotating	  cast	  of	  American	  and	  South	  African	  short	  and	  long-­‐term	  visitors.	  	  While	  the	  professional	  and	  research	  language	  in	  Tugela	  Ferry	  is	  English,	  most	  of	  the	  local	  residents	  speak	  Zulu	  and	  very	  limited	  English.	  I	  had	  prepared	  for	  this	  with	  Zulu	  language	  instruction	  in	  the	  US	  and	  in	  South	  Africa	  and	  was	  able	  to	  engage	  in	  polite	  conversation	  in	  Zulu.	  As	  mentioned	  above,	  I	  worked	  together	  with	  a	  research	  assistant	  when	  interviewing	  people	  (including	  nurses,	  patients,	  and	  community	  members)	  who	  were	  more	  comfortable	  in	  Zulu	  than	  in	  English.	  In	  addition	  to	  serving	  as	  my	  translator	  and	  interview	  transcriber,	  she	  generously	  facilitated	  many	  social	  interactions	  in	  town,	  invited	  me	  to	  social	  functions	  and	  initiated	  conversations	  with	  her	  friends	  about	  HIV/AIDS	  and	  tuberculosis	  for	  my	  benefit.	  She	  and	  other	  Zulu-­‐speaking	  research	  and	  hospital	  staff	  helped	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me	  bridge	  the	  tangible	  divide	  between	  those	  who	  were	  affiliated	  with	  the	  hospital	  compound	  through	  their	  work	  and	  those	  who	  lived	  outside	  of	  it	  and	  only	  came	  there	  as	  patients,	  family,	  and	  visitors.	  The	  goal	  of	  my	  fieldwork	  was	  to	  understand	  the	  significance	  of	  Tugela	  Ferry	  as	  a	  point	  on	  the	  global	  health	  research	  map,	  and	  to	  capture	  what	  XDR-­‐TB	  signified	  not	  only	  to	  health	  professionals,	  but	  also	  to	  patients	  and	  community	  members	  in	  Msinga.	  More	  pragmatically,	  I	  was	  also	  interested	  in	  how	  the	  practice	  of	  tuberculosis	  care	  and	  management	  in	  Tugela	  Ferry	  had	  been	  impacted	  by	  the	  international	  and	  national	  attention	  that	  had	  been	  focused	  on	  the	  area	  due	  to	  the	  broad	  public	  promotion	  of	  the	  XDR-­‐TB	  outbreak	  via	  scientific	  and	  popular	  media.	  This	  was	  not	  my	  first	  visit	  to	  South	  Africa.	  This	  research	  builds	  on	  more	  than	  a	  decade	  of	  engagement	  with	  South	  African	  HIV,	  TB	  and	  AIDS	  activism	  and	  research.	  I	  first	  went	  to	  South	  Africa	  in	  2002	  as	  an	  undergraduate	  intern	  working	  for	  the	  AIDS-­‐activist	  Treatment	  Action	  Campaign	  (TAC)	  in	  Khayelitsha,	  a	  township	  outside	  of	  Cape	  Town.	  I	  was	  able	  to	  return	  to	  South	  Africa	  the	  following	  year,	  this	  time	  to	  Durban	  on	  a	  Fulbright	  Scholarship.	  I	  spent	  ten	  months	  conducting	  HIV	  related	  research;	  first	  in	  a	  molecular	  virology	  laboratory;	  later	  at	  a	  hospital	  in	  Durban	  that	  was	  running	  one	  of	  the	  first	  HIV	  treatment	  programs	  in	  town.	  After	  starting	  medical	  school	  in	  the	  US	  in	  2004,	  I	  returned	  for	  a	  brief	  clinical	  elective	  in	  Mseleni,	  South	  Africa	  in	  2006.	  I	  returned	  to	  Durban	  in	  2007	  and	  2009	  for	  short	  research	  trips	  and	  language	  training	  during	  my	  academic	  summers.	  This	  research	  was	  very	  much	  dependent	  on	  the	  colleagues	  and	  friends	  who	  facilitated	  my	  work	  around	  HIV/AIDS	  and	  tuberculosis	  even	  as	  my	  interests	  shifted	  from	  laboratory	  science	  to	  sociological,	  anthropological	  and	  historical	  questions	  about	  the	  conduct	  of	  HIV	  and	  TB	  research.	  Thus	  I	  was	  able	  to	  gain	  a	  long-­‐term	  understanding	  of	  AIDS	  and	  TB	  research	  in	  Durban	  and	  its	  connection	  to	  international	  projects	  from	  the	  perspective	  of	  activist,	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laboratory	  scientist,	  clinical	  researcher,	  and	  medical	  trainee.	  All	  in	  all,	  I	  spent	  nearly	  two	  years	  between	  2006	  and	  2011	  in	  the	  province	  of	  KwaZulu-­‐Natal,	  South	  Africa	  (in	  Tugela	  Ferry,	  Greytown,	  Pietermaritzburg,	  and	  Durban)	  conducting	  interviews,	  collecting	  documents,	  and	  engaging	  in	  participant	  observation	  around	  different	  aspects	  of	  XDR-­‐TB	  and	  HIV/AIDS	  research	  and	  care.	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CHAPTER	  1:	  Extensively	  Drug-­‐Resistant	  Tuberculosis	  in	  South	  Africa	  –	  The	  Making	  of	  a	  
Global	  Health	  Disease	  
 In	  March	  2006	  a	  new	  disease	  was	  born.	  No	  new	  pathogen	  had	  been	  discovered;	  no	  one	  had	  visibly	  died	  with	  unusual	  symptoms	  or	  of	  mysterious	  causes.	  Yet	  on	  March	  24,	  2006,	  World	  Tuberculosis	  Day,	  the	  US	  Centers	  for	  Disease	  Control	  and	  Prevention	  (CDC)	  and	  the	  World	  Health	  Organization	  (WHO)	  announced	  the	  emergence	  of	  a	  new	  and	  dangerous	  form	  of	  tuberculosis.	  It	  had	  a	  somewhat	  mysterious	  and	  potentially	  powerful	  name:	  XDR-­‐TB.91	  XDR-­‐TB,	  which	  stands	  for	  extensively	  drug-­‐resistant	  tuberculosis,	  refers	  to	  a	  form	  of	  tuberculosis	  that	  has	  mutated	  to	  become	  invulnerable	  to	  almost	  all	  anti-­‐tuberculosis	  drugs.	  The	  first	  publication	  on	  XDR-­‐TB	  was	  in	  the	  Morbidity	  and	  Mortality	  Weekly	  Report	  of	  the	  CDC	  (the	  same	  journal	  which	  in	  1982	  had	  documented	  the	  first	  cases	  of	  a	  new	  illness	  that	  later	  came	  to	  be	  known	  as	  AIDS)	  and	  warned	  that	  XDR-­‐TB	  had	  “emerged	  worldwide	  as	  a	  threat	  to	  public	  health	  and	  TB	  control,	  raising	  concerns	  of	  a	  future	  epidemic	  of	  virtually	  untreatable	  TB.”92	  Detractors	  wondered	  if	  whoever	  had	  determined	  the	  acronym	  had	  made	  a	  mistake.	  Shouldn't	  extensively	  drug	  resistant	  be	  abbreviated	  EDR?	  As	  one	  Lancet	  
Infectious	  Diseases	  commentator	  put	  it:	  "Were	  the	  authors	  trying	  to	  "sex	  up"	  their	  report	  by	  choosing	  the	  abbreviation	  XDR?"93	  Also,	  this	  was	  no	  new	  disease	  –	  hadn't	  highly	  drug	  resistant	  strains	  of	  tuberculosis	  been	  documented	  before	  under	  other	  names?94	  Was	  extensively	  drug-­‐resistant	  tuberculosis	  (XDR-­‐TB)	  significantly	  different	  from	  multi-­‐drug	  resistant	  tuberculosis	  (MDR-­‐TB)?	  
                                                91	  Abigail	  Wright	  et	  al.,	  “Emergence	  of	  Mycobacterium	  Tuberculosis	  with	  Extensive	  Resistance	  to	  Second-­‐line	  Drugs	  –	  Worldwide,	  2000	  –	  2004,”	  Morbidity	  and	  Mortality	  Weekly	  Report	  55,	  no.	  11	  (2006):	  301-­‐305.	  92	  Wright	  et	  al.,	  "Emergence	  of	  Mycobacterium	  Tuberculosis	  with	  Extensive	  Resistance,"	  302.	  93	  “The	  Tuberculosis	  X	  Factor,”	  The	  Lancet	  Infectious	  Diseases	  6,	  no.	  11	  (2006):	  679.	  94	  Sofía	  Samper	  and	  Carlos	  Martín,	  “Spread	  of	  Extensively	  Drug-­‐Resistant	  Tuberculosis,”	  Emerging	  
Infectious	  Diseases	  13,	  no.	  4	  (2007):	  647–648.	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Despite	  these	  critiques,	  however,	  XDR-­‐TB	  eventually	  captured	  the	  attention	  of	  biomedical,	  public	  health,	  and	  lay	  communities.	  By	  early	  2007,	  news	  outlets	  in	  several	  countries	  reported	  about	  the	  growing	  threat	  of	  XDR-­‐TB	  in	  South	  Africa;	  in	  mid	  2007,	  an	  American	  traveler	  diagnosed	  with	  XDR-­‐TB	  was	  the	  focus	  of	  a	  brief	  media	  frenzy	  in	  the	  United	  States.95	  Several	  biomedical	  research	  funders	  (including	  the	  AIDS	  Clinical	  Trial	  Group	  and	  the	  Howard	  Hughes	  Medical	  Institute)	  decided	  to	  expand	  their	  research	  on	  tuberculosis,	  including	  XDR-­‐TB.96	  Tuberculosis	  programs	  in	  Peru	  and	  Russia	  supported	  by	  Partners	  in	  Health	  (PIH)	  reviewed	  their	  patient	  files	  to	  see	  if	  they	  had	  documented	  cases	  of	  XDR-­‐TB	  and	  published	  their	  outcomes;	  researchers	  working	  for	  Doctors	  without	  Borders	  in	  Khayelitsha,	  South	  Africa	  similarly	  re-­‐analyzed	  treatment	  outcomes	  and	  participated	  in	  debates	  about	  the	  best	  treatment	  strategies	  for	  XDR-­‐TB.97	  Partners	  in	  Health	  also	  started	  a	  pilot-­‐project	  in	  Lesotho	  to	  demonstrate	  effective	  strategies	  for	  treating	  XDR-­‐TB,	  using	  funding	  from	  the	  Soros	  foundation.98	  	  	   The	  publication	  of	  the	  first	  XDR-­‐TB	  paper	  in	  MMWR	  was	  only	  one	  of	  a	  number	  of	  events	  that	  contributed	  to	  making	  a	  case	  for	  XDR-­‐TB	  as	  a	  global	  health	  threat	  that	  required	  global	  action.	  Most	  of	  the	  interest	  around	  XDR-­‐TB	  eventually	  focused	  on	  a	  particular	  XDR-­‐TB	  outbreak	  in	  rural	  South	  Africa.	  This	  chapter,	  however,	  looks	  at	  the	  earlier	  events	  that	  led	  up	  to	  the	  first	  publication	  on	  XDR-­‐TB	  worldwide,	  before	  the	  publication	  of	  the	  South	  African	  
                                                95	  Michael	  Wines,	  “Virulent	  TB	  in	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  New	  York	  Times,	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  28,	  2007;	  Lawrence	  K.	  Altman,	  “TB	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  is	  Isolated	  after	  Taking	  Two	  Flights,”	  The	  New	  York	  Times,	  May	  30,	  2007.	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  Claire	  Wingfield,	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  by	  author,	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  March	  2010,	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  K-­‐RITH:	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Research	  Institute	  for	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  and	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  Cesar	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  et	  al.,	  “Management	  of	  Extensively	  Drug-­‐resistant	  Tuberculosis	  in	  Peru:	  Cure	  is	  Possible,”	  PLoS	  One	  3,	  no.	  8	  (2008):	  e2957;	  Salmaan	  Keshavjee	  et	  al.,	  “Treatment	  of	  Extensively	  Drug-­‐resistant	  Tuberculosis	  in	  Tomsk,	  Russia:	  A	  Retrospective	  Cohort	  Study,”	  The	  Lancet	  372,	  no.	  9647	  (2008):	  1403–1409;	  Helen	  S.	  Cox	  et	  al.,	  “Epidemic	  Levels	  of	  Drug	  Resistant	  Tuberculosis	  (MDR	  and	  XDR-­‐TB)	  in	  a	  High	  HIV	  Prevalence	  Setting	  in	  Khayelitsha,	  South	  Africa,”	  PLoS	  One	  5,	  no.	  11	  (2010):	  e13901;	  Eric	  Goemaere	  et	  al.,	  “XDR-­‐TB	  in	  South	  Africa:	  Detention	  is	  not	  the	  Priority,”	  PLoS	  Medicine	  4,	  no.	  4	  (2007):	  e162.	  98	  Donald	  G.	  Mcneil	  Jr,	  “Lesotho:	  Soros	  Pledges	  $3	  Million	  to	  Fight	  Lethal	  TB,”	  The	  New	  York	  Times,	  March	  15,	  2007.	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outbreak.	  I	  pay	  special	  attention	  to	  the	  negotiations	  that	  preceded	  the	  naming,	  definition,	  and	  promotion	  of	  this	  new	  category.	  Among	  other	  things,	  the	  definition	  of	  the	  new	  concept	  of	  XDR-­‐TB	  was	  carefully	  crafted	  in	  order	  to	  be	  helpful	  to	  researchers	  and	  clinicians	  working	  on	  different	  aspects	  of	  tuberculosis.	  XDR-­‐TB	  was	  envisioned	  and	  understood	  as	  an	  amplification	  of	  multi	  drug-­‐resistant	  tuberculosis,	  or	  MDR-­‐TB,	  which	  itself	  had	  generated	  considerable	  media	  attention	  and	  funding	  in	  the	  preceding	  decade.	  Public	  health	  experts	  used	  conventional	  scientific	  strategies	  of	  data	  management	  as	  well	  as	  creative	  language	  in	  order	  to	  draw	  attention	  and	  funds	  to	  the	  new	  disease	  concept	  of	  XDR-­‐TB.	  It	  gained	  traction	  as	  its	  definition	  was	  refined	  by	  scientists	  and	  was	  shared	  at	  meetings,	  and	  as	  existing	  networks	  of	  expertise	  around	  multi	  drug-­‐resistant	  tuberculosis	  (MDR-­‐TB)	  took	  it	  on	  as	  a	  legitimate	  and	  important	  new	  part	  of	  their	  work.	  For	  this	  reason	  I	  begin	  with	  a	  brief	  overview	  of	  the	  policy	  debates	  and	  interventions	  which	  took	  place	  around	  MDR-­‐TB	  in	  the	  1990s	  and	  early	  2000s	  before	  I	  transition	  to	  XDR-­‐TB,	  the	  core	  subject	  of	  this	  dissertation.	  
Inevitable	  Microbiology	  or	  Therapeutic	  Anarchy?	  One	  way	  to	  tell	  the	  story	  of	  tuberculosis	  as	  an	  object	  of	  public	  and	  expert	  interest	  is	  as	  a	  story	  of	  repeated	  cycles	  of	  escalation	  followed	  by	  retreat	  and	  decline.	  In	  May	  2000	  the	  US	  Institute	  of	  Medicine	  issued	  a	  report	  about	  the	  state	  of	  tuberculosis	  in	  the	  US,	  in	  which	  it	  commended	  ongoing	  efforts	  to	  eliminate	  tuberculosis,	  but	  also	  warned	  that	  tuberculosis	  programs	  were	  at	  the	  mercy	  of	  “recurrent	  cycles	  of	  neglect	  followed	  by	  resurgence	  that	  have	  been	  the	  history	  of	  tuberculosis.”99	  Until	  the	  1980s	  American	  public	  health	  experts	  had	  been	  lulled	  into	  believing	  that	  tuberculosis	  (at	  least	  in	  the	  US)	  was	  a	  thing	  of	  the	  past.	  Yet	  in	  1991	  tuberculosis	  expert	  Lee	  Reichman	  had	  to	  report	  that	  “Tuberculosis	  (TB)	  is	  back	  with	  a	  
                                                99	  Lawrence	  Geiter,	  ed.,	  Ending	  Neglect:	  The	  Elimination	  of	  Tuberculosis	  in	  the	  United	  States	  (Washington,	  D.C.:	  National	  Academy	  Press,	  2000),	  viii,	  http://www.nap.edu/openbook.php?isbn=0309070287.	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vengeance.”100	  In	  New	  York	  City,	  in	  particular,	  the	  number	  of	  patients	  with	  tuberculosis	  nearly	  tripled	  from	  1978	  to	  1992.101	  In	  the	  1990s	  public	  health	  experts	  also	  documented	  an	  outbreak	  of	  multi	  drug-­‐resistant	  tuberculosis	  in	  New	  York	  City’s	  correctional	  system,	  as	  well	  as	  across	  the	  city	  more	  generally.102	  Many	  of	  these	  cases	  were	  in	  patients	  with	  compromised	  immune	  systems	  –	  especially	  patients	  with	  AIDS.	  The	  World	  Health	  Organization	  (WHO)	  and	  the	  International	  Union	  against	  Tuberculosis	  and	  Lung	  Disease	  (IUATLD)	  declared	  tuberculosis	  a	  “global	  emergency”	  in	  1993.103	  This	  was	  triggered	  in	  part	  by	  the	  tuberculosis	  outbreak	  in	  New	  York	  City	  and	  increasing	  tuberculosis	  rates	  around	  the	  world	  more	  generally,	  as	  well	  as	  the	  realization	  that	  globally	  increasing	  HIV/AIDS	  rates	  would	  lead	  to	  further	  increases	  of	  tuberculosis.	  The	  WHO’s	  Global	  TB	  Program	  decided	  to	  push	  for	  the	  global	  implementation	  of	  directly	  observed	  tuberculosis	  therapy	  (branded	  in	  1995	  as	  “DOTS,”	  which	  stands	  for	  Directly	  Observed	  Therapy,	  Short	  Course).	  DOTS	  is	  a	  standardized	  treatment	  regimen	  which	  uses	  the	  two	  most	  effective	  tuberculosis	  drugs,	  isoniazid	  (INH)	  and	  rifampin	  (also	  called	  rifampicin),	  together	  with	  two	  additional	  drugs.	  DOTS	  treatment	  occurs	  in	  outpatient	  settings	  (rather	  than	  in	  the	  hospital),	  and	  emphasizes	  the	  need	  to	  ensure	  that	  patients	  take	  all	  their	  medication	  for	  the	  full	  duration	  of	  treatment.	  In	  most	  cases	  standard	  tuberculosis	  treatment	  takes	  six	  months.	  The	  name	  DOTS	  refers	  to	  the	  recommendation	  that	  health	  workers	  (or	  lay	  community	  health	  workers)	  “directly	  observe”	  patients	  as	  they	  take	  their	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medication	  in	  order	  to	  guarantee	  their	  compliance	  –	  or	  full	  participation	  –	  with	  the	  program.	  From	  a	  public	  health	  perspective	  compliance	  is	  both	  crucial	  and	  onerous	  due	  to	  the	  long	  period	  of	  tuberculosis	  treatment.	  The	  WHO	  used	  its	  political	  weight	  to	  advocate	  for	  the	  introduction	  of	  DOTS	  in	  countries	  around	  the	  globe.104	  Wherever	  there	  is	  drug	  treatment	  there	  is	  the	  potential	  for	  drug	  resistance,	  as	  pathogens	  adapt	  to	  the	  medications	  they	  encounter.	  When	  a	  patient’s	  treatment	  course	  is	  shortened,	  or	  when	  patients	  miss	  a	  significant	  number	  of	  medication	  doses,	  this	  has	  two	  potential	  negative	  effects.	  On	  an	  individual	  level,	  a	  patient	  may	  not	  get	  better	  due	  to	  unsuccessful	  treatment	  of	  tuberculosis.	  On	  a	  population	  level,	  incomplete	  or	  inappropriate	  treatment	  can	  lead	  to	  a	  rise	  of	  tuberculosis	  that	  is	  resistant	  to	  the	  standard	  tuberculosis	  drugs.	  Sanctioned	  tuberculosis	  treatment	  employs	  at	  least	  four	  drugs	  in	  order	  to	  minimize	  the	  chances	  that	  treatment	  fails	  when	  tuberculosis	  becomes	  resistant	  to	  one	  (or	  more)	  of	  the	  four	  drugs.	  Despite	  this,	  over	  the	  past	  65	  years	  tuberculosis	  experts	  have	  repeatedly	  observed	  that	  every	  time	  a	  new	  anti-­‐TB	  drug	  is	  introduced,	  “drug-­‐resistant	  cases	  or	  case	  series	  are	  reported	  within	  months	  to	  years.”105	  Thus,	  it	  was	  no	  scientific	  surprise	  when	  the	  1990s	  saw	  the	  rise	  of	  multi-­‐drug	  resistant	  tuberculosis	  (MDR-­‐TB),	  a	  form	  of	  tuberculosis	  that	  is	  resistant	  to	  at	  least	  isoniazid	  and	  rifampin	  (the	  two	  most	  effective	  anti-­‐TB	  drugs).	  MDR-­‐TB	  is	  generally	  impervious	  to	  the	  standard	  TB	  therapy	  regimen,	  which	  relies	  on	  the	  power	  of	  these	  two	  drugs.	  Despite	  the	  fact	  that	  the	  emergence	  of	  drug-­‐resistance	  was	  scientifically	  predictable,	  however,	  the	  difficulty	  of	  treating	  MDR-­‐TB	  effectively,	  together	  with	  TB’s	  airborne	  transmission,	  caught	  the	  attention	  of	  the	  news	  media.	  Both	  the	  popular	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press	  and	  public	  health	  promoters	  warned	  the	  public	  about	  a	  new	  kind	  of	  deadly	  “Ebola	  with	  wings,”	  and	  argued	  for	  increased	  tuberculosis	  control	  measures.106	  One	  thing	  that	  made	  the	  famous	  outbreak	  of	  tuberculosis	  in	  New	  York	  frightening	  was	  that	  it	  included	  many	  MDR-­‐TB	  cases.	  Multiple	  MDR-­‐TB	  "hotspots"	  were	  also	  documented	  in	  Peruvian	  slums	  and	  Russian	  prisons,	  where	  MDR-­‐TB	  was	  spreading	  even	  among	  people	  who	  had	  never	  been	  exposed	  to	  tuberculosis	  medications	  before.	  This	  meant	  that	  drug-­‐resistant	  TB	  was	  being	  transmitted	  from	  person	  to	  person	  and	  not	  just	  arising	  in	  patients	  who	  did	  not	  take	  their	  medications	  very	  well.	  This	  added	  a	  new	  dimension	  to	  tuberculosis,	  a	  disease	  that	  was	  previously	  considered	  beatable	  because	  it	  was	  relatively	  straightforward	  to	  treat	  and	  cure.107	  In	  the	  period	  following	  the	  fall	  of	  the	  Soviet	  Union,	  the	  rise	  of	  drug-­‐resistant	  tuberculosis	  in	  places	  like	  Russia,	  Georgia,	  Latvia	  and	  Uzbekistan	  was	  of	  particular	  concern	  to	  public	  health	  campaigners	  and	  scientists	  and	  garnered	  significant	  media	  attention.	  While	  the	  definition	  of	  MDR-­‐TB	  only	  required	  strains	  to	  be	  resistant	  to	  isoniazid	  and	  rifampin,	  strains	  that	  were	  resistant	  to	  even	  more	  anti-­‐TB	  drugs	  were	  known	  from	  the	  very	  beginning	  of	  documenting	  drug	  resistance.	  At	  least	  as	  early	  as	  1997	  scientists	  called	  a	  strain	  of	  MDR-­‐TB	  which	  was	  common	  in	  New	  York	  “extremely	  drug-­‐resistant”	  due	  to	  the	  fact	  that	  it	  was	  resistant	  to	  five	  important	  tuberculosis	  drugs,	  including	  all	  four	  first-­‐line	  drugs	  and	  one	  second-­‐line	  drug.108	  Pan-­‐resistant	  tuberculosis	  that	  was	  resistant	  to	  all	  first	  and	  second-­‐line	  drugs	  in	  use	  at	  the	  time	  was	  also	  documented	  in	  1997	  and	  was	  especially	  alarming.109	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Interestingly,	  while	  the	  gradual	  rise	  of	  drug-­‐resistance	  can	  be	  considered	  an	  inevitable	  microbiological	  outcome,	  global	  public	  health	  experts	  have	  simultaneously	  read	  the	  rise	  of	  drug-­‐resistant	  tuberculosis	  as	  an	  indicator	  of	  programmatic	  public	  health	  failure.	  As	  the	  authors	  of	  the	  1997	  WHO	  and	  IUATLD	  report	  “Anti-­‐TB	  Drug	  Resistance	  in	  the	  World”	  stated:	  “a	  high	  prevalence	  of	  MDR-­‐TB	  is	  the	  result	  of	  therapeutic	  anarchy”	  and	  the	  rate	  of	  MDR-­‐TB	  should	  be	  considered	  a	  “good	  ‘summary’	  indicator	  of	  the	  performance	  of	  NTPs	  [National	  Tuberculosis	  Programs].”110	  While	  this	  report	  squarely	  blamed	  national	  tuberculosis	  programs	  for	  failing	  to	  contain	  drug-­‐resistant	  tuberculosis,	  others	  held	  international	  structures	  of	  governance	  and	  economics	  accountable.	  MDR-­‐TB	  gained	  an	  increased	  profile	  among	  people	  interested	  in	  public	  health	  and	  social	  justice	  when	  Paul	  Farmer,	  global	  health	  advocate,	  physician,	  medical	  anthropologist,	  and	  co-­‐founder	  of	  the	  organization	  Partners	  in	  Health,	  publicly	  accused	  of	  the	  WHO	  of	  allowing	  poor	  people	  to	  die	  of	  drug-­‐resistant	  tuberculosis.111	  The	  standardized	  DOTS	  approach,	  supported	  by	  the	  WHO,	  focused	  on	  infectious	  cases	  of	  drug-­‐susceptible	  tuberculosis	  while	  ignoring	  those	  cases	  that	  did	  not	  respond	  to	  the	  standard	  drug-­‐regimen.	  In	  practice,	  this	  meant	  that	  the	  WHO	  explicitly	  advocated	  for	  the	  continuation	  of	  a	  one-­‐regimen-­‐fits-­‐all	  first-­‐line	  standard	  drug-­‐regimen	  even	  once	  patients	  had	  documented	  MDR-­‐TB	  that	  was	  known	  to	  be	  resistant	  to	  the	  two	  most	  important	  first-­‐line	  drugs.	  Christopher	  Murray	  and	  other	  health	  economists	  at	  the	  World	  Bank	  had	  declared	  DOTS	  for	  drug-­‐susceptible	  tuberculosis	  one	  of	  the	  most	  cost-­‐effective	  interventions	  in	  human	  health,	  but	  considered	  MDR-­‐TB	  untreatable,	  claiming	  that	  second-­‐line	  drugs	  were	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too	  expensive,	  and	  thus	  not	  cost-­‐effective.112	  As	  Paul	  Nunn,	  TB/HIV	  and	  drug	  resistance	  coordinator	  for	  the	  WHO,	  explained	  in	  2010	  the	  WHO	  preferred	  to	  single-­‐mindedly	  pursue	  DOTS	  as	  their	  “one	  strong	  idea,”	  and	  had	  significant	  success	  in	  encouraging	  countries	  to	  implement	  their	  standardized	  tuberculosis	  program.113	  Even	  as	  the	  problem	  of	  MDR-­‐TB	  grew,	  the	  WHO	  felt	  justified	  in	  neglecting	  drug-­‐resistant	  tuberculosis	  because	  it	  was	  still	  in	  the	  process	  of	  convincing	  countries	  around	  the	  globe	  to	  implement	  DOTS,	  and	  because	  in	  the	  WHO’s	  view,	  MDR-­‐TB	  indicated	  a	  public	  health	  failure	  on	  the	  part	  of	  the	  implementing	  country.114	  If	  national	  tuberculosis	  programs	  managed	  to	  properly	  implement	  the	  new	  DOTS	  strategy	  for	  drug-­‐susceptible	  tuberculosis	  –	  so	  the	  WHO	  reasoning	  went	  –	  then	  MDR-­‐TB	  would	  be	  a	  rare	  occurrence	  (which	  could	  now	  be	  blamed	  on	  individual	  patient	  non-­‐compliance	  rather	  than	  health	  system	  failure),	  and	  ignoring	  these	  few	  cases	  (essentially	  allowing	  them	  to	  die	  without	  receiving	  appropriate	  treatment)	  would	  make	  sense	  on	  a	  broader	  public	  health	  scale.115	  Paul	  Farmer	  and	  others	  made	  the	  moral,	  political	  and	  microbiological	  argument,	  however,	  that	  the	  continued	  inflexible	  and	  futile	  provision	  of	  standard	  DOTS	  treatment	  in	  light	  of	  resistant	  strains	  would	  not	  only	  kill	  those	  (supposedly	  few)	  individuals	  denied	  effective	  drugs,	  but	  would	  quickly	  amplify	  the	  presence	  of	  MDR-­‐TB	  as	  partially	  resistant	  
                                                112	  Christopher	  J.L.	  Murray	  et	  al.,	  “Cost	  Effectiveness	  of	  Chemotherapy	  for	  Pulmonary	  Tuberculosis	  in	  Three	  Sub-­‐Saharan	  African	  Countries,”	  The	  Lancet	  338,	  no.	  8778	  (1991):	  1305–1308.	  113	  Paul	  Nunn,	  interview	  by	  author,	  27	  May	  2010,	  Durban,	  South	  Africa.	  114	  Ernesto	  Jaramillo,	  interview	  by	  author,	  12	  November	  2010,	  Berlin,	  Germany;	  WHO,	  Anti-­‐
tuberculosis	  Drug	  Resistance	  in	  the	  World:	  The	  WHO/IUATLD	  Global	  Project	  on	  Anti-­‐tuberculosis	  Drug	  
Resistance	  Surveillance:	  1994-­‐1997.	  115	  I	  hesitate	  to	  claim	  that	  the	  WHO	  as	  an	  entity	  “thought”	  or	  “claimed”	  anything,	  yet	  this	  is	  how	  my	  sources	  speak	  about	  the	  WHO.	  Questions	  regarding	  who	  the	  individual	  people	  are	  through	  whom	  the	  WHO’s	  actions	  manifest	  themselves	  rarely	  led	  to	  a	  specific	  answer.	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tuberculosis	  strains	  become	  increasingly	  resistant,	  leading	  to	  the	  uncontrollable	  spread	  of	  difficult-­‐to-­‐treat	  MDR-­‐TB,	  and	  worse,	  around	  the	  world.116	  Paul	  Farmer	  had	  first	  encountered	  the	  devastating	  effects	  of	  MDR-­‐TB	  in	  Peru,	  a	  country	  that	  had	  been	  praised	  by	  the	  WHO	  for	  its	  strong	  DOTS	  program.	  By	  using	  expensive	  resources	  available	  to	  him	  due	  to	  his	  position	  as	  a	  physician	  affiliated	  with	  Harvard	  University	  and	  thanks	  to	  his	  particular	  skill	  at	  fundraising,	  Farmer	  and	  his	  organization,	  Partners	  in	  Health,	  demonstrated	  that	  it	  was	  indeed	  possible	  (and	  in	  his	  view	  imperative)	  to	  save	  lives	  in	  poor	  countries	  by	  treating	  MDR-­‐TB.	  Farmer	  also	  called	  attention	  to	  the	  plight	  of	  prisoners	  in	  the	  former	  Soviet	  Union	  who	  were	  being	  kept	  in	  overcrowded	  conditions.	  Crumbling	  prison	  and	  health	  infrastructure	  contributed	  to	  the	  spread	  of	  MDR-­‐TB,	  leading	  to	  situations	  where	  prisoners	  returned	  home	  from	  their	  prison	  terms	  only	  to	  suffer	  and	  die	  from	  drug-­‐resistant	  tuberculosis,	  putting	  their	  families	  and	  communities	  at	  risk	  for	  infection	  in	  the	  process.	  Of	  course	  the	  disease	  was	  not	  limited	  to	  the	  prisons,	  and	  there	  was	  no	  reason	  to	  believe	  that	  an	  air-­‐borne	  illness	  would	  restrict	  itself	  to	  the	  former	  Soviet	  Union,	  either.	  At	  a	  time	  when	  the	  effects	  of	  structural	  adjustment	  programs	  and	  harsh	  post-­‐communist	  market	  transitions	  were	  becoming	  increasingly	  clear,	  the	  rapid	  rise	  of	  MDR-­‐TB	  in	  the	  former	  Soviet	  Union	  served	  as	  a	  metaphor	  for	  the	  global	  abandonment	  of	  the	  needy	  at	  a	  time	  of	  increased	  global	  mobility.	  In	  a	  twist	  of	  retributive	  justice,	  that	  abandonment	  was	  turning	  out	  to	  have	  potentially	  dangerous	  consequences	  for	  the	  first	  world.117	  
                                                116	  Paul	  Farmer	  and	  Jim	  Yong	  Kim,	  “Community	  Based	  Approaches	  to	  the	  Control	  of	  Multidrug	  resistant	  Tuberculosis:	  Introducing	  ‘DOTS-­‐plus’,”	  British	  Medical	  Journal	  317,	  no.	  7159	  (1998):	  671–674.	  117	  Paul	  Farmer,	  Pathologies	  of	  Power	  (Berkeley:	  University	  of	  California	  Press,	  2005);	  Paul	  Farmer,	  “DOTS	  and	  DOTS-­‐Plus,”	  Annals	  of	  the	  New	  York	  Academy	  of	  Sciences	  953b,	  no.	  1	  (2001):	  165–184;	  Reichman,	  Timebomb;	  M.	  A.	  Espinal	  et	  al.,	  “Rational	  ‘DOTS	  Plus’	  for	  the	  Control	  of	  MDR-­‐TB,”	  The	  
International	  Journal	  of	  Tuberculosis	  and	  Lung	  Disease	  3,	  no.	  7	  (1999):	  561–563;	  Paul	  Farmer	  et	  al.,	  “Management	  of	  MDR-­‐TB	  in	  Resource-­‐poor	  Countries,”	  The	  International	  Journal	  of	  Tuberculosis	  and	  
Lung	  Disease	  3,	  no.	  8	  (999):	  643–645;	  Tracy	  Kidder,	  Mountains	  Beyond	  Mountains:	  The	  Quest	  of	  Dr.	  
Paul	  Farmer,	  a	  Man	  Who	  Would	  Cure	  the	  World	  (Random	  House,	  2004).	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The	  debate	  around	  the	  treatability	  or	  untreatability	  of	  MDR-­‐TB	  demarcated	  a	  number	  of	  institutional	  and	  generational	  shifts	  that	  were	  taking	  place	  in	  the	  international	  public	  health	  world.	  As	  described	  in	  the	  introduction,	  the	  problem	  of	  tuberculosis	  was	  mostly	  considered	  solved	  by	  the	  middle	  of	  the	  twentieth	  century,	  as	  improved	  living	  conditions	  contributed	  to	  declining	  rates	  of	  tuberculosis	  in	  wealthier	  countries	  and	  effective	  antibiotic	  therapy	  seemed	  to	  promise	  the	  possibility	  of	  tuberculosis	  elimination	  world	  wide.	  Research	  projects	  around	  tuberculosis	  were	  mostly	  limited	  to	  operational	  questions	  around	  the	  proper	  administration	  of	  known	  drugs,	  and	  few	  young	  biomedical	  practitioners	  made	  their	  careers	  as	  tuberculosis	  specialists.	  The	  WHO’s	  focus	  on	  directly	  observed	  treatment	  of	  tuberculosis	  reflected	  a	  public	  health	  stance	  which	  emphasized	  enforcing	  compliance	  to	  an	  approved	  drug	  regimen	  in	  order	  to	  protect	  the	  health	  of	  populations	  over	  the	  rights	  of	  individuals.	  In	  the	  1990s,	  eager	  young	  professionals	  like	  Paul	  Farmer	  represented	  the	  moral	  energy	  and	  zeal	  of	  a	  new	  generation	  of	  physicians	  and	  public	  health	  experts	  who	  had	  been	  trained	  during	  the	  rise	  of	  HIV/AIDS.	  This	  new	  generation	  became	  involved	  in	  international	  public	  health	  in	  the	  context	  of	  AIDS	  activism	  and	  the	  struggles	  of	  people	  living	  with	  AIDS	  fighting	  for	  their	  rights	  to	  determine	  how	  they	  would	  come	  to	  terms	  with	  a	  deadly	  and	  highly	  stigmatizing	  disease.	  Many	  health	  professionals	  trained	  at	  this	  time	  were	  less	  comfortable	  than	  old-­‐guard	  tuberculosis	  experts	  with	  coercing	  people	  to	  take	  treatment	  for	  the	  sake	  of	  the	  common	  good,	  and	  instead	  argued	  for	  health	  as	  a	  human	  right	  for	  all	  citizens	  of	  the	  world.	  This	  imperative	  for	  health	  underpinned	  activists’	  demands	  for	  access	  to	  expensive	  antiretroviral	  treatments	  for	  people	  with	  HIV	  even	  if	  economic	  analyses	  deemed	  this	  as	  not	  cost-­‐effective	  in	  poor	  countries.	  Thus,	  according	  to	  some,	  the	  debate	  around	  the	  appropriate	  management	  of	  MDR-­‐TB	  in	  poor	  countries	  also	  reflected	  a	  generational	  battle	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between	  old	  guard	  public	  health	  bureaucrats	  and	  a	  new	  generation	  of	  campaigners	  who	  saw	  themselves	  as	  fighting	  for	  the	  lives	  of	  the	  poor	  and	  disenfranchised.118	  	  The	  WHO	  eventually	  acknowledged	  the	  necessity	  to	  identify	  people	  with	  MDR-­‐TB	  and	  to	  treat	  them	  with	  additional	  second-­‐line	  drugs	  beyond	  the	  standard	  four-­‐drug	  DOTS	  treatment	  course.	  In	  1999,	  WHO	  guidelines	  endorsed	  “DOTS-­‐Plus,”	  which	  called	  for	  the	  use	  of	  second-­‐line	  drugs	  to	  treat	  MDR-­‐TB	  in	  appropriate	  settings.	  Large	  partnerships	  were	  created	  and	  funded	  with	  large	  grants	  from	  donors	  such	  as	  the	  Bill	  and	  Melinda	  Gates	  foundation	  to	  facilitate	  a	  new	  drive	  to	  develop	  and	  study	  well-­‐managed	  pilot	  programs	  to	  deal	  with	  MDR-­‐TB.	  In	  2000	  the	  WHO	  created	  the	  Green	  Light	  Committee	  (GLC)	  to	  oversee	  the	  distribution	  of	  concession-­‐priced	  second-­‐line	  anti-­‐TB	  drugs,	  as	  well	  as	  training	  and	  support,	  to	  eligible	  tuberculosis	  control	  programs.119	  The	  Green	  Light	  Committee	  was	  conceived	  not	  as	  an	  agency	  of	  the	  WHO,	  but	  as	  a	  public-­‐private	  partnership	  made	  up	  of	  “academic	  institutions,	  civil	  society	  organizations,	  bilateral	  donors,	  governments	  of	  resource-­‐limited	  countries,	  and	  a	  specialized	  United	  Nations	  agency”120	  which	  would	  facilitate	  the	  global	  expansion	  of	  MDR-­‐TB	  treatment	  programs.121	  During	  this	  time	  period,	  the	  provision	  of	  long-­‐term	  medical	  therapy	  to	  poor	  people	  with	  infectious	  diseases	  was	  becoming	  increasingly	  politically	  acceptable	  (even	  imperative),	  in	  large	  part	  through	  the	  work	  of	  AIDS	  treatment	  activists	  as	  well	  as	  organizations	  like	  Partners	  in	  Health	  and	  others	  who	  managed	  to	  frame	  health	  as	  a	  human	  right,	  rather	  than	  as	  a	  good	  to	  be	  acquired	  with	  a	  set	  pool	  of	  limited	  resources	  that	  could	  only	  be	  distributed	  unfairly.	  At	  the	  same	  time	  a	  vocal	  and	  global	  network	  of	  AIDS	  activists	  convincingly	  argued	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  Wingfield,	  interview	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  author,	  2010;	  Gregg	  Gonsalves,	  interview	  by	  author,	  5	  March	  2010,	  New	  York,	  NY.	  119	  WHO,	  “DOTS-­‐Plus	  and	  the	  Green	  Light	  Committee”	  (World	  Health	  Organization,	  2000).	  120	  Rajesh	  Gupta	  et	  al.,	  “Increasing	  Transparency	  in	  Partnerships	  for	  Health	  –	  Introducing	  the	  Green	  Light	  Committee,”	  Tropical	  Medicine	  &	  International	  Health	  7,	  no.	  11	  (2002):	  970.	  121	  Rajesh	  Gupta	  et	  al.,	  “Increasing	  Transparency	  in	  Partnerships	  for	  Health	  –	  Introducing	  the	  Green	  Light	  Committee,”	  Tropical	  Medicine	  &	  International	  Health	  7,	  no.	  11	  (2002):	  970–976.	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that	  prevention	  messages	  and	  sympathy	  would	  not	  suffice	  in	  a	  world	  where	  almost	  forty	  million	  people	  were	  already	  living	  with	  HIV/AIDS	  and	  suffering	  from	  its	  accompanying	  infections	  –	  including	  tuberculosis.	  In	  New	  York	  the	  immediate	  threat	  of	  tuberculosis,	  including	  drug-­‐resistant	  tuberculosis,	  was	  averted	  in	  the	  1990s	  through	  intense	  treatment	  and	  infection-­‐control	  activities	  led	  by	  New	  York	  City’s	  public	  health	  department.122	  This	  led	  to	  a	  dramatic	  decline	  of	  overall	  tuberculosis	  rates	  in	  New	  York.	  The	  cost	  was	  high,	  however:	  the	  shock	  of	  the	  resurgence	  of	  an	  almost-­‐forgotten	  airborne	  disease	  in	  a	  less	  treatable	  form	  meant	  that	  an	  estimated	  $1	  billion	  were	  spent	  on	  containing	  tuberculosis	  in	  New	  York	  City	  alone.123	  Over	  the	  course	  of	  the	  next	  several	  years,	  pilot	  programs	  for	  the	  treatment	  and	  management	  of	  drug-­‐resistant	  tuberculosis	  were	  also	  put	  in	  place	  in	  “hotspots”	  like	  the	  slums	  of	  Peru	  (by	  Partners	  in	  Health,	  working	  with	  Harvard	  University	  and	  public	  health	  officials	  in	  Peru),	  in	  Latvia	  (by	  the	  Latvian	  government	  and	  supported	  by	  the	  American	  CDC	  and	  the	  US	  Agency	  for	  International	  Development	  -­‐	  USAID),	  and	  in	  prisons	  in	  Siberia	  (supported	  by	  Partners	  in	  Health	  and	  Doctors	  without	  Borders	  (MSF)),	  among	  others.124	  The	  Green	  Light	  Committee	  (together	  with	  funding	  from	  the	  Global	  Fund	  to	  fight	  AIDS,	  TB	  and	  Malaria)	  put	  within	  reach	  affordable	  MDR-­‐TB	  treatment	  programs	  for	  middle-­‐	  and	  low-­‐income	  countries.	  With	  the	  New	  York	  outbreak	  contained,	  and	  international	  MDR-­‐TB	  outbreaks	  managed,	  drug-­‐resistant	  tuberculosis	  slipped	  into	  the	  background	  of	  public	  concern	  and	  was	  no	  longer	  featured	  frequently	  in	  the	  news.125	  
                                                122	  Frieden	  et	  al.,	  “Tuberculosis	  in	  New	  York	  City—Turning	  the	  Tide.”	  123	  Kenneth	  Castro,	  interview	  by	  author,	  phone	  interview,	  23	  February	  2010.	  124	  Marcos	  A.	  Espinal	  and	  Mario	  C.	  Raviglione,	  eds.,	  “WHO	  Meeting	  to	  Co-­‐ordinate	  the	  DOTS-­‐plus	  Workplan	  on	  Pilot	  Projects	  for	  the	  Management	  of	  Multidrug	  Resistant	  (MDR)	  Tuberculosis	  (TB),”	  Conference	  Report,	  29	  January	  1999.	  125	  It	  is	  worth	  noting	  that	  in	  current	  tuberculosis	  and	  public	  health	  lore,	  Partners	  in	  Health	  (PIH)	  has	  reached	  superstar	  status,	  a	  large	  following,	  and	  significant	  moral	  weight.	  However,	  some	  activists	  stress	  that	  PIH	  was	  not	  the	  first	  organization	  to	  demand	  action	  on	  tuberculosis,	  and	  that	  other	  
 55 
A	  new	  cycle	  This,	  then,	  is	  where	  the	  story	  of	  XDR-­‐TB,	  and	  thus	  the	  story	  of	  this	  dissertation	  begins.	  The	  shock	  brought	  on	  in	  the	  1980s	  by	  AIDS	  –	  a	  new	  and	  fatal	  disease	  –	  and	  tuberculosis	  –	  an	  unexpectedly	  resurgent	  and	  increasingly	  untreatable	  disease	  –	  had	  passed.	  AIDS	  continued	  to	  have	  a	  huge	  cultural	  impact	  in	  public	  health	  circles	  as	  well	  as	  on	  the	  broader	  public,	  while	  tuberculosis	  mostly	  retreated	  into	  the	  background.	  Between	  2000	  and	  2005,	  occasional	  reporting	  on	  tuberculosis	  did	  occur	  as	  the	  media	  continued	  to	  report	  on	  the	  hottest	  infectious	  disease	  threats	  of	  a	  given	  season,	  be	  it	  anthrax,	  SARS,	  Dengue	  fever,	  West	  Nile	  Virus,	  bird	  flu,	  super-­‐resistant	  staphylococcus	  or,	  for	  that	  matter,	  New	  York’s	  bed-­‐bug	  epidemic.126	  Experts	  did	  not	  stop	  working	  on	  drug-­‐resistant	  tuberculosis,	  of	  course.	  Dr.	  Peter	  Cegielski,	  the	  Team	  Leader	  for	  Drug-­‐resistant	  Tuberculosis	  at	  the	  CDC	  took	  exception	  to	  my	  characterization	  of	  the	  early	  2000s	  as	  a	  quiet	  time	  for	  tuberculosis.	  Cegielski	  remembered	  the	  period	  as	  a	  very	  active	  time,	  when	  international	  agencies	  finally	  supported	  the	  idea	  that	  resources	  should	  be	  used	  to	  treat	  MDR-­‐TB	  and	  programs	  were	  put	  in	  place,	  accordingly.	  Yet	  it	  was	  also	  clear	  to	  Cegielski	  “that	  the	  suddenness	  of	  the	  outbreaks	  of	  MDR-­‐TB	  in	  the	  early	  90s	  was	  starting	  to	  fade	  a	  little	  bit	  from	  people’s	  memory.”127	  As	  Dr.	  Sarita	  Shah,	  a	  young	  physician	  working	  for	  the	  CDC	  in	  2005	  perceived	  it,	  broad	  interest	  in	  tuberculosis	  had	  waned	  “since	  MDR-­‐TB	  came	  under	  control	  in	  the	  US	  following	  
                                                                                                                                            important	  organizations,	  such	  as	  the	  Public	  Health	  Research	  Institute	  (PHRI)	  and	  George	  Soros’	  Open	  Society	  Institute	  (OSI)	  have	  not	  been	  sufficiently	  credited	  for	  their	  involvement.	  (Nina	  Schwalbe,	  interview	  by	  author,	  phone	  interview,	  3	  February	  2010.)	  126	  “Anthrax,”	  NYTimes.com,	  http://topics.nytimes.com/top/reference/timestopics/subjects/a/anthrax/index.html?8qa;	  Erik	  Eckholm,	  “China	  Admits	  Underreporting	  its	  SARS	  Cases”	  The	  New	  York	  Times,	  April	  21,	  2003;	  Gayathri	  Vaidyanathan,	  “Dengue	  Re-­‐emerges	  in	  U.S.,	  Spurring	  Race	  for	  Vaccine,”	  The	  New	  York	  Times,	  June	  28,	  2010;	  Andrew	  C.	  Revkin,	  “Clues	  to	  an	  Alien	  Virus;	  Scientists	  Begin	  to	  Crack	  the	  Mysteries	  of	  West	  Nile,”	  The	  New	  York	  Times,	  August	  8,	  2000;	  Donald	  G.	  Mcneil	  Jr,	  “Flu:	  Bird	  Flu	  Falls	  Off	  the	  Radar,	  but	  Cases	  Show	  It’s	  Still	  a	  Threat,”	  The	  New	  York	  Times,	  November	  22,	  2010;	  Lawrence	  K.	  Altman,	  “New	  Bacteria	  Strain	  Is	  Striking	  Gay	  Men,”	  The	  New	  York	  Times,	  January	  15,	  2008;	  “Bedbugs,”	  
NYTimes.com,	  http://topics.nytimes.com/top/reference/timestopics/subjects/b/bedbugs/index.html?8qa.	  127	  Peter	  Cegielski,	  interview	  by	  author,	  phone	  interview,	  2	  February	  2010.	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implementation	  of	  strong	  policies	  and	  programs.”	  She	  felt	  that	  by	  the	  time	  she	  was	  involved,	  a	  relatively	  small	  group	  of	  people	  was	  working	  on	  the	  problem	  of	  global	  tuberculosis	  compared	  to	  the	  burden	  of	  the	  disease	  and	  the	  scope	  of	  the	  problem	  worldwide.128	  Thus,	  by	  2005,	  MDR-­‐TB	  no	  longer	  felt	  like	  an	  overwhelming	  crisis	  in	  public	  health	  circles.	  Yet	  away	  from	  the	  headlines,	  MDR-­‐TB	  continued	  to	  spread	  and	  continued	  to	  kill	  people,	  despite	  efforts	  by	  various	  agencies	  and	  countries	  to	  contain	  it.	  Programs	  running	  under	  the	  auspices	  of	  the	  Green	  Light	  Committee	  covered	  only	  a	  small	  percentage	  of	  those	  at	  risk	  for	  drug	  resistant	  tuberculosis.	  Though	  the	  Green	  Light	  Committee	  had	  approved	  37	  pilot	  projects	  for	  almost	  13,	  000	  MDR-­‐TB	  patients	  in	  31	  countries,	  this	  barely	  put	  a	  dent	  in	  the	  approximately	  460,	  000	  MDR-­‐TB	  cases	  that	  were	  estimated	  to	  occur	  every	  year.	  Only	  8	  of	  the	  22	  WHO-­‐designated	  high	  burden	  countries	  addressed	  MDR-­‐TB	  as	  part	  of	  their	  national	  TB	  treatment	  programs	  in	  2005.129	  Even	  when	  second-­‐line	  drugs	  were	  used	  effectively	  to	  treat	  MDR-­‐TB,	  mortality	  rates	  were	  still	  disappointingly	  high,	  at	  over	  20%,	  even	  in	  model	  programs.130	  In	  fact,	  most	  people	  around	  the	  world	  who	  were	  dying	  of	  tuberculosis	  were	  still	  dying	  of	  perfectly	  drug-­‐susceptible	  (non-­‐resistant)	  strains	  of	  tuberculosis,	  which	  would	  respond	  to	  standard	  drug	  regimens	  if	  they	  were	  made	  available.131	  The	  rest	  of	  this	  chapter	  describes	  the	  efforts	  of	  a	  core	  group	  of	  tuberculosis	  experts	  to	  keep	  tuberculosis,	  and	  drug-­‐resistant	  tuberculosis,	  in	  particular,	  in	  the	  public	  eye.	  Just	  as	  the	  under-­‐treatment	  of	  drug-­‐resistant	  tuberculosis	  was	  known	  to	  further	  amplify	  drug	  
                                                128	  Sarita	  Shah,	  interview	  by	  author,	  phone	  interview,	  30	  March	  2007.	  129	  WHO,	  Global	  Tuberculosis	  Control:	  Surveillance,	  Planning,	  Financing:	  WHO	  Report	  2006.	  (World	  Health	  Organization,	  2006),	  48.	  130	  Sonya	  S.	  Shin	  et	  al.,	  “Long-­‐term	  Follow-­‐up	  for	  Multidrug-­‐resistant	  Tuberculosis,”	  Emerging	  
Infectious	  Diseases	  12,	  no.	  4	  (2006):	  687–688;	  Edward	  D.	  Chan	  et	  al.,	  “Treatment	  and	  Outcome	  Analysis	  of	  205	  Patients	  with	  Multidrug-­‐resistant	  Tuberculosis,”	  American	  Journal	  of	  Respiratory	  and	  
Critical	  Care	  Medicine	  169,	  no.	  10	  (2004):	  1103–1109.	  	  131	  WHO,	  Global	  Tuberculosis	  Control:	  Surveillance,	  Planning,	  Financing:	  WHO	  Report	  2006.	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resistance,	  members	  of	  the	  tuberculosis	  community	  found	  they	  had	  to	  amplify	  their	  descriptions	  of	  tuberculosis	  in	  order	  to	  keep	  the	  interest	  of	  funders,	  scientists,	  governments,	  and	  the	  public.	  
Keeping	  the	  momentum	  going	  –	  the	  origins	  of	  XDR-­‐TB	  In	  2000,	  at	  a	  time	  when	  treating	  MDR-­‐TB	  seemed	  urgent,	  Partners	  in	  Health,	  together	  with	  Harvard,	  the	  CDC,	  the	  Peruvian	  Department	  of	  Health,	  and	  the	  Taskforce	  for	  Child	  Survival	  and	  Development	  received	  a	  $4.7	  million	  5-­‐year	  grant	  from	  the	  Bill	  and	  Melinda	  Gates	  Foundation	  to	  help	  lead	  global	  policy	  development	  for	  MDR-­‐TB,	  which,	  among	  other	  things,	  funded	  the	  activities	  of	  the	  Green	  Light	  Committee	  (GLC)	  described	  above.132	  By	  2004,	  the	  Green	  Light	  Committee	  was	  nearing	  the	  end	  of	  this	  funding	  cycle	  and	  it	  was	  unclear	  who	  would	  provide	  future	  funding.133	  Public	  interest	  in	  MDR-­‐TB	  had	  waned	  following	  successful	  anti-­‐MDR-­‐TB	  programs	  in	  the	  US,	  and	  unlike	  for	  HIV/AIDS,	  there	  was	  no	  strong	  tuberculosis	  lobby	  or	  activist	  movement	  working	  to	  leverage	  increased	  funding	  for	  the	  Green	  Light	  Committee.	  Global	  statistics	  compiled	  by	  the	  WHO	  clearly	  demonstrated	  that	  MDR-­‐TB	  was	  still	  a	  global	  concern	  that	  was	  far	  from	  being	  solved,	  but	  experts	  felt	  there	  was	  a	  need	  to	  raise	  public	  awareness	  about	  drug	  resistant	  tuberculosis	  to	  ensure	  future	  funding	  and	  attention.134	  Green	  Light	  Committee	  chair	  Dr.	  Peter	  Cegielski,	  who	  represented	  the	  CDC	  in	  the	  Green	  Light	  Committee,	  often	  had	  the	  opportunity	  to	  visit	  national	  MDR-­‐TB	  programs	  around	  the	  world	  as	  part	  of	  his	  work.135	  When	  visiting	  program	  sites,	  he	  would	  usually	  be	  shown	  the	  most	  complicated	  cases	  and	  he	  would	  hear	  stories	  about	  tuberculosis	  patients	  
                                                132	  Cegielski,	  interview	  by	  author,	  2010.	  133	  Shah,	  interview	  by	  author,	  2007.	  134	  Ibid.	  135	  Peter	  Cegielski	  was	  chairman	  of	  the	  Green	  Light	  Committee	  from	  2004-­‐2006.	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whose	  tuberculosis	  strains	  were	  so	  resistant	  to	  drugs	  that	  they	  were	  not	  responding	  even	  to	  the	  second-­‐line	  drugs	  used	  to	  treat	  MDR-­‐TB	  because	  first-­‐line	  drugs	  no	  longer	  were	  effective.	  As	  mentioned	  earlier,	  such	  resistance	  to	  second-­‐line	  drugs	  had	  in	  fact	  been	  documented	  previously	  and	  was	  considered	  almost	  inevitable	  in	  view	  of	  the	  biology	  of	  drug-­‐resistance.	  Yet	  its	  increasing	  prevalence	  was	  still	  a	  disturbing	  unintended	  consequence	  of	  expanding	  access	  to	  second-­‐line	  tuberculosis	  drugs	  to	  treat	  MDR-­‐TB.	  By	  2004	  Dr.	  Cegielski	  had	  the	  impression	  that	  the	  reports	  of	  severe	  drug-­‐resistance	  were	  becoming	  more	  frequent,	  leading	  him	  to	  believe	  (as	  he	  put	  it)	  that	  “wow,	  this	  is	  an	  emerging	  epidemic.”136	  After	  consulting	  with	  some	  laboratory-­‐based	  tuberculosis	  experts	  who	  agreed	  that	  they,	  too,	  were	  seeing	  this	  trend,	  Cegielski	  decided	  it	  would	  be	  fruitful	  to	  get	  a	  global,	  numerical	  sense	  of	  the	  extent	  of	  second-­‐line	  resistance.	  He	  believed	  that	  compiling	  the	  data	  in	  a	  quantitative	  way	  would	  demonstrate	  that	  increasing	  levels	  of	  drug-­‐resistant	  tuberculosis	  continued	  to	  be	  a	  threat	  and	  would	  highlight	  the	  importance	  of	  well-­‐managed	  second-­‐line	  tuberculosis	  treatment	  programs	  that	  do	  all	  in	  their	  power	  to	  prevent	  the	  rise	  of	  further	  drug-­‐resistance.	  The	  goal,	  in	  part,	  was	  to	  generate	  a	  new	  wave	  of	  excitement	  about	  tuberculosis	  and	  render	  the	  tuberculosis	  funding	  climate	  more	  favorable.137	  
Documenting	  drug	  resistance	  worse	  than	  MDR-­‐TB	  Cegielski	  assigned	  the	  task	  of	  documenting	  these	  highly	  resistant	  tuberculosis	  strains	  in	  a	  systematic	  fashion	  to	  Dr.	  Sarita	  Shah,	  who	  had	  recently	  joined	  the	  CDC’s	  Epidemic	  Intelligence	  Service	  (EIS)	  in	  August	  2004.	  As	  an	  EIS	  officer,	  she	  belonged	  to	  the	  fabled	  “disease	  detective	  corps”	  that	  has	  a	  reputation	  for	  attracting	  people	  who	  are	  “young,	  highly	  trained,	  and	  fiercely	  committed”	  to	  their	  work.138	  Descriptions	  of	  EIS	  work	  often	  
                                                136	  Cegielski,	  interview	  by	  author,	  2010.	  137	  Ibid.;	  Shah,	  interview	  by	  author,	  2007.	  138	  Maryn	  McKenna,	  Beating	  Back	  the	  Devil:	  On	  the	  Front	  Lines	  with	  the	  Disease	  Detectives	  of	  the	  
Epidemic	  Intelligence	  Service	  (New	  York:	  Free	  Press,	  2004),	  2.	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focus	  on	  heroic	  adventures	  that	  involve	  hunting	  down	  deadly	  diseases	  in	  remote	  places.139	  This	  assignment,	  however,	  hinged	  on	  assembling	  and	  analyzing	  statistical	  data	  generated	  around	  the	  world	  and	  could	  be	  completed	  from	  Atlanta	  (where	  Shah	  was	  based)	  or	  any	  other	  location	  with	  a	  computer	  and	  an	  internet	  connection.	  Together	  with	  Dr.	  Cegielski	  and	  her	  immediate	  CDC	  supervisor,	  Dr.	  Kayla	  Laserson,	  Dr.	  Shah	  created	  a	  data-­‐collection	  instrument	  with	  which	  to	  capture	  the	  state	  of	  highly	  drug	  resistant	  tuberculosis	  around	  the	  world.	  They	  decided	  that	  a	  survey	  of	  the	  Global	  Supranational	  TB	  Reference	  Laboratory	  (SRL)	  Network	  would	  be	  the	  most	  efficient	  way	  to	  generate	  credible	  and	  powerful	  global	  data.	   The	  SRL	  Network	  consists	  of	  “25	  reference	  laboratories	  on	  six	  continents	  that	  collaborate	  with	  national	  reference	  laboratories	  to	  increase	  culture	  and	  drug-­‐susceptibility	  testing	  capacity	  and	  provide	  quality	  control	  for	  global	  surveys	  to	  assess	  anti-­‐TB	  drug	  resistance.”140	  These	  laboratories	  were	  originally	  identified	  in	  the	  mid	  1990s	  when	  concern	  about	  MDR-­‐TB	  was	  growing	  but	  only	  limited	  information	  about	  MDR-­‐TB’s	  global	  scope	  was	  available.	  The	  WHO	  sought	  high	  quality	  laboratories	  that	  could	  help	  the	  WHO	  administer	  global	  tuberculosis	  drug	  resistance	  surveys	  and	  use	  standardized	  measures	  to	  assess	  the	  presence	  of	  tuberculosis	  strains	  resistant	  to	  first-­‐line	  anti-­‐tuberculosis	  drugs	  (specifically	  isoniazid	  and	  rifampin).	  The	  Secondary	  Reference	  Laboratories	  that	  were	  selected	  to	  conduct	  these	  surveys	  have	  good	  reputations	  for	  performing	  high	  quality,	  reliable	  work	  relating	  to	  tuberculosis	  diagnostics.	  Not	  only	  are	  they	  globally	  distributed	  and	  receive	  clinical	  samples	  from	  many	  
                                                139	  Mark	  Pendergrast,	  Inside	  the	  Outbreaks:	  The	  Elite	  Medical	  Detectives	  of	  the	  Epidemic	  Intelligence	  
Service	  (Boston:	  Houghton	  Mifflin	  Harcourt,	  2010);	  Maryn	  McKenna,	  Beating	  Back	  the	  Devil:	  On	  the	  
Front	  Lines	  with	  the	  Disease	  Detectives	  of	  the	  Epidemic	  Intelligence	  Service	  (New	  York:	  Free	  Press,	  2004).	  140	  Wright	  et	  al.,	  “Emergence	  of	  Mycobacterium	  Tuberculosis	  with	  Extensive	  Resistance	  to	  Second-­‐Line	  Drugs	  –	  Worldwide,	  2000-­‐2004,”	  302.	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countries,	  but	  they	  also	  participate	  in	  a	  centralized	  quality	  assurance	  program	  to	  ensure	  accuracy	  and	  consistency	  of	  their	  first-­‐line	  drug	  resistance	  data.	  The	  good	  reputation	  of	  the	  labs	  was	  especially	  important	  to	  Dr.	  Shah’s	  study	  of	  highly	  drug	  resistant	  tuberculosis	  because	  testing	  of	  resistance	  to	  second-­‐line	  tuberculosis	  drugs	  (which	  are	  used	  to	  treat	  MDR-­‐TB)	  is	  not	  routinely	  done	  by	  most	  labs,	  and	  has	  not	  been	  universally	  standardized.	  The	  SRLs	  are	  not	  centrally	  managed	  or	  administered,	  however,	  and	  while	  they	  may	  be	  inclined	  to	  participate	  in	  collaborative	  research	  and	  surveillance	  projects	  beyond	  the	  regular	  WHO	  drug	  resistance	  surveillance	  surveys	  (which	  are	  financed	  by	  the	  WHO),	  they	  are	  under	  no	  obligation	  to	  do	  so.141	  In	  addition,	  the	  labs	  are	  not	  distributed	  in	  such	  a	  way	  that	  they	  accurately	  reflect	  global	  tuberculosis	  epidemiology.	  There	  is	  a	  heavy	  concentration	  of	  SRLs	  in	  Europe,	  and	  only	  a	  few	  are	  in	  what	  would	  be	  considered	  “resource-­‐poor”	  regions,	  primarily	  because	  the	  WHO	  relied	  on	  existing,	  reputable	  laboratories	  when	  choosing	  which	  labs	  to	  certify	  as	  SRLs.	  By	  2006,	  there	  were	  26	  SRLs:	  11	  in	  Europe,	  5	  in	  the	  Americas,	  5	  in	  the	  Western	  Pacific	  region,	  2	  in	  South	  Asia	  and	  2	  in	  Africa.142	  	  Meanwhile,	  of	  the	  22	  countries	  designated	  by	  the	  WHO	  as	  having	  a	  high	  burden	  of	  tuberculosis,	  9	  were	  located	  in	  Africa,	  5	  in	  South	  East	  Asia,	  and	  only	  one	  in	  Europe.143	  Despite	  these	  limitations,	  one	  feature	  of	  working	  with	  the	  Supranational	  Reference	  Laboratories	  that	  appealed	  to	  Dr.	  Shah	  and	  the	  CDC	  was	  the	  increased	  credibility	  granted	  to	  collaborative	  work	  by	  the	  scientific	  community.	  Successfully	  bringing	  together	  these	  25	  laboratories	  (or	  a	  subset	  of	  them)	  would	  be	  a	  good	  strategic	  move.	  In	  discussing	  this	  study,	  Dr.	  Shah	  stressed	  the	  importance	  of	  the	  collaborative	  interactions	  between	  the	  different	  SRLs	  and	  her,	  between	  different	  tuberculosis	  researchers	  at	  the	  CDC,	  and	  between	  the	  CDC,	  
                                                141	  Email	  between	  Peter	  Cegielski	  and	  Sarita	  Shah	  on	  31	  March	  2005.	  142	  There	  were	  only	  25	  SRLs	  at	  the	  time	  of	  the	  study	  I	  am	  discussing	  here;	  I	  am	  not	  sure	  which	  of	  these	  26	  labs	  was	  new	  in	  2006.	  143	  WHO,	  Global	  Tuberculosis	  Control:	  Surveillance,	  Planning,	  Financing:	  WHO	  Report	  2006.	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WHO,	  and	  the	  International	  Union	  Against	  Tuberculosis	  and	  Lung	  Disease	  (IUATLD).144	  The	  coordination	  of	  such	  multinational	  and	  multi-­‐organizational	  interactions	  requires	  considerable	  effort,	  but	  is	  highly	  valued	  among	  international	  health	  agencies,	  who	  often	  find	  it	  difficult	  to	  synchronize	  their	  activities.	  In	  the	  letters	  Dr.	  Shah	  sent	  to	  the	  SRL	  directors	  inviting	  them	  to	  contribute	  their	  data	  to	  the	  study,	  she	  emphasized	  the	  collaborative	  nature	  of	  the	  project,	  and	  reminded	  them	  of	  successful	  collaborations	  in	  the	  past.	  145	  Beginning	  in	  October	  2004,	  Dr.	  Cegielski	  and	  later	  Dr.	  Shah	  began	  approaching	  the	  SRL	  directors,	  asking	  them	  to	  contribute	  their	  computerized	  data	  on	  all	  Mycobacterium	  tuberculosis	  isolates	  they	  had	  tested	  for	  second-­‐line	  drugs	  during	  the	  course	  of	  their	  regular	  operations	  between	  2000	  and	  2004.	  It	  was	  Dr.	  Shah's	  responsibility	  to	  collate	  the	  data	  into	  a	  meaningful	  paper.	  This	  was	  essentially	  a	  retrospective	  analysis	  based	  on	  convenience	  –	  the	  designers	  of	  the	  study	  did	  not	  have	  the	  ability	  to	  influence	  the	  ways	  in	  which	  data	  had	  been	  collected	  or	  processed,	  but	  were	  merely	  collecting	  information	  from	  databases	  that	  were	  already	  there.	  Thus	  it	  was	  important	  that	  the	  data	  sources	  be	  reliable	  but	  not	  too	  difficult	  to	  access.	  Most	  of	  the	  SRLs	  agreed	  to	  contribute	  data.	  The	  SRLs’	  characteristics	  as	  reliable	  sources	  of	  data	  ensured	  the	  credibility	  of	  a	  study	  whose	  authors	  essentially	  knew	  what	  results	  they	  were	  going	  to	  find	  –	  alarming	  cases	  of	  tuberculosis	  resistant	  to	  second	  line	  drugs	  –	  before	  they	  set	  out	  to	  find	  them.	  What	  wasn't	  clear	  from	  the	  onset	  was	  how	  many	  cases	  of	  this	  new,	  scary	  disease	  would	  be	  identified,	  or	  exactly	  which	  drugs	  they	  would	  be	  resistant	  to.	  
                                                144	  Supranational	  Reference	  Laboratories	  are	  affiliated	  both	  with	  the	  World	  Health	  Organization	  and	  the	  International	  Union	  Against	  Tuberculosis	  and	  Lung	  Disease.	  145	  Dr.	  Shah	  repeatedly	  stressed	  the	  collaborative	  nature	  of	  the	  study	  to	  the	  author	  and	  included	  the	  following	  comment	  in	  an	  email:	  "I	  think	  an	  important	  thing	  to	  emphasize	  with	  the	  SRL	  survey	  experience	  is	  that	  there	  was	  an	  incredible	  spirit	  of	  collaboration	  in	  the	  interest	  of	  raising	  awareness	  for	  this	  public	  health	  issue.	  I	  had	  never	  met	  any	  of	  the	  SRL	  directors,	  yet	  they	  all	  quickly	  and	  willingly	  shared	  their	  data	  which	  they	  could	  have	  chosen	  to	  publish	  on	  their	  own.	  	  This	  all	  took	  place	  in	  a	  relatively	  short	  time	  span:	  8/04-­‐3/06,	  from	  inception	  to	  MMWR.	  	  It's	  really	  quite	  a	  beautiful	  testament	  to	  the	  commitment	  and	  collegiality	  of	  the	  SRL	  network,	  WHO,	  and	  CDC,"	  personal	  communication,	  April	  11,	  2007.	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Compiling	  these	  cases	  was	  not	  a	  simple	  matter	  of	  merging	  the	  different	  SRL	  databases,	  since	  each	  database	  was	  constructed	  based	  on	  different	  rules	  and	  represented	  different	  facts	  about	  drug-­‐resistance.	  The	  different	  SRLs	  did	  not	  all	  test	  for	  resistance	  to	  the	  same	  drugs.	  Some	  laboratories	  had	  decided	  that	  a	  particular	  test	  was	  not	  reliable	  from	  a	  technical	  standpoint;	  in	  other	  cases	  a	  particular	  drug	  was	  not	  being	  used	  in	  a	  laboratory’s	  catchment	  area,	  thus	  making	  the	  presence	  of	  resistance	  clinically	  unimportant.	  Some	  reference	  laboratories	  (specifically	  the	  one	  located	  in	  South	  Korea)	  had	  drug	  resistance	  information	  on	  every	  single	  person	  in	  their	  catchment	  area	  who	  was	  ever	  tested	  for	  tuberculosis,	  and	  had	  enormous	  databases	  filled	  with	  cases	  of	  drug-­‐resistance	  which	  would	  never	  have	  been	  discovered	  in	  other	  countries.	  Other	  SRLs	  only	  had	  data	  on	  a	  small	  subset	  of	  their	  catchment	  population	  –	  only	  from	  people	  who	  had	  failed	  previous	  first-­‐line	  tuberculosis	  treatment	  multiple	  times,	  for	  example.	  Some	  laboratories	  had	  representative	  data	  for	  the	  country	  or	  region	  they	  were	  located	  in,	  but	  also	  had	  individual	  sporadic	  data	  on	  cases	  from	  other	  countries	  mixed	  in,	  making	  certain	  types	  of	  statistical	  statements	  based	  on	  geographical	  area	  difficult	  to	  calculate.	  Often,	  the	  same	  patient	  would	  appear	  in	  a	  database	  multiple	  times	  –	  this	  needed	  to	  be	  identified	  in	  order	  to	  avoid	  duplicating	  results.	  The	  different	  ways	  that	  information	  had	  been	  generated	  and	  placed	  into	  the	  different	  databases	  needed	  to	  be	  taken	  into	  account	  before	  the	  databases	  could	  be	  merged	  into	  a	  single	  study.	  It	  was	  Dr.	  Shah’s	  job	  to	  “clean	  the	  data”	  in	  order	  to	  assemble	  it	  and	  use	  it	  to	  make	  meaningful	  results.146	  In	  addition,	  none	  of	  the	  SRLs	  included	  substantial	  clinical	  data	  about	  the	  patients	  whose	  samples	  they	  had	  tested	  beyond	  the	  drug	  resistance	  profiles.	  How	  sick	  were	  the	  patients?	  How	  lethal	  was	  a	  particular	  strain	  of	  tuberculosis?	  What	  kind	  of	  tuberculosis	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  Shah,	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  by	  author,	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treatment	  had	  the	  patient	  received?	  Was	  the	  patient	  HIV	  positive?	  These	  were	  questions	  that	  for	  the	  most	  part	  could	  not	  be	  answered	  by	  the	  SRL	  databases.	  
What’s	  in	  a	  name?	  The	  uses	  of	  the	  letter	  X	  The	  soon-­‐to-­‐be-­‐counted	  cases	  of	  highly	  resistant	  tuberculosis	  needed	  a	  name.	  This	  was	  necessary,	  in	  part,	  so	  that	  Shah	  and	  her	  colleagues	  would	  be	  able	  to	  discuss	  the	  results	  in	  an	  efficient	  and	  meaningful	  way.	  Strictly	  speaking,	  these	  cases	  would	  be	  a	  subset	  of	  multi-­‐drug	  resistant	  tuberculosis	  (MDR-­‐TB),	  since	  MDR-­‐TB	  is	  defined	  as	  tuberculosis	  resistant	  to	  
at	  least	  isoniazid	  and	  rifampin.	  This	  would	  have	  to	  be	  the	  minimum	  requirement	  for	  any	  strain	  considered	  even	  more	  concerning	  than	  the	  “baseline”	  MDR-­‐TB.	  MDR-­‐TB	  was	  an	  old	  concept	  at	  this	  point,	  however,	  and	  a	  name	  was	  required	  that	  could	  highlight	  the	  fact	  that	  these	  cases	  were	  worse	  than	  the	  already	  difficult-­‐to-­‐treat	  MDR-­‐TB.	  Ideally,	  the	  new	  name	  would	  capture	  the	  attention	  of	  public	  health	  experts,	  scientists,	  and	  lay	  media	  alike.	  As	  Dr.	  Shah	  tells	  the	  story,	  those	  working	  on	  the	  project	  initially	  used	  whatever	  name	  came	  to	  mind	  in	  order	  to	  communicate	  about	  their	  work.	  Highly	  resistant,	  super	  resistant	  and	  ultra	  resistant	  were	  all	  used,	  among	  others.	  She	  and	  her	  colleagues	  felt,	  however,	  that	  a	  really	  good	  name	  was	  needed;	  one	  that	  would	  drum	  up	  attention	  and	  funds.147	  The	  new	  disease’s	  name	  also	  needed	  to	  be	  one	  that	  worked	  for	  tuberculosis	  researchers	  working	  on	  a	  diverse	  set	  of	  research	  problems	  and	  regions.	  Dr.	  Timothy	  Holtz	  was	  one	  such	  tuberculosis	  researcher;	  he	  was	  a	  medical	  epidemiologist	  working	  under	  Kayla	  Laserson	  at	  the	  CDC’s	  Division	  of	  TB	  Elimination.	  One	  of	  his	  research	  projects	  involved	  working	  together	  with	  MDR-­‐TB	  researchers	  in	  Latvia	  to	  assess	  Latvia’s	  program’s	  cure	  rates	  for	  MDR-­‐TB	  treatment	  depending	  on	  what	  types	  of	  drugs	  were	  used.	  (The	  best	  treatment	  strategies	  for	  MDR-­‐TB	  continue	  to	  be	  an	  object	  of	  study.)	  Something	  he	  was	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taking	  into	  account	  in	  this	  research	  was	  how	  specific	  drug	  resistance	  patterns	  affected	  treatment	  outcomes.148	  Thus	  he,	  too,	  was	  looking,	  among	  other	  things,	  at	  a	  subset	  of	  patients	  whose	  tuberculosis	  strains	  were	  resistant	  to	  all	  or	  most	  available	  anti-­‐tuberculosis	  drugs,	  including	  second-­‐line	  drugs,	  though	  he	  was	  focusing	  specifically	  on	  the	  Latvian	  program.149	  By	  early	  2005,	  both	  Dr.	  Shah	  and	  Dr.	  Holtz’s	  projects	  were	  independently	  making	  progress.	  Some	  of	  the	  Supranational	  Reference	  Laboratories	  had	  submitted	  their	  data	  on	  second-­‐line	  drug	  resistance	  to	  Dr.	  Shah;	  Dr.	  Holtz	  and	  his	  collaborators	  were	  beginning	  to	  see	  interesting	  trends	  in	  the	  success	  of	  certain	  subsets	  of	  MDR-­‐TB	  treatment	  in	  Latvia.	  Both	  groups	  were	  separately	  looking	  ahead	  to	  submitting	  abstracts	  summarizing	  their	  research	  to	  the	  annual	  meeting	  of	  the	  International	  Union	  Against	  Tuberculosis	  and	  Lung	  Disease	  (officially	  called	  the	  Union	  World	  Conference	  on	  Lung	  Health,	  and	  usually	  simply	  called	  “The	  Union”),	  the	  biggest	  annual	  TB-­‐related	  conference.150	  It	  was	  during	  a	  casual	  conversation	  in	  the	  hallway	  at	  the	  CDC	  between	  Peter	  Cegielski	  and	  Timothy	  Holtz	  that	  the	  two	  men	  acknowledged	  they	  were	  working	  on	  related	  questions.	  They	  agreed	  that	  it	  would	  make	  sense	  if	  both	  groups	  used	  the	  same	  language	  to	  describe	  the	  heightened	  degree	  of	  drug	  resistance	  they	  were	  documenting	  in	  their	  respective	  research.	  Dr.	  Cegielski	  had	  suggested	  something	  like	  “superbugs”	  –	  but	  this	  had	  already	  been	  used	  frequently	  to	  describe	  drug-­‐resistant	  staphylococcus	  aureus	  (MRSA)	  skin	  
                                                148	  The	  drug	  resistance	  pattern	  describes	  exactly	  which	  drugs	  a	  given	  tuberculosis	  strain	  is	  resistant	  to.	  While	  MDR-­‐TB	  is	  at	  least	  resistant	  to	  isoniazid	  and	  rifampin,	  a	  given	  strain	  could	  also	  be	  resistant	  to	  any	  combination	  of	  pyrazinamide,	  ethambutol,	  streptomycin	  (these	  are	  first-­‐line	  drugs),	  as	  well	  as	  the	  second	  line	  drugs,	  which	  include	  fluoroquinolones	  (such	  as	  oxofloxacin),	  kanamycin,	  capreomycin,	  and	  several	  others.	  The	  general	  consensus	  today	  is	  that	  increasing	  drug	  resistance	  is	  related	  to	  worse	  treatment	  outcomes,	  but	  that	  certain	  resistance	  combinations	  including	  fluoroquinolone	  resistance	  are	  particularly	  difficult	  to	  treat.	  149	  Timothy	  Holtz,	  interview	  by	  author,	  phone	  interview,	  8	  February	  2010.	  150	  Union	  abstracts	  were	  due	  in	  March	  2005;	  the	  actual	  meeting	  took	  place	  in	  Paris	  in	  October	  2005.	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infections,	  among	  other	  things,	  and	  didn’t	  seem	  specific	  enough.	  Something	  that	  sounded	  similar	  to	  MDR-­‐TB,	  but	  worse,	  would	  be	  compelling.151	  Dr.	  Holtz	  remembers	  thinking	  of	  possible	  letters	  and	  “all	  of	  the	  sudden	  it	  just	  popped	  into	  my	  head	  [...]	  instead	  of	  MDR	  why	  don’t	  we	  think	  of	  another	  letter,	  so	  I	  remember	  thinking	  of	  the	  X-­‐men	  and	  the	  X-­‐games,	  thinking,	  well,	  why	  don’t	  we	  just	  use	  the	  letter	  “X”	  because	  a	  lot	  of	  other	  people	  use	  this	  letter	  “X”	  to	  designate	  something	  that’s	  special	  or	  unique,	  and	  so	  why	  don’t	  we	  just	  call	  it	  XDR.”152	  Dr.	  Holtz	  wasn’t	  sure	  what	  the	  acronym	  would	  stand	  for,	  but	  as	  far	  as	  Dr.	  Cegielski	  was	  concerned,	  this	  was	  “one	  of	  those	  eureka	  moments.	  […]	  We	  both	  kind	  of	  ran	  down	  the	  corridor	  and	  grabbed	  Sarita	  and	  said	  ‘we’re	  going	  to	  call	  it	  XDR.’”153	  As	  Dr.	  Sarita	  Shah	  recalled:	  “It	  sounded	  like	  an	  offshoot	  of	  extreme	  sports,	  […]	  it's	  like	  reality	  TV	  shows	  and	  things	  like	  that.	  And	  X	  is	  an	  exciting	  letter,	  and	  we	  thought	  if	  we	  call	  it	  Extremely	  Drug	  Resistant	  TB	  –	  XDR	  TB	  –	  that	  would	  be	  really	  catchy.	  And	  so	  it	  was	  sort	  of	  just	  like,	  we	  were	  just	  being	  creative,	  standing	  in	  the	  hall,	  and	  the	  whole	  point	  of	  this	  was	  to	  raise	  awareness	  of	  this	  issue.	  And	  so	  we	  called	  it	  extreme,	  drug-­‐resistant	  TB.”154	  The	  quality	  and	  credibility	  of	  data	  was	  very	  important,	  but	  creative	  naming	  and	  creative	  acronyms	  were	  also	  appropriate,	  since	  the	  point	  of	  the	  study	  was	  to	  raise	  awareness	  of	  the	  potential	  threat	  posed	  by	  increasing	  levels	  of	  tuberculosis	  drug	  resistance.	  Cegielski,	  Holtz	  and	  Shah	  all	  described	  being	  energized	  by	  the	  idea	  of	  calling	  tuberculosis	  with	  a	  heightened	  degree	  of	  drug-­‐resistance	  “XDR-­‐TB,”	  or	  extreme.	  They	  explicitly	  tapped	  into	  pre-­‐existing	  cultural	  uses	  of	  the	  letter	  “X”	  both	  as	  an	  unknown	  variable	  (in	  mathematic	  equations),	  unknown	  origins	  (as	  in	  Malcolm-­‐X),	  a	  marker	  for	  an	  unknown	  and	  invisible	  
                                                151	  Holtz,	  interview	  by	  author,	  2010.	  152	  Ibid.	  153	  Cegielski,	  interview	  by	  author,	  2010.	  154	  Shah,	  interview	  by	  author,	  2007.	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mechanism	  (as	  in	  X-­‐Rays)	  as	  well	  as	  a	  designation	  for	  things	  that	  are	  dangerous,	  powerful,	  excessive	  and	  extreme	  (as	  in	  X-­‐games	  and	  X-­‐men),	  or	  forbidden	  (X-­‐rated).	  X	  has	  become	  a	  particularly	  useful	  designation	  for	  things	  that	  combine	  the	  attributes	  of	  mystery	  and	  danger,	  such	  as	  “X-­‐files.”155	  The	  new	  XDR-­‐TB	  could	  similarly	  be	  understood	  as	  being	  an	  entity	  whose	  precise	  nature	  was	  not	  known,	  but	  which	  was	  clearly	  dangerous.	  The	  cultural	  valence	  of	  the	  letter	  “X”	  was	  not	  lost	  on	  professional	  colleagues	  who	  worked	  outside	  of	  the	  CDC.	  Dr.	  Friedland,	  who	  today	  is	  one	  of	  the	  foremost	  experts	  on	  XDR-­‐TB	  due	  to	  his	  research	  on	  XDR-­‐TB	  in	  South	  Africa,	  later	  attributed	  part	  of	  the	  disease’s	  importance	  to	  its	  name:	  “I	  think	  the	  fact	  that	  it's	  X-­‐DR	  TB	  really	  makes	  a	  difference,	  compared	  to	  being	  MDR	  or	  mXDR	  TB.156	  Because,	  sort	  of,	  what's	  in	  a	  word.	  X	  equals	  extreme,	  exaggerated,	  […]	  Excalibur,	  extraordinary,	  you	  know,	  and	  M	  equals	  moderate,	  mild,	  maybe.	  […]	  From	  a	  marketing	  standpoint,	  if	  you	  want	  to	  think	  about	  it	  that	  way,	  the	  fact	  that	  it's	  X	  has	  actually	  contributed	  to	  its	  explosion.”157	  
The	  importance	  of	  an	  moderate,	  yet	  extreme,	  definition	  Once	  the	  name	  of	  the	  object	  of	  study	  was	  determined,	  Dr.	  Shah	  and	  her	  colleagues	  still	  needed	  to	  define	  it,	  however.	  An	  extreme	  name	  seemed	  to	  warrant	  an	  extreme	  definition.	  The	  initial	  idea	  was	  that	  XDR-­‐TB	  should	  be	  resistant	  to	  "all	  of	  the	  drugs	  known	  to	  man	  to	  treat	  tuberculosis."158	  This	  turned	  out	  to	  be	  an	  impractical	  definition,	  since	  very	  few	  labs	  (even	  the	  SRLs)	  actually	  test	  for	  resistance	  to	  all	  drugs	  known	  to	  treat	  tuberculosis,	  and	  only	  very	  few	  cases	  would	  be	  documented.	  There	  was	  little	  point	  in	  defining	  a	  new	  entity	  
                                                155	  For	  an	  interesting,	  light-­‐hearted	  discussion	  of	  the	  uses	  of	  the	  letter	  X	  see	  Jonathon	  Green,	  “X-­‐rated:	  What	  is	  so	  Special	  About	  the	  Letter	  ‘X’,”	  The	  Independent,	  November	  7,	  2006	  http://www.independent.co.uk/news/uk/this-­‐britain/xrated-­‐what-­‐is-­‐so-­‐special-­‐about-­‐the-­‐letter-­‐x-­‐423333.html.	  156	  At	  one	  point	  there	  was	  a	  discussion	  about	  calling	  a	  form	  of	  XDR-­‐TB	  that	  did	  not	  quite	  fit	  the	  official	  definition	  for	  XDR-­‐TB	  “modified”	  XDR-­‐TB	  or	  mXDR-­‐TB.	  157	  Gerald	  Friedland,	  interview	  by	  author,	  27	  March	  2007,	  New	  Haven,	  CT.	  158	  Shah,	  interview	  by	  author,	  2007.	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that	  could	  not	  be	  measured	  and	  was	  not	  clinically	  relevant.	  The	  significance	  of	  the	  term	  did	  not	  only	  require	  a	  good	  name,	  but	  a	  useful	  “real-­‐world”	  application.	  The	  definition	  turned	  out	  to	  be	  the	  object	  of	  extensive	  negotiations	  between	  the	  parties	  involved	  in	  Shah’s	  study.	  What	  was	  clear	  early	  on	  was	  that	  XDR-­‐TB	  would	  be	  defined	  as	  MDR-­‐TB	  plus	  resistance	  to	  some	  other	  drugs.159	  But	  which	  other	  drugs?	  Only	  second-­‐line	  drugs,	  or	  also	  the	  first	  line	  drugs	  not	  included	  in	  the	  minimal	  MDR	  definition?	  If	  only	  second-­‐line	  drugs	  would	  be	  included,	  which	  ones?	  There	  were	  dozens	  of	  more-­‐or-­‐less	  effective	  second-­‐line	  drugs	  to	  choose	  from,	  some	  of	  which	  could	  potentially	  be	  grouped	  into	  similar	  classes.	  Researchers	  were	  trying	  to	  maximize	  the	  sense	  of	  risk	  and	  danger	  associated	  with	  the	  name	  XDR.	  Completely	  untreatable	  tuberculosis	  resistant	  to	  all	  drugs	  available	  on	  planet	  earth	  may	  seem	  frightening,	  but	  if	  only	  one	  or	  two	  cases	  are	  identified,	  it	  is	  hardly	  alarming.	  A	  definition	  was	  needed	  that	  would	  both	  express	  a	  sense	  of	  urgency	  (almost	  untreatable	  tuberculosis)	  and	  yield	  a	  relatively	  large	  number	  of	  cases	  when	  the	  data	  from	  the	  different	  SRLs,	  who	  tested	  their	  samples	  for	  different	  second-­‐line	  drugs	  under	  different	  conditions,	  were	  compiled.	  Scientific	  limitations	  potentially	  had	  to	  be	  taken	  into	  consideration,	  as	  well,	  since	  some	  of	  the	  resistance	  tests	  to	  second	  line	  drugs	  were	  clinically	  meaningless.	  For	  example,	  a	  patient	  with	  a	  strain	  of	  tuberculosis	  that	  is	  apparently	  resistant	  to	  cycloserine	  in	  the	  lab	  may	  still	  get	  better	  when	  treated	  with	  cycloserine.	  All	  of	  the	  CDC	  researchers	  I	  spoke	  to	  described	  the	  task	  of	  settling	  on	  a	  definition	  as	  a	  lengthy	  process	  which	  involved	  hours	  and	  hours	  of	  endless	  meetings	  with	  various	  
                                                159	  There	  are	  eleven	  classes	  of	  anti-­‐TB	  drugs.	  Five	  are	  first-­‐line	  drugs:	  isoniazid,	  rifampin,	  ethambutol,	  streptomycin,	  pyrazinamide,	  whereby	  isoniazid	  and	  rifampin	  are	  the	  most	  effective;	  and	  six	  are	  second-­‐line	  drugs:	  aminoglycosides	  other	  than	  streptomycin	  (e.g.,	  kanamycin	  and	  amikacin),	  cyclic	  polypeptides	  (e.g.,	  capreomycin),	  fluoroquinolones	  (e.g.,	  ofloxacin,	  ciprofloxacin,	  levofloxacin,	  and	  moxifloxacin),	  thioamides	  (e.g.,	  prothionamide	  and	  ethionamide),	  serine	  analogs	  (e.g.,	  cycloserine	  and	  terizidone),	  and	  salicylic	  acid	  derivatives	  (e.g.,	  para-­‐aminosalicyclic	  acid).	  	  Not	  all	  TB	  drugs	  are	  equally	  potent,	  and	  patients	  are	  generally	  treated	  with	  at	  least	  four	  drugs	  at	  a	  time.	  	  Kanamycin,	  amikacin	  and	  capreomycin	  are	  sometimes	  grouped	  together	  as	  “injectables.”	  This	  categorization	  of	  drugs	  into	  these	  eleven	  classes	  was	  first	  made	  explicit	  in	  Dr.	  Shah’s	  work	  on	  XDR-­‐TB.	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researchers,	  department	  heads,	  CDC	  editors,	  and	  others.	  Finding	  a	  definition	  that	  was	  helpful	  for	  Dr.	  Holtz’s	  work	  was	  well	  as	  Dr.	  Shah’s	  work	  turned	  out	  to	  be	  particularly	  sensitive.	  As	  mentioned	  earlier,	  the	  databases	  Dr.	  Shah	  was	  working	  with	  did	  not	  include	  clinical	  data	  that	  could	  help	  portray	  the	  clinical	  impact	  of	  increasing	  MDR-­‐TB	  resistance.	  The	  databases	  did	  not	  conclusively	  reveal	  whether	  or	  not	  people	  with	  (proposed)	  XDR-­‐TB	  were	  sicker	  or	  more	  likely	  to	  die	  than	  people	  with	  the	  minimum	  definition	  of	  MDR-­‐TB	  (resistance	  to	  isoniazid	  and	  rifampin).	  Dr.	  Holtz’s	  database	  from	  Latvia,	  however,	  had	  rich	  information	  on	  treatment	  and	  clinical	  outcomes	  that	  provided	  evidence	  for	  the	  fact	  that	  some	  drug	  resistance	  patterns	  were	  more	  difficult	  to	  treat	  (and	  more	  fatal)	  than	  others.	  160	  Dr.	  Holtz’s	  data	  could	  potentially	  be	  employed	  by	  Dr.	  Shah	  in	  order	  to	  justify	  a	  particular	  definition	  of	  XDR-­‐TB	  as	  clinically	  meaningful	  on	  the	  basis	  that	  the	  newly	  defined	  form	  of	  tuberculosis	  led	  to	  clearly	  worse	  outcomes	  than	  MDR-­‐TB.	  Combining	  some	  of	  Dr.	  Holtz’s	  data	  with	  Dr.	  Shah’s	  analysis	  could	  also	  make	  Dr.	  Shah’s	  data	  more	  compelling	  by	  including	  “the	  life	  or	  death	  aspect	  of	  how	  this	  is	  important,”	  as	  Dr.	  Holtz	  put	  it.161	  However,	  Dr.	  Holtz	  was	  not	  keen	  on	  providing	  too	  much	  of	  his	  data	  for	  Dr.	  Shah’s	  paper,	  since	  this	  would	  put	  him	  and	  his	  research	  colleagues	  at	  risk	  of	  “scooping”	  themselves,	  which	  meant	  he	  and	  his	  group	  would	  not	  be	  able	  to	  take	  full	  credit	  for	  the	  project	  through	  publication	  of	  a	  separately	  authored	  paper,	  but	  instead	  would	  merely	  be	  subsidiary	  co-­‐authors	  in	  a	  broader	  paper	  under	  Shah’s	  leadership.162	  A	  temporary	  compromise	  was	  finally	  reached	  in	  April	  2005,	  when	  a	  traveling	  Dr.	  Cegielski	  sent	  a	  4:00	  am	  email	  from	  Russia	  to	  his	  colleagues	  at	  the	  CDC	  and	  WHO,	  suggesting	  that	  they	  define	  XDR-­‐TB	  as	  MDR-­‐TB	  plus	  resistance	  to	  at	  least	  any	  three	  second	  
                                                160	  Holtz,	  interview	  by	  author,	  2010.	  161	  Ibid.	  162	  Ibid.	  Once	  a	  significant	  amount	  of	  data	  from	  a	  given	  project	  has	  been	  published	  it	  becomes	  difficult	  to	  republish	  it,	  even	  in	  an	  expanded	  version,	  since	  the	  content	  of	  research	  article	  publications	  must	  be	  original.	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line	  drug	  classes	  (out	  of	  six	  classes).	  In	  the	  email	  Cegielski,	  like	  Shah	  previously,	  emphasized	  the	  collaborative	  nature	  of	  the	  project,	  stressing	  that	  XDR-­‐TB	  needed	  to	  be	  defined	  in	  a	  way	  that	  would	  fulfill	  the	  needs	  of	  everyone	  involved.	  He	  acknowledged	  to	  his	  SRL	  collaborators	  that	  Dr.	  Holtz’s	  group	  was	  also	  looking	  at	  the	  effects	  of	  resistance	  to	  all	  first	  line	  tuberculosis	  drugs,	  thus	  making	  the	  inclusion	  or	  exclusion	  of	  first-­‐line	  drugs	  other	  than	  isoniazid	  or	  rifampin	  in	  the	  XDR-­‐TB	  definition	  an	  important	  decision.163	  In	  retrospect,	  Dr.	  Holtz	  argued	  that	  the	  people	  in	  the	  meetings	  within	  the	  CDC	  thought	  like	  epidemiologists	  and	  tuberculosis	  promoters,	  but	  not	  like	  microbiologists	  or	  laboratory	  scientists,	  in	  that	  they	  took	  into	  account	  epidemiological	  and	  clinical	  statistics,	  but	  did	  not	  sufficiently	  consider	  the	  feasibility,	  reliability	  and	  significance	  of	  different	  resistance	  tests	  performed	  in	  the	  laboratory.	  We	  will	  see	  in	  the	  next	  chapter	  why	  this	  eventually	  led	  to	  a	  reconsideration	  of	  this	  much	  debated	  and	  carefully	  constructed	  definition.	  The	  definition	  proposed	  by	  Dr.	  Cegielski	  was	  the	  definition	  both	  Dr.	  Holtz164	  and	  Dr.	  Shah165	  used	  in	  separate	  poster	  presentations	  at	  the	  Union	  meeting	  in	  October	  2005,	  and	  which	  was	  published	  (using	  mostly	  Dr.	  Shah’s	  data	  and	  some	  of	  Dr.	  Holtz’s	  data,	  in	  addition	  to	  population-­‐based	  data	  from	  the	  US	  and	  South	  Korea)	  in	  the	  Morbidity	  and	  Mortality	  
                                                163	  Email	  between	  Peter	  Cegielski	  and	  Sarita	  Shah	  on	  31	  March	  2005.	  	  Email	  provided	  to	  author	  by	  Dr.	  Shah.	  In	  a	  double	  emphasis	  of	  the	  importance	  of	  collaboration,	  Dr.	  Shah	  highlighted	  the	  following	  passage	  from	  Dr.	  Cegielski's	  email:	  “The	  breadth	  of	  global	  collaboration	  in	  this	  project	  has	  been	  astonishing,	  considering	  the	  labs	  themselves	  are	  always	  being	  asked	  to	  do	  x,	  y,	  or	  z,	  and	  they	  generally	  refuse	  to	  participate.	  	  In	  this	  case	  the	  idea	  was	  powerful	  enough	  that	  it	  motivated	  almost	  all	  of	  the	  SRLs	  to	  volunteer	  to	  participate.”	  164	  Timothy	  H.	  Holtz	  et	  al.,	  “XDR-­‐TB:	  Extreme	  Drug-­‐resistance	  and	  Treatment	  Outcome	  under	  DOTS-­‐Plus,	  Latvia,	  2000-­‐2002,”	  in	  Abstract	  Book	  (presented	  at	  the	  36th	  World	  Conference	  on	  Lung	  Health	  of	  the	  International	  Union	  Against	  Tuberculosis	  and	  Lung	  Disease	  (The	  Union),	  Paris,	  France:	  International	  Union	  Against	  Tuberculosis	  and	  Lung	  Disease,	  2005).	  165	  N.	  Sarita	  Shah	  et	  al.,	  “Extreme	  Drug	  Resistance	  in	  Tuberculosis	  (’XDR-­‐TB’):	  Global	  Survey	  of	  Supranational	  Reference	  Laboratories	  for	  Mycobacterium	  Tuberculosis	  with	  Resistance	  to	  Second-­‐line	  Drugs,”	  in	  Abstract	  Book	  (presented	  at	  the	  36th	  World	  Conference	  on	  Lung	  Health	  of	  the	  International	  Union	  Against	  Tuberculosis	  and	  Lung	  Disease,	  Paris,	  France:	  International	  Union	  Against	  Tuberculosis	  and	  Lung	  Disease,	  2005).	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Weekly	  Report	  (MMWR)	  of	  the	  CDC	  in	  March	  2006.166	  This	  is	  the	  paper	  with	  which	  I	  opened	  this	  chapter.	  The	  choice	  of	  definition	  was	  officially	  rationalized	  clinically,	  based	  on	  data	  from	  Latvia,	  as	  well	  as	  data	  from	  the	  US.	  The	  “Editor's	  Comment”	  which	  accompanied	  the	  publication	  of	  XDR-­‐TB	  in	  the	  MMRW	  emphasized	  WHO	  treatment	  guidelines	  rather	  than	  epidemiological	  data,	  however:	  “The	  proposed	  definition	  of	  XDR	  TB	  was	  based	  on	  new	  WHO	  guidelines	  for	  programmatic	  management	  of	  drug-­‐resistant	  TB,	  which	  recommend	  treatment	  with	  at	  least	  four	  drugs	  known	  to	  be	  effective.	  Therefore,	  with	  three	  or	  fewer	  remaining	  classes	  of	  SLDs	  [second-­‐line	  drugs]	  to	  which	  the	  infecting	  organism	  is	  susceptible,	  treatment	  of	  these	  patients	  is	  unlikely	  to	  meet	  international	  standards.”167	  Interestingly,	  this	  consensus	  definition	  of	  XDR-­‐TB	  was	  apparently	  not	  extreme	  enough	  to	  warrant	  the	  name	  extremely	  drug	  resistant	  tuberculosis,	  as	  originally	  suggested.	  CDC	  researchers	  as	  well	  as	  collaborators	  at	  the	  WHO	  had	  actually	  been	  quite	  happy	  with	  the	  name	  extremely	  drug-­‐resistant	  tuberculosis	  and	  had	  submitted	  abstracts	  to	  the	  2005	  Union	  conference	  using	  variants	  of	  that	  designation.	  The	  original	  title	  of	  Sarita	  Shah	  et	  al.’s	  abstract	  was:	  “Extreme	  Drug	  Resistance	  in	  Tuberculosis	  (“XDR	  TB”):	  	  Global	  Survey	  of	  Supranational	  Reference	  Laboratories	  for	  Mycobacterium	  tuberculosis	  with	  	  Resistance	  to	  Second-­‐line	  Drugs.”	  However,	  when	  the	  time	  came	  to	  draft	  the	  publication	  in	  MMWR,	  CDC	  editor	  Ann	  Lanner	  pointed	  out	  that	  “extreme”	  was	  too	  strong	  a	  name	  for	  strains	  of	  tuberculosis	  that	  were	  potentially	  still	  susceptible	  to	  several	  drugs.168	  It	  was	  possible,	  for	  example,	  to	  have	  a	  strain	  of	  XDR-­‐TB	  that	  still	  responded	  to	  the	  two	  weaker	  first-­‐line	  drugs,	  as	  well	  as	  three	  out	  of	  six	  classes	  of	  second-­‐line	  drugs.	  This	  would	  perhaps	  be	  a	  relatively	  treatable	  form	  of	  tuberculosis,	  assuming	  the	  correct	  drugs	  were	  selected.	  What	  would	  
                                                166	  Wright	  et	  al.,	  “Emergence	  of	  Mycobacterium	  tuberculosis	  with	  Extensive	  Resistance	  to	  Second-­‐line	  Drugs	  –	  worldwide,	  2000-­‐2004.”	  167	  Ibid.	  SLDs	  is	  the	  abbreviation	  for	  second-­‐line	  drugs.	  168	  Ibid.;	  Castro,	  interview	  by	  author,	  2010.	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epidemiologists	  call	  strains	  of	  tuberculosis	  that	  really	  were	  resistant	  to	  all	  available	  drugs?	  A	  suggestion	  to	  continue	  calling	  XDR	  “extreme”	  when	  it	  was	  resistant	  to	  all	  anti-­‐tuberculosis	  drugs,	  while	  calling	  less	  extreme	  XDR	  strains	  extensively	  resistant	  was	  discarded.	  In	  another	  discussion	  someone	  unsuccessfully	  suggested	  using	  XXDR	  for	  extreme	  and	  XDR	  for	  extensive	  TB.169	  Sometime	  between	  the	  March	  abstract	  submission	  deadline	  for	  the	  2005	  meeting	  of	  the	  International	  Union	  against	  Tuberculosis	  and	  Lung	  Disease	  and	  the	  September	  poster	  completion	  deadline	  for	  the	  same	  meeting	  the	  meaning	  of	  the	  abbreviation	  was	  permanently	  changed	  to	  extensively	  drug-­‐resistant	  tuberculosis.	  The	  title	  of	  Shah	  et	  al.’s	  poster	  as	  it	  actually	  appeared	  at	  the	  meeting	  was:	  “Extensive	  Second-­‐Line	  Drug	  Resistance	  in	  Tuberculosis	  (“XDR	  TB”):	  Global	  Survey	  of	  Supranational	  Reference	  Laboratories.”170	  Shah’s	  poster	  at	  the	  October	  2005	  Union	  meeting	  in	  Paris	  generated	  some	  interest	  among	  tuberculosis	  drug	  resistance	  experts	  but	  did	  not	  receive	  broader	  play	  –	  Dr.	  Cegielski	  recalls	  that	  he	  tried	  to	  set	  up	  a	  press	  conference	  for	  the	  media,	  but	  that	  there	  was	  not	  enough	  interest	  in	  the	  results.171	  The	  following	  report	  on	  XDR-­‐TB	  in	  the	  March	  2006	  issue	  of	  Morbidity	  and	  Mortality	  Weekly	  Report	  (MMWR),	  which	  was	  dedicated	  to	  World	  TB	  Day,	  received	  some	  more	  attention.172	  Dr.	  Holtz	  remembers	  feeling	  that	  he	  had	  been	  part	  of	  something	  important	  when	  he	  heard	  his	  division	  boss,	  Dr.	  Kenneth	  Castro,	  being	  
                                                169	  By	  the	  time	  of	  writing	  the	  debate	  has	  moved	  on,	  and	  forms	  that	  are	  resistant	  to	  “everything”	  are	  usually	  called	  TDR,	  or	  totally	  drug-­‐resistant	  tuberculosis.	  	  For	  example:	  Maryn	  McKenna,	  “TDR-­‐TB:	  The	  Indian	  Government	  Denies	  it,"	  Wired	  Science	  Blogs/Superbug	  (blog)	  Wired.com,	  January	  29,	  2012,	  http://www.wired.com/wiredscience/2012/01/tdr-­‐india-­‐denies/.	  170	  N.	  Sarita	  Shah	  et	  al.,	  "Poster:	  Extensive	  Second-­‐line	  Drug	  Resistance	  in	  Tuberculosis	  ("XDR	  TB"):	  Global	  Survey	  of	  Supranational	  Reference	  Laboratories,"	  in	  Annual	  Meeting	  of	  International	  Union	  
against	  Tuberculosis	  and	  Lung	  Disease	  (Paris:	  2005),	  N.	  Sarita	  Shah	  et	  al.,	  "Abstract:	  Extreme	  Drug	  Resistance	  in	  Tuberculosis	  ("XDR	  TB"):	  Global	  Survey	  of	  Supranational	  Reference	  Laboratories	  for	  
Mycobacterium	  tuberculosis	  with	  Resistance	  to	  Second-­‐line	  Drugs,"	  in	  Annual	  Meeting	  of	  International	  
Union	  against	  Tuberculosis	  and	  Lung	  Disease	  (Paris:	  2005).	  	  171	  Cegielski,	  interview	  by	  author,	  2010.	  172	  World	  TB	  day	  commemorates	  Robert	  Koch’s	  demonstration	  of	  the	  TB	  bacillus,	  which	  took	  place	  on	  March	  24,	  1883.	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interviewed	  about	  XDR-­‐TB	  on	  the	  radio.173	  The	  CDC	  used	  its	  press	  office	  to	  successfully	  generate	  and	  place	  sound	  bites	  about	  XDR-­‐TB	  in	  the	  news	  at	  this	  time.174	  The	  MMWR	  report	  itself	  framed	  XDR-­‐TB	  as	  the	  global	  emergence	  of	  a	  new	  and	  potentially	  dangerous	  infectious	  disease,	  stressing	  that	  the	  findings	  “suggest	  that	  urgent	  measures	  are	  needed	  to	  establish	  population-­‐based	  surveillance	  for	  SLD	  resistance	  and	  to	  plan	  public	  health	  responses,”	  arguing	  that	  “this	  report	  documents	  the	  existence	  of	  XDR	  TB	  as	  a	  serious	  and	  emerging	  public	  health	  threat.”175	  According	  to	  Sarita	  Shah	  and	  Timothy	  Holtz,	  the	  media	  uptake	  of	  the	  MMWR	  report	  went	  well,	  and	  the	  collaborators	  were	  happy	  with	  what	  they	  had	  achieved.	  Within	  a	  few	  months,	  some	  tuberculosis	  researchers	  were	  using	  the	  term	  XDR-­‐TB	  in	  their	  published	  analyses	  of	  drug-­‐resistant	  tuberculosis.176	  Many	  established	  researchers	  were	  less	  impressed	  with	  the	  new	  concept,	  however,	  and	  wondered	  about	  its	  clinical	  utility.	  In	  particular,	  researchers	  in	  those	  countries	  in	  the	  former	  Soviet	  Union	  that	  had	  been	  struggling	  with	  significant	  MDR-­‐TB	  outbreaks	  at	  least	  since	  the	  mid-­‐1990s	  were	  less	  interested	  in	  whether	  or	  not	  their	  severe	  MDR-­‐TB	  cases	  qualified	  as	  XDR-­‐TB	  than	  in	  the	  strategies	  to	  treat	  specific	  drug-­‐resistance	  patterns	  and	  approaches	  to	  avoiding	  this	  increased	  resistance	  in	  the	  first	  place.	  Dr.	  Vaira	  Leimane,	  one	  of	  the	  leading	  MDR-­‐TB	  researchers	  in	  Latvia	  –	  a	  country	  which	  is	  now	  well-­‐known	  for	  its	  large	  MDR-­‐TB	  problem	  and	  its	  strong	  MDR-­‐TB	  program	  –	  points	  out	  that	  “the	  definition	  is	  not	  so	  important,	  because	  the	  severity	  of	  disease	  and	  the	  possibility	  of	  cure	  depends	  on	  how	  many	  drugs	  have	  
                                                173	  Holtz,	  interview	  by	  author,	  2010.	  174	  Ibid.;	  Brenda	  Wilson,	  “New	  Drug-­‐resistant	  TB	  Strain	  Menaces	  U.S.”	  NPR.org,	  March	  24,	  2006,	  http://www.npr.org/templates/story/story.php?storyId=5298861.	  175	  Wright	  et	  al.,	  “Emergence	  of	  Mycobacterium	  Tuberculosis	  with	  Extensive	  Resistance	  to	  Second-­‐line	  Drugs	  –	  Worldwide,	  2000-­‐2004.”	  176	  Mohamad	  Reza	  Masjedi	  et	  al.,	  “Extensively	  Drug-­‐resistant	  Tuberculosis:	  2	  Years	  of	  Surveillance	  in	  Iran,”	  Clinical	  Infectious	  Diseases	  43,	  no.	  7	  (2006):	  841–847.	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real	  resistance.	  But	  for	  policy	  makers	  the	  definition	  is	  very	  good.”177	  The	  new	  category	  of	  XDR-­‐TB	  as	  presented	  in	  Shah’s	  paper	  only	  gradually	  became	  a	  compelling	  tool	  for	  policy	  makers,	  however.	  Shah	  had	  identified	  347	  cases	  of	  XDR-­‐TB	  around	  the	  world	  (including	  200	  from	  South	  Korea),	  and	  there	  was	  good	  reason	  to	  believe	  that	  XDR-­‐TB	  was	  a	  growing	  problem.	  The	  fact	  that	  7%	  of	  the	  identified	  MDR-­‐TB	  cases	  could	  be	  classified	  as	  XDR-­‐TB	  was	  alarming.	  Yet	  one	  of	  the	  weaknesses	  in	  terms	  of	  public	  interest	  for	  this	  first	  paper	  about	  XDR-­‐TB	  was	  the	  fact	  that	  dispersed	  cases	  of	  XDR-­‐TB	  were	  drawn	  from	  countries	  across	  the	  world,	  and	  very	  little	  information	  was	  available	  about	  these	  cases’	  fates.	  While	  the	  database	  approach	  allowed	  Shah	  and	  her	  collaborators	  to	  argue	  that	  XDR-­‐TB	  was	  already	  a	  dangerous	  global	  problem	  at	  its	  inception,	  it	  did	  not	  lend	  itself	  to	  the	  geographically	  localized	  outbreak	  narrative	  that	  is	  popular	  with	  journalists	  and	  fiction-­‐writers	  alike.178	  There	  was	  no	  patient	  zero	  (or	  location	  zero)	  who	  could	  be	  looked	  at	  as	  the	  origin	  as	  the	  epidemic.179	  The	  paper	  also	  did	  not	  provide	  the	  potential	  for	  individualized	  human-­‐interest	  stories	  that	  feature	  the	  experience	  of	  illness	  and	  recovery	  –	  or	  death.	  	  Sarita	  Shah’s	  MMWR	  report	  found	  XDR-­‐TB	  around	  the	  world,	  yet	  it	  was	  not	  until	  XDR-­‐TB	  came	  to	  be	  understood	  as	  a	  lethal	  disease	  emerging	  from	  a	  particular	  location	  –	  rural	  South	  Africa	  –	  that	  XDR-­‐TB	  truly	  gained	  sufficient	  rhetorical	  power	  to	  mobilize	  public	  health	  policy	  makers	  and	  funders.	  In	  the	  following	  chapter	  I	  turn	  to	  South	  Africa	  to	  consider	  the	  processes	  that	  enabled	  this	  to	  happen	  and	  begin	  to	  look	  at	  the	  consequences.
                                                177	  Vaira	  Leimane,	  interview	  by	  author,	  phone	  interview,	  16	  February	  2010.	  178	  Priscilla	  Wald,	  Contagious:	  Cultures,	  Carriers,	  and	  the	  Outbreak	  Narrative	  (Duke	  University	  Press	  Books,	  2008).	  179	  David	  Barnes,	  “Targeting	  Patient	  Zero,”	  in	  Tuberculosis	  Then	  and	  Now:	  Perspectives	  on	  the	  History	  
of	  an	  Infectious	  Disease,	  ed.	  Flurin	  Condrau	  and	  Michael	  Worboys	  (Montreal	  &	  Kingston:	  McGill-­‐Queen’s	  University	  Press,	  2010),	  49–71.	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CHAPTER	  2:	  How	  XDR-­‐TB	  Became	  South	  African	  
 On	  August	  17,	  2006,	  Dr.	  Neel	  Gandhi,	  a	  young	  physician	  affiliated	  with	  Yale	  University,	  gave	  a	  late-­‐breaker	  presentation	  to	  thousands	  of	  people	  in	  a	  packed	  room	  at	  the	  XVI	  International	  AIDS	  Conference	  in	  Toronto.180	  In	  his	  talk,	  titled	  “High	  Prevalence	  and	  Mortality	  from	  Extensively	  Drug-­‐Resistant	  (XDR)	  TB	  in	  TB/HIV	  Coinfected	  Patients	  in	  Rural	  South	  Africa,”	  he	  announced	  that	  a	  district	  hospital	  in	  Tugela	  Ferry,	  KwaZulu-­‐Natal	  had,	  over	  the	  course	  of	  a	  year,	  identified	  221	  cases	  of	  multi-­‐drug	  resistant	  tuberculosis	  (MDR-­‐TB),	  including	  53	  cases	  of	  extensively	  drug-­‐resistant	  tuberculosis	  (XDR-­‐TB).	  Fifty-­‐two	  of	  the	  53	  cases	  of	  XDR-­‐TB	  in	  Tugela	  Ferry	  had	  died	  (a	  mortality	  rate	  of	  98%!);	  almost	  all	  of	  them	  were	  known	  to	  be	  HIV	  positive.181	  When	  Neel	  Gandhi	  sat	  down	  at	  the	  end	  of	  the	  presentation,	  he	  wasn’t	  sure	  what	  people’s	  reaction	  would	  be.182	  As	  is	  often	  the	  case	  with	  conference	  presentations	  the	  program	  was	  running	  behind	  schedule	  and	  there	  was	  no	  time	  for	  questions.183	  The	  international	  media’s	  response	  soon	  became	  apparent.	  The	  next	  day,	  the	  New	  
York	  Times	  and	  American	  National	  Public	  Radio,	  as	  well	  as	  other	  international	  and	  South	  African	  media	  outlets	  ran	  stories	  about	  a	  powerful	  and	  resistant	  tuberculosis	  strain	  striking	  South	  Africans	  with	  HIV/AIDS.184	  In	  the	  following	  months,	  many	  highly	  reputable	  
                                                180	  Gandhi	  had	  been	  a	  Robert	  Wood	  Johnson	  Clinical	  Scholar	  at	  Yale	  working	  with	  Dr.	  Gerald	  Friedland;	  at	  the	  time	  of	  the	  presentation	  he	  was	  faculty	  at	  Albert	  Einstein	  College	  of	  Medicine.	  181	  Neel	  R.	  Gandhi	  et	  al.,	  “High	  Prevalence	  and	  Mortality	  from	  Extensively	  Drug-­‐resistant	  (XDR)	  TB	  in	  TB/HIV	  Coinfected	  Patients	  in	  Rural	  South	  Africa”	  (presented	  at	  the	  XVI	  International	  AIDS	  Conference,	  Toronto,	  2006).	  182	  Sarita	  Shah,	  interview	  by	  author,	  phone	  interview,	  30	  March	  2007.	  183	  Transcript	  of	  Oral	  Abstract	  Session:	  Late	  Breaker	  Track	  B.	  XVI	  International	  AIDS	  Conference,	  August	  17,	  2006.	  Downloaded	  from	  kaisernetwork.org.	  184	  Lawrence	  K.	  Altman	  and	  Donald	  G	  McNeil,	  “Doctors	  Warn	  of	  Powerful	  and	  Resistant	  Tuberculosis	  Strain,”	  The	  New	  York	  Times,	  August	  18,	  2006;	  Joanne	  Silberner,	  “Resistant	  TB	  Strikes	  South	  Africans	  with	  HIV,”	  NPR.org,	  August	  18,	  2006,	  http://www.npr.org/templates/story/story.php?storyId=5671714;	  Joy	  Victory,	  “Extremely	  Resistant	  TB	  Emerges	  in	  South	  Africa,”	  abcnews.go.com,	  August	  18	  2006,	  http://abcnews.go.com/Health/story?id=2329685&page=1#.T3Ma_45pEyQ;	  SAPA;	  Anso	  Thom,	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biomedical	  science	  journals	  included	  pieces	  summarizing	  Gandhi’s	  findings	  in	  their	  news	  and	  editorials	  sections;185	  in	  Tugela	  Ferry	  itself,	  local	  health	  officials	  found	  themselves	  warding	  off	  interview	  requests	  from	  local	  and	  international	  journalists,	  with	  the	  resulting	  reporting	  ranging	  from	  tabloid	  sensationalism	  to	  high-­‐brow	  analysis.186	  As	  the	  editors	  of	  the	  journal	  Lancet	  Infectious	  Diseases	  commented	  in	  November	  2006,	  “huge	  global	  interest	  was	  sparked	  by	  a	  report	  at	  the	  International	  AIDS	  Conference	  in	  August	  of	  a	  cluster	  of	  cases	  in	  South	  Africa	  of	  XDR	  tuberculosis	  with	  high	  mortality	  among	  HIV	  co-­‐infected	  patients,	  with	  a	  Google	  search	  finding	  130 000	  hits.”187	  By	  January	  2007,	  the	  New	  York	  Times	  reported	  that	  this	  “virtually	  untreatable,”	  “rapidly	  fatal,”	  “extreme”	  illness	  was	  poised	  to	  “imperil	  millions.”188	  A	  writer	  for	  Nature	  Medicine	  apocalyptically	  warned	  of	  impending	  disaster,	  comparing	  XDR-­‐TB	  to	  “something	  out	  of	  a	  horror	  movie,	  [that]	  blazed	  across	  Tugela	  Ferry,	  a	  small	  village	  in	  South	  Africa,	  striking	  down	  nearly	  everyone	  it	  touched.”189	  The	  name	  of	  the	  town	  Tugela	  Ferry	  became	  almost	  synonymous	  with	  XDR-­‐TB	  in	  international	  reporting	  and	  at	  scientific	  conferences.	  The	  response	  to	  XDR-­‐TB	  in	  South	  Africa	  was	  not	  limited	  to	  media	  outlets	  and	  journal	  articles.	  International	  health	  agencies	  formed	  task	  forces,	  had	  meetings,	  and	  
                                                                                                                                            “South	  Africa:	  Super	  Resistant	  XDR	  TB	  Rears	  Its	  Head	  in	  KZN,”	  Health-­‐e,	  August	  15,	  2006,	  http://www.health-­‐e.org.za/news/article.php?uid=20031478.	  185	  Emma	  Marris,	  “Extreme	  TB	  Strain	  Threatens	  HIV	  Victims	  Worldwide,”	  Nature	  443,	  no.	  7108	  (2006):	  131–131;	  “Extreme	  TB	  Threat,”	  The	  Journal	  of	  the	  American	  Medical	  Association	  296,	  no.	  15	  (2006):	  1830–1830;	  “XDR-­‐TB—A	  Global	  Threat,”	  The	  Lancet	  368,	  no.	  9540	  (2006):	  964;	  Mario	  Raviglione,	  “XDR-­‐TB:	  Entering	  the	  Post-­‐antibiotic	  Era?,”	  The	  International	  Journal	  of	  Tuberculosis	  and	  
Lung	  Disease	  10,	  no.	  11	  (2006):	  1185–1187;	  J.	  Cohen,	  “Extensively	  Drug-­‐resistant	  TB	  Gets	  Foothold	  in	  South	  Africa,”	  Science	  313,	  no.	  5793	  (2006):	  1554a–1554a;	  S.	  D.	  Lawn,	  “Extensively	  Drug	  Resistant	  Tuberculosis,”	  British	  Medical	  Journal	  333,	  no.	  7568	  (2006):	  559–560;	  J.	  Cohen,	  “At	  International	  AIDS	  Conference,	  Big	  Names	  Emphasize	  Big	  Gaps,”	  Science	  313,	  no.	  5790	  (2006):	  1030–1031.	  186	  Fikile	  Ngema,	  interview	  by	  author,	  13	  October	  2010,	  Tugela	  Ferry,	  South	  Africa;	  Anthony	  Moll	  interview	  by	  author,	  23	  July	  2007,	  Tugela	  Ferry,	  South	  Africa.	  187	  “The	  Tuberculosis	  X	  Factor,”	  The	  Lancet	  Infectious	  Diseases	  6,	  no.	  11	  (2006):	  679.	  188	  Michael	  Wines,	  “Virulent	  TB	  in	  South	  Africa	  May	  Imperil	  Millions,”	  The	  New	  York	  Times,	  January	  28,	  2007.	  189	  Apoorva	  Mandavilli,	  “Virtually	  Incurable	  TB	  Warns	  of	  Impending	  Disaster,”	  Nature	  Medicine	  13,	  no.	  3	  (2007):	  271–271.	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dispatched	  experts;190	  bioethicists	  called	  for	  indefinite	  quarantine	  of	  patients	  with	  drug-­‐resistant	  tuberculosis;191	  embarrassed	  government	  agencies	  called	  for	  more	  data	  and	  warded	  off	  accusations	  of	  negligence;192	  non-­‐governmental	  and	  transnational	  organizations	  raised	  funds	  to	  generate	  new	  programs	  for	  XDR-­‐TB	  focusing	  on	  research	  and	  treatment.193	  Tugela	  Ferry	  itself	  became	  the	  center	  of	  much	  health	  research	  activity	  by	  international	  and	  local	  researchers.	  Topics	  of	  international	  research	  in	  Tugela	  Ferry	  included	  tuberculosis	  infection	  control,	  cheaper	  and	  improved	  diagnostics	  for	  drug-­‐resistant	  tuberculosis,	  and	  the	  relative	  effectiveness	  of	  hospital	  based	  and	  community	  based	  tuberculosis	  treatment	  interventions,	  among	  others.	  Over	  the	  following	  years	  the	  publicly	  funded	  tuberculosis	  programs	  in	  KwaZulu-­‐Natal	  (the	  province	  in	  which	  Tugela	  Ferry	  is	  located)	  were	  significantly	  restructured	  in	  order	  to	  find	  ways	  to	  treat	  people	  with	  drug-­‐resistant	  tuberculosis	  more	  effectively.	  XDR-­‐TB’s	  characteristics	  as	  a	  contagious,	  airborne	  disease	  with	  a	  high	  mortality	  rate	  of	  98%	  (in	  Tugela	  Ferry)	  and	  no	  known	  effective	  treatment	  made	  it	  a	  frightening	  disease,	  indeed.	  Yet	  it	  should	  not	  be	  taken	  for	  granted	  that	  a	  sad	  but	  indeed	  commonplace	  occurrence	  –	  the	  death	  of	  rural	  South	  Africans	  from	  HIV	  and	  tuberculosis	  –	  became	  an	  urgent	  global	  health	  crisis	  that	  demanded	  –	  and	  received	  –	  attention	  and	  resources.	  As	  we	  saw	  in	  the	  previous	  chapter,	  at	  the	  time	  of	  Gandhi’s	  presentation	  in	  August	  2006,	  the	  term	  XDR-­‐TB	  itself	  had	  only	  recently	  been	  conceived	  and	  published.	  It	  had	  been	  consciously	  assembled	  with	  the	  goal	  of	  piquing	  the	  interest	  of	  those	  who	  heard	  about	  it.	  The	  original	  
                                                190	  WHO,	  Report	  of	  the	  Meeting	  of	  the	  WHO	  Global	  Task	  Force	  on	  XDR-­‐TB	  (Geneva,	  Switzerland:	  World	  Health	  Organization,	  October	  2006).	  191	  Jerome	  Amir	  Singh,	  Ross	  Upshur,	  and	  Nesri	  Padayatchi,	  “XDR-­‐TB	  in	  South	  Africa:	  No	  Time	  for	  Denial	  or	  Complacency,”	  PLoS	  Med	  4,	  no.	  1	  (2007):	  e50.	  192	  SAMRC,	  “Media	  Statement,	  8	  September	  2006:	  Seven	  Point	  Emergency	  Action	  Plan	  to	  Combat	  XDR-­‐TB	  Issued	  by	  Global	  Health	  Agencies,”	  September	  8,	  2006,	  www.mrc.ac.za/pressreleases/2006/8pres2006.htm.	  193	  PIH,	  “PIH	  Receives	  $3	  Million	  Grant	  to	  Develop	  Model	  for	  Treating	  XDR-­‐TB	  and	  HIV,"	  pih.org,	  March	  2007,	  http://www.pih.org/news/entry/pih-­‐receives-­‐3-­‐million-­‐grant-­‐to-­‐develop-­‐model-­‐for-­‐treating-­‐xdr-­‐tb-­‐and-­‐hiv/.	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global	  survey	  of	  XDR-­‐TB	  (published	  in	  March	  2006)	  had	  only	  identified	  one	  case	  of	  XDR-­‐TB	  in	  all	  of	  Africa	  and	  the	  Middle	  East,	  however,	  and	  had	  focused	  on	  clinical	  data	  from	  cases	  in	  Latvia,	  South	  Korea	  and	  the	  US.	  Soon	  after	  publication	  of	  the	  global	  XDR-­‐TB	  survey,	  cases	  of	  XDR-­‐TB	  from	  Norway	  and	  Iran	  were	  reported.194	  Yet	  it	  was	  the	  cases	  of	  XDR-­‐TB	  in	  Tugela	  Ferry,	  South	  Africa	  which	  captured	  the	  imagination	  of	  public	  health	  promoters	  and	  journalists,	  and	  around	  which	  MDR-­‐TB	  experts	  and	  global	  health	  funders	  successfully	  rallied	  in	  order	  to	  call	  for	  increased	  action	  against	  drug-­‐resistant	  tuberculosis.	  The	  rest	  of	  this	  chapter	  considers	  how	  a	  small	  town	  in	  rural	  South	  Africa	  became	  the	  center	  of	  global	  discussions	  around	  XDR-­‐TB.	  I	  will	  pay	  particular	  attention	  to	  the	  historical	  circumstances	  through	  which	  Tugela	  Ferry	  became	  the	  host	  for	  a	  small	  academic	  HIV/TB	  cotreatment	  study	  that	  eventually	  uncovered	  the	  surprising	  cases	  of	  XDR-­‐TB.	  Dr.	  Gandhi’s	  presentation	  on	  XDR-­‐TB	  in	  South	  Africa	  emerged	  from	  the	  context	  of	  a	  global	  AIDS	  pandemic	  which	  had	  motivated	  a	  multi-­‐billion	  dollar	  global	  health	  enterprise	  of	  research	  and	  care,	  a	  South	  African	  government	  which	  had	  long	  denied	  that	  HIV/AIDS	  was	  a	  problem	  despite	  rapidly	  rising	  HIV	  infection	  rates,	  and	  a	  South	  African	  health	  system	  which	  had	  significant	  public	  structures	  to	  address	  tuberculosis,	  though	  they	  were	  struggling	  to	  keep	  tuberculosis	  at	  bay.	  In	  this	  chapter,	  I	  will	  first	  provide	  a	  brief	  overview	  of	  the	  recent	  history	  of	  tuberculosis	  epidemiology	  and	  policy	  in	  South	  Africa.	  In	  the	  second	  half	  of	  the	  chapter	  I	  explain	  how	  international	  tuberculosis	  research	  made	  its	  way	  to	  the	  remote	  trade	  town	  of	  Tugela	  Ferry,	  South	  Africa.	  
                                                194	  U.	  R.	  Dahle,	  “Extensively	  Drug	  Resistant	  Tuberculosis:	  Beware	  Patients	  Lost	  to	  Follow-­‐up,”	  British	  
Medical	  Journal	  333,	  no.	  7570	  (2006):	  705–705;	  Mohamad	  Reza	  Masjedi	  et	  al.,	  “Extensively	  Drug-­‐resistant	  Tuberculosis:	  2	  Years	  of	  Surveillance	  in	  Iran,”	  Clinical	  Infectious	  Diseases	  43,	  no.	  7	  (2006):	  841–847.	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South	  African	  tuberculosis	  and	  the	  world	  	   In	  South	  Africa	  alone,	  an	  estimated	  64	  000	  people	  died	  of	  tuberculosis	  in	  2004.195	  Tuberculosis	  is	  considered	  endemic	  in	  South	  Africa,	  which	  is	  categorized	  as	  a	  “high	  burden	  country”	  by	  the	  World	  Health	  Organization	  (WHO).	  According	  to	  tuberculosis	  experts,	  most	  of	  the	  country’s	  population	  is	  exposed	  to	  tuberculosis	  at	  some	  point	  during	  their	  lifetime.	  This	  is	  usually	  not	  a	  big	  problem	  for	  people	  with	  healthy	  immune	  systems	  –	  in	  most	  people	  the	  tuberculosis	  germs	  are	  kept	  in	  check	  and	  remain	  dormant.	  People	  with	  this	  form	  of	  inactive	  tuberculosis	  (called	  “latent”	  tuberculosis)	  have	  a	  ten	  percent	  chance	  of	  having	  active	  tuberculosis	  during	  their	  life	  times.	  But	  HIV	  positive	  people	  infected	  with	  latent	  tuberculosis	  have	  a	  much	  higher	  chance	  -­‐	  about	  ten	  percent	  a	  year	  -­‐	  of	  becoming	  sick	  with	  active	  tuberculosis.	  	   The	  South	  African	  tuberculosis	  epidemic	  is	  in	  part	  a	  result	  of	  the	  huge	  disparities	  in	  economics,	  infrastructure	  and	  job	  opportunities	  between	  different	  racial	  groups	  that	  are	  a	  legacy	  of	  apartheid.	  Throughout	  the	  20th	  century	  some	  parts	  of	  South	  Africa	  had	  strong	  anti-­‐tuberculosis	  programs,	  but	  they	  focused	  primarily	  on	  protecting	  the	  health	  of	  white	  citizens,	  as	  well	  as	  on	  maintaining	  a	  productive	  black	  labor	  force	  in	  South	  Africa’s	  mines.	  	  The	  mines	  of	  South	  Africa	  were	  an	  incubator	  for	  tuberculosis.	  Difficult	  work	  conditions	  in	  moist	  conditions	  underground,	  crowded	  dormitories,	  and	  poor	  nutrition	  all	  contributed	  to	  high	  rates	  of	  tuberculosis,	  as	  well	  as	  other	  illnesses,	  in	  the	  mines.	  One	  key	  strategy	  for	  minimizing	  tuberculosis	  in	  the	  mines	  was	  to	  send	  sick	  miners	  back	  home	  to	  the	  native	  reserves	  –	  the	  segregated	  areas	  allocated	  to	  blacks	  in	  South	  Africa.	  Predictably,	  this	  led	  to	  
                                                195	  WHO,	  Global	  Tuberculosis	  Control:	  Surveillance,	  Planning,	  Financing:	  WHO	  Report	  2006.	  (World	  Health	  Organization,	  2006)	  I	  calculated	  the	  number	  of	  deaths	  from	  a	  mortality	  rate	  of	  135	  deaths	  per	  100	  000	  population	  per	  year	  and	  a	  total	  population	  of	  47	  208	  000.	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the	  spread	  of	  tuberculosis	  among	  those	  at	  home	  in	  the	  reserves	  who	  did	  not	  themselves	  work	  in	  the	  mines.196	  In	  the	  second	  half	  of	  the	  20th	  century,	  tuberculosis	  rates	  in	  apartheid	  South	  Africa	  differed	  dramatically	  by	  race.	  Tuberculosis	  notification	  rates	  among	  whites	  were	  already	  low	  in	  the	  1950s	  and	  declined	  further	  into	  the	  1980s,	  and	  a	  dramatic	  drop	  in	  urban	  tuberculosis	  mortality	  rates	  was	  seen	  for	  all	  races	  when	  the	  drug	  isoniazid	  (still	  the	  most	  important	  anti-­‐tuberculosis	  drug)	  was	  introduced	  in	  1952.	  Yet	  the	  relatively	  high	  rates	  of	  tuberculosis	  notification	  among	  black	  Africans	  dramatically	  increased	  further	  from	  1952	  to	  the	  late	  1960s	  before	  they	  began	  to	  drop.	  In	  his	  study	  White	  Plague,	  Black	  Labor,	  Randall	  Packard	  concludes	  that	  this	  late	  drop	  was	  not	  evidence	  of	  an	  actual	  drop	  in	  tuberculosis	  rates	  among	  black	  South	  Africans,	  but	  rather	  an	  indicator	  of	  the	  fact	  that	  with	  the	  increased	  forced	  displacement	  of	  black	  South	  Africans	  to	  rural	  reserves	  (also	  called	  homelands	  or	  Bantustans),	  tuberculosis	  cases	  among	  black	  South	  Africans	  were	  no	  longer	  being	  counted	  by	  South	  African	  statistics.197	  By	  the	  early	  1980s	  tuberculosis	  rates	  in	  South	  Africa	  were	  rising	  again,	  as	  they	  were	  in	  much	  of	  the	  world,	  though	  the	  reason	  was	  not	  immediately	  apparent.	  In	  1995,	  Packard	  and	  Coetzee	  argued	  that	  HIV/AIDS	  alone	  could	  not	  account	  for	  the	  rise	  in	  documented	  tuberculosis	  cases	  and	  cited	  other	  social	  causes,	  including	  the	  changing	  demographics	  of	  the	  mining	  labor	  force	  in	  South	  Africa.198	  Today,	  however,	  the	  still-­‐increasing	  rates	  of	  tuberculosis	  in	  South	  Africa	  and	  in	  many	  other	  Sub-­‐Saharan	  African	  countries	  are	  attributed	  
                                                196	  Randall	  M.	  Packard,	  White	  Plague,	  Black	  Labor:	  Tuberculosis	  and	  the	  Political	  Economy	  of	  Health	  
and	  Disease	  in	  South	  Africa	  (University	  of	  California	  Press,	  1989);	  D.	  Stuckler	  et	  al.,	  "Mining	  and	  Risk	  of	  Tuberculosis	  in	  Sub-­‐Saharan	  Africa,"	  American	  Journal	  of	  Public	  Health	  101,	  no.	  3	  (2011):	  524-­‐530.	  197	  Randall	  M.	  Packard,	  White	  Plague,	  Black	  Labor:	  Tuberculosis	  and	  the	  Political	  Economy	  of	  Health	  
and	  Disease	  in	  South	  Africa	  (University	  of	  California	  Press,	  1989).	  198	  Randall	  M.	  Packard	  and	  David	  Coetzee,	  “White	  Plague,	  Black	  Labour	  Revisited:	  TB	  and	  the	  Mining	  Industry,”	  in	  Crossing	  Boundaries:	  Mine	  Migrancy	  in	  a	  Democratic	  South	  Africa,	  ed.	  J.	  Crush	  and	  Wilmot	  Godfrey	  James	  (Cape	  Town:	  IDASA ;	  IDRC,	  1995).	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primarily	  to	  the	  increased	  numbers	  of	  people	  who	  are	  at	  increased	  risk	  for	  tuberculosis	  due	  to	  HIV	  infection.199	  	   Tuberculosis	  in	  South	  Africa,	  then,	  was	  driven	  by	  a	  recent	  and	  dramatic	  rise	  in	  HIV/AIDS,	  and	  by	  the	  early	  2000s	  it	  had	  become	  a	  commonplace	  occurrence	  for	  patients	  with	  tuberculosis	  to	  die,	  even	  when	  they	  had	  access	  to	  appropriate	  medical	  care	  and	  took	  their	  tuberculosis	  medications	  as	  intended.200	  Medicines	  to	  effectively	  treat	  HIV	  (called	  antiretrovirals,	  or	  ARVs)	  were	  not	  available	  to	  most	  South	  Africans	  at	  that	  time,	  and	  people	  with	  AIDS	  eventually	  succumbed	  to	  opportunistic	  illnesses	  like	  tuberculosis,	  even	  if	  the	  opportunistic	  illness	  was	  correctly	  treated.	  Tuberculosis	  became	  the	  most	  common	  cause	  of	  death	  for	  South	  African	  people	  with	  HIV/AIDS,	  and	  inversely	  70%	  of	  tuberculosis	  patients	  in	  the	  country	  were	  coinfected	  with	  HIV.201	  As	  a	  result,	  many	  tuberculosis-­‐related	  deaths	  were	  attributed	  to	  end-­‐stage	  AIDS	  without	  further	  investigation.202	  In	  this	  context,	  a	  death	  from	  tuberculosis	  was	  not	  considered	  particularly	  mysterious	  and	  did	  not	  raise	  questions	  about	  whether	  or	  not	  the	  anti-­‐tuberculosis	  drugs	  would	  have	  been	  effective	  if	  the	  patient	  had	  not	  had	  HIV.	  At	  the	  same	  time,	  many	  AIDS	  deaths	  were	  documented	  as	  tuberculosis-­‐related	  deaths	  on	  death	  certificates	  in	  order	  to	  avoid	  AIDS-­‐related	  stigma.203	  Of	  the	  approximately	  64,	  000	  South	  African	  deaths	  from	  tuberculosis	  in	  2004,	  some	  were	  treated	  for	  tuberculosis	  while	  others	  were	  not.	  In	  most	  cases,	  however,	  those	  who	  died	  had	  never	  
                                                199	  Salim	  S.	  Abdool	  Karim	  et	  al.,	  “HIV	  Infection	  and	  Tuberculosis	  in	  South	  Africa:	  An	  Urgent	  Need	  to	  Escalate	  the	  Public	  Health	  Response,”	  The	  Lancet	  374,	  no.	  9693	  (2009):	  921–933.	  200	  According	  to	  sentinel	  studies,	  HIV	  prevalence	  among	  pregnant	  women	  in	  South	  Africa	  dramatically	  rose	  from	  0.8%	  in	  1990	  to	  7.6%	  in	  1994,	  to	  20.5%	  in	  2000.	  Some	  areas	  of	  the	  country	  were	  more	  heavily	  affected	  than	  others;	  one	  community	  in	  KwaZulu-­‐Natal	  had	  a	  prenatal	  prevalence	  rate	  of	  50.8%	  in	  2001.	  See	  Salim	  S.	  Abdool	  Karim	  et	  al.,	  “HIV	  Infection	  and	  Tuberculosis	  in	  South	  Africa:	  An	  Urgent	  Need	  to	  Escalate	  the	  Public	  Health	  Response,”	  The	  Lancet	  374,	  no.	  9693	  (2009):	  921–933.	  201	  Ibid.	  202	  Anthony	  Moll	  et	  al.,	  “Identification	  of	  a	  multi-­‐drug	  Resistant	  Tuberculosis	  Cluster	  as	  a	  Cause	  of	  Death	  Among	  Coinfected	  Patients	  in	  Rural	  South	  Africa”	  (presented	  at	  the	  Conference	  on	  Retroviruses	  and	  Opportunistic	  Infections	  (CROI),	  Denver,	  2006).	  203	  Johanna	  Mcgeary,	  “Death	  Stalks	  a	  Continent,”	  Time,	  February	  12,	  2001,	  http://www.time.com/time/magazine/article/0,9171,999190,00.html.	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been	  tested	  for	  resistance	  to	  tuberculosis	  drugs.	  A	  national	  drug	  resistance	  survey	  from	  2001-­‐2002	  estimated	  the	  prevalence	  of	  multi-­‐drug	  resistant	  tuberculosis	  in	  South	  Africa	  to	  be	  a	  relatively	  low	  3%,	  though	  this	  is	  now	  considered	  to	  be	  a	  likely	  underestimate	  (and	  even	  a	  low	  percentage	  represents	  a	  large	  total	  number).204	  Thus	  it	  is	  difficult	  to	  say	  with	  any	  certainty	  what	  proportion	  of	  tuberculosis	  deaths	  in	  South	  Africa	  have	  been	  due	  to	  drug-­‐resistant	  tuberculosis.	  The	  absence	  of	  routine	  drug-­‐resistance	  testing	  in	  basic	  tuberculosis	  management	  was	  not	  unique	  to	  South	  Africa,	  but	  followed	  the	  standard	  protocol	  recommended	  by	  the	  World	  Health	  Organization.	  As	  we	  have	  seen,	  the	  WHO’s	  strategy	  for	  managing	  tuberculosis,	  known	  as	  DOTS	  (Directly	  Observe	  Therapy,	  Short	  Course),	  originally	  recommended	  that	  tuberculosis	  programs	  in	  low	  and	  middle-­‐income	  countries	  should	  focus	  on	  treating	  infectious,	  drug-­‐susceptible	  tuberculosis.	  This	  meant	  ignoring	  the	  possibility	  of	  drug	  resistance	  at	  the	  beginning	  of	  treatment,	  and	  making	  sure	  that	  patients	  take	  their	  anti-­‐tuberculosis	  drugs	  properly.	  By	  the	  end	  of	  the	  1990s,	  however,	  the	  WHO	  had	  acknowledged	  the	  importance	  of	  multi-­‐drug	  resistant	  tuberculosis	  and	  recommended	  that	  tuberculosis	  programs	  should	  monitor	  for	  the	  possibility	  of	  drug-­‐resistance	  and	  provide	  patients	  who	  had	  MDR-­‐TB	  with	  second-­‐line	  treatment	  when	  appropriate.205	  South	  Africa	  put	  a	  version	  of	  this	  WHO	  policy	  in	  place	  quite	  early,	  even	  though	  the	  country	  did	  not	  receive	  direct	  support	  from	  the	  Green	  Light	  Committee.	  The	  South	  African	  tuberculosis	  program	  followed	  the	  new	  WHO	  recommendations	  to	  test	  only	  patients	  who	  
                                                204	  Karin	  Weyer	  et	  al.,	  Survey	  of	  Tuberculosis	  Drug	  Resistance	  in	  South	  Africa	  Final	  Report	  (Pretoria,	  South	  Africa:	  Medical	  Research	  Council,	  December	  2004);	  Kristina	  Wallengren	  et	  al.,	  “Drug-­‐resistant	  Tuberculosis,	  KwaZulu-­‐Natal,	  South	  Africa,	  2001–2007,”	  Emerging	  Infectious	  Diseases	  17,	  no.	  10	  (2011):	  1913–1916.	  205	  Paul	  Farmer	  and	  Jim	  Yong	  Kim,	  “Community	  Based	  Approaches	  to	  the	  Control	  of	  Multidrug	  Resistant	  Tuberculosis:	  Introducing	  ‘DOTS-­‐plus’,”	  British	  Medical	  Journal	  317,	  no.	  7159	  (1998):	  671–674;	  World	  Health	  Organization	  and	  STOP	  TB	  Partnership,	  The	  STOP	  TB	  Strategy:	  Building	  on	  and	  
Enhancing	  DOTS	  to	  Meet	  the	  TB	  Related	  Millenium	  Development	  Goals	  (Geneva:	  World	  Health	  Organization,	  2006);	  World	  Health	  Organization,	  Guidelines	  for	  the	  Programmatic	  Management	  of	  
Drug-­‐resistant	  Tuberculosis	  (Geneva:	  World	  Health	  Organization,	  2006).	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failed	  regular	  tuberculosis	  treatment	  for	  first-­‐line	  drug-­‐resistance	  and	  to	  refer	  MDR-­‐TB	  cases	  identified	  this	  way	  to	  specialized	  regional	  tuberculosis	  hospitals,	  where	  they	  would	  be	  treated	  with	  second-­‐line	  drugs.206	  South	  Africa	  had	  first	  restructured	  its	  tuberculosis	  programs	  according	  to	  the	  WHO’s	  DOTS	  guidelines	  around	  1996,	  and	  added	  the	  MDR-­‐TB	  component	  around	  1999/2000.207	  Despite	  this	  forward-­‐looking	  policy,	  however,	  many	  of	  South	  Africa’s	  tuberculosis	  programs	  were	  struggling	  to	  keep	  up	  even	  with	  the	  treatment	  of	  regular	  drug-­‐susceptible	  tuberculosis.	  One	  major	  reason	  for	  this	  was	  South	  Africa’s	  rapidly	  rising	  HIV/AIDS	  epidemic,	  which	  was	  evident	  by	  the	  late	  1990s	  and	  led	  to	  increasing	  numbers	  of	  tuberculosis	  patients,	  more	  and	  more	  of	  whom	  were	  not	  getting	  better	  despite	  appropriate	  tuberculosis	  treatment.	  208	  In	  addition,	  health	  programs	  across	  the	  country,	  and	  tuberculosis	  programs	  in	  particular,	  were	  undergoing	  ongoing	  dramatic,	  structural	  change	  as	  a	  result	  of	  the	  transition	  from	  apartheid	  to	  democratic	  majority	  rule	  in	  1994.	  The	  apartheid	  system,	  which	  had	  legally	  enforced	  the	  political	  and	  economic	  superiority	  of	  the	  white	  minority	  population	  since	  1948,	  had	  maintained	  at	  least	  fourteen	  separate	  health	  systems,	  including	  segregated	  health	  departments	  for	  four	  different	  racial	  groups	  and	  for	  each	  of	  the	  ten	  “homelands.”209	  Homelands,	  or	  Bantustans,	  were	  the	  less	  desirable	  geographic	  areas	  that	  the	  apartheid	  government	  set	  aside	  for	  black	  people,	  according	  to	  tribal	  designation.	  These	  homelands	  were	  incorporated	  into	  the	  new	  democratic	  South	  Africa	  in	  1994,	  yet	  compared	  to	  the	  areas	  that	  had	  been	  reserved	  primarily	  for	  whites	  they	  had	  suffered	  
                                                206	  Karin	  Weyer,	  interview	  by	  author,	  phone	  interview,	  8	  July	  2010.	  207	  Ibid.	  My	  sources	  do	  not	  precisely	  agree	  regarding	  these	  dates.	  Implementation	  ocurred	  over	  time	  and	  did	  not	  occur	  across	  the	  country	  at	  the	  same	  pace.	  208	  David	  Wilkinson	  and	  G.R.	  Davies,	  “The	  Increasing	  Burden	  of	  Tuberculosis	  in	  Rural	  South	  Africa	  –	  Impact	  of	  the	  HIV	  Epidemic,”	  South	  African	  Medical	  Journal	  87,	  no.	  4	  (1997):	  447–50;	  Immo	  Kleinschmidt,	  “South	  African	  Tuberculosis	  Mortality	  Data	  -­‐	  Showing	  the	  First	  Sign	  of	  the	  AIDS	  Epidemic?”	  South	  African	  Medical	  Journal	  89	  (1999):	  269–273.	  209	  Kerry	  Cullinan,	  Health	  Services	  in	  South	  Africa:	  A	  Basic	  Introduction,	  January	  29,	  2006,	  document	  accessed	  at	  http://www.health-­‐e.org.za/2006/01/29/health-­‐services-­‐in-­‐south-­‐africa-­‐a-­‐basic-­‐introduction/;	  The	  four	  racial	  categories	  used	  in	  South	  Africa	  are	  white,	  Indian,	  coloured	  and	  African.	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tremendous	  neglect	  and	  often	  lacked	  basic	  infrastructure.	  This	  included	  lack	  of	  access	  to	  clean	  water,	  sanitation,	  electricity,	  and	  formal	  education.	  In	  the	  1990s,	  South	  Africa	  was	  one	  of	  the	  most	  unequal	  societies	  in	  the	  world.210	  This	  was	  also	  reflected	  in	  its	  health	  system,	  which	  ranged	  from	  urban,	  high-­‐tech	  academic	  hospitals	  of	  international	  repute	  (among	  other	  things,	  the	  first	  ever	  successful	  heart	  transplant	  took	  place	  in	  Cape	  Town,	  South	  Africa	  in	  1967)	  to	  dilapidated	  clinics	  in	  slums	  and	  rural	  areas	  which	  were	  understaffed,	  under-­‐stocked,	  and	  served	  populations	  with	  dismal	  rates	  of	  infant	  mortality	  and	  malnutrition.	  Integrating	  these	  radically	  disparate	  health	  systems	  post-­‐1994,	  as	  well	  as	  changing	  the	  focus	  from	  hospital-­‐based	  curative	  care	  to	  clinic-­‐based	  and	  nurse-­‐driven	  primary	  care,	  was	  only	  one	  subset	  of	  the	  many	  daunting	  tasks	  of	  service	  and	  infrastructure-­‐provision	  facing	  the	  new	  government.211	  Efforts	  to	  improve	  health	  systems	  were	  also	  more	  effective	  in	  places	  that	  were	  already	  better	  off,	  leading	  to	  increasing	  inequality	  even	  as	  attempts	  were	  made	  to	  improve	  the	  public	  health	  system.212	  Providing	  quality	  diagnosis	  and	  treatment	  for	  tuberculosis	  through	  the	  public	  sector	  was	  only	  one	  of	  many	  health	  priorities	  that	  needed	  to	  be	  addressed	  systematically,	  next	  to	  cholera	  and	  measles	  outbreaks	  (the	  former	  due	  to	  poor	  water	  and	  sewage	  access,	  the	  latter	  due	  to	  low	  childhood	  vaccination	  rates),	  as	  well	  as	  growing	  epidemics	  of	  diabetes	  and	  hypertension.	  These	  public	  health	  programs	  in	  transition	  were	  not	  ready	  for	  the	  rapidly	  
                                                210	  Gerald	  Bloom	  and	  Diane	  McIntyre,	  “Towards	  Equity	  in	  Health	  in	  an	  Unequal	  Society,”	  Social	  
Science	  &	  Medicine	  47,	  no.	  10	  (1998):	  1529–1538.	  211	  Cullinan,	  Health	  Services	  in	  South	  Africa:	  A	  Basic	  Introduction.	  	  212	  David	  Stuckler,	  Sanjay	  Basu,	  and	  Martin	  McKee,	  “Health	  Care	  Capacity	  and	  Allocations	  Among	  South	  Africa’s	  Provinces:	  Infrastructure-­‐inequality	  Traps	  after	  the	  end	  of	  Apartheid,”	  American	  
Journal	  of	  Public	  Health	  101,	  no.	  1	  (2011):	  165–172.	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increasing	  rates	  of	  tuberculosis	  and	  other	  diseases	  that	  began	  to	  unrelentingly	  flood	  clinics	  and	  hospitals	  in	  the	  mid	  to	  late	  1990s	  due	  to	  dramatically	  increasing	  rates	  of	  HIV/AIDS.213	  By	  the	  late	  1990s,	  as	  a	  rising	  AIDS	  epidemic	  also	  caused	  an	  increase	  in	  tuberculosis	  cases,	  many	  facilities	  found	  themselves	  completely	  overwhelmed	  by	  the	  increased	  burden.	  The	  Church	  of	  Scotland	  Hospital	  in	  Tugela	  Ferry,	  which	  would	  eventually	  become	  famous	  in	  2006	  for	  its	  high	  rate	  of	  XDR-­‐TB,	  was	  no	  exception.	  Dr.	  Anthony	  Moll	  has	  been	  one	  of	  the	  main	  physicians	  at	  that	  hospital	  since	  the	  1980s	  and	  witnessed	  the	  arrival	  of	  AIDS	  and	  tuberculosis	  patients	  in	  Tugela	  Ferry	  turn	  from	  a	  trickle	  into	  a	  stream	  and	  then	  into	  a	  flood.214	  The	  central	  tuberculosis	  hospital	  in	  Durban	  often	  had	  a	  waiting	  list	  that	  was	  several	  months	  long	  and	  was	  not	  really	  in	  a	  position	  to	  help.215	  Articles	  from	  the	  late	  1990s	  and	  early	  2000s	  document	  how	  South	  African	  hospitals	  and	  clinics	  transformed	  from	  places	  of	  potential	  healing	  to	  places	  of	  death	  and	  hopelessness,	  with	  up	  to	  80%	  of	  hospital	  beds	  being	  taken	  by	  patients	  with	  HIV/AIDS.	  There	  was	  no	  treatment	  for	  HIV	  available	  at	  this	  time,	  and	  stories	  about	  this	  period	  were	  inhabited	  by	  despondent	  nurses,	  physicians-­‐in-­‐training	  complaining	  that	  they	  weren’t	  learning	  proper	  medicine,	  and	  jaded	  senior	  physicians	  who	  either	  tried	  to	  avoid	  AIDS	  patients	  entirely,	  or	  fought	  seemingly	  pointlessly	  to	  help	  those	  patients	  whom	  they	  could.216	  	  
                                                213	  Cullinan,	  Health	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  in	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  Africa:	  A	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  Gerald	  M.	  Oppenheimer	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  (Oxford	  University	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  Anthony	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  by	  author,	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  2011,	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  Ferry,	  South	  Africa.	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  Iqbal	  Master,	  interview	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  author,	  30	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  Ferry,	  South	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  216	  Katherine	  Floyd	  et	  al.,	  “Admission	  Trends	  in	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  African	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  JAMA	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  no.	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  Shattered	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  Author's	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Tuberculosis	  before	  the	  time	  of	  AIDS	  Treating	  tuberculosis	  had	  once	  been	  one	  of	  the	  easiest	  tasks	  for	  physicians	  at	  remote,	  rural	  hospitals	  in	  South	  Africa,	  including	  at	  the	  hospital	  in	  Tugela	  Ferry.217	  In	  the	  1980s,	  it	  was	  the	  norm	  in	  Tugela	  Ferry	  to	  admit	  every	  single	  patient	  diagnosed	  with	  tuberculosis	  to	  the	  hospital	  for	  the	  full	  duration	  of	  his	  or	  her	  treatment.	  This	  generally	  meant	  six	  months	  of	  supervised	  treatment	  as	  an	  inpatient,	  usually	  in	  the	  designated	  tuberculosis	  ward.	  Dr.	  Theo	  van	  der	  Merwe,	  another	  physician	  who	  worked	  at	  the	  hospital	  in	  Tugela	  Ferry	  for	  over	  two	  decades,	  longingly	  remembered	  the	  days	  before	  HIV/AIDS	  when	  being	  the	  doctor	  in	  charge	  of	  the	  tuberculosis	  ward	  meant	  visiting	  it	  once	  a	  month	  to	  discharge	  patients	  who	  had	  completed	  treatment.	  In	  the	  meantime,	  patients’	  care	  was	  supervised	  by	  nurses	  who	  made	  sure	  patients	  took	  their	  treatment	  every	  day,	  and	  who	  provided	  them	  with	  regular	  meals.	  According	  to	  the	  somewhat	  nostalgic	  Dr.	  van	  der	  Merwe	  there	  was	  very	  little	  turnover.	  Patients	  rarely	  died	  while	  undergoing	  tuberculosis	  treatment,	  and	  most	  of	  them	  went	  home	  healthier	  than	  they	  had	  been	  when	  they	  had	  arrived.218	  It	  wasn’t	  just	  in	  rural	  Tugela	  Ferry	  that	  tuberculosis	  was	  considered	  a	  relatively	  unproblematic,	  treatable	  and	  low	  intensity	  disease.	  At	  King	  George	  V	  hospital,	  the	  tuberculosis	  hospital	  in	  Durban	  that	  specializes	  in	  complicated	  cases	  of	  tuberculosis,	  the	  work	  of	  treating	  tuberculosis	  was	  considered	  routine	  and	  not	  too	  hectic.219	  According	  to	  Dr.	  Sheila	  Bamber,	  a	  physician	  who	  worked	  in	  the	  pediatric	  tuberculosis	  ward	  at	  King	  George	  V	  hospital	  from	  1982	  to	  2006	  and	  later	  worked	  in	  Tugela	  Ferry,	  employment	  at	  the	  tuberculosis	  hospital	  in	  Durban	  was	  appealing	  to	  physicians	  looking	  for	  a	  relaxed	  schedule	  and	  a	  job	  that	  was	  not	  too	  challenging.	  She	  herself	  did	  not	  shirk	  hard	  work,	  yet	  the	  
                                                217	  Van	  der	  Merwe,	  interview	  by	  author,	  2011.	  	  218	  Van	  der	  Merwe,	  interview	  by	  author,	  2011.	  219	  Bamber,	  interview	  by	  author,	  2010;	  Master,	  interview	  by	  author,	  2010.	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government	  tuberculosis	  hospital	  brought	  certain	  advantages	  for	  her,	  as	  well.	  There,	  she	  could	  practice	  as	  a	  general	  physician	  without	  the	  administrative	  duties	  of	  private	  practice,	  and	  without	  having	  to	  perform	  bloody	  procedures	  like	  Caesarian	  sections,	  which	  she	  would	  have	  had	  to	  do	  in	  a	  general	  hospital.220	  Over	  the	  course	  of	  the	  1990s	  and	  2000s,	  however,	  the	  tuberculosis	  wards	  in	  Tugela	  Ferry	  and	  in	  Durban	  became	  increasingly	  busy	  and	  changed	  from	  low-­‐intensity	  spaces	  where	  patients	  mostly	  waited	  until	  they	  got	  better,	  to	  places	  with	  increasing	  turnover	  of	  seriously	  ill	  patients	  who	  needed	  increased	  attention	  and	  often	  got	  worse.	  By	  the	  early	  1990s,	  the	  60-­‐75	  beds	  that	  were	  available	  for	  tuberculosis	  patients	  at	  the	  hospital	  in	  Tugela	  Ferry	  became	  insufficient	  for	  the	  number	  of	  people	  diagnosed	  with	  tuberculosis.	  Over	  the	  course	  of	  that	  decade,	  hospital	  stays	  were	  successively	  shortened,	  with	  the	  balance	  of	  treatment	  being	  given	  to	  the	  patients	  to	  take	  back	  home.221	  As	  Dr.	  Moll	  recalled:	  “We	  became	  overwhelmed	  with	  HIV	  plus	  TB	  and	  no	  longer	  could	  we	  admit	  patients	  for	  full	  duration	  of	  their	  six	  months.	  I	  can	  remember	  making	  a	  decision	  with	  other	  hospitals	  to	  bring	  it	  down	  to	  five	  months,	  to	  bring	  it	  down	  to	  four	  months,	  later	  on	  to	  bring	  it	  down	  to	  two	  months,	  we	  lost	  complete	  control	  after	  that,	  and	  basically	  it	  became	  round	  about	  2001/2002,	  any	  patient	  who	  could	  walk	  and	  got	  a	  diagnosis	  of	  TB	  and	  HIV	  mostly	  was	  given	  his	  treatment	  and	  sent	  home.”	  222	  Inpatient	  care	  was	  reserved	  for	  the	  seriously	  sick	  and	  dying.223	  	   Dr.	  Moll	  described	  the	  changing	  outpatient	  management	  of	  tuberculosis	  as	  the	  result	  of	  hospital	  overcrowding	  in	  the	  context	  of	  conversations	  between	  different	  hospitals	  about	  the	  appropriate	  response.	  The	  increased	  move	  to	  outpatient	  treatment	  was	  not	  merely	  an	  
                                                220	  Bamber,	  interview	  by	  author,	  2010.	  221	  Moll,	  interview	  by	  author,	  2007.	  222	  Ibid.	  223	  Ibid.	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ad	  hoc	  reaction	  of	  hospital	  administrators	  to	  the	  rising	  tuberculosis	  burden,	  however.	  By	  1996,	  South	  Africa	  had	  decided	  to	  introduce	  the	  relatively	  new	  WHO	  DOTS	  policies	  for	  managing	  tuberculosis,	  which	  emphasized	  ambulatory	  (out-­‐patient)	  tuberculosis	  care	  in	  the	  community.	  As	  the	  WHO	  and	  South	  African	  policy	  makers	  stressed,	  DOTS	  as	  it	  was	  implemented	  in	  South	  Africa	  consisted	  of	  a	  package	  of	  interventions,	  which	  included	  “four	  elements:	  case	  detection	  using	  sputum	  smear	  microscopy	  among	  symptomatic	  patients	  presenting	  to	  health	  services,	  establishment	  of	  regular	  supplies	  of	  essential	  antituberculosis	  drugs,	  enhancement	  of	  patient	  adherence	  to	  therapy	  by	  ambulatory	  supervised	  care,	  and	  the	  establishment	  of	  standardised	  reporting	  systems	  allowing	  the	  assessment	  of	  treatment	  results.”224	  The	  name	  of	  the	  program,	  however,	  clearly	  emphasized	  its	  observational	  and	  somewhat	  coercive	  aspects,	  which	  called	  for	  patients	  to	  take	  their	  daily	  doses	  of	  medication	  in	  the	  presence	  of	  a	  treatment	  supervisor	  or	  supporter.225	  In	  theory,	  this	  supporter	  could	  be	  a	  paid	  health	  professional,	  a	  volunteering	  shopkeeper,	  schoolteacher,	  neighbor,	  or	  a	  friend.	  Some	  tuberculosis	  programs	  even	  sought	  to	  work	  together	  with	  traditional	  healers	  and	  community	  leaders.	  	   Several	  South	  African	  health	  professionals	  I	  spoke	  to	  perceived	  DOTS	  as	  a	  top-­‐down	  WHO	  intervention	  that	  did	  not	  sufficiently	  consider	  the	  realities	  of	  health	  care	  provision	  in	  South	  African	  communities,	  and	  in	  fact	  did	  not	  provide	  the	  conditions	  that	  allowed	  even	  observed	  treatment.	  As	  Dr.	  van	  der	  Merwe	  explained:	  “beginning	  of	  the	  90s	  the	  DOTS	  program	  came	  in	  to	  being.	  	  […]	  And	  they	  [WHO]	  say,	  no,	  they	  [patients]	  must	  be	  DOTSed.	  […]	  That	  means	  you	  must	  get	  a	  care	  giver	  and	  you	  make	  the	  diagnosis,	  admit	  them,	  maybe,	  treat	  them,	  stabilize	  them,	  and	  then	  they	  go	  out	  and	  they	  are	  DOTSed	  there.	  [They	  are	  
                                                224	  J.	  Dick,	  A.	  Mbewu,	  and	  R.	  Matji,	  “What	  Obstacles	  to	  TB	  Control?,”	  South	  African	  Medical	  Journal	  89,	  no.	  2	  (1999):	  132–133.	  225	  Jessica	  Ogden,	  Gill	  Walt,	  and	  Louisiana	  Lush,	  “The	  Politics	  of	  ‘Branding’	  in	  Policy	  Transfer:	  The	  Case	  of	  DOTS	  for	  Tuberculosis	  Control,”	  Social	  Science	  &	  Medicine	  57,	  no.	  1	  (2003):	  179–188.	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treated	  at	  home.]	  But,	  as	  we	  all	  know,	  it	  is	  a	  fantastic	  program,	  and	  we	  appreciate	  that	  very	  much,	  but,	  it	  was	  again	  a	  World	  Health	  Organization	  program	  and	  I	  don’t	  think	  they	  really	  realized	  what	  is	  going	  on	  at	  the	  coalface;	  at	  the	  grass	  roots	  level.	  You	  don’t	  get	  supporters.	  They	  didn’t	  make	  any	  provision	  for	  paid	  supporters,	  so	  […]	  you	  couldn’t	  get	  supporters.	  […]The	  World	  Health	  Organization	  brought	  that	  program	  out,	  and	  obviously	  we	  adopted	  it.	  And	  there	  we	  are.”226	  	   In	  the	  quote	  above,	  Dr.	  van	  der	  Merwe	  touches	  upon	  a	  common,	  fundamental	  critique	  of	  the	  DOTS	  program.	  Essentially,	  the	  DOTS	  strategy	  relied	  heavily	  on	  minimally	  trained	  community	  members	  to	  carry	  the	  responsibility	  for	  ensuring	  that	  tuberculosis	  patients	  successfully	  took	  their	  medication.	  Yet	  no	  provision	  was	  made	  to	  pay	  these	  workers	  who	  were	  the	  backbone	  of	  the	  DOTS	  program,	  and	  often	  the	  organizational	  connection	  between	  the	  designated	  treatment	  supporters	  and	  the	  trained	  tuberculosis	  nurses	  was	  tenuous.227	  Physicians	  and	  nurses	  working	  in	  clinics	  and	  district	  hospitals	  like	  the	  one	  in	  Tugela	  Ferry	  struggled	  with	  the	  fact	  that	  few	  resources	  had	  been	  allocated	  to	  actually	  identifying,	  training	  and	  compensating	  treatment	  supporters	  “out	  in	  the	  community,”	  who	  generally	  were	  not	  directly	  affiliated	  with	  health	  facilities.	  	  More	  recently,	  the	  weakness	  of	  this	  strategy	  has	  been	  acknowledged	  in	  South	  Africa	  and	  efforts	  have	  been	  made	  to	  pay	  some	  of	  these	  community	  health	  workers	  stipends,	  yet	  DOTS	  is	  still	  considered	  to	  be	  weak	  in	  South	  Africa.	  Several	  South	  African	  tuberculosis	  experts	  even	  went	  so	  far	  as	  to	  argue	  that	  DOTS	  did	  not	  in	  fact	  exist	  in	  South	  Africa	  at	  all.	  When	  I	  asked	  long-­‐time	  tuberculosis	  physician	  Dr.	  Bamber	  when	  South	  Africa	  “became	  a	  DOTS	  country”	  she	  replied:	  “Well,	  let’s	  face	  it,	  it’s	  
                                                226	  Van	  der	  Merwe,	  interview	  by	  author,	  2011.	  227	  See,	  for	  example,	  Partner	  in	  Health’s	  discussion	  of	  the	  payment	  of	  community	  health	  workers	  at	  http://www.pih.org/priority-­‐programs/community-­‐health-­‐workers/about.	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never	  been	  a	  DOTS	  country.	  Never	  been.	  I	  mean,	  a	  couple	  of	  places,	  like	  Hlabisa,228	  where	  they	  had	  a	  very	  dynamic	  superintendent	  and	  he	  organized	  DOTS	  with	  the	  shopkeepers,	  etc.	  […]	  But	  that	  was	  driven	  by	  him.	  And	  then	  he	  left	  and	  things	  just	  got,	  you	  know,	  overwhelming.”229	  According	  to	  Durban-­‐based	  tuberculosis	  researcher	  Nesri	  Padayatchi,	  “of	  course	  South	  Africa	  subscribes	  to	  the	  WHO	  guidelines,	  which	  talks	  about	  DOT	  [directly	  observed	  therapy],	  but	  I	  can	  assure	  you	  […]	  DOT's	  not	  happening	  here.”230	  In	  another	  instance,	  she	  quoted	  a	  colleague	  of	  hers	  as	  saying	  that	  “the	  only	  patients	  that	  get	  DOT	  are	  prisoners.”231	  According	  to	  Dr.	  van	  der	  Merwe,	  inpatient	  treatment	  would	  still	  be	  the	  preferred	  method	  of	  treating	  tuberculosis	  if	  the	  hospital	  had	  the	  capacity	  for	  it,	  since	  patients	  could	  be	  closely	  monitored	  in	  the	  hospital	  and	  could	  be	  prevented	  from	  defaulting	  from	  their	  treatment	  course.	  One	  nurse	  I	  spoke	  to	  in	  Tugela	  Ferry	  pointed	  out	  that	  inpatient	  tuberculosis	  treatment	  at	  least	  ensured	  that	  sick,	  poor,	  rural	  patients	  received	  daily	  meals.	  But	  as	  Sister	  Sithole,	  one	  of	  the	  matrons	  for	  Tugela	  Ferry’s	  primary	  health	  care	  program,	  responded	  when	  I	  asked	  if	  inpatient	  tuberculosis	  treatment	  should	  be	  reinstated:	  “I	  don’t	  think	  we	  could	  go	  back	  to	  admitting	  all	  of	  the	  TB	  patients.	  Where	  would	  they	  all	  sleep?”232	  Thus,	  physicians	  and	  nurses	  working	  at	  district	  hospitals	  in	  South	  Africa	  struggled	  with	  the	  practical	  aspects	  of	  keeping	  track	  of	  overwhelming	  numbers	  of	  tuberculosis	  patients	  who	  had	  been	  dispersed	  from	  tuberculosis	  wards	  to	  their	  homes.	  Some	  South	  African	  tuberculosis	  experts	  associated	  with	  academic	  centers	  in	  Cape	  Town,	  Stellenbosch,	  Pretoria,	  and	  Durban	  were	  unimpressed	  by	  the	  WHO	  guidelines	  for	  other	  reasons.	  They	  felt	  
                                                228	  Hlabisa	  is	  a	  town	  in	  KwaZulu-­‐Natal	  province	  in	  which	  there	  was	  an	  innovative	  tuberculosis	  program	  in	  the	  late	  1990s.	  I	  briefly	  discuss	  this	  program	  later	  in	  this	  chapter.	  229	  Bamber,	  interview	  by	  author,	  2010.	  230	  Nesri	  Padayatchi,	  interview	  by	  author,	  13	  July	  2007,	  Durban,	  South	  Africa.	  231	  Nesri	  Padayatchi	  interview	  by	  author,	  6	  April	  2010	  Durban,	  South	  Africa.	  232	  Lindiwe	  Sithole,	  interview	  by	  author,	  Tugela	  Ferry,	  South	  Africa,	  2011.	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that	  their	  TB	  expertise	  as	  well	  as	  success	  in	  treating	  tuberculosis	  was	  being	  undermined	  by	  the	  standardized	  (and	  thus	  simplified)	  tuberculosis	  treatment	  protocols	  generated	  by	  the	  WHO	  in	  Geneva.233	  Prior	  to	  the	  DOTS	  strategy,	  South	  African	  tuberculosis	  physicians	  would	  use	  their	  own	  individual	  judgments	  in	  deciding	  exactly	  which	  combination	  of	  treatments	  a	  particular	  tuberculosis	  patient	  should	  take	  and	  decided	  when	  to	  test	  a	  patient	  for	  drug-­‐resistance.	  The	  WHO	  guidelines	  set	  standard	  drug	  regimens	  and	  a	  testing	  schedule	  that	  did	  not	  require	  a	  physician’s	  individualized	  intervention.	  While	  the	  WHO’s	  push	  for	  DOTS	  attempted	  to	  increase	  access	  to	  anti-­‐tuberculosis	  treatment	  by	  providing	  standardized	  and	  simplified	  procedures	  for	  managing	  the	  most	  infectious	  cases	  of	  tuberculosis,	  some	  people	  worried	  that	  DOTS	  would	  decrease	  the	  quality	  of	  tuberculosis	  care	  by	  shifting	  the	  task	  of	  caring	  for	  uncomplicated	  tuberculosis	  patients	  away	  from	  physicians	  in	  the	  hospitals	  to	  nurses	  and	  lay-­‐workers	  in	  the	  community.234	  Interestingly,	  the	  resistance	  and	  critique	  of	  the	  DOTS	  strategy	  by	  well-­‐established	  tuberculosis	  specialists	  working	  in	  South	  Africa	  parallels	  the	  resistance	  by	  tuberculosis	  experts	  working	  in	  the	  former	  Soviet	  Union	  documented	  by	  physician-­‐anthropologist	  Gene	  Bukhman.235	  The	  post-­‐Soviet	  physicians	  he	  spoke	  with	  pointed	  out	  that	  the	  DOTS	  strategy	  was	  based	  on	  studies	  conducted	  in	  African	  countries	  in	  the	  1960s	  and	  1980s,	  and	  that	  it	  was	  designed	  to	  be	  simple	  enough	  for	  Africa.	  One	  medical	  officer	  quoted	  by	  Bukhman	  stated	  “They	  say	  it	  is	  a	  very	  primitive	  system	  that	  could	  be	  used	  in	  Africa,	  and	  Russia	  is	  not	  
                                                233	  Karen	  Shean,	  interview	  by	  author,	  7	  May	  2010,	  Cape	  Town,	  South	  Africa;	  Paul	  D.	  van	  Helden,	  Tommie	  Victor,	  and	  Robin	  M.	  Warren,	  “The	  ‘Source’	  of	  Drug-­‐resistant	  TB	  Outbreaks,”	  Science	  314,	  no.	  5798	  (2006):	  419–420;	  Manormoney	  Pillay	  and	  A.	  Willem	  Sturm,	  “Evolution	  of	  the	  Extensively	  drug-­‐Resistant	  F15/LAM4/KZN	  Strain	  of	  Mycobacterium	  tuberculosis	  in	  KwaZulu-­‐Natal,	  South	  Africa.	  	  234	  Shean,	  interview	  by	  author,	  2010.	  235	  Gene	  Bukhman,	  “Reform	  and	  Resistance	  in	  Post-­‐Soviet	  Tuberculosis	  Control”	  (Doctoral	  Dissertation,	  University	  of	  Arizona,	  2001).	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Africa.”236	  Being	  asked	  to	  introduce	  “African”	  (and	  thus	  presumed	  inferior)	  standards	  into	  the	  Russian	  system	  was	  considered	  insulting	  and	  inappropriate	  by	  some	  of	  the	  tuberculosis	  experts	  who	  believed	  in	  the	  superiority	  of	  their	  training,	  resources	  and	  clinical	  acumen	  over	  the	  standardized	  DOTS	  protocols.237	  Intriguingly,	  the	  South	  African	  experts	  resisted	  that	  same	  “Africanization”	  of	  tuberculosis	  care,	  though	  this	  was	  not	  the	  language	  they	  used.	  They,	  too,	  believed	  that	  their	  own	  clinical	  skills	  and	  superior	  laboratories	  would	  lead	  to	  better	  outcomes	  than	  a	  standardized,	  simplified	  strategy.	  Some	  clinics	  and	  hospitals	  in	  South	  Africa	  responded	  proactively	  to	  the	  increasing	  tuberculosis	  burden,	  as	  well	  as	  the	  new	  global	  tuberculosis	  policies,	  by	  putting	  in	  place	  programs	  seeking	  to	  maximize	  the	  effectiveness	  of	  tuberculosis	  treatment,	  and	  documenting	  the	  outcomes.238	  One	  such	  effort	  was	  led	  by	  Dr.	  Wilkinson	  in	  rural	  Hlabisa,	  KwaZulu-­‐Natal.	  He	  worked	  closely	  with	  community	  leaders	  to	  assist	  patients	  and	  demonstrated	  that	  patients	  did	  well	  even	  if	  they	  took	  anti-­‐tuberculosis	  treatment	  every	  other	  day	  instead	  of	  daily.239	  Other	  responses	  to	  the	  increased	  burden	  included	  actively	  putting	  in	  place	  care	  programs	  to	  help	  those	  sick	  and	  dying	  of	  AIDS,	  while	  merely	  trying	  to	  keep	  up	  with	  the	  increasingly	  sick	  tuberculosis	  patients.	  In	  either	  case,	  overburdened	  health	  systems	  sought	  help	  from	  volunteer	  community	  members	  to	  extend	  their	  reach	  into	  sick	  communities,	  and	  South	  African	  health	  programs	  (both	  public	  and	  charitable)	  increasingly	  promoted	  “home-­‐based	  care”	  by	  lay	  people	  in	  various	  forms.	  Providing	  professional	  medical	  care	  for	  people	  with	  AIDS	  and	  tuberculosis	  was	  made	  very	  difficult	  by	  the	  fact	  that	  the	  South	  
                                                236	  Gene	  Bukhman,	  “Reform	  and	  Resistance	  in	  Post-­‐Soviet	  Tuberculosis	  Control”	  (Doctoral	  Dissertation,	  University	  of	  Arizona,	  2001),	  107.	  237	  Bukhman,	  “Reform	  and	  Resistance	  in	  Post-­‐Soviet	  Tuberculosis	  Control.”	  238	  David	  Wilkinson,	  “Tuberculosis	  and	  Health	  Sector	  Reform:	  Experience	  of	  Integrating	  Tuberculosis	  Services	  into	  the	  District	  Health	  System	  in	  Rural	  South	  Africa	  Planning	  and	  Practice,”	  The	  
International	  Journal	  of	  Tuberculosis	  and	  Lung	  Disease	  3,	  no.	  10	  (1999):	  938–943.	  239	  David	  Wilkinson,	  “High-­‐compliance	  Tuberculosis	  Treatment	  Programme	  in	  a	  Rural	  Community,”	  
The	  Lancet	  343,	  no.	  8898	  (1994):	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African	  President	  and	  his	  Minister	  of	  Health	  chose	  for	  several	  years	  to	  deny	  that	  AIDS	  was	  a	  problem	  in	  South	  Africa,	  actively	  undermined	  programs	  that	  sought	  to	  address	  it,	  and	  blocked	  the	  introduction	  of	  anti-­‐HIV	  drugs	  into	  the	  public	  health	  system	  for	  several	  years.240	  
Complexities	  of	  Co-­‐Infection	  Once	  HIV	  treatment	  finally	  did	  become	  available	  in	  South	  Africa	  (first	  through	  HIV/AIDS	  research	  and	  pilot	  projects;	  after	  2004	  through	  government-­‐funded	  programs	  in	  government	  hospitals	  and	  clinics),	  clinicians	  were	  faced	  with	  the	  challenge	  of	  treating	  HIV	  and	  tuberculosis	  at	  the	  same	  time.	  This	  was	  not	  always	  a	  straightforward	  task.	  Many	  of	  the	  opportunistic	  infections	  seen	  in	  people	  with	  AIDS	  (such	  as	  PCP	  pneumonia,	  cryptococcal	  meningitis	  and	  Kaposi’s	  Sarcoma)	  improve	  on	  their	  own	  once	  anti-­‐HIV	  medications	  are	  introduced.	  Tuberculosis,	  however,	  persists	  and	  still	  needs	  to	  be	  treated	  with	  anti-­‐tuberculosis	  drugs,	  even	  once	  an	  HIV	  positive	  person	  is	  being	  treated	  for	  HIV.	  Successful	  treatment	  of	  either	  tuberculosis	  or	  HIV	  disease	  requires	  patients	  to	  take	  several	  drugs	  a	  day,	  several	  times	  a	  day	  for	  prolonged	  periods	  of	  time.	  Standard	  tuberculosis	  treatment	  requires	  at	  least	  six	  months	  of	  medication;	  HIV	  requires	  daily	  medications	  for	  life.	  Treating	  both	  simultaneously	  can	  require	  high	  daily	  pill-­‐consumption.	  Some	  tuberculosis	  drugs	  interact	  with	  some	  HIV	  drugs,	  so	  clinicians	  ideally	  need	  to	  pay	  attention	  to	  this	  and	  monitor	  carefully	  for	  certain	  side-­‐effects.	  In	  addition,	  treating	  HIV	  in	  a	  person	  who	  has	  tuberculosis	  can	  sometimes	  actually	  make	  that	  person	  temporarily	  sicker,	  due	  to	  a	  phenomenon	  called	  Immune	  Reconstitution	  Inflammatory	  Syndrome	  (IRIS).	  As	  a	  person’s	  immune	  system	  recovers	  from	  HIV,	  it	  starts	  to	  recognize	  other	  diseases	  in	  the	  body	  (such	  as	  tuberculosis)	  
                                                240	  Kerry	  Cullinan	  and	  Anso	  Thom,	  The	  Virus,	  Vitamins	  &	  Vegetables:	  The	  South	  African	  HIV/AIDS	  
Mystery	  (Jacana	  Media,	  2010);	  Nicoli	  Nattrass,	  Mortal	  Combat:	  AIDS	  Denialism	  and	  the	  Struggle	  for	  
Antiretrovirals	  in	  South	  Africa.	  (University	  of	  KwaZulu-­‐Natal	  Press,	  2007).	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that	  until	  then	  it	  had	  been	  unable	  to	  fight	  –	  and	  starts	  an	  overwhelming	  immune	  response	  which	  has	  the	  potential	  to	  damage	  the	  body	  more	  than	  the	  tuberculosis	  itself.241	  Most	  importantly,	  however,	  South	  Africa’s	  tuberculosis	  programs	  were	  generally	  run	  separately	  from	  other	  medical	  and	  public	  health	  programs.	  To	  be	  diagnosed	  or	  treated	  with	  tuberculosis	  patients	  would	  go	  to	  the	  nurse-­‐operated	  tuberculosis	  or	  DOTS	  office	  where	  protocols	  specific	  to	  tuberculosis	  were	  followed,	  according	  to	  South	  Africa’s	  version	  of	  WHO	  guidelines.	  Most	  new	  HIV	  programs,	  on	  the	  other	  hand,	  were	  set	  up	  to	  take	  place	  in	  separate	  offices	  or	  at	  separate	  hours	  than	  other	  programs.	  People	  diagnosed	  with	  HIV	  would	  be	  referred	  to	  mostly	  physician-­‐run	  HIV	  clinics,	  where	  their	  HIV	  disease	  would	  be	  managed.	  People	  with	  tuberculosis	  and	  HIV	  might	  find	  themselves	  going	  to	  the	  same	  health	  facility	  to	  stand	  in	  line	  twice	  a	  week	  –	  once	  to	  pick	  up	  anti-­‐tuberculosis	  medications	  from	  the	  TB	  office,	  and	  on	  another	  day	  to	  be	  seen	  about	  HIV	  and	  pick	  up	  antiretroviral	  medication.	  The	  clinicians	  who	  treated	  the	  patients	  did	  not	  usually	  coordinate	  HIV	  and	  TB	  care,	  and	  it	  could	  easily	  happen	  that	  a	  TB	  patient	  was	  never	  tested	  for	  HIV	  (despite	  a	  high	  chance	  that	  he/she	  could	  be	  HIV	  positive),	  or	  that	  an	  HIV	  patient	  was	  not	  thoroughly	  screened	  for	  tuberculosis.	  In	  the	  days	  before	  antiretroviral	  medications	  were	  available	  in	  the	  public	  sector,	  a	  patient	  might	  receive	  their	  HIV	  treatment	  through	  an	  academic	  study,	  a	  private	  hospital,	  or	  a	  charitable	  organization	  –	  but	  if	  they	  wanted	  to	  be	  treated	  for	  tuberculosis,	  they	  would	  still	  have	  to	  seek	  out	  the	  public	  hospital	  system	  for	  free	  tuberculosis	  care.	  In	  such	  cases,	  coordination	  of	  medical	  care	  was	  even	  less	  likely.	  The	  disjointed	  nature	  of	  TB	  and	  HIV	  care	  led	  some	  experts	  to	  call	  for	  the	  integration	  of	  TB	  and	  HIV	  treatment.242	  In	  the	  early	  2000s,	  several	  international	  researchers,	  non-­‐
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  Stephen	  D.	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  and	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  “Pathogenesis	  and	  Prevention	  of	  Immune	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  Review	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  Anti-­‐Infective	  Therapy	  9,	  no.	  4	  (2011):	  415–430.	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governmental	  organizations,	  and	  donor	  organizations	  established	  HIV	  treatment	  and	  care	  programs	  in	  South	  Africa,	  some	  of	  which	  focused	  on	  the	  simultaneous	  treatment	  of	  HIV	  and	  TB	  co-­‐infection.	  Doctors	  without	  Borders	  (MSF)	  initiated	  an	  HIV	  treatment	  pilot	  project	  at	  a	  municipal	  clinic	  in	  Khayelitsha,	  South	  Africa	  and	  soon	  famously	  knocked	  down	  the	  walls	  (quite	  literally)	  between	  the	  adjacent	  HIV	  and	  TB	  clinics	  and	  advocated	  for	  an	  organizationally	  and	  physically	  integrated	  approach	  to	  TB	  and	  HIV	  care.243	  Other	  HIV	  treatment	  programs	  in	  South	  Africa	  explored	  the	  effective	  co-­‐treatment	  of	  HIV/	  TB	  co-­‐infection	  from	  different	  perspectives.	  This	  included	  large,	  internationally	  funded	  trials	  addressing	  the	  perfect	  timing	  for	  starting	  TB	  and	  HIV	  treatment,	  as	  well	  as	  smaller	  proof-­‐of-­‐concept	  studies	  demonstrating	  that	  TB	  and	  HIV	  treatment	  could	  be	  successfully	  integrated.244	  	  	   It	  was	  in	  this	  context	  of	  a	  South	  African	  post-­‐apartheid	  public	  health	  system	  in	  transition;	  a	  burgeoning	  AIDS	  epidemic	  which	  was	  not	  being	  sufficiently	  addressed;	  a	  complex	  relationship	  to	  global	  tuberculosis	  expertise;	  and	  growing	  global	  health	  research	  and	  care	  activity	  that	  a	  group	  of	  researchers	  affiliated	  with	  Yale	  University	  started	  an	  HIV	  and	  TB	  co-­‐treatment	  study	  in	  Tugela	  Ferry,	  South	  Africa.	  This	  research	  eventually	  led	  to	  the	  discovery	  of	  XDR-­‐TB	  and	  to	  the	  presentation	  with	  which	  I	  started	  this	  chapter.	  In	  the	  rest	  of	  this	  chapter,	  I	  will	  describe	  how	  the	  American-­‐South	  African	  collaboration	  that	  eventually	  made	  Tugela	  Ferry	  and	  its	  researchers	  famous	  in	  public	  health	  circles	  came	  about.	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  Resource-­‐limited	  Setting,”	  Journal	  of	  Acquired	  Immune	  Deficiency	  Syndromes	  36,	  no.	  4	  (2004):	  929–934.	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Managing	  TB/HIV	  coinfection	  in	  Tugela	  Ferry	  In	  2001,	  Dr.	  Gerald	  Friedland,	  an	  American	  HIV	  clinical	  researcher	  based	  at	  Yale	  University,	  traveled	  to	  South	  Africa	  on	  a	  research	  sabbatical	  with	  the	  intention	  of	  beginning	  a	  collaboration	  with	  South	  African	  researchers	  at	  the	  Nelson	  R.	  Mandela	  Medical	  school	  of	  the	  University	  of	  KwaZulu-­‐Natal	  (UKZN)	  in	  Durban.	  They	  had	  received	  funding	  from	  the	  US	  National	  Institutes	  of	  Health	  to	  look	  at	  the	  combined	  management	  of	  HIV	  and	  TB.	  Since	  the	  planned	  large-­‐scale	  international	  research	  collaboration	  ran	  into	  complex	  bureaucratic	  hurdles	  and	  was	  slow	  to	  take	  off,	  Dr.	  Friedland	  spent	  some	  of	  his	  time	  in	  Durban	  working	  at	  a	  public	  inner-­‐city	  clinic	  specialized	  on	  sexually	  transmitted	  infections	  and	  tuberculosis.	  There,	  he	  and	  South	  African	  colleagues	  conducted	  a	  small	  pilot	  program	  introducing	  HIV	  treatment	  into	  the	  government	  tuberculosis	  treatment	  program.	  The	  publication	  that	  resulted	  from	  this	  research	  showed	  good	  tuberculosis	  cure	  rates	  and	  stressed	  the	  advantages	  of	  introducing	  HIV	  treatment	  into	  the	  already	  existing	  public	  tuberculosis	  treatment	  infrastructure.245	  While	  working	  in	  Durban,	  Dr.	  Friedland	  decided	  to	  seek	  out	  a	  more	  rural	  location,	  where	  he	  felt	  his	  research	  would	  have	  a	  greater	  impact.	  As	  Dr.	  Friedland	  put	  it,	  once	  he	  started	  looking	  for	  an	  appropriate	  research	  site,	  “all	  roads	  led	  to	  Tugela	  Ferry,”	  a	  small	  trade	  town	  in	  the	  municipal	  district	  of	  Msinga,	  in	  rural	  KwaZulu	  Natal,	  about	  2.5	  hours	  drive	  from	  Durban,	  where	  Dr.	  Friedland	  encountered	  a	  kindred	  spirit	  and	  a	  “magnificent,	  brilliant,	  incredible	  colleague”	  in	  Dr.	  Tony	  Moll.246	  As	  we	  saw	  in	  the	  introduction,	  Dr.	  Moll	  and	  his	  colleagues	  at	  the	  Church	  of	  Scotland	  Hospital	  (a	  district	  hospital	  which	  is	  part	  of	  the	  government	  hospital	  system	  and	  no	  longer	  affiliated	  with	  any	  church	  or	  mission)	  in	  Tugela	  
                                                245	  Gerald	  Friedland,	  interview	  by	  author,	  27	  March	  2007,	  New	  Haven,	  CT;	  Jack	  et	  al.,	  “A	  Pilot	  Study	  of	  Once-­‐daily	  Antiretroviral	  Therapy	  Integrated	  with	  Tuberculosis	  Directly	  Observed	  Therapy	  in	  a	  Resource-­‐limited	  Setting.”	  246	  Friedland,	  interview	  by	  author,	  2007.	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Ferry	  had	  been	  caring	  for	  AIDS	  patients	  with	  extremely	  limited	  tools.	  Unable	  to	  access	  life-­‐saving	  antiretrovirals,	  Dr.	  Moll	  had	  brought	  nurses,	  church-­‐leaders,	  and	  other	  community	  leaders	  together	  in	  1997	  to	  found	  Philanjalo	  (Zulu	  for	  “live	  forever,”	  or	  “live	  well”),	  an	  organization	  which	  trained	  community	  members	  to	  take	  care	  of	  sick	  and	  dying	  people	  with	  AIDS,	  and	  then	  in	  2002	  opened	  a	  small	  hospice	  for	  people	  who	  needed	  palliative,	  end-­‐of-­‐life	  care.247	  By	  1997,	  the	  cause	  and	  manner	  of	  infection	  of	  HIV/AIDS	  was	  well	  known	  in	  much	  of	  the	  world,	  and	  life-­‐saving,	  though	  very	  expensive,	  medications	  had	  become	  available	  in	  the	  US	  and	  Europe	  the	  preceding	  year.	  Yet	  among	  the	  communities	  in	  Msinga	  –	  the	  rural	  area	  that	  surrounds	  the	  trade	  town	  of	  Tugela	  Ferry	  –	  there	  was	  great	  consternation	  concerning	  the	  cause	  for	  the	  recent	  increase	  in	  dramatic	  AIDS	  deaths,	  and	  there	  was	  no	  sign	  of	  effective	  treatment.	  As	  Dr.	  Moll	  recalls	  it,	  his	  group’s	  early	  efforts	  to	  educate	  and	  mobilize	  community	  volunteers	  fell	  on	  fertile	  ground:	  “The	  willingness	  and	  the	  desire	  to	  participate	  was	  incredible.	  […]	  The	  community	  […]	  didn’t	  know	  what	  to	  believe,	  because	  there	  was	  such	  a	  lot	  of	  different	  information	  coming	  through.	  […]	  When	  we	  started	  to	  bring	  in	  groups	  of	  community	  members	  for	  a	  full	  week	  of	  training	  on	  what	  HIV	  was,	  how	  it	  worked,	  what	  was	  the	  natural	  course	  of	  the	  disease	  […],	  they	  felt	  empowered,	  they	  felt	  they	  had	  the	  right	  information,	  they	  understood	  the	  sickness,	  it	  dispelled	  a	  lot	  of	  the	  myths	  surrounding	  HIV	  disease,	  and	  these	  people	  went	  back	  into	  their	  communities	  and	  became	  strong	  pillars	  of	  information.”248	  When	  Yale	  Professor	  Dr.	  Friedland	  first	  visited	  Tugela	  Ferry,	  its	  hospital,	  and	  Moll’s	  Philanjalo	  Care	  organization	  in	  2002,	  Dr.	  Moll	  steered	  him	  away	  from	  the	  district	  hospital	  in	  town	  and	  instead	  took	  him	  in	  a	  four-­‐by-­‐four	  vehicle	  on	  a	  series	  of	  home-­‐visits	  into	  the	  
                                                247	  Moll,	  interview	  by	  author,	  2011.	  248	  Moll,	  interview	  by	  author,	  2011.	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remote	  hills	  surrounding	  Tugela	  Ferry.	  They	  left	  the	  busy	  commercial	  and	  administrative	  crossroads	  near	  the	  river,	  where	  the	  hospital	  is	  located,	  and,	  as	  Dr.	  Moll	  later	  described	  it,	  “went	  into	  the	  tracks,	  left	  the	  tar	  roads	  and	  started	  going	  back	  into	  time	  to	  real	  old	  Africa,	  where	  patients	  basically	  don't	  have	  electricity,	  don't	  have	  water	  supply,	  live	  off	  the	  ground,	  you	  can	  say,	  there's	  no	  cell	  phone	  communication,	  basically	  cut	  off	  from	  modern	  facilities	  and	  these	  patients	  are	  really	  in	  bad	  circumstances	  out	  there	  in	  the	  rural	  community.	  And	  it	  was	  absolutely	  amazing.”249	  They	  drove	  along	  winding	  dirt	  paths	  to	  an	  area	  dominated	  by	  modest	  and	  crumbling	  Zulu	  huts,	  rocks,	  acacia	  trees	  and	  aloes,	  to	  visit	  a	  man	  who	  was	  desperately	  ill,	  lying	  on	  the	  dirt-­‐floor	  of	  his	  hut,	  with	  open,	  oozing	  sores	  all	  over	  his	  body.250	  To	  Dr.	  Moll’s	  surprise,	  Dr.	  Friedland	  was	  soon	  by	  his	  side,	  examining	  him	  –	  touching	  him.251	  The	  idea	  that	  a	  drive	  into	  the	  hills	  of	  Msinga	  allows	  a	  sort	  of	  time	  travel	  to	  “old	  Africa”	  is	  certainly	  problematic	  (and	  will	  be	  discussed	  in	  chapter	  5).	  Yet	  Dr.	  Friedland	  was	  clearly	  affected	  emotionally	  by	  the	  trip	  with	  Dr.	  Moll.	  Dr.	  Friedland	  had	  experienced	  the	  early	  days	  of	  AIDS	  as	  an	  Infectious	  Disease	  specialist	  in	  New	  York	  City,	  and	  the	  intense	  personal	  suffering	  and	  loss	  caused	  by	  AIDS	  in	  KwaZulu-­‐Natal	  reminded	  him	  of	  the	  time	  when	  all	  he	  could	  offer	  his	  own	  dying	  AIDS	  patients	  was	  comfort.252	  The	  day	  of	  visiting	  sick	  patients	  in	  the	  hills	  of	  Msinga	  became	  the	  beginning	  of	  an	  intense	  and	  fruitful	  collaboration	  and	  professional	  friendship	  between	  the	  two	  physicians.	  Dr.	  Friedland	  was	  motivated	  by	  the	  possibility	  of	  conducting	  interesting	  research	  on	  the	  combined	  management	  of	  HIV	  and	  TB	  in	  Tugela	  Ferry,	  as	  well	  as	  the	  opportunity	  of	  
                                                249	  Moll,	  interview	  by	  author,	  2007.	  250	  The	  following	  is	  Dr.	  Friedland's	  description	  of	  the	  research	  site:	  "Tugela	  Ferry	  is	  about	  2.5	  hours	  from	  Durban;	  there's	  one	  tarred	  road	  that	  leads	  into	  what	  was	  the	  former	  Zulu	  homeland.	  	  Everything	  else	  is	  dirt	  roads	  or	  paths.	  	  About	  70%	  of	  people	  don't	  have	  piped	  water	  or	  electricity.	  	  It's	  really	  a	  quite	  impoverished,	  but	  very	  traditional	  Zulu	  community,	  so	  it's	  very	  interesting	  in	  that	  way	  as	  well."	  Friedland,	  interview	  by	  author,	  2007.	  251	  Moll,	  interview	  by	  author,	  2007.	  252	  Gerald	  Friedland,	  “Clinical	  Care	  in	  the	  AIDS	  Epidemic,”	  in	  Living	  with	  AIDS,	  ed.	  Stephen	  R	  Graubard	  (MIT	  Press,	  1990);	  Ronald	  Bayer	  and	  Gerald	  M.	  Oppenheimer,	  AIDS	  Doctors:	  Voices	  from	  the	  
Epidemic:	  An	  Oral	  History.	  (Oxford	  University	  Press,	  USA,	  2000).	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providing	  life-­‐saving	  treatment	  –	  whose	  dramatic	  effects	  he	  could	  personally	  vouch	  for	  –	  to	  people	  who	  would	  otherwise	  die	  sooner	  than	  later.	  Dr.	  Moll,	  meanwhile,	  was	  highly	  motivated	  to	  collaborate	  with	  Dr.	  Friedland	  on	  a	  program	  that	  would	  provide	  antiretroviral	  treatment	  to	  even	  a	  fraction	  of	  his	  patients	  who	  were	  HIV	  positive.	  
The	  Sizonqoba	  Study	  Dr.	  Friedland	  and	  Dr.	  Moll	  designed	  a	  study	  in	  which	  they	  treated	  patients	  infected	  with	  HIV	  and	  tuberculosis	  and	  documented	  the	  outcomes.	  They	  named	  the	  study	  “Sizonqoba,”	  which	  in	  Zulu	  means	  “we	  will	  conquer.”	  As	  Dr.	  Moll	  described	  it,	  they	  put	  together	  a	  “very	  basic	  protocol	  looking	  at	  caring	  for	  HIV	  patients	  co-­‐infected	  with	  TB	  in	  the	  community	  using	  the	  DOT	  program,	  and	  introducing	  antiretroviral	  therapy	  in	  those	  existing	  circumstances	  using	  existing	  infrastructure.”253	  The	  emphasis	  here,	  like	  in	  Friedland’s	  previous	  HIV/TB	  co-­‐treatment	  study	  at	  the	  clinic	  in	  downtown	  Durban,	  was	  the	  integration	  of	  HIV	  treatment	  into	  the	  pre-­‐existing	  public	  tuberculosis	  program.	  At	  that	  time,	  the	  hospital	  in	  Tugela	  Ferry	  had	  a	  relatively	  well-­‐established	  tuberculosis	  treatment	  program	  which,	  according	  to	  Dr.	  Moll,	  was	  more	  successful	  than	  the	  programs	  in	  neighboring	  health	  districts	  in	  identifying	  tuberculosis	  patients	  and	  starting	  them	  on	  treatment.	  However,	  the	  tuberculosis	  office	  consisted	  of	  only	  two	  full-­‐time	  staff-­‐members,	  who	  were	  mostly	  grounded	  to	  the	  hospital	  due	  to	  a	  lack	  of	  vehicles.	  All	  the	  same,	  there	  were	  plenty	  of	  patients	  to	  be	  seen	  and	  administered	  to	  at	  the	  hospital	  every	  day.	  The	  program	  was	  called	  the	  DOT	  program	  –	  directly	  observed	  therapy	  program	  –	  but	  it	  was	  only	  nominally	  seeking	  out	  treatment	  supporters	  who	  could	  “directly	  observe”	  patients	  who	  were	  sent	  back	  home	  ‘into	  the	  community.’	  There	  was	  only	  occasional	  successful	  contact	  tracing	  or	  follow-­‐up	  of	  patients	  who	  stopped	  taking	  their	  treatment	  or	  left	  the	  hospital’s	  catchment	  area.	  As	  Dr.	  Moll	  described	  it	  six	  years	  later,	  there	  was	  good,	  passive	  case-­‐finding	  
                                                253	  Moll,	  interview	  by	  author,	  2007.	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–	  meaning	  that	  when	  sick	  people	  came	  to	  the	  hospital	  they	  would	  be	  diagnosed	  and	  put	  on	  treatment	  –	  but	  the	  program	  was	  crippled	  by	  the	  lack	  of	  a	  community	  system.254	  Thus	  the	  “very	  basic	  protocol”	  that	  was	  put	  together	  required	  a	  significant	  amount	  of	  coordination	  and	  strengthening	  of	  existing	  services	  –	  not	  only	  did	  the	  HIV	  treatment	  component	  need	  to	  be	  added,	  but	  the	  tuberculosis	  program	  needed	  to	  be	  expanded,	  as	  well.	  Conveniently,	  the	  new	  study	  program	  was	  able	  to	  take	  advantage	  of	  Philanjalo’s	  community-­‐based	  lay	  volunteers	  (which	  Dr.	  Moll	  described	  as	  lay	  “nurses	  in	  a	  huge	  community	  ward”255)	  to	  function	  as	  DOT	  supporters.	  In	  addition,	  a	  network	  of	  outlying	  government-­‐run	  primary	  health	  clinics	  affiliated	  with	  the	  hospital	  in	  Tugela	  Ferry	  meant	  that	  the	  tuberculosis	  program’s	  physical	  reach	  did	  in	  fact	  go	  farther	  than	  the	  district	  hospital	  itself.	  The	  study	  was	  able	  to	  provide	  funding	  for	  vehicles	  and	  additional	  staff	  to	  trace	  patients,	  as	  well	  as	  administrative	  support	  to	  allow	  study	  files	  to	  be	  properly	  organized	  and	  completed,	  and	  for	  results	  to	  be	  entered	  into	  databases.256	  Officially,	  the	  TB/HIV	  study	  was	  run	  from	  Philanjalo,	  the	  care	  organization	  Dr.	  Moll	  had	  founded.	  Yet	  Dr.	  Moll	  was	  also	  a	  full-­‐time	  physician	  employed	  by	  the	  department	  of	  health	  to	  work	  at	  COSH,	  the	  government	  hospital.	  Philanjalo	  offices	  were	  in	  or	  adjacent	  to	  the	  hospital,	  and	  the	  patients	  for	  the	  study	  were	  identified	  through	  the	  hospital	  system.	  Thus,	  I	  might	  say	  that	  the	  hospital	  provided	  antiretrovirals	  or	  engaged	  in	  this	  study,	  but	  strictly	  speaking,	  the	  study	  took	  place	  through	  Philanjalo,	  a	  non-­‐governmental	  entity	  only	  loosely	  affiliated	  with	  the	  government	  hospital.	  Over	  time,	  Philanjalo	  became	  more	  established	  and	  more	  independent	  both	  physically	  and	  organizationally.	  In	  view	  of	  the	  South	  African	  government’s	  hostile	  stance	  towards	  HIV	  treatment	  at	  the	  time	  it	  would	  have	  been	  difficult	  (though	  not	  impossible)	  to	  run	  this	  study	  through	  the	  government	  system	  
                                                254	  Moll,	  interview	  by	  author,	  2011.	  255	  Moll,	  interview,	  2011.	  256	  Moll,	  interview,	  2011.	  Author’s	  fieldnotes.	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itself.	  In	  addition,	  Dr.	  Moll	  and	  his	  colleagues	  found	  that	  working	  through	  Philanjalo	  allowed	  them	  to	  launch	  small	  projects	  and	  identify	  next	  steps	  more	  quickly	  and	  effectively	  than	  would	  be	  possible	  through	  cumbersome	  bureaucratic	  channels.257	  
The	  power	  of	  treatment	  and	  the	  disappointment	  of	  treatment	  failure	  By	  2003,	  Philanjalo	  was	  able	  to	  start	  providing	  HIV	  treatment	  to	  about	  100	  HIV	  and	  TB	  patients.	  Initially,	  the	  research	  program	  went	  very	  well.	  It	  was	  a	  time	  of	  great	  excitement	  and	  hope,	  as	  people	  who	  had	  previously	  apparently	  been	  sentenced	  to	  death	  rose	  from	  the	  dead.	  Stories	  abound	  of	  Lazarus-­‐like	  recoveries	  and	  of	  patients	  returning	  to	  thank	  their	  nurses	  and	  doctors,	  only	  to	  find	  that	  their	  caregivers	  did	  not	  recognize	  their	  fatter,	  healthier	  selves.	  Many	  of	  the	  patients	  who	  joined	  the	  study	  were	  very	  sick	  when	  they	  began	  taking	  antiretroviral	  medication	  and	  it	  was	  hard	  to	  believe	  that	  recovery	  could	  be	  possible.	  Gradually,	  Dr.	  Moll	  and	  his	  colleagues	  became	  accustomed	  to	  using	  the	  new,	  powerful	  HIV	  medications	  on	  these	  sick	  patients.	  Dr.	  Moll	  found	  that	  the	  first	  few	  months	  could	  be	  very	  difficult	  for	  patients.	  Once	  they	  had	  managed	  to	  take	  their	  pills	  for	  a	  few	  months,	  however,	  the	  positive	  and	  transforming	  benefits	  of	  their	  treatment	  usually	  became	  apparent.258	  By	  the	  end	  of	  2004,	  however,	  Dr.	  Moll	  noticed	  that	  a	  few	  patients	  were	  dying	  despite	  having	  taken	  antiretroviral	  medication	  for	  several	  months,	  and	  despite	  having	  successfully	  suppressed	  the	  HIV	  according	  to	  laboratory	  tests.	  These	  patients’	  HIV	  was	  kept	  under	  control	  by	  their	  antiretroviral	  medicines,	  and	  the	  patients	  were	  being	  treated	  with	  standard	  anti-­‐tuberculosis	  drugs,	  but	  they	  were	  still	  dying.	  What	  was	  going	  on?	  
Death	  despite	  conquering	  AIDS	  –	  MDR-­‐TB	  was	  a	  surprising	  killer	  By	  the	  time	  that	  HIV	  and	  TB	  co-­‐treatment	  was	  up	  and	  running,	  Dr.	  Friedland	  had	  returned	  to	  New	  Haven,	  Connecticut	  full-­‐time,	  though	  he	  still	  visited	  South	  Africa	  at	  regular	  
                                                257	  Moll,	  interview	  by	  author,	  2011.	  258	  Moll,	  interview	  by	  author,	  2007.	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intervals.	  Dr.	  Friedland,	  Dr.	  Moll	  and	  others	  involved	  in	  the	  study	  had	  weekly	  international	  conference	  calls	  to	  coordinate	  and	  discuss	  the	  progress	  of	  the	  study.259	  They	  both	  remember	  the	  phone	  calls	  where	  they	  debated	  what	  might	  have	  been	  the	  cause	  of	  the	  unanticipated	  and	  disappointing	  deaths	  in	  patients	  who	  had	  consistently	  taken	  both	  their	  HIV	  and	  TB	  medicines.	  Dr.	  Moll	  pointed	  out	  that	  at	  least	  one	  study	  death	  had	  been	  found	  to	  be	  due	  to	  multi	  drug-­‐resistant	  tuberculosis	  (MDR-­‐TB).	  The	  tuberculosis	  culture	  and	  drug-­‐susceptibility	  results	  had	  only	  come	  back	  from	  the	  lab	  after	  the	  patient	  had	  passed	  away,	  however.	  Dr.	  Neel	  Gandhi,	  who	  was	  a	  young	  physician	  working	  under	  Dr.	  Friedland	  as	  a	  clinical	  research	  fellow	  at	  the	  time,	  wondered	  if	  drug	  resistant	  tuberculosis	  might	  explain	  other	  deaths	  and	  wanted	  to	  know	  how	  wide-­‐spread	  drug-­‐resistant	  tuberculosis	  was	  among	  patients	  in	  Tugela	  Ferry.260	  I	  mentioned	  earlier	  that	  the	  South	  African	  tuberculosis	  programs	  recommended	  monitoring	  patients	  who	  were	  on	  tuberculosis	  treatment	  and	  testing	  them	  for	  drug-­‐resistance	  if,	  after	  several	  months	  of	  treatment,	  they	  were	  not	  getting	  better.	  This	  was	  part	  of	  South	  Africa’s	  DOTS-­‐Plus	  strategy	  that	  was	  introduced	  in	  the	  years	  preceding	  the	  study.	  In	  practice,	  however,	  drug	  resistance	  testing	  rarely	  provided	  valuable	  information,	  because	  it	  could	  take	  over	  six	  months	  to	  get	  a	  tuberculosis	  drug-­‐resistance	  test	  result	  from	  the	  lab,	  at	  which	  point	  the	  patient	  would	  no	  longer	  be	  within	  easy	  reach	  of	  the	  hospital,	  and	  in	  many	  cases	  would	  have	  already	  died.	  In	  addition,	  samples	  were	  not	  generally	  sent	  to	  a	  lab	  for	  culture	  and	  drug-­‐resistance	  testing	  at	  the	  beginning	  of	  tuberculosis	  treatment,	  but	  instead	  were	  only	  sent	  once	  it	  became	  apparent	  that	  a	  patient	  was	  not	  getting	  better	  despite	  several	  months	  of	  treatment.	  Thus	  it	  could	  take	  eight	  months	  to	  a	  year	  from	  the	  point	  of	  starting	  
                                                259	  Gail	  Robinson,	  “An	  Epidemic	  Response:	  The	  Evolution	  of	  a	  Community	  Based	  Approach	  to	  Managing	  MDR-­‐TB	  and	  XDR-­‐TB	  at	  Tugela	  Ferry	  in	  KwaZulu-­‐Natal”	  (graduate	  class	  paper,	  University	  of	  KwaZulu-­‐Natal,	  2008).	  260	  Moll,	  interview,	  2007;	  Friedland,	  interview.	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tuberculosis	  treatment	  before	  a	  diagnosis	  of	  drug-­‐resistant	  tuberculosis	  was	  made,	  even	  when	  the	  patient	  was	  carrying	  drug-­‐resistant	  tuberculosis	  from	  the	  onset	  of	  treatment.	  Understandably,	  such	  delayed	  results	  were	  rarely	  useful	  to	  busy	  clinicians	  or	  their	  patients,	  especially	  since	  mechanisms	  to	  ensure	  that	  lab	  results	  of	  absent	  patients	  actually	  made	  it	  into	  their	  files	  or	  were	  brought	  to	  a	  practitioner’s	  attention	  were	  weak.	  This	  meant	  that	  even	  in	  cases	  where	  drug-­‐resistance	  might	  be	  considered,	  clinicians	  did	  not	  always	  send	  samples	  to	  the	  lab,	  since	  they	  did	  not	  expect	  to	  receive	  them	  back	  on	  time.	  When	  the	  protocol	  for	  the	  Sizonqoba	  HIV/TB	  co-­‐treatment	  study	  was	  originally	  developed,	  Dr.	  Friedland	  and	  Dr.	  Moll	  decided	  to	  use	  the	  existing	  South	  African	  tuberculosis	  infrastructure	  and	  guidelines.261	  This	  meant	  that	  for	  the	  tuberculosis	  component	  of	  the	  study	  South	  African	  diagnostic	  and	  laboratory	  protocol	  was	  followed,	  and	  tuberculosis	  patients	  were	  only	  tested	  for	  drug	  resistance	  if	  tuberculosis	  treatment	  failure	  was	  suspected.	  The	  researchers	  in	  Tugela	  Ferry	  hoped	  to	  avoid	  dealing	  with	  MDR-­‐TB	  patients	  entirely	  by	  excluding	  patients	  from	  the	  study	  who	  had	  been	  treated	  for	  tuberculosis	  before	  (retreatment	  cases),	  and	  by	  actively	  supporting	  drug	  adherence	  through	  directly	  observed	  treatment.	  The	  assumption	  was	  that	  patients	  who	  had	  never	  been	  treated	  for	  tuberculosis	  before	  were	  unlikely	  to	  carry	  a	  drug-­‐resistant	  strain	  of	  tuberculosis.	  Excellent	  drug	  adherence	  would	  prevent	  drug-­‐resistant	  tuberculosis	  from	  having	  the	  opportunity	  to	  develop.	  In	  the	  context	  of	  the	  unexplained	  deaths	  in	  this	  new	  TB/HIV	  co-­‐treatment	  study,	  however,	  it	  became	  clear	  that	  a	  heightened	  level	  of	  surveillance	  for	  tuberculosis	  drug-­‐resistance	  was	  needed.	  Thus,	  Dr.	  Gandhi	  and	  Dr.	  Moll	  decided	  to	  look	  more	  actively	  for	  drug-­‐resistant	  tuberculosis	  at	  the	  hospital	  in	  Tugela	  Ferry.	  
                                                261	  An	  alternative	  approach	  would	  have	  been	  to	  introduce	  more	  intensified	  monitoring	  and	  send	  tests	  to	  a	  commercial	  or	  international	  laboratory	  and	  pay	  for	  them	  from	  study	  funds.	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Though	  Dr.	  Moll	  was	  the	  primary	  South	  African	  point	  person	  and	  researcher	  on	  the	  Sizonqoba	  co-­‐treatment	  study,	  he	  was	  first	  and	  foremost	  a	  full-­‐time	  clinician	  at	  the	  district	  hospital.	  He	  was	  also	  the	  main	  physician	  managing	  the	  HIV	  clinic	  where	  study	  participants	  were	  being	  treated,	  along	  with	  many	  other	  HIV	  patients	  whose	  treatment	  was	  now	  finally	  being	  paid	  for	  by	  the	  South	  African	  public	  health	  system.	  After	  several	  years	  of	  resistance,	  the	  South	  African	  government	  had	  agreed	  in	  2004	  to	  provide	  HIV	  treatment	  through	  the	  public	  sector.	  Additional	  research	  activities	  investigating	  the	  unexpected	  deaths	  in	  the	  co-­‐treatment	  study	  had	  to	  be	  fit	  in	  around	  Dr.	  Moll’s	  already	  very	  busy	  schedule.	  Conveniently,	  there	  were	  two	  medical	  students	  from	  the	  University	  of	  KwaZulu-­‐Natal	  visiting	  Tugela	  Ferry	  in	  February	  2005	  looking	  for	  a	  small	  project	  to	  do.	  As	  Dr.	  Moll	  put	  it,	  such	  medical	  students	  were	  usually	  sent	  to	  the	  HIV	  program	  “because	  there’s	  so	  much	  stuff	  to	  go	  on	  there	  that	  it’s	  easy	  to	  think	  up	  a	  project.”262	  On	  February	  7,	  2005,	  these	  students	  agreed	  to	  the	  task	  of	  collecting	  a	  sputum	  sample	  from	  every	  single	  coughing	  patient	  in	  the	  hospital.	  Dr.	  Moll	  had	  decided	  that	  this	  would	  be	  the	  fastest	  way	  to	  get	  a	  snapshot	  of	  the	  tuberculosis	  situation	  at	  the	  hospital,	  and	  received	  permission	  from	  the	  tuberculosis	  laboratory	  in	  Durban,	  which	  was	  in	  charge	  of	  processing	  samples	  from	  Tugela	  Ferry,	  to	  send	  a	  large	  batch	  of	  sputum	  for	  tuberculosis	  culture	  and	  drug-­‐susceptibility	  testing.	  The	  process	  of	  collecting	  these	  samples	  must	  have	  been	  quite	  a	  sight:	  “We	  set	  up	  a	  little	  table	  on	  a	  Monday	  morning	  between	  male	  TB	  ward	  and	  female	  TB	  ward	  outside	  in	  the	  sun,	  and	  we	  had	  a	  list	  of	  all	  coughing	  patients	  in	  the	  whole	  hospital.	  There	  were	  probably	  about	  55	  or	  so	  names	  […].	  And	  so	  one	  by	  one	  we	  brought	  these	  patients	  outside	  and	  we	  provided	  them	  with	  sputum	  bottles,	  we	  set	  them	  up	  with	  chairs	  under	  the	  trees	  in	  the	  sunshine	  and	  we	  asked	  them	  to	  produce	  sputum.	  We	  created	  lists,	  we	  wrote	  down	  their	  
                                                262	  Anthony	  Moll,	  interview	  by	  author,	  2007.	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names	  and	  quite	  a	  few	  of	  the	  patients	  came	  out	  with	  wheelchairs,	  you	  see,	  because	  I	  really	  wanted	  every	  sick	  patient	  who	  could	  cough	  a	  sputum	  sample	  to	  produce	  us	  a	  sample.	  In	  the	  end	  we	  had	  nearly	  covered	  our	  list	  of	  55,	  we	  were	  probably	  in	  the	  late	  30s	  or	  40s,	  and	  there	  was	  a	  group	  of	  patients	  left	  that	  couldn't	  get	  in	  a	  wheelchair	  that	  were	  just	  so	  sick	  on	  their	  beds,	  and	  fortunately	  we	  had	  the	  determination	  to	  bring	  the	  whole	  jolly	  bed	  out	  on	  wheels	  outside,	  and	  we	  actually	  invited	  the	  physiotherapists	  from	  the	  hospital	  to	  come	  and	  help	  us	  to	  induce	  sputum	  with	  some	  kind	  of	  pummeling	  and	  chest	  massaging.263	  Oy,	  these	  guys	  were	  so	  sick,	  I	  mean,	  I	  was	  afraid	  that	  they	  were	  going	  to	  die	  outside	  there	  on	  the	  bed	  during	  the	  procedure	  of	  getting	  sputum	  from	  them,	  and	  at	  the	  end	  of	  the	  day	  we	  had	  45	  samples,	  which	  we	  submitted.	  A	  few	  again	  the	  next	  day	  which	  followed	  afterwards,	  and	  basically	  we	  just	  carried	  on	  with	  our	  work.	  The	  students	  went	  home,	  they	  wrote	  up	  their	  little	  study.	  And	  what	  we	  had	  done	  was	  a	  cross-­‐sectional	  snapshot	  across	  the	  hospital	  at	  that	  one	  time	  of	  all	  coughing	  patients.”264	  It	  was	  this	  ad-­‐hoc	  and	  in	  retrospect	  perhaps	  somewhat	  comical	  scenario	  acted	  out	  by	  un-­‐named	  South	  African	  medical	  students	  and	  coughing	  patients	  which	  eventually	  formed	  the	  basis	  for	  the	  scientific	  paper	  on	  XDR-­‐TB	  that	  was	  presented	  at	  the	  2006	  International	  AIDS	  Conference	  by	  Dr.	  Gandhi.	  It	  should	  not	  be	  taken	  for	  granted	  that	  the	  microbiology	  laboratory	  at	  the	  large,	  modern,	  public,	  academically	  connected	  referral	  hospital	  in	  Durban	  readily	  agreed	  to	  accept	  sputum	  samples	  from	  Dr.	  Moll’s	  snapshot.	  According	  to	  South	  Africa’s	  protocols	  at	  the	  time,	  tuberculosis	  samples	  were	  only	  to	  be	  sent	  for	  culture	  and	  drug-­‐susceptibility	  testing	  once	  treatment	  failure	  was	  suspected,	  not	  for	  a	  sweeping	  hospital	  screen.	  In	  addition,	  standard	  drug-­‐susceptibility	  testing	  recommended	  by	  the	  WHO	  at	  that	  time	  only	  checked	  for	  resistance	  to	  the	  two	  most	  important	  first-­‐line	  tuberculosis	  drugs:	  rifampin	  and	  isoniazid.	  
                                                263	  It	  is	  best	  to	  perform	  sputum	  tests	  outdoors	  in	  order	  to	  reduce	  the	  risk	  of	  transmission	  of	  the	  aerosolized	  bacteria	  (released	  by	  induced	  coughing)	  to	  other	  patients	  in	  the	  wards.	  264	  Moll,	  interview	  by	  author,	  2007.	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The	  hospital	  in	  Tugela	  Ferry,	  however,	  routinely	  sent	  its	  tuberculosis	  lab	  work	  to	  one	  of	  very	  few	  labs	  in	  South	  Africa	  that	  tested	  tuberculosis	  strains	  for	  resistance	  to	  all	  first-­‐line	  tuberculosis	  drugs,	  as	  well	  as	  some	  second-­‐line	  drugs.	  In	  most	  other	  parts	  of	  the	  country	  the	  tests	  would	  not	  have	  been	  available,	  or,	  at	  the	  very	  least,	  the	  American	  researchers	  would	  have	  had	  to	  identify	  and	  pay	  a	  specialized	  research	  laboratory	  to	  conduct	  the	  test.	  Instead,	  Prof.	  Willem	  Sturm,	  the	  head	  of	  the	  microbiology	  lab	  in	  Durban	  that	  provided	  most	  tuberculosis	  culture	  and	  drug-­‐susceptibility	  testing	  for	  the	  province	  of	  KwaZulu-­‐Natal’s	  public	  health	  system,	  had	  a	  keen	  interest	  in	  tuberculosis	  drug-­‐resistance.	  Originally	  from	  the	  Netherlands,	  Sturm	  had	  spent	  some	  time	  working	  in	  Karachi,	  Pakistan	  before	  coming	  to	  South	  Africa	  in	  1993.	  In	  Pakistan	  he	  had	  conducted	  work	  which	  showed	  a	  significant	  amount	  of	  tuberculosis	  drug-­‐resistance	  among	  patients	  in	  Karachi,265	  and	  when	  he	  arrived	  in	  Durban,	  he	  set	  up	  a	  laboratory	  which	  could	  conduct	  conventional	  phenotypic	  tuberculosis	  drug	  susceptibility	  testing,	  as	  well	  as	  employ	  more	  sophisticated	  molecular	  methods	  that	  allowed	  specific	  strains	  of	  tuberculosis	  to	  be	  identified	  and	  traced	  in	  South	  Africa.	  These	  methods	  were	  not	  commonly	  available	  outside	  the	  developed	  world	  at	  the	  time.266	  Between	  1996	  and	  2000	  he	  co-­‐authored	  several	  papers	  with	  David	  Wilkinson,	  looking	  at	  tuberculosis	  treatment	  and	  transmission	  in	  Hlabisa,	  a	  rural	  research	  site	  four	  hours	  north	  of	  Durban,	  where	  Wilkinson	  tested	  innovative	  strategies	  for	  managing	  tuberculosis.267	  The	  timing	  of	  this	  research	  allowed	  Wilkinson,	  Sturm	  and	  colleagues	  to	  document	  the	  parallel	  rise	  of	  TB	  and	  HIV	  in	  a	  rural	  region	  of	  KwaZulu-­‐Natal.	  They	  showed	  
                                                265	  R.	  Hussain	  et	  al.,	  “Pulmonary	  Tuberculosis	  in	  a	  BCG	  Vaccinated	  Area:	  Relationship	  of	  Disease	  Severity	  with	  Immunological	  and	  Hematological	  Parameters	  and	  Drug	  Resistance	  Patterns,”	  The	  
Southeast	  Asian	  Journal	  of	  Tropical	  Medicine	  and	  Public	  Health	  27,	  no.	  2	  (1996):	  257–262.	  266	  Lynette	  Roux,	  interview	  by	  author,	  18	  October	  2011,	  Durban,	  South	  Africa;	  David	  Wilkinson	  et	  al.,	  “Nosocomial	  Transmission	  of	  Tuberculosis	  in	  Africa	  Documented	  by	  Restriction	  Fragment	  Length	  Polymorphism,”	  Transactions	  of	  the	  Royal	  Society	  of	  Tropical	  Medicine	  and	  Hygiene	  91,	  no.	  3	  (1997):	  318.	  267	  Hlabisa	  and	  Tugela	  Ferry	  are	  both	  rural	  towns	  in	  KwaZulu-­‐Natal	  but	  they	  are	  not	  close	  to	  each	  other.	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an	  increase	  in	  nosocomial	  (hospital-­‐based)	  transmission	  of	  tuberculosis	  (especially	  the	  increased	  susceptibility	  of	  hospital	  nursing	  staff	  to	  tuberculosis	  infection),268	  as	  well	  as	  the	  gradual	  rise	  of	  drug-­‐resistant	  tuberculosis	  (including	  MDR-­‐TB)269	  in	  the	  context	  of	  an	  ambitious	  twice-­‐weekly	  tuberculosis	  treatment	  program.	  This	  program	  was	  promoted	  by	  Wilkinson,	  and	  caught	  the	  attention	  of	  tuberculosis	  specialists	  and	  rural	  doctors	  across	  the	  region.270	  By	  2005,	  Professor	  Sturm	  had	  developed	  an	  interest	  in	  documenting	  the	  development	  of	  fluoroquinolone-­‐resistant	  bacteria.	  Physicians	  were	  increasingly	  using	  fluoroquinolones	  broadly	  for	  various	  types	  of	  infections,	  including	  respiratory	  infections	  (pneumonia),	  meningitis,	  and	  gonorrhea.271	  Fluoroquinolones	  (specifically	  ofloxacin)	  were	  also	  increasingly	  being	  used	  in	  tuberculosis	  treatment,	  and	  were	  considered	  effective	  for	  treating	  multi-­‐drug	  resistant	  tuberculosis	  (MDR-­‐TB).	  For	  this	  reason,	  Prof.	  Sturm	  had	  asked	  Lynne	  Roux,	  the	  manager	  of	  the	  tuberculosis	  diagnostics	  laboratory	  in	  Durban,	  which	  was	  
                                                268	  Wilkinson	  et	  al.,	  “Nosocomial	  Transmission	  of	  Tuberculosis	  in	  Africa	  Documented	  by	  Restriction	  Fragment	  Length	  Polymorphism”;	  Manormoney	  Pillay,	  Philip	  Onyebujoh,	  and	  A.	  Willem	  Sturm,	  “Reinfection	  with	  Mycobacterium	  Tuberculosis	  in	  an	  Urban	  Tuberculosis	  Hospital,”	  Clinical	  
Microbiology	  and	  Infection	  4,	  no.	  1	  (1998):	  49–51.	  269	  David	  Wilkinson	  et	  al.,	  “Resistance	  to	  Antituberculosis	  Drugs	  in	  Rural	  South	  Africa:	  Rates,	  Patterns,	  Risks,	  and	  Transmission	  Dynamics,”	  Transactions	  of	  the	  Royal	  Society	  of	  Tropical	  Medicine	  
and	  Hygiene	  90,	  no.	  6	  (1996):	  692–695;	  G.	  R.	  Davies	  et	  al.,	  “Emergence	  of	  Multidrug-­‐resistant	  Tuberculosis	  in	  a	  Community-­‐based	  Directly	  Observed	  Treatment	  Programme	  in	  Rural	  South	  Africa,”	  
The	  International	  Journal	  of	  Tuberculosis	  and	  Lung	  Disease	  3,	  no.	  9	  (1999):	  799–804.	  270	  David	  Wilkinson	  et	  al.,	  “Efficacy	  of	  Twice	  Weekly	  Treatment	  for	  Tuberculosis	  Given	  Under	  Direct	  Observation	  in	  Africa,”	  Transactions	  of	  the	  Royal	  Society	  of	  Tropical	  Medicine	  and	  Hygiene	  91,	  no.	  1	  (1997):	  87–89;	  G.	  R.	  Davies	  et	  al.,	  “Twice-­‐weekly,	  Directly	  Observed	  Treatment	  for	  HIV-­‐infected	  and	  Uninfected	  Tuberculosis	  Patients:	  Cohort	  Study	  in	  Rural	  South	  Africa,”	  AIDS	  13,	  no.	  7	  (1999):	  811–817;	  Bamber,	  interview	  by	  author,	  2010.	  271	  Roux,	  interview	  by	  author,	  2011;	  Anne	  von	  Gottberg	  et	  al.,	  “Emergence	  of	  Fluoroquinolone-­‐resistant	  Streptococcus	  Pneumoniae	  in	  a	  South	  African	  Child	  in	  a	  Tuberculosis	  Treatment	  Facility,”	  
The	  Pediatric	  Infectious	  Disease	  Journal	  22,	  no.	  11	  (2003):	  1020–1021;	  Cheryl	  Cohen	  et	  al.,	  “Increased	  Incidence	  of	  Meningococcal	  Disease	  in	  HIV-­‐infected	  Individuals	  Associated	  with	  Higher	  Case-­‐fatality	  Ratios	  in	  South	  Africa,”	  AIDS	  24,	  no.	  9	  (2010):	  1351–1360;	  Prashini	  Moodley	  and	  A.	  Willem	  Sturm,	  “Ciprofloxacin-­‐resistant	  Gonorrhoea	  in	  South	  Africa,”	  The	  Lancet	  366,	  no.	  9492	  (2005):	  1159;	  Prashini	  Moodley	  et	  al.,	  “Molecular	  Epidemiology	  of	  Recently	  Emergent	  Ciprofloxacin-­‐resistant	  Neisseria	  Gonorrhoeae	  in	  South	  Africa,”	  Sexually	  Transmitted	  Diseases	  33,	  no.	  6	  (2006):	  357–360.	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under	  his	  administration,	  to	  keep	  an	  eye	  out	  for	  cases	  of	  tuberculosis	  coming	  through	  the	  lab	  that	  demonstrated	  ofloxacin	  resistance.272	  On	  May	  13th	  2005,	  a	  few	  months	  after	  Dr.	  Moll’s	  tuberculosis	  “snapshot”	  at	  the	  Church	  of	  Scotland	  Hospital	  in	  Tugela	  Ferry,	  Lynne	  Roux	  was	  reviewing	  the	  tuberculosis	  drug-­‐susceptibility	  results	  in	  her	  laboratory	  database,	  looking	  especially	  for	  ofloxacin	  resistance,	  following	  her	  boss’	  instructions.	  According	  to	  Roux,	  some	  of	  the	  technicians	  in	  the	  lab	  had	  mentioned	  to	  her	  that	  they	  might	  have	  tested	  such	  cases	  and	  entered	  them	  into	  the	  database.	  “I	  looked	  for	  it,	  and	  I	  couldn’t	  believe	  what	  I	  saw:	  […]	  As	  I	  pulled	  these	  up,	  I	  saw	  this	  pattern	  of	  resistance	  that	  shocked	  me.	  Kanamycin	  and	  ofloxacin.”273	  In	  fact,	  the	  cases	  she	  had	  compiled	  were	  not	  just	  resistant	  for	  the	  ofloxacin	  she	  was	  looking	  for,	  but	  resistant	  to	  all	  four	  first-­‐line	  tuberculosis	  drugs	  (isoniazid,	  rifampin,	  pyrazinamid,	  ethambutol)	  and	  the	  two	  second-­‐line	  drugs	  the	  lab	  routinely	  tested	  for	  (kanamycin	  and	  ofloxacin).	  80%	  of	  the	  cases	  she	  found	  came	  from	  the	  Church	  of	  Scotland	  Hospital,	  which	  had	  sent	  dozens	  of	  samples	  containing	  tuberculosis	  that	  was	  resistant	  to	  all	  six	  of	  these	  drugs.	  She	  had	  never	  heard	  of	  this	  hospital	  and	  did	  not	  know	  where	  it	  was	  located.	  Even	  though	  it	  was	  after-­‐hours	  by	  the	  time	  she	  had	  finished	  gathering	  all	  the	  data,	  Roux	  knew	  she	  needed	  to	  alert	  someone	  immediately,	  or	  she	  would	  not	  be	  able	  to	  sleep	  that	  night.	  Rather	  than	  first	  discuss	  the	  finding	  with	  her	  supervisor,	  Professor	  Sturm,	  she	  called	  the	  Church	  of	  Scotland	  Hospital	  switchboard	  and	  asked	  to	  talk	  to	  the	  doctor	  who	  manages	  tuberculosis.274	  The	  switchboard	  connected	  her	  to	  Dr.	  Moll,	  and	  as	  Lynne	  Roux	  remembers	  it,	  he	  already	  suspected	  what	  she	  was	  talking	  about	  when	  she	  broke	  the	  news	  to	  him.	  She	  told	  him	  that	  she	  had	  come	  across	  an	  alarming	  cluster	  of	  drug	  resistance	  coming	  from	  his	  hospital.	  The	  notes	  Lynne	  Roux	  took	  during	  that	  phone	  call	  show	  that	  she	  had	  also	  found	  
                                                272	  Roux,	  interview	  by	  author,	  2011.	  273	  Ibid.	  274	  Ibid.	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cases	  of	  drug	  resistance	  at	  other	  hospitals	  in	  the	  province	  of	  KwaZulu-­‐Natal;	  Dr.	  Moll	  explained	  to	  her	  that	  some	  of	  those	  cases	  were	  also	  not	  too	  far	  from	  Tugela	  Ferry,	  where	  his	  hospital	  was	  located.	  Several	  of	  the	  cases	  she	  had	  identified	  were	  duplicates	  from	  patients	  who	  had	  had	  more	  than	  one	  sample	  sent	  to	  the	  lab,	  but	  whose	  name	  had	  been	  spelled	  differently	  each	  time.	  All	  told,	  Dr.	  Moll	  remembers	  that	  Lynne	  Roux	  had	  identified	  about	  ten	  patients	  from	  Tugela	  Ferry	  who	  were	  resistant	  to	  all	  of	  the	  drugs	  the	  lab	  had	  tested,	  including	  the	  “salvage	  drug”	  streptomycin	  which	  is	  used	  in	  retreatment	  cases	  in	  South	  Africa,	  as	  well	  as	  the	  two	  most	  important	  second-­‐line	  tuberculosis	  drugs	  (kanamycin	  and	  ofloxacin)	  that	  were	  used	  to	  treat	  MDR-­‐TB.275	  MDR-­‐TB	  itself	  would	  have	  been	  bad	  enough,	  but	  there	  were	  at	  least	  theoretically	  government	  health	  programs	  in	  place	  to	  deal	  with	  that.276	  Dr.	  Moll	  was	  devastated	  by	  Roux’s	  report:	  “I	  kind	  of	  just	  remember	  holding	  my	  cellphone	  and	  just	  feeling	  like	  all	  the	  energy	  was	  draining	  out	  of	  my	  body	  and	  feeling	  really	  hopeless	  because	  of	  the	  implications	  of	  this	  in	  terms	  of	  us	  as	  health	  care	  professionals	  providing	  a	  service	  to	  our	  patients.	  […]What	  came	  to	  my	  mind	  was	  the	  early	  days	  of	  HIV	  where	  we	  had	  to	  get	  used	  to	  dealing	  with	  a	  death	  sentence	  disease	  and	  understanding	  its	  transmission	  and	  getting	  used	  to	  it.	  And	  I	  can	  remember	  in	  the	  early	  days	  even	  with	  HIV,	  having	  the	  information	  that	  it	  is	  safe	  to	  touch	  a	  patient,	  that	  you	  can	  hug	  a	  patient.	  But	  taking	  those	  initial	  steps	  to	  actually	  do	  it	  took	  some	  guts	  from	  everybody,	  I	  think,	  […]	  and	  over	  the	  years	  we	  had	  got	  used	  to	  the	  fact	  that	  […]	  it	  was	  quite	  safe	  as	  a	  health	  care	  provider	  to	  work	  with	  HIV	  patients	  and	  there	  wasn't	  really	  an	  issue	  of	  transmission.	  But	  now,	  face	  something	  of	  this	  nature	  where	  it's	  […]	  an	  
                                                275	  Moll,	  interview	  by	  author,	  2007.	  276	  My	  endorsement	  of	  KwaZulu	  Natal's	  MDR-­‐TB	  program	  in	  2005	  is	  tentative	  at	  best.	  MDR-­‐TB	  patients	  were	  not	  quickly	  identified,	  and	  when	  they	  were,	  they	  were	  transported	  to	  Durban	  for	  and	  extended	  hospitalization	  at	  a	  central	  TB	  hospital.	  Durban	  is	  over	  2	  hours	  away	  from	  Tugela	  Ferry	  and	  potentially	  farther	  from	  the	  patient's	  home.	  Beds	  in	  Durban	  were	  often	  not	  available,	  and	  patients	  that	  were	  admitted	  often	  struggled	  to	  complete	  their	  treatment	  for	  social,	  financial	  and	  personal	  reasons.	  Furthermore,	  the	  treatment	  had	  many	  potential	  side-­‐effects	  and	  did	  not	  always	  lead	  to	  cure.	  
 109 
untreatable	  airborne	  disease	  and	  that	  these	  patients	  were	  right	  amongst	  us	  and	  we'd	  been	  caring	  for	  them	  and	  looking	  after	  them.	  […]	  I	  immediately	  thought,	  perhaps	  I've	  already	  got	  it,	  I've	  breathed	  it	  in	  already,	  you	  see,	  I	  really	  had	  this	  feeling	  now.	  Well	  now	  we	  managed	  to	  get	  used	  to	  managing	  HIV	  patients,	  but	  now	  this	  is	  a	  completely	  different	  ballgame.	  Managing	  patients	  with	  a	  deadly	  airborne	  disease	  that's	  untreatable.	  And	  kind	  of	  in	  my	  mind	  I	  just	  saw	  the	  deterioration	  of	  these	  patients.”277	  From	  the	  onset,	  the	  significance	  of	  this	  very	  drug-­‐resistant	  form	  of	  tuberculosis	  in	  Tugela	  Ferry	  was	  understood	  in	  the	  context	  of	  HIV/AIDS.	  HIV	  made	  patients	  more	  susceptible	  to	  tuberculosis	  infection	  and	  made	  tuberculosis	  more	  difficult	  to	  manage.	  In	  addition,	  HIV/AIDS	  was	  the	  terrible	  disease	  against	  which	  the	  impact	  of	  drug-­‐resistant	  tuberculosis	  was	  measured.	  As	  can	  be	  seen	  from	  the	  quote	  above,	  Dr.	  Moll	  had	  learned	  how	  to	  deal	  with	  HIV/AIDS	  and	  was	  able	  to	  contain	  its	  impact,	  both	  emotionally	  and	  physically.	  Highly	  drug-­‐resistant	  tuberculosis,	  on	  the	  other	  hand,	  was	  an	  airborne	  disease	  whose	  management	  had	  not	  yet	  become	  routine.	  The	  threat	  emanating	  from	  it	  was	  not	  clearly	  containable.	  	  The	  report	  from	  the	  Durban	  lab	  was	  alarming,	  indeed.	  In	  addition	  to	  the	  frightening	  cases	  of	  highly	  drug-­‐resistant	  tuberculosis,	  Dr.	  Moll’s	  snapshot	  had	  identified	  a	  large	  number	  of	  patients	  with	  “regular”	  MDR-­‐TB.	  Dr.	  Moll	  went	  to	  Durban	  the	  next	  day	  to	  pick	  up	  the	  lab	  results	  from	  Lynne	  Roux	  in	  person	  at	  Inkosi	  Albert	  Luthuli	  Central	  Hospital.	  There	  he	  conveniently	  encountered	  Professor	  Green-­‐Thompson,	  who	  was	  the	  Head	  of	  Department	  of	  the	  Department	  of	  Health	  in	  KwaZulu-­‐Natal.	  Moll	  took	  the	  opportunity	  to	  inform	  Green-­‐Thompson	  of	  this	  new	  problem	  personally.278	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As	  Dr.	  Moll	  tells	  it,	  the	  initial,	  official	  response	  to	  his	  reporting	  of	  severe	  drug-­‐resistance	  was	  rather	  tepid.	  In	  June	  2005	  the	  department	  of	  health	  sent	  Durban’s	  Professor	  Sturm	  to	  Tugela	  Ferry	  to	  meet	  with	  tuberculosis	  staff	  and	  physicians	  at	  the	  Church	  of	  Scotland	  Hospital	  and	  to	  discuss	  ways	  staff	  could	  protect	  themselves	  from	  infection.	  Among	  other	  things,	  Prof.	  Sturm	  stressed	  the	  need	  to	  isolate	  infected	  patients	  and	  to	  wear	  protective	  masks.	  Yet	  many	  of	  his	  suggestions	  were	  more	  frustrating	  than	  helpful,	  since	  the	  hospital	  did	  not	  have	  separate	  isolation	  facilities.	  Rather,	  the	  hospital	  was	  designed	  as	  a	  series	  of	  open	  wards,	  with	  dozens	  of	  beds	  in	  each	  ward.	  Similarly,	  the	  N95	  masks	  that	  could	  be	  used	  to	  filter	  airborne	  tuberculosis	  were	  not	  yet	  available	  at	  the	  hospital.	  There	  was	  also	  no	  mechanical	  ventilation	  system	  in	  place	  in	  the	  tuberculosis	  ward.	  In	  addition	  to	  promoting	  infection	  control,	  Prof.	  Sturm,	  as	  a	  researcher,	  was	  interested	  in	  getting	  a	  better	  picture	  of	  	  the	  epidemiology	  of	  drug-­‐resistant	  tuberculosis	  in	  the	  Tugela	  Ferry	  area.	  If	  ten	  cases	  of	  highly	  drug-­‐resistant	  tuberculosis	  were	  identified	  in	  a	  single	  day,	  how	  much	  bigger	  was	  this	  problem	  really?279	  Over	  the	  time	  Prof.	  Sturm	  had	  worked	  in	  KwaZulu-­‐Natal,	  he	  had	  accumulated	  samples	  of	  drug-­‐resistant	  tuberculosis	  from	  all	  over	  the	  province	  in	  his	  freezers	  at	  the	  medical	  school.	  He	  hoped	  to	  shed	  light	  on	  the	  origins	  of	  the	  drug	  resistant	  cases	  by	  conducting	  molecular	  studies	  on	  samples	  from	  Tugela	  Ferry	  and	  comparing	  them	  to	  the	  samples	  he	  had	  stored.	  As	  a	  result,	  Dr.	  Moll,	  Prof.	  Sturm,	  the	  Yale	  research	  team	  (specifically	  Dr.	  Friedland	  and	  Dr.	  Gandhi)	  agreed,	  with	  the	  permission	  of	  the	  KwaZulu-­‐Natal	  Department	  of	  Health,	  that	  they	  would	  send	  samples	  from	  as	  many	  tuberculosis	  suspects	  in	  Tugela	  Ferry	  as	  they	  could	  to	  the	  microbiology	  lab	  in	  Durban	  drug-­‐resistance	  testing.	  In	  addition	  to	  providing	  research	  data	  for	  Sturm,	  this	  would	  also	  be	  clinically	  useful	  for	  the	  clinicians	  in	  Tugela	  Ferry,	  since	  they	  would	  be	  able	  to	  identify	  drug-­‐resistant	  tuberculosis	  more	  quickly.	  
                                                279	  Moll,	  interview	  by	  author,	  2011;	  Sturm,	  interview	  by	  author,	  2011.	  
 111 
Over	  the	  course	  of	  the	  next	  several	  months,	  researchers	  affiliated	  with	  Yale,	  Tugela	  Ferry,	  and	  the	  medical	  school	  in	  Durban	  conducted	  a	  more	  formal	  series	  of	  studies	  to	  identify	  tuberculosis	  in	  the	  hospital	  wards	  and	  in	  the	  outpatient	  department	  at	  the	  Church	  of	  Scotland	  Hospital.	  Between	  January	  2005	  and	  August	  2006,	  a	  total	  of	  53	  patients	  with	  tuberculosis	  resistant	  to	  all	  first-­‐line	  tuberculosis	  drugs	  as	  well	  as	  the	  second-­‐line	  drugs	  ciprofloxacin	  and	  kanamycin	  were	  identified.	  By	  the	  end	  of	  the	  study	  period,	  52	  of	  those	  53	  patients	  died	  (a	  mortality	  rate	  of	  98%),	  most	  within	  weeks	  of	  having	  had	  their	  sputum	  collected	  for	  tuberculosis	  drug-­‐resistance	  testing.	  This	  study	  also	  identified	  221	  patients	  with	  "garden	  variety"	  MDR-­‐TB,	  which	  itself	  had	  a	  mortality	  rate	  of	  68%	  in	  this	  series.280	  As	  Gandhi	  pointed	  out	  when	  he	  later	  presented	  this	  information	  at	  the	  2006	  International	  AIDS	  Conference,	  the	  total	  number	  of	  MDR-­‐TB	  cases	  in	  the	  entire	  US	  in	  2004	  was	  only	  128.	  
What	  was	  the	  appropriate	  response?	  These	  alarming	  numbers	  were	  only	  gradually	  compiled	  over	  that	  time	  period,	  however.	  In	  the	  meantime,	  Dr.	  Moll	  and	  others	  were	  trying	  to	  get	  the	  local	  and	  provincial	  department	  of	  health	  to	  understand	  that	  the	  Church	  of	  Scotland	  Hospital	  in	  Tugela	  Ferry	  was	  facing	  a	  severe	  problem	  with	  very	  drug-­‐resistant	  tuberculosis,	  and	  to	  motivate	  for	  the	  resources	  they	  needed	  to	  get	  the	  apparently	  increasing	  tuberculosis	  problem	  under	  control.	  The	  early	  response	  in	  Tugela	  Ferry	  was	  dominated	  by	  questions	  and	  uncertainty	  about	  the	  extent,	  pervasiveness,	  and	  danger	  of	  this	  relatively	  new	  form	  of	  drug-­‐resistant	  tuberculosis.	  There	  was	  also	  a	  perceived	  lack	  of	  assistance	  and	  support	  from	  superiors	  in	  the	  department	  of	  health.	  It	  was	  unclear	  if	  the	  cases	  of	  drug	  resistant	  tuberculosis	  that	  were	  
                                                280	  Neel	  R.	  Gandhi	  et	  al.,	  “Extensively	  Drug-­‐resistant	  Tuberculosis	  as	  a	  Cause	  of	  Death	  in	  Patients	  Co-­‐infected	  with	  Tuberculosis	  and	  HIV	  in	  a	  Rural	  Area	  of	  South	  Africa,”	  The	  Lancet	  368,	  no.	  9547	  (2006):	  1575–1580.	  Mortality	  in	  MDR-­‐TB	  patients	  with	  HIV	  is	  generally	  cited	  as	  over	  50%.	  The	  MDR-­‐TB	  cohort	  in	  Tugela	  Ferry	  had	  a	  mortality	  rate	  of	  68%.	  	  Though	  this	  is	  not	  as	  shocking	  as	  the	  initial	  mortality	  rate	  of	  98%	  for	  XDR-­‐TB	  it	  is	  clearly	  serious.	  As	  new	  cases	  were	  identified,	  the	  mortality	  rate	  for	  XDR-­‐TB	  stabilized	  at	  around	  85%	  by	  mid	  2007.	  	  (Friedland,	  interview	  by	  author,	  2007.)	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uncovered	  constituted	  a	  localized	  outbreak	  specific	  to	  Tugela	  Ferry	  and	  surroundings	  or	  if	  it	  was	  part	  of	  a	  broader	  problem.	  Where	  did	  these	  cases	  of	  drug-­‐resistant	  tuberculosis	  originate?	  Researchers	  suspected	  early	  on	  that	  this	  was	  at	  least	  in	  part	  an	  outbreak	  that	  had	  originated	  in	  Tugela	  Ferry’s	  hospital	  itself,	  or	  at	  least	  been	  amplified	  there.	  Existing	  infection	  control	  practices	  and	  resources	  in	  the	  hospital	  were	  not	  sufficient,	  and	  many	  nurses	  were	  afraid	  to	  work	  with	  tuberculosis	  patients	  and	  wondered	  what	  was	  being	  done	  to	  protect	  them.	  Protocol	  in	  KwaZulu-­‐Natal	  called	  for	  every	  MDR-­‐TB	  patient	  in	  the	  province	  to	  be	  referred	  to	  King	  George	  V	  hospital	  in	  Durban	  for	  treatment	  –	  yet	  that	  hospital	  was	  almost	  immediately	  full	  with	  patients	  from	  Tugela	  Ferry	  and	  had	  a	  waiting	  list	  that	  was	  several	  months	  long,	  even	  as	  physicians	  in	  Tugela	  Ferry	  continued	  to	  identify	  more	  patients.	  This	  left	  the	  physicians	  in	  Tugela	  Ferry	  with	  the	  problem	  of	  what	  to	  do	  with	  patients	  who	  had	  been	  diagnosed	  with	  MDR-­‐TB	  in	  the	  meantime.	  It	  would	  be	  both	  dangerous	  and	  pointless	  to	  keep	  patients	  with	  drug-­‐resistant	  tuberculosis	  at	  the	  hospital	  in	  Tugela	  Ferry,	  since	  they	  could	  infect	  other	  people,	  and	  were	  not	  receiving	  effective	  tuberculosis	  treatment	  there	  anyway.	  At	  the	  same	  time,	  however,	  it	  might	  be	  irresponsible	  to	  send	  them	  back	  home,	  where	  they	  could	  put	  their	  families	  at	  risk.	  Once	  people	  with	  drug-­‐resistant	  tuberculosis	  were	  identified,	  the	  very	  location	  of	  their	  sick	  bodies	  became	  problematic.	  Thus,	  as	  the	  research	  team	  revealed	  increasing	  numbers	  of	  drug-­‐resistant	  tuberculosis	  cases	  that	  they	  were	  unable	  to	  treat,	  the	  problem	  of	  how	  and	  where	  to	  treat	  these	  newly	  identified	  patients	  became	  increasingly	  urgent.	  Yet,	  from	  the	  perspective	  of	  local	  clinicians,	  the	  immediate	  response	  from	  the	  leadership	  in	  the	  department	  of	  health	  seemed	  mostly	  absent.	  As	  we	  shall	  see	  in	  chapter	  4,	  later	  assessments	  of	  the	  South	  African	  government’s	  response	  were	  more	  nuanced	  and	  positive,	  but	  at	  least	  at	  first	  doctors	  in	  Tugela	  Ferry	  did	  not	  get	  the	  sense	  that	  the	  severe	  form	  of	  MDR-­‐TB	  found	  in	  Tugela	  Ferry	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was	  being	  considered	  sufficiently	  urgent	  by	  the	  authorities.	  In	  early	  2006	  there	  was	  some	  South	  African	  news	  coverage	  on	  the	  increased	  number	  of	  drug-­‐resistant	  cases	  of	  tuberculosis	  in	  the	  Tugela	  Ferry	  region,281	  prompting	  the	  provincial	  department	  of	  health	  to	  issue	  a	  press	  statement	  on	  March	  28th	  2006,	  a	  few	  days	  after	  world	  TB	  day.	  The	  headline	  argued,	  among	  other	  things,	  that	  “MDR	  TB	  cases	  in	  Tugela	  Ferry	  [were]	  not	  an	  outbreak	  but	  reflection	  of	  poverty	  and	  hunger	  intensity.”282	  The	  press	  statement	  did	  acknowledge	  that	  the	  provincial	  minister	  of	  health,	  “Neliswa	  Peggy	  Nkonyeni,	  is	  aware	  of	  the	  225	  cases	  of	  MDR	  TB	  for	  the	  period	  of	  January	  2005	  to	  January	  2006	  in	  the	  uMsinga283	  area.”284	  The	  statement	  then	  continued	  to	  describe	  MDR-­‐TB	  as	  a	  moral	  and	  nutritional	  threat	  that	  results	  from	  poverty,	  the	  lack	  of	  food,	  and	  the	  fact	  that	  poor	  people	  “refrain	  from	  taking	  medication."285	  While	  the	  provincial	  department	  of	  health	  was	  able	  to	  list	  several	  activities	  that	  had	  taken	  place	  in	  response	  to	  the	  increased	  number	  of	  MDR-­‐TB	  cases,	  including	  an	  increased	  number	  of	  tuberculosis	  tracing	  teams	  (who	  go	  to	  patient’s	  homes	  to	  find	  patients	  with	  drug-­‐resistant	  tuberculosis	  and	  to	  identify	  contacts	  who	  might	  be	  at	  risk	  for	  tuberculosis	  infection),	  a	  training	  session	  for	  physicians,	  plans	  for	  improved	  ventilation	  in	  the	  hospital	  ward,	  and	  daily	  laboratory	  tests,	  this	  statement	  was	  interpreted	  by	  physician	  and	  research	  colleagues	  in	  Tugela	  Ferry	  as	  a	  dismissive	  brush-­‐off.	  In	  particular,	  the	  reference	  to	  poverty	  and	  nutrition	  as	  the	  major	  problem	  echoed	  other	  language	  coming	  from	  the	  national	  department	  of	  health	  during	  that	  period.	  In	  years	  past,	  South	  Africa’s	  president	  Thabo	  
                                                281	  Kerry	  Cullinan,	  “Health-­‐e:	  Super-­‐resistant	  TB	  Strains	  Overburdened	  Hospital,”	  March	  24,	  2006,	  http://www.health-­‐e.org.za/news/article.php?uid=20031386.	  282	  Department	  of	  Health,	  Province	  of	  KwaZulu-­‐Natal,	  Corporate	  Communication	  Services,	  “To	  All	  Media:	  MDR	  TB	  Cases	  in	  Tugela	  Ferry	  Not	  an	  Outbreak	  but	  Reflection	  of	  Poverty	  and	  Hunger	  Intensity,”	  March	  28,	  2006.	  283	  uMsinga,	  or	  Msinga,	  is	  the	  rural	  sub-­‐district	  in	  which	  Tugela	  Ferry	  is	  located.	  284	  Department	  of	  Health,	  Province	  of	  KwaZulu-­‐Natal,	  Corporate	  Communication	  Services,	  “To	  All	  Media:	  MDR	  TB	  Cases	  in	  Tugela	  Ferry	  Not	  an	  Outbreak	  but	  Reflection	  of	  Poverty	  and	  Hunger	  Intensity.”	  285	  Ibid.	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Mbeki	  and	  his	  health	  minister	  Manto	  Tshabala-­‐Msimang	  had	  tried	  to	  deny	  the	  impact	  of	  HIV/AIDS	  on	  South	  African	  mortality	  and	  morbidity	  statistics	  by	  arguing	  that	  South	  Africans	  were	  dying	  of	  poverty,	  not	  AIDS.	  This	  reasoning	  also	  partially	  justified	  the	  South	  African	  government’s	  initial	  decision	  not	  to	  provide	  HIV	  medications	  via	  the	  public	  health	  system.	  It	  was	  only	  through	  aggressive	  activity	  on	  the	  part	  of	  activists’	  organizations	  and	  civil	  society	  as	  well	  as	  the	  courts	  that	  the	  government	  eventually	  agreed	  to	  roll	  out	  HIV	  treatment	  in	  the	  public	  sector	  in	  2004.286	  In	  fact,	  South	  African	  health	  minister	  Dr.	  Manto	  Tshabala-­‐Msimang	  promoted	  immune	  boosters	  and	  a	  diet	  of	  olive	  oil,	  beetroot,	  African	  potato,	  and	  lemon	  juice	  as	  the	  best	  treatment	  for	  AIDS.	  KwaZulu-­‐Natal’s	  provincial	  minister	  of	  health	  Peggy	  Nkonyeni	  followed	  suit,	  and	  openly	  antagonized	  rural	  physicians	  who	  prescribed	  antiretroviral	  medication	  as	  a	  way	  to	  prevent	  HIV	  infection	  for	  rape-­‐victims.287	  She	  also	  actively	  promoted	  uBhejane,	  an	  untested	  “traditional”	  medicine	  which	  its	  makers	  claim	  can	  cure	  AIDS.288	  Thus,	  while	  no	  such	  claims	  were	  made	  about	  MDR-­‐TB,	  the	  doctors	  in	  Tugela	  Ferry	  still	  interpreted	  the	  press	  statement	  as	  a	  frustrating	  denial.	  The	  three	  physicians	  who	  had	  been	  working	  at	  the	  Church	  of	  Scotland	  Hospital	  in	  Tugela	  Ferry	  the	  longest	  (Dr.	  Moll,	  Dr.	  van	  der	  Merwe,	  and	  Dr.	  Eksteen)	  decided	  to	  send	  a	  letter	  to	  the	  provincial	  minister	  of	  health	  explaining	  to	  her	  that	  there	  was	  indeed	  something	  happening	  in	  Tugela	  Ferry	  that	  required	  further	  action.	  Specifically,	  they	  asked	  for	  the	  resources	  to	  do	  improved	  epidemiological	  surveillance,	  for	  extraction	  fans	  to	  be	  able	  to	  effectively	  ventilate	  the	  hospital	  wards,	  and	  for	  the	  construction	  of	  facilities	  where	  MDR-­‐TB	  
                                                286	  Kerry	  Cullinan	  and	  Anso	  Thom,	  The	  Virus,	  Vitamins	  &	  Vegetables:	  The	  South	  African	  HIV/AIDS	  
Mystery	  (Jacana	  Media,	  2010);	  Nicoli	  Nattrass,	  Mortal	  Combat:	  AIDS	  Denialism	  and	  the	  Struggle	  for	  
Antiretrovirals	  in	  South	  Africa.	  (University	  of	  KwaZulu-­‐Natal	  Press,	  2007).	  287	  Jonathan	  Berger,	  “More	  Manto	  than	  Manto,”	  Thought	  Leader	  (blog),	  Mail	  and	  Guardian	  Blog,	  May	  2,	  2008,	  http://www.thoughtleader.co.za/jonathanberger/2008/05/02/more-­‐manto-­‐than-­‐manto/.	  288	  Kerry	  Cullinan,	  “Health	  officials	  promote	  untested	  uBhejane,”	  health-­‐e.org.za,	  March	  22,	  2006,	  http://www.health-­‐e.org.za/2006/03/22/health-­‐officials-­‐promote-­‐untested-­‐ubhejane/.	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patients	  could	  be	  isolated.	  In	  the	  department	  of	  health	  hierarchy	  it	  was	  considered	  highly	  irregular	  for	  three	  rural	  doctors	  to	  write	  such	  a	  letter	  directly	  to	  the	  provincial	  minister	  of	  health.	  Yet	  they	  were	  able	  to	  convince	  their	  hospital	  CEO	  to	  accept	  the	  letter	  from	  them	  and	  to	  channel	  it	  to	  the	  minister’s	  office.	  According	  to	  Dr.	  Moll	  and	  Dr.	  van	  der	  Merwe	  no	  formal	  response	  was	  ever	  received	  to	  their	  pleas.289	  In	  a	  sense,	  then,	  the	  story	  of	  a	  MDR-­‐TB	  outbreak	  in	  a	  rural	  town	  in	  KwaZulu-­‐Natal	  could	  have	  ended	  there	  –	  alarm	  among	  a	  small	  group	  of	  involved	  researchers	  and	  clinicians,	  tepid	  acknowledgement,	  some	  activity	  and	  news	  interest,	  some	  minor	  improvements	  of	  services,	  an	  eventual	  fading	  of	  interest,	  and	  ongoing	  deaths	  of	  poor	  rural	  people	  living	  with	  AIDS.	  In	  fact,	  however,	  there	  is	  not	  where	  this	  story	  ended.	  As	  I	  already	  laid	  out	  at	  the	  beginning	  of	  this	  chapter,	  the	  cases	  of	  MDR-­‐TB	  in	  Tugela	  Ferry	  instead	  came	  to	  be	  reinterpreted	  as	  a	  local	  manifestation	  of	  the	  international	  XDR-­‐TB	  phenomenon	  that	  I	  described	  in	  the	  previous	  chapter.	  In	  the	  process,	  the	  discovery	  of	  drug-­‐resistant	  tuberculosis	  in	  Tugela	  Ferry	  became	  an	  event	  of	  international	  significance,	  which	  required	  rapid	  action	  on	  the	  part	  of	  public	  health	  experts,	  global	  health	  donors,	  and	  local	  government.	  In	  the	  following	  chapter,	  I	  will	  consider	  the	  networks	  that	  allowed	  this	  to	  happen,	  focusing	  on	  the	  role	  of	  the	  American	  Centers	  for	  Disease	  Control	  and	  Prevention	  (CDC),	  the	  World	  Health	  Organization	  (WHO),	  and	  national	  and	  international	  news	  media.	  
                                                289	  Hans	  Human,	  interview	  by	  author,	  14	  January	  2011,	  Tugela	  Ferry,	  South	  Africa;	  van	  der	  Merwe,	  interview	  by	  author,	  2011;	  Moll,	  interview	  by	  author,	  2011.	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CHAPTER	  3:	  XDR-­‐TB:	  A	  Global	  Threat	  Emerging	  from	  Africa	  
 In	  the	  last	  chapter	  we	  took	  stock	  of	  the	  local	  and	  global	  conditions	  around	  tuberculosis	  control	  and	  HIV/AIDS	  research	  that	  allowed	  international	  researchers	  to	  uncover	  a	  cluster	  of	  highly	  drug-­‐resistant	  tuberculosis	  in	  the	  rural	  town	  of	  Tugela	  Ferry.	  Here	  I	  consider	  how	  news	  about	  deadly	  drug-­‐resistant	  tuberculosis	  spread	  from	  an	  isolated-­‐looking	  rural	  area	  to	  the	  most	  prestigious	  and	  powerful	  venues	  of	  elite	  biomedical	  research	  and	  global	  health	  policy	  formation.	  The	  story	  places	  a	  particular	  emphasis	  on	  professional	  and	  personal	  networks,	  as	  well	  as	  the	  close	  relationship	  between	  scientists,	  policy	  makers,	  and	  the	  media.	  I	  explain	  how	  the	  highly	  drug-­‐resistant	  cases	  of	  tuberculosis	  in	  Tugela	  Ferry	  eventually	  became	  the	  most	  important	  cases	  of	  XDR-­‐TB	  and	  argue	  that	  the	  WHO	  took	  a	  pro-­‐active	  role	  in	  facilitating	  this	  process,	  in	  part	  to	  make	  up	  for	  its	  lack	  of	  early	  action	  when	  MDR-­‐TB	  first	  became	  a	  global	  issue	  in	  the	  1990s	  and	  to	  re-­‐establish	  its	  authority	  in	  the	  field	  of	  drug-­‐resistant	  tuberculosis.	  In	  addition,	  officials	  of	  the	  WHO	  saw	  in	  drug-­‐resistant	  tuberculosis	  an	  opportunity	  to	  engage	  productively	  with	  the	  South	  African	  department	  of	  health,	  which	  had	  a	  very	  difficult	  relationship	  with	  international	  health	  agencies	  and	  funders	  due	  to	  its	  refusal	  to	  acknowledge	  its	  HIV/AIDS	  epidemic.	  
Spreading	  the	  Word	  News	  about	  the	  high	  levels	  of	  drug-­‐resistant	  tuberculosis	  in	  Tugela	  Ferry	  spread	  quickly.	  The	  first	  person	  to	  realize	  that	  the	  Church	  of	  Scotland	  Hospital	  in	  Tugela	  Ferry	  was	  facing	  a	  problem	  with	  MDR-­‐TB	  and	  an	  even	  less	  treatable	  form	  of	  drug-­‐resistant	  tuberculosis	  was	  Lynne	  Roux,	  laboratory	  manager	  for	  the	  microbiology	  laboratory	  in	  Durban,	  who	  noticed	  a	  cluster	  of	  cases	  in	  her	  data	  in	  May	  2005.	  She	  immediately	  called	  the	  hospital,	  where	  she	  reached	  Dr.	  Moll.	  By	  the	  next	  day,	  Professor	  Sturm,	  who	  was	  the	  head	  of	  the	  laboratory,	  as	  well	  as	  Dr.	  Green-­‐Thompson,	  who	  was	  head	  of	  department	  in	  the	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KwaZulu-­‐Natal	  department	  of	  health,	  had	  been	  informed	  of	  the	  problem.	  The	  news	  did	  not	  remain	  within	  official	  government	  health	  channels	  for	  long,	  of	  course.	  Dr.	  Moll	  soon	  apprised	  his	  research	  collaborators	  Dr.	  Friedland	  at	  Yale	  University	  and	  Dr.	  Gandhi	  (then	  at	  Emory	  University)	  of	  the	  situation;	  they	  in	  turn	  soon	  spoke	  with	  contacts	  at	  the	  American	  Centers	  for	  Disease	  Control	  and	  Prevention	  (CDC).290	  Professor	  Sturm	  in	  Durban	  told	  colleague	  Dr.	  Nesri	  Padayatchi,	  an	  HIV/TB	  researcher	  at	  CAPRISA291	  about	  the	  MDR-­‐TB	  cluster.292	  When	  Dr.	  Padayatchi	  gave	  a	  presentation	  on	  MDR-­‐TB	  to	  the	  Southern	  African	  HIV	  Clinicians	  Society	  in	  July	  2005	  (only	  two	  months	  after	  Lynne	  Roux	  had	  compiled	  the	  highly	  drug-­‐resistant	  TB	  cases	  from	  Dr.	  Moll’s	  snapshot	  study),	  she	  included	  Sturm’s	  data	  on	  MDR-­‐TB	  in	  Tugela	  Ferry.	  Sturm	  did	  not	  want	  the	  location	  of	  the	  potential	  outbreak	  to	  be	  disclosed,	  however.	  According	  to	  Dr.	  Padayatchi,	  “he	  actually	  ran	  down	  to	  my	  office	  to	  say,	  ‘do	  not	  mention	  the	  area	  where	  this	  has	  been	  uncovered.’	  […]	  He	  did	  not	  want	  to	  create	  a	  media	  frenzy.”293	  At	  the	  meeting,	  Dr.	  Padayatchi	  described	  these	  highly	  drug	  resistant	  tuberculosis	  cases	  to	  the	  HIV	  Clinicians	  Society	  in	  general	  terms,	  as	  a	  possible	  nosocomial	  (hospital-­‐caused)	  outbreak	  in	  KwaZulu-­‐Natal,	  but	  she	  did	  not	  highlight	  their	  exact	  location.294	  She	  explained	  that	  Professor	  Sturm’s	  lab	  had	  analyzed	  18	  samples	  of	  tuberculosis,	  all	  of	  which	  were	  resistant	  to	  all	  six	  tuberculosis	  drugs	  tested,	  and	  16	  of	  which	  
                                                290	  Anthony	  Moll,	  interview	  by	  author,	  23	  July	  2007,	  Tugela	  Ferry,	  South	  Africa;	  Sarita	  Shah,	  interview	  by	  author,	  phone	  interview,	  30	  March	  2007.	  291	  CAPRISA	  (Centre	  for	  the	  AIDS	  Programme	  of	  Research	  in	  South	  Africa)	  is	  an	  HIV/AIDS	  research	  institute	  at	  the	  Nelson	  R.	  Mandela	  School	  of	  Medicine	  (University	  of	  KwaZulu-­‐Natal,	  Durban)	  and	  was	  funded	  by	  the	  US	  National	  Institutes	  of	  Health	  (NIH).	  It	  was	  the	  then-­‐new	  institute	  with	  which	  Dr.	  Friedland	  intended	  to	  conduct	  HIV/TB	  research	  when	  he	  arrived	  in	  Durban	  for	  a	  sabbatical	  in	  2001.	  Now	  it	  is	  a	  well-­‐established	  research	  institute	  that	  has	  successfully	  conducted	  several	  high-­‐profile	  clinical	  trials,	  including	  HIV/TB	  co-­‐treatment	  studies	  and	  studies	  of	  HIV-­‐preventing	  microbicides.	  292	  Dr.	  Padayatchi	  is	  also	  the	  former	  medical	  director	  of	  King	  George	  V	  hospital,	  where	  all	  MDR-­‐TB	  cases	  in	  the	  province	  are	  seen.	  She	  heard	  about	  the	  cases	  in	  Tugela	  Ferry	  through	  several	  channels.	  293	  Nesri	  Padayatchi,	  interview	  by	  author,	  6	  April	  2010,	  Durban,	  South	  Africa.	  294	  According	  to	  a	  draft	  of	  the	  talk,	  which	  Dr.	  Padayatchi	  shared	  with	  me,	  she	  described	  the	  outbreak	  as	  being	  in	  “the	  KZN	  midlands.”	  	  In	  fact,	  only	  someone	  not	  too	  familiar	  with	  the	  area	  would	  describe	  Tugela	  Ferry	  as	  located	  in	  the	  midlands,	  though	  the	  region	  does	  border	  the	  midlands.	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could	  be	  classed	  as	  belonging	  to	  the	  same	  “highly	  resistant	  KZN	  strain,”295	  whereby	  “KZN	  strain”	  is	  the	  name	  that	  Prof.	  Sturm’s	  research	  group	  gave	  the	  predominant	  molecular	  tuberculosis	  strain	  among	  the	  samples	  they	  were	  studying.296	  Other	  strains	  also	  have	  place-­‐based	  designations	  like	  the	  “Beijing	  strain,”	  for	  example,	  though	  their	  actual	  distribution	  can	  be	  worldwide.297	  	   In	  response	  to	  Dr.	  Padayatchi’s	  presentation,	  one	  of	  the	  physicians	  in	  the	  audience	  commented	  that	  it	  was	  unethical	  not	  to	  identify	  the	  location	  of	  a	  highly	  resistant	  MDR-­‐TB	  outbreak.298	  At	  that	  time,	  however,	  the	  presentation	  did	  not	  lead	  a	  broader	  discussion	  or	  to	  the	  media	  frenzy	  which	  Prof.	  Sturm	  had	  feared.	  According	  to	  several	  South	  African	  clinicians	  I	  spoke	  to	  deadly	  tuberculosis	  had	  become	  commonplace	  enough	  that	  it	  was	  not	  in	  itself	  surprising	  or	  frightening.	  In	  addition,	  Padayatchi’s	  presentation	  was	  based	  entirely	  on	  laboratory	  data	  provided	  by	  Professor	  Sturm’s	  lab	  and	  did	  not	  include	  information	  about	  how	  deadly	  this	  form	  of	  tuberculosis	  might	  be.	  At	  the	  American	  Centers	  for	  Disease	  Control	  and	  Prevention	  (CDC),	  Dr.	  Sarita	  Shah	  (who	  compiled	  the	  first	  scientific	  paper	  on	  global	  XDR-­‐TB)	  was	  probably	  one	  of	  the	  first	  people	  to	  hear	  about	  the	  highly	  drug-­‐resistant	  cases	  in	  Tugela	  Ferry.	  She	  and	  Dr.	  Neel	  Gandhi,	  who,	  as	  we	  have	  seen,	  was	  one	  of	  the	  main	  US	  researchers	  working	  on	  HIV	  and	  TB	  in	  Tugela	  Ferry	  with	  Dr.	  Friedland,	  were	  married	  and	  communicated	  about	  their	  work.299	  Dr.	  Gandhi	  and	  Dr.	  Friedland	  officially	  debriefed	  members	  of	  the	  CDC	  in	  June	  2005	  at	  a	  side	  
                                                295	  Nesri	  Padayatchi,	  “Multi	  Drug	  Resistant	  TB	  (MDR-­‐TB)”	  (Powerpoint	  presented	  at	  the	  Southern	  African	  HIV	  Clinicians	  Society,	  Durban,	  July	  13,	  2005).	  296	  A	  more	  accepted	  name	  for	  the	  KZN	  strain	  is	  the	  F15/LAM4/KZN	  strain.	  See	  Manormoney	  Pillay	  and	  A.	  Willem	  Sturm,	  “Evolution	  of	  the	  Extensively	  Drug-­‐Resistant	  F15/LAM4/KZN	  Strain	  of	  Mycobacterium	  Tuberculosis	  in	  KwaZulu-­‐Natal,	  South	  Africa,”	  Clinical	  Infectious	  Diseases	  45,	  no.	  11	  (2007):	  1409–1414.	  297	  Ingrid	  Filliol	  et	  al.,	  “Snapshot	  of	  Moving	  and	  Expanding	  Clones	  of	  Mycobacterium	  Tuberculosis	  and	  Their	  Global	  Distribution	  Assessed	  by	  Spoligotyping	  in	  an	  International	  Study,”	  Journal	  of	  Clinical	  
Microbiology	  41,	  no.	  5	  (2003):	  1963–1970.	  298	  Padayatchi,	  interview	  by	  author,	  2010.	  299	  Shah,	  interview	  by	  author,	  2007.	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meeting	  of	  the	  Center	  for	  AIDS	  Research	  (CFAR)	  conference	  in	  Boston.300	  Peter	  Cegielski,	  who	  was	  Sarita	  Shah’s	  mentor	  on	  the	  XDR-­‐TB	  study,	  was	  present.	  In	  response,	  the	  CDC	  offered	  to	  support	  the	  investigation	  of	  drug-­‐resistant	  tuberculosis	  in	  Tugela	  Ferry.	  However,	  South	  African	  bureaucrats	  in	  KwaZulu-­‐Natal	  insisted	  that	  the	  CDC,	  as	  a	  government	  agency,	  was	  not	  free	  to	  start	  research	  or	  support	  activities	  in	  South	  Africa	  without	  first	  receiving	  a	  formal	  invitation	  from	  a	  national	  agency	  of	  the	  South	  African	  government.	  This	  invitation	  was	  not	  forthcoming	  despite	  the	  fact	  that	  the	  CDC	  had	  been	  providing	  technical	  assistance	  on	  tuberculosis-­‐related	  research	  projects	  in	  South	  Africa	  for	  several	  years.301	  Thus,	  while	  they	  did	  not	  collaborate	  directly,	  the	  CDC	  and	  the	  Yale/Philanjalo	  group,	  which	  later	  came	  to	  be	  called	  the	  TFCARES302	  collaboration,	  each	  continued	  to	  work	  separately	  on	  documenting	  increasingly	  drug-­‐resistant	  tuberculosis,	  either	  worldwide	  (in	  the	  case	  of	  the	  CDC)	  or	  in	  a	  specific	  region	  of	  South	  Africa	  (in	  the	  case	  of	  Yale/Philanjalo).	  In	  mid	  2005,	  while	  Dr.	  Moll	  and	  his	  colleagues	  were	  grappling	  with	  the	  impact	  of	  the	  newly	  discovered	  cases	  of	  intense	  tuberculosis	  drug	  resistance	  in	  Tugela	  Ferry,	  Dr.	  Shah	  and	  her	  group	  at	  the	  CDC	  in	  Atlanta	  were	  still	  in	  the	  process	  of	  solidifying	  their	  definition	  of	  XDR-­‐TB	  and	  compiling	  global	  cases	  from	  the	  WHO-­‐certified	  Supranational	  Reference	  Laboratories	  (SRLs).	  According	  to	  the	  laboratories’	  records	  there	  were	  almost	  no	  documented	  cases	  of	  the	  new	  XDR-­‐TB	  in	  Africa.	  Even	  if	  the	  Tugela	  Ferry	  cases	  of	  drug	  resistant	  tuberculosis	  had	  been	  captured	  by	  these	  laboratories’	  databases	  (which	  they	  were	  not),	  the	  cases	  would	  not	  have	  fulfilled	  the	  CDC’s	  working	  definition	  for	  XDR-­‐TB,	  which	  
                                                300	  Ibid.	  The	  CFARs	  are	  a	  national	  network	  of	  centers	  funded	  by	  the	  National	  Institutes	  of	  Health	  that	  facilitate	  HIV/AIDS	  related	  research.	  This	  Boston	  side	  meeting	  was	  most	  likely	  at	  a	  national	  symposium	  co-­‐hosted	  by	  the	  UPenn	  and	  Harvard	  CFARs	  entitled	  “Confronting	  TB-­‐HIV	  Co-­‐infection”	  which	  was	  held	  on	  June	  30,	  2005.	  	  301	  Moll,	  interview	  by	  author,	  2011;	  Timothy	  Holtz,	  interview	  by	  author,	  phone	  interview,	  8	  February	  2010;	  Karin	  Weyer,	  interview	  by	  author,	  phone	  interview,	  8	  July	  2010.	  302	  Tugela	  Ferry	  Care	  and	  Research	  Collaboration	  (tfcares.org).	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required	  documented	  resistance	  to	  at	  least	  three	  second-­‐line	  drugs.	  Prof.	  Sturm’s	  lab	  only	  tested	  for	  two	  second-­‐line	  drugs.	  The	  concerning	  cluster	  of	  cases	  in	  Tugela	  Ferry	  clearly	  showed	  the	  limitations	  of	  Shah’s	  database-­‐based	  study	  in	  terms	  of	  accurately	  reflecting	  the	  global	  rates	  of	  drug-­‐resistant	  tuberculosis	  that	  is	  even	  more	  drug-­‐resistant	  than	  MDR-­‐TB.	  As	  discussed	  in	  chapter	  1,	  Dr.	  Shah	  first	  presented	  the	  global	  survey	  of	  XDR-­‐TB	  in	  October	  2005	  in	  Paris	  at	  the	  World	  meeting	  of	  the	  Union	  against	  TB	  and	  Lung	  Disease	  (the	  “Union	  meeting”),	  thus	  publicly	  establishing	  the	  CDC’s	  definition	  of	  XDR-­‐TB	  as	  MDR-­‐TB	  plus	  resistance	  to	  three	  or	  more	  second-­‐line	  drugs.	  The	  Tugela	  Ferry	  group	  had	  hoped	  to	  present	  its	  own	  research	  on	  highly	  drug-­‐resistant	  tuberculosis	  at	  the	  same	  meeting,	  but	  the	  abstract	  that	  had	  been	  submitted	  for	  the	  group	  in	  July	  2005	  as	  a	  late-­‐breaker	  submission	  was	  not	  included	  in	  the	  conference	  program.303	  Instead,	  the	  first	  public	  presentation	  of	  the	  drug	  resistant	  tuberculosis	  cases	  in	  Tugela	  Ferry	  occurred	  in	  a	  poster	  session	  at	  the	  Conference	  on	  Retroviruses	  and	  Opportunistic	  Infections	  (CROI)	  in	  Denver	  in	  February	  2006.	  Since	  Tugela	  Ferry’s	  TB	  cases	  were	  only	  known	  to	  be	  resistant	  to	  two	  second-­‐line	  drugs,	  they	  were	  not	  called	  XDR-­‐TB	  but	  instead	  were	  called	  highly	  drug	  resistant	  tuberculosis,	  or	  HDR-­‐TB.	  	  The	  title	  of	  the	  group's	  poster	  -­‐	  Identification	  of	  a	  Multi-­‐Drug	  Resistant	  Tuberculosis	  
Cluster	  as	  a	  Cause	  of	  Death	  among	  HIV	  Coinfected	  Patients	  in	  Rural	  South	  Africa	  -­‐	  did	  not	  emphasize	  the	  heightened	  level	  of	  drug	  resistance	  in	  their	  patients,	  but	  rather	  highlighted	  the	  many	  cases	  of	  MDR-­‐TB	  seen	  in	  Tugela	  Ferry.304	  The	  poster	  specifically	  highlighted	  the	  fact	  that	  MDR-­‐TB	  had	  previously	  been	  missed	  as	  a	  cause	  of	  death	  with	  HIV	  and	  TB	  coinfection.	  In	  the	  absence	  of	  antiretrovirals	  (and	  even	  after	  their	  introduction),	  such	  deaths	  
                                                303	  Shah,	  interview	  by	  author,	  2007.	  304	  Anthony	  Moll	  et	  al.,	  “Identification	  of	  a	  Multi-­‐Drug	  Resistant	  Tuberculosis	  Cluster	  as	  a	  Cause	  of	  Death	  Among	  Coinfected	  Patients	  in	  Rural	  South	  Africa”	  (presented	  at	  the	  Conference	  on	  Retroviruses	  and	  Opportunistic	  Infections	  (CROI),	  Denver,	  2006).	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were	  still	  likely	  to	  be	  attributed	  to	  “end-­‐stage	  AIDS”	  disease.305	  Now	  that	  antiretrovirals	  were	  increasingly	  being	  used	  for	  AIDS	  patients	  in	  South	  Africa,	  the	  impact	  of	  untreatable	  (or	  merely	  untreated)	  tuberculosis	  would	  become	  more	  apparent.	  The	  data	  in	  their	  presentation	  was	  alarming.	  By	  this	  point	  Moll,	  Gandhi	  and	  colleagues	  had	  documented	  50	  cases	  of	  highly	  drug-­‐resistant	  tuberculosis	  in	  Tugela	  Ferry,	  which	  they	  called	  HDR-­‐TB.	  Forty-­‐four	  of	  them	  had	  already	  died,	  giving	  this	  form	  of	  tuberculosis	  a	  mortality	  rate	  of	  84%.	  According	  to	  most	  reports	  the	  poster	  did	  not	  cause	  much	  of	  a	  stir.	  Dr.	  Graeme	  Meintjes,	  a	  Cape-­‐Town	  based	  tuberculosis	  physician	  and	  researcher,	  remembers	  meeting	  Dr.	  Moll	  at	  the	  CROI	  meeting	  in	  Denver	  and	  being	  immediately	  impressed	  with	  the	  findings	  emerging	  from	  the	  research	  in	  Tugela	  Ferry,	  however.	  Referring	  to	  Moll’s	  poster,	  Dr.	  Meintjes	  recalled	  that	  “anybody	  working	  in	  a	  developing	  world	  situation	  working	  with	  TB	  knew	  that	  this	  was	  a	  staggering	  finding.”306	  He	  was	  particularly	  impressed	  by	  the	  high	  rates	  of	  MDR-­‐TB	  and	  what	  they	  told	  him	  about	  the	  apparent	  failures	  of	  South	  Africa’s	  standardized	  management	  of	  TB	  and	  MDR-­‐TB.	  “This	  was	  happening	  in	  South	  Africa,	  but	  because	  we	  were	  only	  testing	  for	  MDR	  and	  had	  adopted	  a	  policy	  of	  just	  treating	  MDR	  with	  a	  fixed	  regimen	  and	  not	  looking	  for	  further	  resistance.”307	  For	  him,	  the	  poster	  showed	  that	  South	  African	  tuberculosis	  specialists	  “were	  all	  ostriches	  with	  our	  heads	  in	  the	  ground	  as	  a	  result	  of	  the	  national	  policy	  to	  do	  away	  with	  second	  line	  drug	  testing.”308	  He	  also	  observed,	  however,	  that	  most	  conference	  attendees	  did	  not	  pay	  close	  attention	  to	  the	  poster.309	  	  Dr.	  Shah,	  who	  had	  been	  following	  her	  husband	  Neel	  Gandhi’s	  study's	  progress	  and	  knew	  how	  it	  related	  to	  her	  own	  work,	  believed	  that	  the	  results	  from	  Tugela	  Ferry	  warranted	  
                                                305	  Ibid.	  306	  Graeme	  Meintjes,	  interview	  by	  author,	  14	  May	  2010,	  Cape	  Town,	  South	  Africa.	  307	  Ibid.	  308	  Ibid.	  309Ibid.	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a	  much	  greater	  response	  and	  that	  “nobody	  cared	  as	  much	  as	  they	  should	  have.”310	  In	  part,	  she	  attributed	  this	  to	  the	  fact	  that	  the	  researchers	  did	  not	  use	  the	  term	  “XDR-­‐TB”	  to	  describe	  their	  highly	  resistant	  tuberculosis	  cases.	  As	  we	  have	  already	  seen	  in	  chapter	  2,	  the	  reaction	  was	  very	  different	  when	  similar	  data	  was	  presented	  again	  six	  months	  later	  at	  the	  International	  AIDS	  Conference	  in	  Toronto.	  Meanwhile,	  the	  CDC’s	  survey	  of	  XDR-­‐TB	  was	  published	  in	  Morbidity	  and	  Mortality	  
Weekly	  Report	  at	  the	  end	  of	  March	  2006,	  and	  Dr.	  Shah’s	  work	  received	  some	  public	  attention.	  In	  May	  2006,	  the	  PARTNERS	  TB	  Control	  Program	  gathered	  in	  Atlanta	  for	  the	  five-­‐year	  review	  of	  their	  MDR-­‐TB	  treatment	  projects.311	  Dr.	  Shah	  was	  asked	  to	  present	  the	  data	  of	  the	  XDR-­‐TB	  survey	  at	  the	  final	  review	  meeting	  of	  the	  project.	  She	  chose	  to	  share	  her	  10	  minutes	  of	  allocated	  presentation	  time	  with	  Dr.	  Gandhi,	  who	  described	  the	  findings	  from	  Tugela	  Ferry,	  South	  Africa.	  The	  groups	  represented	  at	  this	  meeting	  included	  the	  World	  Health	  Organization	  (WHO),	  the	  American	  CDC,	  the	  US	  Agency	  for	  International	  Development	  (USAID),	  Partners	  in	  Health,	  Harvard	  University	  and	  the	  Peruvian	  government,	  among	  others.	  They	  were	  all	  very	  concerned	  and	  agreed	  that	  global	  XDR-­‐TB	  and	  the	  highly	  drug-­‐resistant	  cases	  of	  tuberculosis	  in	  Tugela	  Ferry	  demanded	  an	  active	  response.	  Dr.	  Ernesto	  Jaramillo,	  of	  the	  STOP	  TB	  department	  of	  the	  World	  Health	  Organization,	  remembers	  this	  meeting	  as	  falling	  into	  an	  important	  transition	  period,	  as	  the	  Bill	  &	  Melinda	  Gates	  Foundation	  was	  ending	  its	  financial	  support	  for	  the	  WHO	  MDR-­‐TB	  
                                                310	  Shah,	  interview	  by	  author,	  2007.	  311	  PARTNERS	  stands	  for	  Partnership	  Against	  Resistant	  Tuberculosis:	  A	  Network	  for	  Equity	  and	  
Resource	  Strengthening.	  	  "The	  PARTNERS	  TB	  Control	  Program	  is	  an	  international	  consortium	  of	  organizations	  addressing	  MDR-­‐TB.	  This	  five-­‐year	  program,	  funded	  by	  the	  Bill	  &	  Melinda	  Gates	  Foundation,	  focuses	  on	  the	  control	  of	  MDR-­‐TB	  in	  Peru	  and	  in	  a	  prison	  population	  in	  Russia	  with	  a	  goal	  of	  developing	  an	  integrated	  program	  model	  that	  can	  be	  used	  in	  other	  resource-­‐poor	  countries".	  http://www.taskforce.org/tb.asp,	  last	  accessed	  4/30/2007.	  According	  to	  the	  Partners	  in	  Health	  (PIH)	  website,	  the	  program	  received	  $44.7	  million	  from	  the	  Bill	  and	  Melinda	  Gates	  Foundation.	  “Partners	  In	  Health	  History"	  pih.org,	  accessed	  February	  29,	  2012,	  http://www.pih.org/pages/partners-­‐in-­‐health-­‐history/.	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Working	  Group	  and	  the	  Green	  Light	  Committee.312	  Over	  the	  five	  years	  of	  Gates	  funding	  it	  had	  become	  clear	  that	  public	  concern	  over	  MDR-­‐TB	  was	  an	  effective	  tool	  with	  which	  to	  advocate	  for	  better	  tuberculosis	  control	  in	  general.	  But	  now	  that	  MDR-­‐TB	  related	  programs	  were	  losing	  an	  important	  source	  of	  funding,	  what	  would	  “be	  the	  way	  to	  do	  advocacy	  for	  MDR-­‐TB?”313	  When	  Dr.	  Shah	  presented	  the	  CDC’s	  findings	  on	  XDR-­‐TB	  worldwide	  along	  with	  Dr.	  Gandhi’s	  cases	  in	  Tugela	  Ferry,	  it	  became	  clear	  to	  many	  present	  that	  XDR-­‐TB	  provided	  an	  opportunity	  for	  public	  health	  advocacy	  that	  would	  in	  turn	  highlight	  MDR-­‐TB.314	  According	  to	  Dr.	  Jaramillo,	  the	  audience	  of	  tuberculosis	  experts	  was	  at	  first	  shocked	  into	  silence	  by	  Dr.	  Gandhi’s	  findings,	  until	  the	  chair	  of	  the	  session,	  Dr.	  Jim	  Kim,	  stated	  that	  he	  couldn’t	  believe	  that	  nobody	  was	  saying	  anything.315	  But	  in	  Jaramillo’s	  view	  the	  group	  immediately	  realized	  that	  XDR-­‐TB	  provided	  a	  great	  opportunity	  to	  help	  people	  understand	  that	  MDR-­‐TB	  is	  in	  fact	  a	  reflection	  of	  a	  failure	  of	  the	  whole	  health	  care	  system.	  Dr.	  Jaramillo	  (like	  many	  other	  public	  health	  experts	  I	  interviewed)	  explicitly	  resisted	  characterizing	  XDR-­‐TB	  as	  a	  crisis	  engineered	  by	  the	  WHO	  or	  CDC,	  yet	  he	  readily	  admitted	  that	  our	  current	  understanding	  of	  XDR-­‐TB	  resulted	  from	  a	  serendipitous	  “convergence”	  of	  events,	  whereby	  “some	  people	  [were]	  offering	  something	  that	  others	  were	  in	  need	  of,”	  and	  that	  as	  a	  result	  XDR-­‐TB	  became	  a	  major	  issue	  which	  was	  heavily	  supported	  and	  promoted	  by	  the	  WHO	  and	  the	  STOP	  TB	  department.316	  The	  CDC	  (especially	  Dr.	  Kenneth	  Castro	  and	  Dr.	  Charles	  Wells)	  also	  felt	  it	  was	  important	  to	  remain	  a	  part	  of	  the	  discussion.317	  Dr.	  Kenneth	  Castro	  put	  it	  more	  diplomatically	  than	  Dr.	  Jaramillo:	  “As	  this	  came	  about	  there	  was	  growing	  concern	  that	  
                                                312	  Ernesto	  Jaramillo,	  interview	  by	  author,	  12	  November	  2010,	  Berlin,	  Germany.	  313	  Ibid.	  314	  Ibid.	  315	  Physician-­‐anthropologist	  Dr.	  Jim	  Kim	  was	  cofounder	  of	  Partners	  in	  Health	  with	  Paul	  Farmer.	  He	  has	  since	  then	  been	  director	  of	  WHO’s	  HIV/AIDS	  department,	  president	  of	  Dartmouth	  College,	  and	  is	  now	  president	  of	  the	  World	  Bank.	  316	  Jaramillo,	  interview	  by	  author,	  2010.	  317	  Kenneth	  Castro,	  interview	  by	  author,	  23	  February	  2010;	  Holtz,	  interview	  by	  author,	  2010.	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the	  world	  was	  uncovering	  the	  existence	  of	  a	  group	  of	  individuals	  with	  MDR	  who	  were	  virtually	  untreatable	  with	  the	  available	  drugs	  and	  many	  of	  us	  who	  were	  part	  of	  the	  global	  STOP-­‐TB	  partnership	  came	  together	  and	  said,	  you	  know,	  it	  would	  be	  irresponsible	  to	  sit	  on	  this	  without	  prompt	  action.”318	  Those	  present	  at	  the	  Atlanta	  meeting	  decided	  to	  convene	  an	  expert	  consultation	  meeting	  on	  XDR-­‐TB	  in	  the	  following	  months,	  and	  scheduled	  it	  to	  take	  place	  in	  South	  Africa	  in	  September	  2006.	  In	  the	  meantime,	  however,	  Dr.	  Gandhi	  was	  encouraged	  to	  submit	  the	  findings	  from	  Tugela	  Ferry	  as	  a	  late-­‐breaker	  abstract	  to	  the	  International	  AIDS	  Conference	  that	  was	  soon	  to	  take	  place	  in	  Toronto,	  in	  August	  2006.	  This	  biennial	  AIDS	  conference	  is	  the	  unrivaled	  highlight	  of	  the	  HIV/AIDS	  conference	  cycle.	  In	  light	  of	  the	  meager	  response	  that	  Dr.	  Moll’s	  poster	  from	  Tugela	  Ferry	  had	  received	  at	  the	  CROI	  meeting	  in	  February,	  Dr.	  Cegielski	  and	  Dr.	  Shah	  suggested	  that	  it	  would	  make	  sense	  for	  the	  Tugela	  Ferry	  team	  to	  call	  their	  strain	  of	  highly	  drug-­‐resistant	  tuberculosis	  XDR-­‐TB	  in	  their	  submission	  to	  the	  conference,	  even	  though	  their	  cases	  did	  not,	  strictly	  speaking,	  fit	  the	  CDC’s	  definition	  for	  XDR-­‐TB.319	  According	  to	  Dr.	  Shah	  this	  was	  quite	  possibly	  justified	  scientifically.	  The	  reason	  that	  Tugela	  Ferry’s	  cases	  had	  not	  been	  called	  XDR-­‐TB	  until	  that	  point	  was	  that	  the	  lab	  in	  Durban	  had	  only	  demonstrated	  that	  they	  were	  resistant	  to	  two	  second-­‐line	  anti-­‐TB	  drugs,	  while	  the	  CDC	  definition	  of	  XDR-­‐TB	  required	  strains	  to	  be	  resistant	  to	  at	  least	  three	  second-­‐line	  drugs.	  Yet	  the	  CDC	  had	  analyzed	  tuberculosis	  cases	  known	  to	  be	  resistant	  to	  two	  second-­‐line	  drugs	  and	  found	  that	  they	  frequently	  were	  also	  resistant	  to	  a	  third	  or	  fourth	  drug.	  Thus,	  it	  could	  be	  argued	  that	  the	  cases	  in	  Tugela	  Ferry	  were	  likely	  to	  be	  resistant	  to	  a	  third	  second-­‐line	  drug	  that	  hadn’t	  been	  tested	  for.	  More	  importantly,	  perhaps,	  it	  was	  clear	  that	  patients	  in	  Tugela	  
                                                318	  Castro,	  interview	  by	  author,	  2010.	  319	  Shah,	  interview	  by	  author,	  2007.	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Ferry	  who	  had	  this	  increased	  level	  of	  drug-­‐resistance	  were	  dying	  at	  an	  alarming	  rate.	  Whether	  or	  not	  they	  fit	  the	  CDC’s	  definition,	  these	  cases	  were	  highly	  concerning	  and	  could	  be	  highlighted	  by	  using	  the	  term	  XDR-­‐TB,	  which	  connected	  them	  both	  to	  the	  CDC’s	  March	  publication	  in	  Morbidity	  and	  Mortality	  Weekly	  Report,	  as	  well	  as	  to	  other	  work	  which	  had	  been	  done	  as	  a	  result	  of	  that	  publication.320	  This	  change	  in	  terminology	  apparently	  paid	  off.	  Dr.	  Gandhi	  submitted	  his	  group’s	  research	  as	  a	  late-­‐breaking	  abstract	  to	  the	  2006	  International	  AIDS	  Conference	  and	  it	  was	  selected	  for	  an	  oral	  presentation	  during	  the	  high	  profile	  late-­‐breaker	  session,	  which	  was	  attended	  by	  several	  thousand	  people.	  At	  the	  session,	  Dr.	  Gandhi	  gave	  a	  clear	  and	  engaging	  ten-­‐minute	  power-­‐point	  presentation	  that	  focused	  on	  the	  most	  dramatic	  aspects	  of	  the	  Tugela	  Ferry	  findings.	  He	  stressed	  just	  how	  high	  the	  rates	  of	  MDR-­‐TB	  and	  XDR-­‐TB	  were	  in	  Tugela	  Ferry	  compared	  to	  other	  areas	  in	  the	  world	  and	  described	  XDR-­‐TB	  as	  “rapidly	  and	  nearly	  completely	  fatal.”	  Instead	  of	  defining	  XDR-­‐TB,	  he	  consistently	  spoke	  of	  cases	  with	  "resistance	  to	  all	  second-­‐line	  drugs	  tested"	  without	  ever	  specifying	  the	  drugs	  actually	  tested,	  thus	  obscuring	  the	  difference	  between	  his	  use	  of	  "XDR"	  and	  the	  CDC/WHO	  definition	  published	  in	  March	  2006.	  He	  ended	  his	  talk	  with	  policy	  recommendations,	  pointing	  out	  that	  MDR-­‐TB	  was	  jeopardizing	  the	  gains	  in	  HIV	  mortality	  brought	  by	  antiretroviral	  therapy	  and	  stressing	  that	  an	  increase	  in	  resources	  was	  required	  to	  strengthen	  necessary	  tuberculosis	  programs.321	  	  When	  Dr.	  Gandhi	  sat	  down	  after	  giving	  his	  ten-­‐minute	  talk,	  there	  was	  no	  time	  for	  questions,	  (eighteen	  speakers	  were	  scheduled	  in	  what	  some	  termed	  a	  marathon	  session	  that	  ran	  through	  the	  lunch	  break),	  and	  he	  wasn't	  sure	  if	  people	  in	  the	  room	  had	  even	  heard	  
                                                320	  Shah,	  interview	  by	  author,	  2007.	  321	  “XVI	  International	  AIDS	  Conference:	  English	  Podcast:	  Oral	  Abstract	  Section:	  Late	  Breaker	  Track	  B",	  kaisernetwork.org,	  http://www.kaisernetwork.org/health_cast/hcast_index.cfm?display=detail&hc=1854.	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what	  he	  had	  said.322	  In	  the	  end,	  his	  presentation	  generated	  a	  very	  large	  response,	  however,	  became	  one	  of	  the	  items	  picked	  up	  by	  the	  scientific	  and	  lay	  media	  covering	  the	  conference,323	  including	  NPR's	  All	  Things	  Considered,324	  the	  New	  York	  Times,325	  and	  Science	  magazine.326	  Scientists	  and	  global	  health	  experts	  who	  became	  aware	  of	  the	  XDR-­‐TB	  problem	  through	  the	  conference	  were	  interested	  in	  attending	  the	  XDR-­‐TB	  expert	  consultation	  meeting	  that	  had	  already	  been	  scheduled	  to	  take	  place	  in	  Johannesburg	  in	  September.327	  	   Soon	  after	  the	  conference,	  the	  editor	  of	  the	  prestigious	  British	  medical	  journal	  
Lancet	  contacted	  Dr.	  Gerald	  Friedland,	  who	  was	  the	  principle	  investigator	  on	  the	  study,	  expressing	  the	  journal’s	  interest	  in	  publishing	  the	  XDR-­‐TB	  results	  as	  a	  "fast	  track"	  article.	  The	  Lancet	  considered	  XDR-­‐TB	  important	  and	  topical	  enough	  to	  be	  published	  as	  quickly	  as	  possible	  –	  fast	  track	  articles	  are	  published	  within	  a	  month	  of	  submission,	  which	  is	  a	  very	  short	  time	  considering	  the	  more	  common	  turn	  around	  time	  of	  months	  to	  years	  for	  biomedical	  articles	  in	  such	  a	  prominent	  journal.328	  Dr.	  Salim	  Abdool	  Karim,	  a	  prominent	  South	  African	  HIV	  and	  TB	  researcher	  who	  attended	  the	  AIDS	  conference,	  remembered	  chatting	  with	  Lancet’s	  editor,	  Richard	  Horton,	  at	  a	  social	  function	  related	  to	  the	  
                                                322	  Some	  people	  thought	  of	  this	  meeting	  as	  an	  emergency	  meeting	  that	  resulted	  directly	  from	  the	  attention	  at	  the	  International	  AIDS	  conference,	  but	  it	  had	  in	  fact	  been	  decided	  on	  at	  the	  earlier	  PARTNERS	  meeting.	  (Shah,	  interview	  by	  author,	  2007.)	  323	  This	  conference	  generates	  many	  articles	  in	  the	  mainstream	  press	  worldwide	  every	  year.	  324	  Joanne	  Silberner,	  “Resistant	  TB	  Strikes	  South	  Africans	  with	  HIV ,”	  NPR.org,	  August	  18,	  2006,	  http://www.npr.org/templates/story/story.php?storyId=5671714.	  325	  Lawrence	  K.	  Altman,	  "Doctors	  Warn	  of	  Powerful	  and	  Resistant	  Tuberculosis	  Strain,"	  New	  York	  
Times,	  August	  18,	  2006.	  326	  Jon	  Cohen,	  "Extensively	  Drug-­‐Resistant	  TB	  Gets	  Foothold	  in	  South	  Africa,"	  Science	  313	  (2006),	  Jon	  Cohen,	  "At	  International	  AIDS	  Conference,	  Big	  Names	  Emphasize	  Big	  Gaps,"	  Science	  313	  (2006).	  327	  Shah,	  interview	  by	  author,	  2007.	  328	  Dr.	  Friedland	  was	  excited	  at	  the	  prospect	  of	  publishing	  the	  work	  in	  Lancet:	  "So	  they	  had	  understood	  the	  importance	  of	  it	  and	  of	  course	  you	  always	  want	  to	  get	  something	  in	  Lancet.	  	  It's	  widely	  read,	  it's	  a	  major	  medical	  journal,	  it's	  read	  internationally,	  probably	  more	  than	  other	  journals,	  so	  that	  this	  information	  would	  be	  widely	  disseminated.	  	  So	  of	  course	  we	  agreed	  to	  do	  it	  and	  we	  very	  quickly	  wrote	  the	  paper."	  Gerald	  Friedland,	  interview	  by	  author,	  27	  March,	  2007,	  New	  Haven,	  CT.	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conference.329	  Abdool	  Karim	  himself	  was	  not	  impressed	  by	  the	  results	  from	  Tugela	  Ferry,	  yet	  “[Richard	  Horton]	  thought	  this	  was	  the	  biggest	  thing	  ever.	  	  […]	  He	  was	  just	  saying,	  this	  is	  amazing,	  look	  at	  these	  problems.	  […]	  And	  it	  was	  the	  Lancet	  actually	  that	  gave	  it	  the	  high	  profile.	  The	  same	  thing,	  you	  know,	  in	  some	  small	  journal	  might	  not	  have	  even	  got	  much	  play.”330	  	   In	  truth,	  by	  the	  time	  the	  Lancet	  article	  went	  to	  press,	  readers	  of	  many	  leading	  scientific	  journals	  had	  already	  heard	  about	  XDR-­‐TB	  in	  South	  Africa	  through	  news-­‐briefs	  and	  conference	  summaries.	  Dr.	  Gandhi’s	  ten-­‐minute	  presentation	  on	  XDR-­‐TB	  in	  South	  Africa	  at	  the	  Toronto	  AIDS	  conference	  rapidly	  led	  to	  a	  broad	  reaction	  and	  further	  exposure	  among	  the	  professional	  HIV/AIDS	  community,	  in	  public	  health	  circles,	  among	  biomedical	  scientists,	  as	  well	  as	  in	  the	  lay	  media	  and	  culminated	  in	  publication	  in	  the	  Lancet	  in	  November	  2006.	  For	  Dr.	  Moll	  and	  his	  department	  of	  health	  colleagues	  and	  superiors	  in	  South	  Africa,	  the	  repercussions	  were	  almost	  immediate:	  “After	  Toronto	  there	  was	  an	  amazing	  press	  interest	  and	  I	  didn't	  know	  what	  I	  was	  coming	  home	  to,	  but	  when	  I	  came	  home	  I	  was	  just	  bombarded	  with	  telephone	  calls,	  with	  requests	  for	  interviews,	  all	  this	  kind	  of	  thing.	  And	  the	  department	  of	  health	  [was]	  also	  bombarded.	  And	  this	  basically	  took	  the	  lid	  off	  everything.	  And	  people	  across	  the	  country,	  across	  the	  world,	  were	  informed	  about	  XDR	  and	  about	  the	  challenges	  and	  the	  dangers.”331	  	   Thus	  the	  response	  to	  the	  deaths	  in	  Tugela	  Ferry	  was	  dramatically	  different	  than	  it	  had	  been	  when	  they	  were	  presented	  at	  Conference	  on	  Retrovirals	  and	  Opportunistic	  Infections	  (CROI)	  in	  Denver,	  only	  six	  months	  earlier.	  The	  intellectual	  content	  of	  the	  two	  
                                                329	  Salim	  Abdool	  Karim,	  interview	  by	  author,	  1	  April	  2010,	  Durban,	  South	  Africa.	  The	  exact	  phrase	  he	  used	  was	  “we	  were	  on	  one	  of	  those	  boat	  things	  where	  they	  have	  these	  dinners.”	  330	  Abdool	  Karim,	  interview	  by	  author,	  2010.	  331	  Moll,	  interview	  interview	  by	  author,	  2007.	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presentations	  was	  very	  similar.332	  Thus	  I	  do	  not	  believe	  it	  was	  not	  the	  data	  per	  se	  that	  did	  or	  did	  not	  precipitate	  an	  international	  reaction.	  I	  will	  take	  a	  little	  time	  here	  to	  consider	  some	  of	  the	  reasons	  that	  this	  second	  presentation	  elicited	  such	  a	  response.	  	   Some	  of	  the	  differences	  between	  the	  two	  presentations	  were	  rather	  banal.	  At	  CROI	  the	  group’s	  abstract	  was	  selected	  for	  a	  poster-­‐session,	  while	  at	  the	  AIDS	  conference	  Dr.	  Gandhi	  had	  the	  opportunity	  to	  give	  an	  oral	  presentation	  to	  a	  large	  audience.	  Posters	  often	  take	  a	  back	  stage	  at	  conferences	  compared	  to	  oral	  presentations,	  and	  dedicated	  poster-­‐time	  in	  a	  conference	  schedule	  can	  easily	  turn	  into	  break-­‐time,	  networking-­‐time	  or	  general	  milling-­‐about	  time.	  Even	  a	  compelling	  poster	  might	  easily	  be	  overlooked.	  A	  late-­‐breaker	  oral	  presentation	  session	  at	  the	  International	  AIDS	  Conference,	  on	  the	  other	  hand,	  is	  likely	  to	  attract	  a	  large	  audience	  that	  includes	  members	  of	  the	  press	  who	  are	  looking	  for	  their	  obligatory	  news	  story	  from	  the	  conference.	  In	  addition,	  presentations	  from	  much	  of	  the	  AIDS	  conference	  were	  broadcast	  on	  the	  internet	  and	  were	  summarized	  through	  numerous	  AIDS-­‐related	  websites	  and	  news	  outlets,	  such	  as	  thebody.com.333	  The	  presentation	  from	  Tugela	  Ferry	  was	  briefly	  previewed	  on	  the	  first	  day	  of	  the	  conference	  in	  the	  opening	  issue	  of	  the	  daily	  in-­‐conference	  newspaper	  as	  one	  of	  several	  promising	  late-­‐breaker	  abstracts	  worth	  attending.334	  The	  presentation	  was	  also	  highlighted	  in	  the	  plenary	  on	  the	  last	  day	  of	  the	  conference	  when	  one	  of	  the	  conference	  rapporteurs,	  Dr.	  James	  McIntyre	  (himself	  from	  South	  Africa),	  included	  a	  slide	  from	  Dr.	  Gandhi’s	  talk	  in	  his	  summary	  of	  the	  findings	  of	  scientific	  Track	  B	  -­‐	  Clinical	  Research,	  Treatment	  and	  Care.	  After	  giving	  a	  thirty-­‐second	  summary	  of	  Dr.	  Gandhi’s	  talk	  with	  an	  emphasis	  on	  the	  high	  rates	  of	  XDR-­‐TB	  in	  Tugela	  Ferry	  
                                                332	  There	  were	  differences:	  the	  AIDS	  2006	  presentation	  included	  a	  few	  more	  XDR-­‐TB	  cases	  (53	  vs	  50),	  and	  a	  higher	  mortality	  rate	  (98%	  vs	  84%)	  than	  the	  CROI	  poster.	  333	  Thebody.com	  also	  summarizes	  research	  findings	  from	  CROI	  but	  there	  is	  more	  information	  about	  the	  AIDS	  conference	  broadly	  available	  in	  more	  sources.	  334	  Mark	  Mascolini,	  “Strong	  AIDS	  2006	  Science	  Programme	  Catalogs	  Key	  Advances,”	  The	  Daily	  Voice:	  
The	  Official	  Newspaper	  of	  the	  XVI	  International	  AIDS	  Conference	  (Toronto,	  August	  13,	  2006),	  1	  edition.	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and	  its	  high	  and	  rapid	  mortality,	  Dr.	  McIntyre	  stated	  that	  “drug-­‐resistant	  TB	  and	  HIV	  co-­‐infection	  are	  challenges	  that	  go	  with	  us	  as	  we	  leave	  this	  conference	  and	  require	  much	  more	  research,	  and	  much	  more	  commitment,	  and	  much	  more	  funding.”335	  Overall,	  the	  AIDS	  conference	  provided	  more,	  higher-­‐profile	  exposure	  of	  XDR-­‐TB	  than	  CROI	  did	  (though	  CROI	  also	  is	  a	  large,	  professional	  conference).336	  	   Graeme	  Meintjes,	  a	  South	  African	  physician	  who	  had	  been	  impressed	  by	  Dr.	  Moll’s	  poster	  at	  CROI,	  attributed	  the	  biggest	  difference	  between	  the	  conferences	  to	  the	  role	  of	  journalists	  in	  spreading	  the	  news	  about	  XDR-­‐TB	  in	  South	  Africa.	  Meintjes	  pointed	  out	  that	  scientifically	  speaking,	  the	  group	  in	  Tugela	  Ferry	  had	  essentially	  performed	  observational	  epidemiology,	  which	  usually	  does	  not	  itself	  attract	  much	  attention.	  The	  scientific	  methodology	  was	  not	  innovative	  (or	  particularly	  rigorous),	  researchers	  had	  not	  developed	  a	  new	  drug	  or	  diagnostic	  test,	  and	  there	  was	  no	  commercial	  entity	  that	  would	  market	  the	  results	  to	  the	  medical	  community.	  Instead,	  it	  was	  journalists	  who	  generated	  the	  conversation	  and	  debate	  that	  generated	  a	  communal	  sense	  of	  shock	  among	  biomedical	  experts	  as	  well	  as	  the	  broader	  public.	  “Often	  what	  happens	  nowadays	  is	  […]	  somebody,	  a	  scientist	  or	  a	  medical	  academic,	  will	  speak	  to	  [a	  journalist]	  and	  say	  ‘this	  is	  a	  major	  story.’	  And	  when	  [XDR-­‐TB]	  hit	  the	  news,	  that	  was	  when	  people	  really	  started	  speaking	  about	  it.	  I	  guess	  it’s	  just	  a	  critical	  mass.	  Because	  individually,	  I’m	  sure	  a	  lot	  of	  people	  found	  it	  shocking.	  
                                                335	  James	  McIntyre,	  “Track	  B:	  Clinical	  Research,	  Treatment	  and	  Care.	  Track	  B	  Rapporteur	  Presentation”	  (Powerpoint	  presented	  at	  the	  XVI	  International	  AIDS	  Conference,	  Toronto,	  August	  18,	  2006).	  Also	  see	  podcast	  of	  presentation:	  “Rapporteur	  Summary	  Session,	  August	  18,	  2006,"	  on	  XVI	  
International	  AIDS	  Conference:	  English	  Podcast	  (podcast),	  downloaded	  from	  itunes	  in	  April	  2007	  .	  336	  It’s	  worth	  pointing	  out	  that	  the	  first	  author	  of	  the	  poster	  at	  CROI	  was	  Dr.	  Moll,	  a	  non-­‐academic	  South	  African	  physician	  at	  a	  rural	  hospital,	  and	  at	  the	  AIDS	  meeting	  the	  first	  author	  was	  listed	  as	  Dr.	  Gandhi	  (who	  was	  a	  striving	  young	  academic	  physician	  from	  the	  US).	  I	  don’t	  know	  how	  this	  change	  in	  authorship	  was	  negotiated	  but	  it	  is	  probably	  significant.	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But	  you	  know,	  it	  kind	  of	  took	  six	  months	  for	  people	  to	  speak	  to	  each	  other,	  and	  I	  think	  that	  step	  of	  medical	  journalists	  highlighting	  it	  is	  what	  really	  [brought]	  it	  to	  the	  fore.”337	  	   While	  this	  is	  a	  much	  simplified	  view	  of	  how	  scientists	  and	  the	  journalists	  who	  report	  on	  them	  relate,	  Meintjes’	  explanation	  hints	  at	  how	  important	  mass	  media	  were	  not	  only	  for	  communicating	  the	  importance	  of	  XDR-­‐TB	  to	  the	  lay	  public,	  including	  potential	  global	  health	  funders	  and	  policy	  makers,	  but	  also	  to	  expert	  tuberculosis	  scientists,	  AIDS	  researchers,	  public	  health	  specialists	  and	  clinicians	  who	  themselves	  shaped	  TB	  research.	  Sociologists	  of	  science	  have	  argued	  that	  lay	  representations	  and	  popularizations	  of	  science	  play	  a	  key	  role	  in	  diffusing	  scientific	  concepts	  within	  and	  across	  disciplinary	  boundaries,	  allowing	  the	  acceleration	  of	  scientific	  communication,	  setting	  the	  tone	  of	  scientific	  debates,	  and	  supporting	  or	  undermining	  the	  authority	  of	  individual	  researchers	  and	  their	  work.338	  As	  Bruce	  Lewenstein	  puts	  it:	  “science	  communication	  is	  not	  a	  linear	  process	  from	  field	  or	  lab	  to	  certified	  “science”	  published	  in	  journals,	  and	  only	  then	  followed	  by	  public	  communication.	  Rather,	  science	  communication	  is	  a	  “web”	  of	  interactions	  among	  different	  actors	  and	  formats.”339	  Media	  coverage	  of	  science	  is	  rarely	  simply	  the	  result	  of	  a	  casual	  conversation	  between	  scientists	  and	  journalists.	  Rather,	  the	  coverage	  is	  often	  very	  actively	  sought	  by	  scientists	  and	  other	  researchers	  –	  often	  using	  formal	  and	  professional	  public	  relations	  strategies	  –	  as	  a	  tool	  with	  which	  to	  promote	  careers	  and	  scientific	  work.	  For	  example,	  Jerome	  Singh,	  a	  South	  African	  bioethicist	  who	  co-­‐authored	  an	  influential	  opinion-­‐piece	  on	  
                                                337	  Meintjes,	  interview	  by	  author,	  14	  May	  2010.	  338	  Danette	  Paul,	  “Spreading	  Chaos:	  The	  Role	  of	  Popularizations	  in	  the	  Diffusion	  of	  Scientific	  Ideas,”	  
Written	  Communication	  21	  (2004):	  32-­‐68;	  Bruce	  V.	  Lewenstein,	  “From	  Fax	  to	  Facts:	  Communication	  in	  the	  Cold	  Fusion	  Saga,”	  Social	  Studies	  of	  Science	  25,	  no.	  3	  (1995):	  403-­‐436;	  Bruce	  V.	  Lewenstein,	  “Cold	  Fusion	  and	  Hot	  History,”	  Osiris	  7(1992):	  	  135-­‐163;	  Stephen	  Hilgartner,	  “The	  Dominant	  View	  of	  Popularization:	  Conceptual	  Problems,	  Political	  Uses,”	  Social	  Studies	  of	  Science	  20,	  no.	  3	  (1990):	  519-­‐539.	  339	  Bruce	  V.	  Lewenstein,	  “Experimenting	  with	  Engagement,”	  Science	  and	  Engineering	  Ethics	  17	  (2011):	  819.	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XDR-­‐TB	  in	  the	  biomedical	  journal	  PLoS	  Med	  in	  January	  2007,	  about	  half	  a	  year	  after	  the	  AIDS	  conference,	  felt	  that	  much	  of	  the	  international	  interest	  in	  XDR-­‐TB	  was	  in	  fact	  generated	  and	  sustained	  by	  coverage	  of	  his	  paper.	  He	  explained	  to	  me	  that	  his	  Canadian	  coauthor	  had	  hired	  a	  public	  relations	  professional	  (a	  “press	  liaison	  officer”)	  through	  his	  academic	  institution.	  340	  This	  person	  was	  tasked	  with	  promoting	  the	  paper,	  scheduling	  media	  appearances	  and	  documenting	  how	  much	  media	  coverage	  the	  paper	  received.	  The	  reports	  he	  generated	  compared	  the	  amount	  of	  coverage	  received	  with	  the	  amount	  of	  money	  that	  would	  have	  been	  required	  to	  pay	  for	  that	  same	  coverage	  in	  form	  of	  advertising.	  As	  Singh	  remembered	  it,	  the	  value	  of	  the	  coverage	  quoted	  to	  him	  around	  two	  or	  three	  weeks	  after	  his	  article	  was	  first	  published	  “worked	  out	  to	  something	  like	  $7.5	  million	  dollars.	  […]	  So	  it	  was	  quite	  phenomenal.”341	  
	   Major	  (and	  minor)	  biomedical	  conferences	  like	  the	  International	  AIDS	  conference	  not	  only	  have	  paper	  presentations	  and	  plenary	  lectures	  which	  pass-­‐carrying	  journalists	  are	  welcome	  to	  attend,	  but	  also	  feature	  press	  conferences	  where	  paper	  presenters	  and	  their	  collaborators	  make	  themselves	  available	  for	  questions	  from	  the	  media,	  especially	  if	  broad	  interest	  is	  anticipated.	  Sometimes	  these	  press	  conferences	  take	  place	  in	  the	  more	  nebulous	  form	  of	  conference	  calls	  or	  online	  web-­‐chats.	  Once	  findings	  are	  about	  to	  be	  published,	  major	  journals	  also	  issue	  press	  statements	  and	  organize	  conference	  calls.	  It	  is	  at	  events	  like	  these	  that	  journalists	  often	  get	  quotes	  from	  experts	  who	  summarize	  the	  salient	  features	  of	  the	  issue	  at	  hand.	  Most	  early	  reports	  about	  Neel	  Gandhi’s	  presentation	  at	  the	  International	  AIDS	  Conference,	  for	  example,	  contained	  quotes	  from	  Dr.	  Gerald	  Friedland	  regarding	  the	  dangers	  of	  XDR-­‐TB	  in	  South	  Africa.	  In	  the	  case	  of	  XDR-­‐TB,	  the	  high-­‐profile	  placement	  of	  Gandhi’s	  talk,	  the	  dramatic	  nature	  of	  the	  results	  (including	  the	  mortality	  rate	  of	  98%),	  the	  broad	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interest	  of	  the	  AIDS	  community	  in	  the	  location	  of	  South	  Africa	  and	  successful	  use	  of	  PR	  strategies	  combined	  to	  generate	  a	  strong	  response	  from	  the	  media.	  It	  also	  helped	  that	  multiple	  agency’s	  representatives	  (including	  WHO	  and	  CDC)	  were	  available	  for	  comment	  at	  the	  same	  conferences,	  as	  is	  evident	  in	  some	  of	  the	  press	  coverage.	  
Emergency	  expert	  consultation	  meeting	  	   The	  response	  to	  Dr.	  Gandhi’s	  presentation	  in	  Toronto	  was	  impressive,	  but	  it	  could	  be	  argued	  that	  it	  wasn’t	  until	  later	  that	  the	  extensive	  interest	  in	  XDR-­‐TB	  truly	  became	  apparent.	  At	  the	  AIDS	  conference,	  those	  who	  were	  interested	  in	  learning	  more	  were	  directed	  to	  a	  global	  expert	  consultation	  on	  XDR-­‐TB	  that	  was	  scheduled	  to	  take	  place	  in	  Johannesburg,	  South	  Africa	  on	  September	  7-­‐8	  2006.	  This	  expert	  consultation	  (also	  called	  an	  emergency	  consultation	  by	  some	  sources)	  was	  hosted	  by	  the	  South	  African	  Medical	  Research	  Council	  (MRC)	  in	  Johannesburg	  and	  was	  funded	  mostly	  by	  the	  CDC,	  who	  had	  a	  long-­‐standing	  relationship	  with	  tuberculosis	  researchers	  at	  the	  MRC.	  As	  Dr.	  Kenneth	  Castro,	  director	  of	  the	  Division	  of	  Tuberculosis	  (TB)	  Elimination	  in	  the	  National	  Center	  for	  HIV,	  STD,	  and	  TB	  Prevention	  at	  the	  CDC,	  explained,	  “we	  had	  the	  linkages	  [in	  South	  Africa]	  with	  Karin	  Weyer	  who	  was	  there	  as	  the	  lead	  laboratorian	  [sic],	  so	  by	  the	  time	  this	  whole	  thing	  happened,	  we	  were	  able	  to	  agree,	  [that]	  we	  can’t	  wait	  long.	  	  […]	  The	  classic	  scenario	  that	  we	  see	  in	  federal	  government	  is	  that	  at	  the	  end	  of	  the	  year	  you	  end	  up	  finding	  some	  unobligated	  dollars	  that	  had	  been	  appropriated	  but	  hadn’t	  been	  spent	  for	  whatever	  reason,	  and	  so	  I	  said,	  oh,	  I	  can	  contribute.	  So	  we	  ended	  up	  transferring	  to	  them	  $50,000	  to	  pull	  this	  meeting	  together,	  and	  recruiting	  a	  bunch	  of	  us	  who	  flew	  there	  to	  be	  a	  part	  of	  that”	  meeting	  to	  provide	  technical	  expertise.342	  	   Many	  of	  the	  people	  who	  attended	  this	  meeting	  described	  it	  as	  an	  intense,	  even	  frenzied	  experience.	  While	  some	  of	  the	  international	  and	  South	  African	  participants	  already	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knew	  each	  other	  from	  past	  collaborations	  and	  conference	  interactions,	  it	  also	  became	  an	  opportunity	  for	  individuals	  who	  had	  not	  been	  as	  involved	  in	  existing	  US-­‐South	  African	  tuberculosis	  research	  networks	  to	  make	  their	  presence	  known.	  This	  is	  where	  Dr.	  Holtz	  (who	  worked	  for	  the	  CDC	  and	  had	  been	  engaged	  in	  TB	  research	  projects	  in	  South	  Africa,	  but	  not	  in	  KwaZulu-­‐Natal)	  met	  Prof.	  Sturm	  (who	  was	  a	  leading	  figure	  in	  academia	  and	  tuberculosis	  research	  in	  KwaZulu-­‐Natal),	  for	  example.	  As	  Holtz	  recalled:	  “We	  had	  this	  emergency	  meeting	  in	  September,	  by	  which	  we	  pulled	  together	  a	  lot	  of	  global	  experts	  to	  talk	  about	  the	  problem	  in	  South	  Africa.	  […]	  It	  was	  then	  that	  we	  really	  got	  to	  meet	  some	  of	  the	  other	  important	  players	  in	  the	  issue,	  particularly	  a	  guy	  named	  Willem	  Sturm	  who	  is	  a	  […]	  pretty	  high	  up	  administrator	  in	  the	  medical	  school.	  	  […]	  He’s	  also	  a	  force	  to	  be	  reckoned	  with.	  He	  really	  wanted	  to	  take	  charge	  of	  the	  microbiologic	  issues	  surrounding	  the	  strain	  that	  he	  had	  since	  looked	  at	  in	  Tugela	  Ferry,	  and	  he’s	  done	  a	  lot	  of	  genotyping	  work	  in	  his	  laboratory	  and	  started	  calling	  it	  the	  KwaZulu-­‐Natal	  strain	  without	  really	  talking	  to	  anybody.	  […]	  It	  was	  the	  first	  time	  we	  all	  met	  him.”343	  	  	   This	  last	  comment	  provides	  a	  clue	  regarding	  the	  contested	  power	  to	  name	  diseases	  and	  molecular	  entities	  and	  the	  importance	  of	  generating	  a	  consensus	  around	  such	  new	  names.	  Dr.	  Holtz	  had	  himself	  just	  recently	  named	  XDR-­‐TB,	  though	  he	  certainly	  would	  not	  describe	  himself	  as	  having	  done	  it	  “without	  really	  talking	  to	  anybody.”	  As	  described	  in	  chapter	  1,	  he	  had	  been	  involved	  in	  a	  series	  of	  meetings	  and	  consultations	  with	  numerous	  experts	  and	  stakeholders	  before	  the	  name	  and	  definition	  of	  XDR-­‐TB	  was	  finally	  solidified.	  Yet	  among	  the	  initial	  responses	  to	  the	  publication	  of	  the	  first	  paper	  on	  the	  global	  XDR-­‐TB	  survey	  there	  were	  some	  who	  expressed	  some	  discontent	  at	  not	  having	  themselves	  been	  consulted	  in	  the	  generation	  of	  this	  new	  disease	  entity.	  Researchers	  from	  Spain,	  Norway	  and	  Iran	  wrote	  brief	  papers	  pointing	  out	  their	  own	  studies	  in	  which	  they	  had	  found	  similar	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cases;	  letters	  to	  the	  editorial	  sections	  of	  scientific	  journals	  asked	  what	  the	  utility	  of	  the	  new	  definition	  was.	  Dr.	  Abdool	  Karim	  recalled	  that	  “interestingly	  a	  whole	  lot	  of	  people	  thought	  the	  use	  of	  X	  in	  the	  XDR	  was	  like	  a	  hype.	  In	  that	  it	  should	  be	  EDR	  not	  XDR!”344	  The	  power	  of	  the	  CDC	  and	  the	  WHO	  to	  name,	  define,	  and	  endorse	  such	  a	  disease	  was	  not	  really	  in	  doubt,	  however.	  Back	  in	  Johannesburg,	  the	  expert	  consultation	  meeting	  on	  XDR-­‐TB	  turned	  out	  to	  be	  a	  political	  tight	  rope	  act	  for	  Dr.	  Karin	  Weyer,	  of	  the	  South	  African	  Medical	  Research	  council	  (MRC).345	  She	  was	  the	  “head	  laboratorian”	  Castro	  mentioned	  who	  organized	  the	  meeting.	  The	  WHO’s	  HIV/TB	  department’s	  Paul	  Nunn	  who	  attended	  from	  Geneva	  described	  her	  as	  having	  organized	  the	  event	  somewhat	  “in	  the	  teeth”	  of	  the	  South	  African	  department	  of	  health,346	  who,	  according	  to	  another	  MRC	  researcher	  were	  “very	  upset	  that	  MRC	  held	  that	  meeting.”347	  	   According	  to	  Dr.	  Weyer,	  the	  MRC	  had	  been	  aware	  of	  the	  MDR-­‐TB	  problem	  in	  Tugela	  Ferry	  for	  about	  a	  year	  before	  the	  September	  2006	  meeting.	  In	  fact,	  the	  department	  of	  health	  of	  KwaZulu-­‐Natal	  had	  asked	  the	  MRC	  (which	  is	  not	  itself	  a	  government	  agency,	  but	  had	  taken	  a	  lot	  of	  responsibility	  for	  the	  South	  African	  tuberculosis	  program	  in	  the	  past)	  to	  help	  the	  province	  in	  investigating	  the	  Tugela	  Ferry	  outbreak.	  The	  MRC	  had	  suggested	  working	  together	  with	  the	  CDC	  under	  an	  existing	  cooperative	  agreement,	  yet	  the	  province	  of	  KwaZulu-­‐Natal	  insisted	  instead	  that	  involving	  the	  CDC	  in	  this	  case	  required	  an	  additional	  formal	  invitation	  from	  the	  national	  department	  of	  health	  to	  the	  CDC.348	  In	  the	  meantime,	  the	  CDC	  and	  WHO	  asked	  Dr.	  Weyer	  to	  organize	  an	  expert	  consultation	  meeting,	  and	  the	  MRC	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  works	  for	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was	  among	  the	  groups	  encouraging	  the	  researchers	  in	  Tugela	  Ferry	  to	  present	  their	  findings	  at	  international	  conferences	  and	  publish	  them.	  According	  to	  Dr.	  Weyer,	  she	  (and	  by	  implication	  the	  department	  of	  health)	  was	  kept	  informed	  of	  the	  upcoming	  presentation	  at	  the	  International	  AIDS	  Conference:	  “We	  knew	  this	  was	  coming.”349	  	   For	  the	  September	  2006	  expert	  consultation,	  Dr.	  Weyer	  invited	  representatives	  from	  all	  nine	  South	  African	  provincial	  departments	  of	  health,	  as	  well	  as	  the	  managers	  of	  the	  South	  African	  National	  TB	  Program	  and	  their	  supervisors.350	  In	  addition	  to	  CDC	  and	  WHO	  colleagues,	  representatives	  from	  other	  Southern	  African	  Development	  Community	  (SADC)	  countries	  were	  also	  included.351	  The	  participation	  of	  the	  South	  African	  national	  department	  of	  health	  was	  confirmed	  until	  two	  days	  before	  the	  meeting,	  when	  the	  office	  of	  the	  Minister	  of	  Health	  requested	  via	  the	  National	  TB	  Program	  that	  the	  expert	  consultation	  be	  canceled.	  By	  this	  time,	  the	  press	  had	  already	  started	  reacting	  to	  Dr.	  Gandhi’s	  presentation	  that	  had	  occurred	  on	  August	  17,	  only	  two	  weeks	  before,	  so	  it	  may	  be	  that	  the	  government	  was	  trying	  to	  shut	  down	  a	  press	  reaction	  that	  they	  would	  be	  unable	  to	  control.	  Since	  it	  was	  too	  short	  notice	  to	  cancel	  the	  meeting,	  Dr.	  Weyer	  decided	  to	  proceed	  anyway.	  Interestingly,	  representatives	  from	  all	  nine	  South	  African	  provinces	  still	  attended	  the	  meeting,	  even	  though	  the	  national	  department	  of	  health	  was	  not	  represented	  at	  a	  high	  level.	  Dr.	  Weyer	  saw	  this	  as	  evidence	  that	  the	  provincial	  departments	  were	  very	  concerned	  about	  XDR-­‐TB	  and	  were	  not	  willing	  to	  ignore	  it.352	  
                                                349	  Weyer,	  interview	  by	  author,	  2010.	  350	  “National	  TB	  Program”	  is	  standardized	  language	  used	  by	  the	  WHO	  to	  describe	  just	  that;	  it	  is	  usually	  abbreviated	  “NTP.”	  351	  Member	  states	  of	  the	  Southern	  African	  Development	  Community	  include	  Angola,	  Botswana*,	  Democratic	  Republic	  of	  Congo,	  Lesotho*,	  Malawi*,	  Mauritius,	  Mozambique*,	  Namibia*,	  Seychelles,	  South	  Africa,	  Swaziland*,	  Tanzania,	  Zambia,	  Zimbabwe*).	  Seven	  of	  these	  (followed	  by	  *)	  are	  direct	  neighbors	  of	  South	  Africa.	  352	  Weyer,	  interview	  by	  author,	  2010.	  
 136 
	   The	  real	  surprise,	  however,	  was	  the	  degree	  of	  interest	  that	  the	  press	  showed	  in	  this	  particular	  meeting.	  According	  to	  Dr.	  Weyer,	  the	  MRC	  put	  out	  a	  press	  advisory	  about	  the	  event	  the	  day	  before,	  as	  it	  usually	  would.	  The	  organizers	  had	  booked	  a	  room	  for	  twelve	  journalists	  for	  half	  an	  hour.	  In	  fact,	  more	  than	  40	  journalists,	  including	  some	  from	  major	  international	  media	  outlets	  like	  CNN	  and	  BBC	  appeared	  for	  the	  press	  conference,	  which	  lasted	  an	  hour	  and	  a	  half.	  The	  department	  of	  health	  had	  not	  allowed	  the	  press	  to	  visit	  the	  TB	  program	  in	  Tugela	  Ferry,353	  making	  the	  journalists	  even	  more	  eager,	  and	  making	  the	  absence	  of	  the	  national	  department	  of	  health	  (and	  of	  the	  Minister	  of	  Health	  or	  her	  representative,	  specifically)	  from	  this	  press	  conference	  even	  more	  apparent.	  It	  seemed	  that	  the	  initial	  press	  coverage	  after	  the	  International	  AIDS	  Conference	  combined	  with	  the	  South	  African	  department	  of	  health’s	  inclination	  towards	  secrecy	  made	  XDR-­‐TB	  even	  more	  interesting	  to	  local	  and	  international	  media	  outlets.	  	   The	  WHO	  representatives	  who	  attended	  the	  meeting	  were	  keenly	  aware	  of	  the	  potential	  political	  sensitivity	  of	  this	  meeting,	  especially	  considering	  MDR-­‐TB’s	  (and	  by	  extension	  XDR-­‐TB’s)	  status	  as	  a	  WHO	  indicator	  of	  public	  health	  system	  failure.354	  In	  light	  of	  the	  absence	  of	  high	  level	  national	  level	  South	  African	  department	  of	  health	  representatives	  at	  the	  meeting,	  Paul	  Nunn,	  the	  coordinator	  of	  TB/HIV	  activities	  at	  WHO	  in	  Geneva,	  decided	  to	  have	  his	  subordinate,	  Ernesto	  Jaramillo,	  represent	  him	  at	  the	  event’s	  official	  press	  conference.355	  The	  meeting	  achieved	  significant	  coverage	  in	  the	  scientific	  and	  lay	  press.	  Timothy	  Holtz	  remembered	  Paul	  Nunn	  “running	  around	  all	  day	  doing	  interviews...	  with	  the	  BBC,	  on	  CNN,	  and	  it	  was	  just	  kind	  of	  a	  surreal	  situation.	  […]	  I	  remember	  going	  over	  to	  the	  TV	  station	  and	  Paul	  Nunn	  was	  being	  interviewed	  by	  the	  BBC	  in	  this	  small	  little	  media	  room,	  and	  I	  just	  remember	  it	  just	  seemed	  like	  non-­‐stop.	  The	  attention,	  it	  just	  kept	  going	  on	  and	  on	  and	  
                                                353	  Anthony	  Moll,	  interview	  by	  author,	  13	  May	  2011,	  Tugela	  Ferry,	  South	  Africa.	  354	  Jaramillo,	  interview	  by	  author,	  2010.	  355	  Jaramillo,	  interview	  by	  author,	  2010.	  
 137 
on	  everyday	  there	  was	  someone	  else	  who	  wanted	  to	  talk	  to	  us	  about	  this	  problem.	  And	  that’s	  when	  I	  think	  we	  all	  realized	  that	  this	  really	  was	  something	  that	  we	  could	  harness	  and	  benefit	  from,	  call	  attention	  to	  the	  problem	  of	  drug	  resistance	  and	  try	  to	  get	  more	  resources	  for	  the	  fight	  against	  drug	  resistant	  tuberculosis.”356	  	  	   Though	  the	  press	  conference	  and	  interviews	  were	  not	  the	  only	  events	  at	  this	  two-­‐day	  meeting,	  they	  did	  help	  fulfill	  some	  of	  the	  aims	  of	  the	  consultation	  as	  they	  were	  stated	  afterwards	  in	  a	  brief	  report	  generated	  by	  the	  WHO.357	  According	  to	  the	  report,	  the	  WHO	  aimed	  to	  “call	  attention	  to	  the	  problem	  of	  TB	  drug	  resistance	  in	  SADC	  countries”	  and	  “call	  attention	  to	  the	  WHO	  Guidelines	  for	  Programmatic	  Management	  of	  TB	  Drug	  Resistance,	  launched	  in	  May	  2006,”	  –	  both	  of	  these	  goals	  benefitted	  from	  publicity.	  	  In	  addition,	  formal	  presentations	  and	  discussions	  on	  the	  topics	  of	  “epidemiology	  and	  surveillance	  of	  drug-­‐resistant	  TB,	  programmatic	  management	  of	  such	  patients,	  drug-­‐resistant	  TB	  outbreaks,	  and	  infection	  control	  measures	  needed	  within	  the	  context	  of	  high-­‐burden	  HIV	  settings”	  helped	  to	  achieve	  other	  stated	  aims.358	  These	  were	  to	  “define	  the	  gaps	  in	  surveillance	  of	  TB	  drug	  resistance	  in	  the	  region;”	  	  “define	  essential	  components	  of	  TB	  infection	  control,	  particularly	  in	  high-­‐HIV	  prevalence	  settings;”	  and	  “identify	  the	  steps	  necessary	  for	  SADC	  countries	  to	  effectively	  address	  the	  problem	  of	  drug-­‐resistant	  TB.”359	  	   Interestingly,	  the	  meeting’s	  published	  aims	  attempted	  to	  spread	  the	  attention	  across	  countries	  of	  the	  Southern	  African	  Development	  Community	  (SADC)	  generally,	  rather	  than	  place	  the	  onus	  directly	  on	  South	  Africa.	  Despite	  the	  WHO’s	  attempts	  to	  be	  sensitive	  and	  not	  single	  out	  South	  Africa	  as	  the	  source	  of	  the	  XDR-­‐TB	  problem,	  however,	  it	  seemed	  that	  the	  South	  African	  government’s	  strategy	  to	  avoid	  controversy	  had	  backfired.	  According	  to	  Dr.	  
                                                356	  Holtz,	  interview	  by	  author,	  2010.	  357	  “WHO	  |	  Report	  from	  the	  Expert	  Consultation	  on	  Drug-­‐Resistant	  Tuberculosis,”	  accessed	  March	  6,	  2012,	  http://www.who.int/tb/features_archive/johannesburg_report/en/index.html.	  358	  Ibid.	  359	  Ibid.	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Weyer	  the	  expert	  consultation	  and	  the	  extensive	  press	  coverage	  which	  emerged	  from	  it	  opened	  up	  the	  National	  Department	  of	  Health	  for	  criticism,	  and	  the	  department	  was	  accused	  of	  “trying	  to	  hide	  the	  problem	  and	  not	  paying	  enough	  attention	  as	  was	  warranted.”360	  In	  response	  to	  this	  criticism,	  “the	  national	  department	  of	  health	  organized	  another	  consultation	  with	  the	  SADC	  countries	  as	  well	  as	  the	  nine	  provinces	  one	  month	  later,”	  this	  time	  in	  Pretoria.	  Once	  again,	  the	  MRC,	  CDC	  and	  WHO	  attended.361	  In	  an	  effort	  to	  appear	  proactive,	  the	  Johannesburg	  meeting	  had	  issued	  a	  7-­‐point	  action	  plan.362	  The	  seven	  proposed	  actions	  included	  the	  conduction	  of	  epidemiological	  surveys,	  the	  enhancement	  of	  laboratory	  capacity,	  the	  improvement	  of	  the	  technical	  skills	  of	  public	  health	  managers,	  the	  implementation	  of	  infection	  control	  measures,	  increased	  research	  for	  anti-­‐TB	  drug	  development,	  increased	  research	  for	  diagnostic	  test	  development,	  and	  improved	  access	  to	  HIV	  and	  TB	  drugs	  in	  joint	  programs.363	  In	  the	  short	  term,	  especially	  the	  points	  about	  increasing	  anti-­‐TB	  drug	  and	  diagnostics	  research	  seemed	  unrealistically	  ambitious	  and	  beyond	  the	  control	  of	  those	  attending	  the	  meeting.364	  The	  plan	  showed	  the	  imprint	  of	  the	  scientific	  and	  technical	  experts	  at	  the	  meeting	  by	  focusing	  almost	  entirely	  on	  technical,	  knowledge-­‐based	  interventions.	  The	  report	  resulting	  from	  the	  meeting	  did	  not	  reflect	  any	  consideration	  of	  the	  reasons	  why	  South	  Africa	  and	  Tugela	  Ferry	  suffered	  from	  such	  high	  rates	  of	  tuberculosis	  to	  begin	  with,	  and	  did	  not	  engage	  with	  the	  fact	  that	  
                                                360	  Weyer,	  interview	  by	  author,	  2010.	  361	  Ibid.	  362	  Willem	  Sturm,	  interview	  by	  author,	  26	  May	  2010,	  Durban,	  South	  Africa;	  SAMRC,	  “Media	  Statement,	  8	  September	  2006:	  Seven	  Point	  Emergency	  Action	  Plan	  to	  Combat	  XDR-­‐TB	  Issued	  by	  Global	  Health	  Agencies,”	  September	  8,	  2006,	  www.mrc.ac.za/pressreleases/2006/8pres2006.htm.	  363	  SAMRC,	  “Media	  Statement,	  8	  September	  2006:	  Seven	  Point	  Emergency	  Action	  Plan	  to	  Combat	  XDR-­‐TB	  Issued	  by	  Global	  Health	  Agencies.”	  364	  In	  hindsight	  the	  progress	  made	  in	  these	  domains	  on	  a	  global	  level	  is	  actually	  quite	  impressive	  and	  include	  the	  development	  of	  novel	  diagnostic	  techniques,	  new	  drugs	  which	  are	  currently	  in	  clinical	  trials,	  and	  new	  insights	  into	  effective	  infection	  control	  measures.	  
 139 
tuberculosis	  is	  well	  known	  to	  be	  a	  disease	  which	  thrives	  in	  conditions	  of	  poverty	  and	  deprivation	  and	  which	  responds	  well	  to	  improved	  living	  conditions.365	  
The	  WHO	  task-­‐force	  on	  XDR-­‐TB	  	   The	  most	  concrete	  outcome	  of	  the	  meeting	  in	  Johnannesburg	  was	  the	  convening	  of	  another	  meeting:	  the	  global	  WHO	  task-­‐force	  on	  XDR-­‐TB	  met	  at	  WHO	  headquarters	  in	  Geneva,	  Switzerland	  (more	  politically	  neutral	  territory	  than	  South	  Africa)	  on	  October	  9-­‐10,	  2006	  to	  deal	  with	  specific	  epidemiology,	  policy,	  and	  advocacy	  questions	  regarding	  XDR-­‐TB.	  According	  to	  the	  Report	  of	  the	  meeting	  of	  the	  WHO	  global	  task	  force	  on	  XDR-­‐TB,	  “more	  than	  110	  participants	  representing	  the	  most	  affected	  countries	  attended	  the	  meeting,	  together	  with	  global	  experts	  in	  TB	  control	  and	  MDR-­‐TB	  management;	  HIV	  prevention,	  care	  and	  control;	  infection	  control	  and	  occupational	  health;	  communicable	  disease	  preparedness	  and	  response;	  advocacy,	  communication	  and	  social	  mobilization	  (ACSM);	  and	  representatives	  from	  bilateral	  and	  multilateral	  agencies	  and	  organizations.”366	  	   The	  September	  meeting	  in	  Johannesburg,	  South	  Africa	  and	  the	  October	  meeting	  in	  Geneva,	  Switzerland	  demonstrated	  that	  the	  WHO	  and	  CDC,	  among	  others,	  had	  decided	  to	  take	  on	  XDR-­‐TB	  as	  an	  important	  issue	  which	  had	  momentum	  that	  could	  be	  built	  on	  relatively	  quickly.	  An	  emphasis	  was	  placed	  on	  urgency.	  The	  stated	  goal	  of	  the	  task-­‐force	  meeting	  in	  Geneva	  was	  to	  “define	  key	  issues,	  make	  recommendations	  and	  propose	  urgent	  actions	  required	  in	  the	  next	  three	  to	  six	  months.”367	  People	  attending	  the	  meeting	  (some	  of	  whom	  had	  been	  involved	  in	  the	  discussions	  about	  XDR-­‐TB	  from	  the	  very	  beginning,	  while	  others	  were	  only	  just	  being	  introduced	  to	  the	  concept)	  were	  brought	  on	  the	  same	  page	  with	  
                                                365	  SAMRC,	  “Media	  Statement,	  8	  September	  2006:	  Seven	  Point	  Emergency	  Action	  Plan	  to	  Combat	  XDR-­‐TB	  Issued	  by	  Global	  Health	  Agencies”;	  Thomas	  McKeown	  and	  R.	  G.	  Record,	  “Reasons	  for	  the	  Decline	  of	  Mortality	  in	  England	  and	  Wales	  During	  the	  Nineteenth	  Century,”	  Population	  Studies	  16	  (1962):	  94–122.	  366	  WHO,	  Report	  of	  the	  Meeting	  of	  the	  WHO	  Global	  Task	  Force	  on	  XDR-­‐TB	  (Geneva,	  Switzerland:	  World	  Health	  Organization,	  October	  2006),	  1.	  367	  WHO,	  Report	  of	  the	  Meeting	  of	  the	  WHO	  Global	  Task	  Force	  on	  XDR-­‐TB,	  2.	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presentations	  by	  key	  players,	  including	  Sarita	  Shah	  (CDC),	  Paul	  Nunn	  (WHO),	  Tony	  Moll	  (Tugela	  Ferry),	  and	  Ernesto	  Jaramillo	  (WHO),	  among	  others.	  These	  speakers	  set	  the	  stage	  for	  framing	  XDR-­‐TB	  as	  a	  global	  crisis	  that	  affected	  the	  broader,	  global	  public	  health	  community,	  and	  the	  global	  AIDS	  community,	  in	  particular.	  Geographically,	  the	  emphasis	  of	  the	  background	  presentations	  at	  the	  meeting	  was	  on	  Estonia,	  Latvia,	  Peru	  and	  the	  Philippines.	  These	  countries	  had	  in	  previous	  times	  been	  the	  focus	  of	  MDR-­‐TB	  concerns	  in	  global	  discussions	  and	  were	  now	  seen	  as	  model	  countries	  for	  the	  management	  of	  MDR-­‐TB.	  In	  addition,	  three	  Southern	  African	  countries	  (Lesotho,	  South	  African	  and	  Swaziland)	  were	  now	  introduced	  as	  the	  new	  loci	  of	  concern	  with	  regards	  to	  drug	  resistant	  tuberculosis.	  While	  the	  reports	  from	  South	  Africa	  were	  the	  main	  motivator	  for	  this	  meeting,	  the	  focus	  was	  again	  diffused	  in	  part	  onto	  its	  neighboring	  countries.368	  For	  parts	  of	  the	  XDR-­‐TB	  taskforce	  meeting	  participants	  were	  split	  into	  groups	  to	  address	  the	  different	  topics	  of	  XDR-­‐TB	  management	  and	  surveillance,	  infection	  control,	  the	  protection	  of	  health	  workers;	  advocacy,	  communication	  and	  social	  mobilization,	  as	  well	  as	  the	  laboratory	  definition	  of	  XDR-­‐TB.	  The	  WHO	  had	  taken	  an	  active	  role	  in	  the	  past	  of	  increasing	  the	  epidemiological	  surveillance	  of	  tuberculosis	  (the	  use	  of	  Supranational	  Reference	  Laboratories	  to	  keep	  track	  of	  drug-­‐resistant	  tuberculosis	  is	  one	  such	  example)	  and	  in	  issuing	  policy	  recommendations	  for	  the	  operational	  and	  clinical	  management	  of	  tuberculosis	  (with	  DOTS,	  in	  particular,	  being	  the	  WHO’s	  flagships	  TB	  program).	  The	  WHO	  also	  has	  a	  long	  history	  of	  involvement	  in	  standardizing	  biomedical	  terminology.369	  Thus,	  the	  key	  domains	  of	  discussion	  identified	  for	  this	  taskforce	  meeting	  were	  in	  keeping	  with	  the	  WHO’s	  traditional	  roles	  in	  shaping	  action	  around	  disease.	  
                                                368	  WHO,	  Report	  of	  the	  Meeting	  of	  the	  WHO	  Global	  Task	  Force	  on	  XDR-­‐TB.	  	  369	  Joanna	  Radin,	  “Life	  on	  Ice:	  Frozen	  Blood	  and	  Biological	  Variation	  in	  a	  Genomic	  Age,	  1950-­‐2010”	  (Doctoral	  Dissertation,	  University	  of	  Pennsylvania,	  2012).	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The	  definition	  of	  XDR-­‐TB	  –	  once	  again,	  a	  problem	  The	  most	  significant	  decision	  at	  the	  XDR-­‐TB	  taskforce	  meeting	  emerged	  from	  the	  group	  that	  discussed	  the	  laboratory	  definition	  of	  XDR-­‐TB.	  Laboratory	  specialists,	  researchers	  and	  policy	  makers	  had	  started	  to	  think	  of	  the	  existing	  definition	  for	  XDR-­‐TB	  as	  a	  problem.	  As	  we	  have	  seen,	  the	  standing	  definition	  for	  XDR-­‐TB	  had	  been	  solidified,	  after	  much	  negotiation,	  around	  Dr.	  Shah	  and	  Dr.	  Holtz’s	  research	  (under	  the	  leadership	  of	  Dr.	  Peter	  Cegielski),	  and	  was	  published	  in	  Morbidity	  and	  Mortality	  Weekly	  Report	  (MMWR)	  in	  March	  2006	  as	  MDR-­‐TB	  plus	  resistance	  to	  3	  out	  of	  6	  classes	  of	  second	  line	  anti-­‐TB	  drugs.370	  Yet	  by	  October	  2006	  this	  definition	  was	  no	  longer	  satisfactory.	  Some	  of	  the	  reasons	  for	  this	  were	  related	  to	  the	  techniques	  of	  laboratory	  science:	  few	  labs	  in	  the	  world	  actually	  tested	  for	  three	  or	  more	  second-­‐line	  drugs,	  rendering	  the	  conditions	  for	  XDR-­‐TB	  un-­‐fulfillable,	  and	  thus	  useless.	  Some	  of	  the	  six	  second-­‐line	  drug	  classes	  were	  more	  effective	  than	  others,	  making	  some	  resistance	  patterns	  that	  were	  included	  under	  the	  rubric	  of	  XDR-­‐TB	  much	  more	  difficult	  to	  treat	  than	  others.	  Several	  experts,	  including	  CDC’s	  Dr.	  Kenneth	  Castro,	  connected	  the	  review	  of	  the	  definition	  of	  XDR-­‐TB	  with	  the	  need	  for	  a	  standardized	  definition	  which	  would	  mean	  the	  same	  thing	  everywhere	  in	  the	  world:	  “One	  of	  the	  key	  components	  of	  case	  definitions	  is	  to	  facilitate	  consistent	  and	  universal	  reporting	  so	  that	  if	  you	  live	  in	  China	  and	  you	  call	  this	  XDR	  it’s	  pretty	  much	  consistent	  with	  what	  we	  in	  the	  US	  call	  XDR.	  Whereas	  if	  you	  have	  a	  case	  definition	  that	  [is]	  ...	  well	  I’ll	  use	  the	  scientific	  term	  ”mushy“...	  then	  you	  don’t	  quite	  know	  if	  the	  cases	  reported	  in	  China	  are	  indeed	  similar	  to	  the	  ones	  reported	  in	  the	  States.	  […]	  And	  in	  this	  we	  were	  trying	  to	  find	  a	  sweet	  spot	  that	  was	  both	  sensitive	  and	  specific.”371	  
                                                370	  Abigail	  Wright	  et	  al.,	  “Emergence	  of	  Mycobacterium	  Tuberculosis	  with	  Extensive	  Resistance	  to	  Second-­‐line	  Drugs	  –	  Worldwide,	  2000	  –	  2004,”	  Morbidity	  and	  Mortality	  Weekly	  Report	  55,	  no.	  11	  (2006):	  301-­‐305.	  371	  Castro,	  interview	  by	  author,	  2010.	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Castro’s	  ironic	  use	  of	  the	  surely	  not	  scientific	  term	  “mushy”	  highlights	  two	  things.	  First,	  the	  fact	  that	  the	  definition	  of	  XDR-­‐TB	  used	  by	  Shah	  and	  Holtz	  was	  “mushy”	  was	  initially	  more	  of	  an	  asset	  than	  a	  drawback,	  since	  it	  allowed	  tuberculosis	  samples	  that	  were	  obtained	  and	  tested	  in	  different	  settings,	  using	  different	  standards,	  by	  different	  laboratories	  and	  for	  different	  research	  purposes	  to	  be	  collected	  under	  an	  umbrella	  term	  and	  definition	  as	  “XDR-­‐TB.”	  The	  need	  for	  resistance	  to	  “3	  out	  of	  6	  classes	  of	  second-­‐line	  drugs”	  to	  fill	  the	  definition	  was	  both	  restrictive	  and	  capacious,	  since	  the	  exact	  combination	  of	  drugs	  classes	  was	  not	  pre-­‐determined,	  and	  there	  was	  no	  hierarchy	  of	  second-­‐line	  drugs	  –	  they	  all	  equally	  contributed	  to	  the	  XDR-­‐TB	  diagnosis.	  The	  “mushy”	  quality	  of	  such	  a	  capacious	  definition,	  however,	  became	  problematic	  in	  part	  because	  laboratory	  and	  clinical	  specialists	  came	  to	  the	  conclusion	  that	  there	  should	  be	  a	  hierarchy	  of	  second-­‐line	  drugs.	  Some	  cases	  of	  XDR-­‐TB	  by	  the	  original	  definition	  were	  apparently	  more	  difficult	  to	  treat	  than	  others,	  and	  some	  laboratory	  studies	  were	  more	  difficult	  to	  conduct	  accurately	  than	  others,	  leading	  to	  Castro’s	  hypothetical	  scenario	  that	  Chinese	  and	  American	  cases	  of	  “XDR-­‐TB”	  could	  be	  based	  on	  quite	  different	  physical	  realities	  as	  far	  as	  the	  condition	  of	  actual	  patients,	  and	  actual	  threat	  to	  public	  health	  was	  concerned.	  Other	  motivations	  to	  revisit	  the	  definition	  of	  XDR-­‐TB	  were	  more	  explicitly	  political.	  The	  highly	  drug-­‐resistant	  tuberculosis	  cases	  from	  Tugela	  Ferry	  were	  being	  called	  XDR-­‐TB	  ever	  since	  Neel	  Gandhi’s	  presentation	  at	  the	  AIDS	  conference	  in	  Toronto	  in	  August	  2006.	  Yet	  strictly	  speaking,	  these	  cases	  did	  not	  fit	  the	  original	  XDR-­‐TB	  definition	  published	  by	  the	  CDC	  and	  WHO	  in	  March	  2006.372	  While	  this	  discrepancy	  may	  have	  gone	  unnoticed	  (or	  unremarked	  upon)	  at	  Neel	  Gandhi’s	  oral	  presentation	  for	  the	  Toronto	  AIDS	  conference,	  it	  
                                                372	  As	  explained	  earlier,	  the	  original	  definition	  required	  XDR-­‐TB	  cases	  to	  be	  resistant	  to	  at	  least	  (any)	  3	  classes	  of	  second-­‐line	  drugs.	  The	  microbiology	  laboratory	  in	  Durban,	  South	  Africa	  only	  tested	  for	  resistance	  to	  2	  classes	  of	  second-­‐line	  drugs.	  (These	  tests	  are	  expensive	  and	  not	  readily	  available.)	  As	  a	  result,	  even	  a	  “proper”	  case	  of	  XDR-­‐TB	  could	  never	  be	  identified	  by	  the	  Durban	  lab	  as	  such.	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became	  a	  point	  of	  resistance	  in	  later	  discussions.	  When	  Dr.	  Moll	  presented	  his	  group’s	  findings	  at	  the	  WHO	  task-­‐force	  meeting	  in	  Geneva,	  for	  example,	  South	  African	  department	  of	  health	  representative	  Professor	  Ronald	  Green-­‐Thompson,373	  immediately	  challenged	  his	  “abuse	  of	  this	  term	  XDR-­‐TB.”374	  As	  Dr.	  Moll	  remembered	  the	  exchange,	  Green-­‐Thompson	  argued	  that	  Dr.	  Moll	  and	  his	  collaborators	  “were	  not	  using	  the	  definition	  scientifically.”375	  What	  he	  meant	  by	  this	  was	  that	  Dr.	  Moll	  and	  his	  colleagues	  were	  incorrectly	  claiming	  to	  have	  identified	  XDR-­‐TB	  cases	  in	  Tugela	  Ferry,	  even	  though	  the	  laboratory	  tests	  they	  had	  done	  merely	  demonstrated	  that	  they	  had	  cases	  that	  were	  resistant	  to	  all	  four	  first-­‐line	  anti-­‐tuberculosis	  drugs,	  as	  well	  as	  two	  second-­‐line	  drugs	  (not	  three).	  As	  a	  representative	  of	  the	  South	  African	  national	  department	  of	  health,	  Green-­‐Thompson	  implied	  that	  Moll’s	  group	  was	  blowing	  cases	  of	  drug-­‐resistant	  tuberculosis	  out	  of	  proportion	  and	  ignoring	  scientifically	  established	  categories	  in	  order	  to	  gain	  attention.	  In	  Dr.	  Moll’s	  view,	  Green-­‐Thompson	  was	  all	  the	  while	  clouding	  the	  issue	  that	  “boy,	  there's	  a	  problem	  here,	  we	  need	  a	  national	  response	  to	  it.	  […]	  Forget	  the	  definition.”376	  Professor	  Green-­‐Thompson’s	  critique	  was	  in	  line	  with	  the	  KwaZulu-­‐Natal	  provincial	  Health	  Minister’s	  statement	  that	  the	  department	  of	  health	  already	  had	  programs	  in	  place	  for	  multi-­‐drug	  resistant	  tuberculosis,	  and	  was	  thus	  already	  dealing	  with	  the	  problems	  in	  Tugela	  Ferry.	  Dr.	  Moll	  meanwhile	  did	  not	  really	  care	  about	  whether	  or	  not	  his	  patients’	  versions	  of	  tuberculosis	  fit	  any	  particular	  definition,	  but	  was	  invested	  in	  applying	  the	  terminology	  required	  to	  get	  the	  government	  and	  private	  response	  that	  the	  patients	  required.	  Professor	  Green-­‐Thompson	  was	  not	  the	  only	  person	  who	  balked	  at	  the	  use	  of	  the	  
                                                373	  Professor	  Green-­‐Thompson	  had	  been	  secretary	  general	  for	  the	  KwaZulu	  Natal	  provincial	  department	  of	  health	  when	  Tugela	  Ferry	  first	  identified	  the	  highly	  drug-­‐resistant	  cases	  of	  TB.	  	  At	  this	  point	  he	  was	  an	  advisor	  to	  the	  national	  department	  of	  health	  in	  South	  Africa.	  374	  Moll,	  interview	  by	  author,	  2007.	  375	  Ibid.	  376	  Moll,	  interview	  by	  author,	  2007.	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term	  XDR-­‐TB.	  Some	  tuberculosis	  scientists	  and	  clinicians	  from	  other	  regions	  of	  the	  world	  also	  resisted	  the	  XDR-­‐TB	  terminology,	  especially	  if	  they	  had	  been	  dealing	  with	  advanced	  forms	  of	  MDR-­‐TB	  for	  quite	  some	  time.	  This	  resistance	  was	  partially	  motivated	  by	  the	  pragmatic	  fact	  that	  in	  clinical	  settings	  the	  case-­‐definition	  was	  less	  important	  than	  assessing	  and	  appropriately	  treating	  the	  specific	  drug-­‐resistance	  patterns	  present	  in	  individual	  tuberculosis	  patients.	  Especially	  scientists	  from	  the	  former	  Soviet	  Union	  were	  not	  too	  convinced	  of	  the	  need	  for	  the	  XDR-­‐TB	  term.377	  Some	  scientists	  and	  clinicians	  who	  worked	  in	  areas	  with	  low	  HIV	  prevalence	  also	  worried	  that	  the	  focus	  on	  XDR-­‐TB	  as	  a	  byproduct	  of	  a	  massive	  HIV-­‐epidemic	  in	  South	  Africa	  would	  pull	  attention	  and	  resources	  away	  from	  their	  own	  MDR	  and	  XDR-­‐TB	  problems.378	  Still	  other	  scientists	  seemed	  a	  bit	  miffed	  that	  scientists	  working	  on	  XDR-­‐TB	  in	  Tugela	  Ferry	  were	  getting	  the	  attention	  they	  were	  by	  being	  imprecise	  in	  their	  embrace	  of	  a	  new	  term,	  even	  though	  others	  had	  in	  fact	  identified	  very	  resistant	  forms	  of	  tuberculosis	  much	  earlier,	  and	  employed	  more	  rigorous	  epidemiological	  and	  scientific	  criteria	  to	  do	  so,	  without	  an	  equivalent	  response.379	  Finally,	  the	  discrepancy	  between	  the	  Tugela	  Ferry	  cases	  and	  the	  “official”	  definition	  of	  XDR-­‐TB	  needed	  to	  be	  resolved	  one	  way	  or	  another	  before	  Dr.	  Friedland,	  Dr.	  Gandhi,	  Dr.	  Moll	  and	  colleagues	  could	  publish	  their	  results	  in	  a	  peer-­‐reviewed,	  prestigious	  journal,	  such	  as	  the	  Lancet.	  There	  was	  some	  urgency	  to	  this	  question,	  as	  well,	  since	  the	  Lancet	  had	  agreed	  to	  publish	  the	  results	  in	  a	  fast-­‐track	  paper	  and	  wanted	  Friedland’s	  group	  to	  submit	  the	  final	  draft	  of	  their	  publication	  on	  XDR-­‐TB	  in	  Tugela	  Ferry	  with	  a	  clarified	  definition	  of	  their	  cases’	  degree	  of	  drug	  resistance	  by	  mid	  October.380	  
                                                377	  Vaira	  Leimane,	  interview	  by	  author,	  phone	  interview,	  16	  February,	  2010;	  Holtz,	  interview	  by	  author,	  2010.	  378	  Leimane,	  interview	  by	  author,	  2010.	  379	  Holtz,	  interview	  by	  author,	  2010.	  380	  Friedland,	  interview	  by	  author,	  2007;	  Nunn,	  interview	  by	  author	  2010;	  Shah,	  interview	  by	  author,	  2007.	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Thus,	  there	  were	  several	  potential	  reasons	  to	  reconsider	  the	  definition	  of	  XDR-­‐TB.	  Karin	  Weyer	  (the	  South	  African	  laboratory-­‐based	  tuberculosis	  expert	  who	  had	  organized	  the	  expert	  consultation	  meeting	  in	  Johannesburg)	  had	  been	  given	  the	  task	  of	  reviewing	  the	  literature	  and	  writing	  a	  discussion	  document	  suggesting	  a	  new	  definition	  for	  XDR-­‐TB	  that	  was	  based	  more	  solidly	  on	  a	  technical	  laboratory	  foundation	  than	  the	  existing	  definition.	  Her	  paper	  sought	  a	  “pragmatic	  working	  definition”	  which	  would	  be	  relevant	  in	  an	  operational	  setting,	  taking	  into	  account	  the	  limited	  availability	  of	  second-­‐line	  anti-­‐tuberculosis	  drugs,	  the	  global	  lack	  of	  laboratory	  capacity	  to	  diagnose	  second-­‐line	  drug-­‐resistance,	  and	  the	  highly	  limited	  treatment	  options	  available	  for	  XDR-­‐TB.381	  Weyer’s	  document	  focused	  on	  the	  laboratory.	  The	  main	  problem,	  as	  her	  discussion	  document	  formulated	  it,	  lay	  in	  the	  technical	  limitations	  of	  second-­‐line	  drug	  resistance	  testing.	  These	  limitations	  included	  the	  lack	  of	  international	  standards	  for	  many	  of	  these	  tests,	  the	  poor	  reproducibility	  of	  results	  for	  some	  drugs,	  the	  unclear	  relationship	  between	  lab-­‐based	  resistance	  findings	  and	  the	  degree	  of	  resistance	  seen	  clinically,	  and	  the	  fact	  that	  some	  of	  the	  tests	  have	  not	  been	  systematically	  verified	  or	  can	  only	  be	  conducted	  in	  developed	  countries.	  In	  addition,	  Weyer	  organized	  all	  the	  available	  anti-­‐tuberculosis	  drugs	  in	  a	  hierarchy	  of	  efficacy	  (based	  on	  WHO	  TB	  treatment	  guidelines).	  Unlike	  the	  Dr.	  Shah’s	  paper	  in	  Morbidity	  and	  Mortality	  Weekly	  Report	  (MMWR),	  which	  categorized	  second-­‐line	  anti-­‐tuberculosis	  drugs	  into	  six	  classes	  (based	  on	  chemical	  properties)	  which	  were	  treated	  equally	  in	  terms	  of	  their	  ability	  to	  activate	  the	  XDR-­‐TB	  definition,382	  Weyer’s	  hierarchy	  identified	  four	  groups	  of	  second-­‐line	  drugs,	  including	  injectables,	  fluoroquinolones,	  “oral	  
                                                381	  Karin	  Weyer,	  “Revised	  Definition	  for	  Extensively	  Resistant	  Tuberculosis	  (XDR-­‐TB),”	  October	  10,	  2006.	  382	  Peter	  Cegielski,	  interview	  by	  author,	  phone	  interview,	  2	  February	  2010;	  A.	  Wright	  et	  al.,	  “Emergence	  of	  Mycobacterium	  Tuberculosis	  with	  Extensive	  Resistance	  to	  Second-­‐Line	  Drugs	  –	  Worldwide,	  2000-­‐2004,”	  Morbidity	  and	  Mortality	  Weekly	  Report	  55,	  no.	  11	  (2006):	  301–305.	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bacteriostatic	  2nd	  line	  drugs”	  (which	  included	  several	  different	  types	  of	  drugs	  which	  have	  been	  shown	  to	  be	  somewhat	  effective	  against	  tuberculosis)	  and	  a	  group	  of	  “unclear	  efficacy,”	  which	  mostly	  included	  drugs	  that	  had	  been	  tried	  in	  patients	  where	  there	  were	  no	  other	  options,	  but	  seemed	  to	  have	  some	  effect.383	  This	  newly-­‐constructed	  drug-­‐hierarchy,	  as	  well	  as	  evidence	  from	  Latvia	  “which	  shows	  that	  the	  rate	  of	  successful	  treatment	  outcomes	  precipitously	  falls	  as	  resistance	  to	  the	  key	  [second	  line	  drugs]	  increases”384	  logically	  and	  successfully	  led	  to	  the	  proposal	  that	  from	  then	  on,	  XDR-­‐TB	  should	  be	  defined	  as	  "the	  occurrence	  of	  TB	  in	  persons	  whose	  M.	  
tuberculosis	  isolates	  are	  resistant	  to	  isoniazid	  and	  rifampin	  plus	  resistant	  to	  any	  fluoroquinolone	  and	  at	  least	  one	  of	  three	  injectable	  second-­‐line	  drugs	  (i.e.	  amikacin,	  kanamycin,	  or	  capreomycin)."385	  This	  new	  definition	  also	  allowed	  the	  neat	  inclusion	  of	  the	  cases	  from	  Tugela	  Ferry	  in	  the	  category	  of	  XDR-­‐TB,	  though	  this	  is	  not	  mentioned	  in	  Dr.	  Weyer’s	  discussion	  document.386	  The	  definition	  for	  XDR-­‐TB	  was	  revised	  just	  days	  before	  the	  final	  version	  of	  the	  fast-­‐tracked	  Lancet	  paper	  reporting	  the	  findings	  from	  Tugela	  Ferry	  was	  submitted	  to	  the	  publisher.	  The	  53	  cases	  of	  tuberculosis	  resistant	  to	  all	  first	  and	  second-­‐line	  drugs	  tested	  reported	  at	  the	  2006	  International	  AIDS	  Conference	  could	  still	  be	  called	  XDR-­‐TB,	  and	  the	  Lancet	  paper	  discussing	  them	  could	  use	  the	  term	  XDR-­‐TB.387	  Interestingly,	  the	  53	  cases	  in	  the	  Lancet	  paper	  now	  more	  than	  fulfilled	  the	  definition	  of	  XDR-­‐TB	  because	  they	  displayed	  resistance	  to	  all	  four	  first-­‐line	  drugs,	  not	  merely	  isoniazid	  and	  rifampin.	  A	  re-­‐analysis	  of	  the	  same	  dataset	  using	  the	  new	  definition	  meant	  that	  Tugela	  
                                                383	  Weyer,	  “Revised	  Definition	  for	  Extensively	  Resistant	  Tuberculosis	  (XDR-­‐TB).”	  384	  Ibid.	  385	  CDC,	  "Notice	  to	  Readers:	  Revised	  Definition	  of	  Extensively	  Drug-­‐Resistant	  Tuberculosis,"	  
Morbidity	  and	  Mortality	  Weekly	  Report	  55	  (2006):	  1176.	  386	  Weyer,	  “Revised	  Definition	  for	  Extensively	  Resistant	  Tuberculosis	  (XDR-­‐TB).”	  387	  Neel	  R.	  Gandhi	  et	  al.,	  “Extensively	  Drug-­‐resistant	  Tuberculosis	  as	  a	  Cause	  of	  Death	  in	  Patients	  Co-­‐infected	  with	  Tuberculosis	  and	  HIV	  in	  a	  Rural	  Area	  of	  South	  Africa,”	  Lancet	  368,	  no.	  9547	  (2006):	  1575–1580.	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Ferry	  could	  have	  claimed	  even	  more	  XDR-­‐TB	  cases	  at	  the	  time,	  though	  the	  authors	  chose	  to	  publish	  their	  original	  analysis.	  It	  is	  worth	  pointing	  out	  that	  though	  these	  Tugela	  Ferry	  cases	  could	  now	  be	  included	  in	  the	  global	  tally,	  this	  did	  not	  automatically	  mean	  that	  there	  was	  an	  
increase	  in	  documented	  XDR-­‐TB	  cases	  worldwide.	  When	  Shah’s	  data	  from	  the	  global	  XDR-­‐TB	  survey	  was	  reanalyzed	  according	  to	  the	  new	  definition,	  the	  number	  of	  detected	  XDR-­‐TB	  cases	  decreased	  from	  347	  to	  234.388	  This	  no	  longer	  hurt	  the	  case	  for	  the	  importance	  of	  XDR-­‐TB,	  however.	  
	   Judging	  by	  the	  retrospective	  musings	  of	  several	  of	  the	  leading	  tuberculosis	  experts	  who	  were	  involved	  in	  suggesting	  and	  deciding	  the	  change	  in	  XDR-­‐TB	  definition,	  it	  was	  in	  fact	  a	  rather	  uncontroversial	  decision	  to	  make	  the	  change.	  Once	  the	  change	  had	  been	  decided	  upon	  and	  published,	  there	  was	  soon	  a	  general	  consensus	  around	  the	  new	  definition,	  to	  the	  extent	  that	  even	  people	  who	  were	  intimately	  involved	  in	  the	  discussions	  around	  XDR-­‐TB	  in	  mid	  2006	  seemed	  almost	  to	  forget	  that	  there	  ever	  was	  a	  different	  definition	  than	  there	  is	  now.	  As	  Dr.	  Holtz	  explained:	  “When	  it	  was	  published	  in	  November	  [2006]	  there	  [were]	  various	  dissenting	  letters	  and	  people	  asking	  […]	  ‘do	  you	  think	  this	  is	  really	  the	  best	  definition?’	  But	  there	  has	  really	  been	  no	  strong	  counterargument	  why	  we	  need	  to	  go	  back	  or	  change	  anything.	  Since	  November	  of	  2006	  the	  name	  has	  stuck	  and	  the	  entity	  has	  stuck	  and	  now	  there	  have	  been	  growing	  numbers	  of	  papers	  that	  have	  been	  published	  looking	  at	  XDR.”389	  	   Those	  most	  intimately	  involved	  in	  the	  decision-­‐making	  deny	  that	  the	  need	  to	  include	  Tugela	  Ferry’s	  cases	  in	  the	  definition	  (be	  it	  in	  order	  to	  have	  a	  high-­‐profile	  publication	  on	  XDR-­‐TB	  in	  the	  Lancet,	  or	  in	  order	  to	  be	  able	  to	  put	  pressure	  on	  the	  South	  African	  department	  of	  health)	  was	  a	  significant	  factor	  in	  the	  decision	  (or	  a	  factor	  at	  all).	  
                                                388	  N.	  Sarita	  Shah	  et	  al.,	  “Worldwide	  Emergence	  of	  Extensively	  Drug-­‐resistant	  Tuberculosis,”	  
Emerging	  Infectious	  Diseases	  13,	  no.	  3	  (2007):	  380–387.	  389	  Holtz,	  interview	  by	  author,	  2010.	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There	  was	  some	  awareness	  of	  the	  fact	  that	  the	  new	  definition	  had	  such	  advantages,	  but	  most	  of	  the	  participants	  in	  the	  laboratory	  definition	  breakout	  group	  at	  the	  task-­‐force	  meeting	  were	  laboratory	  specialists	  who	  had	  no	  difficulty	  arguing	  for	  the	  change	  in	  microbiological	  terms.	  	   In	  2007,	  Dr.	  Friedland	  stressed	  the	  clinical	  aspects	  of	  the	  revised	  definition:	  "Prognostically,	  the	  important	  resistance	  in	  second-­‐line	  drugs	  is	  to	  the	  fluoroquinolones	  and	  an	  injectable.	  In	  terms	  of	  clinical	  meaning	  it	  makes	  sense	  to	  actually	  define	  it	  with	  those	  two	  classes	  of	  drugs	  rather	  than	  any	  three	  classes	  of	  drugs."390	  Some	  of	  the	  players	  closest	  to	  the	  policy-­‐making	  process	  were	  relatively	  open	  about	  the	  political	  dimensions	  of	  the	  definitional	  change,	  as	  well.	  In	  a	  CDC	  podcast,	  Dr.	  Cegielski	  stated	  that	  the	  definition	  was	  changed	  "partly	  for	  microbiological	  reasons,	  partly	  for	  political	  reasons."391	  Dr.	  Shah	  apologetically	  stated:	  "I	  wish	  I	  could	  say	  it	  was	  the	  clinical	  and	  the	  lab	  parameters,	  but	  there	  was	  also	  a	  large	  political	  component	  to	  it."392	  Dr.	  Moll,	  the	  one	  person	  present	  at	  all	  these	  meetings	  who	  was	  also	  an	  almost	  daily	  witness	  to	  the	  suffering	  and	  death	  brought	  by	  tuberculosis	  and	  HIV	  in	  Tugela	  Ferry,	  agreed	  that	  the	  term	  XDR-­‐TB	  had	  political	  power,	  but	  also	  emphasized	  that	  compared	  to	  MDR-­‐TB	  –	  or	  even	  the	  first	  definition	  of	  XDR-­‐TB	  –	  the	  newly	  defined	  XDR-­‐TB	  “was	  a	  different	  disease	  with	  a	  different	  outcome	  and	  different	  treatment	  challenges.	  That's	  what	  we	  as	  physicians	  felt	  here	  [in	  Tugela	  Ferry].	  That	  married	  very	  well	  with	  technical	  aspects	  of	  the	  definition	  in	  terms	  of	  being	  able	  to	  reliably	  reproduce	  it	  across	  the	  world.	  […]	  The	  injectables	  and	  the	  fluoroquinolones	  were	  the	  next	  after	  rifampicin	  and	  INH	  [as]	  the	  most	  potent	  TB	  drugs.393	  And	  if	  you	  take	  them	  out	  together	  with	  
                                                390	  Friedland,	  interview	  by	  author,	  2007.	  391	  "Emergence	  of	  Extensively	  Drug	  Resistant	  Tuberculosis,"	  on	  CDC	  podcast	  (podcast),	  	  http://www2a.cdc.gov/podcasts/index.asp	  (search	  for	  "tuberculosis"),	  last	  accessed	  April	  30,	  2007.	  392	  Shah,	  interview	  by	  author,	  2007.	  393	  Rifampicin	  is	  an	  alternative	  name	  for	  rifampin;	  INH	  is	  the	  commonly	  used	  abbreviation	  for	  isoniazid,	  the	  most	  powerful	  anti-­‐TB	  drug.	  
 149 
INH	  and	  rifampicin	  you	  are	  now	  in	  a	  treatment	  dilemma.	  So	  the	  new	  definition	  XDR-­‐TB	  accommodated	  that	  very	  well.	  So	  take	  away	  all	  the	  press	  hype,	  etc.	  It	  is	  to	  me	  a	  totally	  logical	  scientific	  conclusion	  to	  come	  to.	  	  […]	  What	  the	  new	  definition	  very	  nicely	  did	  was	  to	  package	  fluoroquinolones	  and	  injectables	  exclusively	  into	  the	  definition	  and	  that	  really	  took	  the	  disease	  into	  a	  treatment	  dilemma.”394	  Thus,	  in	  Dr.	  Moll’s	  view,	  the	  change	  in	  definition	  reflected	  the	  material	  reality	  of	  a	  more	  acute	  and	  desperate	  clinical	  situation	  that	  meant	  that	  patients	  were	  worse	  off,	  and	  that	  those	  who	  were	  trying	  to	  take	  care	  of	  them	  were	  left	  with	  very	  few	  options.	  Dr.	  Moll	  himself	  had	  actively	  pursued	  media	  involvement	  in	  order	  to	  put	  pressure	  on	  his	  superiors	  in	  the	  South	  African	  department	  of	  health,	  and	  had	  discounted	  the	  importance	  of	  the	  definition	  of	  XDR-­‐TB	  (and	  whether	  or	  not	  it	  was	  “scientific”	  according	  to	  Dr.	  Green-­‐Thompson	  of	  the	  Department	  of	  Health).	  He	  did,	  however,	  support	  a	  definition	  that	  highlighted	  the	  clinical	  and	  human	  devastation	  that	  could	  be	  caused	  by	  drug-­‐resistant	  tuberculosis	  and	  emphasized	  its	  scientific,	  and	  thus	  moral	  validity.	  	   The	  publication	  of	  the	  research	  from	  Tugela	  Ferry	  in	  the	  Lancet	  in	  November	  2006	  brought	  closure	  to	  the	  process	  of	  naming	  and	  defining	  of	  XDR-­‐TB,	  while	  also	  clearly	  anchoring	  XDR-­‐TB	  in	  a	  specific	  place.	  The	  article	  supported	  a	  narrative	  in	  which	  XDR-­‐TB	  could	  claim	  clinical	  and	  political	  meaning	  in	  the	  context	  of	  HIV/AIDS,	  emerging	  infectious	  diseases	  and	  global	  health	  research	  in	  resource-­‐limited	  settings.	  In	  South	  Africa,	  activating	  the	  term	  XDR-­‐TB	  for	  use	  in	  Tugela	  Ferry	  and	  elsewhere	  had	  the	  potential	  to	  allow	  clinicians	  within	  the	  South	  African	  health	  system	  to	  make	  increased	  claims	  on	  government	  agencies,	  holding	  them	  accountable	  for	  the	  citizens	  in	  their	  care.	  In	  part	  two	  of	  the	  dissertation	  I	  transition	  away	  from	  the	  international	  making	  of	  XDR-­‐TB	  to	  focus	  more	  closely	  on	  South	  African	  responses	  to	  this	  new	  disease	  entity.	  As	  we	  will	  see	  in	  chapter	  four	  South	  African	  government	  health	  agencies	  initially	  responded	  
                                                394	  Moll,	  interview	  by	  author,	  2007.	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ambivalently	  as	  they	  both	  resisted	  and	  worked	  together	  with	  researchers	  and	  clinicians	  to	  study	  and	  address	  the	  extent	  of	  drug-­‐resistance	  that	  had	  been	  uncovered.	  Nurses,	  research	  assistants,	  logbooks,	  databases	  and	  rural	  landscapes	  are	  the	  subject	  matter	  of	  chapter	  five	  which	  further	  examines	  the	  complex	  relationship	  between	  international	  and	  South	  African	  expertise,	  research,	  and	  clinical	  intervention	  around	  drug-­‐resistant	  tuberculosis.
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CHAPTER	  4:	  Dealing	  with	  a	  Time	  Bomb	  –	  At	  the	  Interface	  Between	  Government	  Health	  
Departments	  and	  Global	  Health	  Research	  
	  
“You	  could	  be	  sitting	  on	  a	  time	  bomb	  you	  don’t	  even	  know.”	  –Bruce	  Margot,	  TB	  Program	  Manager	  for	  KwaZulu-­‐Natal.	  
	  “I	  knew	  it	  would	  be	  a	  bombshell,	  should	  it	  break.”	  –	  Dr.	  Anthony	  Moll,	  physician	  at	  Church	  of	  Scotland	  Hospital	  in	  Tugela	  Ferry.	  
	  “We	  were	  saying,	  you	  know,	  that	  something’s	  going	  to	  happen.	  […]	  You	  know,	  saying	  we’re	  
just	  sitting	  on	  a	  bomb.	  We’re	  waiting	  for	  this	  bomb,	  and	  that	  was	  it.”	  –	  Karen	  Shean,	  South	  African	  nurse-­‐researcher.	  
“No	  one	  came	  up	  to	  actually	  alert	  [the	  district	  office]	  that	  we	  are	  going	  towards	  the	  time	  
bomb.”	  -­‐	  Jabulani	  Mndebele,	  Umzinyathi	  District	  Manager.	  	  	   According	  to	  most	  early	  accounts,	  the	  immediate	  official	  South	  African	  response	  to	  the	  discovery	  of	  highly	  drug-­‐resistant	  tuberculosis	  in	  Tugela	  Ferry	  appeared	  half-­‐hearted.	  Prof.	  Sturm	  came	  to	  Tugela	  Ferry	  from	  Durban	  to	  discuss	  infection	  control	  and	  he	  made	  his	  laboratory	  available	  to	  test	  all	  tuberculosis	  samples	  from	  Tugela	  Ferry	  for	  drug	  resistance	  (with	  backing	  from	  the	  department	  of	  health).	  Beyond	  this,	  however,	  Dr.	  Moll	  and	  his	  colleagues	  struggled	  to	  get	  their	  department	  of	  health	  superiors	  to	  respond	  with	  a	  true	  sense	  of	  urgency.	  The	  number	  of	  MDR-­‐TB	  and	  XDR-­‐TB	  patients	  was	  overwhelming,	  and	  the	  doctors	  in	  Tugela	  Ferry	  needed	  the	  department	  to	  make	  a	  plan	  to	  get	  their	  patients	  access	  to	  appropriate	  medications	  and	  care.	  Dr.	  Moll	  described	  himself	  as	  shouting	  until	  his	  voice	  was	  hoarse,	  and	  his	  colleague	  Dr.	  van	  der	  Merwe	  similarly	  recalled	  that	  getting	  the	  department	  of	  health	  on	  board	  was	  a	  challenge.395	  Dr.	  Moll	  tried	  to	  convince	  the	  department	  
                                                395	  Anthony	  Moll,	  interview	  by	  author,	  13	  May	  2011,	  Tugela	  Ferry,	  South	  Africa;	  Theo	  van	  der	  Merwe,	  interview	  by	  author,	  19	  June	  2011,	  Tugela	  Ferry,	  South	  Africa.	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that	  it	  was	  in	  their	  best	  interest	  to	  be	  proactive	  and	  remembered	  warning	  “the	  provincial	  public	  health	  relations	  person,	  begging	  him	  to	  leak	  the	  information	  about	  MDR	  and	  XDR	  because	  I	  knew	  it	  would	  be	  a	  bombshell,	  should	  it	  break.”396	  As	  late	  as	  mid	  2007,	  after	  the	  news	  about	  XDR-­‐TB	  had	  already	  received	  a	  broad,	  international	  audience,	  Dr.	  Nesri	  Padayatchi,	  a	  South	  African	  doctor	  and	  tuberculosis	  researcher	  in	  Durban,	  lamented	  that	  “the	  whole	  world	  is	  concerned	  about	  MDR	  and	  XDR-­‐TB	  except	  us.	  And	  really,	  you	  know,	  the	  department	  of	  health	  is	  really	  not	  coming	  to	  the	  party.”397	  By	  2010,	  however,	  assessments	  of	  the	  South	  African	  government’s	  response	  to	  MDR-­‐TB	  and	  XDR-­‐TB	  were	  much	  more	  generous.	  Dr.	  Padayatchi	  was	  more	  optimistic	  and	  was	  able	  to	  list	  a	  number	  of	  tuberculosis	  programs	  supported	  by	  the	  department	  of	  health:	  “In	  terms	  of	  comparing	  what’s	  happened	  since	  2007,	  yes,	  we	  are	  moving	  in	  leaps	  and	  bounds.”398	  In	  the	  meantime	  there	  had	  been	  a	  change	  in	  the	  South	  African	  presidency	  and	  in	  the	  leadership	  of	  the	  department	  of	  health,	  and	  scientists	  and	  physicians	  were	  feeling	  much	  more	  positive	  about	  the	  future	  of	  public	  medicine	  in	  South	  Africa.	  Though	  many	  people	  still	  described	  South	  Africa’s	  public	  health	  system	  as	  difficult	  to	  work	  with	  or	  even	  dysfunctional,	  several	  people	  I	  spoke	  to	  emphasized	  that	  the	  government	  employees	  responsible	  for	  tuberculosis	  in	  the	  province	  of	  KwaZulu-­‐Natal	  and	  the	  district	  of	  Umzinyathi	  (the	  administrative	  district	  in	  which	  Tugela	  Ferry	  is	  located),	  in	  particular,	  were	  admirably	  attentive	  and	  proactive	  in	  addressing	  drug-­‐resistant	  tuberculosis.	  Physicians	  and	  researchers	  in	  Tugela	  Ferry	  had	  developed	  a	  functional	  working	  relationship	  with	  district	  and	  provincial	  tuberculosis	  program	  offices.	  International	  and	  local	  researchers,	  clinicians,	  administrators	  and	  policy	  makers	  had	  worked	  together	  to	  design	  and	  implement	  new,	  innovative	  public	  health	  programs	  to	  deal	  
                                                396	  Moll,	  interview	  by	  author,	  2011.	  397	  Nesri	  Padayatchi,	  interview	  by	  author,	  13	  July	  2007,	  Durban,	  South	  Africa.	  398	  Nesri	  Padayatchi,	  interview	  by	  author,	  6	  April	  2010,	  Durban,	  South	  Africa.	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with	  MDR-­‐TB	  and	  XDR-­‐TB,	  including	  a	  program	  for	  the	  decentralized,	  community-­‐based	  management	  of	  MDR-­‐TB	  and	  XDR-­‐TB.	  The	  outcomes	  of	  these	  programs	  were	  being	  evaluated	  by	  research	  groups,	  and	  promising	  early	  results	  were	  presented	  at	  South	  African	  and	  international	  tuberculosis	  and	  HIV/AIDS	  conferences.399	  This	  chapter	  highlights	  the	  important	  contributions	  made	  by	  district	  and	  provincial	  government	  employees	  to	  tuberculosis	  control	  in	  Tugela	  Ferry	  while	  taking	  seriously	  the	  critiques	  that	  the	  South	  African	  government	  was	  slow	  to	  respond	  to	  XDR-­‐TB.	  I	  argue	  that	  department	  of	  health	  workers,	  including	  administrators	  and	  nurses,	  played	  a	  greater	  role	  in	  responding	  to	  the	  “outbreak”	  of	  drug-­‐resistant	  tuberculosis	  in	  Tugela	  Ferry	  than	  common	  conceptions	  of	  global	  health	  research	  and	  intervention	  might	  predict,	  even	  as	  international	  researchers,	  foreign	  development	  agencies	  (including	  the	  Italian	  Cooperation	  and	  USAID),	  transnational	  health	  agencies	  and	  health	  consulting	  companies	  were	  all	  involved	  in	  the	  response	  to	  XDR-­‐TB.	  The	  chapter	  is	  based	  in	  part	  on	  interviews	  conducted	  in	  2011	  with	  local	  department	  of	  health	  officials	  from	  the	  Umzinyathi	  district,	  which	  oversees	  four	  sub-­‐districts,	  including	  the	  Msinga	  sub-­‐district,	  where	  the	  town	  of	  Tugela	  Ferry	  and	  its	  Church	  of	  Scotland	  Hospital	  are	  located.	  From	  these	  officials’	  perspectives	  the	  discovery	  of	  XDR-­‐TB	  in	  Tugela	  Ferry	  triggered	  a	  significant	  and	  relatively	  rapid	  response,	  not	  only	  from	  the	  international	  community	  and	  the	  media,	  but	  also	  from	  parts	  of	  the	  South	  African	  government	  bureaucracy.	  In	  the	  short	  term,	  the	  Umzinyathi	  health	  district	  shuffled	  its	  own	  resources	  and	  worked	  together	  with	  representatives	  from	  the	  Italian	  Cooperation	  (Italy’s	  aid	  agency)	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and	  Philanjalo	  to	  gather	  epidemiological	  data	  and	  to	  actively	  pursue	  cases	  of	  drug-­‐resistant	  tuberculosis.400	  In	  the	  long	  term,	  tuberculosis	  management	  in	  Msinga	  was	  transformed	  by	  a	  new	  paradigm	  of	  community-­‐based	  management	  and	  by	  the	  addition	  of	  over	  a	  dozen	  government-­‐funded	  nurses,	  drivers	  and	  data	  managers	  to	  Tugela	  Ferry’s	  previously	  small	  tuberculosis	  office.	  In	  addition,	  increased	  supervision	  and	  support	  of	  designated	  tuberculosis	  nurses	  in	  outlying	  clinics	  was	  initiated.	  In	  2008	  the	  Umzinyathi	  district	  opened	  a	  dedicated	  MDR-­‐TB	  hospital	  and	  clinic	  where	  MDR-­‐TB	  patients	  from	  Tugela	  Ferry	  and	  other	  parts	  of	  the	  district	  could	  be	  treated.	  Systems	  were	  put	  in	  place	  to	  coordinate	  TB,	  MDR-­‐TB,	  and	  XDR-­‐TB	  patients’	  care	  between	  sub-­‐district,	  district,	  and	  province	  level	  to	  ensure	  that	  acceptable	  care	  was	  available.401	  South	  African	  government	  support	  for	  drug-­‐resistant	  tuberculosis	  programs	  was	  not	  a	  straightforward	  answer	  to	  international	  pressure,	  however.	  Government	  actors	  simultaneously	  demanded,	  resisted,	  and	  reluctantly	  embraced	  international	  expertise	  and	  interventions	  in	  efforts	  to	  assert	  their	  own	  authority	  over	  the	  drug-­‐resistant	  tuberculosis	  problem.	  There	  was	  an	  awareness	  among	  South	  African	  officials	  that	  even	  as	  outside	  tuberculosis	  researchers	  provided	  skills	  and	  expertise	  and	  attempted	  to	  work	  together	  with	  local	  officials,	  they	  also	  used	  South	  African	  resources	  (both	  in	  the	  form	  of	  patient	  access	  and	  uncompensated	  laboratory	  testing)	  to	  build	  their	  own	  careers	  and	  gain	  prestige.	  Government	  officials	  did	  not	  always	  consider	  outsiders’	  (or	  even	  South	  African	  researchers’)	  help	  benign,	  and	  tried	  to	  control	  the	  form	  that	  such	  help	  took.	  The	  correct	  response	  to	  MDR-­‐TB	  and	  XDR-­‐TB	  in	  South	  Africa	  was	  an	  open	  question	  that	  South	  African	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experts	  and	  administrators	  grappled	  with	  seriously	  while	  under	  close	  scrutiny	  from	  WHO	  officials,	  international	  researchers,	  humanitarian	  medical	  organizations,	  well-­‐connected	  human	  rights	  activists	  and	  investigative	  journalists.	  South	  African	  tuberculosis	  experts	  and	  administrators	  used	  a	  variety	  of	  strategies	  both	  to	  contain	  and	  harness	  the	  attention,	  energy	  and	  potential	  resources	  which	  came	  with	  the	  high	  profile	  of	  XDR-­‐TB	  and	  the	  at	  times	  overwhelming	  international	  interest.	  This	  chapter	  is	  organized	  chronologically,	  showing	  a	  progression	  in	  research,	  clinical,	  and	  government	  responses	  to	  the	  knowledge	  that	  Tugela	  Ferry	  had	  a	  serious	  problem	  with	  drug-­‐resistant	  tuberculosis,	  from	  fact	  gathering	  and	  consternation,	  to	  program	  development	  and	  management.	  After	  documenting	  the	  initial	  shock	  of	  discovery,	  this	  chapter	  discusses	  how	  district	  and	  provincial	  TB	  managers	  related	  to	  international	  expertise	  and	  used	  international	  experts	  to	  help	  gather	  and	  interpret	  information	  about	  the	  causes	  of	  XDR-­‐TB	  in	  Tugela	  Ferry	  and	  the	  province	  as	  a	  whole.	  The	  chapter	  culminates	  in	  a	  discussion	  of	  the	  choices	  that	  led	  to	  the	  placement	  of	  Umzinyathi’s	  MDR-­‐TB	  hospital	  in	  Greytown,	  only	  45	  kilometers	  from	  Tugela	  Ferry,	  but	  not	  in	  Tugela	  Ferry,	  a	  choice	  that	  I	  argue	  simultaneously	  expressed	  some	  resistance	  against	  international	  authority	  and	  maverick	  physicians	  while	  allowing	  the	  province	  to	  continue	  to	  benefit	  from	  the	  resources	  provided	  by	  these	  experts	  and	  physicians.	  
The	  tip	  of	  a	  deadly	  iceberg?	  	   As	  we	  have	  seen,	  Lynn	  Roux’s	  revelation	  to	  Dr.	  Moll	  in	  May	  2005	  that	  she	  had	  identified	  at	  least	  ten	  cases	  of	  highly	  drug-­‐resistant	  tuberculosis	  opened	  a	  wide	  range	  of	  questions	  for	  the	  staff	  at	  the	  Church	  of	  Scotland	  Hospital	  in	  Tugela	  Ferry.	  Where	  did	  the	  severe	  drug-­‐resistance	  come	  from?	  How	  deadly	  was	  it?	  Were	  the	  discovered	  cases	  just	  the	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tip	  of	  an	  iceberg	  of	  a	  widespread	  epidemic?	  402	  On	  a	  personal	  level,	  Dr.	  Moll	  and	  everyone	  else	  working	  in	  the	  hospital	  had	  reason	  to	  be	  concerned	  for	  their	  own	  safety	  in	  the	  face	  of	  this	  air-­‐borne	  disease,	  and	  it	  was	  unclear	  what	  protective	  measures	  would	  be	  feasible	  and	  effective.	  This	  was	  highlighted	  by	  the	  fact	  that	  the	  first	  cluster	  of	  documented	  XDR-­‐TB	  cases	  included	  several	  health	  workers	  who	  were	  employed	  at	  the	  hospital,	  as	  well	  as	  hospital	  workers’	  relatives.	  In	  the	  absence	  of	  a	  robust	  government	  response	  Dr.	  Moll	  and	  his	  colleagues	  turned	  to	  American	  research	  collaborator	  Dr.	  Gerald	  Friedland,	  his	  colleague	  Neel	  Gandhi	  and	  their	  extensive	  international	  network	  around	  infectious	  diseases	  research	  and	  policy	  for	  support.	  Early	  research	  efforts	  focused	  on	  quantifying	  the	  extent	  and	  lethality	  of	  the	  apparent	  outbreak	  of	  drug-­‐resistant	  tuberculosis.	  This	  work	  led	  to	  presentations	  at	  the	  2006	  Conference	  on	  Retroviruses	  and	  Opportunistic	  Infections	  (CROI)	  and	  the	  2006	  conference	  of	  the	  International	  AIDS	  Society,	  as	  well	  as	  the	  2006	  Lancet	  paper	  that	  made	  Tugela	  Ferry	  famous,	  as	  discussed	  in	  previous	  chapters.	  Dr.	  Moll	  was	  able	  to	  travel	  to	  Denver,	  Colorado	  to	  formally	  present	  the	  tuberculosis	  cases	  from	  Tugela	  Ferry	  at	  the	  Conference	  on	  Retroviruses	  and	  Opportunistic	  Infections	  in	  February	  2006.	  He	  was	  amazed	  at	  the	  intensity	  of	  the	  feedback	  he	  received	  from	  international	  experts:	  “This	  allowed	  me	  to	  come	  home	  thinking	  that	  if	  it	  really	  is	  so	  serious,	  why	  is	  it	  that	  in	  South	  Africa	  we’re	  not	  jumping	  or	  doing	  anything	  about	  it?	  I	  [was]	  starting	  to	  get	  embarrassed	  that	  the	  international	  community	  was	  saying,	  oh,	  this	  is	  serious,	  and	  in	  South	  Africa	  we’re	  saying,	  sorry	  about	  that,	  it’s	  just	  another	  problem	  and	  we’ll	  get	  around	  to	  it	  some	  time.”403	  This	  feeling	  was	  only	  further	  enhanced	  by	  the	  interest	  in	  XDR-­‐TB	  generated	  at	  the	  International	  AIDS	  Society	  conference	  a	  few	  months	  later.	  Moll	  was	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encouraged	  to	  demand	  further	  action	  against	  drug-­‐resistant	  tuberculosis	  from	  his	  superiors	  in	  the	  South	  African	  department	  of	  health.404	  South	  African	  officials,	  meanwhile,	  had	  reason	  to	  feel	  embarrassed	  by	  the	  presentations	  about	  drug-­‐resistant	  tuberculosis	  made	  at	  these	  large	  international	  conferences.	  Observers	  privy	  to	  meetings	  at	  the	  national	  level	  indicated	  that	  the	  department	  of	  health	  felt	  attacked	  by	  the	  Tugela	  Ferry	  research	  group’s	  public	  presentation	  of	  unflattering	  statistics	  without	  fully	  involving	  them.	  This	  in	  part	  explained	  early	  official	  government	  responses	  of	  denying	  the	  severity	  of	  the	  problem	  and	  attempting	  to	  block	  media	  access	  to	  information	  about	  XDR-­‐TB.	  At	  one	  point	  Dr.	  Moll	  was	  even	  informed	  that	  as	  a	  government	  employee	  he	  did	  not	  have	  permission	  to	  speak	  about	  XDR-­‐TB	  at	  another	  conference	  that	  he	  had	  been	  scheduled	  to	  attend.405	  According	  to	  other	  sources,	  however,	  government	  offices	  had	  in	  fact	  been	  regularly	  updated	  about	  research	  developments	  in	  Tugela	  Ferry.	  Bruce	  Margot,	  TB	  program	  manager	  for	  the	  province	  of	  KwaZulu-­‐Natal,	  remembers	  being	  aware	  of	  the	  elevated	  drug-­‐resistance	  rates	  in	  Tugela	  Ferry	  by	  May	  2005,	  not	  long	  after	  Dr.	  Moll	  discovered	  the	  problem.	  According	  to	  Margot,	  the	  WHO	  was	  conducting	  a	  review	  of	  South	  Africa’s	  TB	  program	  that	  year,	  and	  he	  invited	  WHO	  and	  national	  TB	  program	  representatives	  to	  visit	  Tugela	  Ferry	  as	  part	  of	  that	  review.	  The	  extent	  of	  the	  problem	  had	  not	  yet	  been	  fully	  documented	  at	  the	  point,	  however,	  and	  “no-­‐one”	  –	  neither	  the	  WHO	  nor	  the	  national	  TB	  program	  –	  got	  “overly	  excited	  at	  that	  stage.”406	  As	  we	  have	  seen,	  Margot’s	  office	  also	  asked	  the	  South	  African	  Medical	  Research	  Council	  for	  assistance	  in	  assessing	  MDR-­‐TB	  in	  KwaZulu-­‐Natal.	  He	  and	  
                                                404	  In	  2006	  Dr.	  Moll	  was	  not	  the	  only	  South	  African	  health	  worker	  embarrassed	  about	  the	  inadequacy	  of	  South	  Africa’s	  response	  to	  a	  pressing	  public	  health	  issue.	  At	  the	  2006	  International	  AIDS	  Society	  meeting,	  for	  example,	  the	  official	  South	  African	  display	  booth	  made	  international	  headlines	  for	  featuring	  garlic,	  beetroot	  and	  lemons	  as	  treatment	  for	  AIDS,	  but	  no	  HIV	  medication,	  enraging	  South	  African	  physicians	  and	  activists.	  405	  Anthony	  Moll,	  personal	  communication,	  2011.	  406	  Bruce	  Margot,	  interview	  by	  author,	  18	  April	  2010,	  Pietermaritzburg,	  South	  Africa.	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other	  government	  representatives	  at	  national	  and	  provincial	  level	  had	  also	  been	  invited	  to	  attend	  the	  upcoming	  September	  expert	  consultation	  on	  XDR-­‐TB	  organized	  by	  the	  South	  African	  Medical	  Research	  Council	  and	  the	  American	  CDC.	  The	  department	  did	  not	  anticipate	  the	  extent	  of	  media	  interest	  in	  XDR-­‐TB	  that	  followed	  the	  AIDS	  conference	  in	  Toronto	  in	  August	  2006,	  however,	  and	  was	  “caught	  with	  their	  pants	  off,”	  as	  one	  doctor	  put	  it,	  after	  the	  presence	  of	  XDR-­‐TB	  in	  Tugela	  Ferry	  was	  announced	  at	  the	  conference.	  They	  “were	  totally	  unprepared	  for	  the	  media	  onslaught	  that	  took	  place,”	  according	  to	  one	  observer.	  One	  issue	  clearly	  was	  a	  lack	  of	  effective	  communication	  between	  different	  levels	  and	  branches	  of	  the	  department	  of	  health	  itself.	  Government	  health	  administrators	  for	  the	  Umzinyathi	  district	  (in	  which	  Msinga	  and	  Tugela	  Ferry	  are	  located)	  agree	  that	  the	  media	  storm	  around	  XDR-­‐TB	  caught	  them	  by	  surprise.	  Some	  administrators	  and	  hospital	  staff	  in	  Tugela	  Ferry	  claimed	  that	  it	  was	  from	  these	  sensationalist	  news	  reports	  that	  they	  first	  heard	  about	  the	  XDR-­‐TB	  problem	  in	  their	  midst.	  Others	  remembered	  learning	  about	  it	  in	  meetings	  at	  the	  hospital.	  Sister	  Msomi,	  the	  TB	  coordinator	  for	  Msinga	  and	  head	  of	  the	  clinical	  TB	  DOTS	  office	  at	  the	  hospital	  in	  Tugela	  Ferry	  recalls	  attending	  a	  presentation	  by	  Dr.	  Moll	  and	  being	  surprised	  about	  what	  was	  being	  reported:	  “I	  wasn’t	  aware	  that	  we	  were	  having	  a	  crisis.”407	  She	  was	  miffed	  that	  her	  office	  had	  not	  been	  more	  closely	  involved	  in	  investigating	  drug-­‐resistant	  tuberculosis	  cases	  from	  the	  start.	  Referring	  to	  the	  “snapshot”	  study	  which	  first	  revealed	  the	  extent	  of	  highly	  drug-­‐resistant	  tuberculosis	  in	  Tugela	  Ferry	  she	  stated:	  “In	  fact	  Dr.	  Moll	  was	  doing	  a	  study	  through	  Philanjalo	  [the	  AIDS	  NGO	  founded	  by	  Dr.	  Moll	  through	  which	  HIV/TB	  research	  was	  channeled]	  and	  they	  didn’t	  involve	  us	  [at]	  DOTS.	  They	  were	  just	  doing	  their	  own	  thing.”408	  
                                                407	  Nonhlanhla	  Msomi,	  interview	  by	  author,	  10	  December	  2010,	  Tugela	  Ferry,	  South	  Africa.	  408	  Ibid.	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Zanele	  Radebe,	  the	  senior	  technical	  advisor	  for	  tuberculosis	  for	  the	  Umzinyathi	  district	  (the	  district’s	  “TB	  coordinator”)	  explained	  that	  before	  the	  XDR-­‐TB	  outbreak	  became	  known,	  the	  district	  was	  already	  aware	  of	  the	  fact	  that	  their	  tuberculosis	  program	  required	  strengthening.409	  Umzinyathi	  district	  (like	  many	  South	  African	  districts)	  was	  not	  meeting	  the	  WHO-­‐prescribed	  cure	  rate	  target	  of	  85%,	  and	  the	  province	  of	  KwaZulu-­‐Natal	  had	  been	  encouraging	  its	  districts	  to	  improve	  their	  statistics,	  in	  part	  as	  the	  result	  of	  a	  meeting	  of	  WHO	  Afro	  in	  Maputo	  in	  2005	  (before	  XDR-­‐TB	  was	  discovered),	  in	  which	  tuberculosis	  was	  established	  as	  a	  priority	  disease.410	  But	  when	  Church	  of	  Scotland	  Hospital	  CEO	  Hans	  Human	  reported	  the	  discovery	  of	  drug-­‐resistant	  tuberculosis	  in	  Tugela	  Ferry	  at	  one	  of	  Umzinyathi	  district’s	  regular	  executive	  committee	  meetings,	  Radebe	  was	  alarmed.	  Immediate	  action	  was	  required.	  As	  Radebe	  recalled:	  “First	  thing	  the	  following	  day	  I	  was	  on	  the	  road	  to	  Church	  of	  Scotland	  to	  look	  at	  the	  infection	  control.	  The	  clients	  that	  have	  been	  detected	  that	  they’ve	  got	  MDR.	  Have	  they	  been	  traced?	  	  What	  is	  going	  on?	  	  They	  must	  go	  to	  King	  George	  [hospital	  in	  Durban]	  to	  get	  treatment,	  you	  know?	  Just	  a	  nightmare.”411	  Fikile	  Ngema,	  then	  the	  Umzinyathi	  deputy	  district	  manager	  for	  the	  department	  of	  health412	  in	  charge	  of	  17	  priority	  health	  programs	  (including	  TB,	  HIV/AIDS,	  and	  maternal	  and	  child	  health)	  remembered	  being	  doubtful	  when	  she	  first	  heard	  about	  Tugela	  Ferry’s	  cases	  of	  multi-­‐drug	  resistant	  (MDR)	  tuberculosis:	  “It	  was	  very	  rare	  to	  hear	  that	  there	  is	  an	  MDR	  case.	  MDR,	  here!	  […]	  We	  could	  not	  believe.	  […]	  We	  were	  horrified.”413	  Ngema	  admitted	  that	  there	  was	  some	  initial	  denial	  on	  the	  part	  of	  her	  department,	  and	  that	  she	  had	  been	  
                                                409	  Zanele	  Radebe,	  interview	  by	  author,	  19	  April	  2011,	  Greytown,	  South	  Africa.	  410	  TB	  had	  been	  declared	  a	  priority	  at	  a	  meeting	  in	  Maputo,	  Mozambique	  in	  2005,	  before	  the	  MDR/XDR-­‐TB	  cluster	  in	  Tugela	  Ferry	  was	  even	  known.	  This	  had	  led	  to	  a	  series	  of	  activities	  around	  TB	  in	  KwaZulu-­‐Natal,	  including	  the	  declaration	  of	  “crisis	  districts”	  that	  received	  additional	  funding	  for	  tuberculosis	  control.	  Umzinyathi	  district	  was	  not	  originally	  one	  of	  these	  crisis	  districts,	  but	  the	  district	  was	  later	  added	  due	  to	  XDR-­‐TB.	  Margot,	  interview	  by	  author,	  2010.	  411	  Radebe,	  interview	  by	  author,	  2011.	  412	  Ngema	  later	  became	  director	  of	  Philanjalo.	  413	  Fikile	  Ngema,	  interview	  by	  author,	  13	  October,	  Tugela	  Ferry,	  South	  Africa.	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tempted	  to	  question	  the	  researchers’	  motives.	  She	  wondered:	  “Where	  are	  they	  getting	  those	  patients?	  Are	  these	  people	  looking	  for	  funding?”	  She	  was	  impressed	  by	  the	  media	  response.	  “The	  story	  just	  blew	  out	  of	  proportion.	  The	  news,	  the	  papers.	  And	  as	  a	  district	  office	  […]	  we	  were	  frustrated	  because	  we	  were	  receiving	  calls	  from	  all	  over.	  All	  the	  radio	  stations.”	  In	  the	  shadow	  of	  the	  press	  coverage	  there	  was	  a	  sense	  of	  urgency,	  and	  Ngema	  traveled	  frequently	  from	  district	  headquarters	  in	  Dundee	  to	  Tugela	  Ferry,	  over	  an	  hour	  away.	  Her	  efforts	  also	  immediately	  benefitted	  from	  the	  resources	  and	  interest	  of	  Philanjalo,	  the	  affiliated	  American	  HIV/TB	  researchers,	  as	  well	  as	  Italian	  development	  assistance.	  “We	  had	  to	  stay	  here	  at	  COSH	  [Church	  of	  Scotland	  Hospital]	  most	  of	  the	  time,	  checking,	  what	  is	  happening,	  the	  infection	  control.	  We	  involved	  other	  people.	  Philanjalo	  was	  involved	  full	  time,	  the	  Italian	  Cooperation	  was	  there,	  we	  had	  to	  try	  and	  do	  something,	  set	  up	  teams,	  trace.	  And	  during	  that	  time,	  most	  of	  the	  patients	  were...	  by	  the	  time	  they	  were	  discovered	  some	  were	  dead.”414	  	  Overall,	  Umzinyathi	  district	  employees	  indicated	  that	  their	  first	  reaction	  to	  hearing	  about	  the	  high	  rates	  of	  drug-­‐resistant	  tuberculosis	  was	  one	  of	  surprise	  and	  consternation,	  while	  their	  second	  reaction	  was	  one	  of	  frenzied	  action.	  In	  2011	  Church	  of	  Scotland	  Hospital	  CEO	  Hans	  Human	  explained	  that	  the	  official	  reaction	  could	  not	  be	  considered	  slow	  in	  government	  terms:	  “I	  think	  that	  in	  the	  context	  of	  working	  for	  government	  things	  happened	  quite	  fast,	  for	  me.	  Because	  really	  it’s	  very,	  very	  slow,	  because	  we’ve	  got	  the	  financial	  year	  and	  in	  that	  financial	  year	  you	  must	  [have]	  a	  budget	  allocation,	  adjustments,	  and	  money	  must	  come	  from	  somewhere	  that’s	  not	  been	  allocated	  this	  financial	  year,	  and	  create	  more	  staff,	  and	  create	  more	  post	  levels,	  […]	  and	  create	  office	  space	  and	  get	  extra	  budget	  for	  your	  extractor	  fans,	  to	  find	  the	  money.	  	  You’ve	  got	  all	  of	  these	  in-­‐house	  protocols,	  politics,	  procedures,	  systems	  that	  you	  have	  to	  overcome.”415	  
                                                414	  Ngema,	  interview	  by	  author,	  2010.	  415	  Hans	  Human,	  interview	  by	  author,	  14	  January	  2011,	  Tugela	  Ferry,	  South	  Africa.	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The	  news	  media	  featured	  heavily	  in	  administrators’	  accounts	  of	  how	  they	  came	  to	  understand	  the	  importance	  of	  drug-­‐resistant	  tuberculosis	  in	  Msinga.	  This	  lends	  some	  credence	  to	  claims	  that	  a	  strong	  response	  to	  drug-­‐resistant	  tuberculosis	  in	  Tugela	  Ferry	  took	  place	  only	  after	  higher	  level	  officials	  had	  been	  embarrassed	  by	  critical	  and	  alarmist	  reports	  in	  the	  South	  African	  and	  international	  media.	  Mr.	  Jabulani	  Mndebele,	  the	  Umzinyathi	  district	  manager,	  in	  particular,	  asserted	  that	  he	  learned	  about	  XDR-­‐TB	  from	  the	  news.416	  In	  his	  view,	  any	  government	  delay	  in	  response	  to	  drug-­‐resistant	  tuberculosis	  in	  Tugela	  Ferry	  was	  not	  related	  to	  his	  department’s	  denial	  or	  incompetence,	  but	  was	  due	  to	  the	  fact	  that	  researchers	  had	  not	  followed	  the	  correct	  reporting	  hierarchy.	  “They	  never	  alerted	  anyone	  to	  say	  we	  are	  now	  going	  in	  explosion.	  So	  people	  started	  using	  different	  routes	  to	  actually	  make	  the	  problem	  be	  known	  all	  over.	  And	  that	  was	  not	  going	  to	  help	  it,	  because	  only	  [we	  –	  the	  district	  office]	  were	  responsible	  to	  solve	  that	  problem.”417	  I	  interpret	  this	  to	  mean	  that	  he	  had	  information	  about	  a	  problem	  with	  drug-­‐resistant	  tuberculosis	  in	  his	  district	  but	  had	  not	  seen	  the	  urgency	  of	  the	  situation	  or	  of	  XDR-­‐TB,	  per	  se,	  until	  he	  saw	  alarmist,	  international	  media	  reports.	  In	  the	  context	  of	  media	  pressure,	  Mndebele	  called	  the	  different	  stakeholders	  who	  were	  involved	  in	  the	  response	  to	  XDR-­‐TB	  together	  for	  a	  meeting	  so	  that	  they	  could	  “come	  and	  present:	  what	  it	  is	  that	  you	  are	  talking	  about,	  what	  is	  that	  XDR,	  how	  did	  you	  find	  it?	  What	  exactly	  needs	  to	  happen	  in	  order	  for	  us	  to	  try	  to	  actually	  minimize	  and	  turn	  this	  cycle	  around?”418	  According	  to	  one	  of	  the	  American	  researchers	  present,	  the	  visiting	  tuberculosis	  researchers	  anticipated	  resistance	  from	  the	  district	  manager	  and	  worried	  about	  the	  future	  of	  their	  research.	  To	  their	  surprise,	  the	  district	  manager	  expressed	  a	  desire	  to	  see	  the	  work	  continue.	  He	  requested	  that	  they	  do	  a	  better	  job	  of	  communicating	  their	  research	  to	  the	  
                                                416	  This	  contradicts	  some	  accounts	  from	  other	  sources.	  417	  Jabulani	  Mndebele,	  interview	  by	  author,	  10	  March	  2011,	  Tugela	  Ferry,	  South	  Africa.	  	  418	  Ibid.	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district	  leadership	  and	  of	  more	  explicitly	  coordinating	  visiting	  researchers	  through	  appropriate	  government	  authorization	  processes.	  Seeking	  official	  permissions	  for	  tuberculosis	  research	  in	  Tugela	  Ferry	  was	  not	  just	  an	  official	  hurdle.	  It	  allowed	  government	  officials	  to	  be	  apprised	  of	  research	  occurring	  at	  their	  public	  hospital	  and	  be	  informed	  about	  interesting	  results.	  It	  also	  potentially	  enabled	  research	  efforts	  to	  be	  more	  evenly	  distributed	  across	  hospital	  sites	  –	  district	  manager	  Mndebele	  argued,	  for	  example,	  that	  he	  encouraged	  new	  applicants	  who	  wanted	  to	  do	  research	  on	  tuberculosis	  to	  look	  beyond	  Tugela	  Ferry	  and	  set	  up	  projects	  in	  one	  of	  the	  other	  three	  hospitals	  in	  his	  district.	  Finally,	  it	  was	  implied	  to	  me	  by	  several	  people	  that	  researchers	  affiliated	  with	  the	  original	  research	  team	  in	  Tugela	  Ferry	  (specifically	  Dr.	  Moll	  and	  his	  American	  collaborators	  Dr.	  Friedland	  and	  Dr.	  Gandhi)	  were	  more	  likely	  to	  receive	  research	  permission	  for	  work	  in	  Tugela	  Ferry	  than	  new	  research	  teams.	  This	  guaranteed	  that	  the	  original	  research	  group	  had	  continued	  access	  to	  the	  research	  site	  and	  discouraged	  competition	  from	  other	  interested	  institutions.	  It	  also	  fostered	  the	  building	  of	  friendly	  relationships	  between	  researchers	  and	  government	  representatives.	  In	  fact,	  the	  increased	  inclusion	  of	  district	  and	  provincial	  government	  employees	  as	  authors	  on	  research	  papers	  and	  as	  presenters	  at	  meetings	  may	  well	  be	  an	  indicator	  of	  improving	  mutual	  relationships	  between	  the	  two	  groups	  over	  time.	  	  Regular	  meetings	  between	  researchers,	  physicians,	  TB	  coordinators	  and	  the	  district	  manager	  were	  set	  up	  to	  review	  and	  improve	  the	  tuberculosis	  program.	  One	  priority	  was	  to	  find	  and	  bring	  into	  care	  the	  patients	  whose	  laboratory	  results	  had	  shown	  that	  they	  had	  drug-­‐resistant	  tuberculosis.	  Another	  included	  improving	  tuberculosis	  infection	  control	  in	  order	  to	  protect	  staff	  and	  patients.	  Finally,	  dramatic	  changes	  needed	  to	  be	  made	  to	  the	  organization	  of	  tuberculosis	  care	  in	  order	  to	  give	  patients	  timely	  access	  to	  treatment	  for	  MDR-­‐TB	  and	  XDR-­‐TB.	  Umzinyathi	  TB	  coordinator	  Zanele	  Radebe	  recalls	  tracing	  the	  newly	  identified	  MDR-­‐
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TB	  patients:	  “So	  first	  what	  we	  did	  is	  to	  organize	  teams	  so	  that	  they	  go	  out	  and	  trace,	  these	  teams.	  It	  just	  took	  us	  plus-­‐minus	  three	  months	  to	  do	  the	  whole	  exercise.	  And	  there	  were	  more	  than	  100	  clients	  that	  were	  just	  roaming	  around	  in	  the	  community,	  not	  on	  treatment	  and	  we	  were	  not	  aware	  whether	  they	  died,	  or	  they	  are	  still	  alive.”419	  Patients	  were	  dispersed	  across	  the	  extensive	  hospital	  catchment	  area;	  many	  of	  them	  lived	  in	  remote	  settings,	  far	  from	  main	  roads,	  and	  without	  regular	  (or	  known)	  phone	  access.	  Philanjalo	  was	  able	  to	  make	  community	  health	  workers,	  research	  workers,	  vehicles	  and	  fuel	  available,	  while	  the	  Umzinyathi	  district	  reallocated	  some	  of	  its	  vehicles.	  Existing	  hospital	  resources	  were	  also	  focused	  on	  tracing	  these	  patients.	  Sister	  Msomi	  who	  oversaw	  the	  teams	  stated:	  “Many	  patients	  needed	  to	  be	  traced,	  so	  our	  teams	  were	  going	  out	  on	  a	  daily	  basis	  looking	  for	  these	  contacts.	  And	  newly	  diagnosed	  patients	  were	  dying	  like	  flies.”420	  She	  emphasized	  that	  her	  hospital-­‐based	  DOTS	  staff	  worked	  together	  with	  non-­‐government	  Philanjalo	  employees	  that	  were	  provided	  to	  help	  her:	  “We	  were	  very	  busy.	  We	  were	  working	  hand	  in	  hand	  to	  identify	  suspects.”421	  Later,	  Zanele	  Radebe	  oversaw	  the	  hiring	  of	  dedicated	  TB	  nurses	  at	  each	  outlying	  primary	  health	  care	  clinic	  and,	  with	  help	  from	  the	  Italian	  Cooperation,	  introduced	  TB	  diaries	  with	  which	  the	  nurses	  could	  keep	  better	  track	  of	  their	  patients.422	  The	  simple	  provision	  of	  improved	  stationery	  paired	  with	  hospital-­‐based	  tracer	  teams	  who	  sought	  out	  patients	  who	  had	  not	  made	  it	  to	  their	  clinic	  appointments	  improved	  patients’	  ability	  to	  complete	  their	  treatment	  and	  the	  nurses’	  ability	  to	  hold	  them	  accountable.	  The	  supervision	  
                                                419	  Radebe,	  interview	  by	  author,	  2011.	  420	  Msomi,	  interview	  by	  author,	  2010.	  421	  Ibid.	  422	  The	  TB	  diary	  is	  a	  simple	  ring-­‐bound	  calendar	  that	  allows	  nurses	  to	  see	  each	  day	  which	  patients	  are	  due	  to	  come	  in	  to	  receive	  their	  treatment	  and	  which	  patients	  have	  not	  come.	  It	  was	  mentioned	  several	  times	  to	  me	  (including	  by	  clinic	  nurses)	  as	  a	  major	  improvement	  in	  how	  they	  managed	  their	  patients.	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and	  support	  of	  nurses	  who	  were	  stationed	  at	  remote	  clinics	  was	  strengthened,	  as	  well,	  though	  retention	  and	  ongoing	  support	  of	  these	  nurses	  remained	  a	  challenge.423	  
The	  risk	  of	  infection	  Next	  to	  identifying	  patients	  and	  bringing	  them	  in	  to	  the	  hospital	  for	  evaluation	  and	  treatment,	  another	  priority	  was	  to	  protect	  hospital	  staff,	  researchers,	  patients	  and	  visitors	  from	  infection	  with	  drug-­‐resistant	  tuberculosis.	  When	  nurses,	  therapists,	  research	  assistants,	  technicians	  and	  physicians	  first	  heard	  about	  the	  presence	  of	  the	  deadly,	  airborne,	  treatment-­‐resistant	  disease	  in	  their	  midst	  many	  of	  them	  understandably	  reacted	  with	  panic.	  Msinga	  TB	  coordinator	  Sister	  Msomi	  recalled	  that	  one	  newspaper	  hyperbolically	  claimed	  that	  if	  “you	  come	  to	  Msinga	  within	  six	  hours	  you’ll	  be	  dead,”	  and	  that	  some	  hospital	  physicians	  and	  nurses	  stopped	  coming	  to	  work.424	  One	  HIV	  counselor	  said	  that	  she	  was	  shocked	  when	  she	  first	  heard	  about	  MDR-­‐TB	  on	  the	  radio,	  and	  her	  relatives	  asked	  her	  if	  she	  was	  bringing	  a	  deadly	  disease	  home	  with	  her.	  It	  was	  not	  until	  shortly	  thereafter	  that	  information	  about	  the	  disease	  was	  cascaded	  to	  her	  through	  the	  ranks	  in	  the	  hospital	  through	  meetings	  and	  workshops.	  Many	  South	  African	  newspaper	  articles	  emphasized	  the	  individual	  patients	  who	  did	  not	  take	  their	  treatment	  correctly,	  thereby	  causing	  drug-­‐resistant	  tuberculosis,	  as	  well	  as	  the	  risks	  that	  arose	  at	  facilities	  that	  housed	  such	  patients.425	  Nurses,	  HIV	  counselors	  and	  technicians	  were	  nervous	  about	  working	  with	  sick,	  coughing	  patients	  who	  could	  potentially	  expose	  them	  to	  a	  deadly	  illness.	  Several	  health	  workers	  framed	  their	  fear	  in	  terms	  of	  HIV,	  the	  disease	  that	  had	  so	  dramatically	  increased	  their	  workload	  and	  increased	  the	  stakes	  of	  working	  in	  medicine	  over	  the	  previous	  decade.	  
                                                423	  Radebe,	  interview	  by	  author,	  2011.	  424	  Msomi,	  interview	  by	  author,	  2010.	  425	  For	  an	  analysis	  of	  the	  English-­‐language	  South	  African	  newspaper	  coverage	  see:	  Mark	  Daku,	  Andrew	  Gibbs	  and	  Jody	  Heymann,	  “Representations	  of	  MDR	  and	  XDR-­‐TB	  in	  South	  African	  newspapers,”	  Social	  Science	  &	  Medicine	  75	  (2012):	  410-­‐418.	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As	  one	  technician	  explained:	  “I	  don’t	  have	  a	  problem	  with	  an	  HIV	  positive	  person	  and	  I’m	  not	  afraid	  of	  him.	  I	  can	  even	  nurse	  him.	  But	  I’m	  very	  afraid	  of	  MDR[-­‐TB].”	  The	  district,	  with	  assistance	  from	  the	  Italian	  Cooperation,	  Philanjalo,	  and	  a	  South	  African	  health	  consulting	  organization	  called	  Health	  Systems	  Trust,	  conducted	  workshops	  to	  train	  the	  hospital	  staff	  on	  TB	  infection	  control.	  One	  individual-­‐based	  line	  of	  defense	  against	  tuberculosis	  infection	  is	  to	  wear	  a	  protective	  mask	  called	  an	  N95	  mask	  that	  seals	  tightly	  over	  nose	  and	  mouth.	  These	  masks	  are	  different	  from	  standard	  surgical	  masks	  and	  were	  not	  readily	  available	  through	  the	  government	  hospital	  at	  first,	  but	  they	  were	  supplied	  by	  the	  University	  of	  KwaZulu-­‐Natal	  and	  through	  international	  research	  sources.426	  Later,	  they	  were	  supplied	  through	  government	  procurement	  sources.	  Consistent	  mask-­‐wearing	  could	  be	  very	  difficult	  to	  maintain,	  however.	  Eugene	  Meyer,	  a	  missionary	  from	  Cape	  Town,	  was	  working	  as	  a	  data	  manager	  for	  Philanjalo’s	  TB/HIV	  cotreatment	  study	  and	  remembers	  that	  the	  discovery	  of	  highly	  drug-­‐resistant	  tuberculosis	  in	  Tugela	  Ferry	  “just	  changed	  my	  life.”427	  He	  spent	  many	  hours	  each	  week	  interacting	  with	  TB	  and	  HIV	  patients	  as	  they	  arrived	  in	  clinic,	  and	  he	  sought	  ways	  to	  protect	  himself,	  but	  found	  masks	  were	  very	  cumbersome	  to	  wear,	  especially	  in	  hot	  weather:	  “The	  problem	  was	  wearing	  a	  mask.”428	  Many	  of	  the	  other	  health	  care	  workers	  I	  spoke	  to	  agreed.	  In	  the	  hospital,	  the	  masks	  were	  not	  only	  uncomfortable,	  but	  were	  the	  first	  indicator	  for	  some	  staff,	  patients,	  and	  visitors	  that	  something	  very	  concerning	  was	  happening.	  They	  gave	  some	  nurses	  and	  staff	  sense	  of	  security,	  while	  others	  wondered	  what	  the	  point	  was,	  considering	  that	  they	  had	  relatives,	  friends	  and	  neighbors	  with	  HIV	  and	  TB	  and	  they	  did	  not	  wear	  masks	  at	  home.	  Health	  workers	  learned	  in	  infection-­‐control	  workshops	  that	  healthy,	  well-­‐fed	  bodies	  with	  strong	  immune	  systems	  (unencumbered	  by	  HIV/AIDS,	  old-­‐age,	  stress,	  
                                                426	  Eugene	  Meyer,	  interview	  by	  author,	  October	  10	  2010,	  Tugela	  Ferry,	  South	  Africa.	  427	  Ibid.	  428	  Ibid.	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or	  systemic	  diseases)	  were	  less	  likely	  to	  become	  ill	  with	  tuberculosis.	  Many	  of	  the	  nurses	  and	  auxiliary	  staff	  I	  spoke	  to	  concluded	  that	  they	  must	  never	  be	  hungry	  or	  tired	  when	  seeing	  patients.	  Thus	  for	  some	  the	  consumption	  of	  snacks	  and	  lunch	  during	  well-­‐timed	  breaks	  became	  an	  existential	  matter	  more	  important	  than	  the	  masks.	  Many	  health	  workers	  relied	  on	  their	  faith	  in	  God	  to	  safely	  get	  them	  through	  days	  filled	  with	  potentially	  risky	  encounters	  with	  contagious	  patients.	  Others	  resigned	  themselves	  to	  their	  fates	  and	  decided	  that	  their	  odds	  of	  infection	  were	  not	  so	  high	  to	  make	  their	  jobs	  unacceptable.	  Sheila	  Bamber,	  a	  white	  South	  African	  physician	  in	  her	  70s	  who	  had	  treated	  tuberculosis	  patients	  for	  four	  decades,	  took	  her	  chances	  and	  never	  wore	  a	  mask,	  even	  when	  sitting	  in	  a	  room	  with	  several	  known	  MDR-­‐TB	  patients.	  She	  pointed	  out	  that	  she	  had	  lived	  a	  long	  life	  and	  laughed	  at	  the	  other	  physicians	  and	  students	  who	  started	  the	  day	  wearing	  masks	  around	  their	  faces	  but	  soon	  found	  them	  hanging	  around	  their	  necks	  (or	  arms,	  or	  elbows,	  or	  in	  their	  pockets).429	  Several	  other	  physicians	  I	  spoke	  to	  had	  an	  air	  of	  invulnerability	  to	  them	  and	  seemed	  to	  reassure	  themselves	  that	  the	  social	  distance	  from	  their	  patients,	  their	  good	  health,	  and	  their	  avoidance	  of	  disease	  until	  now	  would	  protect	  them.	  Some	  doctors	  pointed	  out	  that	  the	  mask	  was	  incompatible	  with	  their	  chosen	  facial	  hairstyle	  and	  found	  that	  explanation	  enough	  for	  opting	  out	  of	  wearing	  one.	  One	  nurse	  said	  he	  always	  wore	  a	  mask	  when	  at	  work,	  including	  when	  going	  on	  home	  visits.	  But	  other	  practitioners	  had	  a	  more	  selective	  approach.	  Another	  nurse	  explained	  that	  she	  wore	  the	  mask	  if	  she	  knew	  that	  the	  patient	  might	  have	  drug-­‐resistant	  tuberculosis,	  but	  not	  when	  dealing	  with	  all	  patients.	  But	  how	  could	  she	  know	  for	  sure?	  Yet	  another	  nurse	  explained	  that	  she	  tried	  to	  wear	  the	  mask	  at	  the	  hospital	  but	  became	  discouraged	  when	  she	  took	  public	  transportation	  to	  go	  home,	  because	  she	  couldn’t	  know	  what	  she	  was	  exposed	  to	  there.	  
                                                429	  Sheila	  Bamber,	  interview	  by	  author,	  26	  August	  2010,	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  Ferry,	  South	  Africa.	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Not	  only	  health-­‐care	  workers	  but	  also	  patients	  were	  at	  risk	  of	  infection	  in	  the	  hospital.	  The	  Church	  of	  Scotland	  Hospital	  in	  Tugela	  Ferry,	  like	  most	  South	  African	  hospitals,	  had	  large,	  open	  wards,	  and	  only	  minimal	  ability	  to	  isolate	  individual	  patients	  suspected	  to	  harbor	  dangerous	  diseases.	  Before	  the	  discovery	  of	  XDR-­‐TB	  the	  TB	  wards	  were	  often	  filled	  beyond	  capacity,	  with	  patients	  sleeping	  on	  “floor	  beds”	  –	  mattresses	  placed	  between	  the	  formal	  beds.	  In	  retrospect	  many	  people,	  including	  the	  CEO	  of	  the	  Church	  of	  Scotland	  Hospital,	  acknowledged	  that	  this	  was	  a	  predictable	  recipe	  for	  the	  rapid	  spread	  of	  an	  illness	  like	  XDR-­‐TB.	  As	  CEO	  Hans	  Human	  put	  it:	  “From	  an	  environmental	  perspective,	  the	  more	  patients	  you’ve	  got	  in	  the	  TB	  ward	  the	  more	  risk	  of	  spread.	  It	  doesn’t	  matter	  where	  in	  the	  hospital	  you	  are,	  because	  you’ve	  got	  bad	  germs	  and	  because	  everybody	  is	  coming	  here	  sick	  with	  some	  kind	  of	  illness.	  So	  actually	  the	  hospital	  is	  a	  very	  dangerous	  place	  to	  be	  and	  it’s	  better	  to	  discharged	  as	  soon	  as	  possible.”430	  Until	  XDR-­‐TB	  made	  itself	  known,	  however,	  patients’	  need	  for	  compassionate	  care,	  including	  nursing,	  medication,	  and	  regular	  meals,	  took	  precedence,	  especially	  for	  the	  core	  group	  of	  physicians	  who	  had	  been	  administering	  to	  the	  impoverished	  community	  in	  Msinga	  for	  many	  years.	  Once	  the	  MDR/XDR	  problem	  became	  evident	  in	  the	  wards,	  Moll	  and	  his	  colleagues	  started	  clamoring	  for	  extraction	  fans	  to	  be	  installed	  in	  order	  to	  remove	  the	  TB	  bacillus	  from	  the	  hospital	  air	  and	  help	  protect	  patients	  and	  staff.	  The	  department	  of	  health	  eventually	  installed	  such	  a	  system	  in	  the	  tuberculosis	  wards	  though	  no	  corresponding	  investment	  in	  the	  maintenance	  of	  the	  system	  was	  made.	  Small	  side-­‐wards	  were	  made	  available	  for	  people	  with	  known	  MDR-­‐TB	  or	  XDR-­‐TB.	  Yet	  considering	  the	  slow	  diagnostics	  for	  drug-­‐resistant	  tuberculosis,	  patients	  with	  drug-­‐resistant	  tuberculosis	  could	  lie	  together	  with	  dozens	  of	  other	  patients	  for	  days	  to	  weeks	  before	  their	  status	  as	  MDR	  patients	  was	  known.	  Formal	  studies	  eventually	  confirmed	  the	  suspicion	  that	  prolonged	  stays	  at	  the	  Church	  of	  Scotland	  
                                                430	  Human,	  interview	  by	  author,	  2011.	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Hospital	  were	  in	  fact	  a	  key	  contributor	  to	  the	  spread	  of	  MDR-­‐TB	  and	  XDR-­‐TB	  in	  the	  Msinga	  region.431	  Interestingly,	  closer	  evaluation	  of	  tuberculosis	  infection	  control	  techniques	  indicated	  that	  old-­‐fashioned	  or	  low-­‐tech	  methods	  of	  infection	  control	  could	  potentially	  be	  as	  effective	  as	  high-­‐cost	  extraction	  systems,	  negative	  pressure	  isolation	  rooms,	  or	  ultraviolet	  lamps	  (which	  are	  used	  to	  kill	  the	  TB	  bacillus).432	  Systemic	  strategies	  that	  could	  lower	  the	  likelihood	  of	  hospital-­‐based	  spread	  of	  tuberculosis	  included	  keeping	  windows	  in	  hospital	  wards	  open	  at	  all	  times	  for	  cross-­‐ventilation	  (and	  providing	  blankets	  in	  cold	  weather),	  conducting	  sputum	  collection	  in	  the	  open	  air	  and	  in	  sunlight	  in	  order	  avoid	  the	  spread	  of	  germs	  in	  a	  closed	  space,	  as	  well	  as	  implementing	  changes	  in	  waiting-­‐room	  policies.	  Researchers	  used	  mathematical	  modeling	  studies	  to	  argue	  for	  a	  comprehensive	  package	  of	  low	  and	  high-­‐tech	  interventions.433	  Increasingly,	  funders	  and	  government	  agencies	  perhaps	  had	  reason	  to	  feel	  justified	  in	  resisting	  the	  purchase	  of	  expensive	  infection	  control	  equipment.	  In	  Tugela	  Ferry	  American	  researchers,	  working	  together	  with	  an	  infection	  control	  nurse	  hired	  by	  the	  department	  of	  health,	  surveyed	  hospital	  staff	  to	  determine	  barriers	  to	  effective	  infection	  control	  and	  implemented	  education	  sessions	  and	  policies	  with	  the	  goal	  of	  preventing	  infections	  at	  the	  hospital.434	  International	  visitors	  working	  for	  Philanjalo	  also	  assembled	  educational	  materials	  and	  visual	  aids	  to	  explain	  XDR-­‐TB	  and	  infection	  control	  to	  
                                                431	  Neel	  Gandhi	  et	  al.,	  “Nosocomial	  Transmission	  of	  Extensively	  Drug-­‐Resistant	  Tuberculosis	  in	  a	  Rural	  Hospital	  in	  South	  Africa,”	  Journal	  of	  Infectious	  Diseases	  207,	  no.1	  (2013):	  9-­‐17.	  432	  A.R.	  Escombe	  et	  al.,	  “Natural	  Ventilation	  for	  the	  Prevention	  of	  Airborne	  Contagion,”	  PLoS	  Medicine	  4,	  no.	  2	  (2007):	  e68.	  433	  Sanjay	  Basu,	  et	  al.,	  “Prevention	  of	  nosocomial	  transmission	  of	  extensively	  drug-­‐resistant	  tuberculosis	  in	  rural	  South	  African	  district	  hospitals:	  An	  epidemiological	  modelling	  study.”	  Lancet	  370	  no.	  9597	  (2007):	  1500–1507.	  434	  Zahir	  Kanjee	  et	  al.,	  “Tuberculosis	  infection	  control	  in	  rural	  South	  Africa:	  survery	  of	  knowledge,	  attitude	  and	  practice	  in	  hospital	  staff,”	  Journal	  of	  Hospital	  Infection	  79,	  no.	  4(2011):	  333-­‐338;	  Zahir	  Kanjee	  et	  al.,	  “Tuberculosis	  infection	  control	  in	  a	  high	  drug-­‐resistance	  setting	  in	  rural	  South	  Africa:	  information,	  motivaton,	  and	  behavioral	  skills,”	  Journal	  of	  Infection	  and	  Public	  Health	  5,	  no.1	  (2012):	  67-­‐81.	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staff	  and	  patients.	  New	  outpatient	  department	  policies	  called	  for	  coughing	  patients	  to	  be	  screened	  upon	  arrival	  and	  to	  be	  given	  simple	  surgical	  masks	  to	  prevent	  droplet	  formation	  in	  the	  waiting	  room.	  These	  patients	  were	  also	  to	  be	  seen	  ahead	  of	  others	  so	  that	  their	  time	  in	  the	  waiting	  room	  (spreading	  potential	  infection)	  could	  be	  minimized.	  These	  and	  other	  “low-­‐tech”	  interventions	  were	  frequently	  re-­‐emphasized	  and	  re-­‐affirmed.	  Infection	  control	  was	  a	  crucial	  yet	  surprisingly	  complicated	  issue	  that	  demanded	  a	  high	  level	  of	  motivation	  and	  institutional	  will	  in	  order	  to	  be	  successful.	  It	  was	  clear	  that	  repeated	  re-­‐evaluation	  and	  input	  from	  outsiders	  (especially	  outsiders	  who	  were	  themselves	  wary	  about	  the	  risks	  of	  infection	  in	  their	  new	  environment)	  helped	  local	  staff	  maintain	  (and	  periodically	  re-­‐introduce)	  effective	  infection	  control	  practices.435	  
Getting	  people	  into	  care:	  introducing	  community-­‐based	  management	  of	  MDR-­‐TB	  As	  we	  have	  seen,	  early	  efforts	  to	  deal	  with	  the	  news	  of	  MDR-­‐TB	  and	  XDR-­‐TB	  in	  Tugela	  Ferry	  focused	  on	  identifying	  the	  patients	  with	  positive	  laboratory	  tests	  and	  finding	  them	  in	  the	  “real	  world.”	  This	  was	  a	  challenging	  task	  made	  worse	  by	  the	  fact	  that	  many	  of	  the	  patients	  were	  already	  dead	  by	  the	  time	  hospital	  staff	  found	  them,	  or	  were	  in	  desperate	  need	  of	  effective	  treatment.	  As	  Fikile	  Ngema	  recounted	  years	  later:	  “More	  than	  half	  of	  them	  were	  dead,	  and	  we	  realized	  that	  this	  problem	  was	  discovered	  late.	  Because	  when	  you	  got	  to	  the	  families	  they	  were	  saying	  no,	  the	  father	  died	  six	  months	  ago,	  had	  the	  same	  symptoms,	  was	  working	  in	  Jo-­‐burg…”436	  The	  new	  practice	  of	  testing	  all	  tuberculosis	  patients	  for	  drug-­‐resistant	  pathogens	  at	  the	  start	  of	  their	  treatment	  course	  led	  to	  a	  further	  increase	  of	  the	  number	  of	  patients	  with	  drug	  resistant	  tuberculosis	  who	  were	  identified.	  Yet	  in	  2006	  the	  South	  African	  health	  system	  had	  little	  to	  offer	  these	  patients.	  
                                                435	  Author’s	  field	  notes.	  436	  Ngema,	  interview	  by	  author,	  2010.	  
 170 
One	  of	  the	  biggest	  structural	  limitations	  to	  an	  effective	  response	  to	  XDR-­‐TB	  in	  Tugela	  Ferry	  was	  the	  fact	  that	  King	  George	  V	  Hospital	  (KGV),	  the	  government	  referral	  hospital	  in	  Durban	  that	  was	  responsible	  for	  treating	  MDR-­‐TB	  cases	  in	  KwaZulu-­‐Natal,	  was	  clearly	  not	  equipped	  to	  take	  care	  of	  all	  cases	  of	  MDR-­‐TB	  and	  XDR-­‐TB	  across	  the	  province.	  In	  the	  1980s	  King	  George	  V	  hospital	  had	  primarily	  been	  the	  hospital	  for	  complicated	  tuberculosis	  cases,	  such	  as	  TB	  meningitis	  and	  tuberculosis	  of	  the	  bones	  and	  joints,	  for	  the	  wider	  Durban	  region.	  As	  outpatient	  therapy	  according	  to	  DOTS	  became	  standard	  practice	  in	  the	  mid	  1990s,	  the	  tuberculosis	  hospital	  in	  Durban	  reduced	  its	  number	  of	  beds	  and	  focused	  on	  MDR-­‐TB	  cases.	  Following	  WHO	  recommendations,	  KwaZulu-­‐Natal	  designated	  King	  George	  V	  hospital	  as	  the	  center	  of	  excellence	  for	  MDR-­‐TB	  treatment	  for	  the	  entire	  province.	  The	  reduction	  of	  the	  number	  of	  beds,	  a	  dramatic	  increase	  in	  the	  rate	  of	  tuberculosis	  in	  the	  province,437	  and	  the	  fact	  that	  MDR-­‐TB	  patients	  require	  very	  long	  treatment	  courses	  (at	  least	  a	  year)	  meant	  that	  the	  Durban	  hospital	  became	  increasingly	  overwhelmed	  by	  the	  patient	  load	  over	  the	  course	  of	  the	  1990s	  and	  2000s.438	  In	  2005,	  when	  Tugela	  Ferry	  discovered	  its	  MDR-­‐TB	  and	  XDR-­‐TB	  problem,	  King	  George	  V	  hospital	  was	  quickly	  full	  with	  the	  referred	  patients	  and	  its	  waiting	  list	  was	  months	  long.439	  This	  left	  the	  Church	  of	  Scotland	  Hospital	  in	  Tugela	  Ferry	  with	  dozens	  of	  patients	  who	  had	  been	  identified	  as	  having	  MDR-­‐TB	  or	  XDR-­‐TB,	  but	  who	  did	  not	  have	  access	  to	  appropriate	  treatment	  or	  care	  for	  their	  drug-­‐resistant	  strain	  of	  tuberculosis.	  Tugela	  Ferry’s	  tuberculosis	  program	  was	  able	  to	  dispense	  first-­‐line	  tuberculosis	  drugs,	  but	  these	  would	  not	  significantly	  help	  people	  with	  drug-­‐resistant	  tuberculosis.	  Sister	  Msomi	  remembered	  the	  
                                                437	  “The	  TB	  notification	  rate	  in	  KwaZulu-­‐Natal	  rose	  from	  about	  54,000	  in	  2002	  to	  over	  119,000	  in	  2007.	  The	  number	  of	  MDR	  TB	  cases	  rose	  more	  quickly	  from	  210	  in	  2001	  to	  2799	  in	  2007.”	  (Kristina	  Wallengren	  et	  al.,	  “Resistance	  to	  TB	  drugs	  in	  KwaZulu-­‐Natal:	  causes	  and	  prospects	  for	  control.”	  http://arxiv.org/abs/1107.1800).	  438	  Iqbal	  Master,	  interview	  by	  author,	  30	  April	  2010,	  Durban,	  South	  Africa.	  439	  Anso	  Thom,	  “South	  Africa:	  Super	  Resistant	  XDR	  TB	  Rears	  Its	  Head	  in	  KZN,”	  Health-­‐e,	  August	  15,	  2006,	  http://www.health-­‐e.org.za/news/article.php?uid=20031478.	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patients	  who	  died	  waiting:	  “They	  had	  to	  book	  a	  bed	  at	  King	  George	  [V	  hospital]	  and	  they	  had	  to	  wait	  at	  home	  until	  there	  is	  a	  bed.	  So	  the	  time	  would	  go	  and	  you	  would	  find	  that	  the	  patient	  is	  dead.	  It	  was	  bad.	  Bad.	  […]	  Really,	  many	  patients	  died	  while	  they	  were	  waiting	  for	  a	  bed.”440	  The	  hospital	  had	  the	  option	  of	  admitting	  patients	  with	  drug-­‐resistant	  tuberculosis	  in	  Tugela	  Ferry	  and	  giving	  them	  supportive	  therapy	  as	  best	  they	  could.	  This,	  however,	  came	  with	  a	  significant	  risk	  of	  transmitting	  drug-­‐resistant	  tuberculosis	  to	  other	  patients	  and	  staff.	  Sending	  people	  home	  without	  any	  tuberculosis	  treatment	  after	  they	  had	  been	  diagnosed	  with	  MDR-­‐TB	  or	  XDR-­‐TB	  was	  also	  highly	  unpalatable,	  but	  seemed	  to	  be	  a	  better	  option,	  since	  the	  waiting	  list	  at	  King	  George	  V	  hospital	  remained	  long,	  even	  as	  the	  hospital	  prioritized	  XDR-­‐TB	  patients	  from	  Tugela	  Ferry.	  Faced	  with	  these	  unacceptable	  scenarios,	  physicians	  and	  researchers	  in	  Tugela	  Ferry	  decided	  they	  needed	  to	  find	  a	  way	  to	  treat	  patients	  in	  Msinga.	  Physicians,	  administrators,	  and	  nurses	  in	  Tugela	  Ferry,	  with	  the	  cooperation	  of	  their	  counterparts	  in	  Durban,	  cobbled	  together	  a	  pragmatic	  solution	  to	  this	  treatment	  dilemma.	  When	  doctors	  in	  Tugela	  Ferry	  identified	  patients	  as	  having	  MDR-­‐TB	  or	  XDR-­‐TB,	  they	  notified	  the	  doctors	  at	  King	  George	  V	  hospital	  and	  sent	  stable	  patients	  to	  Durban	  for	  an	  outpatient	  clinic	  appointment.	  They	  were	  then	  sent	  back	  to	  Tugela	  Ferry	  with	  a	  supply	  of	  medications	  for	  drug-­‐resistant	  tuberculosis,	  including	  medications	  that	  needed	  to	  be	  injected	  by	  a	  nurse.	  Once	  the	  patients	  were	  back	  home,	  teams	  of	  nurses	  from	  Tugela	  Ferry	  regularly	  visited	  them	  to	  provide	  the	  injections	  required	  for	  MDR-­‐TB	  and	  XDR-­‐TB	  treatment	  in	  addition	  to	  their	  pills.	  These	  nurses	  could	  also	  check	  for	  side-­‐effects	  and	  other	  problems.	  This	  solution	  freed	  up	  beds	  at	  the	  TB	  hospital	  in	  Durban	  and	  allowed	  patients	  with	  drug-­‐resistant	  tuberculosis	  to	  access	  treatment	  close	  to	  home	  in	  Msinga.	  
                                                440	  Msomi,	  interview	  by	  author,	  2010.	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This	  home	  treatment	  program	  required	  a	  significant	  investment	  of	  resources	  on	  the	  part	  of	  the	  Church	  of	  Scotland	  Hospital’s	  TB	  program	  and	  the	  Umzinyathi	  district.	  The	  human	  resources	  and	  transport	  capacity	  that	  was	  required	  for	  such	  intense	  outreach	  was	  initially	  facilitated	  and	  funded	  by	  Philanjalo	  and	  the	  Italian	  Cooperation	  and	  later	  expanded	  with	  public	  government	  funds.	  Tugela	  Ferry’s	  hospital-­‐based	  DOTS	  office	  was	  greatly	  expanded	  with	  tracer	  teams,	  injection	  teams	  and	  vehicles	  in	  order	  to	  provide	  this	  home-­‐based	  service	  and	  was	  moved	  to	  larger	  quarters	  within	  the	  hospital.	  By	  mid	  2008	  the	  DOTS	  office	  had	  expanded	  from	  a	  handful	  of	  office-­‐based	  staff	  to	  at	  least	  thirteen	  field	  teams	  of	  about	  two	  people	  each,	  and	  at	  least	  five	  dedicated	  hospital	  vehicles,	  in	  addition	  to	  office	  based	  nurses,	  technicians	  and	  data	  capturers.	  Tugela	  Ferry’s	  move	  towards	  treating	  people	  with	  MDR	  and	  XDR-­‐TB	  at	  home	  was	  not	  uncontroversial	  and	  harked	  back	  to	  the	  debates	  of	  the	  1990s	  about	  the	  best	  ways	  to	  manage	  MDR-­‐TB.	  While	  some	  public	  health	  experts	  viewed	  this	  approach	  as	  an	  innovative	  and	  positive	  strategy	  for	  dealing	  with	  an	  MDR-­‐TB	  epidemic,	  others	  preferred	  inpatient	  treatment	  of	  drug-­‐resistant	  tuberculosis	  and	  felt	  that	  not	  putting	  patients	  under	  quarantine	  was	  irresponsible.441	  Managing	  MDR-­‐TB	  in	  the	  community	  raised	  many	  questions	  about	  the	  risks	  of	  sending	  people	  with	  tuberculosis	  back	  home,	  where	  they	  might	  infect	  family	  and	  community	  members	  with	  their	  drug-­‐resistant	  strains.	  One	  the	  other	  hand,	  hospitals	  are	  themselves	  places	  that	  tend	  to	  facilitate	  the	  spread	  of	  airborne	  diseases	  among	  its	  patients.	  Some	  experts	  argued	  that	  it	  was	  more	  efficient	  to	  monitor	  people’s	  treatment	  course	  in	  the	  hospital,	  and	  believed	  that	  it	  was	  unrealistic	  in	  the	  long	  run	  to	  provide	  nurses	  with	  vehicles	  who	  drive	  to	  patients’	  homes	  every	  day	  to	  give	  them	  their	  treatment	  injections.	  Some	  
                                                441	  Nesri	  Padayatchi	  and	  Gerald	  Friedland,	  “Managing	  Multiple	  and	  Extensively	  Drug-­‐resistant	  Tuberculosis	  and	  HIV,”	  Expert	  Opinion	  on	  Pharmacotherapy	  8,	  no.	  8	  (2007):	  1035-­‐1037;	  Jerome	  A.	  Singh,	  Ross	  Upshur	  and	  Nesri	  Padayatchi,	  “XDR-­‐TB	  in	  South	  Africa:	  No	  Time	  for	  Denial	  or	  Complacency,”	  PLoS	  Medicine	  4,	  no.	  1	  (2007):	  e50.	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patients,	  nurses	  and	  physicians	  argued	  that	  especially	  poor	  patients	  found	  it	  easier	  to	  take	  treatment	  in	  an	  inpatient	  facility,	  where	  meals	  and	  nursing	  care	  were	  provided	  and	  the	  hunger	  caused	  by	  the	  healing	  body	  was	  not	  an	  existential	  problem.	  WHO	  experts	  did	  not	  immediately	  support	  community-­‐based	  management,	  but	  instead	  advocated	  for	  an	  expansion	  of	  hospitals	  specialized	  in	  treating	  MDR-­‐TB.	  Even	  the	  organization	  Doctors	  without	  Borders	  (MSF),	  which	  had	  started	  to	  treat	  MDR-­‐TB	  and	  XDR-­‐TB	  patients	  in	  a	  community-­‐based	  program	  in	  Khayelitsha	  (in	  the	  Cape	  Town	  area)	  and	  had	  advocated	  for	  patient-­‐centered	  integration	  of	  HIV	  and	  TB	  management	  in	  its	  own	  work,	  was	  initially	  weary	  about	  endorsing	  outpatient	  treatment	  of	  MDR-­‐TB	  and	  XDR-­‐TB	  too	  strongly.	  Doctors	  without	  Borders’	  Eric	  Goemaere	  explained	  that	  he	  wanted	  to	  be	  sure	  that	  community-­‐based	  MDR-­‐TB	  and	  XDR-­‐TB	  treatment	  was	  the	  best	  option	  before	  promoting	  it,	  since	  some	  government	  agencies	  were	  perhaps	  prematurely	  enthusiastic	  when	  they	  realized	  it	  was	  cheaper	  and	  less	  permanent	  than	  building	  and	  staffing	  new	  tuberculosis	  hospitals.442	  The	  organization	  Partners	  in	  Health,	  on	  the	  other	  hand,	  actively	  advocated	  for	  community-­‐based	  management	  of	  MDR-­‐TB	  and	  XDR-­‐TB	  from	  the	  onset	  and	  soon	  entered	  the	  conversation	  around	  XDR-­‐TB	  in	  Southern	  Africa	  by	  initiating	  a	  pilot	  program	  for	  community-­‐based	  treatment	  in	  Lesotho.443	  Partners	  in	  Health’s	  programs	  in	  Haiti,	  Peru	  and	  Lesotho	  had	  shown	  that	  patients	  could	  successfully	  complete	  MDR-­‐TB	  treatment	  at	  home,	  especially	  when	  supported	  with	  food,	  transport,	  and	  frequent	  visits	  from	  a	  paid	  community	  health	  worker.444	  
                                                442	  Eric	  Goemaere,	  interview	  by	  author,	  17	  May	  2010,	  Khayelitsha,	  South	  Africa.	  443	  “Studies	  confirm	  XDR-­‐TB	  can	  be	  cured,”	  Partners	  in	  Health	  (blog),	  PIH.org,	  August	  1,	  2008,	  http://www.pih.org/blog/studies-­‐confirm-­‐xdr-­‐tb-­‐can-­‐be-­‐cured#disqus_thread.	  444	  Cesar	  A.	  Bonilla	  et	  al.,	  “Management	  of	  Extensively	  Drug-­‐resistant	  Tuberculosis	  in	  Peru:	  Cure	  Is	  Possible,”	  PloS	  One	  3,	  no.	  8	  (2008):	  e2957;	  Kwonjune	  J.	  Seung	  et	  al.,	  “Early	  Outcomes	  of	  MDR-­‐TB	  Treatment	  in	  a	  High	  HIV-­‐prevalence	  Setting	  in	  Southern	  Africa,”	  PloS	  One	  4,	  no.	  9	  (2009):	  e7186;	  Paul	  Farmer,	  Infections	  and	  Inequalities:	  The	  Modern	  Plagues,	  Updated	  with	  a	  New	  Preface.	  (University	  of	  California	  Press,	  2001).	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The	  KwaZulu-­‐Natal	  provincial	  TB	  office,	  the	  Umzinyathi	  district	  office	  and	  the	  Church	  of	  Scotland	  Hospital	  administration	  at	  first	  tacitly	  and	  then	  actively	  supported	  the	  home-­‐based	  approach	  to	  MDR-­‐TB	  and	  XDR-­‐TB	  treatment	  that	  was	  developing	  in	  Tugela	  Ferry	  under	  the	  steam	  of	  Dr.	  Moll	  and	  his	  South	  African	  and	  international	  colleagues.	  The	  national	  department	  of	  health	  appeared	  to	  withhold	  judgment	  for	  several	  years,	  and	  other	  South	  African	  provinces	  chose	  to	  act	  differently.	  The	  Western	  and	  Eastern	  Cape	  provinces,	  for	  example,	  enforced	  long-­‐term	  hospitalization	  of	  XDR-­‐TB	  patients,	  and	  tried	  to	  prevent	  patients	  from	  leaving	  fenced-­‐in	  hospital	  compounds.	  The	  escape	  of	  several	  patients	  with	  drug-­‐resistant	  tuberculosis	  from	  a	  hospital	  in	  the	  Eastern	  Cape	  gained	  considerable	  media	  attention	  in	  South	  Africa,	  and	  was	  even	  reported	  in	  the	  New	  York	  Times.445	  In	  the	  Western	  Cape,	  the	  burden	  of	  XDR-­‐TB	  was	  low	  enough	  that	  an	  expert	  panel	  could	  convene	  to	  discuss	  the	  options	  for	  each	  individual	  case.446	  In	  KwaZulu-­‐Natal,	  however,	  the	  tuberculosis	  hospital	  was	  so	  overwhelmed	  by	  XDR-­‐TB	  and	  MDR-­‐TB	  that	  community-­‐based	  management	  seemed	  like	  the	  only	  possible	  option,	  next	  to	  not	  treating	  patients	  at	  all.	  	  Researchers	  and	  clinicians	  working	  in	  Tugela	  Ferry	  argued	  that	  community-­‐based	  management	  was	  not	  simply	  the	  most	  expedient	  option	  for	  improving	  TB	  treatment	  outcomes,	  but	  the	  best	  option.	  Infection	  control	  studies	  had	  showed	  that	  MDR-­‐TB	  patients	  were	  most	  infectious	  when	  they	  were	  not	  being	  treated	  at	  all,	  before	  they	  were	  diagnosed,	  and	  the	  investigation	  of	  families	  with	  clusters	  of	  TB	  patients	  did	  not	  show	  significant	  transmission	  of	  MDR-­‐TB	  between	  family	  members.447	  Thus	  returning	  patients	  home	  once	  they	  had	  started	  appropriate	  treatment	  (after	  appropriate	  lead-­‐time)	  should	  not	  
                                                445	  Celia	  W.	  Dugger,	  “TB	  Patients	  Chafe	  Under	  Lockdown	  in	  South	  Africa,”	  The	  New	  York	  Times,	  March	  25,	  2008,	  http://www.nytimes.com/2008/03/25/world/africa/25safrica.html.	  446	  Karen	  Shean,	  interview	  by	  author,	  7	  May	  2010,	  Cape	  Town,	  South	  Africa.	  447	  V.	  Vella	  et	  al,	  “Household	  contact	  investigation	  of	  multidrug-­‐resistant	  and	  extensively	  drug-­‐resistant	  tuberculosis	  in	  a	  high	  HIV	  prevalence	  setting”	  International	  Journal	  of	  Tuberculosis	  and	  Lung	  
Disease	  15,	  no.	  9	  (2011):	  1170-­‐1175.	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significantly	  increase	  the	  risk	  of	  infecting	  family	  members	  and	  neighbors,	  and	  would	  hopefully	  improve	  their	  chances	  at	  completing	  treatment.	  Mathematical	  modeling	  exercises	  supported	  the	  claim	  that	  community-­‐based	  management	  of	  MDR-­‐TB	  would	  be	  more	  effective	  than	  hospital-­‐based	  care.448	  American	  researchers	  in	  the	  Tugela	  Ferry	  research	  network	  designed	  a	  study	  protocol	  with	  which	  to	  assess	  the	  effectiveness	  of	  the	  community-­‐based	  model.449	  In	  the	  aftermath	  of	  the	  discovery	  of	  XDR-­‐TB	  in	  Tugela	  Ferry,	  South	  African	  physicians	  and	  administrators	  from	  the	  Church	  of	  Scotland	  Hospital	  and	  from	  the	  Umzinyathi	  district	  (including	  district	  TB	  coordinator	  Zanele	  Radebe)	  had	  the	  opportunity	  to	  visit	  Partners	  in	  Health’s	  MDR-­‐TB	  program	  in	  Lesotho.	  The	  Msinga	  treatment	  program	  was	  partially	  modeled	  after	  this	  and	  other	  Partners	  in	  Health	  treatment	  programs	  that	  emphasized	  the	  importance	  of	  supporting	  patients’	  basic	  needs	  and	  providing	  treatment	  support	  in	  the	  form	  of	  paid	  community	  health	  workers.	  In	  keeping	  with	  the	  model,	  Philanjalo	  and	  the	  South	  African	  department	  of	  health	  found	  ways	  to	  pay	  many	  (though	  not	  all)	  community	  health	  workers	  in	  Msinga	  a	  stipend	  for	  their	  work	  with	  MDR-­‐TB	  and	  XDR-­‐TB	  patients.	  It	  was	  also	  decided	  that	  all	  people	  on	  MDR-­‐TB	  treatment	  in	  Msinga	  should	  be	  assisted	  in	  obtaining	  a	  government-­‐funded	  disability	  grant	  for	  the	  duration	  of	  their	  treatment.450	  One	  difference	  between	  the	  programs	  in	  Lesotho	  and	  Msinga	  was	  that	  in	  South	  
                                                448	  Sanjay	  Basu	  and	  Allison	  P.	  Galvani,	  “The	  transmission	  and	  control	  of	  XDR	  TB	  in	  South	  Africa:	  an	  operations	  research	  and	  mathematical	  modelling	  approach,”	  Epidemiology	  and	  Infection	  136,	  no.	  12	  (2008):	  1585-­‐1598.	  449	  James	  Brust	  et	  al.	  “Integrated,	  home-­‐based	  treatment	  for	  MDR-­‐TB	  and	  HIV	  in	  rural	  South	  Africa:	  an	  alternate	  model	  of	  care,”	  The	  International	  Journal	  of	  Tuberculosis	  and	  Lung	  Disease	  16,	  no.	  8	  (2012):	  998-­‐1004.	  450	  The	  South	  African	  government’s	  social	  benefits	  system	  relies	  on	  a	  series	  of	  modest	  monthly	  grants	  including	  disability	  grants	  (for	  people	  with	  chronic	  illnesses	  and	  disabilities),	  child	  support	  grants	  and	  foster	  grants	  (for	  people	  caring	  for	  children	  under	  a	  qualifying	  age)	  and	  old	  age	  grants	  (pensions	  for	  people	  above	  a	  qualifying	  age).	  In	  an	  age	  of	  high	  AIDS	  rates	  among	  economically	  productive	  age	  groups	  as	  well	  as	  high	  unemployment	  rates	  many	  poor	  South	  Africans	  depend	  on	  AIDS-­‐related	  disability	  grants,	  older	  relatives’	  pensions	  and	  younger	  relatives’	  child	  care	  grants	  for	  financial	  survival.	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Africa	  injections	  had	  to	  be	  given	  by	  nurses.	  While	  community	  health	  workers	  in	  Lesotho	  helped	  give	  shots	  this	  was	  not	  considered	  an	  option	  in	  South	  Africa’s	  highly	  professionalized	  and	  regulated	  nursing	  environment.	  From	  provincial	  headquarters	  in	  Pietermaritzburg	  KwaZulu-­‐Natal’s	  TB	  coordinator,	  Bruce	  Margot,	  instigated	  further	  changes	  to	  the	  TB	  program	  that	  went	  well	  beyond	  the	  reach	  of	  Tugela	  Ferry	  and	  Msinga’s	  surrounding	  areas.	  Faced	  with	  the	  lack	  of	  capacity	  at	  the	  central	  tuberculosis	  hospital	  in	  Durban	  he	  distributed	  the	  hospital	  care	  for	  MDR-­‐TB	  in	  the	  province	  to	  four	  hospitals	  located	  in	  different	  parts	  of	  KwaZulu-­‐Natal,	  essentially	  	  decentralizing	  the	  management	  of	  MDR-­‐TB	  instead	  of	  expanding	  the	  Durban	  TB	  hospital.	  His	  plans	  were	  also	  informed	  by	  the	  MDR-­‐TB	  treatment	  models	  promoted	  by	  Partners	  in	  Health.	  Karen	  Wallengren,	  a	  WHO	  technical	  advisor	  working	  with	  Margot	  on	  MDR-­‐TB	  and	  XDR-­‐TB,	  helped	  design	  the	  decentralized,	  community-­‐based	  MDR-­‐TB	  program	  at	  the	  provincial	  level.	  She,	  in	  turn,	  sought	  advice	  from	  a	  friend	  and	  colleague	  who	  worked	  for	  Partners	  in	  Health	  in	  Peru.451	  One	  of	  the	  four	  decentralized	  MDR-­‐TB	  hospitals	  in	  the	  province	  was	  placed	  in	  the	  town	  of	  Greytown	  in	  Umzinyathi	  district,	  45	  kilometers	  (and	  45	  minutes	  drive)	  from	  Tugela	  Ferry.	  When	  the	  MDR-­‐TB	  hospital	  in	  Greytown	  was	  opened	  in	  2008,	  this	  meant	  that	  MDR-­‐TB	  patients	  identified	  in	  Tugela	  Ferry	  could	  be	  treated	  more	  locally	  and	  no	  longer	  needed	  to	  travel	  to	  the	  overburdened	  hospital	  in	  Durban.	  They	  were	  admitted	  to	  the	  hospital	  in	  Greytown	  for	  initial	  medical	  stabilization	  and	  education	  on	  MDR-­‐TB	  treatment	  and	  management.	  If	  they	  were	  well	  enough	  they	  were	  then	  sent	  home	  to	  be	  managed	  on	  an	  outpatient	  basis	  with	  regular	  visits	  from	  DOTS	  nurses	  as	  well	  as	  a	  community	  health	  worker.	  Once	  a	  week,	  the	  facility	  in	  Greytown	  hosted	  an	  outpatient	  MDR-­‐TB	  clinic	  where	  nurses	  and	  physicians	  monitored	  the	  progress	  of	  MDR-­‐TB	  patients	  living	  in	  Umzinyathi	  on	  a	  
                                                451	  Wallengren,	  interview	  by	  author,	  2010.	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monthly	  basis.	  King	  George	  V	  hospital	  in	  Durban	  continued	  to	  be	  responsible	  for	  caring	  for	  XDR-­‐TB	  patients	  who	  required	  hospitalization,	  though	  Greytown	  could	  house	  XDR-­‐TB	  patients	  for	  brief	  periods	  of	  time,	  as	  well.	  Even	  as	  more	  decentralized	  structures	  for	  managing	  MDR-­‐TB	  and	  worse	  drug-­‐resistant	  tuberculosis	  were	  put	  in	  place	  the	  treatment	  of	  XDR-­‐TB	  remained	  extremely	  difficult.	  Activists	  and	  physicians	  had	  successfully	  advocated	  for	  the	  introduction	  of	  third-­‐line	  drugs	  to	  treat	  XDR-­‐TB,	  including	  capreomycin	  and	  PAS,	  and	  they	  were	  available	  at	  King	  George	  V	  hospital	  in	  Durban	  by	  December	  2006.452	  But	  XDR-­‐TB	  treatment	  requires	  patients	  to	  take	  these	  medications	  that	  have	  significant	  potential	  side-­‐effects	  for	  several	  years,	  and	  even	  then	  a	  cure	  is	  not	  guaranteed.	  Known	  possible	  adverse	  effects	  from	  these	  drugs	  include	  loss	  of	  hearing,	  loss	  of	  normal	  vision,	  serious	  psychiatric	  effects,	  and	  fatal	  electrolyte	  disturbances.	  Furthermore,	  even	  as	  Tugela	  Ferry	  and	  the	  district	  of	  Umzinyathi	  reorganized	  their	  TB	  treatment	  structures	  and	  improved	  their	  methods	  for	  reaching	  patients	  in	  their	  own	  homes,	  King	  George	  V	  hospital	  in	  Durban	  had	  a	  much	  weaker	  outpatient	  and	  community	  presence	  and	  struggled	  to	  keep	  patients	  in	  care	  once	  they	  left	  the	  four	  walls	  of	  the	  hospital.	  Indeed,	  it	  appears	  that	  Umzinyathi’s	  tuberculosis	  program	  specifically	  benefitted	  from	  administrators,	  researchers	  and	  clinicians	  who	  understood	  how	  to	  capitalize	  on	  the	  spotlight	  that	  had	  been	  focused	  on	  them	  and	  Tugela	  Ferry’s	  XDR-­‐TB	  “outbreak.”	  According	  to	  Fikile	  Ngema	  the	  attention	  towards	  XDR-­‐TB	  and	  MDR-­‐TB	  helped	  Msinga	  sub-­‐district	  and	  Umzinyathi	  district	  strengthen	  many	  aspects	  of	  its	  overall	  TB	  program	  (for	  all	  kinds	  of	  tuberculosis).	  At	  the	  onset	  this	  required	  proactive	  reshuffling	  of	  the	  government	  district’s	  resources	  and	  the	  willingness	  to	  work	  closely	  with	  outside	  partners.	  “We	  tried	  to	  reorganize	  ourselves,	  using	  available	  resources.	  […]	  We	  had	  to	  take	  stock	  of	  the	  vehicles	  that	  [were]	  
                                                452	  Nesri	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available,	  and	  identify	  those	  that	  [could]	  be	  dedicated	  to	  tracer	  teams.”	  The	  district	  also	  allowed	  the	  Church	  of	  Scotland	  Hospital	  to	  redistribute	  existing	  posts	  in	  order	  to	  address	  the	  tuberculosis	  problem,	  and	  to	  let	  the	  hospital	  advertise	  posts	  that	  hadn’t	  been	  filled	  due	  to	  budget	  constraints.	  “We	  allowed	  them	  to	  overspend.	  […]	  	  We	  had	  to	  write	  some	  motivations	  to	  say	  ‘we	  are	  going	  to	  overspend,	  because	  of	  this.’”453	  Ngema	  also	  claimed	  that	  many	  of	  these	  efforts	  originated	  in	  her	  administrative	  district,	  not	  in	  the	  province	  or	  at	  the	  national	  level.	  She	  argued	  that	  by	  the	  time	  the	  province	  of	  KwaZulu-­‐Natal	  made	  funds	  available	  to	  districts	  to	  hire	  additional	  TB	  coordinators,	  for	  example,	  the	  Umzinyathi	  district	  already	  had	  those	  people	  in	  place.	  Marian	  Loveday,	  a	  researcher	  who	  studied	  the	  establishment	  of	  decentralized	  treatment	  programs	  for	  MDR-­‐TB	  across	  the	  province	  of	  KwaZulu-­‐Natal,	  confirmed	  that	  Umzinyathi’s	  district	  leadership	  seemed	  particularly	  proactive	  and	  effective.	  When	  Umzinyathi	  started	  offering	  treatment	  for	  MDR-­‐TB	  at	  Greytown	  hospital	  in	  2008,	  for	  example,	  the	  district	  procured	  audiology	  equipment	  in	  order	  to	  monitor	  the	  adverse	  effects	  MDR-­‐TB	  drugs	  could	  have	  on	  patients’	  hearing.	  By	  the	  time	  the	  province	  offered	  funding	  to	  its	  decentralized	  MDR-­‐TB	  programs	  with	  which	  to	  buy	  such	  equipment,	  Umzinyathi’s	  machine	  was	  already	  in	  place.454	  At	  the	  same	  time,	  Loveday	  and	  most	  other	  sources	  acknowledged	  that	  Bruce	  Margot’s	  provincial	  TB	  office	  was	  very	  supportive	  and	  actively	  funneled	  resources	  and	  personnel	  to	  TB	  programs	  in	  distress	  when	  they	  were	  brought	  to	  his	  attention.	  Intriguingly,	  despite	  the	  XDR-­‐TB	  outbreak	  in	  Umzinyathi,	  the	  Umzinyathi	  district	  was	  one	  of	  the	  better	  performing	  districts	  in	  the	  province	  in	  terms	  of	  TB	  program	  indicators.	  
                                                453	  Ngema,	  interview	  by	  author,	  2010.	  454	  Marian	  Loveday	  et	  al.,	  “A	  Health	  Systems	  Assessment	  of	  the	  KwaZulu-­‐Natal	  Tuberculosis	  Programme	  in	  the	  Context	  of	  Increasing	  Drug	  Resistance,”	  The	  International	  Journal	  of	  Tuberculosis	  
and	  Lung	  Disease	  12,	  no.	  9	  (2008):	  1042–1047;	  Marian	  Loveday,	  interview	  by	  author,	  19	  May	  2010,	  Durban,	  South	  Africa.	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Mr.	  Human,	  the	  CEO	  of	  Tugela	  Ferry’s	  Church	  of	  Scotland	  Hospital,	  credited	  Dr.	  Moll’s	  leadership,	  in	  particular,	  with	  the	  hospital’s	  success	  in	  uncovering	  and	  responding	  to	  its	  drug-­‐resistant	  tuberculosis	  problem,	  and	  for	  embracing	  the	  opportunities	  that	  were	  provided	  by	  “his	  friends	  from	  America.”455	  He	  counted	  Dr.	  Moll	  as	  one	  of	  a	  larger	  group	  of	  people	  who	  were	  crucial,	  however,	  including	  his	  colleague	  Dr.	  van	  der	  Merwe,	  “people	  from	  the	  district,”	  and	  Bruce	  Margot	  from	  the	  provincial	  head	  office	  of	  the	  department	  of	  health.	  Human	  saw	  himself	  as	  the	  man	  who	  passed	  the	  “wish-­‐list”	  to	  the	  higher-­‐ups,	  asking	  for	  more	  staff,	  more	  vehicles	  and	  a	  bigger	  budget,	  while	  Dr.	  Moll	  provided	  plans,	  results,	  and	  projections	  which	  motivated	  further	  projects	  and	  actions.	  From	  Human’s	  perspective	  his	  hospital’s	  involvement	  in	  research	  allowed	  Dr.	  Moll,	  and	  with	  him	  the	  administrative	  district	  of	  Umzinyathi,	  to	  be	  at	  the	  leading	  edge	  of	  tuberculosis	  research	  and	  policy,	  having	  a	  say	  in	  new	  global	  policy	  development,	  and	  influencing	  decisions	  about	  new	  laboratory	  technology.456	  
Why	  Tugela	  Ferry?	  
	   Earlier	  in	  this	  chapter	  I	  stated	  that	  the	  response	  to	  the	  high	  rates	  of	  MDR-­‐TB	  and	  XDR-­‐TB	  in	  Tugela	  Ferry	  took	  place	  in	  the	  context	  of	  many	  open	  questions	  concerning	  the	  causes,	  extent,	  and	  lethality	  of	  the	  discovered	  epidemic.	  Why	  did	  XDR-­‐TB	  come	  to	  Tugela	  Ferry,	  and	  how	  bad	  was	  it?	  As	  Dr.	  Moll	  recounted	  later:	  “we	  felt	  we	  were	  looking	  through	  a	  keyhole	  and	  we	  were	  seeing	  just	  a	  little	  bit	  of	  the	  province	  through	  the	  keyhole	  but	  having	  no	  clue	  what	  was	  happening	  in	  the	  rest	  of	  the	  province.	  […]	  That	  was	  the	  question	  on	  the	  table.	  And	  there	  was	  no	  quick	  way	  of	  answering	  it.”457	  We	  have	  seen	  that	  WHO	  and	  CDC	  experts	  were	  as	  uncertain	  about	  the	  answer	  to	  this	  question	  as	  the	  clinicians	  in	  Tugela	  Ferry.	  Public	  health	  experts	  in	  the	  South	  African	  department	  of	  health,	  in	  academia,	  and	  in	  
                                                455	  Human,	  interview	  by	  author,	  2011.	  456	  Ibid.	  457	  Moll,	  interview	  by	  author,	  2007.	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public	  policy	  circles	  across	  the	  world	  clamored	  for	  more	  epidemiological	  data.	  The	  first	  expert	  consultation	  on	  XDR-­‐TB	  in	  South	  Africa	  in	  September	  in	  2006	  focused	  heavily	  on	  the	  lack	  of	  diagnostic	  capacity	  for	  drug-­‐resistant	  tuberculosis	  in	  Africa,	  “because	  you	  could	  be	  sitting	  on	  a	  time	  bomb	  and	  you	  don’t	  even	  know.”458	  Put	  in	  the	  context	  of	  the	  existing	  WHO	  recommendations	  it	  dawned	  on	  global	  TB	  experts	  that	  “we	  were	  so	  busy	  watching	  smear	  positive	  [drug-­‐susceptible]	  TB	  that	  no	  one	  was	  watching	  what	  was	  going	  on	  with	  MDR	  and	  XDR.	  […]	  It	  was	  quite	  an	  hysterical	  conference.”459	  XDR-­‐TB	  in	  Tugela	  Ferry	  did	  not	  arise	  in	  a	  total	  data	  vacuum,	  however.	  Laboratories	  in	  Durban	  had	  been	  conducting	  TB	  drug-­‐susceptibility	  tests	  on	  various	  kinds	  of	  samples	  and	  collecting	  the	  data	  in	  dispersed	  databases	  and	  files	  during	  the	  decade	  preceding	  the	  discovery	  of	  the	  XDR-­‐TB	  despite	  WHO	  guidelines	  that	  recommended	  against	  it.	  There	  was	  no	  single	  source	  that	  could	  provide	  the	  answer	  to	  the	  origins	  of	  XDR-­‐TB	  in	  Tugela	  Ferry	  or	  project	  its	  future,	  but	  it	  seemed	  that	  the	  information	  might	  not	  be	  completely	  elusive.	  	  At	  the	  time	  when	  international	  alarm	  about	  XDR-­‐TB	  was	  at	  its	  peak,	  the	  WHO	  offered	  to	  provide	  technical	  assistance	  to	  South	  Africa	  around	  XDR-­‐TB.	  The	  provincial	  TB	  manager	  in	  KwaZulu-­‐Natal	  requested	  someone	  who	  could	  help	  him	  assemble	  the	  disparate	  data	  on	  drug-­‐resistant	  tuberculosis	  that	  existed	  across	  the	  province	  and	  conduct	  a	  “situational	  analysis”	  of	  the	  origins	  and	  causes	  of	  XDR-­‐TB	  in	  Tugela	  Ferry.	  (South	  Africa	  was	  apparently	  more	  open	  to	  take	  up	  such	  an	  offer	  from	  the	  WHO	  than	  from	  the	  American	  CDC.)	  Understanding	  the	  root	  causes	  and	  progression	  of	  XDR-­‐TB	  in	  the	  province	  could	  potentially	  direct	  the	  department	  of	  health	  towards	  reasonable	  solutions.	  According	  to	  another	  observer	  an	  additional,	  important	  effect	  of	  requesting	  this	  help	  was	  the	  fact	  that	  a	  WHO	  presence	  in	  KwaZulu-­‐Natal	  was	  mirrored	  by	  the	  placement	  of	  a	  WHO	  representative	  in	  the	  
                                                458	  Margot,	  interview	  by	  author,	  2010.	  459	  Ibid.	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national	  TB	  program	  office.	  This	  encouraged	  increased	  communication	  and	  accountability	  between	  provincial	  and	  national	  departments.	  It	  also	  kept	  the	  WHO	  involved	  with	  South	  Africa’s	  attempts	  to	  address	  the	  XDR-­‐TB	  problem,	  so	  the	  WHO	  could	  not	  argue	  that	  South	  Africa’s	  problems	  were	  due	  to	  the	  country’s	  resistance	  to	  expertise.	  Kristina	  Wallengren,	  a	  Harvard-­‐trained	  public	  health	  specialist	  from	  Sweden,	  was	  hired	  by	  the	  WHO	  as	  the	  technical	  expert	  to	  assist	  the	  KwaZulu-­‐Natal	  TB	  program	  in	  its	  analysis	  of	  the	  XDR-­‐TB	  outbreak	  in	  Tugela	  Ferry	  and	  KwaZulu-­‐Natal.	  She	  was	  given	  the	  task	  of	  collecting,	  compiling	  and	  cleaning	  data	  on	  drug-­‐resistant	  tuberculosis	  from	  disparate	  excel	  sheets,	  clinical	  databases,	  and	  laboratory	  computers	  in	  numerous	  locations	  across	  the	  province.	  None	  of	  them	  had	  been	  designed	  to	  provide	  information	  in	  a	  format	  that	  made	  sense	  for	  this	  project.460	  Wallengren	  started	  her	  work	  in	  2006,	  and	  due	  to	  the	  dispersed	  data	  it	  took	  her	  over	  a	  year	  to	  complete	  the	  analysis.	  The	  results	  of	  her	  study	  were	  only	  published	  in	  abbreviated	  form	  several	  years	  after	  that,	  though	  she	  presented	  her	  work	  in	  various	  forms	  at	  conferences	  and	  meetings.461	  Publication	  was	  initially	  delayed	  because	  the	  South	  African	  department	  of	  health	  was	  not	  entirely	  comfortable	  sharing	  the	  results	  publicly;	  later	  scientific	  journals	  were	  perhaps	  not	  as	  interested	  in	  such	  a	  report	  as	  they	  might	  have	  been	  closer	  to	  the	  original	  report	  of	  the	  outbreak.462	  There	  were	  many	  theories	  in	  circulation	  in	  South	  African	  and	  international	  scientific	  and	  lay	  circles	  regarding	  the	  causes	  of	  the	  XDR-­‐TB	  outbreak	  in	  Tugela	  Ferry.	  One	  theory	  that	  I	  encountered	  frequently	  was	  that	  the	  long-­‐term	  mismanagement	  of	  MDR-­‐TB	  patients	  at	  King	  George	  V	  hospital	  in	  Durban	  had	  caused	  XDR-­‐TB	  to	  arise	  in	  a	  patient	  in	  Durban,	  who	  later	  was	  released	  from	  hospital	  and	  returned	  home	  to	  Msinga,	  causing	  an	  outbreak	  there.	  
                                                460	  Margot,	  interview	  by	  author,	  2010;	  Wallengren,	  interview	  by	  author,	  2010.	  461	  Kristina	  Wallengren	  et	  al.,	  “Drug-­‐Resistant	  Tuberculosis,	  KwaZulu-­‐Natal,	  South	  Africa,	  2001–2007,”	  Emerging	  Infectious	  Diseases	  17,	  no.	  10	  (October	  2011):	  1913–1916.	  462	  Wallengren,	  interview	  by	  author,	  2010.	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No	  specific	  “patient	  zero”	  who	  had	  spread	  the	  disease	  in	  this	  way	  was	  ever	  identified,	  however,	  and	  molecular	  and	  epidemiological	  data	  showed	  that	  the	  extent	  of	  XDR-­‐TB	  in	  Tugela	  Ferry	  could	  not	  be	  fully	  explained	  by	  such	  a	  mechanism.	  Another	  common	  theory,	  especially	  among	  nurses	  and	  other	  hospital	  staff	  members	  in	  Tugela	  Ferry,	  was	  that	  the	  extent	  of	  XDR-­‐TB	  in	  the	  Msinga	  region	  was	  a	  direct	  result	  of	  poverty	  and	  lack	  of	  education.	  The	  argument	  played	  out	  in	  two	  different	  ways.	  Firstly,	  some	  argued	  that	  poverty,	  poor	  nutrition,	  overcrowding,	  and	  a	  lack	  of	  education	  regarding	  health	  risks	  made	  the	  population	  of	  Msinga	  fundamentally	  susceptible	  to	  infectious	  diseases	  like	  XDR-­‐TB.	  This	  is	  in	  keeping	  with	  conventional	  readings	  of	  tuberculosis	  as	  a	  fundamentally	  social	  disease.	  The	  second	  version	  of	  this	  argument	  was	  less	  conventional.	  Some	  hospital	  staff	  essentially	  argued	  that	  they	  did	  not	  believe	  that	  Tugela	  Ferry	  had	  more	  XDR-­‐TB	  cases	  than	  anywhere	  else,	  but	  that	  the	  poverty	  and	  lack	  of	  education	  in	  the	  district	  prevented	  individuals	  from	  keeping	  their	  illness	  a	  secret	  by	  keeping	  up	  the	  appearances	  of	  health	  through	  increased	  nutrition	  and	  expensive	  clothing.	  One	  person	  also	  argued	  that	  wealthier	  South	  Africans	  escaped	  being	  captured	  by	  government	  statistics	  because	  they	  avoided	  public	  hospitals	  and	  sought	  treatment	  from	  private	  doctors,	  while	  poor	  patients	  like	  those	  who	  lived	  in	  Msinga	  showed	  up	  in	  the	  numbers.	  This	  argument	  did	  not	  mesh	  with	  the	  epidemiological	  evidence	  available.	  However,	  this	  view	  effectively	  pointed	  out	  that	  the	  experiences	  of	  illness	  and	  the	  options	  for	  projecting	  an	  image	  of	  well-­‐being	  in	  South	  Africa	  were	  profoundly	  different	  depending	  on	  the	  means	  of	  the	  sick	  persons	  and	  their	  families.	  	   Several	  laboratory-­‐based	  tuberculosis	  experts	  in	  South	  Africa,	  including	  Professor	  Sturm	  at	  the	  University	  of	  KwaZulu-­‐Natal,	  blamed	  the	  WHO’s	  TB-­‐related	  policy	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recommendations	  from	  the	  1990s	  for	  the	  rise	  of	  XDR-­‐TB	  in	  KwaZulu-­‐Natal.463	  Before	  DOTS	  was	  introduced	  to	  the	  South	  African	  public	  health	  system	  in	  1996,	  each	  province	  had	  its	  own	  tuberculosis	  treatment	  policies.	  Tuberculosis	  physicians	  in	  KwaZulu-­‐Natal	  could	  use	  TB	  drug	  sensitivity	  testing	  (DST)	  to	  help	  guide	  treatment	  decisions,	  even	  in	  first-­‐time	  TB	  patients.	  The	  1996	  national	  TB	  policy	  eliminated	  routine	  drug	  sensitivity	  screening	  and	  introduced	  standardized	  first-­‐time	  treatment	  regimens	  for	  all	  tuberculosis	  patients.	  KwaZulu-­‐Natal	  effectively	  ignored	  this	  new	  policy	  and	  continued	  to	  provide	  DST	  until	  2001,	  when	  KwaZulu-­‐Natal	  aligned	  its	  practices	  with	  the	  rest	  of	  the	  country.	  Prof.	  Sturm	  (whose	  laboratory	  performed	  DST	  for	  much	  of	  the	  province)	  has	  argued	  that	  it	  was	  this	  switch	  that	  allowed	  XDR-­‐TB	  to	  rise	  unhindered.	  Several	  tuberculosis	  researchers	  in	  Cape	  Town	  and	  Stellenbosch	  also	  argued	  that	  the	  cause	  for	  the	  rise	  of	  MDR	  and	  XDR-­‐TB	  in	  South	  Africa	  was	  primarily	  programmatic.	  For	  example,	  Robert	  Warren	  and	  his	  research	  group	  used	  molecular	  and	  genetic	  studies	  to	  argue	  that	  the	  standardized	  sequence	  of	  anti-­‐tuberculosis	  drugs	  followed	  by	  the	  South	  African	  TB	  program	  led	  to	  the	  amplification	  of	  a	  particular	  resistance-­‐favoring	  mutation	  among	  South	  African	  patients.464	  His	  team	  also	  believed	  that	  the	  standardized	  TB	  treatment	  program	  did	  not	  sufficiently	  distinguish	  between	  “retreatment”	  patients	  who	  had	  been	  infected	  multiple	  times	  (by	  different	  strains	  of	  TB)	  and	  patients	  who	  had	  never	  cleared	  their	  previous	  TB	  infection.465	  Karen	  Shean,	  a	  nurse	  who	  had	  worked	  on	  drug-­‐resistant	  tuberculosis	  government	  TB	  programs	  in	  the	  Western	  and	  Eastern	  Cape	  and	  later	  for	  several	  research	  projects	  (including	  a	  collaboration	  with	  the	  American	  CDC	  to	  assess	  MDR-­‐
                                                463	  Manormoney	  Pillay	  and	  A.	  Willem	  Sturm,	  “Evolution	  of	  the	  Extensively	  Drug-­‐Resistant	  F15/LAM4/KZN	  Strain	  of	  Mycobacterium	  Tuberculosis	  in	  KwaZulu-­‐Natal,	  South	  Africa,”	  Clinical	  
Infectious	  Diseases	  45,	  no.	  11	  (December	  1,	  2007):	  1409–1414.	  464	  B.	  Müller	  et	  al.,	  “inhA	  promoter	  mutations:	  a	  gateway	  to	  extensively	  drug-­‐resistant	  tuberculosis	  in	  South	  Africa?”	  International	  Journal	  of	  Tuberculosis	  and	  Lung	  Disease	  15,	  no.	  3	  (2011):	  344-­‐351.	  465	  Warren	  et	  al.,	  “Use	  of	  spoligotyping	  for	  accurate	  classification	  of	  recurrent	  tuberculosis,”	  Journal	  of	  
Clinical	  Microbiology	  40,	  no.	  10	  (2002):	  3851-­‐3853.	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TB	  in	  parts	  of	  South	  Africa)	  argued	  that	  imperfect	  treatment	  programs	  that	  lacked	  a	  strategy	  to	  deal	  with	  treatment	  defaulters	  led	  to	  increases	  in	  levels	  of	  drug-­‐resistance.466	  In	  addition	  she	  saw	  that	  South	  African	  MDR-­‐TB	  treatment	  staff	  were	  increasingly	  overwhelmed	  by	  the	  burden	  of	  increasing	  numbers	  of	  patients.	  “DOTS	  is	  only	  as	  good	  as	  the	  clinic	  you	  start	  in.	  Because	  if	  you	  don’t	  have	  motivated	  staff	  that	  are	  actually	  going	  to	  make	  it	  work,	  forget	  it.	  […]	  You	  got	  nurses	  that	  are	  completely	  overwhelmed	  by	  HIV,	  by	  the	  primary	  health	  care	  they	  have	  to	  do.	  [...]	  We	  know	  that	  nurses’	  attitudes	  have	  a	  lot	  to	  do	  with	  defaulting.”467	  Difficult	  conditions	  also	  led	  to	  high	  turnover	  of	  new	  physicians	  who	  were	  not	  sufficiently	  familiar	  with	  the	  side-­‐effects	  of	  the	  drugs	  they	  were	  prescribing.468	  	   Finally,	  one	  Durban	  based	  physician	  I	  spoke	  to	  blamed	  the	  outbreak	  of	  XDR-­‐TB	  in	  Tugela	  Ferry	  on	  a	  combination	  of	  backwards,	  though	  compassionate,	  rural	  doctors	  and	  the	  dangerous	  mixing	  of	  HIV	  and	  TB	  patients	  caused	  by	  the	  American	  HIV/TB	  treatment	  intervention.	  Based	  on	  circulating	  theories,	  rumors,	  and	  hallway	  conversations	  with	  people	  who	  had	  seen	  provincial	  data	  (but	  not	  first-­‐hand	  information),	  this	  person	  argued	  that	  Tugela	  Ferry	  had	  a	  poor	  tuberculosis	  program	  to	  begin	  with,	  which	  was	  exacerbated	  by	  “very	  caring”	  Christian	  physicians	  who	  admitted	  everyone	  to	  the	  hospital	  who	  was	  very	  sick.	  Patients	  with	  AIDS,	  many	  of	  whom	  had	  severe	  diarrhea,	  were	  treated	  with	  fluoroquinolones	  (a	  type	  of	  antibiotic)	  in	  an	  attempt	  to	  get	  the	  diarrhea	  under	  control.	  In	  his	  theory,	  this	  exposure	  to	  fluoroquinolones	  could	  have	  caused	  patients	  who	  also	  had	  tuberculosis	  to	  develop	  tuberculosis	  that	  was	  resistant	  to	  fluoroquinolones	  (a	  drug	  also	  used	  to	  treat	  MDR-­‐TB).	  The	  final	  factor	  that	  was	  rumored	  to	  have	  caused	  high	  rates	  of	  XDR-­‐TB,	  however,	  was	  the	  fact	  the	  Yale/Philanjalo	  HIV/TB	  cotreatment	  program	  put	  people	  with	  
                                                466	  Karen	  P.	  Shean	  et	  al.,	  “Treatment	  outcome	  and	  follow-­‐up	  of	  multidrug-­‐resistant	  tuberculosis	  patients,	  West	  Coast/Winelands,	  South	  Africa,	  1992-­‐2002.”	  International	  Journal	  of	  Tuberculosis	  and	  
Lung	  Disease	  12,	  no.	  10	  (2008):	  1182-­‐1189.	  467	  Karen	  Shean,	  interview	  by	  author,	  7	  May	  2010,	  Cape	  Town,	  South	  Africa.	  468	  Ibid.	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tuberculosis	  and	  AIDS	  in	  close	  proximity	  with	  each	  other,	  without	  putting	  in	  place	  appropriate	  infection	  control	  measures.	  This	  way,	  he	  argued,	  what	  may	  have	  started	  as	  a	  single	  case	  of	  XDR-­‐TB	  could	  easily	  spread	  to	  a	  cohort	  of	  immune-­‐suppressed	  people.	  	   Kristina	  Wallengren’s	  official	  situational	  analysis	  of	  MDR-­‐TB	  and	  XDR-­‐TB	  in	  KwaZulu-­‐Natal	  was	  not	  immediately	  published,	  yet	  the	  results	  of	  the	  study	  circulated,	  both	  as	  formal	  presentations	  at	  TB	  meetings	  and	  conferences,	  as	  well	  as	  through	  one-­‐on-­‐one	  conversations.	  Her	  full,	  unpublished	  report	  more	  diplomatically	  confirmed	  some	  of	  the	  above	  source’s	  impressions.	  Wallengren	  concluded	  that	  while	  XDR-­‐TB	  was	  present	  in	  small	  numbers	  throughout	  the	  province	  of	  KwaZulu-­‐Natal,	  large	  numbers	  were	  mostly	  limited	  to	  Umzinyathi	  (the	  district	  which	  includes	  the	  Msinga	  subdistrict).	  In	  her	  analysis,	  the	  spread	  of	  XDR-­‐TB	  through	  the	  province	  had	  not	  (up	  to	  that	  point)	  been	  facilitated	  by	  patients	  who	  had	  stayed	  at	  King	  George	  V	  hospital	  in	  Durban	  for	  their	  tuberculosis	  treatment.469	  Wallengren	  noted	  that	  the	  Church	  of	  Scotland	  Hospital	  in	  Tugela	  Ferry	  had	  cared	  for	  HIV	  patients	  with	  enthusiasm	  and	  commitment	  and	  had	  admitted	  these	  patients	  to	  the	  hospital	  on	  a	  regular	  basis	  even	  before	  antiretroviral	  therapy	  was	  available.	  She	  compared	  this	  practice	  to	  other	  institutions	  around	  the	  province,	  whose	  HIV	  clinics	  “were	  rather	  half	  hearted	  efforts	  [where]	  HIV	  patients	  were	  treated	  as	  outpatients.”470	  Her	  report	  noted	  that	  it	  was	  common	  at	  the	  Church	  of	  Scotland	  Hospital	  to	  use	  a	  two-­‐week	  course	  of	  ciprofloxacin	  (a	  fluoroquinolone471)	  to	  treat	  HIV	  patients	  who	  had	  diarrhea.	  She	  also	  pointed	  out	  the	  hospital’s	  proactive	  efforts	  in	  integrating	  HIV	  and	  TB	  care	  and	  in	  educating	  HIV	  and	  TB	  patients	  about	  antiretrovirals	  prior	  to	  the	  public	  rollout	  of	  antiretroviral	  drugs.	  Interestingly,	  she	  did	  not	  explicitly	  mention	  the	  Yale/Philanjalo	  treatment	  study	  that	  was	  
                                                469	  Kristina	  Wallengren,	  Tuberculosis	  Drug-­‐Resistance	  in	  KwaZulu-­‐Natal	  Situational	  Analysis,	  May	  7,	  2008.	  470	  Kristina	  Wallengren,	  Tuberculosis	  Drug-­‐Resistance	  in	  KwaZulu-­‐Natal	  Situational	  Analysis,	  May	  7,	  2008,	  20.	  471	  Fluoroquinolones	  are	  a	  class	  of	  drugs	  which	  is	  used	  to	  treat	  MDR-­‐TB.	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the	  reason	  Tugela	  Ferry	  was	  engaged	  in	  TB/HIV	  integration	  and	  antiretroviral	  education.	  Wallengren	  emphasized	  that	  tuberculosis	  infection	  control	  measures	  remained	  very	  poor	  in	  most	  of	  the	  province	  even	  after	  the	  XDR-­‐TB	  scare.472	  	  Wallengren	  was	  also	  able	  to	  exclude	  several	  theories	  why	  XDR-­‐TB	  had	  become	  such	  a	  problem	  in	  Tugela	  Ferry.	  She	  pointed	  out	  that	  HIV	  rates	  in	  Umzinyathi	  district	  are	  not	  higher	  than	  elsewhere	  in	  the	  province;	  that	  the	  poor	  performance	  of	  the	  TB	  program	  was	  not	  to	  blame	  (compared	  to	  other	  districts),	  though	  the	  provision	  of	  six	  months	  of	  TB	  treatment	  at	  a	  time	  may	  have	  been	  a	  problem.	  She	  did	  point	  out	  that	  no	  matter	  how	  XDR-­‐TB	  first	  took	  hold	  at	  in	  Tugela	  Ferry,	  “mixing	  the	  susceptible	  HIV	  population	  with	  infectious	  TB	  cases	  transpired	  to	  be	  very	  efficient	  at	  COSH	  [Church	  of	  Scotland	  Hospital].	  Mixing	  occurred	  in	  congregate	  settings	  such	  as	  hospital	  wards,	  HIV	  literacy	  classes	  and	  waiting	  rooms.	  A	  higher	  throughput	  of	  HIV	  and	  TB	  patients	  in	  these	  settings	  occurred	  at	  COSH	  due	  to	  HIV	  patients	  being	  hospitalised	  more	  frequently	  (compared	  to	  treated	  as	  out-­‐patients	  in	  other	  settings),	  COSH	  made	  particular	  efforts	  to	  integrate	  TB	  and	  HIV	  programmes	  (compared	  to	  poor	  programme	  integration	  elsewhere),	  and	  the	  practice	  of	  HIV	  literacy	  classes	  prior	  to	  the	  ARV	  rollout	  (compared	  to	  no	  pre-­‐ARV	  training).	  Due	  to	  non-­‐existent	  infection	  control	  for	  TB,	  these	  well	  intended	  efforts	  may	  have	  created	  the	  conditions	  suitable	  for	  an	  epidemic	  to	  expand.”473	  Though	  Wallengren	  was	  very	  careful	  not	  to	  lay	  blame	  on	  the	  clinicians	  and	  researchers	  in	  Tugela	  Ferry	  when	  she	  gave	  public	  presentations	  at	  TB	  conferences,	  her	  report	  implicitly	  concludes	  that	  some	  of	  the	  very	  conditions	  that	  made	  Tugela	  Ferry	  an	  appealing	  place	  for	  Dr.	  Friedland	  to	  attempt	  his	  HIV/TB	  cotreatment	  study	  (in	  particular	  the	  
                                                472	  Kristina	  Wallengren,	  Tuberculosis	  Drug-­‐Resistance	  in	  KwaZulu-­‐Natal	  Situational	  Analysis,	  May	  7,	  2008.	  473	  Kristina	  Wallengren,	  Tuberculosis	  Drug-­‐Resistance	  in	  KwaZulu-­‐Natal	  Situational	  Analysis,	  May	  7,	  2008,	  27.	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enthusiasm	  and	  commitment	  on	  the	  part	  of	  physicians	  and	  nurses	  in	  treating	  HIV),	  as	  well	  as	  his	  cotreatment	  study	  itself,	  appear	  to	  have	  inadvertently	  created	  a	  fertile	  ground	  for	  XDR-­‐TB	  in	  Tugela	  Ferry.	  This	  was	  not	  the	  dominant	  narrative	  in	  the	  world	  of	  tuberculosis	  experts,	  however.	  Overall	  the	  research	  and	  treatment	  work	  conducted	  in	  Tugela	  Ferry	  is	  much	  admired	  and	  outsiders	  are	  impressed	  with	  the	  interventions	  put	  in	  place	  once	  MDR-­‐TB	  and	  XDR-­‐TB	  in	  Tugela	  Ferry	  were	  discovered.	  Medical	  personnel	  at	  the	  Church	  of	  Scotland	  Hospital	  and	  their	  international	  collaborators	  led	  the	  charge	  in	  responding	  to	  XDR-­‐TB	  in	  Tugela	  Ferry.	  American	  physician-­‐researcher	  Dr.	  James	  Brust,	  who	  is	  based	  at	  Albert	  Einstein	  College	  of	  Medicine	  and	  worked	  together	  with	  Dr.	  Neel	  Gandhi	  (who	  himself	  worked	  with	  Dr.	  Gerald	  Friedland)	  listed	  on	  his	  website	  that	  he	  “designed	  and	  implemented	  a	  novel,	  home-­‐based	  treatment	  program	  for	  patients	  co-­‐infected	  with	  HIV	  and	  MDR	  TB”	  in	  rural	  KwaZulu-­‐Natal,	  South	  Africa.474	  Sarita	  Shah,	  who	  was	  hired	  by	  Einstein	  College	  of	  Medicine	  and	  began	  to	  research	  MDR-­‐TB	  and	  XDR-­‐TB	  in	  Tugela	  Ferry	  after	  she	  left	  the	  CDC,	  used	  the	  pronoun	  “we”	  when	  describing	  the	  improvements	  in	  the	  MDR-­‐TB	  program	  in	  Umzinyathi	  in	  an	  interview	  in	  2010:	  “The	  other	  thing	  we’ve	  done	  in	  KwaZulu-­‐Natal	  is,	  in	  the	  district	  where	  Tugela	  Ferry	  is	  located,	  we’re	  treating	  MDR	  patients	  in	  their	  community,	  at	  their	  homes.”475	  But	  it	  was	  department	  of	  health	  employees	  at	  the	  clinic,	  hospital,	  district,	  provincial	  and	  eventually	  national	  level	  who	  enacted,	  institutionalized	  and	  to	  a	  large	  extent	  funded	  improvements	  to	  the	  tuberculosis	  program	  in	  Tugela	  Ferry	  and	  beyond.	  Others	  can	  also	  take	  partial	  credit	  for	  the	  development	  of	  the	  decentralized,	  community-­‐based	  management	  of	  MDR-­‐TB	  in	  the	  
                                                474	  “James	  C.M.	  Brust,	  M.D.	  |	  Albert	  Einstein	  College	  of	  Medicine,”	  accessed	  October	  25,	  2012,	  http://www.einstein.yu.edu/faculty/11307/james-­‐brust/.	  475	  Deirdre	  Shesgreen	  “XDR	  becoming	  more	  resistant:	  we	  will	  run	  out	  of	  letters	  soon,”	  Science	  Speaks:	  
HIV	  &	  TB	  News	  (blog),	  sciencespeaksblog.org,	  March	  30,	  2010,	  http://sciencespeaksblog.org/2010/03/30/xdr-­‐becoming-­‐more-­‐resistant-­‐we-­‐will-­‐run-­‐out-­‐of-­‐letters-­‐soon/.	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province,	  including	  WHO	  consultants	  and	  advisors	  from	  other	  countries’	  TB	  programs	  who	  provided	  and	  sought	  expertise.	  Government	  officials	  did	  not	  simply	  enact	  outside	  recommendations	  (which	  were	  inconsistent),	  but	  took	  their	  own	  initiative	  and	  heavily	  influenced	  the	  possibilities	  available	  to	  researchers	  and	  clinicians.	  In	  the	  following	  section	  I	  look	  more	  closely	  at	  an	  event	  that	  illustrates	  how	  government	  offices	  attempted	  to	  simultaneously	  engage	  in	  international	  research	  partnership	  and	  demonstrate	  the	  independence	  and	  authority	  of	  the	  local	  public	  health	  system:	  the	  placement	  of	  an	  MDR-­‐TB	  hospital	  and	  clinic	  in	  Greytown.	  	  
From	  Tugela	  Ferry	  to	  Greytown	  and	  back	  
	   The	  enmeshed	  relationship	  between	  government	  public	  health	  programs,	  research,	  and	  clinical	  practice	  around	  MDR-­‐TB	  in	  South	  Africa	  was	  strikingly	  demonstrated	  to	  me	  soon	  after	  I	  moved	  to	  Tugela	  Ferry	  to	  conduct	  fieldwork.	  On	  a	  Wednesday	  morning	  I	  accompanied	  two	  doctors	  –	  one	  a	  government	  physician	  at	  the	  Church	  of	  Scotland	  Hospital,	  one	  a	  physician	  hired	  by	  Philanjalo	  to	  live	  in	  Tugela	  Ferry	  take	  care	  of	  patients	  at	  Philanjalo’s	  hospice	  as	  well	  as	  to	  help	  with	  MDR-­‐TB	  related	  research	  projects	  –	  on	  their	  weekly	  trip	  to	  the	  MDR-­‐TB	  clinic	  at	  the	  Greytown	  MDR-­‐TB	  hospital.	  We	  met	  at	  the	  front	  gate	  of	  the	  Church	  of	  Scotland	  Hospital	  and	  made	  our	  way	  to	  Greytown,	  a	  45	  minute	  drive	  towards	  the	  southern	  boundary	  of	  the	  Umzinyathi	  district,	  in	  a	  department	  of	  health	  vehicle.	  That	  first	  week	  I	  rode	  in	  the	  back	  of	  the	  car	  contemplating	  the	  view	  as	  it	  transitioned	  from	  the	  dry,	  rocky,	  desolate	  landscape	  of	  Msinga	  to	  the	  fertile	  agricultural	  land	  of	  Greytown.	  The	  doctors	  up	  front	  talked	  about	  the	  happenings	  of	  the	  week	  and	  discussed	  recently	  admitted	  MDR-­‐TB	  patients	  they	  were	  worried	  about.	  
	   When	  we	  arrived	  at	  the	  MDR-­‐TB	  hospital	  and	  adjoining	  clinic	  in	  Greytown	  we	  were	  greeted	  by	  two	  Greytown-­‐based	  department	  of	  health	  nurses	  who	  provided	  the	  list	  of	  patients	  to	  be	  seen	  for	  the	  day.	  Some	  patients	  had	  already	  arrived	  for	  the	  MDR-­‐TB	  clinic	  and	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were	  forming	  lines	  to	  see	  an	  adherence	  counselor,	  to	  get	  blood	  drawn	  by	  a	  nurse,	  to	  get	  X-­‐rays,	  to	  give	  sputum	  (assisted	  by	  a	  physical	  therapist)	  and	  to	  have	  their	  hearing	  evaluated	  by	  an	  audiologist.	  In	  addition	  the	  patients	  were	  waiting	  to	  being	  seen	  by	  a	  doctor	  and	  receive	  the	  next	  month’s	  medications	  from	  the	  pharmacist.	  	   At	  the	  clinic	  the	  two	  doctors	  I	  had	  come	  with	  were	  joined	  by	  two	  more	  physicians,	  one	  of	  whom	  was	  another	  government	  physician	  from	  Tugela	  Ferry	  (who	  had	  come	  in	  his	  own	  vehicle),	  and	  the	  other	  was	  a	  government	  physician	  who	  worked	  at	  the	  main	  hospital	  in	  Greytown	  in	  addition	  to	  overseeing	  the	  medical	  care	  at	  the	  MDR-­‐TB	  hospital.	  (In	  other	  weeks	  a	  young	  visiting	  American	  physician	  might	  also	  join	  the	  fray.)	  The	  Greytown-­‐based	  doctor	  was	  the	  most	  recent	  addition	  to	  the	  team;	  until	  recently	  all	  of	  the	  doctors	  had	  commuted	  in	  from	  Tugela	  Ferry.	  The	  four	  doctors	  got	  to	  work	  in	  a	  single,	  moderately-­‐sized	  room	  with	  one	  exam	  table	  and	  four	  desks,	  at	  which	  the	  doctors	  sat	  and	  saw	  patients.	  In	  addition	  to	  the	  four	  doctors	  (who	  were	  all	  over	  45;	  2	  white	  males,	  1	  white	  female	  and	  one	  black	  male)	  there	  were	  several	  young	  black	  Zulu	  women	  sitting	  at	  tables	  and	  moving	  about	  the	  room	  carrying	  stacks	  of	  files	  and	  paperwork.	  As	  I	  learned	  later,	  these	  women	  were	  research	  assistants	  hired	  for	  the	  US-­‐based	  research	  project	  evaluating	  the	  outcomes	  of	  community-­‐based	  treatment	  of	  MDR-­‐TB	  in	  Msinga.	  They	  sat	  with	  the	  doctors	  filling	  out	  forms	  that	  documented	  the	  clinical	  encounters	  taking	  place.	  They	  also	  translated	  between	  Zulu	  and	  English	  when	  this	  was	  needed.	  At	  the	  end	  of	  each	  encounter	  they	  would	  point	  out	  parts	  of	  the	  form	  that	  still	  needed	  to	  be	  completed	  and	  hand	  them	  to	  the	  physician	  to	  quickly	  finish.	  These	  research	  assistants,	  like	  the	  doctors,	  had	  traveled	  from	  Tugela	  Ferry	  to	  Greytown.	  They	  had	  traveled	  in	  a	  Philanjalo-­‐funded	  vehicle	  together	  with	  a	  Philanjalo-­‐funded	  nurse	  who	  was	  also	  worked	  for	  the	  American	  study.	  The	  researchers	  were	  in	  Greytown	  to	  make	  sure	  that	  the	  visits	  of	  patients	  enrolled	  in	  a	  study	  assessing	  MDR-­‐TB	  treatment	  outcomes	  in	  Msinga	  were	  properly	  conducted	  and	  documented.	  They	  were	  also	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engaged	  in	  many	  other	  activities	  that	  day	  (and	  throughout	  the	  week)	  that	  helped	  clinic	  run	  smoothly.	  In	  Greytown,	  MDR-­‐TB	  patients	  from	  all	  four	  subdistricts	  of	  Umzinyathi	  were	  evaluated	  and	  placed	  onto	  treatment.	  The	  majority	  of	  patients	  who	  were	  seen	  at	  the	  outpatient	  clinic	  in	  Greytown	  each	  week,	  however,	  were	  from	  Msinga	  (one	  of	  those	  subdistricts).	  Every	  week,	  dozens	  of	  MDR-­‐TB	  patients	  assembled	  at	  the	  Church	  of	  Scotland	  Hospital	  in	  Tugela	  Ferry,	  Msinga	  in	  the	  early	  morning	  to	  be	  transported	  to	  the	  Greytown	  MDR-­‐TB	  hospital	  in	  a	  department	  of	  health	  vehicle	  (usual	  a	  bus	  or	  minivan),	  accompanied	  by	  a	  driver	  and	  a	  nurse	  who	  worked	  for	  the	  TB-­‐DOTS	  office	  in	  Tugela	  Ferry.	  This	  particular	  transport	  was	  easily	  recognizable	  when	  it	  left	  Tugela	  Ferry	  by	  the	  fact	  that	  all	  the	  patients	  in	  the	  bus	  as	  well	  as	  the	  driver	  wore	  masks	  for	  the	  trip.	  I	  found	  it	  somehow	  comical	  that	  physicians,	  nurses,	  researchers	  and	  most	  of	  the	  patients	  all	  traveled	  (in	  separate	  vehicles)	  from	  Tugela	  Ferry	  to	  Greytown	  in	  the	  morning	  and	  all	  had	  to	  travel	  back	  again	  in	  the	  afternoon.476	  This	  seemed	  like	  a	  highly	  inefficient	  way	  of	  dealing	  with	  a	  problem	  that	  was	  well	  known	  to	  be	  most	  severe	  in	  Tugela	  Ferry	  and	  the	  surrounding	  region	  of	  Msinga.	  Even	  for	  the	  Umzinyathi	  district	  as	  a	  whole,	  Greytown	  was	  not	  the	  most	  logical	  geographical	  location	  for	  the	  MDR-­‐TB	  clinic	  and	  hospital,	  since	  Tugela	  Ferry	  is	  more	  central	  to	  the	  whole	  district	  than	  Greytown,	  and	  patients	  from	  another	  hospital	  had	  to	  pass	  through	  Tugela	  Ferry	  to	  get	  to	  Greytown.	  Despite	  the	  fact	  that	  not	  
everyone	  came	  from	  Tugela	  Ferry	  –	  the	  Greytown	  hospital	  provided	  nurses,	  pharmacists,	  an	  adherence	  counselor,	  an	  X-­‐ray	  technician,	  a	  physiotherapist	  and	  a	  data	  capturer,	  for	  example	  –	  these	  circumstances	  demanded	  an	  explanation.	  When	  I	  asked	  why	  Greytown	  was	  selected	  as	  the	  location	  for	  the	  MDR-­‐TB	  clinic	  and	  hospital	  most	  people	  simply	  pointed	  out	  that	  Greytown	  had	  a	  suitable	  building	  readily	  
                                                476	  During	  part	  of	  my	  research	  the	  audiologist	  also	  made	  this	  trip.	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available,	  while	  Tugela	  Ferry	  did	  not.	  As	  a	  result	  of	  South	  Africa’s	  apartheid	  past,	  Greytown	  had	  a	  government-­‐owned	  hospital	  building	  that	  was	  underutilized	  and	  could	  be	  repurposed	  as	  the	  MDR-­‐TB	  hospital.	  The	  structure	  that	  is	  now	  the	  MDR-­‐TB	  hospital	  used	  to	  be	  Greytown’s	  “white”	  hospital	  during	  apartheid,	  when	  health	  services,	  like	  everything	  else,	  where	  segregated	  by	  race,	  even	  in	  small	  towns	  like	  Greytown.	  (As	  a	  Zulu	  friend	  from	  Durban	  once	  said	  to	  me:	  “I	  hear	  that	  Greytown	  is	  so	  small,	  that	  you	  can	  easily	  walk	  from	  the	  [black]	  location	  into	  [white]	  town.”)	  After	  1994,	  hospital	  services	  in	  Greytown	  for	  all	  people	  were	  moved	  to	  the	  formerly	  “black”	  hospital.	  For	  a	  while,	  private	  physicians	  in	  Greytown	  still	  used	  the	  white	  hospital	  as	  a	  sort	  of	  semi-­‐private	  hospital	  that	  they	  could	  admit	  their	  patients	  to	  directly	  (thus	  partially	  replicating	  apartheid	  divisions	  by	  race	  and	  income).	  Given	  the	  facility’s	  ambiguous	  status,	  both	  the	  province	  and	  the	  district	  were	  happy	  to	  repurpose	  the	  property	  as	  an	  MDR-­‐TB	  hospital.477	  Yet,	  according	  to	  some	  sources	  the	  availability	  of	  underutilized	  space	  was	  not	  the	  only	  issue.	  Rather,	  Greytown	  was	  consciously	  selected	  as	  a	  location	  that	  was	  relatively	  close	  
to	  Tugela	  Ferry	  and	  the	  majority	  of	  patients	  in	  KwaZulu-­‐Natal	  who	  required	  MDR-­‐TB	  treatment,	  but	  not	  in	  Tugela	  Ferry.	  Tugela	  Ferry	  had	  become	  closely	  associated	  with	  XDR-­‐TB	  in	  international	  public	  health	  circles,	  and	  the	  research	  that	  took	  place	  in	  Tugela	  Ferry	  had	  played	  a	  significant	  role	  both	  in	  ensuring	  that	  HIV	  and	  TB	  would	  be	  treated	  in	  Msinga,	  as	  well	  as	  in	  uncovering	  a	  devastating	  epidemic	  of	  drug-­‐resistant	  tuberculosis.	  As	  the	  research	  in	  Tugela	  Ferry	  expanded,	  however,	  some	  people	  in	  the	  department	  of	  health	  felt	  that	  the	  department	  had	  lost	  control	  of	  hospital	  activities	  and	  the	  use	  of	  resources	  in	  Tugela	  Ferry.	  American	  researchers	  had	  brought	  significant	  attention	  to	  Tugela	  Ferry,	  much	  of	  which	  was	  negative	  –	  putting	  department	  of	  health	  officials	  in	  a	  difficult	  position.	  The	  researchers’	  propensity	  to	  presenting	  and	  promoting	  their	  work	  also	  had	  the	  potential	  of	  
                                                477	  Mndebele,	  interview	  by	  author,	  2011;	  Margot,	  interview	  by	  author,	  2010.	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creating	  momentum	  for	  interventions	  that	  the	  department	  of	  health	  could	  not	  control.	  As	  importantly,	  however,	  Americans	  had	  used	  South	  African	  resources	  and	  samples	  to	  collect	  the	  data	  they	  needed	  to	  conduct	  their	  research	  –	  research	  that	  was	  used	  to	  a	  large	  extent	  to	  boost	  American	  careers.	  As	  one	  source	  put	  it:	  “All	  these	  Americans	  using	  South	  African	  money	  to	  conduct	  their	  research.	  Order	  this	  test,	  that	  test,	  the	  next	  test.	  It’s	  the	  only	  way	  I’m	  maintaining	  some	  control.	  So	  [moving	  MDR-­‐TB	  treatment	  to	  Greytown]	  was	  a	  political	  decision.”	  Wallengren’s	  analysis	  of	  the	  events	  leading	  up	  to	  the	  rise	  of	  XDR-­‐TB	  in	  Tugela	  Ferry	  (which	  partially	  implicated	  the	  HIV/TB	  research	  efforts)	  also	  may	  have	  motivated	  attempts	  to	  reduce	  the	  American	  research	  influence	  on	  MDR-­‐TB	  and	  XDR-­‐TB	  care	  in	  Tugela	  Ferry.	   For	  the	  most	  part,	  however,	  this	  resistance	  to	  American	  research	  influence	  was	  not	  overt	  –	  only	  one	  person	  I	  interviewed	  brought	  up	  the	  issue	  of	  excessive	  influence	  of	  American	  researchers	  and	  their	  potentially	  inappropriate	  use	  of	  South	  African	  resources	  unprompted.	  Others	  carefully	  assented	  that	  this	  was	  a	  concern	  when	  I	  brought	  it	  up,	  and	  still	  others	  explicitly	  stated	  that	  they	  disagreed	  with	  the	  notion	  that	  the	  international	  researchers	  were	  a	  nuisance	  or	  potentially	  exploitative,	  and	  affirmed	  that	  as	  a	  rule	  American	  researchers	  and	  clinicians	  have	  been	  helpful	  and	  a	  wonderful	  asset.	  Not	  only	  South	  African	  versus	  international	  dynamics	  were	  at	  play.	  I	  believe	  the	  placement	  of	  the	  MDR-­‐TB	  hospital	  in	  Greytown	  could	  also	  be	  interpreted	  as	  a	  way	  of	  a	  post-­‐apartheid	  bureaucracy	  resisting	  the	  idiosyncratic	  methods	  of	  the	  three	  long-­‐time,	  white,	  Afrikaans-­‐speaking	  physicians	  working	  in	  Tugela	  Ferry.	  Dr.	  Moll,	  Dr.	  van	  der	  Merwe	  and	  their	  equally	  passionate	  colleague	  Dr.	  Eksteen	  were	  driven	  by	  compassion	  and	  missionary	  zeal	  (like	  many	  rural	  doctors	  in	  South	  Africa)	  and	  they	  often	  felt	  justified	  in	  using	  unorthodox	  treatment	  strategies	  if	  they	  were	  convinced	  that	  their	  patients	  would	  benefit.	  They	  were	  highly	  valued	  by	  the	  community	  in	  Tugela	  Ferry.	  But	  they	  were	  also	  well	  known	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by	  the	  department	  of	  health	  and	  by	  their	  colleagues	  for	  their	  independent	  streaks	  that	  allowed	  them	  to	  follow	  their	  convictions	  rather	  than	  department	  of	  health	  policy.	  This	  was	  demonstrated	  both	  by	  their	  refusal	  to	  allow	  abortions	  to	  be	  performed	  by	  anyone	  at	  the	  Church	  of	  Scotland	  Hospital	  (despite	  the	  fact	  that	  they	  are	  legal	  in	  South	  Africa),478	  as	  well	  as	  their	  early,	  inspirational	  work	  in	  the	  field	  of	  HIV	  in	  the	  face	  of	  department	  of	  health	  reluctance.479	  We	  have	  seen	  that	  the	  doctors	  in	  Tugela	  Ferry	  admitted	  AIDS	  patients	  who	  were	  very	  ill,	  and	  aggressively	  treated	  their	  diarrhea	  with	  ciprofloxacin	  (a	  fluoroquinolone)	  –	  a	  relatively	  expensive	  drug	  used	  in	  South	  Africa	  primarily	  for	  the	  treatment	  of	  sexually	  transmitted	  infections.	  Tugela	  Ferry’s	  physicians’	  independence	  expressed	  itself	  in	  the	  sometimes-­‐idiosyncratic	  –	  though	  not	  incorrect	  –	  ways	  they	  prescribed	  tuberculosis	  treatment,	  as	  well.	  Confronted	  with	  a	  high	  percentage	  of	  MDR-­‐TB	  cases	  the	  doctors	  in	  Tugela	  Ferry	  were	  sometimes	  willing	  to	  treat	  patients	  for	  MDR-­‐TB	  empirically	  when	  they	  suspected	  that	  a	  patient	  was	  not	  responding	  to	  treatment,	  even	  if	  they	  did	  not	  have	  a	  definitive	  laboratory	  confirmation	  of	  the	  diagnosis.	  They	  did	  this	  despite	  the	  potentially	  severe	  side	  effects	  of	  MDR-­‐TB	  medications.480	  They	  also	  modified	  standardized	  treatment	  regimens	  according	  to	  their	  own	  individual	  (though	  well-­‐informed)	  judgment.	  The	  physicians’	  willingness	  to	  overrule	  guidelines	  could	  frustrate	  administrators,	  protocol-­‐bound	  nurses	  and	  protocol-­‐
                                                478	  Francois	  J.	  Eksteen,	  Anthony	  P.	  Moll	  and	  Theo	  L.	  van	  der	  Merwe,	  “Abortion	  objectors	  –	  further	  points,”	  South	  African	  Medical	  Journal	  87,	  no.	  11	  (1997):	  1557-­‐1558;	  Theo	  L.	  van	  der	  Merwe,	  Anthony	  P.	  Moll,	  Francois	  J.	  Eksteen,	  “Abortion	  on	  demand,”	  South	  African	  Medical	  Journal	  87,	  no.	  1	  (1997):	  74-­‐75.	  479	  Gerald	  M.	  Oppenheimer	  and	  Ronald	  Bayer,	  Shattered	  dreams?	  An	  oral	  history	  of	  the	  South	  African	  
AIDS	  epidemic.	  (Oxford	  University	  Press,	  2007),	  74.	  480	  The	  potential	  danger	  of	  empirical	  treatment	  became	  clear	  to	  me	  when	  I	  encountered	  Z,	  a	  patient	  who	  had	  symptoms	  consistent	  with	  tuberculosis	  but	  had	  not	  responded	  well	  to	  first-­‐line	  anti-­‐tuberculosis	  drugs.	  His	  TB	  sputum	  test	  had	  been	  inconclusive.	  When	  I	  met	  him	  he	  was	  in	  the	  process	  of	  being	  evaluated	  to	  start	  MDR-­‐TB	  treatment.	  What	  he	  had	  not	  told	  the	  doctors	  in	  Tugela	  Ferry,	  however,	  was	  that	  a	  private	  doctor	  in	  another	  town	  had	  (correctly)	  diagnosed	  him	  with	  lymphoma	  (one	  of	  several	  diseases	  that	  can	  sometimes	  be	  mistaken	  for	  tuberculosis).	  In	  Tugela	  Ferry	  it	  makes	  sense	  to	  first	  think	  TB	  (a	  common,	  treatable	  disease)	  before	  thinking	  lymphoma.	  But	  MDR-­‐TB	  treatment	  was	  not	  likely	  to	  help	  this	  particular	  patient.	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loving	  researchers	  alike.	  Department	  of	  health	  officials	  may	  have	  been	  trying	  to	  rein	  in	  some	  of	  these	  practices	  even	  as	  they	  desperately	  relied	  on	  those	  passionate	  physicians	  to	  see	  MDR-­‐TB	  patients	  and	  provide	  their	  expertise.	  Considering	  that	  physicians	  from	  Tugela	  Ferry	  still	  traveled	  to	  Greytown	  every	  week	  to	  see	  their	  MDR-­‐TB	  patients,	  and	  that	  American	  researchers	  still	  had	  studies	  running	  through	  the	  Greytown	  clinic	  and	  hospital,	  the	  attempt	  to	  remove	  MDR-­‐TB	  from	  Tugela	  Ferry’s	  influence	  clearly	  did	  not	  succeed.	  Doctors	  and	  researchers	  working	  in	  Tugela	  Ferry	  instead	  became	  mobile	  and	  traveled	  with	  their	  patients	  to	  the	  new	  treatment	  location.	  American	  researchers	  and	  their	  South	  African	  employees	  continued	  to	  document	  the	  outcomes	  of	  the	  MDR-­‐TB	  patients	  treated	  through	  the	  program	  in	  Umzinyathi.	  This	  happened	  in	  part	  because	  the	  department	  of	  health	  was	  initially	  unable	  to	  find	  a	  physician	  to	  staff	  the	  MDR-­‐TB	  hospital,	  and	  because	  physicians	  from	  Tugela	  Ferry	  –	  very	  experienced	  with	  MDR-­‐TB	  by	  2008	  –	  took	  an	  interest	  in	  ensuring	  that	  their	  patients	  from	  Tugela	  Ferry	  were	  taken	  care	  of.	  Physicians,	  nurses	  and	  researchers	  from	  Tugela	  Ferry	  worked	  together	  with	  the	  full-­‐time	  nurses	  at	  the	  Greytown	  MDR-­‐TB	  hospital	  and	  department	  of	  health	  officials	  to	  put	  together	  a	  functioning	  MDR-­‐TB	  treatment	  program,	  and	  American	  researchers	  documented	  the	  outcomes	  of	  this	  program,	  as	  it	  related	  to	  patients	  from	  Tugela	  Ferry,	  in	  particular.	  The	  extra	  research	  staff	  funded	  by	  American	  research	  grants	  helped	  make	  sure	  that	  the	  MDR-­‐TB	  clinic	  ran	  smoothly,	  and	  that	  people	  from	  Msinga	  made	  it	  to	  Greytown	  each	  week	  for	  care.	  The	  main	  nurses	  in	  Greytown	  who	  were	  in	  charge	  of	  the	  clinic	  clearly	  enjoyed	  the	  interaction	  with	  the	  Tugela	  Ferry-­‐based	  clinicians	  who	  were	  passionate	  about	  their	  tuberculosis	  subject-­‐matter,	  and	  they	  engaged	  with	  enthusiasm	  with	  the	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researchers.	  Yet	  one	  Pietermaritzburg-­‐based	  observer	  remained	  wary	  and	  noted:	  “things	  have	  gone	  so	  wrong	  up	  there,	  that	  department	  needs	  to	  monitor	  things	  quite	  carefully.”481	  
The	  presence	  and	  absence	  of	  government	  in	  global	  health	  –	  a	  South	  African	  perspective	  I	  argued	  earlier	  that	  government	  involvement	  in	  the	  management	  of	  XDR-­‐TB	  in	  Tugela	  Ferry	  ended	  up	  being	  greater	  than	  I	  might	  have	  anticipated.	  This	  statement	  reflects	  my	  own	  experiences	  and	  the	  biases	  that	  I	  developed	  over	  the	  course	  of	  a	  decade	  of	  engaging	  with	  global	  HIV/AIDS	  activism,	  research	  and	  clinical	  care.	  At	  the	  start	  of	  this	  project	  my	  own	  expectations	  for	  the	  South	  African	  government’s	  pro-­‐active	  involvement	  in	  the	  expansion	  of	  tuberculosis	  programs	  in	  KwaZulu-­‐Natal	  were	  low.	  My	  impression	  of	  South	  African	  government	  action	  on	  matters	  of	  deadly	  infectious	  diseases	  had	  been	  formed	  during	  the	  presidency	  of	  Thabo	  Mbeki,	  who	  openly	  doubted	  that	  HIV	  caused	  AIDS	  and,	  together	  with	  his	  Minister	  of	  Health	  Manto	  Tshabalala-­‐Msimang	  had	  actively	  and	  vocally	  resisted	  providing	  effective	  treatment	  for	  HIV/AIDS	  in	  public	  hospitals.	  The	  early	  HIV	  programs	  that	  I	  witnessed	  as	  an	  AIDS	  activists	  and	  HIV	  laboratory	  scientist	  in	  South	  Africa	  between	  2002	  and	  2004	  relied	  heavily	  on	  funding	  that	  did	  not	  come	  from	  the	  South	  African	  government,	  and	  were	  in	  some	  cases	  actively	  hindered	  by	  high-­‐level	  government	  action.	  News	  reports	  in	  2006	  and	  2007	  that	  the	  South	  African	  government	  was	  not	  sufficiently	  paying	  attention	  to	  drug-­‐resistant	  tuberculosis	  were	  consistent	  with	  this	  narrative.	  South	  African	  scientists	  and	  physicians	  themselves	  seemed	  surprised	  that	  the	  South	  African	  government	  eventually	  took	  ownership	  of	  MDR-­‐TB	  and	  XDR-­‐TB	  as	  health	  problems	  it	  needed	  to	  address.	  Interviews	  I	  conducted	  with	  South	  African	  researchers	  in	  2007	  and	  2010	  reveal	  a	  noticeable	  shift	  in	  their	  stances	  regarding	  what	  they	  could	  expect	  from	  the	  South	  African	  Department	  of	  Health.	  	  
                                                481	  Loveday,	  interview	  by	  author,	  2010.	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Another	  reason	  I	  was	  surprised	  by	  the	  degree	  of	  South	  African	  government	  involvement	  in	  addressing	  XDR-­‐TB	  was	  that	  I	  had	  an	  incomplete	  idea	  about	  what	  global	  health	  research	  programs	  “do.”	  My	  experience	  in	  early	  HIV	  treatment	  research	  in	  South	  Africa	  led	  me	  to	  conclude	  that	  in	  order	  to	  do	  responsible	  and	  publishable	  research	  as	  part	  of	  a	  global	  health	  project	  most	  of	  the	  resources	  used	  –	  both	  for	  the	  intervention	  being	  studied,	  and	  for	  the	  study	  itself	  –	  would	  have	  to	  come	  from	  external	  grant	  funding.	  Possible	  funding	  sources	  included	  entities	  like	  the	  National	  Institutes	  of	  Health	  (NIH)	  or	  the	  Doris	  Duke	  Foundation,	  the	  Global	  Fund	  to	  Fight	  AIDS,	  Malaria,	  and	  Tuberculosis	  (“Global	  Fund”),	  the	  Presidential	  Emergency	  Plan	  for	  AIDS	  Relief	  (PEPFAR),	  the	  US	  Agency	  for	  International	  Development	  (USAID)	  or	  the	  Bill	  and	  Melinda	  Gates	  foundation.	  Early	  international	  HIV	  treatment	  research	  programs	  not	  only	  provided	  expensive	  HIV	  medications	  (antiretrovirals),	  but	  had	  to	  put	  in	  place	  all	  the	  structures	  of	  HIV	  care:	  laboratories	  that	  could	  perform	  diagnostic	  testing	  and	  monitoring,	  clinicians	  who	  were	  confortable	  administering	  HIV	  medications,	  educational	  materials	  for	  patients	  and	  nurses,	  and	  statistical	  documentation	  capacities.	  In	  some	  international	  HIV	  treatment	  projects,	  research	  was	  a	  sub-­‐component	  of	  a	  humanitarian	  intervention.	  When	  the	  organization	  Doctors	  without	  Borders	  (MSF)	  started	  their	  HIV	  treatment	  program	  in	  Khayelitsha,	  outside	  Cape	  Town,	  for	  example,	  the	  primary	  objectives	  were	  humanitarian	  and	  political,482	  but	  the	  organization	  documented	  outcomes	  and	  published	  the	  results	  in	  respected	  biomedical	  journals.483	  For	  other	  HIV	  projects,	  
                                                482	  As	  stated	  on	  MSF’s	  website:	  “Médecins	  Sans	  Frontières	  (MSF)	  is	  an	  international,	  independent,	  medical	  humanitarian	  organisation	  that	  delivers	  emergency	  aid	  to	  people	  affected	  by	  armed	  conflict,	  epidemics,	  healthcare	  exclusion	  and	  natural	  or	  man-­‐made	  disasters.”	  	  “Médecins	  Sans	  Frontières,”	  accessed	  December	  29,	  2012,	  http://www.msf.org/.	  483	  David	  Coetzee	  et	  al.,	  “Outcomes	  After	  Two	  Years	  of	  Providing	  Antiretroviral	  Treatment	  in	  Khayelitsha,	  South	  Africa,”	  AIDS	  18,	  no.	  6	  (2004):	  887–895;	  David	  Coetzee	  et	  al.,	  “Integrating	  Tuberculosis	  and	  HIV	  Care	  in	  the	  Primary	  Care	  Setting	  in	  South	  Africa,”	  Tropical	  Medicine	  &	  
International	  Health	  9,	  no.	  6	  (2004):	  A11–15.	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research	  was	  the	  primary	  reason	  for	  putting	  in	  place	  clinical,	  laboratory,	  and	  HIV	  treatment	  structures	  and	  the	  fact	  that	  people	  gained	  new	  access	  to	  life-­‐saving	  drugs	  was	  a	  humanitarian	  bonus	  that	  could	  be	  used	  to	  help	  justify	  the	  research.484	  Finally,	  there	  were	  HIV	  treatment	  projects	  that	  were	  designed	  as	  research,	  but	  whose	  investigators	  had	  consciously	  set	  up	  their	  programs	  so	  that	  they	  could	  access	  research	  funds	  to	  provide	  expensive,	  life-­‐saving	  HIV	  drugs	  to	  people	  who	  would	  not	  have	  had	  HIV	  treatment	  otherwise.485	  Some	  of	  this	  research	  was	  also	  consciously	  used	  to	  support	  pro-­‐treatment	  arguments	  in	  the	  ongoing	  debates	  around	  the	  feasibility	  of	  HIV	  treatment	  in	  Africa.	  The	  question	  of	  how	  people	  access	  care	  for	  a	  life-­‐threatening	  or	  chronic	  illness	  in	  the	  setting	  of	  insufficient	  financial	  resources	  and	  an	  essentially	  absent	  state	  has	  occupied	  many	  medical	  anthropologists	  in	  the	  past	  decade,	  especially	  in	  the	  context	  of	  HIV/AIDS	  in	  Africa.	  Vinh-­‐Kim	  Nguyen,	  Joao	  Biehl,	  Susan	  Reynolds-­‐Whyte,	  Hansjörg	  Dilger	  and	  Ippolitos	  Kalofonos	  have	  documented	  how	  non-­‐governmental	  organizations	  (both	  local	  and	  international)	  and	  faith	  based	  organizations	  have	  found	  ways	  of	  assisting	  people	  in	  their	  time	  of	  existential	  medical	  need	  –	  some	  more	  effectively	  than	  others.486	  Access	  to	  support	  requires	  a	  declaration	  of	  belonging,	  however.	  Nguyen	  uses	  the	  concept	  of	  “therapeutic	  citizenship”	  to	  describe	  the	  ways	  some	  HIV	  positive	  individuals	  were	  able	  to	  trade	  their	  ability	  to	  openly	  “disclose”	  their	  HIV	  positive	  status	  for	  access	  to	  medical	  care	  and	  jobs	  with	  
                                                484	  Much	  of	  the	  research	  I	  was	  engaged	  in	  while	  working	  in	  Sharon	  Cassol’s	  molecular	  virology	  laboratory	  at	  the	  Africa	  Centre	  belonged	  in	  this	  category.	  See,	  for	  example,	  the	  following	  studies:	  Edana	  Cassol	  et	  al.,	  “Therapeutic	  Response	  of	  HIV-­‐1	  Subtype	  C	  in	  African	  Patients	  Coinfected	  with	  Either	  Mycobacterium	  Tuberculosis	  or	  Human	  Herpesvirus-­‐8,”	  The	  Journal	  of	  Infectious	  Diseases	  191,	  no.	  3	  (2005):	  324–332;	  Anisa	  Mosam	  et	  al.,	  “Generic	  Antiretroviral	  Efficacy	  in	  AIDS-­‐associated	  Kaposi’s	  Sarcoma	  in	  sub-­‐Saharan	  Africa,”	  AIDS	  19,	  no.	  4	  (2005):	  441–443.	  485	  Dr.	  Friedland	  and	  Dr.	  Moll’s	  HIV/TB	  cotreatment	  study	  in	  Tugela	  Ferry	  appears	  to	  belong	  in	  this	  category.	  486	  Vinh-­‐Kim	  Nguyen,	  The	  Republic	  of	  Therapy:	  Triage	  and	  Sovereignty	  in	  West	  Africa’s	  Time	  of	  AIDS,	  1st	  ed.	  (Duke	  University	  Press	  Books,	  2010);	  Susan	  Reynolds	  Whyte,	  Sjaak	  van	  der	  Geest,	  and	  Anita	  Hardon,	  Social	  Lives	  of	  Medicines.	  (Cambridge	  University	  Press,	  2003);	  Hansjörg	  Dilger,	  Leben	  Mit	  
Aids	  (Campus	  Verlag	  GmbH,	  2005);	  Ippolytos	  Kalofonos,	  “Living	  with	  HIV/AIDS	  at	  the	  Dawn	  of	  the	  Treatment	  Era	  in	  Central	  Mozambique”	  (Doctoral	  Dissertation,	  University	  of	  California,	  2008).	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AIDS	  NGOs.	  In	  the	  rather	  different	  setting	  of	  Ukraine	  after	  the	  nuclear	  power	  plant	  accident	  in	  Chernobyl,	  Adriana	  Petryna	  shows	  that	  identifying	  as	  a	  Chernobyl	  sufferer	  brought	  with	  it	  the	  ability	  to	  claim	  support	  from	  the	  Ukrainian	  state	  –	  also	  often	  facilitated	  by	  NGOs	  –	  at	  a	  time	  when	  the	  state	  was	  unable	  to	  fulfill	  its	  broader	  obligations	  toward	  its	  citizens.487	  In	  Tugela	  Ferry	  in	  the	  1990s	  and	  early	  2000s	  clinical	  research	  and	  non-­‐governmental	  organizations	  did	  indeed	  play	  an	  important	  role	  in	  filling	  the	  large	  gaps	  left	  by	  a	  state	  which	  had	  not	  managed	  to	  provide	  well	  for	  its	  poor	  citizens,	  and	  which	  ignored	  the	  pressing	  needs	  of	  HIV	  positive	  individuals.	  When	  the	  Yale/Philanjalo	  research	  collaboration	  on	  HIV/TB	  (Sizonqoba)	  started	  in	  2002/2003,	  this	  carefully	  monitored	  and	  documented	  treatment	  intervention	  with	  a	  total	  study	  population	  of	  125	  people	  –	  described	  by	  Friedland	  as	  “operational	  research”	  	  –	  was	  the	  only	  way	  to	  access	  HIV	  treatment	  in	  Msinga.	  The	  uncertainty	  being	  studied	  was	  not	  a	  new	  drug	  with	  incompletely	  known	  properties,	  but	  instead	  lay	  in	  the	  operational	  possibilities	  of	  using	  a	  particular	  protocol	  to	  successfully	  treat	  a	  particular	  set	  of	  comorbidities	  (TB	  and	  HIV)	  in	  a	  particular	  location	  (Msinga).	  Not	  all	  global	  health	  research	  takes	  place	  in	  the	  absence	  of	  appropriate	  state-­‐sponsored	  care,	  however.	  By	  the	  time	  Dr.	  Friedland’s	  research	  group	  uncovered	  XDR-­‐TB	  in	  2005	  the	  participation	  in	  research	  was	  no	  longer	  a	  condition	  of	  survival	  for	  HIV	  positive	  people	  in	  Msinga.	  The	  South	  African	  state	  had	  started	  funding	  HIV	  medication	  and	  rolling	  it	  out	  to	  its	  citizens	  in	  2004.	  Meanwhile,	  research	  on	  tuberculosis	  in	  South	  Africa,	  unlike	  early	  research	  on	  HIV	  and	  AIDS,	  plugged	  into	  pre-­‐existing,	  nurse-­‐driven	  tuberculosis	  program	  structures	  that	  were	  maintained	  by	  the	  South	  African	  department	  of	  health	  and	  supported	  by	  organizations	  like	  the	  South	  African	  Medical	  Research	  Council	  and	  Health	  Systems	  Trust.	  
                                                487	  Adriana	  Petryna,	  Life	  Exposed:	  Biological	  Citizens	  After	  Chernobyl.	  (Princeton	  University	  Press,	  2002).	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The	  government	  had	  been	  providing	  free	  treatment	  for	  tuberculosis	  –	  including	  multi-­‐drug	  resistant	  tuberculosis	  –	  since	  the	  1990s.	  Though	  the	  quality	  of	  TB	  program	  was	  highly	  variable,	  and	  often	  poor,	  the	  DOTS	  office	  in	  Msinga	  –	  like	  DOTS	  offices	  in	  many	  districts	  in	  KwaZulu-­‐Natal	  –	  provided	  free	  anti-­‐TB	  drugs,	  basic	  TB	  diagnostic	  testing	  on	  site,	  drug-­‐resistance	  testing	  via	  a	  laboratory	  in	  Durban,	  and	  the	  ability	  to	  refer	  drug-­‐resistant	  tuberculosis	  cases	  to	  King	  George	  V	  hospital	  in	  Durban,	  “only”	  2.5	  hours	  drive	  away.	  Many	  components	  of	  tuberculosis	  programs	  were	  weak,	  and	  researchers	  studying	  them	  supplemented	  staffing	  and	  provided	  resources	  that	  improved	  program	  quality	  and	  the	  ability	  to	  document	  outcomes.	  Unlike	  research	  on	  HIV,	  however,	  tuberculosis	  research	  did	  not	  involve	  putting	  in	  place	  the	  entire	  TB	  program,	  including	  TB	  drugs,	  TB	  clinic	  staff	  and	  TB	  laboratory	  services	  and	  providing	  the	  funding	  for	  it.	  When	  Dr.	  Moll	  and	  Dr.	  Friedland	  designed	  their	  study	  of	  the	  co-­‐treatment	  of	  HIV	  and	  TB	  in	  Tugela	  Ferry	  they	  designed	  the	  HIV	  treatment	  component	  from	  scratch.	  The	  tuberculosis	  treatment	  component	  of	  the	  study,	  however,	  was	  adapted	  to	  existing	  tuberculosis	  treatment	  structures	  and	  employed	  existing	  treatment	  regimens	  and	  diagnostic	  laboratory	  protocols	  that	  were	  paid	  for	  and	  regulated	  by	  the	  government	  health	  system.	  Thus	  it	  would	  be	  difficult	  to	  argue	  that	  international	  TB	  research	  in	  Tugela	  Ferry	  stepped	  into	  a	  true	  absence	  of	  care	  and	  treatment.	  Yet	  it	  was	  through	  the	  act	  of	  careful	  looking	  and	  documenting	  of	  TB	  outcomes	  that	  international	  HIV/TB	  researchers	  “discovered”	  XDR-­‐TB	  –	  or	  rather,	  made	  XDR-­‐TB	  visible,	  and	  with	  that	  also	  revealed	  a	  dangerous	  gap	  in	  government-­‐sponsored	  health	  care	  demanding	  a	  response.	  
From	  worst-­‐case	  scenario	  to	  best	  practice	  By	  the	  time	  I	  moved	  to	  Tugela	  Ferry	  in	  2011	  the	  town	  was	  making	  the	  transition	  from	  being	  internationally	  known	  as	  the	  site	  of	  the	  worst-­‐case	  scenario	  for	  drug-­‐resistant	  tuberculosis	  to	  being	  seen	  as	  the	  site	  of	  a	  best-­‐practice	  model	  for	  combatting	  MDR-­‐TB	  and	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XDR-­‐TB	  in	  a	  patient-­‐centered,	  effective	  manner.	  Rates	  of	  new	  XDR-­‐TB	  cases	  in	  Msinga	  had	  fallen	  significantly	  –	  so	  much	  so	  that	  one	  American	  research	  study	  evaluating	  XDR-­‐TB	  transmission	  in	  Msinga	  had	  to	  expand	  its	  catchment	  area	  to	  the	  entire	  province	  of	  KwaZulu-­‐Natal	  in	  order	  to	  capture	  the	  required	  number	  of	  study	  patients.	  Dr.	  Moll,	  who	  had	  facilitated	  the	  research	  on	  MDR-­‐TB	  and	  XDR-­‐TB	  in	  Tugela	  Ferry,	  felt	  that	  it	  was	  time	  to	  “shift	  from	  that	  sort	  of	  hard-­‐core	  research	  to	  the	  next	  phase,	  which	  will	  be	  technical	  assistance	  to	  the	  rest	  of	  the	  country	  in	  terms	  of	  establishing	  MDR	  best	  practices	  in	  terms	  of	  community	  management	  of	  MDR-­‐TB.”	  In	  fact,	  in	  2011	  Philanjalo	  had	  received	  a	  grant	  with	  which	  to	  set	  up	  a	  center	  of	  excellence	  for	  MDR-­‐TB	  treatment	  and	  promote	  the	  community-­‐based	  model	  around	  the	  country,	  including	  in	  skeptical	  provinces	  and	  districts.	  Even	  as	  researchers	  and	  forward-­‐thinking	  clinicians	  moved	  on,	  however,	  the	  every-­‐day	  challenge	  of	  managing	  a	  staggering	  number	  of	  MDR-­‐TB	  patients	  in	  Umzinyathi	  (and	  the	  province	  as	  a	  whole)	  remained.	  Nurses	  in	  the	  TB-­‐DOTS	  office	  in	  Tugela	  Ferry,	  together	  with	  doctors	  and	  other	  staff	  at	  the	  hospital,	  under	  the	  direction	  of	  the	  local	  department	  of	  health	  had	  to	  find	  ways	  to	  cope	  with	  a	  new	  category	  of	  patient	  which	  had	  unexpectedly	  been	  uncovered	  and	  for	  whom	  an	  obvious	  plan	  of	  treatment	  had	  not	  yet	  been	  developed.	  Using	  the	  existing	  public	  health	  structure	  designed	  for	  regular	  tuberculosis	  patients,	  individuals	  with	  drug-­‐resistant	  tuberculosis	  had	  to	  be	  identified,	  traced,	  referred,	  and	  treated,	  and	  their	  care	  needed	  to	  be	  documented.	  The	  following	  chapter	  focuses	  on	  the	  labor	  of	  the	  nurses	  and	  researchers	  whose	  daily	  job	  it	  was	  to	  engage	  in	  these	  tasks.
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CHAPTER	  5:	  Finding	  Data	  in	  a	  Global	  Landscape	  
 The	  centerpiece	  of	  Tugela	  Ferry’s	  response	  to	  the	  high	  prevalence	  of	  drug-­‐resistant	  tuberculosis	  was	  the	  decentralized,	  community-­‐based	  (or	  home-­‐based)	  treatment	  of	  MDR-­‐TB.488	  In	  this	  innovative	  and	  somewhat	  controversial	  program	  MDR-­‐TB	  patients	  were	  only	  briefly	  hospitalized	  in	  Greytown	  (ideally	  two	  weeks	  or	  less,	  if	  stable)	  and	  they	  received	  most	  of	  their	  treatment	  (including	  injections)	  in	  their	  own	  homes.	  Tugela	  Ferry’s	  MDR-­‐TB	  patients	  attended	  the	  MDR-­‐TB	  clinic	  in	  Greytown	  only	  once	  a	  month	  to	  be	  evaluated	  and	  to	  receive	  the	  next	  month’s	  medication.	  During	  the	  initial	  intensive	  phase	  of	  treatment	  (usually	  the	  first	  six	  months)	  TB	  nurses	  visited	  patients	  in	  their	  homes	  every	  day	  to	  administer	  the	  injections	  that	  were	  part	  of	  MDR-­‐TB	  treatment	  (in	  addition	  to	  pills)	  as	  well	  as	  to	  monitor	  potential	  side-­‐effects	  and	  to	  provide	  treatment	  support.	  Additional	  support	  was	  provided	  by	  lay	  community	  health	  workers.	  XDR-­‐TB	  patients	  were	  treated	  in	  a	  similar	  manner,	  though	  their	  hospitalizations	  took	  place	  in	  Durban	  and	  were	  often	  longer.	  As	  we	  have	  seen,	  this	  program	  was	  made	  possible	  in	  part	  by	  the	  fact	  that	  the	  province	  of	  KwaZulu-­‐Natal	  opened	  a	  “decentralized”	  hospital	  and	  clinic	  for	  MDR-­‐TB	  in	  Greytown,	  about	  45	  minutes	  drive	  from	  Tugela	  Ferry,	  so	  that	  patients	  with	  MDR-­‐TB	  no	  longer	  had	  to	  be	  sent	  to	  Durban.	  In	  Greytown	  patients	  were	  seen	  by	  doctors,	  nurses,	  and	  research	  staff	  based	  in	  Tugela	  Ferry	  and	  Greytown.	  In	  addition,	  the	  number	  of	  staff	  in	  Tugela	  Ferry’s	  outpatient	  tuberculosis	  program	  was	  greatly	  expanded,	  and	  vehicles	  were	  procured	  so	  that	  nurses	  and	  other	  community	  outreach	  workers	  could	  reach	  tuberculosis	  patients	  in	  their	  homes	  throughout	  Msinga,	  the	  catchment	  area	  for	  the	  Church	  of	  Scotland	  Hospital	  in	  Tugela	  Ferry.	  Researchers,	  government	  employees	  and	  clinicians	  began	  sharing	  news	  of	  this	  community-­‐based	  model	  of	  care	  at	  scientific	  meetings	  and	  workshops	  not	  long	  after	  the	  
                                                488	  James	  Brust,	  et	  al.	  “Integrated,	  Home-­‐based	  Treatment	  for	  MDR-­‐TB	  and	  HIV	  in	  Rural	  South	  Africa:	  An	  Alternate	  Model	  of	  Care,”	  The	  International	  Journal	  of	  Tuberculosis	  and	  Lung	  Disease	  16,	  no.	  8	  (2012):	  998-­‐1004.	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program	  was	  initiated.489	  Tugela	  Ferry’s	  efforts	  to	  combat	  drug-­‐resistant	  tuberculosis	  were	  also	  featured	  in	  news-­‐articles	  and	  television	  documentaries,	  including	  a	  South	  African	  investigative	  reporting	  program	  and	  a	  documentary	  for	  BBC	  television.490	  According	  to	  research	  presentations	  in	  2010	  and	  beyond	  the	  program	  was	  innovative;	  the	  rate	  of	  successful	  treatment	  outcomes	  was	  high;	  the	  risk	  of	  infection	  to	  family	  members	  was	  low;	  and	  the	  relationship	  between	  different	  levels	  of	  government	  of	  administration	  and	  researchers	  was	  productive.	  A	  key	  feature	  in	  presentations	  both	  for	  the	  lay	  public	  and	  the	  scientific	  audience	  was	  the	  Msinga	  landscape.	  Conference	  presentations	  on	  MDR-­‐TB	  and	  XDR-­‐TB	  in	  Tugela	  Ferry	  almost	  always	  included	  compelling	  photographs	  of	  four-­‐by-­‐four	  vehicles	  negotiating	  rugged	  rural	  terrain.	  They	  featured	  striking	  views	  of	  ragged	  cliffs,	  traditional	  Zulu	  round	  houses	  with	  thatched	  or	  tin	  roofs,	  poor	  patients	  (sometimes	  in	  traditional	  attire),	  and	  uniformed	  nurses	  with	  syringes	  poised.	  Images	  of	  rural	  Msinga	  and	  its	  heroic	  healthworkers	  offered	  a	  picturesque	  backdrop	  for	  more	  focused	  discussions	  of	  treatment	  program	  outcomes,	  adverse	  event	  statistics,	  and	  infection	  control	  concerns.	  Yet	  the	  images	  and	  conditions	  of	  rural	  Msinga	  were	  not	  incidental	  to	  these	  discussions.	  Difficult	  terrain,	  resilient	  health	  care	  workers,	  and	  patients	  in	  difficult	  circumstances	  who	  needed	  to	  be	  met	  halfway	  helped	  conveyed	  the	  structural	  challenges	  of	  providing	  effective	  tuberculosis	  care	  in	  South	  Africa.	  	  They	  shaped	  the	  meaning	  and	  communicated	  the	  significance	  of	  work	  on	  drug-­‐resistant	  tuberculosis	  for	  global	  public	  health	  and	  for	  biomedical	  science.	  Other	  MDR-­‐TB	  and	  XDR-­‐TB	  treatment	  programs	  similarly	  employed	  visual	  evidence	  
                                                489	  James	  Brust,	  et	  al.	  “Abstract:	  Community-­‐based	  treatment	  of	  multidrug-­‐resistant	  tuberculosis	  (MDR	  TB)	  and	  HIV	  in	  rural	  South	  Africa,”	  AIDS	  2008	  -­‐	  XVII	  International	  AIDS	  Conference:	  Abstract	  no.	  WEPE0147;	  Marian	  Loveday,	  et	  al.	  “Abstract:	  Comparing	  the	  early	  treatment	  outcomes	  of	  MDR-­‐TB	  in	  a	  decentralized	  setting	  with	  a	  centralized	  setting,”	  The	  International	  Journal	  of	  Tuberculosis	  and	  Lung	  
Disease	  14,	  no.	  11	  S2	  (2010):	  S208.	  490	  Fiona	  Lloyd-­‐Davies,	  “Life	  in	  the	  Shadow	  of	  Deadly	  New	  TB,”	  BBC	  News	  14	  November,	  2008,	  http://news.bbc.co.uk/2/hi/africa/7729184.stm.	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to	  underline	  these	  challenges.	  At	  the	  South	  African	  TB	  conference	  in	  2010	  researchers	  working	  for	  MSF	  (Doctors	  without	  Borders)	  in	  Khayelitsha	  –	  a	  large,	  black	  township	  outside	  of	  Cape-­‐Town	  known	  for	  tin	  shacks,	  bustling	  commerce,	  and	  high	  rates	  of	  crime	  –	  presented	  a	  video	  of	  a	  young,	  outspoken	  community	  worker	  going	  from	  door	  to	  door,	  visiting	  grannies	  in	  cramped,	  run-­‐down	  shacks	  in	  order	  to	  convince	  them	  to	  keep	  taking	  their	  medicines.	  The	  images	  from	  both	  urban	  and	  rural	  South	  Africa	  resonated	  with	  common	  tropes	  of	  “real	  Africa,”	  which	  I	  will	  discuss	  later	  in	  this	  chapter.	  It	  was	  easy	  to	  imagine	  nurses	  and	  community	  health	  workers	  suffering	  through	  adverse	  conditions	  in	  order	  to	  make	  a	  personal	  connection	  with	  their	  poor,	  suffering	  patients.	  This	  chapter	  deals	  with	  three	  types	  of	  activities:	  the	  work	  of	  providing	  community-­‐based	  MDR-­‐TB	  treatment	  in	  Msinga,	  and	  the	  tasks	  of	  documenting	  and	  representing	  this	  work.	  I	  consider	  the	  challenges	  of	  translating	  the	  repetitive	  and	  dull	  tasks	  of	  maintaining	  an	  effective	  public	  health	  treatment	  program	  into	  exciting,	  publishable	  science	  and	  cutting-­‐edge	  global	  health.	  In	  the	  following	  sections	  I	  follow	  nurses	  as	  they	  go	  about	  their	  daily	  business	  –	  signing	  out	  cars,	  driving	  up	  hillsides,	  finding	  patients	  at	  their	  houses,	  providing	  injections	  and	  reporting	  back	  at	  the	  office	  any	  problems	  encountered.	  I	  watch	  doctors	  as	  they	  see	  patient	  after	  patient,	  review	  X-­‐ray	  after	  X-­‐ray	  and	  prescribe	  similar	  treatment	  courses	  for	  each.	  I	  also	  detail	  the	  ways	  research	  workers,	  data	  capturers	  and	  academics	  capture	  this	  (everything	  but?)	  routine	  work	  and	  convert	  it	  into	  data.	  The	  nurses’	  physical	  environment,	  the	  landscape	  that	  surrounds	  them,	  and	  the	  hardships	  of	  their	  patients	  necessarily	  shape	  their	  daily	  experience,	  in	  the	  same	  way,	  perhaps,	  that	  uncomfortable	  office	  chairs	  and	  demanding	  clients	  impact	  an	  urban,	  office-­‐based	  customer-­‐service	  representative.	  The	  landscape	  becomes	  an	  important	  actor	  in	  itself,	  however,	  when	  the	  work	  is	  presented	  and	  explained	  to	  an	  outside	  audience.	  South	  African	  and	  American	  representatives	  alike	  demonstrated	  a	  strong	  need	  to	  explain	  the	  location	  of	  Msinga	  in	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addition	  to	  providing	  quantitative	  evidence	  for	  the	  needs	  and	  successes	  of	  MDR-­‐TB	  treatment.	  This	  was	  particularly	  evident	  in	  less	  formal	  powerpoint	  presentations	  that	  could	  easily	  make	  use	  of	  photographs	  as	  well	  as	  in	  colorful	  publicity	  materials	  summarizing	  the	  research	  work	  being	  done	  in	  Tugela	  Ferry.	  But	  it	  was	  also	  apparent	  in	  formal,	  published	  scientific	  papers	  where	  stunning	  photographs	  were	  replaced	  with	  brief,	  elliptical	  descriptions	  (like	  “rural”)	  and	  laden	  words	  (like	  “traditional,”	  and	  “resource-­‐poor”)	  that	  coded	  Msinga	  as	  a	  site	  of	  global	  health	  intervention.491	  The	  core	  content	  of	  these	  papers,	  however,	  was	  based	  on	  a	  comprehensive	  accounting	  of	  patients’	  treatment	  course,	  laboratory	  values,	  radiologic	  findings,	  and	  health	  status.	  Great	  effort	  was	  exerted	  to	  acquire	  this	  information.	  I	  argue	  that	  it	  is	  in	  part	  this	  combination	  of	  public	  health	  intervention,	  solid	  quantitative	  documentation	  and	  the	  context	  of	  an	  “othering”	  landscape	  that	  make	  the	  community-­‐based	  treatment	  of	  MDR-­‐TB	  in	  Tugeal	  Ferry	  a	  model	  “global	  health”	  project.	  
Controlling	  an	  Epidemic	  with	  Paperwork	  
	  
“We	  had	  a	  DOT	  [Directly	  Observed	  Tuberculosis	  Treatment]	  team	  in	  the	  hospital.	  In	  fact	  the	  
DOT	  team	  was	  one	  professional	  nurse	  -­‐	  a	  nursing	  sister	  -­‐	  and	  a	  staff	  nurse.	  	  And	  at	  any	  one	  
time	  they	  would	  be	  looking	  after	  about	  700	  TB	  patients	  in	  the	  community,	  right,	  but	  without	  
wheels	  and	  basically	  just	  grounded	  in	  the	  hospital,	  using	  paper	  registers	  to	  try	  and	  control	  
these	  patients	  coming	  in	  and	  out.”	  	  
-­‐	  Dr.	  Moll	  (in	  2007),	  speaking	  about	  tuberculosis	  treatment	  before	  2005.	  492	  
                                                491	  Neel	  R.	  Gandhi	  et	  al.,	  “Extensively	  Drug-­‐resistant	  Tuberculosis	  as	  a	  Cause	  of	  Death	  in	  Patients	  Co-­‐infected	  with	  Tuberculosis	  and	  HIV	  in	  a	  Rural	  Area	  of	  South	  Africa,”	  Lancet	  368,	  no.	  9547	  (2006):	  1575–1580;	  James	  Brust,	  et	  al.	  “Integrated,	  Home-­‐based	  Treatment	  for	  MDR-­‐TB	  and	  HIV	  in	  Rural	  South	  Africa:	  An	  Alternate	  Model	  of	  Care,”	  The	  International	  Journal	  of	  Tuberculosis	  and	  Lung	  Disease	  16,	  no.	  8	  (2012):	  998-­‐1004;	  Neel	  Gandhi,	  et	  al.,	  “Nosocomial	  Transmission	  of	  Extensively	  Drug-­‐Resistant	  Tuberculosis	  in	  a	  Rural	  Hospital	  in	  South	  Africa,”	  Journal	  of	  Infectious	  Diseases	  207,	  no.1	  (2013):	  9-­‐17.	  492	  Anthony	  Moll,	  interview	  by	  author,	  12	  July	  2007,	  Tugela	  Ferry,	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  Africa.	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Before	  the	  discovery	  of	  XDR-­‐TB	  in	  Tugela	  Ferry	  tuberculosis	  control	  was	  essentially	  “grounded	  in	  the	  hospital.”	  Dr.	  Moll’s	  quote	  above	  evokes	  the	  jarring	  –	  perhaps	  comical	  –	  image	  of	  two	  lonely	  nurses	  staving	  off	  a	  tide	  of	  infectious	  disease	  with	  paperwork.	  He	  elaborated:	  “Now	  these	  two	  ladies	  would	  be	  sitting	  in	  the	  office,	  basically,	  when	  a	  patient	  is	  diagnosed	  with	  TB	  in	  the	  hospital,	  whether	  from	  the	  wards	  or	  the	  outpatients	  department,	  they	  would	  go	  via	  the	  DOT	  office,	  be	  registered,	  their	  names	  would	  be	  filled	  in	  all	  the	  different	  stationary	  that’s	  used	  for	  TB.	  There’s	  a	  carrier	  card,	  there’s	  a	  register	  […].	  The	  patients	  would	  be	  given	  brief	  health	  education,	  given	  their	  tablets	  and	  sent	  home	  with	  a	  come	  back	  date.”493	  By	  2010,	  five	  years	  after	  the	  discovery	  of	  XDR-­‐TB,	  Tugela	  Ferry’s	  tuberculosis	  office’s	  ability	  to	  reach	  out	  to	  patients	  in	  the	  community	  and	  to	  follow-­‐up	  their	  care	  through	  community	  workers,	  injection	  teams	  and	  tracer	  teams	  had	  expanded	  considerably.	  The	  TB	  office	  was	  still	  trying	  to	  fight	  tuberculosis	  with	  paperwork,	  however.	  During	  my	  fieldwork	  I	  spent	  many	  days	  sitting	  in	  the	  tuberculosis	  office	  observing	  tuberculosis	  management	  in	  action.	  Each	  morning,	  after	  injection	  nurses	  and	  tracers	  had	  left	  for	  their	  work	  in	  the	  surrounding	  area,	  two	  or	  three	  office-­‐based	  nurses	  sat	  at	  a	  large	  table	  in	  the	  tuberculosis	  office,	  managing	  the	  flow	  of	  tuberculosis	  patients	  by	  writing	  on	  paper.	  As	  each	  patient	  came	  in	  the	  nurses	  started	  diligently	  writing	  down	  the	  patient’s	  information	  on	  the	  many	  documents	  required.	  Each	  person	  with	  drug-­‐susceptible	  tuberculosis	  generated	  at	  least	  six	  hand-­‐written	  entries	  (not	  including	  carbon	  copies)	  onto	  color	  coded	  cards,	  files,	  and	  registers.	  The	  records	  produced	  in	  the	  TB	  office	  reflected	  –	  to	  varying	  degrees	  –	  the	  needs	  of	  clinical	  care,	  public	  health	  bureaucracy,	  funder	  reporting	  requirements	  and	  academic	  research.	  The	  centerpiece	  of	  official	  TB	  documentation	  was	  the	  tuberculosis	  register,	  which	  
                                                493	  Anthony	  Moll,	  interview	  by	  author,	  12	  July	  2007,	  Tugela	  Ferry,	  South	  Africa.	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was	  required	  by	  the	  South	  African	  tuberculosis	  program.	  It	  is	  a	  long	  booklet	  (that	  opens	  up	  to	  about	  a	  meter	  in	  length)	  that	  lists	  every	  tuberculosis	  patient	  (ten	  per	  page)	  and	  captures	  over	  35	  key	  facts	  about	  each	  patient	  and	  their	  treatment	  course.	  The	  register	  attempted	  to	  represent	  each	  standardized	  treatment	  decision	  as	  a	  tick	  box	  or	  entry.	  In	  theory,	  it	  fulfilled	  an	  important	  function	  in	  ensuring	  the	  compliance	  of	  both	  patients	  and	  nurses	  with	  national	  tuberculosis	  protocol	  and	  provided	  a	  tool	  for	  epidemiological	  surveillance.	  In	  addition,	  the	  content	  of	  the	  register	  was	  of	  potential	  interest	  to	  researchers	  studying	  tuberculosis	  epidemiology	  and	  treatment.494	  According	  to	  TB	  nurses	  in	  Tugela	  Ferry	  the	  primary	  purpose	  of	  the	  tuberculosis	  register	  was	  “for	  stats,”	  or	  statistical	  reports	  for	  the	  department	  of	  health.	  The	  register	  constituted	  the	  basis	  for	  the	  reporting	  of	  Msinga	  sub-­‐district	  level	  TB	  program	  statistics	  to	  the	  Umzinyathi	  district	  level	  and	  upward,	  eventually	  reaching	  the	  national	  tuberculosis	  program.	  Every	  tuberculosis	  case	  that	  was	  diagnosed	  and	  treated	  via	  the	  Church	  of	  Scotland	  Hospital	  was	  listed	  in	  the	  register	  (except	  for	  tuberculosis	  cases	  identified	  at	  the	  HIV	  clinic,	  which	  had	  its	  own	  TB	  register).	  Information	  from	  registers	  at	  outlying	  clinics	  in	  the	  catchment	  area	  was	  also	  compiled	  at	  the	  hospital’s	  TB	  office.	  Each	  page	  of	  the	  register	  generated	  three	  color-­‐coded	  carbon	  copies	  that	  were	  submitted	  at	  key	  times	  in	  order	  to	  produce	  data	  on	  important	  reporting	  items.	  These	  included	  the	  total	  number	  of	  tuberculosis	  patients	  enrolled	  in	  treatment,	  the	  number	  of	  patients	  who	  had	  “sputum	  conversions”495	  and	  the	  number	  of	  patients	  who	  completed	  treatment.	  In	  combination	  with	  other	  registers	  in	  the	  country,	  the	  register	  generated	  the	  raw	  data	  for	  the	  official	  statistics	  of	  the	  South	  
                                                494	  Neel	  R.	  Gandhi	  et	  al.,	  “Nosocomial	  Transmission	  of	  Extensively	  Drug-­‐Resistant	  Tuberculosis	  in	  a	  Rural	  Hospital	  in	  South	  Africa,”	  Journal	  of	  Infectious	  Diseases	  207	  (2013):	  9-­‐17;	  Marian	  Loveday,	  interview	  by	  author,	  19	  May	  2010,	  Durban,	  South	  Africa.	  495	  Patients	  who	  experience	  “sputum	  conversion”	  are	  patients	  with	  positive	  TB	  sputum	  results	  at	  the	  beginning	  of	  treatment	  who	  later	  have	  a	  negative	  sputum	  result.	  Ideally	  this	  indicates	  successful	  treatment.	  This	  is	  a	  poor	  measure	  to	  rely	  on,	  however,	  since	  patients	  can	  be	  sputum	  negative	  despite	  having	  TB,	  especially	  in	  the	  context	  of	  HIV/AIDS.	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African	  tuberculosis	  programs	  that	  were	  reported	  to	  the	  WHO	  and	  its	  STOP-­‐	  TB	  program.	  	   Despite	  the	  Tuberculosis	  Register’s	  apparent	  utility	  for	  statistical	  reporting,	  however,	  many	  clinicians,	  administrators	  and	  researchers	  (ranging	  from	  Tugela	  Ferry’s	  nurses	  to	  Durban-­‐based	  scientists,	  to	  WHO	  experts)	  found	  the	  register	  inherently	  problematic.	  The	  paper	  register	  alone	  did	  not	  really	  facilitate	  clinical	  care	  and	  inflexibly	  constrained	  nurses	  in	  their	  clinical	  decision-­‐making	  by	  assuming	  a	  standard	  treatment	  algorithm.	  Sputum	  samples	  were	  to	  be	  taken	  at	  3	  months	  and	  6	  months	  of	  treatment,	  for	  example,	  and	  sent	  to	  the	  laboratory	  for	  a	  smear	  (with	  direct	  microscopy),	  not	  culture	  (and	  drug	  sensitivity).	  But	  if,	  for	  some	  reason,	  an	  extra	  sputum	  sample	  was	  taken	  at	  4	  months,	  there	  was	  no	  place	  to	  write	  it	  down.	  Similarly,	  if,	  for	  some	  reason,	  a	  patient	  received	  a	  sputum	  culture	  and	  drug-­‐sensitivity	  testing	  at	  an	  “inappropriate”	  time,	  there	  would	  be	  no	  space	  to	  account	  for	  this.	  Such	  gaps	  potentially	  allowed	  failing	  treatment	  and	  drug-­‐resistance	  to	  go	  undocumented	  (and	  thus	  	  “unnoticed”).496	  	   Clinically,	  it	  was	  problematic	  that	  patients	  in	  the	  tuberculosis	  register	  were	  listed	  in	  sequence	  of	  their	  registration	  date	  at	  the	  TB	  office.	  This	  could	  make	  finding	  a	  particular	  patient	  by	  name	  very	  tedious,	  though	  identifying	  a	  patient	  by	  date	  of	  encounter	  was	  not	  difficult.	  The	  paper-­‐based	  register	  also	  meant	  that	  analysis	  and	  distribution	  of	  information	  required	  multiple	  entries	  and	  re-­‐entries,	  which	  was	  labor-­‐intensive	  and	  error-­‐prone.	  In	  one	  attempt	  at	  simplifying	  data	  compilation,	  the	  national	  tuberculosis	  program	  created	  an	  electronic	  database	  that	  allowed	  the	  computer-­‐based	  entry	  of	  the	  data.	  Yet,	  as	  one	  clinician	  explained	  to	  me,	  the	  database	  “sucked	  away”	  the	  data,	  not	  leaving	  the	  local	  TB	  office	  an	  
                                                496	  By	  the	  time	  I	  observed	  work	  in	  the	  TB	  office	  in	  Tugela	  Ferry	  in	  2010,	  the	  standard	  tuberculosis	  register	  had	  space	  to	  enter	  some	  information	  about	  drug-­‐resistance;	  information	  that	  previously	  had	  only	  been	  located	  only	  in	  the	  patient’s	  chart.	  Separate	  MDR-­‐TB	  registers	  had	  been	  designed	  for	  the	  MDR-­‐TB	  hospitals	  in	  KwaZulu-­‐Natal,	  including	  the	  one	  in	  Greytown	  which	  MDR-­‐TB	  patients	  from	  Tugela	  Ferry	  were	  referred	  to.	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electronic	  record	  to	  reference	  or	  manipulate.	  Thus,	  the	  motivation	  on	  the	  part	  of	  local	  clinicians	  to	  fill	  out	  this	  database	  (in	  addition	  to	  the	  paper	  register)	  was	  low,	  since	  it	  did	  not	  improve	  their	  ability	  to	  care	  for	  their	  patients.	  One	  South	  African	  operational	  researcher	  encouraged	  nurses	  to	  prioritize	  more	  helpful	  forms	  of	  documentation.497	  Originally,	  TB	  registers	  assumed	  every	  patient	  had	  drug-­‐susceptible	  tuberculosis.	  KwaZulu-­‐Natal’s	  provincial	  tuberculosis	  coordinator	  Bruce	  Margot	  explained	  that	  MDR-­‐TB	  reporting	  and	  recording	  systems	  were	  poor,	  both	  globally	  and	  locally:	  “There	  was	  nothing,	  really.	  No	  decent[ly]	  designed	  paper	  systems,	  and	  no	  software	  systems	  to	  support	  your	  analysis.	  So	  with	  no	  official	  reporting	  and	  recording	  system	  for	  MDR-­‐TB	  in	  the	  country	  you	  had	  little	  bits	  of	  information	  lying	  all	  over	  the	  place.	  Most	  of	  it	  lying	  in	  clinical	  files.”498	  Accessing	  these	  clinical	  files	  meant	  going	  to	  file	  rooms,	  sorting	  through	  irrelevant	  charts	  to	  find	  patients	  of	  interest	  and	  manually	  browsing	  their	  files	  for	  information	  that	  may	  or	  may	  not	  have	  been	  documented.	  As	  interest	  in	  HIV/AIDS	  research	  in	  South	  Africa	  increased,	  so	  did	  the	  interest	  in	  tuberculosis	  statistics	  from	  public	  health	  officials,	  international	  agencies,	  and	  academic	  researchers.	  The	  interest	  –	  especially	  in	  drug-­‐resistant	  tuberculosis	  –	  became	  more	  pronounced	  once	  Tugela	  Ferry’s	  XDR-­‐TB	  cases	  were	  publicized.	  Physicians	  at	  the	  King	  George	  V	  hospital,	  the	  specialized	  tuberculosis	  hospital	  in	  Durban,	  started	  receiving	  increasingly	  frequent	  requests	  for	  data	  from	  outside	  researchers.	  Tuberculosis	  physician	  Sheila	  Bamber	  recalled:	  “For	  a	  long	  time,	  when	  TB	  started	  being	  interesting,	  people	  used	  to	  come	  and	  say,	  oh,	  have	  you	  got	  stats?	  I’d	  say	  ‘we	  don’t	  keep	  stats	  here.’	  […]	  It	  was	  very	  embarrassing.	  So	  I	  actually	  recruited	  a	  colleague	  and	  we	  set	  up	  a	  database.”499	  A	  laboratory	  worker	  at	  the	  hospital	  also	  set	  up	  his	  own	  database	  based	  on	  the	  diagnostic	  tests	  he	  
                                                497	  Loveday,	  interview	  by	  author,	  2007.	  498	  Bruce	  Margot,	  interview	  by	  author,	  18	  April	  2010,	  Pietermaritzburg,	  South	  Africa.	  499	  Sheila	  Bamber,	  interview	  by	  author,	  26	  August	  2010,	  Tugela	  Ferry,	  South	  Africa.	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oversaw.500	  Another	  clinical	  and	  laboratory	  database	  was	  located	  at	  Inkosi	  Albert	  Luthuli	  Central	  Hospital,	  the	  modern	  academic	  teaching	  hospital	  in	  Durban	  where	  the	  government	  tuberculosis	  laboratory	  was	  located.	  However,	  this	  database	  was	  proprietary	  and	  very	  difficult	  to	  work	  with.	  According	  to	  Bruce	  Margot,	  “whoever	  designed	  it	  had	  never	  heard	  of	  TB,	  so	  it	  was	  very	  difficult	  to	  extract	  the	  information.”501	  When	  Kristina	  Wallengren	  was	  hired	  by	  the	  WHO	  to	  investigate	  MDR	  and	  XDR-­‐TB	  epidemiology	  in	  KwaZulu-­‐Natal,	  a	  large	  part	  of	  her	  job	  was	  to	  find	  the	  various	  ad-­‐hoc	  local	  systems	  for	  documentation	  of	  TB	  cases	  that	  were	  scattered	  across	  the	  province	  and	  to	  compile	  and	  clean	  the	  data	  that	  emerged	  from	  them.502	  Though	  tuberculosis	  registers	  could	  not	  answer	  many	  of	  the	  researchers’	  and	  public	  health	  officials’	  questions,	  they	  were	  part	  of	  a	  public	  health	  surveillance	  effort	  that	  sought	  to	  bureaucratically	  capture	  people	  with	  tuberculosis	  and	  count	  them	  as	  part	  of	  a	  local,	  provincial,	  national	  and	  global	  program	  of	  tuberculosis	  therapy.	  A	  patient’s	  entry	  in	  the	  tuberculosis	  register	  was	  not	  envisioned	  as	  a	  once-­‐off	  data	  point:	  tools	  existed	  to	  account	  for	  patients’	  movements	  from	  one	  health	  facility	  to	  another,	  and	  out	  of	  one	  health	  district	  into	  another.	  In	  theory	  (though	  not	  necessarily	  in	  practice),	  a	  patient’s	  movements	  could	  be	  traced	  through	  a	  series	  of	  tuberculosis	  registers	  in	  different	  health	  centers	  and	  hospitals,	  as	  long	  as	  a	  patient	  transferred	  out	  of	  one	  tuberculosis	  program	  and	  transferred	  into	  another.	  Appointments	  missed,	  medications	  not	  taken,	  and	  laboratory	  results	  received	  could	  all	  theoretically	  be	  found	  in	  registers	  and	  accompanying	  documentation.	  Yet	  gathering	  the	  traces	  of	  any	  particular	  patient	  from	  these	  disparate	  sources	  could	  be	  daunting,	  if	  not	  impossible.	  It	  required	  physical	  travel	  from	  one	  TB	  register	  to	  the	  next,	  and	  assumed	  that	  
                                                500	  Kristina	  Wallengren,	  interview	  by	  author,	  23	  September	  2010,	  Durban,	  South	  Africa.	  501	  Margot,	  interview	  by	  author,	  2007.	  502	  Kristina	  Wallengren	  et	  al.,	  “Drug-­‐Resistant	  Tuberculosis,	  KwaZulu-­‐Natal,	  South	  Africa,	  2001–2007,”	  Emerging	  Infectious	  Diseases	  17,	  no.	  10	  (2011):	  1913–1916;	  Margot,	  interview	  by	  author,	  2007.	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documentation	  closely	  represented	  clinical	  reality.	  While	  in	  Tugela	  Ferry	  I	  witnessed	  one	  such	  data-­‐tracing	  attempt	  by	  South	  African	  tuberculosis	  researchers	  based	  in	  Cape	  Town	  trying	  to	  piece	  together	  missing	  information	  on	  a	  group	  of	  patients	  they	  were	  studying.	  They	  found	  themselves	  travelling	  across	  the	  country,	  to	  Greytown	  and	  to	  Tugela	  Ferry,	  among	  other	  places,	  spending	  their	  days	  visiting	  TB	  offices,	  paging	  through	  old	  tuberculosis	  registers	  half-­‐forgotten	  in	  the	  back	  of	  filing	  cabinets.	  Perhaps	  it	  is	  not	  surprising,	  then,	  that	  it	  was	  not	  through	  the	  paper	  documentation	  of	  the	  TB	  office	  in	  Tugela	  Ferry	  that	  the	  MDR-­‐TB	  and	  XDR-­‐TB	  outbreak	  in	  Tugela	  Ferry	  was	  identified.	  As	  we	  have	  seen	  this,	  instead,	  was	  accomplished	  by	  physicians	  and	  researchers	  who	  overrode	  the	  government	  protocol	  and	  conducted	  additional	  screening	  for	  drug-­‐resistant	  tuberculosis	  in	  the	  context	  of	  the	  unexpected	  deaths	  of	  research	  participants.503	  Retrospective	  chart-­‐reviews	  partially	  helped	  the	  researchers	  piece	  together	  patients’	  treatment	  course	  leading	  up	  to	  diagnosis.	  Close	  evaluation	  of	  the	  published	  research	  paper	  that	  resulted	  from	  this	  work	  shows	  that	  this	  ad	  hoc	  method	  left	  several	  gaps	  in	  the	  data,	  as	  well.504	  
Foraging	  for	  information:	  The	  essential	  role	  of	  data	  managers	  The	  official	  bureaucratic	  method	  for	  keeping	  track	  of	  patients	  at	  the	  TB	  office	  in	  Tugela	  Ferry	  remained	  the	  bound,	  paper	  tuberculosis	  register,	  however.	  Once	  the	  MDR-­‐TB	  and	  XDR-­‐TB	  problem	  in	  Tugela	  Ferry	  became	  known,	  researchers	  sought	  more	  comprehensive	  ways	  to	  prospectively	  capture	  cases,	  evaluate	  their	  impact	  and	  assess	  interventions	  that	  were	  introduced	  in	  response.	  The	  tangible	  and	  intangible	  value	  of	  this	  data	  on	  the	  global	  health	  research	  market	  has	  been	  made	  clearly	  visible:	  Dr.	  Sarita	  Shah	  and	  
                                                503	  See	  Chapter	  2	  for	  a	  description	  of	  the	  way	  Dr.	  Moll	  and	  his	  colleagues	  became	  aware	  of	  the	  high	  rates	  of	  drug-­‐resistance	  at	  the	  hospital	  in	  Tugela	  Ferry.	  504	  Neel	  R.	  Gandhi	  et	  al.,	  “Extensively	  Drug-­‐resistant	  Tuberculosis	  as	  a	  Cause	  of	  Death	  in	  Patients	  Co-­‐infected	  with	  Tuberculosis	  and	  HIV	  in	  a	  Rural	  Area	  of	  South	  Africa,”	  Lancet	  368,	  no.	  9547	  (2006)	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Dr.	  Neel	  Gandhi,	  for	  example,	  both	  obtained	  large	  grants	  from	  the	  National	  Institutes	  of	  Health	  (NIH)	  to	  study	  XDR-­‐TB	  in	  KwaZuluNatal;	  Dr.	  Sheela	  Shenoi	  received	  funding	  from	  USAID	  to	  study	  the	  impact	  of	  intensified	  case-­‐finding	  for	  XDR-­‐TB	  in	  Msinga,	  and	  several	  American	  medical	  students	  obtained	  fellowships	  that	  allowed	  them	  to	  engage	  in	  TB	  research	  in	  Tugela	  Ferry,	  among	  others.505	  The	  Howard	  Hughes	  Medical	  Institute,	  inspired	  in	  part	  by	  the	  findings	  from	  Msinga,	  built	  a	  multi-­‐million	  dollar	  basic	  science	  facility	  in	  Durban	  for	  the	  study	  of	  HIV	  and	  TB	  and	  provided	  funds	  for	  housing	  and	  research	  buildings	  in	  Tugela	  Ferry.506	  Researchers	  with	  the	  South	  African	  Medical	  Research	  Council	  sought	  access	  to	  research	  infrastructure	  in	  Tugela	  Ferry	  and	  built	  collaborations	  with	  the	  American	  researchers	  who	  worked	  there.	  The	  MDR-­‐TB	  and	  XDR-­‐TB	  data	  at	  the	  specialized	  MDR-­‐TB	  hospital	  in	  Durban	  was	  also	  in	  high	  demand,	  and	  young	  physician-­‐scientists	  such	  as	  Dr.	  Max	  O’Donnell	  built	  careers	  analyzing	  KwaZulu-­‐Natal’s	  drug-­‐resistance	  problem	  from	  the	  Durban	  perspective.507	  In	  some	  cases,	  data	  was	  freely	  given	  to	  those	  who	  showed	  an	  interest	  in	  it;	  in	  others	  case	  hurdles	  were	  set,	  permissions	  were	  required,	  or	  favors	  were	  asked	  for	  in	  exchange.508	  
Assessing	  the	  community-­‐based	  treatment	  of	  MDR-­‐TB	  (from	  outside	  the	  community)	  When	  I	  arrived	  in	  Tugela	  Ferry	  in	  2010	  researchers	  under	  the	  leadership	  of	  Dr.	  
                                                505	  “Major	  Funding	  Awarded	  to	  Improve	  Treatment	  of	  Drug-­‐Resistant	  Tuberculosis	  and	  HIV	  Co-­‐Infection"	  Albert	  Einstein	  College	  of	  Medicine,	  accessed	  December	  28,	  2012,	  http://www.einstein.yu.edu/news/releases/552/major-­‐funding-­‐awarded-­‐to-­‐improve-­‐treatment-­‐of-­‐drug-­‐resistant-­‐tuberculosis-­‐and-­‐hiv-­‐co-­‐infection/;	  "New	  Projects	  Supported	  by	  NIH	  and	  USAID,"	  
TFCares.org,	  accessed	  April	  16	  2014,	  http://tfcares.org/;	  “2010-­‐2011	  CRF	  Fellows,”	  Doris	  Duke	  
Charitable	  Foundation,	  accessed	  December	  28,	  2012,	  http://www.ddcf.org/Programs/Medical-­‐Research/Goals-­‐and-­‐Strategies/Build-­‐the-­‐Clinical-­‐Research-­‐Career-­‐Ladder/Clinical-­‐Research-­‐Fellowships-­‐for-­‐Medical-­‐Students/Lists-­‐of-­‐Fellows-­‐by-­‐Year/2010-­‐2011-­‐CRF-­‐Fellows/.	  506	  “K-­‐RITH:	  Kwazulu-­‐Natal	  Research	  Institute	  for	  Tuberculosis	  and	  HIV,”	  K-­‐RITH.org,	  accessed	  December	  7,	  2012,	  http://www.k-­‐rith.org/;	  Eugene	  Meyer,	  interview	  by	  author,	  10	  October	  2010,	  Tugela	  Ferry,	  South	  Africa.	  507	  Max	  R.	  O’Donnell	  et	  al.,	  “Extensively	  Drug-­‐resistant	  Tuberculosis	  in	  Women,	  KwaZulu-­‐Natal,	  South	  Africa,”	  Emerging	  Infectious	  Diseases	  17,	  no.	  10	  (2011):	  1942–1945;	  Max	  R.	  O'Donnell	  et	  al.,	  "Treatment	  Outcomes	  for	  Extensively	  Drug-­‐resistant	  Tuberculosis	  and	  HIV	  Co-­‐infection,"	  Emerging	  
Infectious	  Diseases	  19,	  no.	  3	  (2013):	  416-­‐24.	  508	  Iqbal	  Master,	  interview	  by	  author,	  30	  April	  2010,	  Durban,	  South	  Africa.	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James	  Brust	  and	  Dr.	  Neel	  Gandhi	  (then	  both	  based	  at	  Albert	  Einstein	  College	  of	  Medicine)	  were	  evaluating	  the	  outcomes	  of	  the	  community-­‐based	  management	  of	  MDR-­‐TB	  in	  order	  to	  determine	  the	  impact	  of	  injection	  nurses,	  tracers,	  and	  the	  new	  MDR-­‐TB	  clinic	  and	  hospital	  in	  Greytown.	  Patients	  moved	  between	  local	  Msinga	  clinics,	  the	  TB	  office	  in	  Tugela	  Ferry	  and	  the	  MDR-­‐TB	  clinic	  in	  Greytown.	  Laboratory	  results	  were	  generated	  in	  Tugela	  Ferry,	  Greytown,	  and	  Durban.	  Thus	  a	  successful	  study	  required	  patient	  information	  from	  all	  these	  places.	  At	  this	  point	  the	  government	  tuberculosis	  program	  was	  happy	  to	  work	  together	  with	  (some)	  external	  experts,	  but	  existing	  forms	  of	  documentation	  did	  not	  accommodate	  researchers’	  needs.	  Valuable	  information	  about	  MDR-­‐TB	  in	  Tugela	  Ferry	  was	  inscribed	  in	  patients’	  medical	  charts	  as	  well	  as	  numerous	  registers,	  binders,	  print-­‐outs	  and	  computer	  files	  in	  many	  locations,	  from	  hospital	  registration	  rooms,	  to	  radiologists’	  shelves,	  to	  clinic	  desks	  to	  patient	  pockets.	  Information	  was	  not	  easily	  extractable	  for	  an	  internationally	  residing	  researcher.	  Certainly,	  data	  from	  registers	  and	  clinical	  charts	  would	  have	  to	  be	  converted	  into	  an	  electronic	  format	  before	  it	  would	  be	  useful.	  	  Negotiations	  over	  access	  to	  and	  content	  of	  medical	  records	  and	  other	  kinds	  of	  health	  data	  are	  a	  crucial	  part	  of	  the	  interactions	  between	  public	  health,	  research,	  and	  humanitarian	  interventions.	  As	  anthropologist	  Ramah	  McKay’s	  work	  in	  a	  busy	  public	  health	  center	  in	  Mozambique	  has	  shown,	  medical	  files	  are	  contested	  objects	  used	  and	  shaped	  not	  only	  by	  the	  clinical	  requirements	  of	  doctors,	  nurses,	  and	  patients,	  but	  also	  by	  the	  research,	  reporting	  and	  technical	  evaluation	  needs	  of	  international	  non-­‐governmental	  organizations,	  researchers	  and	  funders.509	  Different	  stakeholders	  are	  interested	  in	  different	  information	  and	  seek	  ways	  to	  make	  sure	  that	  the	  data	  they	  need	  is	  captured	  during	  the	  course	  of	  clinical	  encounters.	  McKay	  argues	  that	  “medical	  documents	  are	  multiple,	  simultaneously	  enacting	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and	  articulating	  a	  range	  of	  ethical,	  bureaucratic,	  and	  knowledge-­‐	  producing	  activities,”	  and	  that	  through	  “documentary	  practices,	  authority	  itself	  is	  made	  multiple.”510	  In	  South	  African	  TB	  work,	  as	  well,	  academic	  careers,	  government	  allocations,	  and	  donor	  funding	  were	  in	  part	  determined	  by	  the	  successful	  collection,	  compilation,	  and	  interpretation	  of	  such	  medical	  information.	  The	  TB	  office	  in	  Tugela	  Ferry,	  the	  MDR-­‐TB	  clinic	  and	  hospital	  in	  Greytown,	  and	  other	  sites	  of	  MDR-­‐TB	  treatment	  and	  assessment	  were	  very	  busy	  places,	  however.	  Health	  care	  workers	  were	  kept	  occupied	  with	  the	  task	  at	  hand:	  diagnosing	  and	  evaluating	  patients	  and	  providing	  them	  with	  appropriate	  medical	  treatment.	  It	  was	  an	  additional	  step	  to	  translate	  the	  diverse	  and	  complex	  clinical	  contributions	  of	  nurses,	  doctors	  and	  other	  health	  workers	  treating	  drug-­‐resistant	  tuberculosis	  into	  a	  coherent	  narrative	  –	  populated	  by	  authoritative	  numbers	  and	  assessments	  of	  outcomes	  –	  worthy	  of	  public	  and	  scientific	  presentations.	  The	  following	  section	  looks	  at	  some	  of	  the	  ways	  researchers	  not	  only	  ensured	  access	  to	  existing	  clinical	  information	  about	  the	  treatment	  of	  MDR-­‐TB,	  but	  inserted	  themselves	  into	  its	  production	  at	  both	  a	  bureaucratic	  and	  clinical	  level,	  thus	  improving	  completeness	  of	  the	  variables	  the	  researchers	  were	  most	  interested	  in	  and	  improving	  patients’	  ability	  to	  behave	  in	  ways	  that	  were	  in	  keeping	  with	  research	  protocols.	  	   One	  way	  outside	  researchers	  gained	  access	  to	  public	  health	  information	  that	  they	  were	  not	  directly	  in	  charge	  of	  was	  by	  employing	  computer-­‐literate	  data-­‐capturers	  and	  lending	  them	  to	  offices	  and	  laboratories	  where	  data	  was	  generated.	  In	  the	  TB	  office	  in	  Tugela	  Ferry,	  for	  a	  example,	  an	  employee	  of	  Philanjalo	  (the	  research	  and	  care	  organization	  through	  which	  most	  tuberculosis	  research	  in	  Tugela	  Ferry	  was	  channeled)	  spent	  each	  morning	  copying	  the	  previous	  day’s	  entries	  from	  the	  tuberculosis	  register	  into	  an	  excel	  spreadsheet	  which	  had	  been	  designed	  to	  mimic	  the	  register.	  When	  I	  first	  saw	  this	  electronic	  
                                                510	  Ramah	  McKay,	  “Documentary	  Disorders:	  Managing	  Medical	  Multiplicity	  in	  Maputo,	  Mozambique,”	  
American	  Ethnologist	  39,	  no.	  3	  (2012):	  545.	  
 214 
file	  I	  imagined	  that	  it	  might	  be	  clinically	  useful	  for	  the	  tuberculosis	  nurses.	  Yet	  over	  the	  course	  of	  several	  months	  in	  the	  TB	  office	  I	  only	  witnessed	  one	  occasion	  when	  nurses	  (unsuccessfully)	  looked	  for	  a	  patient	  entry	  on	  the	  computer	  register	  after	  an	  extensive,	  unsuccessful	  search	  of	  the	  hand-­‐written	  tuberculosis	  registers.	  Once	  the	  register	  was	  copied	  into	  electronic	  form,	  however,	  it	  was	  available	  to	  researchers,	  who	  could	  generate	  their	  own	  statistics	  and	  conduct	  their	  own	  analyses	  independent	  from	  the	  statistics	  generated	  by	  the	  TB	  office	  for	  the	  national	  tuberculosis	  program.	  The	  head	  of	  the	  TB	  office	  was	  aware	  that	  the	  data	  was	  shared	  in	  this	  way	  and	  benefitted	  from	  the	  presence	  of	  an	  extra	  person	  in	  her	  office	  –	  when	  he	  was	  not	  busy	  recreating	  the	  register	  she	  gave	  him	  other	  tasks	  to	  do.	  Outside	  researchers	  had	  no	  authority	  over	  the	  government	  TB	  office	  staff	  who	  could	  have	  filled	  out	  the	  electronic	  spreadsheet	  themselves,	  but	  instead	  provided	  an	  extra	  pair	  of	  hands	  who	  was	  at	  the	  disposal	  of	  the	  TB	  office	  once	  his	  own	  work	  for	  the	  research	  program	  was	  done,	  allowing	  him	  to	  unobtrusively	  extract	  useful	  data	  as	  it	  was	  generated,	  hopefully	  in	  accurate	  form,	  and	  without	  impacting	  ongoing	  clinical	  operations	  or	  baseline	  data	  collection.	  Such	  data-­‐collectors	  were	  present	  in	  other	  departments	  in	  the	  hospital	  in	  Tugela	  Ferry,	  as	  well.	  Researchers	  paid	  for	  a	  laboratory	  technician	  who	  assisted	  with	  data	  entry	  in	  the	  hospital’s	  diagnostics	  laboratory	  after	  they	  encountered	  difficulties	  in	  accessing	  the	  data	  from	  the	  central	  diagnostic	  database;	  researchers	  also	  paid	  someone	  to	  laboriously	  scan	  hundreds	  of	  chest	  X-­‐ray	  films	  of	  tuberculosis	  patients	  onto	  a	  computer	  and	  load	  them	  onto	  a	  server	  which	  could	  be	  accessed	  by	  researchers	  based	  in	  the	  US.	  These	  data	  scavengers	  entered	  into	  every-­‐day	  operations	  and	  worked	  around	  the	  often-­‐inflexible	  workflows	  and	  documentation	  methods	  of	  government	  workers,	  quietly	  duplicating	  and	  siphoning	  off	  the	  information	  that	  was	  of	  interest,	  converting	  it	  into	  a	  research-­‐friendly	  format.	  Clinical	  and	  laboratory	  departments	  accepted	  the	  help	  of	  additional	  data-­‐capturers	  in	  part	  because	  they	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gained	  free	  man-­‐power	  for	  tedious	  and	  repetitive	  tasks,	  which	  they	  traded	  for	  a	  much	  reduced	  capacity	  to	  firmly	  withhold	  information.	  As	  Johanna	  Crane	  has	  shown	  on	  the	  example	  of	  HIV	  patient	  databases	  in	  Uganda,	  the	  ownership	  of	  clinical	  databases	  shared	  between	  local	  clinical	  programs	  and	  international	  researchers	  can	  become	  a	  highly	  contentious	  issue.511	  The	  above	  strategies	  helped	  work	  around	  such	  conflict	  and	  allowed	  the	  duplication	  of	  local	  databases	  in	  exchange	  for	  the	  labor	  of	  this	  duplication.	  
Improving	  the	  data	  	   A	  second	  strategy	  used	  by	  researchers	  to	  improve	  access	  to	  quality	  research	  data	  around	  the	  community-­‐based	  treatment	  of	  MDR-­‐TB	  involved	  strengthening	  the	  program	  itself	  by	  supplying	  qualified	  clinical	  staff	  to	  help	  oversee	  patient	  care.	  These	  clinicians	  paid	  close	  attention	  to	  the	  production	  of	  standardized	  clinical	  documents	  and	  data	  collection	  tools.	  This	  served	  two	  functions	  –	  on	  the	  one	  hand	  the	  MDR-­‐TB	  program	  itself	  was	  improved	  through	  the	  activities	  of	  staff	  dedicated	  to	  the	  research	  project;	  on	  the	  other	  hand,	  the	  data	  was	  improved	  by	  ensuring	  that	  forms	  were	  accurately	  completed	  and	  that	  the	  public	  health	  and	  research	  protocols	  were	  followed	  and	  documented.	  As	  we	  saw	  in	  the	  previous	  chapter,	  doctors,	  nurses,	  and	  other	  clinical	  staff	  at	  the	  MDR-­‐TB	  clinic	  in	  Greytown	  were	  joined	  each	  week	  by	  a	  cadre	  of	  research	  assistants	  and	  a	  research	  nurse	  who	  helped	  the	  clinic	  run	  smoothly	  by	  assisting	  with	  the	  flow	  of	  patients,	  charts,	  and	  other	  materials.	  During	  the	  week	  the	  research	  nurse,	  Sister	  Makhubu,	  was	  based	  in	  Tugela	  Ferry’s	  TB	  office	  and	  helped	  prepare	  the	  MDR-­‐TB	  patients	  of	  Msinga	  for	  their	  upcoming	  MDR-­‐TB	  clinic	  appointments	  in	  Greytown.	  Officially,	  managing	  Msinga’s	  MDR-­‐TB	  patients	  fell	  to	  government	  nurses	  based	  at	  the	  Tugela	  Ferry	  TB	  office	  and	  at	  outlying	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clinics.512	  Yet	  Sister	  Makhubu	  made	  sure	  that	  clinical	  details	  were	  not	  overlooked	  and	  did	  not	  become	  too	  onerous.	  For	  example,	  MDR-­‐TB	  patients	  had	  their	  blood	  drawn	  on	  the	  Monday	  before	  their	  monthly	  Greytown	  clinic	  appointment	  (on	  Wednesday)	  so	  that	  the	  blood	  results	  would	  be	  available	  when	  clinic	  doctors	  saw	  their	  patients.	  Sister	  Makhubu	  reminded	  patients	  of	  their	  upcoming	  blood	  draws	  and	  clinic	  appointments	  by	  calling	  them	  from	  her	  research-­‐funded	  cell-­‐phone.	  Patients	  could	  conveniently	  go	  to	  their	  closest	  clinic	  to	  have	  the	  blood	  draws	  done.	  Sister	  Makhubu	  left	  little	  up	  to	  chance,	  and	  she	  filled	  out	  all	  the	  paperwork	  needed	  for	  the	  blood	  draws,	  labeled	  the	  blood	  tubes,	  and	  placed	  them	  in	  specimen	  bags	  for	  every	  MDR-­‐TB	  patient	  in	  the	  region.	  She	  then	  gave	  these	  tubes	  to	  the	  TB	  office	  tracers	  so	  that	  they	  could	  distribute	  them	  to	  the	  appropriate	  outlying	  primary	  care	  clinic	  nurses.	  The	  clinic	  nurses	  merely	  had	  to	  draw	  their	  patients’	  blood	  and	  send	  the	  samples	  back	  to	  the	  hospital	  via	  an	  established	  system.	  This	  pro-­‐active	  approach	  in	  which	  the	  burden	  of	  ensuring	  that	  each	  step	  took	  place	  was	  on	  clinicians	  rather	  than	  the	  patients	  was	  not	  typical	  of	  public	  health	  programs	  in	  South	  Africa	  that	  I	  have	  witnessed.	  By	  making	  the	  work	  required	  from	  patients	  and	  outlying	  nurses	  as	  easy	  as	  possible	  Sister	  Makhubu	  and	  the	  research	  project	  she	  represented	  helped	  ensure	  that	  clinical	  care	  was	  successful.	  She	  also	  ensured	  that	  sample	  collection	  required	  for	  the	  production	  of	  complete	  and	  convincing	  quantitative	  data	  occurred.	  Patients	  and	  researchers	  benefited	  from	  the	  individualized	  attention	  of	  a	  dedicated	  nurse.	  Blood	  results	  were	  available	  on	  time,	  and	  according	  to	  the	  research	  protocol.	  Several	  possible	  hurdles	  that	  could	  undermine	  the	  successful	  acquisition	  of	  data	  and	  lead	  to	  gaps,	  such	  as	  missing	  or	  incorrectly	  filled	  out	  paperwork,	  transport	  problems	  or	  missing	  blood	  tubes	  were	  minimized.	  
                                                512	  Sister	  Makhubu	  left	  the	  research	  project	  towards	  the	  end	  of	  my	  fieldwork	  stay	  and	  this	  task	  reverted	  back	  to	  the	  TB	  office	  nurses	  when	  she	  departed.	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The	  research	  project	  made	  its	  presence	  known	  in	  other	  ways,	  as	  well.	  In	  the	  MDR-­‐TB	  clinic	  in	  Greytown	  three	  or	  four	  study-­‐funded	  research	  assistants	  sat	  together	  with	  physicians	  (most	  of	  whom	  were	  funded	  by	  the	  department	  of	  health)	  with	  folders,	  filled	  with	  carefully	  designed	  forms	  whose	  templates	  reflected	  the	  information	  needed	  for	  the	  study	  protocol.	  While	  the	  doctors	  and	  nurses	  talked	  to	  the	  patients	  and	  filled	  out	  the	  standard	  government	  MDR-­‐TB	  treatment	  forms	  and	  clinical	  charts,	  the	  research	  assistants	  followed	  along	  and	  filled	  out	  research	  forms	  which	  for	  the	  most	  part	  duplicated	  information	  from	  the	  clinical	  interaction	  in	  a	  more	  explicit	  and	  detailed	  format.	  The	  study	  forms	  included	  reminders	  about	  the	  types	  of	  information	  that	  should	  be	  sought	  at	  each	  visit,	  including	  lab	  tests,	  X-­‐ray	  studies,	  and	  questions	  about	  medication	  side-­‐effects.	  The	  research	  assistants	  filled	  out	  large	  proportion	  of	  the	  study	  forms	  on	  their	  own,	  while	  listening	  to	  clinical	  interactions.	  Occasionally	  they	  came	  across	  parts	  that	  only	  the	  physician	  could	  complete.	  Then	  the	  research	  assistant	  simply	  handed	  over	  the	  page	  in	  question,	  compelling	  the	  doctor	  to	  complete	  it.	  These	  forms	  and	  their	  keepers	  disciplined	  clinicians	  to	  ensure	  that	  the	  needs	  of	  the	  study	  were	  met,	  even	  when	  the	  actual	  clinical	  interaction	  did	  not	  require	  the	  same	  level	  of	  documentation.	  During	  the	  week	  the	  standardized	  charts	  were	  entered	  into	  electronic	  databases	  by	  the	  research	  assistants.	  This	  way	  all	  the	  information	  that	  the	  researchers	  were	  interested	  in	  analyzing	  was	  already	  available	  in	  standardized	  and	  complete	  form	  and	  did	  not	  have	  to	  be	  retroactively	  abstracted	  from	  the	  free-­‐flowing	  clinical	  charts	  that	  were	  more	  typically	  used	  in	  clinical	  encounters.	  Not	  all	  patients	  who	  were	  seen	  at	  the	  MDR-­‐TB	  clinic	  in	  Greytown	  were	  from	  Msinga.	  Those	  from	  neighboring	  sub-­‐districts	  were	  not	  enrolled	  in	  the	  study	  of	  community-­‐based	  management	  of	  MDR-­‐TB	  (which	  had	  arisen	  specifically	  out	  of	  the	  interest	  in	  the	  outbreak	  in	  Tugela	  Ferry).	  Though	  the	  same	  doctors	  and	  nurses	  attended	  to	  all	  MDR-­‐TB	  patients	  at	  the	  clinic	  and	  the	  research	  assistants	  translated	  clinical	  interactions	  for	  these	  patients,	  too,	  their	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care	  was	  not	  managed	  with	  the	  help	  of	  research	  forms.	  That	  level	  of	  documentation	  was	  not	  considered	  necessary	  for	  the	  sake	  of	  the	  clinical	  encounter	  itself	  or	  for	  the	  sake	  of	  government	  program	  reporting.	  Thus,	  even	  as	  researchers	  sought	  to	  document	  the	  impact	  of	  a	  government-­‐run	  program	  for	  the	  treatment	  of	  MDR-­‐TB,	  this	  documentary	  research	  added	  both	  steps	  and	  resources	  to	  the	  clinical	  encounter	  that	  would	  not	  have	  been	  present	  in	  the	  absence	  of	  the	  research	  effort.	  The	  main	  aim	  of	  these	  extra	  resources,	  then,	  was	  to	  improve	  data;	  yet	  it	  most	  likely	  improved	  the	  nature	  of	  care,	  as	  well.	  	  
Traversing	  the	  landscape:	  the	  banal	  nature	  of	  heroic	  and	  innovative	  work	  While	  successful	  research	  on	  MDR-­‐TB	  management	  in	  Tugela	  Ferry	  required	  the	  successful	  acquisition	  of	  clinical	  and	  public	  health	  data,	  the	  successful	  implementation	  of	  the	  community-­‐based	  treatment	  of	  MDR-­‐TB	  itself	  relied	  heavily	  on	  nurses’	  and	  community	  health	  workers’	  capacity	  to	  trace	  the	  actual	  patients	  –	  finding	  them	  in	  their	  homes	  and	  providing	  them	  with	  treatment.	  The	  strategy	  of	  fighting	  tuberculosis	  with	  paperwork	  was	  ineffective	  until	  it	  was	  paired	  with	  intense,	  pro-­‐active	  outreach	  and	  educational	  activities	  of	  TB	  workers	  who	  spent	  their	  days	  seeking	  out	  patients.	  Some	  patients	  were	  easy	  to	  find	  and	  engage	  in	  treatment,	  while	  others	  lived	  in	  particularly	  remote	  or	  challenging	  circumstances,	  or	  actively	  resisted	  being	  found.	  Just	  as	  MDR-­‐TB	  researchers	  worked	  around	  official	  bureaucratic	  practices	  to	  gain	  access	  to	  information	  they	  were	  most	  interested	  in,	  TB	  nurses	  in	  the	  office	  and	  the	  field	  developed	  strategies	  which	  enhanced	  the	  official	  tools	  of	  TB	  documentation	  in	  order	  to	  better	  do	  their	  jobs	  and	  serve	  their	  patients.	  As	  we	  have	  seen,	  fieldwork	  was	  the	  most	  visually	  impressive	  component	  of	  the	  community-­‐based-­‐management	  of	  MDR-­‐TB.	  Injection	  nurses	  and	  tracer	  teams	  in	  action	  drove	  across	  the	  Msinga	  landscape	  to	  reach	  patients	  who	  lived	  on	  remote	  hillsides,	  often	  in	  rustic-­‐looking	  traditional	  round-­‐huts	  located	  well	  beyond	  the	  end	  of	  a	  gravel	  road.	  Nurses	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drove	  into	  the	  community	  every	  day	  to	  find	  8-­‐15	  patients	  at	  home	  and	  give	  them	  injections	  while	  TB	  tracers	  drove	  across	  the	  Msinga	  landscape	  to	  notify	  new	  patients	  who	  had	  just	  been	  diagnosed	  by	  the	  lab,	  to	  survey	  patients’	  households	  to	  determine	  if	  family	  members	  had	  been	  infected,	  and	  to	  find	  patients	  who	  had	  stopped	  coming	  to	  clinic	  visits.	  Routines	  of	  bureaucratic	  documentation,	  patient	  visits,	  and	  clinical	  protocol	  were	  broken	  up	  by	  meal	  breaks,	  car	  washes,	  road-­‐side	  flirtation,	  and	  the	  entertainment	  of	  visitors,	  including	  myself,	  who	  arrived	  to	  “see”	  MDR-­‐TB	  management	  in	  Msinga	  in	  action.	  The	  following	  section	  is	  compiled	  from	  the	  field-­‐notes	  I	  wrote	  after	  several	  “ride-­‐alongs”	  with	  TB	  office	  staff	  between	  August	  2010	  and	  June	  2011.	  I	  rode	  with	  several	  different	  nurses	  as	  they	  traveled	  across	  Msinga	  to	  give	  their	  MDR-­‐TB	  and	  XDR-­‐TB	  patients	  injections	  of	  TB	  medication	  and	  I	  accompanied	  tracers	  as	  they	  notified	  patients	  in	  their	  homes	  of	  their	  drug-­‐resistant	  TB	  and	  looked	  for	  patients	  who	  had	  stopped	  reporting	  to	  their	  clinic	  appointments.513	  I	  employ	  a	  series	  of	  vignettes	  to	  describe	  the	  actual	  day-­‐to-­‐day	  activities	  entailed	  in	  “community-­‐based	  management”	  of	  drug-­‐resistant	  tuberculosis	  and	  to	  illustrate	  some	  of	  the	  strategies	  used	  by	  nurses	  to	  keep	  track	  of	  their	  patients.	  These	  stories	  demonstrate	  the	  importance	  of	  TB	  nurses	  to	  the	  success	  of	  a	  global	  health	  research	  endeavor	  even	  as	  their	  contributions	  may	  be	  constrained	  by	  the	  parameters	  of	  their	  mandate	  and	  their	  actions	  minimized	  (or	  at	  least	  anonymized)	  in	  the	  research	  record.	  I	  also	  consider	  my	  own	  experience	  as	  a	  visitor	  riding	  along	  to	  see	  patients	  in	  order	  to	  portray	  the	  ambivalent	  romanticism	  of	  rural	  poverty	  for	  a	  global	  health	  worker	  –	  a	  romanticism	  which	  I	  believe	  forms	  the	  foundation	  of	  the	  global	  health	  enterprise.	  The	  chapter	  ends	  with	  a	  reflection	  on	  the	  significance	  of	  Msinga	  –	  a	  place	  that	  evokes	  complex	  connotations	  in	  many	  South	  Africans	  and	  well-­‐read	  visitors	  to	  the	  area	  –	  as	  a	  global	  heatlh	  site.	  
                                                513	  The	  nurses	  also	  visit	  “retreatment”	  patients	  who	  have	  failed	  the	  standard	  TB	  regimen	  and	  are	  now	  being	  treated	  with	  the	  injectable	  streptomycin,	  though	  they	  have	  not	  been	  diagnosed	  as	  having	  drug-­‐resistant	  tuberculosis.	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Going	  “out	  into	  the	  community”	  One	  day	  in	  August	  2010	  I	  went	  “out	  into	  the	  community”	  with	  NF,	  a	  TB	  injection	  nurse.	  I	  waited	  for	  her	  in	  the	  TB	  office	  for	  an	  hour	  while	  she	  filled	  out	  paper	  work	  to	  sign	  out	  her	  hospital	  vehicle	  and	  she	  collected	  her	  supplies,	  including	  syringes,	  alcohol	  swabs,	  vials	  of	  streptomycin,	  blue	  patient	  charts,	  and	  a	  cooler	  box.	  We	  set	  out	  in	  a	  battered	  yellow	  bakkie	  (pick-­‐up	  truck)	  marked	  on	  the	  door	  with	  the	  insignia	  of	  the	  KwaZulu-­‐Natal	  Department	  of	  Health.	  Before	  we	  left	  the	  commercial	  crossroads	  of	  Tugela	  Ferry,	  however,	  we	  filled	  up	  on	  petrol	  at	  the	  chaotic	  Tugela	  Ferry	  petrol	  (gas)	  station,	  waiting	  for	  several	  minutes	  in	  a	  disorderly	  line	  along	  with	  several	  other	  department	  of	  health	  bakkies,	  as	  well	  as	  bakkies	  belonging	  to	  other	  government	  departments	  and	  to	  the	  local	  non-­‐government	  organization,	  Philanjalo.	  We	  then	  stopped	  at	  the	  car	  wash	  across	  from	  the	  hospital	  to	  clean	  off	  the	  dust	  of	  the	  previous	  days’	  journeys.	  As	  we	  were	  waiting,	  we	  went	  to	  a	  small	  shop	  to	  buy	  provisions	  for	  the	  road	  –	  coke,	  chips	  and	  apples	  to	  keep	  us	  going.	  We	  spent	  hours	  driving	  through	  the	  hilly,	  dry	  landscape	  to	  places	  without	  any	  obvious	  nearby	  water	  source	  or	  easy	  access	  to	  food	  or	  commerce.	  In	  some	  places	  there	  was	  evidence	  of	  agricultural	  activity	  and	  small-­‐scale	  gardening,	  but	  in	  most	  areas	  I	  could	  not	  help	  imagining	  that	  isolated	  huts	  had	  been	  dropped	  on	  vast	  fields	  of	  stones	  and	  thorns,	  or	  that	  in	  some	  freak	  phenomenon	  it	  had	  rained	  rocks	  instead	  of	  water.	  On	  occasion	  we	  were	  slowed	  down	  as	  we	  passed	  small	  herds	  of	  cattle	  lying	  in	  the	  middle	  of	  the	  road.	  NF	  would	  chuckle	  as	  she	  told	  me	  we	  needed	  to	  wait	  for	  the	  “robots”	  (this	  is	  the	  South	  African	  word	  for	  traffic	  lights).	  The	  cows	  reluctantly	  got	  up	  and	  we	  would	  continue	  our	  journey.	  On	  some	  of	  the	  roads	  (marked	  Zibambele,	  which	  means	  “doing	  it	  for	  ourselves”)	  we	  passed	  older	  women	  wearing	  orange	  vests	  over	  their	  clothing	  and	  big	  floppy	  hats	  to	  protect	  themselves	  from	  the	  sun.	  They	  were	  working	  at	  the	  side	  of	  the	  road,	  clearing	  out	  drainage	  ditches	  and	  cutting	  brush	  as	  part	  of	  a	  public	  employment	  program.	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Over	  the	  course	  of	  the	  day,	  we	  visited	  eight	  patients	  in	  six	  hours.	  Several	  of	  NF’s	  patients	  were	  evidently	  living	  in	  dire	  conditions.	  One	  client	  appeared	  to	  be	  squatting	  in	  an	  abandoned	  compound	  surrounded	  by	  dust	  –	  her	  home	  was	  in	  a	  cluster	  of	  decaying	  rondavels	  with	  brittle	  walls	  and	  absent	  roofs,	  situated	  around	  a	  former	  cattle	  enclosure	  which	  was	  missing	  most	  of	  its	  wooden	  beams.	  Only	  her	  own	  round	  room	  was	  covered	  with	  an	  intact	  sheet-­‐metal	  roof.514	  Each	  encounter	  was	  slightly	  different.	  We	  drove	  to	  a	  patient’s	  house,	  waited	  a	  few	  seconds	  to	  be	  invited	  in,	  and	  then	  entered	  the	  patient’s	  room,	  where	  the	  she	  handed	  NF	  her	  treatment	  card,	  and	  lowered	  her	  pants	  for	  the	  injection.	  NF	  ticked	  off	  the	  date	  on	  the	  card	  to	  show	  that	  she	  had	  come,	  while	  the	  patient	  rubbed	  the	  painful	  injection	  site	  with	  a	  swab.	  In	  another	  case,	  we	  rode	  up	  to	  an	  area	  and	  then	  dramatically	  honked	  the	  truck’s	  horn.	  We	  waited	  a	  few	  minutes	  until	  a	  gaunt	  figure	  emerged	  in	  the	  distance.	  Only	  partially	  hidden	  from	  view,	  he	  received	  the	  injection	  leaning	  against	  the	  door	  of	  the	  truck.	  Next,	  we	  met	  a	  gogo	  (local	  vernacular	  for	  elderly	  woman)	  and	  her	  TB-­‐patient	  husband	  on	  a	  clearing	  that	  was	  littered	  with	  several	  dozen	  alcohol	  swabs	  –	  the	  evidence	  of	  months	  of	  daily	  injections.	  Another	  patient	  met	  our	  vehicle	  under	  a	  pre-­‐designated	  tree,	  away	  from	  neighbors	  who	  might	  see	  the	  clearly	  marked	  government	  vehicle.	  One	  patient	  had	  given	  up	  waiting	  for	  NF	  when	  she	  arrived	  later	  than	  usual	  and	  had	  gone	  to	  the	  shops	  in	  the	  next	  town.	  No	  matter,	  NF	  would	  find	  her	  tomorrow.	  When	  we	  arrived	  at	  our	  last	  patient’s	  house	  only	  his	  mother	  was	  there,	  saying	  that	  she	  had	  received	  a	  call	  from	  the	  hospital	  claiming	  that	  her	  son	  was	  dead.	  NF	  was	  surprised	  and	  she	  promised	  his	  mother	  she	  would	  look	  into	  it	  when	  she	  got	  back	  to	  the	  hospital.	  Most	  of	  these	  encounters	  were	  cordial	  but	  brief.	  There	  was	  a	  friendly	  conversation	  
                                                514	  I	  was	  later	  reminded	  of	  this	  place	  when	  a	  nurse	  I	  interviewed	  stated	  that	  it	  didn’t	  matter	  whether	  or	  not	  we	  ever	  found	  the	  cure	  for	  AIDS	  since	  the	  people	  were	  already	  dead	  and	  the	  houses	  were	  already	  abandoned	  and	  decaying.	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here,	  a	  moment	  of	  support	  there,	  but	  as	  the	  day	  got	  longer,	  the	  goal	  seemed	  to	  be	  to	  get	  back	  to	  home	  base	  soon.	  It	  felt	  like	  we	  were	  racing	  from	  house	  to	  house	  across	  surprising	  distances	  to	  then	  simply	  have	  the	  patient	  drop	  her	  pants,	  so	  that	  we	  could	  move	  on.	  Injections	  were	  provided	  for	  tuberculosis	  patients	  who	  needed	  them.	  It	  was	  strange	  to	  realize	  that	  this	  was	  the	  foundation	  of	  internationally	  celebrated	  public	  health	  program	  with	  the	  evocative	  word	  “community”	  in	  the	  title.	  While	  injection	  teams	  performed	  necessary,	  even	  interesting	  work,	  there	  was	  little	  glory	  in	  chasing	  down	  patients	  and	  giving	  them	  injections.	  Our	  vehicle	  apparently	  had	  no	  suspension	  to	  speak	  of,	  and	  after	  we	  had	  spent	  a	  day	  driving	  through	  the	  Msinga	  countryside	  on	  roads	  that	  ranged	  from	  tarred,	  to	  dirt,	  to	  rocky	  ruts	  covered	  in	  mud,	  I	  was	  completely	  exhausted.	  My	  back	  was	  aching	  and	  my	  shoulders	  were	  stiff,	  and	  I	  was	  suffering	  from	  a	  headache.	  Had	  the	  conference	  presentations	  on	  the	  community-­‐based	  management	  of	  MDR-­‐TB	  in	  Tugela	  Ferry	  oversold	  something	  that	  was	  not	  more	  than	  an	  injection	  service?	  Is	  this	  what	  community	  meant?	  
Moments	  of	  tenderness,	  care,	  and	  concern	  Not	  all	  injection	  work	  was	  rushed	  business	  as	  usual.	  On	  another	  day	  I	  watched	  another	  nurse,	  NC,	  carefully	  touch	  the	  left	  butt-­‐cheek	  of	  an	  XDR-­‐patient	  who	  had	  been	  receiving	  injections	  from	  her	  for	  well	  over	  a	  year.	  She	  was	  looking	  for	  a	  patch	  of	  flesh	  that	  wasn’t	  already	  sore	  and	  swollen.	  Eventually,	  NC	  and	  her	  patient	  agreed	  on	  a	  location.	  The	  patient	  closed	  her	  eyes	  and	  grimaced	  as	  NC	  tried	  to	  be	  as	  gentle	  as	  she	  could	  be	  with	  her	  sharp	  needle.	  NC	  was	  concerned	  about	  this	  patient,	  since	  she	  was	  soon	  scheduled	  to	  finish	  injections	  but	  wasn’t	  really	  looking	  any	  better	  than	  when	  she	  had	  started	  treatment.	  Another	  nurse,	  RB,	  and	  I	  saw	  a	  patient	  with	  bright	  red,	  painful	  eyes	  and	  shingles	  in	  his	  face.	  The	  nurse	  expressed	  grave	  concern	  for	  his	  well	  being	  and	  mentioned	  his	  case	  in	  the	  nurses’	  meeting	  the	  next	  morning.	  A	  few	  weeks	  later	  NF	  found	  a	  patient	  lying	  on	  a	  dirty	  mattress	  in	  a	  very	  untidy	  room	  that	  had	  not	  been	  cleaned	  recently.	  NF	  called	  in	  the	  patient’s	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sister-­‐in-­‐law	  and	  informed	  her	  in	  no	  uncertain	  terms	  that	  it	  was	  her	  responsibility	  to	  keep	  the	  patient’s	  room	  clean.	  She	  implied	  that	  if	  the	  patient	  didn’t	  get	  better,	  it	  might	  be	  the	  sister-­‐in-­‐law’s	  fault	  for	  not	  giving	  the	  medication	  a	  chance	  to	  work.	  Several	  patients	  clearly	  appreciated	  the	  convenience	  of	  receiving	  injections	  at	  home,	  while	  others	  enjoyed	  the	  opportunity	  to	  chat	  and	  learn	  about	  what	  was	  happening	  in	  town.	  Sometimes	  injection	  nurses	  would	  come	  with	  food	  packages	  and	  news	  about	  other	  patients	  they	  had	  seen	  at	  the	  monthly	  clinic.	  In	  one	  case,	  an	  injection	  visit	  revealed	  one	  MDR-­‐TB	  patient	  to	  another	  neighbor	  with	  MDR-­‐TB	  and	  they	  asked	  their	  injection	  nurse	  if	  she	  could	  arrange	  for	  their	  monthly	  MDR-­‐TB	  clinic	  in	  Greytown	  to	  be	  coordinated	  onto	  the	  same	  schedule	  so	  that	  they	  could	  travel	  together.	  Neighbors	  not	  receiving	  tuberculosis	  care	  occasionally	  sought	  to	  benefit	  from	  the	  nurses’	  passing	  by	  –	  an	  old	  man	  flagged	  us	  down	  to	  ask	  the	  nurse	  behind	  the	  wheel	  to	  explain	  what	  the	  prescription	  medications	  that	  he	  was	  carrying	  with	  him	  were	  for,	  and	  if	  it	  was	  safe	  to	  combine	  them.	  Interactions	  with	  patients	  and	  their	  families	  could	  be	  incredibly	  frustrating	  –	  when	  SM	  (another	  nurse),	  my	  research	  assistant,	  and	  I	  approached	  one	  patient’s	  home	  we	  realized	  that	  we	  had	  entered	  in	  the	  middle	  of	  a	  domestic	  fight.	  The	  patient’s	  mother	  was	  screaming,	  accusing	  the	  patient	  of	  being	  an	  abusive	  alcoholic	  and	  was	  asking	  us	  for	  help.	  The	  nurse	  suggested	  that	  she	  needed	  to	  go	  speak	  to	  the	  hospital	  social	  worker,	  or,	  if	  her	  son	  was	  dangerous,	  to	  call	  the	  police.	  We	  listened	  to	  the	  dramatic	  exchanges	  for	  several	  minutes,	  but	  the	  nurse	  sitting	  behind	  the	  wheel	  eventually	  decided	  to	  drive	  on.	  The	  entire	  household	  was	  still	  yelling;	  this	  family’s	  problems	  were	  left	  completely	  unresolved.	  When	  injection	  nurses	  attempted	  to	  help	  their	  patients	  beyond	  the	  injections	  themselves,	  it	  was	  often	  unclear	  what	  the	  next	  step	  would	  be.	  While	  the	  nurses	  had	  a	  clear	  mandate	  to	  provide	  injections,	  some	  other	  resources	  were	  not	  always	  satisfactory.	  Nurses	  could	  report	  medical	  events	  to	  a	  physician	  who	  might	  prescribe	  medication	  or	  recommend	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that	  the	  patient	  come	  in	  to	  the	  hospital,	  and	  they	  could	  refer	  their	  patient	  to	  the	  hospital	  social	  worker.	  Yet	  nurses	  were	  rarely	  in	  a	  position	  to	  fully	  address	  patient	  problems	  that	  were	  not	  strictly	  related	  to	  tuberculosis	  medication.	  In	  fact,	  nurses’	  interventions	  were	  not	  always	  fully	  welcomed	  by	  their	  patients.	  Most	  of	  the	  TB	  team’s	  vehicles	  were	  painted	  a	  particular	  shade	  of	  yellow	  and	  bore	  a	  department	  of	  health	  logo	  and	  thus	  were	  easily	  recognizable	  as	  department	  of	  health	  vehicles,	  even	  from	  a	  distance.	  This	  was	  a	  large	  problem	  for	  some	  patients	  who	  complained	  that	  they	  did	  not	  want	  regular	  visits	  from	  these	  conspicuous	  cars,	  since	  all	  the	  neighbors	  would	  see	  them	  and	  know	  something	  was	  wrong.	  Some	  were	  specifically	  concerned	  that	  the	  neighbors	  would	  assume	  they	  were	  being	  treated	  for	  HIV/AIDS,	  since	  the	  department	  of	  health	  vehicles	  had	  become	  most	  closely	  associated	  with	  HIV-­‐related	  activities	  in	  recent	  years.	  Many	  (though	  not	  all)	  of	  the	  tuberculosis	  patients	  in	  question	  were	  in	  fact	  HIV	  positive,	  but	  did	  not	  necessarily	  want	  this	  to	  be	  announced	  to	  everyone	  living	  off	  the	  country	  roads	  used	  by	  injection	  nurses	  and	  TB	  tracers	  to	  get	  to	  their	  houses.	  Many	  people	  I	  spoke	  to	  said	  that	  attitudes	  towards	  HIV	  had	  changed	  so	  that	  it	  was	  no	  longer	  considered	  as	  shameful	  or	  stigmatizing	  as	  a	  decade	  earlier.	  Tuberculosis	  was	  still	  a	  better	  disease	  to	  admit	  to,	  however.	  As	  FS,	  a	  TB	  tracer,	  put	  it:	  “With	  a	  yellow	  vehicle	  everyone	  sees	  it’s	  a	  government	  vehicle,	  and	  it’s	  from	  health.	  And	  if	  the	  vehicle	  comes	  to	  your	  house,	  they’ve	  got	  this	  thing	  in	  their	  mind	  that	  […]	  someone’s	  got	  HIV.	  And	  HIV,	  I	  don’t	  know,	  they	  don’t	  treat	  HIV	  as	  a	  disease.	  […]	  If	  you	  [have]	  HIV	  and	  TB,	  they	  treat	  those	  things	  as	  different.	  […]	  It’s	  embarrassing	  to	  have	  HIV,	  in	  people’s	  mind.	  	  If	  you	  have	  TB	  it’s	  better.”	  	  Some	  people	  tried	  to	  hide	  their	  disease	  from	  their	  own	  spouses	  and	  children,	  as	  well	  as	  their	  neighbors.	  One	  nurse	  told	  me	  that	  a	  patient	  hid	  her	  medications	  among	  other	  multicolored	  pills	  and	  told	  her	  husband	  she	  was	  taking	  vitamins.	  Some	  made	  arrangements	  with	  their	  nurses	  to	  see	  them	  far	  from	  their	  own	  homes	  and	  preferred	  waiting	  in	  the	  sun	  for	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the	  nurse	  and	  the	  truck	  to	  arrive	  at	  a	  semi-­‐public	  roadside	  over	  a	  home	  visit.	  When	  a	  tracer	  came	  to	  find	  a	  new	  or	  lost	  patient,	  however,	  there	  was	  no	  way	  to	  hide	  –	  once	  the	  tracer	  arrived	  in	  the	  general	  area	  of	  the	  person	  he	  was	  looking	  for,	  he	  would	  ask	  as	  many	  neighbors	  as	  necessary	  where	  this	  person	  lived,	  until	  the	  patient	  was	  found.	  	  
Enrolling	  the	  global	  patient,	  locally	  Nurses	  and	  tracers	  often	  talked	  about	  the	  difficulties	  of	  finding	  patients	  who	  did	  not	  want	  to	  be	  found	  and	  the	  strategies	  they	  used	  to	  find	  them.	  The	  effort	  started	  with	  the	  more-­‐than-­‐complete	  documentation	  of	  potential	  tuberculosis	  patients	  even	  before	  they	  were	  fully	  diagnosed.	  The	  routine	  medical	  charts	  recorded	  patient	  addresses,	  but	  TB	  nurses	  found	  that	  the	  standard	  registration	  process	  often	  did	  not	  document	  sufficient	  accurate	  information	  to	  successfully	  find	  a	  patient	  in	  the	  mostly	  unmapped	  Msinga	  landscape.	  	  In	  fact, Msinga	  residents	  were	  notorious	  in	  some	  circles	  for	  choosing	  to	  live	  in	  a	  remote	  backwater	  and	  actively	  trying	  not	  to	  be	  found	  by	  government-­‐sponsored	  surveillance.	  In	  news	  articles	  and	  novels,	  Msinga	  was	  often	  portrayed	  as	  a	  place	  where	  people	  who	  had	  gotten	  in	  trouble	  in	  the	  big	  city	  returned	  to	  hide	  or	  –	  in	  the	  case	  of	  HIV	  and	  TB	  –	  to	  die.515	  Others	  had	  willingly	  made	  themselves	  known	  to	  the	  TB	  office	  by	  seeking	  medical	  care	  in	  Tugela	  Ferry	  but	  found	  the	  TB	  program	  onerous	  and	  wanted	  to	  escape.	  According	  to	  TB	  nurses	  and	  tracers,	  patients	  often	  offered	  vague,	  incomplete,	  temporary,	  or	  obsolete	  contact	  information.	  For	  this	  reason,	  TB	  staff	  did	  not	  rely	  on	  addresses,	  but	  instead	  meticulously	  documented	  the	  name	  of	  each	  patient’s	  home	  area,	  the	  name	  of	  the	  closest	  school,	  and	  the	  name	  and	  grade	  of	  a	  child-­‐relative	  who	  attended	  that	  school	  and	  would	  be	  able	  to	  direct	  TB	  tracers	  to	  the	  patient’s	  house	  (and	  squeezed	  it	  into	  boxes	  on	  forms	  that	  
                                                515	  Roger	  Smith,	  Dust	  Devils	  (Tin	  Town,	  2011);	  Johanna	  Mcgeary,	  “Death	  Stalks	  A	  Continent,”	  Time,	  February	  12,	  2001,	  http://www.time.com/time/magazine/article/0,9171,999190,00.html.	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were	  not	  designed	  to	  accommodate	  so	  much	  information).	  When	  patients	  changed	  addresses	  or	  left	  home,	  tracers	  sought	  information	  from	  relatives	  and	  neighbors	  about	  the	  patients’	  new	  whereabouts.	  One	  patient,	  for	  example,	  tried	  to	  run	  away	  from	  the	  painful	  injections	  by	  going	  to	  stay	  with	  her	  husband’s	  family	  in	  another	  part	  of	  Msinga.	  The	  TB	  team	  questioned	  her	  relatives,	  found	  her,	  and	  convinced	  her	  to	  finish	  her	  treatment,	  letting	  her	  know	  that	  “if	  I	  run	  away,	  it’s	  my	  life.”516	  The	  tracing	  team	  and	  its	  active	  approach	  represented	  an	  important	  surveillance	  arm	  of	  this	  state-­‐sponsored	  public	  health	  program.	  Without	  it	  even	  thorough	  documentation	  in	  the	  TB	  registers	  only	  performed	  a	  weak	  function.	  Tracers	  occasionally	  remarked	  on	  their	  role	  as	  arms	  of	  the	  government.	  As	  a	  tracer	  and	  I	  were	  negotiating	  a	  narrow	  road	  hugging	  a	  mountain	  one	  day,	  he	  pointed	  to	  huts	  in	  the	  distance,	  saying:	  “there	  didn’t	  used	  to	  be	  a	  road	  here	  –	  the	  government	  built	  this	  road	  so	  that	  we	  could	  find	  these	  people.	  But	  they	  don’t	  want	  to	  be	  found.”	  While	  it	  was	  hyperbole	  to	  say	  that	  the	  road	  had	  been	  built	  specifically	  so	  that	  he	  could	  find	  his	  patients,	  I	  often	  heard	  that	  road	  development	  that	  had	  taken	  place	  over	  the	  previous	  several	  years	  in	  this	  remote	  area	  in	  transition	  had	  made	  it	  significantly	  harder	  to	  hide.	  TB	  tracers	  also	  enrolled	  government-­‐funded	  school	  teachers	  dispersed	  in	  schools	  across	  the	  region	  in	  their	  task	  of	  finding	  patients.	  On	  several	  occasions	  I	  witnessed	  teachers	  identifying	  young	  school	  children	  to	  the	  TB	  tracers	  and	  releasing	  them	  from	  class	  so	  they	  could	  direct	  the	  tracers	  to	  the	  relatives	  they	  were	  looking	  for.517	  Tracers	  also	  participated	  in	  a	  flow	  of	  paper	  between	  the	  hospital	  TB	  office	  in	  Tugela	  Ferry	  and	  outlying	  clinics,	  where	  the	  care	  of	  standard	  drug-­‐susceptible	  tuberculosis	  patients	  was	  managed.	  Though	  most	  TB	  patients	  in	  the	  region	  passed	  through	  the	  hospital	  
                                                516	  Anonymous	  Patient,	  interview	  by	  author,	  October	  2010,	  Tugela	  Ferry,	  South	  Africa.	  517	  Many	  Msinga	  schools	  were	  in	  poor	  condition,	  and	  many	  children	  had	  to	  walk	  substantial	  distances	  to	  get	  to	  schools,	  but	  from	  the	  perspective	  of	  TB	  tracers	  with	  vehicles,	  they	  provided	  relatively	  good	  coverage	  of	  the	  area.	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TB	  office	  to	  be	  registered,	  they	  were	  generally	  “transferred	  out”	  of	  the	  hospital	  register	  to	  their	  most	  convenient	  local	  clinic	  as	  soon	  as	  their	  paperwork	  was	  processed.	  Patients	  were	  sent	  away	  with	  a	  few	  days	  worth	  of	  tuberculosis	  treatment	  and	  instructions	  to	  see	  their	  local	  clinic	  nurse.	  Tracers	  would	  often	  drive	  these	  patients	  to	  their	  local	  clinics	  and	  then	  home,	  both	  to	  ensure	  that	  the	  patient	  remained	  in	  care,	  and	  so	  that	  they	  would	  know	  first-­‐hand	  where	  the	  patient	  lived	  –	  another	  tool	  with	  which	  to	  stave	  off	  patients	  efforts	  to	  elude	  the	  reach	  of	  the	  TB	  program.	  To	  ensure	  that	  patients	  actually	  made	  contact	  with	  their	  local	  clinics,	  their	  information	  was	  not	  only	  entered	  into	  the	  tuberculosis	  register,	  the	  blue	  patient	  chart	  and	  the	  green	  carrier	  card,	  but	  also	  into	  a	  book	  of	  transfer	  forms.	  A	  slip	  from	  this	  form	  was	  given	  to	  the	  patient,	  who	  in	  turn	  was	  to	  give	  it	  to	  the	  clinic	  nurse,	  who	  in	  turn	  returned	  it	  back	  to	  the	  TB	  office	  in	  Tugela	  Ferry	  via	  a	  TB	  tracer.	  Back	  at	  the	  office,	  the	  TB	  office	  clerk	  regularly	  sifted	  through	  returned	  stubs,	  found	  the	  original	  entries	  in	  the	  transfer	  book,	  and	  stapled	  the	  stubs	  back	  onto	  the	  form.	  Using	  this	  tool,	  the	  clerk	  could	  determine	  if	  patients	  had	  successfully	  made	  the	  transition	  from	  the	  hospital	  to	  the	  local	  clinic.	  The	  patients	  found	  in	  this	  way	  were	  then	  available	  to	  feed	  into	  research	  efforts	  around	  tuberculosis	  as	  well.	  Thus	  researchers	  both	  directly	  and	  indirectly	  relied	  on	  extensive	  government	  involvement	  even	  in	  this	  remote	  populations’	  lives.	  
Memory:	  Clinically	  useful,	  ineffective	  for	  research	  As	  we	  have	  seen,	  the	  office-­‐based	  TB	  DOTS	  staff	  spent	  an	  extensive	  amount	  of	  time	  and	  energy	  writing	  and	  re-­‐writing	  patient	  information	  onto	  various	  types	  of	  stationery,	  and	  great	  emphasis	  was	  placed	  on	  the	  completion	  and	  submission	  of	  these	  forms.	  The	  most	  valued	  TB	  nurses,	  however,	  did	  not	  rely	  on	  tuberculosis	  registers,	  medical	  charts,	  and	  transfer	  forms	  to	  keep	  track	  of	  their	  patients.	  Instead,	  the	  nurses	  and	  tracers	  in	  Tugela	  Ferry	  emphasized	  their	  memory	  as	  the	  most	  important	  tool	  required	  for	  their	  work.	  Paper	  was	  used	  primarily	  to	  fulfill	  bureaucratic	  reporting	  requirements,	  which	  were	  many.	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Clinical	  effectiveness	  required	  much	  more	  than	  well-­‐kept	  paper	  records,	  however.	  It	  required	  a	  personal	  memory	  archive	  of	  patient	  histories	  and	  local	  geography.	  Tracers,	  in	  particular,	  took	  pride	  in	  their	  unaided	  mastery	  of	  the	  Msinga	  landscape.	  One	  tracer	  explained	  to	  me	  that	  after	  working	  on	  MDR-­‐TB	  for	  six	  years,	  he	  knew	  his	  way	  around	  every	  part	  of	  Msinga	  on	  one	  side	  of	  the	  river,	  and	  that	  everyone	  knew	  him:	  “They	  call	  me	  by	  name	  as	  I	  drive	  out	  there	  –	  anywhere.”	  Rather	  than	  relying	  on	  documented	  information,	  this	  tracer	  preferred	  locating	  people	  without	  formal	  assistance,	  based	  on	  his	  knowledge	  of	  area	  designations	  and	  common	  family	  names.	  He	  boasted	  that	  the	  physician	  who	  worked	  most	  closely	  with	  the	  MDR-­‐TB	  research	  project	  had	  recognized	  his	  intimate	  knowledge	  of	  the	  landscape:	  “Dr.	  Bamber	  calls	  me	  the	  map.”	  Dr.	  Bamber	  herself	  had	  introduced	  another	  tracer	  to	  me	  stating	  that	  this	  was	  the	  man	  who	  knew	  all	  of	  the	  XDR-­‐TB	  patients	  in	  Msinga	  and	  could	  find	  them	  all,	  no	  matter	  how	  remote.	  Even	  as	  TB	  tracers	  prided	  themselves	  in	  knowing	  where	  their	  (past	  and	  future)	  patients	  were	  located,	  the	  expansive	  and	  partially	  “uncharted”	  nature	  of	  Msinga’s	  landscape	  constituted	  a	  particular	  challenge	  to	  outside	  researchers.	  Tracers’	  memories	  were	  a	  good	  clinical	  tool	  with	  which	  to	  ensure	  that	  patients	  had	  the	  opportunity	  to	  access	  tuberculosis	  treatment.	  Memory	  was	  not	  a	  great	  research	  tool,	  however,	  unless	  it	  was	  somehow	  translated	  into	  data	  that	  outside	  researchers	  could	  use.	  Researchers	  found	  it	  difficult,	  for	  example,	  to	  determine	  whether	  or	  not	  there	  was	  family	  or	  regional	  clustering	  of	  MDR-­‐TB	  and	  XDR-­‐TB	  cases	  in	  the	  community.	  There	  was	  a	  technological	  fix:	  in	  the	  wake	  of	  the	  discovery	  of	  XDR-­‐TB	  in	  Tugela	  Ferry,	  Umzinyathi	  district’s	  funding	  partner,	  the	  Italian	  Cooperation,	  provided	  tracers	  with	  GPS	  devices.	  The	  Italian	  Cooperation,	  in	  coordination	  with	  the	  local	  department	  of	  health	  and	  the	  American	  researchers	  studying	  XDR-­‐TB,	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requested	  that	  the	  tracers	  note	  down	  patients’	  GPS	  coordinates.518	  Tracers	  were	  initially	  paid	  by	  the	  Italian	  Cooperation,	  and	  maps	  showing	  the	  distribution	  of	  the	  MDR-­‐TB	  and	  XDR-­‐TB	  in	  Msinga	  have	  been	  made	  based	  on	  such	  GPS	  data.	  Early	  maps	  were	  displayed	  on	  the	  TB	  office	  walls	  and	  were	  presented	  at	  scientific	  conferences.	  Yet	  over	  time,	  the	  TB	  tracers	  found	  the	  GPS	  technology	  unnecessary	  and	  tended	  to	  “forget”	  it	  in	  the	  office.	  By	  the	  time	  I	  spent	  time	  with	  tracers	  in	  2010	  they	  only	  rarely	  used	  GPS,	  though	  they	  continued	  to	  carry	  forms	  with	  them	  that	  called	  for	  the	  entry	  of	  GPS	  data.	  GPS	  technology	  did	  not	  help	  tracers	  locate	  their	  patients	  or	  bring	  them	  into	  treatment.	  For	  this,	  they	  relied	  on	  their	  memory	  and	  the	  maps	  in	  their	  own	  heads,	  along	  with	  local	  information	  provided	  by	  people	  they	  met	  along	  the	  way.	  	  Like	  the	  memories	  of	  tracers,	  the	  strength	  of	  specific	  nurses	  ‘	  memories	  was	  noted	  and	  praised	  by	  physicians,	  as	  well.	  Dr.	  Moll	  recommended	  a	  particular	  TB	  nurse	  to	  me	  by	  praising	  the	  fact	  that	  she	  knew	  all	  of	  her	  patients	  off	  the	  top	  of	  her	  head,	  without	  the	  help	  of	  the	  tuberculosis	  register,	  and	  could	  always	  answer	  questions	  he	  had	  about	  the	  patients.	  I	  myself	  saw	  Sister	  Madi	  in	  action	  when	  a	  question	  arose	  about	  a	  patient	  who	  had	  been	  seen	  at	  the	  TB	  office	  some	  time	  ago,	  and	  she	  was	  immediately	  able	  to	  answer	  it.	  She	  confirmed	  the	  information	  by	  quickly	  leafing	  through	  dozens	  of	  pages	  in	  the	  tuberculosis	  register	  and	  almost	  immediately	  pointing	  to	  just	  the	  right	  entry.	  The	  organizational	  weakness	  of	  the	  tuberculosis	  register	  (which	  is	  organized	  by	  treatment	  start	  date	  rather	  than,	  say,	  patient	  name)	  was	  overcome	  by	  the	  nurse’s	  ability	  to	  recollect	  the	  details	  of	  the	  many	  patients	  who	  came	  through	  the	  office.	  
                                                518	  The	  Italian	  Cooperation	  is	  the	  development	  agency	  of	  the	  Italian	  government,	  equivalent,	  perhaps,	  to	  the	  United	  States’	  Agency	  for	  International	  Development	  (USAID).	  Claudio	  Marra,	  interview	  by	  author,	  10	  August	  2010,	  Tugela	  Ferry,	  South	  Africa;	  V.	  Vella	  et	  al.,	  “Household	  Contact	  Investigation	  of	  Multidrug-­‐resistant	  and	  Extensively	  Drug-­‐resistant	  Tubercaulosis	  in	  a	  High	  HIV	  Prevalence	  Setting,”	  The	  International	  Journal	  of	  Tuberculosis	  and	  Lung	  Disease	  15,	  no.	  9	  (2011):	  1170–1175.	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In	  practice,	  the	  extensive	  use	  of	  memory	  by	  nurses	  and	  tracers	  to	  effectively	  manage	  their	  clinical	  program	  was	  perhaps	  not	  surprising.	  Clinical	  memory	  strategies	  were	  insufficient,	  however,	  to	  produce	  good	  data	  for	  research	  and	  bureaucratic	  reporting.	  Clinical	  practice	  needed	  to	  be	  translated	  into	  standardized,	  transportable	  forms	  of	  knowledge	  that	  could	  be	  rendered	  independent	  of	  individual	  nurses	  and	  TB	  staff,	  and	  which	  were	  legible	  to	  public	  health	  bureaucrats	  and	  academic	  researchers.	  At	  the	  level	  of	  the	  TB	  office	  in	  Tugela	  Ferry,	  the	  requirements	  of	  public	  health	  reporting	  were	  dealt	  with	  by	  making	  the	  production	  of	  official	  documents	  such	  as	  the	  TB	  registers,	  transfer	  forms	  and	  patient	  charts	  part	  of	  the	  routine	  of	  being	  a	  TB	  nurse.	  These	  routine	  practices	  of	  document-­‐completion	  were	  regularly	  reinforced	  through	  trainings,	  site	  visits	  from	  supervisors,	  monthly	  reporting	  requirements,	  and	  the	  demands	  of	  the	  nursing	  hierarchy.	  As	  we	  have	  seen,	  researchers’	  data	  needs	  were	  dealt	  with	  by	  adding	  yet	  another	  layer	  of	  data	  documenters	  who	  duplicated	  and	  reformatted	  clinical	  and	  public	  health	  data.	  
Nursing	  work	  in	  a	  global	  community	  context	  Unlike	  physicians	  and	  administrators,	  TB	  nurses	  and	  tracers	  in	  Tugela	  Ferry	  did	  not	  frequently	  express	  a	  sense	  of	  being	  important	  players	  in	  a	  broader	  international	  research	  endeavor,	  even	  as	  I	  sought	  them	  out	  to	  spend	  time	  with	  them	  on	  their	  drives	  to	  patients’	  houses	  and	  asked	  them	  to	  agree	  to	  be	  interviewed	  for	  my	  own	  research.	  Tracers	  were	  unable	  to	  name	  the	  researchers	  who	  were	  likely	  to	  use	  the	  GPS-­‐derived	  information	  in	  their	  work,	  even	  though	  their	  jobs	  as	  tracers	  required	  them	  to	  actively	  collect	  household	  data	  on	  MDR-­‐TB	  and	  XDR-­‐TB	  patients;	  nurses,	  similarly,	  were	  unable	  to	  identify	  the	  roles	  of	  most	  of	  the	  numerous	  American	  principal	  investigators	  who	  occasionally	  came	  through	  town	  to	  monitor	  the	  progress	  of	  their	  research	  projects.	  Tugela	  Ferry’s	  government	  TB	  workers	  did	  not	  speak	  of	  themselves	  as	  working	  for	  the	  “community-­‐based	  management	  of	  MDR-­‐TB,”	  let	  alone	  as	  being	  part	  of	  a	  global	  debate	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about	  the	  merits	  of	  different	  strategies	  of	  drug-­‐resistant	  tuberculosis	  management.	  While	  the	  work	  they	  did	  was	  presented	  in	  national	  and	  international	  venues,	  their	  own	  relationship	  to	  the	  representation	  of	  their	  work	  was	  quite	  removed.	  Sister	  Msomi,	  the	  nurse-­‐manager	  for	  Tugela	  Ferry’s	  TB	  office	  did	  attend	  the	  South	  African	  TB	  conference,	  among	  others,	  and	  she	  sometimes	  presented	  her	  office’s	  work	  on	  MDR-­‐TB	  and	  XDR-­‐TB	  to	  colleagues	  from	  other	  provinces	  and	  countries	  who	  came	  Tugela	  Ferry	  to	  learn	  more	  about	  how	  they	  could	  improve	  their	  own	  programs.	  My	  conversations	  with	  several	  injection	  nurses	  made	  clear,	  however,	  that	  most	  of	  them	  only	  partially	  understood	  that	  their	  activities	  were	  an	  object	  of	  great	  interest	  both	  nationally	  and	  internationally.	  Though	  they	  had	  received	  training	  on	  the	  South	  African	  TB	  program	  and	  the	  management	  of	  MDR-­‐TB,	  they	  had	  not	  been	  explicitly	  trained	  on	  the	  fact	  that	  they	  were	  now	  conducting	  “community-­‐based	  management	  of	  MDR-­‐TB”	  as	  it	  was	  called	  by	  researchers	  and	  higher-­‐level	  department	  of	  health	  managers.	  This	  became	  apparent	  when	  Mr	  Mndebele,	  the	  Umzinyathi	  district	  manager	  who	  oversaw	  department	  of	  health	  operations	  in	  Tugela	  Ferry,	  conducted	  a	  small	  research	  project	  in	  which	  he	  interviewed	  his	  own	  subordinate	  tuberculosis	  staff	  at	  the	  Church	  of	  Scotland	  Hospital	  and	  asked	  them	  what	  training	  they	  had	  received	  on	  the	  community-­‐based	  management	  of	  MDR-­‐TB	  (something	  they	  were	  actively	  doing	  every	  day).	  They	  all	  replied	  that	  they	  had	  not	  received	  any.	  
Fundamental	  building	  block	  or	  donkey	  work?	  In	  Tugela	  Ferry	  injection	  nurses	  were	  the	  primary	  professional	  witnesses	  to	  MDR-­‐TB	  and	  XDR-­‐TB	  patients’	  process	  of	  going	  through	  community-­‐based	  tuberculosis	  treatment.	  They	  were	  not	  usually	  the	  ones,	  however,	  who	  were	  given	  the	  task	  of	  providing	  input	  on	  the	  program’s	  successes	  and	  failures.	  As	  Steven	  Feierman	  has	  pointed	  out	  in	  his	  piece	  When	  physicians	  meet,	  a	  major	  challenge	  in	  global	  health	  programs	  is	  that	  those	  people	  on	  the	  ground	  carrying	  out	  the	  work	  rarely	  have	  the	  opportunity	  to	  provide	  fine-­‐
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tuned	  feedback	  to	  those	  administering	  and	  funding	  the	  programs.	  In	  Tugela	  Ferry	  the	  local	  physicians	  easily	  spoke	  to	  international	  partners	  and	  funders	  and	  were	  very	  empowered	  toward	  them,	  yet	  it	  seemed	  like	  communication	  and	  feedback	  broke	  down	  at	  the	  level	  of	  the	  tuberculosis	  nurses,	  even	  as	  nurses	  officially	  bore	  the	  responsibility	  for	  the	  tuberculosis	  program.	  	  This	  became	  blatantly	  clear	  when	  Mr.	  Mndebele,	  the	  above-­‐mentioned	  department	  of	  health	  district	  manager,	  in	  an	  exception	  to	  this	  rule,	  interviewed	  several	  injection	  nurses	  in	  2011	  as	  part	  of	  a	  small	  evaluation	  of	  the	  community-­‐based	  management	  of	  MDR-­‐TB	  that	  he	  was	  conducting	  as	  part	  of	  an	  academic	  Masters	  program.	  When	  he	  asked	  the	  nurses	  what	  their	  biggest	  challenges	  were,	  most	  of	  them	  mentioned	  logistics	  and	  material	  infrastructure,	  such	  as	  the	  state	  of	  their	  vehicles,	  or	  the	  complexities	  of	  caring	  for	  patients	  who	  came	  to	  Tugela	  Ferry	  despite	  living	  in	  a	  different	  health	  district.	  Several	  nurses	  were	  elated	  about	  being	  able	  to	  communicate	  with	  the	  district	  manager	  about	  their	  work	  (for	  the	  first	  time	  in	  three	  years),	  and	  hoped	  there	  would	  soon	  be	  improvements.	  Mr.	  Mndebele,	  meanwhile,	  admitted	  that	  he	  was	  aware	  of	  some	  of	  the	  problems	  with	  vehicles	  which	  had	  accumulated	  since	  the	  vehicles	  were	  originally	  allocated	  when	  the	  TB	  office	  was	  expanded	  in	  2007,	  but	  that	  it	  was	  difficult	  to	  keep	  up	  with	  the	  ongoing	  budgeting	  that	  the	  program	  required	  now	  that	  the	  acute	  crisis	  related	  to	  XDR-­‐TB	  was	  no	  longer	  felt.519	  Mr	  Human,	  the	  CEO	  of	  the	  hospital	  in	  Tugela	  Ferry,	  discredited	  the	  importance	  of	  the	  hospital’s	  TB	  office	  nurses’	  input	  almost	  entirely.	  He	  argued	  that	  despite	  the	  fact	  that	  the	  management	  of	  tuberculosis	  treatment	  is	  almost	  entirely	  nurse-­‐driven,	  it	  was	  not	  the	  nurses	  who	  uncovered	  the	  MDR-­‐TB/XDR-­‐TB	  outbreak,	  and	  it	  was	  never	  the	  nurses	  who	  provided	  significant	  intellectual	  input	  into	  how	  to	  manage	  the	  MDR-­‐TB/XDR-­‐TB	  outbreak.	  In	  his	  view,	  TB	  nurses	  did	  the	  routine	  “donkey	  work”	  of	  discharging,	  transporting	  and	  transferring	  patients,	  while	  it	  was	  researchers	  from	  outside	  who	  had	  truly	  made	  an	  impact	  
                                                519	  Jabulani	  Mndebele,	  interview	  by	  author,	  10	  March	  2011,	  Tugela	  Ferry,	  South	  Africa.	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on	  programs	  for	  MDR-­‐TB	  in	  Msinga.520	  He	  –	  perhaps	  correctly	  –	  attributed	  the	  bulk	  of	  the	  success	  that	  the	  hospital	  in	  Tugela	  Ferry	  had	  seen	  in	  improving	  its	  tuberculosis	  program	  to	  the	  hard	  work	  of	  Dr.	  Moll	  and	  the	  input	  provided	  by	  people	  in	  his	  international	  networks.	  Yet	  I	  would	  argue	  that	  without	  the	  so-­‐called	  donkey-­‐work	  very	  little	  would	  have	  gotten	  done,	  in	  the	  end.	  
In	  the	  field	  TB	  nurses	  were	  frequently	  reminded	  of	  the	  broader	  world’s	  interest	  in	  their	  work,	  however,	  when	  Dr.	  Moll	  arranged	  for	  outside	  visitors	  such	  as	  myself	  to	  ride	  along	  with	  one	  of	  them	  as	  they	  traveled	  to	  see	  their	  patients.	  Many	  visitors	  to	  Tugela	  Ferry	  showed	  a	  great	  interest	  in	  learning	  more	  about	  what	  had	  happened	  in	  the	  aftermath	  of	  the	  discovery	  of	  XDR-­‐TB	  and	  wanted	  to	  spend	  time	  traveling	  through	  Msinga.	  In	  this	  sense,	  TB	  nurses	  were	  very	  involved	  with	  promoting	  the	  community-­‐based	  management	  of	  MDR-­‐TB.521	  Ride-­‐alongs	  with	  TB	  nurses	  served	  numerous	  purposes.	  For	  tuberculosis	  program	  coordinators	  from	  other	  provinces	  and	  countries	  who	  were	  starting	  or	  improving	  MDR-­‐TB	  treatment	  programs	  they	  served	  a	  pragmatic	  educational	  purpose.522	  Other	  common	  riders	  belonged	  to	  rotating	  groups	  of	  visiting	  medical	  residents	  (junior	  physicians)	  who	  spent	  six	  weeks	  in	  Tugela	  Ferry	  helping	  with	  patients	  at	  the	  HIV	  clinic.	  For	  them,	  the	  ‘purpose’	  of	  the	  trip	  was	  perhaps	  less	  obvious.	  I	  thought	  of	  these	  ride-­‐alongs	  primarily	  as	  a	  type	  of	  global	  health	  tourism	  –	  a	  form	  of	  entertainment	  that	  gave	  foreign	  visitors	  to	  Tugela	  Ferry	  a	  glimpse	  of	  the	  “Africa”	  they	  had	  expected	  to	  find.	  The	  young	  American	  doctors	  spent	  busy	  
                                                520	  Hans	  Human,	  interview	  by	  author,	  14	  January	  2011,	  Tugela	  Ferry,	  South	  Africa.	  521	  The	  nurses	  in	  Tugela	  Ferry	  seemed	  unaware	  of	  the	  global	  uniqueness	  of	  the	  epidemiological	  situation	  they	  worked	  in	  every	  day,	  however.	  Months	  after	  my	  first	  ride-­‐along,	  after	  I	  had	  spent	  many	  days	  with	  the	  TB	  nurses	  in	  Tugela	  Ferry,	  one	  of	  the	  nurses	  asked	  a	  question	  that	  had	  been	  bothering	  her:	  “Erica,	  why	  is	  it	  that	  you	  guys	  come	  from	  overseas	  to	  work	  on	  TB	  and	  HIV?	  Don’t	  you	  have	  drug-­‐resistant	  TB	  in	  America?”	  My	  answer	  was	  truly	  devastating:	  “No,	  we	  don’t.	  Not	  to	  this	  extent.”	  522	  Around	  the	  time	  I	  left	  Tugela	  Ferry	  in	  2011,	  Philanjalo	  was	  setting	  up	  a	  training	  program	  (funded	  by	  URC)	  which	  would	  use	  Tugela	  Ferry	  and	  Greytown	  as	  a	  “center	  of	  excellence”	  to	  train	  others	  on	  MDR-­‐TB	  care.	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weeks	  working	  in	  a	  new,	  modern-­‐looking	  HIV	  clinic,	  dispensing	  standard	  drug-­‐therapies	  with	  the	  help	  of	  trained,	  uniformed,	  bilingual	  nurses	  and	  the	  support	  of	  experienced	  South	  African	  doctors.	  They	  enjoyed	  spending	  a	  day	  off	  “out	  in	  the	  community”	  visiting	  the	  region,	  seeing	  people’s	  houses	  and	  poor	  living	  conditions	  up-­‐close.	  Some	  international	  visitors	  (including	  medical	  students)	  achieved	  the	  same	  aim	  by	  accompanying	  a	  community	  worker	  as	  she	  visited	  orphans	  and	  vulnerable	  children.	  I	  was	  frequently	  present	  when	  at	  the	  end	  of	  a	  ride-­‐along	  day	  Americans	  would	  assemble	  in	  hospital	  guest-­‐houses	  over	  dinner	  and	  share	  their	  photographs	  of	  cute	  African	  children	  and	  colorful	  round	  houses	  overlooking	  rolling	  hills,	  in	  some	  cases	  talking	  about	  the	  T-­‐shirts	  they	  had	  donated,	  or	  the	  game	  of	  peek-­‐a-­‐boo	  they	  had	  played	  with	  a	  toddler.	  Beyond	  tourism	  or	  voyeurism,	  these	  ride-­‐alongs	  also	  provided	  an	  opportunity	  for	  visitors	  to	  witness	  the	  conditions	  of	  life	  and	  work	  in	  Msinga	  and	  Tugela	  Ferry	  in	  order	  to	  solidify	  the	  argument	  for	  the	  moral	  necessity	  of	  biomedical	  (and	  social)	  intervention.	  Though	  encounters	  were	  fleeting,	  these	  trips	  provided	  opportunities	  for	  visitors	  to	  “see	  how	  Zulu	  people	  lived,”	  and	  affirm	  the	  belief	  (widely	  held	  among	  these	  visitors)	  that	  health	  care	  should	  be	  provided	  even	  in	  dire	  circumstances.523	  Global	  health	  practitioners	  in	  some	  humanitarian	  traditions	  have	  had	  an	  explicitly	  stated	  function	  of	  not	  only	  providing	  medical	  care	  to	  people	  in	  need,	  but	  of	  vocally	  bearing	  witness	  to	  the	  conditions	  in	  which	  they	  operate.	  The	  organization	  Doctors	  without	  Borders,	  for	  example,	  calls	  its	  members	  to	  “witness”	  suffering	  and	  human	  rights	  abuses	  and	  stand	  in	  solidarity	  with	  those	  who	  are	  suffering.524	  The	  founders	  of	  Partners	  in	  Health,	  similarly,	  draw	  on	  catholic	  liberation	  
                                                523	  I	  take	  this	  phrase	  from	  the	  aunt	  of	  a	  Zulu	  nurse	  I	  lived	  with	  for	  several	  months	  in	  Durban.	  When	  she	  briefly	  met	  me	  at	  a	  family	  function	  she	  named	  me	  Thandeka	  (loved),	  because	  I	  loved	  the	  Zulu	  people	  and	  wanted	  to	  “see	  how	  we	  Zulus	  live.”	  This	  was	  all	  very	  tongue	  in	  cheek	  and	  was	  part	  of	  a	  conversation	  that	  included	  a	  discussion	  of	  how	  generous	  her	  white	  employer	  had	  been	  when	  she	  was	  a	  domestic	  worker,	  and	  ended	  with	  a	  request	  for	  money	  from	  me.	  524	  Peter	  Redfield,	  “A	  Less	  Modest	  Witness,”	  American	  Ethnologist	  33,	  no.	  1	  (2006):	  3-­‐26.	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theology	  to	  demand	  that	  health	  professionals	  make	  a	  preferential	  option	  for	  the	  poor,	  since	  “those	  who	  are	  in	  any	  way	  and	  for	  any	  reason	  deprived,	  marginalized,	  or	  vulnerable	  have	  a	  special	  moral	  claim	  on	  the	  community.”525	  Successful	  global	  health	  organizations	  employ	  first-­‐hand	  accounts	  of	  the	  lives	  of	  the	  poor	  and	  disenfranchised	  to	  make	  a	  moral	  argument	  for	  intervention	  and	  are	  able	  to	  attract	  funds	  this	  way,	  as	  well.	  Especially	  in	  international	  work	  around	  HIV/AIDS	  first-­‐hand	  knowledge	  and	  compelling	  narratives	  provide	  valuable	  currency	  that	  can	  be	  traded	  for	  monetary	  support	  when	  deployed	  effectively.526	  Much	  of	  Paul	  Farmer’s	  argument	  for	  a	  right	  to	  health	  and	  international	  health	  intervention	  consists	  of	  telling	  the	  stories	  of	  people	  and	  places	  he	  has	  met	  and	  seen,	  and	  explaining	  the	  world	  from	  the	  perspective	  of	  having	  been	  there.527	  In	  a	  similar	  vein,	  much	  of	  the	  lower-­‐profile	  global-­‐health	  work	  conducted	  by	  undergraduates,	  medical	  students,	  and	  resident	  physicians	  comes	  at	  least	  in	  part	  from	  a	  desire	  to	  “be	  there;”	  to	  experience	  first	  hand	  what	  the	  conditions	  of	  the	  world	  are,	  and	  from	  the	  wish	  to	  be	  able	  to	  tell	  their	  own	  morally	  compelling	  stories	  of	  suffering,	  and	  including	  themselves	  in	  part	  of	  the	  solution.528	  I	  do	  not	  exclude	  myself	  from	  this	  analysis.	  Towards	  the	  end	  of	  my	  first	  day-­‐trip	  with	  an	  injection	  nurse	  I	  could	  not	  help	  thinking	  that	  that	  I	  had	  now	  “seen”	  MDR-­‐TB	  in	  Msinga.	  I	  took	  note	  of	  this	  thought	  in	  my	  fieldnotes	  and	  immediately	  questioned	  it.	  What	  had	  I	  seen?	  In	  brief	  visits	  to	  people’s	  houses	  I	  had	  perhaps	  come	  to	  understand	  a	  little	  more	  about	  the	  material	  conditions	  in	  which	  tuberculosis	  patients	  in	  Msinga	  lived;	  as	  we	  drove	  along	  I	  eyed	  a	  harsh-­‐looking	  landscape	  through	  the	  window.	  I	  saw	  dry	  riverbeds	  and	  occasional	  
                                                525	  “Partners	  In	  Health,”	  accessed	  December	  26,	  2012,	  http://www.pih.org/pages/faq/;	  Peter	  Redfield,	  “A	  Less	  Modest	  Witness,”	  American	  Ethnologist	  33,	  no.	  1	  (2006):	  3–26.	  526	  Vinh-­‐Kim	  Nguyen,	  The	  Republic	  of	  Therapy:	  Triage	  and	  Sovereignty	  in	  West	  Africa’s	  Time	  of	  AIDS,	  (Duke	  University	  Press	  Books,	  2010).	  527	  Paul	  Farmer,	  Pathologies	  of	  Power:	  Health,	  Human	  Rights,	  and	  the	  New	  War	  on	  the	  Poor	  (University	  of	  California	  Press,	  2004).	  528	  Betsey	  Brada,	  “‘Not	  Here’:	  Making	  the	  Spaces	  and	  Subjects	  of	  ‘Global	  Health’	  in	  Botswana.”	  Culture,	  
Medicine,	  and	  Psychiatry	  35	  (2011):285–312.	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boreholes	  or	  water	  pumps;	  a	  few	  vegetable	  gardens	  and	  a	  tractor,	  but	  mostly	  dusty	  hillsides	  with	  few	  clues	  as	  to	  how	  people	  sustained	  themselves.	  I	  wondered:	  Why	  were	  water	  pumps	  so	  far	  from	  houses?	  We	  passed	  several	  schools	  and	  clinics	  in	  various	  conditions.	  One	  school	  had	  a	  big	  solar	  panel	  in	  front	  –	  I	  wondered	  whether	  the	  others	  had	  any	  electricity.	  We	  passed	  four	  clinics	  –	  markers	  of	  the	  department	  of	  health’s	  presence	  even	  in	  more	  remote	  parts	  of	  the	  district.	  But	  how	  effectively	  were	  they	  staffed	  and	  how	  well	  did	  they	  function?	  I	  found	  the	  geology	  intriguing.	  How	  did	  all	  the	  stones	  get	  here	  in	  this	  formation?	  Why	  are	  there	  so	  many	  dry	  riverbeds	  that	  make	  it	  look	  like	  instead	  of	  water,	  rocks	  flow	  through	  these	  valleys?	  It	  was	  dry	  season,	  but	  I	  was	  told	  that	  even	  in	  the	  wet	  summers,	  most	  of	  these	  river	  beds	  would	  still	  be	  dry,	  though	  others	  would	  flood,	  cutting	  off	  roads.529	  We	  passed	  strange	  aloes,	  including	  enormous	  leafy	  grassy	  structures	  that	  dry	  up	  into	  gnarled	  papery	  branches	  in	  different	  shades	  of	  brown	  and	  black;	  we	  also	  passed	  acacias	  whose	  small	  leaves	  were	  surrounded	  by	  thorns,	  though	  these	  did	  not	  seem	  to	  prevent	  goats	  from	  eating	  them.	  Much	  of	  the	  landscape	  was	  nearly	  free	  of	  vegetation.	  	   The	  harsh	  landscape	  was	  also	  stunningly	  beautiful.	  I	  took	  note	  of	  the	  intricate	  afternoon	  play	  of	  shadow	  and	  light	  on	  the	  mountains.	  The	  hillsides	  offered	  so	  many	  hues	  of	  greens	  and	  browns.	  The	  clouds	  were	  striking,	  reflecting	  a	  combination	  of	  fluffy	  white	  and	  dark	  grey	  against	  a	  bright	  blue	  background	  with	  clearings	  of	  brilliant	  radiance	  emerging	  from	  behind	  them.	  The	  buildings	  added	  to	  the	  color.	  A	  small	  one-­‐room	  tuck-­‐shop	  had	  been	  painted	  neon	  blue.	  Other	  houses	  along	  the	  hillside	  were	  painted	  in	  bright	  pinks	  and	  bright	  greens.	  On	  the	  way	  back	  to	  town	  we	  sighted	  several	  birds	  of	  prey	  cruising	  in	  the	  sky,	  majestically	  surveying	  the	  landscape.	  Our	  trip	  was	  briefly	  delayed	  by	  a	  rather	  more	  pedestrian	  pack	  of	  donkeys	  being	  led	  down	  to	  the	  river.	  
                                                529	  I	  later	  came	  across	  newspaper	  articles	  featuring	  Msinga	  school	  children	  who	  need	  to	  wade	  or	  swim	  through	  neck-­‐high	  water	  in	  order	  to	  get	  to	  school	  every	  day.	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One	  day,	  when	  NF	  and	  I	  had	  been	  driving	  for	  about	  four	  hours,	  we	  parked	  to	  eat	  our	  lunch	  under	  a	  tree	  on	  the	  top	  of	  a	  hill	  from	  which	  we	  could	  see	  rolling	  hills	  and	  a	  river	  winding	  away	  in	  the	  distance.	  I	  pointed	  out	  how	  beautiful	  the	  scenery	  was.	  She	  looked	  at	  me	  skeptically	  and	  shrugged,	  saying,	  “The	  people	  here	  live	  like	  animals.”530	  Perhaps	  she	  wondered	  how	  I	  had	  missed	  this,	  considering	  we	  had	  just	  left	  the	  house	  of	  a	  dying	  XDR-­‐TB	  patient	  who	  was	  lying	  alone	  on	  a	  mat	  in	  a	  dark	  hut	  that	  was	  in	  disarray	  –	  a	  picture-­‐perfect	  scene	  of	  another	  kind.	  It	  dawned	  on	  me	  that	  I	  had	  succumbed	  to	  the	  rural	  romanticism	  of	  the	  “real	  African”	  landscape.	  With	  that	  simple	  sentence	  she	  simultaneously	  made	  clear	  to	  me	  that	  the	  view	  was	  not	  the	  point,	  but	  she	  also	  socially	  distinguished	  herself,	  an	  employed,	  educated	  nurse,	  from	  the	  poor,	  rural,	  often	  uneducated	  clients	  she	  was	  visiting.	  	   As	  I	  tried	  to	  “read”	  the	  landscape	  and	  gain	  an	  “understanding”	  of	  Msinga,	  it	  became	  blatantly	  clear	  how	  far	  removed	  a	  ride-­‐along	  was	  from	  really	  providing	  such	  understanding.	  In	  my	  notes	  I	  asked	  myself	  a	  series	  of	  both	  obvious	  and	  naïve	  questions	  that	  a	  ride-­‐along	  was	  not	  equipped	  to	  answer.	  For	  me,	  these	  ride-­‐alongs	  were	  one	  part	  of	  a	  much	  longer	  and	  broader	  project	  that	  would	  help	  answer	  some	  of	  these	  questions,	  while	  others	  remained	  unanswered.	  There	  was	  a	  clear	  risk,	  however,	  that	  a	  ride-­‐along	  like	  this	  one	  could	  become	  a	  once-­‐off	  event	  which	  left	  a	  dramatic	  impression	  without	  really	  providing	  the	  insight	  it	  seemed	  to	  offer.	  Photographs	  taken	  on	  such	  ride-­‐alongs,	  meanwhile,	  found	  their	  ways	  into	  private	  photo-­‐albums,	  public	  blogs,	  and	  research	  presentations	  that	  hit	  home	  the	  importance	  of	  providing	  tuberculosis	  treatment	  to	  patients	  in	  such	  a	  simultaneously	  beautiful	  and	  desperate	  setting.	  
                                                530	  This	  was	  not	  the	  only	  time	  a	  Zulu	  in	  Tugela	  Ferry	  was	  bemused	  by	  my	  admiration	  for	  the	  landscape.	  A	  Zulu	  mission	  worker	  who	  spent	  a	  lot	  of	  time	  organizing	  activities	  and	  outreach	  for	  mostly	  white	  visitors	  (some	  of	  them	  international,	  though	  many	  South	  African)	  once	  took	  me	  to	  a	  spot	  on	  the	  top	  of	  a	  hill	  that	  has	  a	  beautiful	  vista.	  She	  had	  brought	  me	  there	  because	  “I	  know	  that	  you	  white	  people	  like	  to	  look	  at	  our	  mountains.”	  In	  a	  similar	  incident,	  I	  took	  a	  walk	  with	  a	  Tugela	  Ferry	  municipal	  worker	  along	  the	  Thukela	  river.	  He	  pointed	  to	  a	  picturesque	  small	  island	  in	  the	  middle	  of	  the	  river	  and	  postulated	  that	  it	  would	  probably	  appeal	  to	  white	  people.	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The	  “first”	  ride-­‐along	  In	  chapter	  3	  I	  described	  how	  Dr.	  Moll	  decided	  to	  impress	  Dr.	  Friedland	  the	  first	  time	  he	  came	  to	  Tugela	  Ferry	  by	  leaving	  the	  modest	  hospital	  in	  the	  tiny	  town,	  and	  instead	  taking	  the	  American	  Professor	  to	  outlying	  areas	  of	  the	  district.	  Friedland	  had	  been	  getting	  frustrated	  with	  the	  slow	  pace	  of	  setting	  up	  research	  on	  combined	  HIV	  and	  TB	  treatment	  in	  Durban	  and	  had	  decided	  to	  look	  elsewhere:	  “It	  seemed	  like	  it	  was	  going	  to	  take	  a	  long	  time	  if	  ever	  for	  this	  larger	  project	  in	  Durban	  to	  actually	  materialize,	  and	  I	  had	  an	  idea,	  and	  the	  funding	  source	  for	  the	  work	  that	  I	  was	  doing	  was	  very	  encouraging	  about	  it,	  to	  actually	  test	  this	  strategy	  in	  a	  rural	  area.	  Because	  that’s	  where	  most	  people	  still	  live	  in	  Africa,	  that’s	  where	  probably	  the	  worst	  HIV	  and	  TB	  epidemics	  are,	  though	  they	  are	  bad	  everywhere.”531	  When	  explaining	  how	  their	  collaboration	  came	  about,	  Dr.	  Moll	  and	  Dr.	  Friedland	  both	  credited	  Tugela	  Ferry’s	  rural,	  “African”	  location	  with	  a	  crucial	  role	  in	  bringing	  them	  together.	  Moll	  took	  him	  on	  dirt	  tracks	  to	  the	  “real	  old	  Africa”532	  in	  the	  hills	  and	  together	  they	  visited	  destitute	  people	  in	  their	  traditional	  Zulu	  huts.	  When	  Dr.	  Friedland	  later	  discussed	  the	  HIV/TB	  research	  in	  Tugela	  Ferry,	  he	  described	  the	  inhabitants	  there	  as	  a	  “very	  traditional	  Zulu	  community”	  and	  emphasized	  the	  town’s	  remote	  location	  far	  from	  the	  infrastructure	  of	  Durban.	  “There’s	  one	  tarred	  road	  that	  leads	  into	  what	  was	  the	  former	  Zulu	  homeland.	  	  Everything	  else	  is	  dirt	  roads	  or	  tracks.	  About	  70%	  of	  people	  don't	  have	  piped	  water	  or	  electricity.	  	  It's	  really	  quite	  impoverished.”533	  Friedland	  emphasized	  the	  poverty	  of	  the	  area’s	  inhabitants,	  and	  called	  the	  location	  a	  “very	  resource-­‐limited	  setting,”	  whereby	  the	  point	  of	  his	  research	  was	  to	  test	  the	  feasibility	  of	  integrating	  TB	  and	  HIV	  in	  such	  a	  setting.	  Neither	  Dr.	  Moll	  nor	  Dr.	  Friedland	  described	  Tugela	  Ferry’s	  poverty	  or	  rural	  location	  as	  a	  disadvantage	  or	  limitation	  for	  the	  research	  project	  itself.	  Instead,	  these	  features	  meant	  that	  
                                                531	  Gerald	  Friedland,	  interview	  by	  author,	  27	  March	  2007,	  New	  Haven,	  CT.	  532	  Anthony	  Moll,	  interview	  by	  author,	  23	  July	  2007,	  Tugela	  Ferry,	  South	  Africa.	  533	  Ibid.	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researchers	  had	  a	  good	  reason	  for	  being	  there,	  and	  they	  provided	  some	  compelling	  detail	  about	  the	  condition	  of	  the	  people	  being	  provided	  for.	  Friedland	  emphasized	  the	  collaborative	  nature	  of	  the	  relationship	  between	  Yale,	  UKZN,	  Philanjalo,	  and	  his	  US-­‐based	  donor.	  Philanjalo,	  as	  an	  organization,	  had	  well-­‐established	  ties	  with	  poor	  people	  in	  their	  own	  remote,	  and	  visibly	  traditional	  community	  settings.	  I	  suspect	  this	  was	  an	  appealing	  feature	  of	  doing	  research	  in	  Tugela	  Ferry	  that	  mitigated	  potential	  ethical	  concerns	  Friedland	  might	  have	  had	  about	  conducting	  research	  among	  poor,	  disempowered	  people.534	  	   The	  distinctly	  “African”	  landscape	  provided	  the	  appropriate	  backdrop	  with	  which	  to	  highlight	  the	  human	  suffering	  which	  AIDS	  and	  tuberculosis	  were	  causing	  in	  the	  context	  of	  poverty	  and	  cultural	  difference.	  Peripherally	  involved	  South	  African	  clinicians	  who	  knew	  about	  Tugela	  Ferry	  were	  inclined	  to	  believe	  in	  the	  intrinsic	  wholesome	  nature	  and	  justification	  of	  research	  there.	  Dr.	  Moll	  and	  some	  of	  his	  colleagues	  in	  Tugela	  Ferry	  were	  famous	  in	  clinical	  circles	  for	  their	  inspirational	  dedication	  to	  working	  in	  difficult	  conditions	  to	  help	  their	  destitute,	  rural	  patients.	  It	  was	  tempting	  to	  think	  of	  Tugela	  Ferry	  and	  its	  Church	  of	  Scotland	  Hospital	  (COSH)	  as	  home	  to	  a	  close-­‐knit	  community	  where	  poor	  patients	  work	  hand-­‐in-­‐hand	  with	  physicians	  and	  researchers.	  Durban-­‐based	  researcher	  Nesri	  Padayatchi,	  in	  a	  conversation	  about	  community	  advisory	  boards	  (a	  formal	  mechanism	  through	  which	  community	  members	  are	  consulted	  about	  research),	  stated:	  “I	  think	  the	  way	  COSH	  operates,	  you	  know,	  and	  it’s	  a	  small	  community,	  COSH	  is	  actually	  a	  whole	  CAB	  [community	  advisory	  board]	  in	  itself,	  because	  they	  work	  quite	  closely	  with	  the	  
                                                534	  I	  credit	  Friedland	  with	  being	  a	  thoughtful	  researcher	  who	  had	  extensive	  experience	  working	  in	  conditions	  of	  unequal	  power	  relations,	  as	  well	  as	  a	  respect	  for	  history	  and	  justice.	  His	  past	  experiences	  included	  working	  for	  the	  peace-­‐corps	  in	  Nigeria	  in	  the	  1960s,	  working	  as	  an	  inner-­‐city	  physician	  who	  saw	  AIDS	  patients	  early	  in	  the	  epidemic	  as	  an	  infectious	  disease	  specialist	  who	  took	  a	  special	  interest	  in	  injection	  drug	  users	  in	  New	  York,	  and	  as	  a	  global	  health	  AIDS	  physician	  who	  set	  up	  programs	  in	  South	  Africa.	  Even	  people	  who	  were	  very	  critical	  of	  the	  international	  research	  endeavors	  happening	  in	  South	  Africa	  appreciated	  Dr.	  Friedland’s	  work	  and	  respected	  him.	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community.”535	  This	  was	  a	  rather	  bold	  claim,	  considering	  that	  the	  Church	  of	  Scotland	  Hospital	  is	  a	  350-­‐bed	  hospital	  with	  hundreds	  of	  nurses	  and	  sometimes	  over	  a	  dozen	  doctors,	  serving	  a	  potential	  population	  of	  just	  under	  200,000	  people.536	  Implicit	  in	  the	  ways	  both	  Friedland	  and	  Moll	  spoke	  about	  Tugela	  Ferry	  is	  the	  notion	  that	  there	  is	  an	  “Africa”	  or	  “real	  Africa”	  out	  there	  that	  desperately	  requires	  intervention.	  In	  modern,	  urbanized,	  industrialized	  South	  Africa,	  this	  real	  Africa	  is	  not	  always	  readily	  apparent,	  but	  must	  first	  be	  found.	  Friedland	  left	  his	  research	  site	  at	  a	  clinic	  in	  bustling	  downtown	  Durban	  to	  find	  a	  more	  rural	  location	  where	  he	  might	  have	  a	  greater	  impact;	  Moll,	  similarly,	  turned	  away	  from	  the	  little	  rural	  town	  of	  Tugela	  Ferry	  on	  the	  main	  access	  road	  to	  the	  less	  accessible	  bush	  in	  order	  to	  make	  a	  more	  compelling	  argument	  that	  his	  potential	  collaborator	  should	  chose	  his	  area	  as	  a	  research	  site.	  Of	  course,	  Durban,	  Tugela	  Ferry,	  and	  outlying	  Msinga	  are	  all	  “in	  Africa.”	  What,	  then,	  does	  this	  term	  mean	  (other	  than	  a	  continent	  which	  can	  be	  found	  on	  a	  map),	  and	  what	  work	  does	  it	  do	  in	  global	  health	  research?	  As	  James	  Ferguson	  has	  pointed	  out,	  Africa	  is	  often	  represented	  as	  a	  continent	  in	  constant	  crisis	  and	  in	  need	  of	  help,	  defined	  by	  “tradition,”	  “simple	  societies,”	  and	  “societies	  without	  history.”537	  The	  concept	  of	  Africa	  serves	  as	  a	  type	  of	  pre-­‐formed	  shorthand	  that	  draws	  on	  a	  cluster	  of	  associations	  and	  pre-­‐conceived	  notions.	  These	  associations	  are	  at	  work	  in	  the	  fundraising	  campaigns	  which	  show	  bloated	  black	  children	  in	  ragged	  clothes	  looking	  with	  pleading	  eyes	  into	  the	  camera;	  the	  same	  shorthand	  is	  in	  operation	  when	  a	  Lufthansa	  clerk	  in	  the	  Berlin	  airport	  tells	  me	  I	  should	  not	  be	  surprised	  that	  the	  airline	  lost	  my	  luggage	  on	  a	  flight	  that	  originated	  in	  Africa,	  afterall.	  As	  Ferguson	  puts	  it	  (paraphrasing	  
                                                535	  Nesri	  Padayatchi,	  interview	  by	  author,	  6	  April	  2010,	  Durban,	  South	  Africa.	  536	  The	  assumption	  that	  COSH	  has	  essentially	  achieved	  the	  aspirational	  ideal	  of	  immediate	  community	  involvement	  was	  also	  somewhat	  dangerous,	  since	  it	  rendered	  unnecessary	  a	  close	  consideration	  of	  research	  ethics	  in	  Tugela	  Ferry.	  	  537	  James	  Ferguson,	  Global	  Shadows:	  Africa	  in	  the	  Neoliberal	  World	  Order	  (Duke	  University	  Press	  Books,	  2006),	  2.	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Achille	  Mbembe),	  Africa	  “serves	  as	  a	  metaphor	  of	  absence	  –	  a	  “dark	  continent”	  against	  which	  the	  lightness	  and	  whiteness	  of	  “Western	  Civilization”	  can	  be	  pictured.”538	  Dr.	  Moll	  taps	  into	  a	  complex	  set	  of	  notions	  about	  Africa,	  then,	  when	  he	  says	  he	  drove	  Dr.	  Friedland	  “back	  in	  time	  to	  real	  old	  Africa,	  where	  patients	  […]	  are	  really	  in	  bad	  circumstances	  out	  there	  in	  the	  rural	  community.”539	  Time-­‐travel	  has	  been	  achieved	  by	  moving	  through	  space	  to	  find	  something	  that	  matches	  a	  more	  authentic	  conception	  of	  Africa,	  whose	  inhabitants	  “don’t	  have	  electricity,	  don’t	  have	  water	  supply,	  live	  off	  the	  ground,	  you	  can	  say,	  there’s	  no	  cell	  communication,	  basically	  cut	  off	  from	  modern	  facilities.”540	  This	  depiction	  implicitly	  (even	  if	  not	  explicitly)	  coexists	  with	  the	  notion	  that	  poor,	  traditional	  Zulus	  have	  been	  scratching	  away	  at	  the	  earth	  for	  generations,	  barely	  getting	  by	  for	  lack	  of	  initiative,	  lack	  of	  environmental	  stewardship,	  and	  held	  back	  by	  their	  own	  backwards	  cultural	  practices.541	  Of	  course,	  Friedland	  himself	  acknowledged	  KwaZulu-­‐Natal	  and	  South	  Africa’s	  much	  more	  complicated	  and	  exploitative	  history	  by	  describing	  Msinga	  as	  a	  “former	  Zulu	  homeland.”542	  
Finding	  the	  real	  Africa	  In	  the	  minds	  of	  visitors	  and	  locals,	  the	  “Africa”	  of	  poverty,	  lack	  of	  infrastructure,	  disease,	  backward	  culture	  and	  much-­‐needed	  intervention	  coexists	  with	  a	  more	  romantic	  
                                                538	  Ferguson,	  Global	  Shadows,	  2.	  539	  Moll,	  interview	  by	  author,	  2007.	  540	  Ibid.	  541	  I	  regularly	  encountered	  these	  ideas	  during	  my	  stay	  in	  South	  Africa,	  including	  in	  Tugela	  Ferry.	  Doctors	  working	  in	  Tugela	  Ferry	  often	  expressed	  the	  opinion	  that	  their	  patients	  were	  in	  part	  to	  blame	  for	  their	  own	  poverty	  and	  backwardness;	  the	  main	  Zulu	  preacher	  at	  the	  local	  mission	  frequently	  blamed	  people’s	  misfortunes	  on	  traditional	  ancestor	  worship;	  one	  of	  my	  Zulu	  hosts	  wondered	  out	  loud	  why	  it	  was	  that	  Zulus	  were	  lazy	  and	  poor,	  while	  refugees	  in	  the	  community	  managed	  to	  eke	  a	  living	  through	  resourcefulness	  and	  very	  hard	  work	  in	  difficult	  conditions;	  one	  physician	  (who	  worked	  very	  hard	  for	  his	  Zulu	  patients)	  commonly	  made	  comments	  that	  Zulus	  only	  had	  their	  own	  backwardness	  to	  blame	  for	  their	  misfortunes.	  542	  Friedland,	  interview	  by	  author,	  2007.	  Dr.	  Friedland’s	  own	  sense	  of	  South	  African	  history	  was	  in	  part	  shaped	  by	  the	  novels	  of	  South	  African	  author	  Zakes	  Mda.	  He	  recommended	  the	  novel	  Hearts	  of	  
Redness	  –	  a	  book	  which	  is	  inspired	  by	  Xhosa	  history	  and	  which	  traces	  the	  causes	  of	  contemporary	  conflict	  to	  unresolved	  historical	  grievances	  and	  the	  merciless	  march	  of	  capitalism	  –	  to	  all	  of	  his	  colleagues	  who	  came	  to	  work	  in	  Tugela	  Ferry.	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“Africa”	  of	  stunning	  landscapes,	  traditional	  arts	  and	  crafts,	  exuberant	  song	  and	  dance	  and	  large	  majestic	  animals,	  as	  well	  as	  mystical	  moments	  of	  self-­‐recognition.	  In	  the	  city	  of	  Durban,	  international	  visitors	  (including	  biomedical	  researchers)	  are	  often	  surprised	  at	  just	  how	  difficult	  it	  is	  to	  find	  either	  “Africa”	  in	  this	  town	  of	  sunny	  beaches,	  Botanical	  Gardens,	  horse-­‐races,	  casinos,	  and	  several	  large,	  fancy,	  air-­‐conditioned	  indoor	  malls	  selling	  familiar	  brands	  at	  familiar	  prices.	  McCord	  hospital,	  for	  example,	  a	  common	  site	  for	  clinical	  tourists543	  in	  Durban,	  is	  located	  at	  the	  edge	  of	  a	  wealthy	  and	  mostly	  white	  part	  of	  town	  where	  gated	  villas	  and	  apartment	  complexes	  compete	  for	  views	  of	  the	  Indian	  Ocean.	  Nearby	  coffee	  shops	  offer	  wireless	  internet,	  scones	  for	  breakfast	  and	  pizza	  topped	  with	  avocado,	  butternut	  and	  feta	  for	  dinner.	  Local	  flavor	  can	  be	  found	  at	  down-­‐town	  tourist	  traps:	  Indian	  spice	  markets,	  the	  muthi	  market	  (where	  African	  women	  in	  traditional	  attire	  sell	  herbs	  and	  roots),	  and	  beachfront	  stalls	  selling	  beaded	  jewelry,	  Zulu	  hats	  and	  carvings	  from	  all	  over	  the	  continent.	  Durban	  presents	  itself	  to	  biomedical	  visitors	  as	  a	  stuffy	  suburb	  of	  a	  sunny	  beach	  town.	  Those	  with	  aspirations	  to	  discover	  the	  “real”	  Africa	  often	  find	  they	  need	  to	  leave	  the	  confines	  of	  the	  city	  to	  do	  so.	  	   Relatively	  few	  visitors	  sought	  out	  Msinga.	  For	  many	  South	  Africans	  Tugela	  Ferry	  and	  the	  surrounding	  Msinga	  represent	  a	  “deep,	  deep”	  rural	  Africa	  in	  its	  most	  intimidating	  and	  devastating	  form.	  South	  Africans	  remember	  Msinga	  as	  the	  site	  of	  intense	  “faction	  fighting”	  or	  “tribal	  violence,”	  in	  the	  1980s	  and	  1990s	  and	  as	  far	  back	  as	  the	  1880s.544	  During	  the	  apartheid	  era,	  Msinga	  was	  emblematic	  for	  South	  Africa’s	  long-­‐standing	  legacy	  of	  segregation	  and	  devastating	  policies	  of	  the	  apartheid	  government	  that	  actively	  removed	  black	  people	  from	  their	  homes	  and	  relocated	  them	  to	  some	  of	  the	  least	  desirable	  territories	  of	  the	  
                                                543	  I	  borrow	  this	  term	  from	  Claire	  Wendland,	  “Moral	  Maps	  and	  Medical	  Imaginaries:	  Clinical	  Tourism	  at	  Malawi’s	  College	  of	  Medicine,”	  American	  Anthropologist	  114,	  no.1	  (2012):	  108-­‐122.	  544	  Jonathan	  Clegg,	  “Ukubuyisa	  Isidumbu	  -­‐	  Bringing	  Back	  the	  Body":	  An	  Examination	  into	  the	  Ideology	  of	  Vengeance	  in	  the	  Msinga	  and	  Mpofana	  Rural	  Locations.	  (1882-­‐1944).,”	  in	  Working	  Papers	  in	  
Southern	  African	  Studies,	  ed.	  P.	  Bonner,	  1979.	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country.	  Due	  to	  low	  rainfall	  and	  poor	  soil,	  only	  limited	  parts	  of	  Msinga	  were	  suitable	  for	  cultivation	  even	  before	  people	  were	  concentrated	  there.	  As	  early	  as	  1846,	  the	  first	  British	  Magistrate	  assigned	  to	  the	  Msinga	  region	  was	  dismayed	  to	  arrive	  in	  an	  area	  as	  “barren	  as	  the	  sand	  of	  Arabia.”545	  Today,	  the	  area	  is	  still	  known	  for	  deadly	  criminal	  and	  political	  violence,	  crushing	  poverty	  and	  disease,	  as	  well	  as	  a	  strong	  adherence	  to	  traditional	  Zulu	  culture,	  including	  polygamy,	  practices	  of	  deference	  and	  respect	  (ruling	  the	  relationships	  between	  women	  and	  men)	  and	  the	  keeping	  of	  cattle	  and	  goats.546	  The	  circulating	  notions	  and	  mental	  images	  are	  dramatic	  –	  one	  Bed	  and	  Breakfast	  owner	  in	  a	  more	  quaint	  part	  of	  KwaZulu-­‐Natal	  asked	  a	  friend	  living	  in	  Tugela	  Ferry	  how	  she	  coped	  with	  hearing	  the	  screams	  of	  the	  women	  being	  raped	  at	  night;	  another	  friend	  of	  mine	  once	  asked	  me	  how	  often	  I	  heard	  gun-­‐shots.547	  As	  a	  1990	  book	  review	  in	  the	  New	  York	  Times	  put	  it,	  “Msinga	  is	  one	  of	  the	  most	  violent,	  most	  ecologically	  devastated	  places	  in	  South	  Africa.”548	  One	  person	  who	  shaped	  both	  South	  African	  and	  international	  outsiders’	  perceptions	  of	  the	  Msinga	  region	  is	  South	  African	  journalist	  and	  author	  Rian	  Malan.	  In	  the	  final	  chapters	  of	  his	  internationally	  circulated	  best-­‐selling	  memoir	  My	  Traitor’s	  Heart,	  Malan	  engages	  with	  simultaneously	  beautiful	  and	  devastating	  images	  of	  Msinga.549	  Throughout	  the	  book,	  Malan	  explores	  his	  social	  position	  and	  conscience	  as	  a	  white,	  Afrikaaner,	  South	  African	  who	  identifies	  as	  an	  anti-­‐apartheid	  liberal	  expat	  in	  the	  US,	  yet	  finds	  himself	  both	  unable	  to	  
                                                545	  Thanks	  to	  Jeffrey	  Guy	  for	  this	  quote.	  I	  don’t	  currently	  have	  the	  correct	  citation	  for	  the	  source.	  546	  I	  am	  not	  claiming	  that	  these	  accounts	  are	  accurate	  in	  any	  simple	  way,	  but	  that	  these	  are	  the	  dominant	  circulating	  descriptions.	  547	  The	  answers	  to	  those	  questions:	  though	  no	  doubt	  women	  were	  raped	  in	  Msinga	  and	  throughout	  the	  world	  during	  my	  stay	  there,	  I	  never	  heard	  their	  cries;	  I	  also	  never	  heard	  gun-­‐shots	  (though	  I	  heard	  several	  stories	  about	  shootings).	  548	  “Books	  of	  The	  Times;	  The	  Harsh	  Judgments	  of	  a	  White	  South	  African,”	  New	  York	  Times,	  accessed	  June	  2,	  2012,	  http://www.nytimes.com/1990/01/19/books/books-­‐of-­‐the-­‐times-­‐the-­‐harsh-­‐judgments-­‐of-­‐a-­‐white-­‐south-­‐african.html?pagewanted=all&src=pm.	  549	  Rian	  Malan,	  My	  Traitor’s	  Heart:	  a	  South	  African	  Exile	  Returns	  to	  Face	  His	  Country,	  His	  Tribe,	  &	  His	  
Conscience	  (New	  York:	  Vintage	  International,	  1990).	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process	  his	  white	  guilt	  and	  unable	  to	  identify	  with	  black	  Africans	  in	  the	  rapidly	  changing	  South	  Africa	  of	  the	  late	  1980s.	  In	  an	  attempt	  to	  gain	  meaning	  from	  these	  conflicted	  emotions,	  he	  travels	  to	  Msinga	  to	  seek	  out	  Creina	  Alcock,	  the	  widow	  of	  Neil	  Alcock,	  a	  white	  liberal	  who	  immersed	  himself	  in	  rural	  Msinga	  life	  and	  dedicated	  himself	  to	  helping	  Zulu	  agricultural	  development	  but	  ended	  up	  being	  murdered.550	  The	  book	  was	  read	  by	  many	  of	  the	  mid	  to	  long-­‐term	  clinical	  visitors	  to	  Tugela	  Ferry,	  and	  also	  by	  some	  of	  the	  short-­‐term	  medical	  residents.	  In	  the	  book,	  Malan	  grants	  that	  the	  Msinga	  landscape	  at	  sunrise	  has	  “enormous	  dramatic	  potential,”551	  but	  he	  also	  describes	  Msinga	  as	  a	  “shithole”552	  and	  “famine-­‐stricken	  hellhole,”553	  which	  is	  incredibly	  resistant	  to	  change	  or	  improvement.	  Malan	  struggles	  to	  “explain”	  Msinga	  and	  its	  significance:	  	  Msinga	  is	  …	  Oh,	  God,	  how	  do	  I	  explain	  Msinga?	  Msinga	  is	  wild,	  and	  yet	  it	  is	  not	  leaping	  with	  buck	  and	  lions.	  There	  is	  probably	  not	  a	  single	  antelope	  left	  alive	  in	  the	  entire	  valley.	  The	  district	  is	  crisscrossed	  by	  tar	  roads	  and	  power	  lines,	  packed	  with	  tin-­‐roofed	  shanties	  and	  mud	  huts.	  It	  is	  a	  place	  of	  head-­‐spinning	  contrasts.	  In	  Msinga,	  you	  see	  black	  men	  driving	  goats,	  and	  black	  men	  driving	  BMWs.	  You	  see	  Zulu	  women	  going	  down	  on	  all	  fours	  at	  the	  feet	  of	  nondescript	  old	  men	  in	  ill-­‐fitting	  three-­‐piece	  suits;	  they	  are	  tribal	  chiefs	  or	  headmen,	  and	  must	  be	  shown	  respect.	  You	  see	  bare-­‐breasted	  Zulu	  maidens	  with	  shaved	  heads	  and	  bodies	  draped	  with	  beads.	  They	  seem	  to	  have	  stepped	  out	  of	  National	  Geographic,	  but	  if	  you	  look	  closer	  you	  see	  that	  they’re	  wearing	  Day-­‐Glo	  leg	  warmers	  and	  running	  shoes.	  You	  see	  men	  in	  traditional	  dress	  carrying	  briefcases	  through	  the	  bush,	  and	  school-­‐uniformed	  teenagers	  dancing	  through	  the	  wastelands	  with	  ghetto	  blasters	  on	  their	  shoulders.	  So	  Msinga	  
isn’t	  quaint,	  and	  it’s	  not	  storybook	  Africa.	  It	  is	  a	  sprawling	  rural	  slum,	  infested	  with	  dope	  smugglers,	  gunrunners,	  and	  bandits.	  It	  is	  the	  iron	  age	  shat	  squalling	  and	  sullen	  into	  the	  twentieth	  century.	  Its	  people	  look	  broken	  as	  they	  eat	  the	  dust	  of	  your	  passing	  car,	  but	  in	  their	  hearts	  they	  are	  proud	  and	  untamed,	  and	  utterly	  ungovernable	  by	  anyone554	  (emphasis	  added).	  	  	  How	  Malan	  knows	  what	  is	  in	  Msinga	  residents’	  hearts	  I	  cannot	  say,	  but	  in	  other	  words,	  Msinga	  is	  a	  confusing	  mess	  that	  simultaneously	  conforms	  to	  African	  stereotypes	  and	  defies	  them.	  I	  quote	  Malan	  at	  length	  not	  to	  argue	  that	  his	  impressions	  of	  have	  shaped	  
                                                550	  Ibid.	  551	  Ibid.,	  344.	  552	  Ibid.,	  360.	  553	  Ibid.,	  367.	  554	  Ibid.,	  354–355.	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tuberculosis	  research	  in	  Tugela	  Ferry	  in	  any	  meaningful	  way,	  but	  as	  a	  tool	  with	  which	  to	  explore	  the	  complex	  and	  confusing	  ways	  in	  which	  global	  health	  research	  relies	  on	  the	  ambiguous	  and	  contradictory	  juxtaposition	  of	  tradition	  and	  modernity	  or	  poverty	  and	  commercial	  (and	  academic)	  resources.	  Visitors	  and	  locals	  alike	  emphasize	  that	  Msinga	  is	  a	  traditional	  place.	  The	  logo	  of	  the	  research	  and	  care	  organization,	  Philanjalo,	  is	  a	  sketch	  of	  an	  iconic	  traditional	  Zulu	  thatched-­‐roof	  rondavel	  (round-­‐hut)	  on	  a	  hill	  surrounded	  by	  trees;	  photographs	  from	  Msinga	  often	  feature	  women	  in	  traditional	  Zulu	  attire.	  Modern	  Tugela	  Ferry	  residents	  are	  often	  fashion	  conscious	  and	  dress	  in	  trendy	  jeans	  and	  tailored	  blouses	  but	  they	  also	  show	  off	  their	  Zulu	  style,	  documenting	  their	  tradition-­‐inspired	  wedding	  and	  heritage	  day	  outfits	  of	  leather	  loin	  cloths	  and	  shields,	  or	  beaded	  necklaces	  and	  skirts	  on	  facebook.	  In	  narratives	  about	  Msinga	  and	  Tugela	  Ferry,	  appealing	  images	  of	  a	  traditional,	  rural,	  self-­‐sustaining,	  self-­‐contained	  agricultural	  life	  were	  easily,	  yet	  uncomfortably,	  linked	  with	  less	  appealing	  notions	  of	  African	  poverty,	  violence,	  lack	  of	  infrastructure	  (roads,	  electricity,	  water,	  sewage,	  education),	  corruption,	  cultural	  “backwardness”	  and	  disease.	  Hans	  Human,	  the	  CEO	  of	  the	  Church	  of	  Scotland	  Hospital	  in	  Tugela	  Ferry	  between	  2005	  and	  2011,	  is	  a	  white	  Afrikaans-­‐speaker	  who	  had	  worked	  his	  way	  through	  municipal	  bureaucracy	  positions	  in	  small	  towns	  of	  different	  South	  African	  provinces.	  When	  he	  decided	  to	  take	  the	  job	  in	  Tugela	  Ferry	  he	  imagined	  the	  area	  as	  a	  calm,	  restorative	  place:	  “When	  you	  drive	  through	  small	  little	  towns,	  you	  see	  the	  old	  people,	  sitting,	  moving	  after	  the	  sunshine,	  at	  the	  rondavel.555	  You	  see	  the	  women	  working	  in	  the	  mealies,556	  [who]	  carry	  wood,	  everything	  looks	  so	  peaceful,	  and	  so	  quiet,	  and	  so	  relaxed.”557	  His	  first	  impressions	  of	  a	  rural	  idyll	  were	  deceiving.	  Instead	  he	  found	  a	  stressful	  work-­‐environment,	  where	  the	  staff	  was	  
                                                555	  Rondavel	  =traditional	  Zulu	  round	  hut.	  556	  Mealies	  =	  Field	  corn.	  557	  Hans	  Human,	  interview	  by	  author,	  14	  January	  2011,	  Tugela	  Ferry,	  South	  Africa.	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embroiled	  in	  institutional	  politics	  and	  infighting:	  “My	  perception	  quickly	  died	  off.	  From	  ‘this	  peaceful	  little	  village’	  to	  ‘It’s	  just	  chaos.’”558	  Dr.	  Ade	  Apelehin,	  a	  Nigerian	  physician	  who	  came	  to	  Tugela	  Ferry	  as	  a	  stepping	  stone	  towards	  geographic	  upward	  mobility,	  similarly	  thought	  that	  a	  job	  in	  Tugela	  Ferry	  would	  be	  a	  wholesome	  change	  from	  his	  urban	  hospital	  job.559	  Years	  earlier,	  during	  an	  assignment	  in	  rural	  Nigeria,	  he	  said	  he	  enjoyed	  relative	  calm	  and	  a	  high	  degree	  of	  respect.	  Yet	  he	  soon	  learned	  that	  African	  rural	  quaintness	  was	  not	  the	  same	  everywhere.	  He	  had	  known	  about	  high	  rates	  of	  tuberculosis	  and	  AIDS,	  but	  also	  struggled	  with	  xenophobia,	  professional	  jealousies,	  and	  a	  constantly	  perceived	  undercurrent	  of	  the	  risk	  of	  violence.560	  The	  Time	  Magazine	  article	  that	  launched	  Dr.	  Moll’s	  AIDS	  work	  to	  international	  prominence	  (and	  the	  attention	  of	  President	  Bush’s	  speech-­‐writers)	  in	  2001	  presented	  Msinga	  as	  one	  of	  the	  many	  sites	  of	  a	  generic	  African	  nightmare,	  where	  AIDS	  is	  a	  fire	  in	  the	  “dry	  timber	  of	  African	  societies,”561	  which	  is	  killing	  millions.	  It	  is	  a	  silent	  fire,	  not	  evoking	  the	  outrage	  and	  action	  it	  deserves	  due	  to	  overwhelming	  stigma	  and	  denial	  that	  “cannot	  keep	  the	  virus	  at	  bay.”	  The	  author	  describes	  how,	  accompanied	  by	  Dr.	  Tony	  Moll,	  “who	  has	  driven	  [her]	  up	  the	  dirt	  track	  from	  the	  350-­‐bed	  hospital	  he	  heads	  in	  Tugela	  Ferry,”	  she	  noticed	  the	  potential	  -­‐	  yet	  unfulfilled	  –	  beauty	  and	  promise	  of	  Msinga’s	  landscape:	  “The	  spectacular	  view	  of	  hills	  and	  veld	  would	  gladden	  a	  well	  man,	  but	  the	  22-­‐year-­‐old	  we	  will	  call	  Fundisi	  Khumalo,	  though	  he	  does	  not	  know	  it,	  has	  AIDS,	  and	  his	  eyes	  seem	  to	  focus	  inward	  on	  his	  simple	  fear.”	  According	  to	  McGeary,	  Msinga	  at	  this	  time	  was	  not	  a	  place	  to	  live,	  but	  a	  place	  to	  
                                                558	  Ibid.	  559	  Pay	  was	  also	  better	  since	  government	  physicians	  working	  in	  Tugela	  Ferry	  receive	  hardship	  pay	  for	  working	  in	  a	  former	  homeland	  area.	  The	  difficulty	  of	  recruiting	  physicians	  also	  meant	  that	  Dr.	  Apelehin,	  a	  relatively	  young	  doctor,	  was	  promoted	  to	  a	  higher	  ranking	  physician	  than	  he	  would	  have	  been	  in	  Pietermaritzburg.	  560	  Ade	  Apelehin,	  interview	  by	  author,	  24	  February	  2011,	  Pietermaritzburg,	  South	  Africa.	  561	  Johanna	  Mcgeary,	  “Death	  Stalks	  A	  Continent,”	  Time.com,	  February	  12,	  2001,	  http://www.time.com/time/magazine/article/0,9171,999190,00.html.	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die.	  Mr	  Khumalo	  had	  been	  working	  in	  Johannesburg,	  and	  knew	  many	  other	  men	  who	  were	  “on-­‐and	  off	  sick.”	  “When	  they	  fell	  too	  ill	  to	  work	  anymore,	  like	  him,	  they	  straggled	  home	  to	  rural	  villages	  like	  Msinga	  Top.”562	  Msinga	  was	  not	  just	  the	  place	  of	  final	  despair,	  however.	  McGeary	  found	  hope	  from	  this	  despair	  in	  the	  fact	  that	  “every	  day	  good	  people	  are	  doing	  good	  things.	  Like	  Dr.	  Moll,	  who	  uses	  his	  after-­‐job	  time	  and	  his	  own	  fund	  raising	  to	  run	  an	  extensive	  volunteer	  home-­‐care	  program	  in	  KwaZulu-­‐Natal.”	  Msinga	  was	  also	  a	  place	  for	  redemption	  and	  respite.	  As	  one	  Cape	  Town	  Christian	  blogger	  stated	  after	  returning	  from	  a	  mission	  trip:	  “Msinga	  is	  about	  hills	  and	  hills	  of	  dry	  grasslands,	  breathtaking	  sunsets,	  life-­‐changing	  spiritual	  sessions,	  resting	  and	  finding	  yourself	  part	  of	  a	  new	  family,	  the	  family	  of	  Christ.	  It's	  about	  reaching	  out	  to	  those	  who	  really	  need	  it	  the	  most,	  it's	  about	  forgetting	  about	  yourself	  for	  at	  least	  two	  weeks,	  letting	  God	  work	  through	  you	  and	  it's	  about	  meeting	  and	  learning	  from	  new	  and	  interesting	  people.”563	  At	  this	  point	  you,	  the	  reader,	  may	  wonder	  what	  all	  these	  meandering	  and	  contradictory	  impressions	  of	  Msinga	  really	  mean	  for	  drug-­‐resistant	  tuberculosis	  or	  global	  health	  research.	  	  In	  my	  view,	  the	  simultaneous	  conception	  of	  Tugela	  Ferry	  as	  rural	  African	  idyll	  and	  African	  disaster	  was	  not	  just	  incidental	  to	  the	  HIV	  and	  tuberculosis	  research	  and	  care	  that	  took	  place	  there.	  In	  the	  1980s	  Dr.	  Moll,	  who	  had	  recently	  completed	  his	  medical	  training	  in	  Cape	  Town,	  South	  Africa,	  found	  himself	  seeking	  out	  Tugela	  Ferry	  as	  a	  place	  to	  practice	  bread	  and	  butter	  medicine	  as	  a	  Christian	  and	  to	  fulfill	  his	  sense	  of	  mission	  among	  people	  who	  needed	  him.564	  He	  has	  been	  described	  as	  a	  country	  doctor	  who	  actively	  eschewed	  high-­‐powered	  academic	  medicine	  and	  research	  at	  the	  beginning	  of	  his	  career	  in	  
                                                562	  Ibid.	  563	  “Huis	  Francie,”	  Msinga	  2011	  (blog),	  accessed	  June	  6,	  2012,	  http://www0.sun.ac.za/hkfranci/pages/nuus/view.php?id=23.	  564	  Anthony	  Moll,	  interview	  by	  author,	  13	  May	  2011,	  Tugela	  Ferry,	  South	  Africa.	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order	  to	  live	  in	  a	  remote	  area.565	  At	  the	  same	  time,	  international	  biomedical	  professionals	  like	  Prof.	  Friedland	  found	  themselves	  drawn	  to	  Tugela	  Ferry	  by	  the	  opportunity	  to	  conduct	  such	  research	  at	  the	  peak	  of	  a	  devastating	  and	  internationally	  important	  epidemic	  while	  having	  a	  maximum	  impact	  on	  an	  identifiable	  community.566	  In	  the	  wake	  of	  Dr.	  Friedland’s	  involvement	  in	  Tugela	  Ferry,	  dozens	  of	  US-­‐trained	  physicians,	  medical	  students	  and	  nursing	  students	  (among	  others)	  sought	  out	  opportunities	  to	  work	  in	  Tugela	  Ferry,	  as	  well.	  For	  his	  part,	  Dr.	  Moll	  turned	  out	  not	  to	  be	  a	  “simple”	  country	  doctor	  and	  became	  comfortable	  conducting	  research	  and	  representing	  XDR-­‐TB	  to	  the	  international	  community	  at	  HIV/AIDS	  and	  tuberculosis	  meetings	  around	  the	  world.	  Yet	  the	  rural	  and	  remote	  nature	  of	  Tugela	  Ferry	  as	  a	  research	  location,	  and	  the	  intense	  needs	  of	  the	  poor,	  rural,	  black	  and	  South	  African	  study	  population	  remained	  central	  to	  Friedland	  and	  Moll’s	  presentations	  on	  XDR-­‐TB.	  The	  local	  details	  get	  somewhat	  lost	  in	  front	  of	  an	  international	  audience,	  however,	  as	  Tugela	  Ferry	  morphs	  into	  a	  generic	  sub-­‐Saharan	  African	  site	  of	  biomedical	  and	  social	  intervention.	  The	  rural	  African	  location	  of	  Tugela	  Ferry	  remained	  crucial	  in	  the	  recruitment	  of	  clinicians	  and	  researchers	  to	  the	  area.	  Researchers	  almost	  seemed	  to	  work	  off	  a	  generic,	  though	  compelling,	  script	  when	  describing	  the	  place	  to	  biomedical	  audiences.	  Dr.	  Sheela	  Shenoi,	  who	  was	  a	  Yale	  infectious	  disease	  fellow	  conducting	  operational	  research	  in	  Tugela	  Ferry	  under	  Dr.	  Gerald	  Friedland’s	  mentorship,	  who	  also	  supervised	  visiting	  medical	  residents	  working	  in	  Tugela	  Ferry’s	  HIV	  clinic	  explained	  to	  me	  how	  she	  described	  Tugela	  Ferry	  to	  a	  Yale	  audience.	  (I	  asked	  her	  what	  her	  “spiel”	  is.)	  	  The	  spiel	  is	  that	  this	  is	  a	  small,	  very	  rural	  area,	  serving	  about	  200,000	  people,	  at	  a	  district	  level	  hospital	  that’s	  serving	  a	  very	  traditional	  Zulu	  population,	  who	  are	  very	  poor	  and	  disadvantaged,	  and	  in	  an	  area	  that’s	  been	  hugely	  affected	  by	  HIV	  and	  TB,	  and	  there’s	  a	  large-­‐scale	  epidemic	  of	  both	  HIV	  and	  TB	  here,	  reflective	  of	  HIV/TB	  in	  -­‐	  generally	  -­‐	  in	  sub-­‐Saharan	  Africa.	  There’s	  a	  third	  epidemic	  of	  MDR/XDR-­‐TB	  here	  
                                                565	  Graeme	  Meintjes	  interview	  by	  Erica	  Dwyer,	  Cape	  Town,	  South	  Africa,	  May	  14,	  2010.	  566	  Clearly	  there	  is	  something	  to	  be	  said	  here	  about	  the	  perceived	  moral	  value	  of	  helping	  (helpless)	  rural	  “traditional	  communities”	  versus	  helping	  disparate,	  mobile,	  urban	  moderns.	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that	  complicates	  everything.	  But	  that	  there	  is	  a	  lot	  of	  fascinating	  clinical	  pathology	  to	  be	  learned,	  and	  the	  exposure	  to	  HIV	  and	  TB	  is	  immense,	  and	  that	  is	  something	  you	  will	  not	  get	  anywhere	  else;	  certainly	  not	  in	  the	  US.	  And	  [visiting	  doctors	  are]	  just	  going	  to	  have	  a	  fantastic	  clinical	  experience.	  You	  know,	  the	  other	  part	  of	  that	  is	  to	  understand	  a	  little	  bit	  about	  traditional	  Zulu	  culture,	  and	  to	  learn	  about	  the	  interplay	  between	  social-­‐cultural	  factors	  and	  the	  relationship	  to	  HIV	  and	  TB.	  Obviously	  there’s	  a	  limit	  to	  what	  you	  can	  do	  with	  that,	  but	  it’s	  not	  solely	  clinical	  practice.	  So,	  like	  what	  are	  ARVs,	  and	  the	  side	  effects	  of	  TB	  meds	  and	  stuff	  like	  that.567	  	  	   In	  her	  description,	  Dr.	  Shenoi	  considers	  both	  generalizable	  and	  unique	  aspects	  of	  Tugela	  Ferry.	  She	  emphasizes	  that	  Tugela	  Ferry	  is	  generalizable	  to	  sub-­‐Saharan	  Africa	  as	  a	  
whole	  in	  as	  much	  as	  it	  is	  rural,	  small,	  traditional,	  poor,	  and	  HIV/TB	  affected,	  as	  well	  as	  a	  great	  clinical	  training	  site	  superior	  to	  opportunities	  available	  in	  the	  US.	  Tugela	  Ferry	  is	  
unique	  in	  its	  emphasis	  on	  MDR/XDR-­‐TB,	  and	  in	  its	  particular	  (limited)	  local	  color,	  where	  social	  context	  is	  important,	  though	  primarily	  interesting	  as	  it	  relates	  to	  clinical	  treatment.	  	   Similar	  pitches	  were	  used	  in	  promotional	  materials	  used	  by	  Yale	  and	  Philanjalo.	  Shenoi	  stressed	  that	  Tugela	  Ferry	  is	  in	  a	  “Zulu”	  area	  –	  not	  simply	  African	  –	  and	  mentioned	  the	  unique	  status	  of	  drug-­‐resistant	  tuberculosis	  in	  this	  region.	  The	  rest	  of	  the	  description,	  however,	  applies	  to	  many	  sites	  of	  global	  health	  research	  in	  sub-­‐Saharan	  Africa.	  It	  ignores	  some	  of	  the	  darker	  things	  that	  preoccupy	  South	  Africans	  when	  they	  discuss	  Tugela	  Ferry	  –	  including	  the	  risk	  of	  violence	  and	  the	  risk	  of	  infection	  with	  deadly	  tuberculosis.	  Also	  not	  incorporated	  is	  the	  fact	  that	  visitors	  who	  come	  to	  this	  “small,	  very	  rural”	  area	  find	  themselves	  in	  the	  bustling	  trade	  town	  of	  Tugela	  Ferry,	  living	  in	  comfortable	  accommodations	  within	  a	  gated	  compound.	  	   This	  last	  point	  could	  lead	  to	  surprise.	  One	  medical	  student	  who	  came	  to	  Tugela	  Ferry	  on	  a	  clinical	  fellowship	  blogged	  praises	  for	  the	  comforts	  that	  were	  available:	  “My	  new	  place,	  [...]	  is	  pretty	  plush.	  It	  is	  fully	  equipped	  with	  electricity	  which	  runs	  an	  air	  conditioner,	  ceiling	  fans,	  refrigerator,	  and	  microwave	  reliably.	  Likewise,	  there	  is	  running	  hot	  and	  cold	  
                                                567	  Sheela	  Shenoi,	  interview	  by	  author,	  20	  August	  2010,	  Tugela	  Ferry,	  South	  Africa.	  
 250 
water	  that	  leads	  to	  functioning	  toilets,	  sinks,	  shower	  and	  even	  a	  washing	  machine.	  Last,	  but	  certainly	  not	  least,	  in	  the	  amenities	  category	  is	  the	  wireless	  internet	  that	  is	  allowing	  me	  to	  write	  this	  post	  -­‐	  it	  is	  sometimes	  a	  slow	  connection,	  but	  it	  gets	  the	  job	  done”568	  [emphasis	  in	  original].	  Zahir	  Kanjee,	  who	  first	  went	  to	  Tugela	  Ferry	  as	  a	  Yale	  medical	  student	  to	  conduct	  research	  on	  infection	  control	  in	  2007	  also	  found	  the	  accommodations	  “much	  nicer	  than	  [he]	  expected”	  and	  “pretty	  comfortable.”569	  He	  came	  to	  the	  conclusion	  that	  “practicing	  medicine	  in	  resource-­‐poor	  settings	  […]	  can	  be	  very	  much	  like	  practicing	  medicine	  in	  other,	  non-­‐resource-­‐poor	  settings.”570	  Years	  later	  he	  expressed	  regret	  about	  the	  lack	  of	  direct	  community	  contact	  during	  his	  stay:	  “I	  didn’t	  go	  out	  in	  the	  community	  a	  whole	  lot,	  I	  didn’t	  make	  a	  lot	  of	  friends	  out	  here.	  I	  worked.	  A	  lot.”571	  Dzovag	  Minassian,	  a	  doctor	  who	  came	  to	  Tugela	  Ferry	  for	  five	  weeks	  as	  part	  of	  the	  Johnson	  and	  Johnson	  global	  scholars	  program	  in	  2011,	  and	  wrote	  a	  highly	  readable	  blog	  about	  her	  experiences,	  was	  less	  impressed	  with	  her	  accommodations.572	  While	  the	  students	  mentioned	  above	  blogged	  frequently	  about	  other	  visiting	  Americans	  at	  the	  hospital,	  Minassian	  presented	  herself	  as	  a	  lonely,	  heroic,	  white	  doctor	  roughing	  it	  in	  difficult	  circumstances	  as	  she	  provided	  medicines	  to	  masses	  of	  sick	  Zulus.573	  The	  importance	  of	  well-­‐trodden	  tropes	  about	  Africa	  was	  made	  explicit	  in	  her	  narrative:	  just	  as	  Rian	  Malan	  compared	  the	  inhabitants	  of	  Msinga	  to	  ethnographic	  photographs	  in	  National	  Geographic,574	  Minassian	  compares	  herself	  to	  explorers	  on	  the	  cover	  of	  National	  Geographic.	  She	  finds	  inspiration	  for	  her	  weekends	  away	  from	  the	  hospital	  in	  the	  luxury	  getaways	  depicted	  in	  
                                                568	  “Mary	  Duke	  Biddle	  Clinical	  Scholars	  Program"	  	  Center	  for	  Global	  Health	  -­‐	  Stanford	  University	  School	  of	  Medicine	  (blog),	  accessed	  October	  5,	  2012,	  http://globalhealth.stanford.edu/marydukescholarsprogram/2012/02/greetings-­‐from.html.	  569	  Zahir	  Kanjee,	  Zahir	  in	  Tugela	  (blog)	  2007,	  zahirintugela.blogspot.com.	  570	  Ibid.	  571	  Zahir	  Kanjee,	  interview	  by	  author,	  25	  August,	  2010,	  Tugela	  Ferry,	  South	  Africa.	  572	  “	  Global	  Health	  Scholars	  Program"	  Yale	  University,	  accessed	  September	  8,	  2012,	  http://globalhealthscholar.yale.edu/index.aspx.	  573	  Dzovag	  Minassian,	  Red	  Chair	  Radio	  (blog)	  2011,	  redchairradio.wordpress.com.	  574	  Malan,	  My	  Traitor’s	  Heart,	  354.	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Condé	  Nast	  Traveler.	  She	  articulately	  conveys	  Tugela	  Ferry	  as	  a	  place	  that	  is	  and	  is	  not	  African	  and	  rural	  and	  describes	  it,	  among	  other	  things,	  as	  “anytownafrica,”	  “a	  bustling	  rurapolis,”	  and	  “where	  the	  donkey	  croaks.”	  Other	  expats	  and	  white	  helpers	  tend	  to	  disappear	  from	  her	  narrative,	  and	  the	  trilingual	  Zulu	  law	  student	  who	  babysits	  for	  her	  toddler-­‐aged	  son	  becomes	  simply	  a	  Zulu	  nanny.	  She	  assumes	  herself,	  her	  son,	  and	  a	  friend	  who	  accompanied	  her,	  the	  center	  of	  a	  racially	  precarious	  spectacle:	  “Two	  white	  women	  in	  a	  shiny	  Chevy,	  a	  blond-­‐haired	  boy	  with	  piercing	  blue	  eyes	  and	  a	  khaki	  hat	  in	  a	  carseat	  in	  the	  back	  […].	  He	  is	  craning	  his	  neck	  to	  soak	  in	  the	  unfamiliar	  scene	  of	  people	  spilling	  into	  the	  road	  balancing	  sacks	  of	  potatoes	  on	  their	  heads,	  toting	  sleeping	  babies	  bundled	  tightly	  in	  towels	  cinched	  around	  their	  waists,	  pushing	  wheelbarrows	  or	  pulling	  cattle.	  And	  they	  are	  staring	  back.”575	  Echoing	  Conrad’s	  Heart	  of	  Darkness,	  Minassian	  tries	  to	  “make	  sense	  of	  how	  anyone,	  including	  ourselves,	  can	  stay	  afloat	  in	  this	  wild	  place.”576	  After	  staring	  death	  in	  the	  face	  at	  the	  HIV	  clinic,	  she	  finds	  comfort	  in	  the	  fact	  that	  in	  the	  absence	  of	  a	  sense	  of	  time	  or	  urgency,	  and	  away	  from	  her	  American	  city	  obligations,	  she	  learns	  to	  let	  things	  go	  and	  to	  focus	  on	  the	  big	  things,	  primarily	  her	  toddler-­‐age	  son.577	  Thus	  Msinga	  is	  experienced	  in	  multiple,	  intensely	  loaded	  ways:	  a	  hostile	  and	  deceptive	  place	  of	  dark	  violence	  and	  despair;	  a	  redemptive	  place	  where	  meaning	  can	  be	  found;	  a	  place	  of	  community	  and	  wholesome	  values;	  an	  under-­‐resourced,	  rural	  place	  waiting	  for	  an	  intervention.	  Malan	  calls	  the	  notion	  of	  rurality	  into	  question	  with	  his	  description	  of	  Msinga	  not	  as	  storybook	  Africa,	  but	  a	  “sprawling	  rural	  slum;”	  similarly	  ambivalent	  is	  Minassian’s	  use	  of	  the	  term	  “rurapolis.”	  Msinga’s	  being	  “rural”	  means	  different	  things	  to	  different	  people:	  For	  Hans	  Human	  and	  Ade	  Apelehin,	  rural	  deceptively	  meant	  peaceful.	  For	  American	  Peace	  Corps	  workers	  and	  student	  missionaries	  from	  Cape	  Town,	  
                                                575	  Dzovag	  Minassian,	  Red	  Chair	  Radio	  (blog)	  2011,	  redchairradio.wordpress.com.	  576	  Ibid.	  577	  Ibid.	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rural	  often	  meant	  dealing	  with	  extensive	  language	  difficulties.	  One	  urban	  Zulu	  research	  worker	  had	  thought	  that	  rural	  people	  were	  particularly	  friendly	  until	  she	  came	  to	  Msinga	  and	  found	  the	  population	  polite,	  but	  distant.	  Several	  visiting	  Americans	  described	  difficulties	  connecting	  with	  “locals”	  that	  violated	  their	  expectations	  for	  close	  relationships	  with	  their	  rural	  neighbors.	  As	  one	  American	  student	  expressed,	  it	  was	  rather	  strange	  to	  travel	  all	  the	  way	  to	  South	  Africa	  to	  spend	  evenings	  and	  weekends	  with	  Americans	  (and	  Europeans)	  from	  elite	  medical	  schools	  inside	  a	  gated	  compound.	  In	  many	  conversations	  rural	  simply	  implied	  a	  lack	  of	  basic	  infrastructure.	  Even	  as	  Tugela	  Ferry’s	  rural	  location	  and	  lack	  of	  resources	  seemed	  important	  to	  its	  essence	  as	  a	  site	  of	  global	  health	  research,	  Americans	  who	  spent	  time	  working	  there	  both	  undermined	  and	  reified	  the	  implied	  ideas	  about	  remoteness,	  hardship,	  and	  community.	  Sara	  Anjargolian,	  a	  photographer	  who	  accompanied	  Dr.	  Dzovag	  Minassian	  to	  Tugela	  Ferry	  for	  five	  weeks	  to	  document	  life	  with	  HIV,	  struggled	  –	  like	  many	  others	  –	  with	  the	  difficulties	  of	  connecting	  to	  an	  unfamiliar	  place	  on	  a	  tight	  timetable.	  She,	  too,	  needed	  to	  find	  a	  narrative	  that	  matched	  both	  her	  conceptions	  of	  herself	  and	  of	  rural	  Africa.	  For	  her,	  coming	  to	  Msinga	  became	  an	  exercise	  in	  redemption	  as	  she	  learned	  patience,	  and	  discovered	  how	  to	  “think	  like	  a	  Zulu,”	  as	  she	  put	  it	  in	  a	  TEDx	  talk	  about	  her	  work.578	  After	  initial	  challenges	  accessing	  her	  desired	  photographic	  subjects	  Anjargolian	  left	  town	  with	  some	  compelling	  images	  that	  emphasized	  the	  dignity	  of	  her	  photographic	  subjects.579	  Anjargolian	  was	  one	  of	  many	  photographers	  who	  had	  come	  through	  Tugela	  Ferry	  to	  document	  the	  suffering	  and	  resilience	  of	  “the	  Zulu	  people”	  in	  the	  face	  of	  AIDS	  and	  
                                                578	  TEDxYerevan	  -­‐	  Sara	  Anjargolian	  -­‐	  What	  the	  Zulu	  People	  Taught	  Me	  About	  Photography	  and	  Life,	  2011,	  http://www.youtube.com/watch?v=cfdthcNLoVw&feature=youtube_gdata_player.	  579	  TEDxYerevan	  -­‐	  Sara	  Anjargolian	  -­‐	  What	  the	  Zulu	  People	  Taught	  Me	  About	  Photography	  and	  Life.	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tuberculosis	  in	  the	  past	  10	  years.580	  In	  my	  own	  research	  in	  Tugela	  Ferry	  I	  often	  heard	  grumblings	  about	  photographers	  and	  the	  images	  they	  literally	  “took”	  from	  Tugela	  Ferry.	  People	  especially	  expressed	  concern	  about	  a	  style	  of	  photography	  (used	  by	  James	  Nachtwey,	  for	  example,)	  which	  emphasized	  the	  emaciated	  bodies	  of	  dying	  black	  subjects	  by	  employing	  the	  high	  contrast	  of	  well-­‐lit	  black-­‐and-­‐white	  images.	  One	  black	  HIV	  counselor	  broke	  polite	  racial	  protocol	  while	  referring	  to	  photography	  from	  Tugela	  Ferry	  that	  she	  had	  seen:	  “I	  think	  I	  am	  not	  going	  to	  be	  appropriate	  now.	  We	  as	  blacks	  feel	  […]	  ‘Why	  do	  they	  always	  have	  cases	  of	  black	  people?	  They	  don’t	  have	  maybe	  whites	  and	  if	  white,	  they	  are	  nice	  and	  they	  are	  good	  looking.	  Not	  very	  sick,	  you	  know?	  I	  just	  had	  that	  thing	  in	  my	  mind.	  That	  it’s	  not	  good	  and	  then	  we	  feel	  sad	  and	  bad	  for	  the	  person.	  Really	  bad	  for	  the	  person	  who	  is	  on	  the	  photos.”	  These	  photographs	  (of	  Nachtwey’s	  emaciated	  patients	  in	  hospital	  beds	  as	  well	  as	  Anjargolian’s	  nicely	  dressed	  TB	  patients	  in	  front	  of	  their	  houses)	  help	  represent	  the	  under-­‐resourced	  yet	  worthy	  place	  that	  is	  stressed	  the	  most	  in	  research	  presentations	  and	  papers,	  in	  photo-­‐essays	  and	  brochures,	  and	  which	  provides	  the	  justification	  for	  the	  expenditure	  of	  considerable	  resources	  and	  effort	  in	  conducting	  scientific	  research	  and	  initiating	  treatment	  interventions	  in	  countless	  global	  health	  locations	  around	  the	  world.	  It	  is	  the	  successful	  accumulation	  and	  analysis	  of	  data	  generated	  by	  this	  research	  which	  builds	  the	  foundations	  for	  conference	  presentations,	  journal	  publications	  and	  academic	  careers.	  Yet	  it	  is	  a	  sense	  of	  adventure,	  moral	  obligation,	  and	  complex	  set	  of	  assumptions	  about	  the	  relationships	  of	  power	  and	  obligation	  between	  “us”	  and	  “them”	  that	  drives	  individuals	  to	  engage	  in	  the	  global	  health	  enterprise.581
                                                580	  Professional	  photographers	  include	  James	  Nachtwey,	  Damian	  Schumann	  and	  Jonas	  Steengard,	  among	  others.	  581	  Betsey	  Brada,	  “‘Not	  Here’:	  Making	  the	  Spaces	  and	  Subjects	  of	  ‘Global	  Health’	  in	  Botswana.”	  Culture,	  
Medicine,	  and	  Psychiatry	  35	  (2011):285–312.	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POSTLUDE:	  An	  Ongoing	  Crisis	  and	  the	  Tyranny	  of	  Koch	  	   In	  chapter	  1	  I	  argued	  that	  the	  story	  of	  public	  interest	  in	  tuberculosis	  can	  be	  told	  as	  a	  story	  of	  repeated	  cycles	  of	  escalation	  followed	  by	  retreat	  and	  decline,	  or,	  inversely,	  as	  “recurrent	  cycles	  of	  neglect	  followed	  by	  resurgence.”582	  This	  dissertation	  has	  followed	  XDR-­‐TB	  from	  its	  early	  stages	  as	  the	  predicted	  but	  as	  yet	  undocumented	  (and	  unnamed)	  consequence	  of	  imperfect	  and	  underfunded	  MDR-­‐TB	  treatment	  programs	  to	  its	  mature	  existence	  as	  a	  well-­‐documented,	  well-­‐studied	  infectious	  disease	  that	  threatened	  the	  health	  and	  lives	  of	  people	  across	  the	  globe,	  but	  especially	  in	  Tugela	  Ferry,	  South	  Africa.	  As	  we	  have	  seen,	  global	  emergency	  meetings	  were	  called,	  treatment	  pilot	  programs	  in	  Southern	  Africa	  were	  initiated,	  new	  HIV/TB	  research	  programs	  in	  South	  Africa	  obtained	  funding,	  and	  scores	  of	  people	  were	  drawn	  to	  Tugela	  Ferry	  to	  participate	  in	  the	  response	  to	  XDR-­‐TB.	  Tuberculosis	  care	  in	  Tugela	  Ferry	  was	  transformed	  as	  the	  local	  public	  health	  structure	  worked	  with	  international	  experts,	  local	  nurses,	  and	  motivated	  researchers	  to	  put	  in	  place	  a	  simultaneously	  innovative	  and	  pragmatic	  program	  for	  the	  community-­‐based	  management	  of	  drug-­‐resistant	  tuberculosis.	  The	  global	  narrative	  of	  XDR-­‐TB,	  with	  its	  media-­‐ready	  name	  that	  conjured	  up	  notions	  of	  danger	  and	  mystery,	  was	  a	  crucial	  part	  of	  the	  success	  in	  generating	  interest	  and	  action	  in	  South	  Africa	  and	  abroad.	  Scientists,	  public	  health	  policy	  experts	  and	  clinicians	  worked	  to	  give	  XDR-­‐TB	  a	  name	  and	  definition	  that	  was	  scary	  and	  inclusive;	  in	  South	  Africa,	  XDR-­‐TB	  took	  on	  the	  emotive	  power	  of	  the	  African	  AIDS	  epidemic.	  Bodies	  ravished	  by	  tuberculosis	  and	  the	  backdrop	  of	  the	  stark	  Msinga	  landscape	  provided	  compelling	  visual	  evidence	  for	  the	  human	  toll	  drug-­‐resistant	  tuberculosis	  was	  taking.	  International	  health	  agencies,	  private	  
                                                582	  Lawrence	  Geiter,	  ed.,	  Ending	  Neglect:	  The	  Elimination	  of	  Tuberculosis	  in	  the	  United	  States	  (Washington,	  D.C.:	  National	  Academy	  Press,	  2000),	  viii,	  http://www.nap.edu/openbook.php?isbn=0309070287.	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donors,	  academic	  institutions,	  as	  well	  as	  government	  agencies	  at	  every	  level	  responded	  with	  expertise	  and	  resources.	  	   By	  the	  time	  I	  arrived	  in	  Tugela	  Ferry	  in	  2010	  much	  of	  the	  excitement	  and	  trepidation	  of	  dealing	  with	  a	  new	  and	  life-­‐threatening	  illness	  had	  given	  way	  to	  the	  every	  day	  work	  of	  treating	  patients	  and	  collecting	  data	  according	  to	  now-­‐established	  protocols	  and	  practices.	  	  Many	  clinicians	  and	  researchers	  felt	  they	  had	  determined	  some	  of	  the	  key	  epidemiologic	  facts	  about	  XDR-­‐TB	  and	  MDR-­‐TB	  in	  Tugela	  Ferry	  and	  were	  ready	  to	  focus	  on	  operational	  details	  of	  TB	  treatment	  and	  to	  share	  their	  experiences	  in	  treating	  and	  managing	  drug-­‐resistant	  tuberculosis	  with	  programs	  in	  other	  parts	  of	  the	  country.	  General	  public	  interest	  in	  XDR-­‐TB	  in	  Tugela	  Ferry	  had	  significantly	  died	  off,	  though	  numerous	  presentations	  on	  XDR-­‐TB	  in	  South	  Africa	  kept	  the	  conversation	  going	  at	  scientific	  conferences	  and	  in	  public	  health	  forums.	  XDR-­‐TB	  rates	  in	  Tugela	  Ferry	  had	  significantly	  declined	  within	  three	  years	  after	  its	  discovery	  and	  in	  June	  2014	  Dr.	  Friedland	  could	  proudly	  give	  a	  keynote	  address	  to	  the	  South	  African	  TB	  Conference	  titled	  “The	  rise	  and	  fall	  of	  XDR-­‐TB	  in	  Tugela	  Ferry	  –	  how	  we	  did	  it.”583	  	   Even	  as	  XDR-­‐TB	  risked	  falling	  into	  a	  phase	  of	  neglect	  (or	  triumph),	  however,	  South	  Africa	  continued	  to	  be	  an	  essential	  reference	  point	  in	  discussions	  about	  drug-­‐resistant	  tuberculosis.	  In	  2011	  the	  death	  of	  a	  health	  care	  worker	  in	  the	  UK	  whose	  MDR-­‐TB	  was	  linked	  back	  to	  his	  previous	  employment	  in	  Tugela	  Ferry	  via	  molecular	  epidemiology	  (thus	  proving	  one	  instance	  of	  the	  global	  spread	  of	  MDR-­‐TB	  from	  South	  Africa)	  was	  of	  sufficient	  interest	  to	  warrant	  publication	  in	  a	  reputable	  medical	  journal.584	  More	  recently,	  in	  October	  2012,	  an	  online	  report	  about	  the	  use	  of	  a	  new	  medication	  for	  drug-­‐resistant	  tuberculosis	  in	  South	  
                                                583	  Plenary	  Speakers,	  4th	  SA	  TB	  Conference,	  last	  accessed	  April	  21,	  2014,	  http://www.tbconference.co.za/plenaries.html	  584	  Graham	  S.	  Cook	  et	  al.,	  “International	  Spread	  of	  MDR	  TB	  from	  Tugela	  Ferry,	  South	  Africa,”	  Emerging	  
Infectious	  Diseases	  17	  no.	  11	  (2011):	  2035-­‐2037.	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Korea	  was	  introduced	  with	  a	  vignette	  about	  Tugela	  Ferry	  and	  included	  an	  image	  of	  the	  Msinga	  landscape.	  585	  It	  seemed	  like	  the	  author	  decided	  that	  cases	  in	  South	  Korea	  alone	  could	  not	  sufficiently	  convince	  the	  reader	  of	  the	  importance	  of	  MDR-­‐TB	  and	  XDR-­‐TB	  treatment.586	  In	  July	  2014	  a	  South	  African	  XDR-­‐TB	  patient,	  who	  was	  successfully	  cured	  with	  a	  new,	  expensive	  drug	  that	  is	  not	  yet	  widely	  available,	  brought	  the	  work	  of	  MSF	  (Doctors	  Without	  Borders)	  in	  Khayelitsha,	  South	  Africa,	  to	  public	  attention	  when	  she	  and	  her	  doctor	  delivered	  a	  Drug-­‐Resistant	  TB	  Manifesto	  to	  the	  World	  Health	  Assembly	  in	  Geneva,	  Switzerland.587	  
Escalation	  is	  inevitable	  Of	  course,	  XDR-­‐TB	  in	  South	  Africa	  is	  not	  the	  final	  chapter	  of	  the	  history	  of	  escalating	  TB-­‐drug	  resistance.	  In	  January	  2012	  I	  came	  across	  the	  following	  headline:	  “India	  Reports	  Completely	  Drug-­‐Resistant	  TB.”588	  After	  a	  epidemiological	  paper	  documenting	  four	  cases	  of	  “Totally	  Drug-­‐Resistant	  Tuberculosis”	  (or	  TDR-­‐TB)	  at	  a	  hospital	  in	  Mumbai,	  India,	  generated	  low	  levels	  of	  interest,	  Indian	  physicians	  reported	  their	  apparently	  untreatable	  cases	  (then	  twelve)	  to	  the	  Indian	  press.589	  This	  was	  soon	  taken	  up	  by	  international	  science	  and	  news	  publications,	  including	  Wired	  and	  Nature.590	  As	  had	  been	  the	  case	  with	  South	  African	  XDR-­‐TB,	  reports	  pointed	  out	  that	  TDR-­‐TB	  in	  India	  was	  the	  result	  of	  long-­‐standing	  systemic	  problems	  with	  the	  implementation	  and	  management	  of	  TB	  treatment	  as	  well	  as	  difficulties	  
                                                585	  Myungsun	  Lee	  et	  al.,	  “Linezolid	  for	  Treatment	  of	  Extensively	  Drug-­‐Resistant	  Tuberculosis,”	  New	  
England	  Journal	  of	  Medicine	  367,	  (2012):	  1508-­‐1518.	  586	  Sushrut	  Jangi,	  “Linezolid	  in	  XDR	  –	  Useful	  to	  an	  Extent,”	  Now@NEJM:	  A	  Blog	  for	  Physicians	  about	  
NEJM	  (blog),	  October	  18,	  2012,	  http://blogs.nejm.org/now/index.php/linezolid-­‐in-­‐xdr-­‐useful-­‐to-­‐an-­‐extent/2012/10/18/.	  587	  Laura	  Lopez	  Gonzalez,	  “Boost	  for	  XDR-­‐TB	  Patients	  as	  Cheaper	  Pills	  Allowed,”	  health-­‐e.org.za,	  July	  1,	  2014,	  http://www.health-­‐e.org.za/2014/07/01/boost-­‐xdr-­‐tb-­‐patients-­‐cheaper-­‐pills-­‐allowed/.  588	  Maryn	  McKenna,	  “India	  Reports	  Completely	  Drug-­‐Resistant	  TB,”	  Wired	  Science	  (blog),	  Wired.com,	  January	  19,	  2012,	  http://www.wired.com/2012/01/invincible-­‐tb-­‐india/.	  589	  Zarir	  F.	  Udwadia	  et	  al.,	  “Totally	  Drug-­‐Resistant	  Tuberculosis	  in	  India,”	  Clinical	  Infectious	  Diseases	  54,	  no.	  4	  (2012):	  579-­‐581.	  590	  Katherine	  Rowland,	  “Totally	  Drug-­‐Resistant	  TB	  emerges	  in	  India:	  Discovery	  of	  a	  Deadly	  Form	  of	  TB	  Highlights	  Crisis	  of	  ‘Mismanagement,’”	  Nature,	  13	  January	  2012,	  http://www.nature.com/news/totally-­‐drug-­‐resistant-­‐tb-­‐emerges-­‐in-­‐india-­‐1.9797#/references.	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of	  diagnosis.591	  The	  revelations	  of	  TDR-­‐TB	  in	  India	  also	  led	  to	  a	  reaction	  from	  the	  WHO:	  a	  series	  of	  meetings	  was	  called	  to	  discuss	  the	  problem.	  However,	  unlike	  with	  XDR-­‐TB,	  the	  WHO	  chose	  not	  to	  endorse	  yet	  another	  name	  for	  an	  increased	  degree	  of	  TB	  drug-­‐resistance,	  and	  decided	  that	  the	  cases	  seen	  in	  Mumbai	  should	  be	  categorized	  as	  a	  sub-­‐type	  of	  XDR-­‐TB.	  This,	  meanwhile,	  allowed	  the	  Indian	  government	  (in	  a	  response	  not	  so	  different	  from	  early	  official	  South	  African	  responses	  to	  XDR-­‐TB)	  to	  argue	  that	  the	  doctors	  in	  question	  were	  being	  misleading	  by	  claiming	  their	  patients	  had	  a	  disease	  that	  did	  not	  officially	  exist.592	  The	  cases	  in	  India	  were	  not	  the	  first	  ones	  for	  which	  the	  term	  TDR-­‐TB	  had	  been	  used	  in	  the	  published	  literature:	  a	  2009	  publication	  from	  Iran	  had	  announced	  the	  “Emergence	  of	  New	  Forms	  of	  Totally	  Drug-­‐Resistant	  Tuberculosis	  Bacilli.”593	  Interestingly,	  the	  same	  research	  group	  had	  published	  a	  series	  of	  Iranian	  XDR-­‐TB	  cases	  in	  2006	  before	  the	  now-­‐famous	  South	  African	  cases	  were	  published.594	  The	  Iranian	  cases	  alone	  did	  not	  generate	  much	  traction	  in	  the	  international	  conversation	  about	  drug-­‐resistant	  tuberculosis,	  however.	  As	  we	  have	  seen	  throughout	  this	  dissertation,	  documented,	  published	  epidemiological	  data	  is	  only	  one	  part	  of	  a	  compelling	  infectious-­‐disease	  narrative.	  Several	  technological	  advances	  in	  TB	  treatment	  and	  diagnosis	  have	  taken	  place	  since	  the	  naming	  of	  XDR-­‐TB	  in	  2005.	  At	  that	  time,	  TB	  diagnosis	  in	  most	  places	  still	  relied	  on	  techniques	  developed	  in	  the	  late	  19th	  century,	  and	  no	  new	  anti-­‐TB	  drugs	  had	  been	  approved	  by	  regulatory	  authorities	  since	  the	  1970s.	  When	  early	  policy	  responses	  to	  XDR-­‐TB	  focused	  
                                                591	  In	  South	  Africa	  analysis	  focused	  mostly	  on	  failing	  government	  systems	  and	  the	  difficulties	  of	  accessing	  care;	  in	  India	  government	  physicians	  often	  blamed	  the	  rampant,	  uncontrolled	  access	  to	  tuberculosis	  drugs	  from	  private	  doctors	  and	  other	  medical	  practitioners	  who	  did	  not	  prescribe	  the	  correct	  treatment	  course	  and	  did	  not	  monitor	  the	  drugs	  appropriately.	  592	  Maryn	  McKenna,	  “TDR-­‐TB:	  The	  Indian	  Government	  Denies	  it	  Exists,”	  Wired	  Science	  (blog),	  
Wired.com,	  January	  29,	  2012,	  http://www.wired.com/2012/01/tdr-­‐india-­‐denies/.	  593	  Ali	  Akbar	  Velayati	  et	  al.,	  “Emergence	  of	  New	  Forms	  of	  Totally	  Drug-­‐Resistant	  Tuberculosis	  Bacilli:	  Super	  Extensively	  Drug-­‐Resistant	  Tuberculosis	  or	  Totally	  Drug-­‐Resistant	  Strains	  in	  Iran,”	  Chest	  136,	  no.	  2	  (2009):	  420-­‐425.	  594	  Mohammad	  Reza	  Masjedi	  et	  al.,	  “Extensively	  drug-­‐resistant	  tuberculosis:	  2	  years	  of	  surveillance	  in	  Iran”	  Clinical	  Infectious	  Diseases	  43,	  no.	  7	  (2006):	  841-­‐847.	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on	  technological,	  pharmaceutical	  and	  laboratory	  interventions	  I	  was	  intensely	  skeptical.	  It	  seemed	  self-­‐evident	  to	  me	  that	  the	  solution	  for	  a	  fundamentally	  social	  disease	  tied	  to	  poverty	  and	  poor	  living	  conditions	  had	  to	  be	  social,	  rather	  than	  technological.	  Improved	  socioeconomic	  conditions	  and	  old	  technologies	  had	  been	  sufficient	  in	  many	  “developed”	  countries	  to	  keep	  tuberculosis	  at	  bay	  most	  of	  the	  time.	  	  There	  clearly	  was	  room	  for	  technological	  improvement,	  however,	  and	  new	  funding	  mechanisms	  and	  partnership	  models	  motivated	  by	  the	  XDR-­‐TB	  scare	  have	  been	  credited	  with	  supporting	  the	  successful	  design	  and	  implementation	  of	  new	  or	  improved	  TB	  diagnostics	  tests	  that	  are	  faster	  and	  more	  effective	  than	  previous	  methods.	  Specifically,	  a	  technology	  called	  GeneXpert	  has	  shown	  promise	  as	  a	  low-­‐skill	  technique	  for	  detecting	  drug-­‐resistant	  tuberculosis	  and	  has	  been	  implemented	  in	  many	  TB	  treatment	  sites.595	  In	  addition,	  there	  has	  been	  active	  development	  of	  new	  anti-­‐tuberculosis	  drugs,	  three	  of	  which	  have	  shown	  the	  potential	  for	  improving	  the	  chances	  of	  survival	  for	  people	  with	  XDR-­‐TB	  and	  MDR-­‐TB.596	  Unfortunately,	  even	  as	  the	  diagnosis	  and	  treatment	  of	  drug-­‐resistant	  tuberculosis	  improves	  the	  diagnosis	  of	  MDR-­‐TB	  or	  XDR-­‐TB	  remains	  a	  bleak	  event.	  MDR-­‐TB,	  when	  managed	  according	  to	  WHO	  guidelines,	  continues	  to	  have	  an	  overall	  treatment	  success	  rate	  
                                                595	  S.	  Walusimbi	  et	  al.,	  “Meta-­‐analysis	  to	  compare	  the	  accuracy	  of	  Genepert,	  MODS	  and	  the	  WHO	  2007	  algorithm	  for	  diagnosis	  of	  smear-­‐negative	  pulmonary	  tuberculosis,”	  BMC	  Infectious	  Diseases	  13	  (2013):	  507.	  It	  has	  been	  endorsed	  by	  the	  WHO	  as	  an	  effectively	  technology	  with	  which	  to	  detect	  drug-­‐resistant	  tuberculosis	  in	  setting	  with	  limited	  laboratory	  expertise.	  The	  cost	  for	  the	  device	  and	  its	  disposable	  cartridges,	  however,	  remains	  limiting.	  UNITAID-­‐funded	  TBXpert	  Project	  will	  make	  funding	  available	  to	  roll	  out	  this	  technology	  in	  21	  countries.	  See	  for	  example:	  “WHO	  monitoring	  of	  Xpert	  MTB/RIF	  roll-­‐out”	  WHO.int,	  http://who.int/tb/laboratory/mtbrifrollout/en/;	  Amy	  S.	  Piatek	  et	  al.,	  “GeneXpert	  for	  TB	  diagnosis:	  planned	  and	  purposeful	  implementation,”	  Global	  Health:	  Science	  and	  
Practice	  1	  no.	  1	  (2013):	  18-­‐23.	  	  596	  Myungsun	  Lee	  et	  al.,	  “Linezolid	  for	  Treatment	  of	  Extensively	  Drug-­‐Resistant	  Tuberculosis,”	  New	  
England	  Journal	  of	  Medicine	  367,	  (2012):	  1508-­‐1518;	  Katie	  Thomas,	  “F.D.A.	  Approves	  Drug	  for	  Resistant	  Tuberculosis,”	  The	  New	  York	  Times,	  December	  31,	  2012,	  http://www.nytimes.com/2013/01/01/business/fda-­‐approves-­‐new-­‐tuberculosis-­‐drug.html,	  Betsy	  McKay,	  “Tuberculosis	  Drug	  Wins	  Backing	  of	  European	  Panel,”	  Wall	  Street	  Journal,	  November	  22,	  2003,	  http://online.wsj.com/news/articles/SB10001424052702304607104579214491854484538.	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of	  less	  than	  50%.597	  On	  the	  occasion	  of	  World	  TB	  Day	  2014	  health	  journalists	  in	  South	  Africa	  took	  the	  opportunity	  to	  review	  the	  state	  of	  MDR-­‐TB	  and	  XDR-­‐TB	  treatment	  in	  the	  country	  and	  came	  to	  the	  conclusion	  that	  despite	  increasing	  efforts	  to	  combat	  tuberculosis	  of	  all	  forms	  the	  situation	  looked	  grim.	  The	  ability	  to	  diagnose	  MDR-­‐TB	  had	  improved	  (and	  recorded	  cases	  between	  2007	  and	  2012	  doubled),	  but	  only	  42%	  of	  those	  diagnosed	  with	  MDR-­‐TB	  initiated	  treatment.	  Of	  those,	  only	  40%	  successfully	  completed	  treatment,	  according	  to	  government	  figures.598	  The	  decentralized	  management	  of	  MDR-­‐TB	  whose	  success	  was	  heralded	  in	  KwaZulu-­‐Natal	  in	  2011	  has	  not	  yet	  been	  successfully	  implemented	  in	  all	  provinces.	  According	  to	  WHO	  statistics,	  South	  Africa	  also	  continues	  to	  have	  the	  world’s	  third-­‐largest	  MDR-­‐TB	  burden	  and	  the	  biggest	  case-­‐load	  of	  XDR-­‐TB	  world-­‐wide.599	  In	  neighboring	  Swaziland,	  the	  potentially	  devastating	  personal	  journey	  of	  MDR-­‐TB	  patients	  was	  highlighted	  in	  a	  recent	  PBS	  Frontline	  documentary.600	  The	  protagonists	  of	  the	  film	  struggle	  greatly	  to	  follow	  their	  treatment	  course,	  and	  only	  one	  of	  them	  reaches	  the	  conclusion	  of	  her	  multi-­‐year	  treatment	  for	  drug-­‐resistant	  tuberculosis	  during	  the	  filming	  period	  –	  through	  death.	  There	  are	  no	  simple	  success	  stories	  here.	  A	  recent	  Lancet	  publication	  from	  three	  provinces	  in	  South	  Africa	  (not	  including	  KwaZulu-­‐Natal)	  found	  that	  long-­‐term	  outcomes	  of	  patients	  treated	  for	  XDR-­‐TB	  were	  very	  poor,	  independent	  of	  HIV	  status,	  with	  only	  16%	  of	  the	  patients	  followed	  having	  a	  favorable	  
                                                597	  Lee	  B.	  Reichman,	  et	  al.,	  “A	  New	  Paradigm	  for	  Multidrug-­‐resistant	  Tuberculosis,”	  International	  
Journal	  of	  Tuberculosis	  and	  Lung	  Disease	  18,	  no.	  8	  (2014):	  884.	  598	  Brendon	  Bosworth,	  “South	  Africa	  Battles	  Drug-­‐Resistant	  TB,”	  Inter	  Press	  Service	  12	  March	  2014,	  http://allafrica.com/stories/201403121337.html?viewall=1.	  599	  Ibid.	  600	  Trailer	  for	  the	  PBS	  Frontline	  documentary	  TB	  Silent	  Killer	  by	  Jezza	  Neumann,	  shown	  on	  PBS	  on	  March	  25,	  2014	  is	  posted	  at	  http://www.npr.org/blogs/health/2014/03/26/294824775/a-­‐silent-­‐killer-­‐returns-­‐live-­‐chat-­‐with-­‐filmmaker-­‐on-­‐fighting-­‐tb?utm_medium=facebook&utm_source=npr&utm_campaign=nprnews&utm_content=03262014;	  The	  film	  itself	  can	  be	  found	  at	  http://www.pbs.org/wgbh/pages/frontline/tb-­‐silent-­‐killer/.	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outcome	  (cure	  or	  completion	  of	  treatment)	  after	  24	  months	  of	  follow-­‐up.601	  In	  addition,	  researchers	  documented	  transmission	  of	  MDR-­‐TB	  and	  XDR-­‐TB	  from	  patients	  to	  community	  members	  once	  patients	  were	  discharged	  home.	  Thus	  the	  debate	  regarding	  the	  dangers	  of	  discharging	  infectious	  MDR-­‐TB	  and	  XDR-­‐TB	  patients	  home	  rather	  than	  keeping	  them	  in	  hospitals	  is	  ongoing.602	  Reviewing	  the	  study,	  Neil	  Schluger	  and	  Max	  O’Donnell	  (who	  has	  worked	  on	  XDR-­‐TB	  in	  Durban)	  concluded	  that	  “drug	  resistant	  tuberculosis	  is	  an	  acute	  global	  health	  crisis”	  and	  that	  “the	  situation	  regarding	  MDR	  and	  XDR	  tuberculosis	  is	  bleak.”603	  	  As	  we	  have	  seen,	  the	  drug	  resistant	  tuberculosis	  crisis	  has	  been	  “acute”	  for	  almost	  three	  decades	  now.	  Harvard	  epidemiologist	  Carole	  Mitnick	  has	  been	  co-­‐authoring	  papers	  highlighting	  the	  global	  dilemma	  of	  MDR-­‐TB	  at	  least	  since	  1998,604	  and	  in	  2012	  stated	  that	  neither	  XDR-­‐TB	  or	  TDR-­‐TB	  were	  new,	  but	  simply	  described	  a	  phenomenon	  that	  “in	  general	  doesn’t	  receive	  a	  lot	  of	  attention.”605	  Long-­‐time	  CDC-­‐based	  TB	  specialist	  Peter	  Cegielski	  was	  alluding	  to	  the	  repeated	  escalation	  of	  TB	  drug-­‐resistance	  and	  the	  recurring	  waves	  of	  interest	  in	  it	  when	  he	  quoted	  Bob	  Dylan	  in	  the	  title	  of	  a	  paper:	  "There	  Must	  Be	  Some	  Kind	  of	  Way	  Out	  of	  Here.”606	  Even	  as	  TB	  experts	  are	  well	  aware	  of	  the	  cycling	  and	  escalating	  history	  of	  the	  TB	  crisis	  narrative,	  however,	  successful	  advocates	  for	  TB	  care	  and	  research	  seem	  to	  have	  also	  recognized	  that	  repeated	  volleys	  of	  powerful	  language,	  compelling	  narratives,	  and	  
                                                601	  Elize	  Pietersen	  et	  al.,	  “Long-­‐term	  Outcomes	  of	  Patients	  with	  Extensively	  Drug-­‐resistant	  Tuberculosis	  in	  South	  Africa:	  A	  Cohort	  Study,”	  Lancet	  383	  no.	  9924	  (2014):	  1230-­‐1239.	  602	  Kate	  Kelland,	  “South	  Africa	  Risks	  Spreading	  Totally	  Drug-­‐resistant	  TB	  –	  Study,”	  Reuters,	  January	  17,	  2014,	  http://in.reuters.com/article/2014/01/17/health-­‐tuberculosis-­‐southafrica-­‐idINL5N0KQ26F20140117.	  603	  Max	  R.	  O’Donnell	  and	  Neil	  W.	  Schluger,	  “Long	  Walk	  to	  Treatment	  for	  XDR	  Tuberculosis	  in	  South	  Africa,”	  Lancet	  383	  (2014):	  1194.	  604Paul	  Farmer,	  et	  al.,	  “The	  Dilemma	  of	  MDR-­‐TB	  in	  the	  Global	  Era,”	  International	  Journal	  of	  
Tuberculosis	  and	  Lung	  Disease	  2	  no.	  11	  (1999):	  643-­‐645.	  	  	  605	  Katherine	  Rowland,	  “Totally	  Drug-­‐Resistant	  TB	  emerges	  in	  India:	  Discovery	  of	  a	  Deadly	  Form	  of	  TB	  Highlights	  Crisis	  of	  ‘Mismanagement,’”	  Nature,	  13	  January	  2012,	  http://www.nature.com/news/totally-­‐drug-­‐resistant-­‐tb-­‐emerges-­‐in-­‐india-­‐1.9797#/references.	  606	  J.	  Peter	  Cegielski,	  “Extensively	  Drug-­‐Resistant	  Tuberculosis:	  ‘There	  Must	  Be	  Some	  Kind	  of	  Way	  Out	  of	  Here’,”	  Clinical	  Infectious	  Diseases	  50,	  no.	  S3	  (2010):	  S195–S200.	  The	  quote	  is	  from	  Bob	  Dylan’s	  “All	  along	  the	  Watchtower,”	  1967.	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impressive	  imagery	  are	  crucial	  to	  directing	  funding	  and	  attention	  towards	  their	  cause.	  Many	  TB	  experts	  are	  well	  trained	  in	  the	  social	  conditions	  that	  underlie	  tuberculosis	  and	  know	  that	  poverty,	  inequality,	  and	  local	  politics	  can	  undermine	  well-­‐intentioned	  efforts	  to	  provide	  tuberculosis	  care.607	  Often,	  however,	  calls	  for	  TB	  funding	  focus	  on	  alarming	  statistics,	  potential	  risk	  of	  personal	  harm,	  and	  the	  pursuit	  of	  technical	  fixes.	  It	  is	  easier	  to	  operate	  politically	  in	  terms	  of	  epidemiology,	  laboratory	  standards,	  and	  technical	  definitions	  than	  to	  directly	  advocate	  for	  specific	  types	  of	  poverty	  alleviation	  strategies,	  let	  alone	  fundamental	  economic	  and	  political	  reform.608	  This	  is	  especially	  true	  for	  action	  within	  the	  WHO,	  which	  specializes	  in	  expert	  meetings	  and	  technical	  reports	  based	  on	  a	  negotiated	  global	  consensus.	  	  In	  the	  introduction	  to	  this	  dissertation	  the	  German	  physicians	  Rudolf	  	  Virchow	  and	  Robert	  Koch	  represented	  two	  schools	  of	  late	  19th	  century	  thought	  regarding	  the	  causation	  of	  tuberculosis,	  whereby	  Virchow	  emphasized	  the	  social	  causes	  of	  disease,	  and	  Koch	  whole-­‐heartedly	  supported	  the	  search	  for	  bacteria	  as	  the	  cause	  of	  illness.	  Intriguingly,	  the	  Berlin	  conference	  venue	  of	  the	  2012	  World	  Union	  Meeting	  of	  the	  International	  Union	  against	  Tuberculosis	  and	  Lung	  Disease	  sported	  both	  a	  “Virchow”	  room	  and	  a	  “Koch”	  room.	  During	  and	  interview	  in	  the	  lobby	  of	  a	  nearby	  hotel,	  Ernesto	  Jaramillo,	  of	  the	  STOP	  TB	  department	  of	  the	  WHO,	  lamented	  the	  lack	  of	  Virchowian	  spirit	  in	  the	  Union	  and	  wished	  for	  an	  increased	  focus	  on	  poverty	  alleviation.	  “We	  live	  under	  the	  tyranny	  of	  [Robert]	  Koch,	  […]	  fixated	  on	  new	  diagnosis,	  new	  drugs,	  and	  new	  vaccines.”609	  Meanwhile,	  physician	  and	  anthropologist	  Salmaan	  Keshavjee,	  who	  worked	  for	  Partners	  in	  Health’s	  MDR-­‐TB	  programs	  in	  Russia	  and	  
                                                607	  Several	  of	  them	  have	  combined	  training	  in	  medicine	  and	  anthropology,	  for	  example,	  and	  have	  conducted	  extensive	  fieldwork	  studying	  the	  connections	  of	  poverty	  and	  disease.	  Examples	  of	  MD/PhD’s	  in	  anthropology	  who	  have	  played	  a	  role	  in	  TB	  policy	  include	  Paul	  Farmer,	  Jim	  Kim,	  Salmaan	  Keshavjee	  and	  Jennifer	  Furin.	  Others,	  such	  as	  Ernesto	  Jaramillo,	  identify	  themselves	  as	  having	  been	  trained	  in	  social	  medicine.	  608	  For	  discussions	  of	  the	  politics	  of	  WHO	  technical	  reports	  see,	  for	  example,	  Joanna	  Radin,	  “Life	  on	  Ice:	  Frozen	  Blood	  and	  Biological	  Variation	  in	  a	  Genomic	  Age,	  1950-­‐2010”	  (Doctoral	  Dissertation,	  University	  of	  Pennsylvania,	  2012)	  and	  Hodžić,	  Saida,	  "Ascertaining	  Deadly	  Harms:	  Aesthetics	  and	  
Politics	  of	  Global	  Evidence,"	  Cultural	  Anthropology	  28,	  no.	  1	  (2013):	  86-­‐109.	  609	  Ernesto	  Jaramillo,	  interview	  by	  author,	  12	  November	  2010,	  Berlin,	  Germany.	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Lesotho	  and	  helped	  develop	  the	  Green	  Light	  Committee	  (which	  provided	  concession	  priced	  MDR-­‐TB	  drugs	  to	  pilot	  projects),	  was	  less	  interested	  in	  dwelling	  on	  the	  socio-­‐economic	  causes	  of	  tuberculosis.	  “TB	  is	  linked	  with	  poverty.	  […]	  You	  know,	  we’ve	  known	  that	  for	  millennia.”610	  Instead	  he	  compared	  tuberculosis	  with	  a	  broken	  leg:	  “We	  don’t	  know	  why	  you	  broke	  your	  leg.	  You	  could	  live	  in	  this	  unsafe	  environment,	  you	  could	  have	  been	  abused	  […]	  you	  could	  live	  in	  a	  bad	  neighborhood	  where	  they	  don’t	  fix	  the	  potholes	  and	  then	  you	  tripped.	  […]	  But	  the	  leg	  is	  broken,	  so	  when	  you	  see	  the	  doctor	  do	  you	  want	  the	  doctor	  say	  […]	  ‘let’s	  sit	  on	  this	  for	  a	  bit	  and	  figure	  it	  out?’	  Or	  do	  you	  want	  him	  to	  put	  a	  cast	  on	  you?	  […]	  Certain	  things	  require	  reductionism	  because	  they’re	  urgent.	  Or	  emergent	  in	  the	  case	  of	  XDR-­‐TB.”611	   The	  multi-­‐layered,	  complex	  process	  of	  translating	  the	  smoldering	  crisis	  mode	  surrounding	  drug-­‐resistant	  tuberculosis	  into	  urgent	  (or	  emergent),	  technocratic,	  global	  and	  local	  public	  action	  has	  been	  at	  the	  center	  of	  this	  dissertation.	  I	  have	  attempted	  to	  link	  the	  the	  global	  and	  the	  local	  by	  tracing	  the	  movement	  of	  XDR-­‐TB	  related	  data,	  expertise	  and	  processes	  of	  meaning-­‐making	  between	  placeless612	  halls	  of	  power	  (be	  they	  in	  Geneva,	  Atlanta,	  New	  Haven,	  Seattle,	  Boston,	  Toronto,	  Paris,	  Berlin,	  Durban	  or	  Johannesburg)	  and	  the	  clearly	  “placed,”	  or	  locatable,	  district	  hospital	  in	  rural	  Tugela	  Ferry,	  South	  Africa.	  XDR-­‐TB	  did	  not	  really	  gain	  the	  ability	  to	  mobilize	  attention	  and	  resources	  until	  it	  became	  associated	  with	  Tugela	  Ferry,	  a	  place	  upon	  which	  public	  health	  experts	  as	  well	  as	  the	  interested	  lay	  public	  could	  project	  their	  fears.	  These	  included	  the	  fear	  of	  a	  global	  epidemic	  of	  a	  deadly,	  untreatable,	  airborne	  illness	  in	  the	  context	  of	  a	  devastating	  AIDS	  epidemic	  and	  
                                                610	  Salmaan	  Keshavjee,	  interview	  by	  author,	  11	  November	  2010,	  Berlin,	  Germany.	  611	  Salmaan	  Keshavjee,	  interview	  by	  author,	  11	  November	  2010,	  Berlin,	  Germany.	  612	  Of	  course	  these	  halls	  of	  power	  themselves	  are	  shaped	  by	  their	  location.	  I	  use	  the	  term	  “placeless”	  here	  primarily	  to	  indicate	  that	  the	  powerful	  experts	  I	  discuss	  in	  this	  dissertation	  can	  meet	  and	  make	  decisions	  in	  any	  number	  of	  places.	  It	  does	  not	  really	  matter,	  as	  long	  as	  there	  is	  an	  airport	  nearby	  and	  a	  venue	  to	  meet.	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the	  fear	  that	  intense	  efforts	  to	  improve	  access	  to	  medical	  treatment	  for	  people	  with	  HIV/AIDS	  in	  South	  Africa	  were	  being	  undermined	  by	  a	  local	  failure	  to	  manage	  tuberculosis,	  a	  curable	  disease.613	  Here	  I	  have	  tied	  together	  into	  one	  document	  the	  creative	  craftsmanship	  that	  goes	  into	  naming	  and	  defining	  a	  new,	  scientific	  disease	  entity,	  the	  political	  messiness	  of	  acknowledging	  an	  expensive	  and	  life-­‐threating	  disease	  affecting	  a	  region,	  and	  the	  challenges	  of	  riding	  a	  vehicle	  with	  poor	  suspension	  across	  packed-­‐dirt	  roads	  in	  order	  to	  then	  tenderly	  probe	  a	  painful	  buttock	  to	  find	  a	  good	  injection	  location.	  These	  seemingly	  disparate	  activities,	  however,	  all	  are	  linked	  together	  through	  a	  particular	  disease	  entity	  –	  XDR-­‐TB	  –	  and	  each	  one	  of	  them	  (along	  with	  many	  more)	  helps	  constitute	  our	  understanding	  of	  XDR-­‐TB,	  its	  significance,	  and	  how	  we	  interpret	  the	  response	  to	  it.	  The	  story	  of	  XDR-­‐TB	  in	  Tugela	  Ferry	  is	  a	  complex	  story	  of	  presences	  and	  absences:	  combined	  TB/HIV	  treatment	  in	  Tugela	  Ferry	  began	  as	  an	  international	  research	  project	  due	  to	  the	  South	  African	  government’s	  reluctance	  to	  provide	  anti-­‐HIV	  medication	  in	  the	  public	  sector;	  but	  it	  was	  also	  the	  presence	  of	  organized	  community	  members	  who	  were	  already	  providing	  compassionate	  HIV	  care	  that	  drew	  the	  project	  there.	  The	  name	  XDR-­‐TB	  emerged	  from	  concerns	  over	  the	  absence	  of	  continued	  global	  MDR-­‐TB	  funding,	  yet	  it	  was	  the	  presence	  of	  MDR-­‐TB	  treatment	  that	  put	  the	  world	  at	  risk	  for	  the	  development	  of	  XDR-­‐TB.	  Global	  meetings	  planning	  the	  response	  to	  XDR-­‐TB	  would	  have	  had	  very	  little	  to	  discuss	  if	  it	  hadn’t	  been	  for	  clinical	  activity	  and	  data	  collection	  practices	  in	  places	  like	  Tugela	  Ferry,	  and	  global	  health	  researchers	  would	  not	  have	  had	  much	  to	  work	  to	  do	  if	  government	  health	  systems	  –	  however	  rocky	  –	  had	  not	  allowed	  them	  to	  insinuate	  themselves	  into	  the	  workings	  of	  hospitals,	  clinics,	  and	  laboratories.	  Even	  as	  government	  TB	  nurses	  went	  about	  their	  limited	  routines	  of	  seeking	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out	  patients	  and	  providing	  medications,	  they	  were	  an	  essential	  executive	  arm	  of	  a	  global	  health	  endeavor	  that	  reached	  well	  beyond	  their	  own	  practice.	  Of	  course	  the	  true	  centerpieces	  of	  the	  entire	  XDR-­‐TB	  story,	  nearly	  absent	  in	  this	  dissertation,	  yet	  right	  in	  the	  eye	  of	  the	  storm,	  are	  patients	  suffering	  and	  dying	  from	  XDR-­‐TB	  and	  other	  forms	  of	  tuberculosis.	  As	  Dr.	  Friedland	  pointed	  out	  to	  the	  South	  African	  TB	  Conference	  in	  his	  presentation	  on	  the	  rise	  and	  fall	  of	  XDR-­‐TB	  in	  South	  Africa,	  “the	  statistics	  of	  epidemiology	  are	  human	  beings	  with	  the	  tears	  removed.”	  614
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